[
  {
    "page": 1,
    "content": "209\nFundamental Science\nPART III\n10.  Medical Evaluation of the Dental Implant ­Patient, 210\n11.  Radiographic Evaluation in Oral Implantology, 275\n12.  Applied Anatomy for Dental Implants, 331\n13.  Dental Implant Infections, 341\n14.  Pharmacology in Implant Dentistry, 359"
  },
  {
    "page": 2,
    "content": "210\n10\nMedical Evaluation of the \nDental Implant Patient\nRANDOLPH R. RESNIK AND ROBERT J. RESNIK\nT\nhe medical evaluation of patients considering dental \nimplant treatment is an important and vital aspect of the \ntreatment planning process. A retrospective analysis of \nVeterans’ Administration Registry data found that the medical \nstatus of patients (i.e., medical history, American Society of Anes-\nthesiologists [ASA] category, and medication history) correlated \nwith dental implant failure.1 It is the primary goal of the clini-\ncian to assess the inherent risks associated with the treatment of \npatients. There exist many factors associated with evaluating the \npatient’s health status and risk including the patients current and \npast medical and dental history, current and past use of medica-\ntions, history of allergies, social history, type of treatment, length \nof treatment, invasiveness of treatment, degree of urgency of treat-\nment, and the past use of sedation (Box 10.1).\nPatients presenting for dental implant treatment may appar-\nently appear “healthy”; however, they may actually have serious \nsystemic diseases or taking medications that may increase the mor-\nbidity of treatment. Patients today, even those with life-threaten-\ning diseases, are more socially active and have a better quality of \nlife because of advances in surgical and medical care. Studies have \nshown that 30% of dental patients have some type of relevant \nmedical condition.2 Evaluating patients over the age of 60 years \nold, 40% have been shown to be on five or more prescription \nmedications, 15% are taking 10 or more prescription medica-\ntions, and 67% are taking a combination of five or more prescrip-\ntion and over-the-counter (OTC) medications.3\nAlthough difficult in many situations, the clinician should do \neverything possible to identify the medically compromised patient. \nThe goal is for every patient to be treated in a safe and efficient man-\nner. Increased risk to patients may arise from procedures that are too \ninvasive or outside the patient’s tolerance in an office setting. There-\nfore it is imperative for the clinician to make an assessment of risk \nbased on medical and dental history and be conscious of the extent \nof trauma and stress to the patient with the anticipated procedures.\nThis chapter is specific for an implant candidate and focuses \non the importance of the initial medical evaluation with primary \nemphasis on the medical history questionnaire and the physical \nexamination. Relevant systemic diseases along with medications \nthat directly affect the dental implant patient are addressed with \nrecommendations on the treatment plan, intraoperative treat-\nment, and postoperative care modifications.\nMedical Evaluation\nThe medical evaluation remains of paramount importance in \nimplant dentistry, perhaps more so than in other disciplines of \ndentistry. Dental implant treatment is well accepted today as a \nsurgical, prosthetic, and maintenance discipline for patients rang-\ning from adolescence to the elderly population. The need for \nimplant-related treatment increases with the age of the patient; as \na result, the implant dentist treats more elderly patients than other \nspecialists in dentistry.\nAn estimated 12% of the US population is 65 years of age or \nolder; this number is expected to reach 21% (64.6 million) in the \nyear 2030.4 A 65-year-old person has a life expectancy of another \n16.7 years, and an 80-year-old person can expect to live an addi-\ntional 8 years.5 These patients often request implant support for \ntheir failing fixed restorations or to improve the conditions of \ntheir removable prostheses. An increased life span indicates that \nthe number of elderly patients in the dental practice is highly \nlikely to increase in the future. Therefore it is important to design \nthe medical and physical evaluations to accommodate the special \nconditions of these patients. \nMedical History\nAn extensive written medical history is mandatory for every dental \nimplant candidate. The review of the patient’s medical history is \nthe first opportunity for the dentist to speak with the patient. The \n • \u0007Current and past medical history\n • \u0007Current and past dental history\n • \u0007Current and past use of medications\n • \u0007History of allergies\n • \u0007Social history and use of recreational drugs\n • \u0007Type of required treatment\n • \u0007Length of treatment\n • \u0007Invasiveness of treatment\n • \u0007Psychological status\n • \u0007Degree of urgency of treatment\n • \u0007Use and type of sedation\n\t • BOX 10.1\t       \u0007Factors Affecting the Risk Assessment \nof the Implant Patient"
  },
  {
    "page": 3,
    "content": "211\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\ntime and consideration taken at the onset will set the tone for the \nentire subsequent treatment. This first impression should reflect a \nwarm, caring practitioner who is highly trained to help patients \nwith complex medical and dental histories. A sincere interest and \nactive note-taking process are beneficial. The practitioner should \nnot underestimate the value of the medical history interview. Ask-\ning questions that show an understanding of listed medical condi-\ntions and related common problems offer several benefits.\nThe two basic categories of information addressed during the \nreview of the medical history include the medical history and \na review of the patient’s systemic health. The dental office uses \na medical evaluation form to obtain most of this information \n(Fig. 10.1). Of particular importance is the history of medica-\ntion usage including OTC medications, herbs and supplements, \nallergies, and a review of the body systems. The pathophysiology \nof the systems, the degree of involvement, and the medications \nbeing used to treat the conditions are evaluated. It is important to \nreview this form with the patient to ensure that comprehension is \nadequate to answer all questions accurately and truthfully.\nExtraoral and Intraoral Examinations\nAfter the medical history is reviewed, the medical physical exam-\nination is initiated because this is the first physical contact the \noffice staff has with the patient. A gentle, caring approach should \ncontinue throughout the examination. A complete evaluation of \nthe head and neck is important initially and at all subsequent pre-\nventive maintenance (recall) appointments.\nThe extraoral and intraoral examinations are similar to those \naddressed in any oral diagnosis textbook. The exposed areas of \nthe patient need to be evaluated (face, neck, arms, and hands) \nand documented accordingly. Features and facial symmetry are \nobserved, including the ears, nose, and eyes. If the midline, \nocclusal plane, or smile line of the natural teeth or existing pros-\nthesis is not harmonious, the etiology should be determined. \nThe temporomandibular joint should be evaluated along with \nmaximum occlusal opening because this may complicate or \ncontraindicate surgical and prosthetic procedures. Patients are \nvery receptive to critical evaluation and treatment limitations \n*,\u0014\u0011\u0003\u0003\u0003\u0003\u0003\u0003 'R\u0003\\RX\u0003KDYH\u0003$1< VWRPDFK\u0003XOFHUV\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n*,\u0015\u0011\n'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u001d\n*,\u0015$\u0011\u0003\u0003\u0003\u0003$FLF\u00035HIOX[\u0003\u000b*(5'\f\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n*\u0014\u0015%\u0011\u0003\u0003\u0003+HSDWLWLV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n*,\u0015&\u0011\u0003\u0003\u0003\u0003-DXQGLFH\"\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n*,\u0015'\u0011 \u0003 /LYHU\u0003GLVHDVH\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n*,\u0016\u0011\u0003\u0003\u0003\u0003\u0003\u0003+DYH\u0003\\RX\u0003HYHU\u0003YRPLWHG\u0003EORRG\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n*,\u0017\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003$1< GLDUUKHD\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n5(\u0014\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003D\u0003SHUVLVWHQW\u0003FRXJK\u0003RU\u0003FROG\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n5(\u0015\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u0003WXEHUFXORVLV\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n5(\u0016\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003,V\u0003WKHUH\u0003$1< KLVWRU\\\u0003RI\u0003WXEHUFXORVLV\u0003LQ\u0003\\RXU\u0003IDPLO\\\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n5(\u0017\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003DQ\\\u0003VLQXVLWLV\u000f\u0003VLQXV\u0003WURXEOH\"\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n5(\u0018\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003HPSK\\VHPD\u000f\u0003FKURQLF\u0003EURQFKLWLV\u000f\u0003DVWKPD\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&1\u0014\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u001d\n&1\u0014$\u0011\u0003(SLOHSV\\\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&1\u0014%\u0011\u0003)DLQWLQJ\u0003VSHOOV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&1\u0014&\u0011\u00036HL]XUHV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&1\u0014'\u0011\u0003(PRWLRQDO\u0003GLVWXUEDQFHV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&1\u0015\u0011\n'R\u0003\\RX\u0003IROORZ\u0003DQ\\\u0003WUHDWPHQW\u0003IRU\u0003D\u0003QHUYRXV\u0003GLVHDVH\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&HQWUDO\n1HUYRXV\n6\\VWHP\n&9\u0014\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u0003DQ\\\u0003RI\u0003WKH\u0003IROORZLQJ\u001d\u00033OHDVH\u0003&KHFN\n+HDUW\u0003WURXEOH\u0003\u0003\n+HDUW\u0003DWWDFN\u0003\u0003\n&RURQDU\\\u0003LQVXIILFLHQF\\\u0003\nMitral Valve Prolapse\n6WURNH\u0003\n'DPDJHG\u0003KHDUW\u0003YDOYHV\u0003\n&RQJHQLWDO\u0003KHDUW\u0003GLVHDVH\n&9\u0015\u0011\n5KHXPDWLF\u0003KHDUW\u0003\u0003GLVHDVH\u000f\u0003KHDUW\u0003PXUPXU\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&9\u0016\u0011\n&KHVW\u0003SDLQ\u0003DIWHU\u0003H[HUWLRQ\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&9\u0017\u0011\u0003\u0003\u0003\u0003\u00036KRUWQHVV\u0003RI\u0003EUHDWK\u0003DIWHU\u0003PLOG\u0003H[HUFLVH\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&9\u0018\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RXU\u0003DQNOHV\u0003VZHOO\"\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&9\u0019\u0011\n'R\u0003\\RX\u0003XVH\u0003H[WUD\u0003SLOORZV\u0003WR\u0003VOHHS\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&9\u001a\u0011\n'R\u0003\\RX\u0003KDYH\u0003D\u0003FDUGLDF\u0003SDFHPDNHU\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n&9\u001b\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003DQ\\\u0003EORRG\u0003SUHVVXUH\u0003SUREOHPV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n,I\u0003<(6\u000f\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0003\u0003\u0003\u0003\u0003\n$ERXW\u0003<RXU\u00030HGLFDO\u0003+LVWRU\\\n)RU\u0003WKH\u0003IROORZLQJ\u0003TXHVWLRQV\u000f\u0003FKHFN\u0003<(6\u0003RU\u000312\u000f\u0003ZKLFKHYHU\u0003DSSOLHV\u0011\u0003\u0003<RXU\u0003DQVZHUV\u0003DUH\u0003IRU\u0003RXU\u0003UHFRUGV\u0003RQO\\\u000f\u0003DQG\nZLOO\u0003EH\u0003FRQILGHQWLDO\u0011\n7+(6(\u0003)$&76\u0003+$9(\u0003$ ',5(&7 %($5,1*\u000321\u0003<285\u0003'(17$/ +($/7+\n6H[\u001dBBBBBBBB\u0003\u0003+HLJKW\u001dBBBBBBBBB\u0003:HLJKW\u001dBBBBBBBBBB\u00035DFH\u001dBBBBBBBBBBB\n\u0014\u0011\u0003\u0003$UH\u0003\\RX\u0003LQ\u0003JRRG\u0003JHQHUDO\u0003KHDOWK\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n\u0015\u0011\u0003\u0003+DV\u0003WKHUH\u0003EHHQ\u0003$1< FKDQJH\u0003LQ\u0003\\RXU\u0003JHQHUDO\u0003KHDOWK\u0003LQ\u0003WKH\u0003SDVW\u0003\\HDU\"\n\u0016\u0011\u0003\u00030\\\u0003ODVW\u0003SK\\VLFDO\u0003H[DPLQDWLRQ\u0003ZDV\u0003RQ\u000f\u0003DSSUR[LPDWH\u0003GDWH \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n\u0017\u0011\u0003\u0003$UH\u0003\\RX\u000335(6(17/< XQGHU\u0003D\u0003SK\\VLFLDQ¶V\u0003FDUH\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n,I\u0003<(6\u000f\u0003ZKDW\u0003FRQGLWLRQ\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n\u0018\u0011\u0003\u00037KH\u0003physician’s QDPH\u0003DQG\u0003DGGUHVV\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n\u0019\u0011\u0003\u0003+DYH\u0003\\RX\u0003KDG\u0003DQ\\\u0003VHULRXV\u0003LOOQHVV\u0003RU\u0003RSHUDWLRQ\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n,I\u0003<(6\u000f\u0003SOHDVH\u0003OLVW\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n\u001a\u0011\u0003\u0003+DYH\u0003\\RX\u0003HYHU\u0003EHHQ\u0003KRVSLWDOL]HG\u0003RU\u0003KDG\u0003D\u0003VHULRXV\u0003LOOQHVV\u0003ZLWKLQ\u0003WKH\nSDVW\u0003\u0018\u0003\\HDUV\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n,I\u0003<(6\u000f\u0003UHDVRQ\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003\u0003\n*HQHUDO\n0HGLFDO\n+LVWRU\\\n'DWH\nBBB\u0012BBB\u0012BBB\n<(6\u0003\u0003\n12\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\n1R\n<HV\u0003\u0003\n1R\n+LJK\n/RZ\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n'DWH\nBBB\u0012BBB\u0012BBB\n<(6\u0003\u0003\n12\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n+LJK\n/RZ\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n&DUGLRYDVFXODU\n6\\VWHP\n5HVSLUDWRU\\\n6\\VWHP\n'LJHVWLYH\n6\\VWHP\nA\n• Fig. 10.1  (A–D) Medical history form."
  },
  {
    "page": 4,
    "content": "212\nPART III     Fundamental Science\n%-\u0014\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u001d\n%-\u0014$\u0011\u0003\u0003$UWKULWLV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n%-\u0014%\u0011\u0003\u0003,QIODPPDWRU\\\u0003UKHXPDWLVP\"\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n%-\u0014&\u0011\u0003\u0003%RQH\u0003LQIHFWLRQ\"\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n%-\u0014'\u0011 2VWHRSRURVLV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n%-\u0014(\u0011\u0003\u0003$UWLILFLDO\u0003-RLQW\u00035HSODFHPHQW\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n%-\u0014)\u0011 \u0014\u0011\u0003Have you received or are you currently receiving the intravenous\nmedication known as biphosphonate for example, Zomata (IV) (zoledronic acid)\nor Aridia (IM) (pamidronate)\n2. Are you taking or have you taken the oral medication known as\nbiphosphonate for osteoporosis or another medical condition for example,\nFosamax  (alendronate), Actonal (risedronate) or Boniva (ibandronate sodium)\nIf yes to 1 or 2\n3.Have you noticed any changes in your mouth or jaws?\n4.Have you had any jaw pain or toothache(s)?\n5. Have you noticed any foul smell, swelling or discharge in your mouth?          \u0003\u0003\u0003\u0003\u0003\u0003\n85\u0014\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u001d\n85\u0014$\u0011\u0003.LGQH\\\u0003WURXEOH\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n85\u0014%\u0011\u0003'LDO\\VLV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n85\u0014%\u0011\u00036\\SKLOLV\u000f\u0003JRQRUUKHD\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014\u0011\n$UH\u0003\\RX\u0003DOOHUJLF\u0003WR\u0003RU\u0003KDYH\u0003\\RX\u0003UHDFWHG\u0003DGYHUVHO\\\u0003WR\u001d\n$/\u0014$\u0011\u0003/RFDO\u0003DQHVWKHWLF \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014%\u0011\u0003$QWLELRWLFV\u000f\u00033HQLFLOOLQ\u000f\u00036XOID\u0003'UXJV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014&\u0011\u0003%DUELWXUDWHV\u000f\u0003VHGDWLYHV\u000f\u0003RU\u0003VOHHSLQJ\u0003SLOOV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014'\u0011\u0003$VSLULQ\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014(\u0011\u0003,RGLQH\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014)\u0011 &RGHLQH\u0003RU\u0003RWKHU\u0003QDUFRWLFV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014*\u0011\u0003/DWH[\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0014+\u0011\u00032WKHUV\"\u00033OHDVH\u00036SHFLI\\\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0015\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003DVWKPD\u000f\u0003KD\\\u0003IHYHU\u0003RU\u0003VHDVRQDO\u0003DOOHUJLHV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$/\u0016\u0011\u0003\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u0003KLYHV\u0003RU\u0003VNLQ\u0003UDVK\"\u0003\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n+%\u0014\u0011 'R\u0003\\RX\u0003KDYH\u0003DQHPLD\u000f\u00036LFNOH\u0003&HOO\u0003GLVHDVH\u000f\u0003EORRG\u0003GLVRUGHU\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n+%\u0015\u0011 ,V\u0003WKHUH\u0003$1< IDPLO\\\u0003KLVWRU\\\u0003RI\u0003EORRG\u0003GLVRUGHUV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n+%\u0016\u0011 $UH\u0003\\RX\u0003KHPRSKLOLF\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n+%\u0017\u0011\u0003\u0003+DYH\u0003\\RX\u0003KDG\u0003DEQRUPDO\u0003EOHHGLQJ\u0003DIWHU\u0003DQ\\\u0003VXUJHU\\\u000f\u0003H[WUDFWLRQ\u000f\u0003RU\u0003WUDXPD\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0003\n+%\u0018\u0011\u0003\u0003+DYH\u0003\\RX\u0003HYHU\u0003KDG\u0003D\u0003EORRG\u0003WUDQVIXVLRQ\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n+%\u0019\u0011\u0003\u0003,PPXQRGHILFLHQF\\\u0003SUREOHP\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n$ERXW\u0003<RXU\u00030HGLFDO\u0003+LVWRU\\\n(QGRFULQH\n6\\VWHP\n(1\u0014\u0011 'R\u0003\\RX\u0003KDYH\u0003GLDEHWHV\"\u0003FRQWUROOHG\u0012XQFRQWUROOHG\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n(1\u0015\u0011 'RHV\u0003DQ\\RQH\u0003LQ\u0003\\RXU\u0003IDPLO\\\u0003KDYH\u0003GLDEHWHV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n(1\u0016\u0011 'R\u0003\\RX\u0003XULQDWH\u0003PRUH\u0003WKDQ\u0003VL[\u0003WLPHV\u0003D\u0003GD\\\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n(1\u0017\u0011 $UH\u0003\\RX\u0003WKLUVW\\\u0003YHU\\\u0003RIWHQ\u0003RU\u0003GR\u0003\\RX\u0003KDYH\u0003D\u0003GU\\\u0003PRXWK\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n(1\u0018\u0011 'R\u0003\\RX\u0003KDYH\u0003K\\SRWK\\URLGLVP\u0003RU\u0003K\\SHUWK\\URLGLVP\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n'DWH\nBBB\u0012BBB\u0012BBB\n'DWH\nBBB\u0012BBB\u0012BBB\n+HPDWRJHQLF\n6\\VWHP\n$OOHUJLHV\n6\\VWHP\n%RQHV\u0003\t\n-RLQWV\n2WKHU\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n:LGH\n&ORVH\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n<HV\u0003\u0003\n1R\n:LGH\n&ORVH\n75\u0014\u0011\n'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u001d\n75\u0014$\u0011\u00037XPRU\u0003RU\u0003PDOLJQDQF\\\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n75\u0014%\u0011\u0003&KHPRWKHUDS\\\u0003RU\u0003UDGLDWLRQ\u0003WKHUDS\\\"\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n'R\u0003\\RX\u0003KDYH\u0003RU\u0003KDYH\u0003\\RX\u0003HYHU\u0003KDG\u0003$1< GLVHDVH\u000f\u0003FRQGLWLRQ\u0003RU\nSUREOHP\u0003127 OLVWHG\u0003DERYH\u0003WKDW\u0003\\RX\u0003WKLQN\u0003ZH\u0003VKRXOG\u0003NQRZ\u0003DERXW\"\n,I\u0003VR\u000f\u0003SOHDVH\u0003H[SODLQ\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n75\u0015\u0011\u0003\n$UH\u0003\\RX\u0003UHJXODUO\\\u0003H[SRVHG\u0003WR\u0003[\u0010UD\\V\u0003RU\u0003$1<\nRWKHU\u0003LRQL]LQJ\u0003UDGLDWLRQ\u0003RU\u0003WR[LF\u0003VXEVWDQFHV\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n75\u0016\u0011\u0003\u0003\u0003\u0003\u0003\u0003'R\u0003\\RX\u0003KDYH\u0003JODXFRPD\" \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\n,I\u0003VR\u000f \u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0011\u0003\nB\n75\u0017\u0011\u0003\u0003\u0003+DYH\u0003\\RX\u0003HYHU\u0003KDG\u0003DQ\\\u0003W\\SH\u0003RI\u0003UDGLDWLRQ\u0003WUHDWPHQW\"\n\u0003\u0003\u0003\u0003\u0003\u0003\u0003\u0003\u0003\u0003\u0003,I\u0003VR\u000f\u0003ZKDW\u0003SDUW\u0003RI\u0003\\RXU\u0003ERG\\\u0003ZDV\u0003WUHDWHG\u0003DQG\u0003ZKHQ\"\n• Fig. 10.1, cont’d"
  },
  {
    "page": 5,
    "content": "213\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nAbout Your Medical History\nYour\nMedications ME1.  Are you taking any of the following medications:\nME1B. Anticoagulants, blood thinning agents?..............................\nME1C. Medicine for high blood pressure?......................................\nME1D. Tranquilizers? ......................................................................\nME1E. Iodine? ................................................................................\nME1F. Aspirin?................................................................................\nME1G. Codeine or other narcotics? ................................................\nME1H. Steroids? ..............................................................................\nME1I.  Other? ..................................................................................\nIf so, please explain...............................\nDate\n___/___/___\nDate\n___/___/___\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nMEDICATION LIST\nName/Type of drugs\nDosage\nHow many\ntimes per day? \nTR4.\nAre you wearing or do you wear contact lenses? ..........................\nTR5.\nDo you drink alcohol?....................................................................\nIf so, how much and how often?....................................................\nTR6.\nDo you smoke tobacco?.................................................................\nTR7.\nDo you use oral tobacco?...............................................................\nIf so, how much and how often?.....................................\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nPlease provide a list of any type of medication you are presently taking as well as the dosage.\n(Prescription or Over the Counter)\nNEVER DISCONTINUE OR MODIFY ANY MEDICATION THAT WAS PRESCRIBED\nBY YOUR PHYSICIAN \nC\n• Fig. 10.1, cont’d"
  },
  {
    "page": 6,
    "content": "214\nPART III     Fundamental Science\nWhat is your chief dental complaint?\nAre you experiencing any discomfort or pain at this time? ........................\nAre you satisfied with the appearance of your teeth?.....................\nAre you able to eat and chew foods satisfactorily?........................\nDo you have headaches, ear aches, or neck pain?..........................\nDo you frequently experience sinus problems?..............................\nHave you had ANY serious trouble associated with ANY\nprevious dental treatment?..............................................................\nIf YES please explain..........................\nAre you pregnant?...........................................................................\nAre you nursing?.............................................................................\nDo you have any problems associated with your menstrual period?\nAre you taking oral contraceptives?...............................................\nAre you undergoing hormonal therapy?.........................................\nAbout Your Medical History\nFor\nWomen\nDate\n___/___/___\nDate\n___/___/___\nYes   \nNo\nYes   \nNo\nYes   \nNo\nYes   \nNo\nYes   \nNo\nDental\nHistory\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nOther\nConditions\nNot Listed \nGeneral\nDental\nResponsibility\nAnd Consent\nStatement\nI hereby authorize and request the performance of dental services for myself or for:\n_____________________________________________________________    _________________________________\n_______________________________         _____________________________\n_______________________________         _____________________________\n_______________________________         _____________________________\nSignature of Patient or Guardian\nSignature of Witness\nSignature of Doctor\nDate\nDate\nDate\nYes   \nNo\nYes   \nNo\nYes   \nNo\nYes   \nNo\nYes   \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nYes  \nNo\nI also give my consent to ANY advisable and necessary dental procedures, medications or anesthetics to be\nadministered by the attending dentist or his supervised staff for diagnostic purposes or dental treatment. These\nrecords may include study  models, photographs, x-rays and blood studies.  I understand and acknowledge that\nI am financially responsible for the services provided for myself and or the above named, regardless of insur-\nance coverage. Treatment plans involving  extended  credit circumstances are subject to a credit check.  I also\nunderstand that the treatment estimate presented to me  is only an estimate.  Occasionally, the need may arise\nto modify treatment.  In such a case, I will be informed of the need for additional treatment, and any fee mod-\nification.\n  To the best of my knowledge the information in this form is accurate.    \nD\n• Fig. 10.1, cont’d\nrelating to facial esthetics before reconstruction begins. The \nhigh smile should be evaluated, because this may pose esthetic \ncomplications related to dental implants. Visible signs of anxi-\nety, abnormal body movements, tremors, lethargy, or difficulty \nin breathing should be noted along with any abnormalities in \nthe face (e.g., expression, pallor, cyanosis or jaundice, droop-\ning eyelids), neck (e.g., lumps, swelling), arms (e.g., bruising or \npetechiae), or hands (e.g., finger clubbing, Raynaud phenom-\nenon, rashes, dexterity issues).\nThe submental, submandibular, parotid, and cervical areas \nare palpated for lymphadenopathy or unusual swelling. The area \nbetween the cricoid notch and the suprasternal notch is palpated \nfor enlargement of the thyroid gland. Thyroid disorders may \ninfluence bone metabolism and implant management. Intraoral \nexamination of the lips, labial and buccal mucosa, hard and soft \npalate, tongue, and oral pharynx is then performed. Any lesions or \ndisease states must be further evaluated before implant procedures \ncommence. \nVital Signs\nThe recording of vital signs (blood pressure, pulse, temperature, \nrespiration, weight, and height) is also part of the physical exami-\nnation. Trained dental auxiliary personnel can often gather this \ninformation before the patient’s history is reviewed by the dentist. \nIf any findings are unusual, the doctor can repeat the evaluation \nas needed.\nBlood Pressure\nBlood pressure is a critical component of the medical examina-\ntion and is often neglected in dental offices. Studies have shown \nthat approximately 10% of dental offices record the patient’s \nblood pressure.6 The importance of obtaining and recording \nthe blood pressure in every implant patient is twofold. First, the \ninitial recording may serve as a baseline measurement, which, \nif too high, may indicate an underlying cardiovascular disease \nthat may contraindicate a surgical procedure. Second, when in"
  },
  {
    "page": 7,
    "content": "215\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nan acceptable range, the initial blood pressure acts as a baseline \nmeasurement specific for that patient. If the patient has a future \nproblem during treatment, the blood pressure difference between \nbaseline and the current situation may alter the medical risk of \nthe patient.\nBlood pressure is measured in the arterial system. This makes \nusing a wrist cuff more difficult and less accurate, as the arteries in \nthe wrist are narrower than in the elbow. It is always advisable to \nuse a cuff that measures the blood pressure just above the elbow. \nUsing a cuff that is too small will give you an artificially higher \nblood pressure, and using a cuff that is too large will give an arti-\nficially low blood pressure. Bladder length is a helpful guide in \nchoosing the appropriate cuff size. The American Heart Associa-\ntion (AHA) recommends the cuff to be 80% of the patient’s arm \ncircumference and 40% for ideal width.\nThere are several standard-size cuffs. The small adult size is \nfor an arm circumference of approximately 7 to 9 inches. Regu-\nlar adult-sized cuffs can be used for arm circumferences that are \nbetween 9 and 13 inches. A large adult cuff can be used when the \narm circumference exceeds 13 inches but is less than 17 inches.\nBlood pressure may be directly influenced by the cardiac out-\nput, blood volume, viscosity of the blood, condition of blood ves-\nsels (especially the arterioles), and heart rate. The systolic blood \npressure is the maximum amount of pressure in your arteries dur-\ning the contraction of your heart muscle. The diastolic blood pres-\nsure is the pressure in the arteries between beats. The difference \nbetween the diastolic and systolic blood pressure is the pulse pres-\nsure. The pulse pressure is the amount of pressure the heart cre-\nates every time is beats. For example, a blood pressure of 120/80 \nwould have a pulse pressure of 40 mm Hg. The average pulse pres-\nsure is 30 to 50 mm Hg. A high pulse pressure is greater than 60 \nmm Hg and is more common in the elderly. Along with age, a \nhigh pulse pressure can be indicative of accelerated hypertension \nor atherosclerosis of the arteries. Blood pressure may be directly \ninfluenced by the cardiac output, blood volume, viscosity of the \nblood, condition of blood vessels (especially the arterioles), and \nheart rate.\nIn 2017, the standards for evaluating blood pressure readings \nwere updated with the release of the “Seventh Report of the Joint \nNational Committee on Prevention, Detection, Evaluation and \nTreatment of High Blood Pressure” (Joint National Committee \n[JNC] 7).7 Blood pressure is now divided into four different cat-\negories: normal, elevated, stage 1, and stage 2. Normal blood pres-\nsure is defined as <120/<80 mm Hg; elevated blood pressure is \ndefined as 120 to 129/<80 mm Hg; stage 1 hypertension is defined \nas 130 to 139 or 80 to 89 mm Hg; and stage 2 hypertension is \ndefined as >140 or ≥90 mm Hg. A diagnosis of hypertension is \nnot made on a single reading. The diagnosis should be confirmed \non at least two or more readings on at least two or more occasions. \nIf the blood pressure reading exceeds a systolic of 140 or diastolic \nof 90 on two separate readings, then the patient should be referred \nto their primary care physician.8\nWhite-coat hypertension in a medical office can occur with \nsome patients. This is especially true for patients in a dental office, \nwho may be anxious or apprehensive about the pending dental \nprocedure. Before making a diagnosis of hypertension in these \nindividuals, the patient should monitor the blood pressure at \nhome or out of the office. Hypertension tends to have a higher \nprevalence in African Americans compared with Caucasians. The \nrisk of death from a stroke or heart disease can be doubled for \nevery 20 mm Hg of elevation in systolic blood pressure and every \n10 mm Hg in elevation of diastolic blood pressure.\nOnly personnel that have been trained and retrained on a \nregular basis in the standardized technique should perform blood \npressure monitoring. It is advised to record the blood pressure in \nboth arms and provide at least 2 to 3 minutes between repeat-\ning the blood pressure readings. You should always verbally give \nthe patient their blood pressure reading in addition to recording \nit in their chart. Usually giving the patient at least 5 minutes to \nrest before checking their blood pressure is advisable. Most dental \noffices will use an automatic electronic cuff, which will inflate the \ncuff to the appropriate pressure and automatically measure the \nblood pressure. It is important that the cuff is in the appropri-\nate position, with the tubes from the cuff running directly over \nthe brachial artery. The patient’s feet should be supported on the \nfloor and the arm supported on a table or chair arm at the level \nof the heart. Do not use one measurement to determine whether \na patient has blood pressure issues. Repeat the reading to confirm \nelevated blood pressure, and refer the patient to their primary care \nprovider when appropriate.\nLow blood pressure can also create issues for dental implant \nsurgery. Blood pressure readings of less than 90 mm Hg systolic \nor less than 60 mm Hg diastolic is considered abnormal, and elec-\ntive dental implant surgery should be postponed until consulta-\ntion with the patient’s physician. It is always important to recheck \nthe blood pressure to verify the low readings. Low blood pressure \ncan result from dehydration, hypothyroidism, or the patient being \nover-medicated with antihypertensive medications.\nNote: If a female patient presents with a history of a mastec-\ntomy, blood pressure should be taken on the arm opposite the \nside of the mastectomy to avoid possible lymphedema. If a patient \nrelates a history of a double mastectomy, blood pressure should \nbe taken on the ankle (this will usually result in an elevated blood \npressure reading). \nPulse\nThe second vital sign of importance is the pulse. The pulse repre-\nsents the force of the blood against the aortic walls for each con-\ntraction of the left ventricle. The pulse wave travels through the \narteries and reaches the wrist 0.1 to 0.2 seconds after each contrac-\ntion. The actual blood flow takes longer to travel this distance. \nThe usual location to record pulse is the radial artery in the wrist. \nHowever, other locations, such as the carotid artery in the neck \nand the temporal artery in the temporal region, are convenient to \nuse during implant surgery or dental treatment. Pulse monitors \nare easy to use and are beneficial during surgery or long prosthetic \nappointments.\nPulse Rate. The normal pulse rate varies from 60 to 90 beats/\nmin in a relaxed, nonanxious patient. Many of the automated blood \npressure machines will check the pulse. If there is any significant \nvariation in the blood pressure readings or there is an error on the \nautomated machine, you should check a manual pulse in the bra-\nchial or radial artery to ensure the rhythm is regular. The pulse rate \ncan be verified manually for a minimum of 30 seconds to 1 minute.\nIf you feel any irregularities in the pulse, you should refer the \npatient back to their primary care provider before proceeding. \nSometimes premature ventricular or atrial contractions are normal \nand can be felt manually with the pulse rate. These extra beats will \nusually be infrequent. More frequent irregular beats or beat that \nseem to be just erratically irregular without any particular pattern \nmay indicate a need for primary care provider consultation before \nproceeding with dental surgery.\nSome patients with chronic atrial fibrillation will have an \nerratically irregular heart rate. These patients are usually on blood"
  },
  {
    "page": 8,
    "content": "216\nPART III     Fundamental Science\nthinners (anticoagulants). A rate greater than 100 or less than 60 \nin these patients can also be problematic and should indicate the \nneed for physician consultation.\nThe normal cardiac rhythm originates in the sinoatrial node; \nthe pulse reflects the ventricular contractions. The upper limit of \nnormal is considered 100 beats/min; patients in excellent physical \ncondition may have a pulse rate of 40 to 60 beats/min. A pulse \nrate less than 60 beats/min in a nonathlete or higher than 110 \nbeats/min in a relatively calm patient could be suspect and warrant \nfurther medical consultation.\nA decreased pulse rate of normal rhythm (less than 60 beats/\nmin) indicates a sinus bradycardia. Naturally, some patients may \nreach as low as 40 beats/min, although most patients become \nsymptomatic with lightheadedness, dizziness, or can experience \nsyncope with a rate lower than 40 beats/min. An adult pulse \nrate lower than 60 beats/min in a nonathlete mandates medical \nevaluation before surgical procedures. Patients receiving beta-\nblocker medications may have lower than normal pulse rates. \nThese patients may be asymptomatic, but consultation with their \nphysician should be considered. During implant surgery, inap-\npropriate bradycardia may indicate a very serious problem. If the \npulse rate of the patient decreases to less than 60 beats/min and \nis accompanied by sweating, weakness, chest pain, or dyspnea, \nthe implant procedure should be stopped, oxygen administered, \nand immediate medical assistance obtained. If the resting pulse \nof the patient is greater than 60 beats/min and drops into the \n40s or lower, the dental procedure should be suspended, even if \nthe patient is asymptomatic, until the pulse returns closer to the \nresting rate.\nAn increased pulse rate of regular rhythm (more than 100 \nbeats/min) is termed sinus tachycardia. This rate is normal if expe-\nrienced during exercise or anxiety. However, a medical consulta-\ntion is suggested when a nonanxious patient has a resting pulse \nrate higher than 100 beats/min. In patients with anemia or severe \nhemorrhage, the heart rate increases to compensate for the deple-\ntion of oxygen in the tissues. Therefore when increased bleed-\ning during surgery is observed, evaluate the pulse rate and blood \npressure.\nPulse rate and temperature are also related, with the pulse rate \nincreasing 5 beats/min for each degree that the body temperature \nrises. Hyperthyroidism and acute or chronic heart disease also may \nresult in sinus tachycardia. Some patients may be asymptomatic \nand experience a condition called paroxysmal atrial tachycardia. \nThis condition is characterized by episodes of very fast heartbeats \nthat may last a few minutes or several weeks. All of these con-\nditions affect the surgical procedure and may increase postop-\nerative swelling. The increased swelling favors the occurrence of \ninfections and complications during the first critical weeks after \nimplant placement. This can lead to increased morbidity and fail-\nure of the implants. \nPulse Rhythm. As described previously it is critical to not only \nrely on the automated pulse calculation but also to manually check \nthe pulse for regularity or irregularity for at least 30 seconds in \nthe radial or brachial artery. Extremely anxious patients can have \naccelerated pulse rates, which can then become irregular with a \npremature ventricular contraction (PVC) or premature atrial con-\ntraction (PAC). Stress reduction protocols can be implemented, \nand implant procedures may even be contraindicated if the causal \nconditions are severe.\nThe presence of an extra pulse beat may indicate a PVC. This \ncondition may be associated with fatigue, stress, or excessive use \nof tobacco or coffee, but it is also observed during myocardial \ninfarction (MI). If the PVCs are more frequent over a short period \nof time, physician consultation should be initiated. If during \nimplant surgery, five or more PVCs are recorded within 1 min-\nute, especially when accompanied by dyspnea or pain, the surgery \nshould be stopped, oxygen administered, the patient placed in a \nsupine position, and immediate medical assistance obtained. If the \nhealth history includes cardiovascular disease, including hyperten-\nsion, the pulse rhythm should be recorded. Sudden death in per-\nsons older than 30 years with PVC is six times more frequent than \nin younger persons.9 \nPulse Strength. The patient’s pulse rate and rhythm may be \nnormal, yet the blood volume can affect the character of the pulse. \nIn anxious patients, the pulse may be bounding as the heart is \nforced to pump large amounts of blood. If the pulse seems to be \nstrong then weak with some alteration back and forth, this could \nindicate pulsus alternans, which is frequently observed in left ven-\ntricular failure, severe arterial high blood pressure, and advanced \ncoronary disease. Implant surgery is contraindicated, and medical \nconsultation with an electrocardiographic examination is needed \nto obtain a diagnosis. \nTemperature\nTechnology has altered the way we can now check a patient’s tem-\nperature. Automated thermometers allow for an accurate tem-\nperature by placing a probe under the tongue. Another option is \na digital ear thermometer. These devices give quick and reliable \ntemperature measurements of the infrared radiation or heat com-\ning from the tympanic membrane. Axillary and forehead measur-\ning devices are much less sensitive and probably have no utility in \na dental implant office. For every degree of fever, the pulse rate \nraises 5 beats/min and the respiratory rate increases 4 beats/min. If \nthe patient’s temperature is greater than 100.5°F, implant surgery \nshould be postponed. If the temperature is greater than 102°F or \nhigher, medical consultation is suggested.\nThe usual cause of elevated body temperature is bacterial infec-\ntion and its toxic by-products. Other causes can be exercise, hyper-\nthyroidism, MI, congestive heart failure (CHF), and tissue injury \nfrom trauma or surgery. Dental conditions causing an elevated \ntemperature include severe dental abscess, cellulitis, and acute her-\npetic stomatitis. Elective dental treatment (such as implant sur-\ngery or bone grafting) is contraindicated when the patient is febrile \n(>100.5). The cause of the fever may complicate the postsurgi-\ncal phase of healing. In addition, because elevated temperature \nincreases the patient’s pulse rate, the risks of hemorrhage, edema, \ninfection, and postoperative discomfort are greater. Special atten-\ntion must be given to a prolonged, sustained fever after surgery \nbecause sepsis or possible brain abscess could be present. Very low \nbody temperatures can also be problematic but can also result from \ninaccurate measurement. If the body temperature is less than 97°F, \nan alternative method of testing should be used to verify the read-\ning or at a minimum the reading should be repeated. More elderly \npatients can have normal body temperatures that run just higher \nthan 97°F. Low body temperature can be found in hypothyroidism. \nRespiration\nRespiration is evaluated while the patient is at rest. The normal \nrate in the adult varies between 16 and 20 breaths per minute \nand is regular in rate and rhythm. Patients with advanced respira-\ntory conditions including chronic obstructive pulmonary disease \n(COPD), CHF, and some forms of asthma may use accessory \nmuscles in the neck or shoulders for inspiration, whether before \nor during surgery. This is considered a form of dyspnea (difficult"
  },
  {
    "page": 9,
    "content": "217\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nor labored breathing). During dental implant surgery, the use of \nintravenous (IV) drugs including narcotics can cause patients to \ndevelop dyspnea.\nIf dyspnea occurs during surgery, it is important to evaluate \nthe patient’s airway for swelling or obstruction. The pulse should \nimmediately be evaluated to rule out the presence of PVCs or irreg-\nularity. This could indicate a more serious condition such as a MI.\nHyperventilation is the result of both an increased rate and \ndepth of respiration and may be preceded by frequent sighs, such \nas is seen in the anxious patient. A respiratory rate greater than 20 \nbreaths per minute requires investigation. Anxiety may increase \nthis rate, in which case sedatives or stress reduction protocols are \nindicated before implant surgery. Other causes for an increased \nrespiration rate are severe anemia, advanced bronchopulmonary \ndisease, and CHF. All three can affect the surgical procedure or \nhealing response of the implant candidate.\nHaving a portable pulse oximeter available is always advisable \nto measure oxygen concentration. It is important to keep the oxy-\ngen saturation greater than 90%. This may require supplemental \noxygen. There was previous concern regarding oxygen supple-\nmentation in patients with chronic COPD depressing the hypox-\nemic drive. Currently the accepted use of supplemental oxygen \nin COPD patients is to keep the oxygen level at their baseline \nor greater than 90%. It is important that every dental office have \nsupplemental oxygen and both a nasal cannula for routine oxy-\ngen supplementation and a nonrebreather mask to deliver higher \nlevels of oxygen.\nHypoventilation can also occur from IV sedation. However, \nthe initial evaluation of a patient that is experiencing hypoven-\ntilation with or without IV sedation should always be the airway \nfor possible obstruction. If the airway is clear and hypoventilation \npersists, then pharmaceutical reversal of the sedative agent should \nbe considered. \nHeight\nThe height of the patient should be determined, especially in an \nadolescent patient, to evaluate their growth and development in \nthe determination of when dental implants would be appropriate. \nIdeally, growth cessation must occur before implant placement is \ninitiated. \nWeight\nWeight is an important factor when using sedation for implants \nprocedures, because there exists a direct correlation between dos-\nage of sedative drugs and body weight. Additionally, significant \nchanges in weight (gain or loss) should be evaluated to assess mal-\nnutrition, obesity, or retention of fluid from either kidney or heart \ndysfunction. Unintentional loss of weight may be a sign of malig-\nnancy, diabetes, or various other systemic diseases. A significant \nincrease in weight may be a sign of cardiovascular disease such \nas CHF, hypothyroidism, or possible systemic diseases. Of spe-\ncial concern are patients with a history of gastric bypass because \nabsorption rates of certain medications may be affected. \nLaboratory Evaluation\nRoutine laboratory screening of patients in a general dental set-\nting who previously reported a normal health history have found \nthat 12% to 18% have undiagnosed systemic diseases.10,11 Many \nof these disorders may influence implant surgery protocol or \nlong-term success rates. The percentage of implant patients with \nunreported systemic illnesses is most likely higher because the \naverage implant patient is older than those in these general stud-\nies. Implant therapy consists of an elective surgery that involves a \nconsiderable investment of time and money by the patient.\nAlthough clinical laboratory tests are not a required compo-\nnent of the physical examination in the dental setting, the implant \nclinician must be well versed in the interpretation of results. In \ngeneral, the implant clinician should never prescribe laboratory \nprocedures. The reason for this is twofold. First, the patient’s phy-\nsician should be the first to interpret laboratory results because \nthey are more knowledgeable about the specific medical condition \nof their patients. Second, there exists a medicolegal issue because \nthe implant clinician would be responsible for interpretation of \nthe entire laboratory tests requested.\nThe most common clinical laboratory evaluation is obtained \nfrom urinalysis and venous blood samples and may include a com-\nplete blood count (CBC), basic metabolic panel (BMP), compre-\nhensive metabolic panel (CMP), and bleeding disorder tests such \nas prothrombin time (PT) or partial prothrombin time (PTT). An \nA1c should also be obtained if the patient relates prediabetic or \ndiabetic conditions because this test gauges how well the patient’s \ndiabetes is managed.\nUrinalysis\nA simple dipstick urinalysis can serve as a valuable screening tool \nfor systemic disease. Urine is a by-product of the kidney and \nperforms several critical functions: filters wastes from the blood-\nstream; maintains water balance; and reabsorbs or conserves vital \nproteins and minerals that the body needs. Anything the body \ndoes not need is excreted in the urine. For the most part, urine is \ngenerally yellow and clear rather than cloudy. However, the color \nand consistency of urine can change, especially in the presence of \nsystemic disease, infection, or focal urinary tract infection. Gly-\ncosuria or sugar spilling in the urine would be one of the most \nconcerning findings for a dentist because this could indicate the \npresence of diabetes. In normal individuals sugar is absent from \nthe urine. Many individuals with diabetes may not show sugars in \nthe urine; therefore blood screening is the most sensitive way to \nscreen for diabetes.\nA urinalysis is not indicated as a routine procedure for dental \npatients and is rarely used in implant dentistry. The major uses for \nthe urinalysis are a screening for diabetes, renal cancer with the \npresence of blood, kidney damage evidenced by the presence of \nprotein or microalbumin, issues involving the liver with elevated \nlevels of bilirubin, and infection with the presence of leukocytes or \nnitrates. Women that are menstruating will frequently have blood \nin their urine sample. \nComplete Blood Cell Count\nA CBC is a common screening test that evaluates the cells that \ncirculate in the blood. There are three types of cells suspended in \nblood plasma: white blood cells (WBCs), red blood cells (RBCs), \nand platelets. The bone marrow produces these cells and allows \nthem to mature before releasing them into the bloodstream.\nThe blood sample is read by an automated machine that the cells \npresent and performs a number of other measurements including \nthe physical characteristics of the cells. This would include the size \nof RBCs; which can be abnormal in cases of anemia (smaller), or \nvitamin deficiencies like B12 or folate (larger). The CBC is a good \ngeneral screening test, but it may not be required unless major \nblood loss is anticipated."
  },
  {
    "page": 10,
    "content": "218\nPART III     Fundamental Science\nHowever, in implant dentistry, CBCs would be important \nin patients with a history of anemia or bleeding disorders. \nCBCs are also useful for patients with chronic renal conditions, \nwhich can cause anemia or those that have been on recent (<3 \nmonths) steroid or glucocorticoid therapy. Any patient that \nreceived chemotherapy for cancer, cured or in remission, or \nhistory of WBC disease such as neutropenia (low WBC) or \nchronic leukemia (markedly elevated WBC) would also require \na CBC.12 \nWhite Blood Cell Count\nWBCs are also referred to as leukocytes. The normal total WBC \ncount ranges from 4500 to 11,000 cells/mm3, and the normal range \ncan vary between laboratories. An increase in WBCs, or leukocyto-\nsis, is not specific to one WBC type. Some of the more common \nissues that create an elevated WBC are acute infection, inflamma-\ntion, steroid therapy, or abnormal bone marrow production.\nThere are five different types of WBCs. Neutrophils, which \nhelp fight infection, are the most numerous. Lymphocytes, which \nare usually less than 25 % of the total cell count, help form anti-\nbodies and help the body get rid of foreign substances. They can \nbe elevated in viral infections and decreased in immunocompro-\nmised patients such as in HIV. One of the first signs of immu-\nnodeficiency including HIV may be low lymphocyte count. \nBasophils are less than 1% of the total count and can increase or \ndecrease based on certain disease states. Infections, severe aller-\ngies, and an overactive thyroid can cause abnormally high counts \nof basophils. Eosinophils, which are usually less than 3% of the \ntotal cell count, are elevated in the presence of allergic responses \nor parasitic infections. Monocytes, making up less than 10% of \nthe count, are responsible for ingesting bacteria or foreign par-\nticles. Monocyte counts can be elevated in inflammatory bowel \ndisease (IBD), endocarditis, or bacterial infections of heart, and \nparasitic or viral infections. A decrease in the number of total \nWBCs is referred to as leukopenia. Decreased WBC counts usu-\nally are the result of a viral infection, immune disorder, or bone \nmarrow disease.\nFrom an implant dentistry perspective, abnormalities in WBC \ncounts can have significant implications. Inflammatory processes \ncan be present with normal WBC counts, but certain types of \ncells, when increased, can indicate ongoing inflammation or pos-\nsibly infection. Elevation in band neutrophils or absolute neutro-\nphil counts (ANCs) usually indicates a more serious process like \ninfection or severe inflammation.\nWhen using a WBC count to monitor infection level, it is \nimportant to realize that early in the disease process the WBC \ncounts may be normal. It is important to pay attention to shifts in \nthe number of specific WBCs, such as neutrophils, basophils, or \nmonocytes, which is reported as the differential (the breakdown \nof the five different types of WBCs). WBC counts are critical to \ndental outpatient care, particularly for patients with immune dis-\neases or undergoing chemotherapy. The counts can indicate infec-\ntions, leukemic disease (myeloproliferative), immune diseases, and \ntoxicity of drugs (especially chemotherapeutic drugs). The ANC \nis very important in evaluating a patient’s ability to fight infec-\ntion. This count is calculated by multiplying the WBC count by \nthe percentage of neutrophils. When not using antibiotic prophy-\nlaxis, the ANC must be greater than 2000. Counts less than 1500 \nare considered neutropenia. These individuals should be seen \nand evaluated by a hematologist or primary care physician and \nshould be given clearance before continuing with implant surgery. \nConsideration for antibiotics should begin at an ANC of less than \n2500 and most definitely should be used for ANC levels of 1000 \nto 2000. Dental implant procedures should never be considered in \na patient with an ANC of less than 1000. \nRed Blood Cell Count\nRBCs are responsible for the transport of oxygen and carbon diox-\nide throughout the body and for control of the blood pH. These \ncells represent the largest segment of the formed elements of the \nblood. The normal RBC count is higher in men than in women. \nIncreases may result from polycythemia, smoking, testosterone \nuse, congenital heart disease, or Cushing syndrome. The most \ncommon finding is a decreased cell count, which usually indicates \nanemia. \nHemoglobin\nHemoglobin (Hb) is responsible for carrying oxygen throughout \nthe bloodstream. Each Hb protein carries up to four molecules \nof oxygen that can be delivered to various cells in the body. The \nnormal level of Hb is 13.5 to 18 g/dL in men and 12 to 16 g/dL \nin women. The preoperative threshold of 10 g/dL is often used \nas a minimum baseline for surgery. However, many patients can \nundergo surgical procedures safely at 8 g/dL as long as their ane-\nmia has been chronic and stable.\nIt is critical for patients with Hb values less than 10 that the \nhistory of the rate of decrease be evaluated. Levels that have been \nconsistently decreasing over time could indicate chronic blood loss \nin the gastrointestinal (GI) tract or through other means includ-\ning malformation of blood vessels. Patients with a chronic stable \nanemia can have consistently lower Hb levels as their baseline. \nWomen with heavy periods can develop low Hb counts over time \nthat can sometimes drop below 10 and require supplementation \nwith iron.\nIt is always a good idea to check with the patient’s physician to \nconfirm the chronicity of their anemia and baseline Hb. Signifi-\ncant acute decreases can be just as important at indicating a new \nprocess that may need to be addressed before the implant. \nHematocrit\nWhite and red blood cells are suspended in serum and make up \nthe contents of blood. The hematocrit is the percentage of RBCs \nin a given volume of blood. The hematocrit is a significant indi-\ncator of anemia or blood loss. Adult males have a normal value \nof about 42% to 54% and women 38% to 46%. Values within \n75% to 80% of normal are required before sedation or general \nanesthesia. \nBleeding Tests\nBleeding disorders are the underlying cause of critical bleeding \nepisodes in any type of dental surgery. Blood changes from liquid \nto solid through the coagulation cascade, which is a complex series \nof steps that result in a fibrin clot. The body uses platelets to plug \nthe site of injury, and clotting factors then help form the fibrin \nclot that maintains the platelets in place.\nIt is important to realize that the platelet count alone does \nnot necessarily provide all the information needed to evaluate \na patient for a potential clotting disorder. It is critical to screen \nthe patient for other signs such as easy bruising, heavy menstrual"
  },
  {
    "page": 11,
    "content": "219\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\ncycles, frequent nosebleeds, and prolonged bleeding after small \ncuts. The patient’s medical history may be a better detector than \nplatelet counts.\nUnderstanding the normal clotting process determines which \nbleeding test to evaluate. Whenever the integrity of a vessel wall is \naltered surgically, hemostasis is achieved in three phases: vascular \nspasm, formation of the platelet plug, and then blood coagulation, \nwhich through the formation of fibrin stabilizes the platelet plug. \nFor hemostasis to be maintained or achieved, the blood vessels \nmust be normal, and functional platelets must be present in suf-\nficient number with all clotting factors in the coagulation cascade \nworking properly. In a normal, healthy individual, coagulation is \ninitiated within 20 seconds of blood vessel damage. This is accom-\nplished by two phases of hemostasis: primary and secondary. \nPrimary hemostasis is initiated when platelets adhere to collagen \nfibers in the vascular endothelium and form the platelet plug. The \nplatelets become inactivated, which results in additional plate-\nlet activation and expansion of the platelet plug. The secondary \nphase consists of a coagulation cascade that has two pathways (Fig. \n10.2): contact activation pathway (formerly the intrinsic pathway) \nand the tissue factor pathway (formerly the extrinsic pathway). \nThese pathways involve a series of enzymatic reactions in which an \ninactive coagulation factor is converted to an active form, which \nthen activates the next coagulation factors in a series of reactions \nthat result in the formation of fibrin to strengthen the clot. The \nclotting cascade requires cofactors such as calcium and vitamin K \nto assist with the synthesis of additional clotting factors.\nThe tissue factor pathway (extrinsic system) and the contact \nactivation pathway (intrinsic system) lead to completion of hemo-\nstasis along a common pathway. Both systems are necessary for \nnormal coagulation. The extrinsic system is activated outside the \nblood vessels; the intrinsic system is activated within the blood \nvessels.\nThree ways to detect potential bleeding problems are (1) to \ncheck the medical history, including any family history of bleeding \ndisorders; (2) to review the physical examination; and (3) to screen \nthe clinical laboratory tests. More than 90% of bleeding disorders \ncan be diagnosed on the basis of the medical history alone.13\nBleeding problems in relatives are significant because they indi-\ncate inherited coagulation disorders. Hemophilia is a rare inherited \ncondition that can cause minor or major bleeding. It is classified \nas hemophilia A (lacking clotting factor VIII) and hemophilia B \n(lacking clotting factor IX, the Christmas factor). Hemophilia B \nis mostly a hereditary disorder, but 33% of the cases are caused by \na spontaneous mutation. The von Willebrand factor is needed to \nproperly carry factor VIII and help blood clot. Without sufficient \nlevels of this factor, blood will not clot properly, resulting in pro-\nlonged bleeding after damage to tissue. This hereditary disorder \nis classified as type 1, 2, or 3 depending on the level of deficiency \nof the von Willebrand factor. Type 1 is the mildest and type 3 is \nthe most serious. In all of these conditions, WBC, RBC, Hb, and \nhematocrit most likely will be normal.\nIt is important to obtain a history of complications from any \nprevious dental or other surgeries. These acquired disorders are \npresent from birth, so uncomplicated previous surgeries most \nlikely indicate there are no inherited disorders. A full personal and \nfamily history is still needed, especially in the case of milder forms \nof the acquired deficiencies. Milder forms of the disease may not \ncause excessive bleeding in certain conditions but could still create \nissues during dental implant surgery.\nAnticoagulants prevent the production of certain clotting fac-\ntors and do not break up clots that have already formed. Examples \ninclude warfarin, rivaroxiban (Xarelto), apixaban (Eliquis), edoxa-\npan (Savaysa), and dabigatran (Pradaxa). Vitamin K can be used \nto reverse the effects of Coumadin or warfarin. The newer antico-\nagulants require more specific reversal medication such as Prax-\nbind for Pradaxa. Currently the Food and Drug Administration \n(FDA) is evaluating a reversal agent for the other, newer antico-\nagulant medications like Xarelto and Eliquis. Many times, within \n5 days of stopping the medications, the anticoagulant effect of the \ndrug is minimal or eliminated.\nAntiplatelet medications decrease platelet aggregation for up \nto 2 weeks and inhibit the formation of the thrombus. Examples \nof these medications include aspirin, clopidogrel (Plavix), pra-\nsugrel (Effient), ticagrelor (Brilinta), and dipyridamole/aspirin \n(Aggrenox). Nonsteroidal antiinflammatory drugs (NSAIDs) such \nas ibuprofen and naproxen may interfere with platelets by block-\ning platelet aggregation for up to 1 week. This can directly affect \nclotting during dental surgery.\nAny blood dyscrasia history, such as anemia, leukemia, throm-\nbocytopenia (too few platelets), and liver diseases, such as hepati-\ntis or cirrhosis, can be associated with current bleeding disorders. \nThe liver is responsible for synthesizing certain clotting factors and \ncausing defects in both in the quantity and quality of platelet pro-\nduction. Vitamin K is essential for productions of PT, which is \nrequired for normal clotting. Therefore it is important that indi-\nviduals consume daily foods such as green leafy vegetables, such \nas spinach, lettuce, broccoli, and cabbage, which are high in \nvitamin K.\nPhysical Examination\nThe second method by which the implant dentist can detect \na patient with a bleeding disorder is the physical examination. \nThe exposed skin and oral mucosa must be examined for objec-\ntive signs. Petechiae, ecchymosis, spider angioma, or jaundice \nmay be observed in liver disease patients with bleeding com-\nplications. Intraoral petechiae, bleeding gingiva, ecchymosis, \nhemarthroses, and hematomas may be present in patients with \ngenetic bleeding disorders. Patients with acute or chronic leu-\nkemia show signs of oral mucosa ulceration, hyperplasia of the \nContact system:\nHMWK, PK, F XII\nCellular injury:\nTissue  Factor (TF)\nF XIIa, Kallikrein\nF X       F Xa\nProthrombin (F II)\nF V       F Va\nF VIIa        F VII\nTFPI\nAntithrombin\nF VIII           F VIIIa\nActivated protein C\nProtein S\nProtein C + Thrombomodulin\nCross-linked fibrin\nFibrinogen\nThrombin (F IIa)\nFibrin monomer\nFibrin multimer\nFactor XIIIa\nFactor XIII\nF IX       F IXa\nF XI         F XIa\n• Fig. 10.2  Secondary phase of hemostasis is a coagulation cascade."
  },
  {
    "page": 12,
    "content": "220\nPART III     Fundamental Science\ngingiva, petechiae or ecchymosis of the skin or oral mucosa, or \nlymphadenopathy. Macular or nodular lesions could be a sign of \nmultiple myeloma. \nClinical Laboratory Testing\nThe third option for detecting a bleeding disorder is clinical labo-\nratory testing. If a patient’s health history and physical examina-\ntion do not reveal potential bleeding disorders, routine screening \nwith a coagulation profile is not indicated. However, if exten-\nsive surgical procedures are expected, a coagulation profile is \nindicated.\nScreening tests for bleeding disorders should include a platelet \ncount, bleeding time, international normalized ratio (INR; for-\nmally PT), activated partial thromboplastin time (aPTT), and \na thrombin time (TT). In the near future, more sophisticated \nplatelet function analytic studies could replace the bleeding time. \nNSAIDs (example ibuprofen) and aspirin used within 10 days of \nthis test can affect the results.14\nInternational Normalized Ratio and Prothrombin Time. In \nmany cases the most appropriate tests to evaluate patients that are \non anticoagulant therapy are the INR and PT. The PT is a test that \ndetermines how long it takes blood to clot. Until the early 1990s, \nthe PT was used exclusively to measure the effect of Coumadin on \nblood clotting. The PT was the test used to measure the effective-\nness of the tissue factor pathway (extrinsic system) and common \npathways of coagulation. However, because of the variability in \nlaboratory reporting, the World Health Organization (WHO) \ndeveloped a more standardized system called the INR. In a normal \nindividual, the INR value should be 1.0. The recommended thera-\npeutic range of continuous anticoagulation is an INR between 2.0 \nand 3.0 for all conditions except artificial heart valves, for which \nthe INR should be between 2.5 and 3.5 (Table 10.1).15 Each 0.1 \nincrease in the INR means the blood is slightly thinner. An INR \n> 1.2 in patients not on blood-thinning medication may require \nadditional workup including liver function. \nPartial Thromboplastin Time. The PTT is another coagula-\ntion test that measures the contact activation pathway (intrinsic \nsystem) and common pathways. A more sensitive version of the \nPTT is the aPTT, which has a normal range of 30 to 40 seconds \nand is used to monitor heparin therapy. The normal range of the \nPTT is 25 to 35 seconds and should be used as a routine screen-\ning test. Low-dose aspirin only has a minimal effect of INR/PT \nor PTT. \nBleeding Time. The bleeding time test is used to evaluate \nplatelet function The Ivy method is the standardized test usually \nused. In this test, a blood pressure cuff is placed on the upper \narm and inflated to 40 mm Hg. A lancet or scalpel blade is used \nto make a cut on the underside of the forearm, and the time is \nmeasured until bleeding has stopped. Normal values fall between \n2 and 9 minutes depending on the method used. The bleeding \ntime measures both coagulation pathways and platelet function \nand capillary activity. Bleeding time will be elevated in the pres-\nence of aspirin for 2 weeks or NSAIDs for up to 10 days. It is \nimportant to realize that clotting time is different from bleeding \ntime. Clotting time takes longer because it is the time for blood \nto actually coagulate or form a clot. Normal values are between 8 \nand 15 minutes. \nPlatelet Count. The platelet count is part of the CBC and is \nusually in range of 150,000 to 450,000 cells/mL of blood. This \ntest identifies the number of platelets (thrombocytes), which is \nvital to the formation of the blood clot. If the count falls below \n150,000 cells/mL, the patient is said to have thrombocytopenia. \nAs platelet counts drop below 100,000, there can be significant \nbleeding problems in implant patients. Low platelet counts will \nnot affect the PT/INR or PTT tests. \nThrombin Time. The enzymes in thrombin help fibrinogen \nform fibrin, which help form and strengthen the clot. The TT \nmeasures the activity of factor Xa (FXa), which activates pro-\nthrombin to thrombin. Thrombin then helps form fibrin and also \nhelps stabilize the clot through cross-linking by activating factor \nXIII. The reference range for TT is usually less than 20 seconds \ndepending on the test kit used. This test in conjunction with the \nother coagulation tests can provide valuable information about \nthe patient’s ability to form clots. \nAdditional Oral Anticoagulants. In the United States there \nare several approved novel oral anticoagulants (NOACs) includ-\ning rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), \nand dabigatran (Pradaxa). These drugs were approved for the \ntreatment of venous thromboembolism, pulmonary embolism, \nand nonvalvular atrial fibrillation. Because their pharmacokinet-\nics is more predictable than Coumadin/warfarin, they do not \nrequire laboratory monitoring. In the studies to approve these \ndrugs they were shown to be as or more effective and safe than \nCoumadin/warfarin. These drugs are not approved for patients \nwith artificial heart valves or atrial fibrillation related to a defec-\ntive heart valve.\nThe previously mentioned coagulation studies do not ade-\nquately provide information on the effective inhibition of clot-\nting potential for these drugs. Activity of these NOACs is difficult \nto measure because of several variables including the reagent and \nanalyzer used. Each NOAC affects the PT/INR test differently, \nwhich is more dependent on the time when the blood sample was \ndrawn relative to the time of the most recent dose. In contrast, \nthe INR/PT measurement for Coumadin/warfarin demonstrates \nactivity based on the cumulative effect of several of the most \nrecent doses.\nPradaxa (dabigatran) has almost no effect on coagulation stud-\nies and does not correlate to the measurement of INR/PT and \nPTT until supertherapeutic levels are taken. A normal aPTT usu-\nally indicates there are no excess drug levels. The TT is also sensi-\ntive to Pradaxa, and a normal TT usually indicates normal blood \ndrug levels.\nIn contrast, Rivaroxaban (Xarelto) has a sensitivity to INR/\nPT, and a normal INR/PT usually excludes significant drug lev-\nels. Rivaroxaban has no effect on aPTT or TT. Apixaban (Eliquis) \n  \u0007Target International Normalized Values for \nSpecific Medical Conditions\nPatient Condition\nINR Value\nNormal\n1.0\nPrevention of myocardial infarction\n2.0–3.0\nTreatment of pulmonary embolism\n2.0–3.0\nTreatment of atrial fibrillation\n2.0–3.0\nPulmonary embolism\n2.0–3.0\nProsthetic heart valves\n2.5–3.5\nPrevention of venous thrombosis\n2.5–3.5\nINR, International normalized ratio.\n   \nTABLE \n10.1"
  },
  {
    "page": 13,
    "content": "221\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\ncannot be measured by and has no effect on INR/PT, aPTT, or \nTT. Edoxaban (Savaysa) has almost no effect on INR/PT or TT, \nbut it is sensitive to measurement by aPTT.16-18\nDialysis patients pose a number of challenges to the implant \ndentistry. There are just a few infections that alter drug metabo-\nlism and bone lesions. Dialysis patients may be at increased risk \nfor bleeding as well. If the PTT is more than 1.5 times the normal \nvalue, surgery should be postponed until physician approval.\nLong-term antibiotic therapy can affect the intestinal bacteria \nthat help produce vitamin K, which is necessary for prothrom-\nbin production in the liver. Therefore if the implant patient has \nused long-term administration of antibiotics, then a PT should be \nobtained to evaluate possible bleeding complications.\nIt is very important to suspect bleeding disorders in a patient \nthat consumes excessive amounts of alcohol for prolonged periods \nof time or who has a history of alcohol abuse, because this can lead \nto liver dysfunction. The liver is the primary site of synthesis of the \nvitamin K–dependent clotting factors II, VII, IX, and X. Patients \nwith intestinal absorption issues or a diet low in vitamin K can \nexacerbate this problem.\nAlcoholism, independent of liver disease, has been shown to \ndecrease platelet production by megakaryocytes and increased \nplatelet destruction. Most coagulation factors are produced in \nthe liver; 50% of patients with liver disease have hypersplenism \nresulting from the destruction of platelets. The PT is the single \nmost useful test used to evaluate impaired hepatocyte synthesis of \nprothrombin complex factors and to assess hemostasis in patients \nwith liver disease. Factor VII has the shortest half-life and is the \nfirst to decrease. Factor VIII and the von Willebrand factor tend \nto increase in chronic hepatic disease patients.\nThe PT and PTT may be used together to determine coagu-\nlation factor defects. A normal PT and abnormal PTT suggest \nhemophilia. An abnormal PT and a normal PTT suggest factor \nVII deficiency. If both PT and PTT are longer, then a deficiency \nof factors II, V, or X or fibrinogen should be considered.\nNo surgical procedures should be performed on a patient sus-\npected of having a bleeding problem based on history, examina-\ntion, and clinical laboratory tests without proper preparation, \nunderstanding, and concerted management by the dentist and the \nphysician. If the bleeding disorder has been previously undiag-\nnosed, the underlying cause should be addressed before the elec-\ntive implant surgical procedures begin. \nBiochemical Profiles (Serum Chemistry)\nThe tenets of laboratory diagnosis should be understood, particu-\nlarly as they relate to implant dentistry. The interpretation of bio-\nchemical profiles and the ability to communicate effectively with \nmedical consultants will enhance the treatment of many patients.\nThe decision to proceed with oral implant treatment may be \naffected by the results of biochemical profiles by contraindicating \nthe procedure completely, altering the type of implant surgery and \nreconstruction, postponing the treatment until therapy controls \nthe disease entity, or simply changing the sequence of medications \nnormally used during treatment. Biochemical sanguine profiles \nare a more necessary part of the medical evaluation for an implant \ncandidate in the presence of systemic diseases or advanced surgical \nprocedures.19 They are not indicated for every potential implant \npatient.\nThe most common metabolic screening assays are the BMP and \nCMP. The BMP measures the blood levels of the calcium, carbon \ndioxide (bicarbonate), chloride, creatinine, glucose, potassium, \nsodium, and blood urea nitrogen (BUN). The CMP measures all \nof the same tests in the BMP with the addition of albumin, total \nbilirubin, protein, and the liver enzymes alanine aminotransferase \n(ALT), aspartate aminotransferase (AST), and alkaline phospha-\ntase (ALP). \nIt is imperative that dental implant clinicians have a strong \nunderstanding of the more common blood chemistry tests. With \nan understanding of the basic blood profiles such as the BMP and \nCMP, a dental implant surgeon can have greater insight into the \nbiochemical parameters reflecting the patient’s health.\nTo be comfortable in interpreting the biochemical profile, \nsome time must be spent in learning the BMP/CMP pattern of \nsystemic diseases. This pattern recognition is similar to the tis-\nsue patterns a pathologist looks at during a biopsy. The BMP/\nCMP profile has been described as a “biochemical biopsy” of the \nblood. These profiles include normal and abnormal values that \nhave interrelationships in the diagnosis of systemic diseases. It is \nnot wise to single out one value to establish a diagnosis. The data \nshould be related with other values obtained in the profile before \nfurther determinations are rendered.\nNormal Range\nThe normal values found on the BMP/CMP represent a statisti-\ncal norm. Any population characteristically shows a bell-shaped \ncurve for a particular measurement. It has been shown that 56% \nof a sample fall within one standard deviation of the mean and \n95% are within two standard deviations. The normal value in \nthe biochemical profile represents two standard deviations. Thus \n“normal” in the statistical sense does not necessarily mean healthy; \ninstead, the word merely describes the typical range of values \nexpected in any given population. Approximately 1 in 20 results \nwill be outside the two standard deviation ranges. The further \nfrom the average value a particular value falls, the more certain \nits clinical significance. Different laboratories can have different \nnormal results.\nAs biochemical profiles are compiled for an individual patient \nover several years, the deviation in a given test may indicate a radi-\ncal change for that individual, although the result should never \ndeviate from the normal population range. The implant dentist \nshould remember that the healthy patient of today might have a \nsystemic disease in the future. Therefore when evaluating long-\nterm complications, it is of interest to relate a recent biochemical \nprofile to the one first reviewed before the initial surgery.\nThe patient should fast for at least 6 to 8 hours before the blood \nis collected to avoid artificial elevations of blood glucose. Most of \nthe other elements of the profile will not be affected. This chapter \nwill limit discussion to the most common tests that are beneficial \nto the implant dentist (Table 10.2): glucose, calcium, inorganic \nphosphorus, ALP, lactic dehydrogenase (LDH), creatinine, and \nbilirubin. \nSerum Glucose\nThe normal range of glucose found in the blood is 70 to 100 mg/\nmL and is maintained within fairly narrow limits. It is important \nwhen evaluating the serum glucose to make sure the specimen \nhas been collected after the patient was fasting for at least 6 to \n8 hours. If not, the serum blood level may exceed 120 to 140 \ndepending on the timing of the test from the last meal. Elevated \nfasting blood sugars are becoming more common as our popula-\ntion ages. Sugars between 100 to 120 fasting can be consistent \nwith the beginning of glucose intolerance, which is a precursor \nfor diabetes (Table 10.3)."
  },
  {
    "page": 14,
    "content": "222\nPART III     Fundamental Science\nThe most common cause of hyperglycemia is diabetes mel-\nlitus. If fasting levels of glucose are found to be greater than \n120, then a referral to a physician may be warranted. If fasting \nsugar is greater than 100, then an HbA1c should be added to the \nblood profile. This test is also referred to as glycosylated Hb and \nprovides average blood sugar concentrations for the past 90 days. \nFor most diabetics the target is less than 7.0%; however, recent \nstudies now show that targets are individualized based on other \nfactors. Patients with longer life expectancy, monotherapy with \nmetformin, and no cardiovascular complications have a target of \n<6.5%. Patients with frequent hypoglycemic episodes, advanced \nvascular disease, other comorbidities, and longer history of hav-\ning diabetes may have a target of <8.0%. An HbA1c greater than \n8% should be considered an absolute contraindication to dental \nimplant surgery, and a consultation between the physician and \nthe patient is warranted.\nOther causes of hyperglycemia include obesity, insulin resis-\ntance, chronic pancreatitis, Cushing syndrome (excess cortico-\nsteroid production), polycystic ovary disease, acromegaly, and \nhemochromatosis (excess iron stores). High fasting blood sugars \ncan be seen in patients that have taken recent or concurrent oral \nsteroids. Hypoglycemia can occur but is much more rare and can \nbe associated with liver damage or excessive insulin production \nfrom an insulinoma tumor in the pancreas. \nSerum Calcium\nCalcium plays a role in several important body functions \nincluding nerve impulse transmission, blood coagulation, and \nmuscle contraction. The overwhelming majority of calcium \n(>99%) is present in the skeleton and teeth. Calcium in the \nbone provides strength to the skeleton and supplies the intra-\ncellular and extracellular calcium. Serum calcium ranges from \nabout 8.8 to 10.4. Bone balance of calcium changes over time. \nKids have a positive bone balance (formation > resorption) for \nskeletal growth. Young adults are usually in neutral bone bal-\nance (formation = resorption). Elderly individuals are usually \nin negative balance during which formation is greater than \nresorption.\nThe implant dentist may be the first to detect diseases affect-\ning the bones. Serum calcium levels are influenced by the \nparathyroid hormone and calcitonin. Serum calcium levels are \nincreased by bone resorption, intestinal absorption, and renal \nreabsorption of calcium. Vitamin D helps with intestinal reab-\nsorption of calcium and is activated by the parathyroid hormone \nto allow the intestine to double and even quadruple the absorp-\ntion of calcium.\nDecreased levels of calcium are primarily seen in hypopara-\nthyroidism, decreased dietary or absorptive conditions, hypo-\nproteinemic conditions, and renal disease. Renal disease is much \nmore common, but the diet of the potential implant patient may \nbe severely affected by the lack of denture comfort and stability. \nThe cause and treatment of hypocalcemic serum levels should be \naddressed before implant reconstruction.\nElevated levels of serum calcium are associated with carcinoma \nin bones, dietary or absorptive disturbances, and hyperparathy-\nroidism. The osteoporosis that accompanies this disorder has \nbeen observed in the mandible. Hyperparathyroidism also causes \nhypophosphatemia. Hypercalcemia associated with a significant \nelevation of ALP suggests Paget disease. With all other biochemi-\ncal values being normal, an elevated calcium value may be the \nresult of laboratory error.20 If phosphorus or ALP levels are also \naffected, medical evaluation and treatment are indicated before \nimplant surgery. Calcium levels greater than 11 should be investi-\ngated immediately. It is important that lower elevations of calcium \nalso are evaluated, and the patient should be referred back to his \nor her physician. \nInorganic Phosphorus\nParathyroid hormone also regulates serum levels of phosphorus \nbecause of the relationship between calcium and phosphorus \nin the blood serum. The normal level is between 3 to 4 mg/100 \nmL. Similar to calcium, it is readily absorbed through the GI \ntract and can be increased with vitamin D intake. Phosphorus \nmaintains a reciprocal relationship with calcium: as the level \nof one increases, the other decreases. The most common cause \nof hyperphosphatemia is renal disease. Low levels of calcium \naccompany high levels of phosphorus. This results in increased \nlevel of parathyroid hormone (PTH), which then increases \nbone turnover resulting in significant bone mass and density \nloss.\nIf an increase in phosphorus is associated with a decrease in \ncalcium and normal renal function, hypoparathyroidism is sus-\npected. If kidney function is abnormal (high BUN/creatinine \nratio), the increased phosphorus level is most likely caused by \n  \u0007Hemoglobin A1c Values versus Blood Glucose \nLevels (Approximate)\nHemoglobin A1c (%)\nAverage Blood Sugar (mg/dL)\n6\n120\n7\n150\n8\n180\n9\n210\n10\n240\n11\n270\n12\n300\n   \nTABLE \n10.3\n  \u0007Laboratory Evaluation of Disease Indicators\nChemistry\nDisease\nGlucose\nDiabetes, steroid dysfunction\nCalcium\nRenal disease, diet, bone diseases, (carcinoma, \nparathyroid disease, Paget disease)\nInorganic phosphorus\nRenal disease, endocrine (parathyroid, thyroid, \nsteroids), antacids\nAlkaline phosphatase\nLiver disease, bone diseases (Paget disease, \nmetastases, fractures, hyperparathyroidism)\nLactic dehydrogenase\nHemolytic disorders, liver disorders, myocardial \ninfarction\nCreatinine\nRenal function\nBilirubin\nLiver disease\nTABLE \n10.2"
  },
  {
    "page": 15,
    "content": "223\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nkidney dysfunction. Other endocrine disorders associated with \nan increased phosphorus level include hyperthyroidism, increased \ngrowth hormone secretion, and Cushing syndrome.\nDecreased levels of phosphorus may appear in patients with \nhyperparathyroidism, especially when it is associated with hyper-\ncalcemia. The chronic use of antacids containing aluminum \nhydroxide also may induce hypophosphatemia and warrants \ninvestigation for a peptic ulcer. \nAlkaline Phosphatase\nALP is an enzyme that is present in the liver, bones, kidneys, and \ndigestive system. The normal ranges are from 44 to 147 IU/mL. \nThere is a rise in ALP levels in all forms of cholestasis (reduction \nof bile flow), especially in obstructive jaundice. Any damage to \nthe liver can raise the ALP level because damaged cells release ALP \ninto the bloodstream.\nIn the absence of liver disease, elevations of ALP are often \na sign of osteoblastic activity in the skeletal system. Therefore \nbone metastases, fractures, Paget disease, multiple myeloma, and \nhyperparathyroidism increase the level of this serum enzyme. \nSerum ALP is normal in patients with adult osteoporosis. Low \nlevels of ALP are usually not of clinical significance for the \ndentist. \nLactic Dehydrogenase\nLDH is an intracellular enzyme present in all tissues (normal \n100–190 U/L) including blood, muscles, brain, kidneys, and pan-\ncreas. This enzyme helps convert sugar into energy. If cells become \ndamaged, then LDH is released into the bloodstream. Falsely ele-\nvated LDH levels occur as a result of hemolyzed blood specimens. \nTherefore if all other blood values including liver function tests \n(LFTs) are normal, LDH testing should be repeated before further \ninvestigation.\nBecause LDH is in many cell types, high levels of LDH can \nindicate a number of conditions including a cerebrovascular \naccident (CVA)/stroke, certain cancers, MI, hemolytic anemia, \nmononucleosis, liver disease (hepatitis), muscle injury, pancre-\natitis, and sepsis. Elevated levels can be further differentiated to \ntheir source as isoenzymes: LDH-1 and LDH-2 are found in the \nheart and RBCs; LDH-3 is found in lymph tissue, lung, and pan-\ncreas; and LDH-4 and LDH-5 are found in the liver and muscle \ntissue.\nWhen LDH values are elevated, the isoenzyme test should be \nperformed to determine the etiology of the elevation, and the CBC \nand a blood smear should be evaluated for any abnormalities. \nBilirubin\nBilirubin is a pigment formed by the liver as it breaks down Hb \nand excretes it into the bile. There are two types of bilirubin: indi-\nrect (unconjugated), which is not attached to glucuronic acid; and \ndirect (conjugated), which is attached to glucuronic acid. These \nvalues are added together to give the total bilirubin. The level of \nbilirubin can be an indicator of liver health. Normal serum values \nof total bilirubin typically are 0.2 to 1 mg/dL. Direct bilirubin \nshould be no more than 0.2 mg/dL.\nWhen evaluating an elevated bilirubin, it is important to dif-\nferentiate the source of the elevation (indirect, or direct, or both). \nSome patients are born with a condition called Gilbert syndrome \nin which the liver does not properly conjugate bilirubin, leading \nto elevated unconjugated (indirect) bilirubin levels. This condition \nis present at birth, and most patients will be told some time early \nin life that they have this harmless condition. Acute elevations of \nindirect bilirubin are usually a result of hemolytic anemia. The \nincrease in indirect bilirubin in both of these diseases is caused by \nexcess production of bilirubin.\nHigh levels of bilirubin can be associated with jaundice, which \ncan be a result of acute or chronic liver disease or failure, cancer, \ndysfunction of the bile duct including gallstones, or acute inflam-\nmation of the liver such as in hepatitis.\nWhen evaluating liver function, it is important to look at all \nthe tests available in the BMP or CMP because proper liver func-\ntion is important for healing, drug metabolism, and long-term \nhealth. \nAminotransferases\nThe most sensitive tests to indicate liver damage are liver enzymes \nreferred to as the aminotransferases. The two most common and \nincluded in a CMP and LFT profile are the AST (or SGOT) and \nALT (or SGPT). An injury to the liver will cause the release of \nthese enzymes into the bloodstream.\nAST is less specific for liver damage because it can be found \nin other tissues outside the liver such as the heart, kidneys, mus-\ncles, and brain. Damage to these cells will cause release of AST. \nALT or SGPT elevation is more specific for liver disease such \nas hepatitis or cirrhosis. Some patients have chronic higher than \nnormal levels from conditions like fatty liver, which are usually \nbenign. Some may have mild elevation from medications they \ntake, such as statins. Higher than normal levels should not always \nbe assumed to be from liver damage. The levels are a marker that \nmay or may not demonstrate damage to the liver. Elevation in \nlevels can occur from muscle damage. The level of increase may \nnot be directly proportional to the amount of liver disease or \nprognosis. Some patients with end-stage liver disease may have \nonly mildly elevated levels. In viral hepatitis A from food these \nlevels can reach the thousands, but recovery is usually full and \ncomplete. Patients with chronic hepatitis C infections may have \nno elevation or only minimal elevation and still develop chronic \nliver disease or failure. \nCreatinine\nCreatinine levels are one of the ways to monitor kidney function \nor kidney disease. If the kidneys become impaired, the blood level \nof creatinine will rise because the kidneys are unable to excrete \nenough creatinine into the urine. There is a fairly constant pro-\nduction and excretion of creatinine, which provides a reasonable \nway to monitor kidney function. The normal creatinine range is \n0.6 to 1.1 mg/dL in women and 0.7 to 1.3 mg/dL in men. Dia-\nbetics have a high incidence of kidney dysfunction but may have \na normal creatinine. In diabetics, a microalbumin screen of the \nurine can pick up early kidney dysfunction. Microalbumin in the \nurine is the earliest form of nephropathy or damage from diabetes.\nThe renal system should not be impaired during implant surgery. \nKidney dysfunction may lead to osteoporosis and decreased bone \nhealing. The kidney is required for appropriate activation of Vitamin \nD to aid in Calcium absorption. Medications can alter pharmaco-\nkinetics, and normal healing can also be affected by kidney disease.\nLow creatinine levels could be from an issue with the muscles \nor liver. In older adults reduced muscle mass can cause a low cre-\natine level. \nEstimated Glomerular Filtration Rate\nThe estimated glomerular filtration rate (eGFR) is often included \nin the BMP or CMP blood panel and can provide more detailed \ninformation on kidney function. This test can detect early kidney"
  },
  {
    "page": 16,
    "content": "224\nPART III     Fundamental Science\ndamage and help with the diagnosis of chronic kidney disease \n(CKD). More important is a consistent way to monitor kidney \nstatus. Normal kidney (stage 1) will have a GFR of 90 or more. \nStage 2 kidney disease demonstrates some mild loss of kidney \nfunction and has an eGFR between 60 and 89. Stage 3 kidney \ndisease indicates more moderate to severe loss of kidney function \nand has values of 30 to 59. Stage 4 disease indicates severe loss of \nkidney function and has values between 15 and 29. Stage 5 indi-\ncates kidney failure and has an eGFR of 15 or less. The eGFR will \ndecline with age, even when kidney disease is absent. For example, \nages 40 to 49 have an average eGFR of 99, whereas ages 60 to \n69 have an average eGFR of 85. A reduced eGFR may require a \nreduction in dosages of medications metabolized by the kidney. \nBlood Urea Nitrogen\nUrea is produced mainly in the liver. It enters the bloodstream \nand is excreted by the kidney in the renal tubules; sweat also \ncan excrete a very small amount of urea. The BUN level can \nbe used as an indicator of kidney and/or liver function. The \nusual range is 3 to 20 mg/dL. Elevated levels can be seen in a \nurinary tract obstruction, CHF, a GI bleed, dehydration, use \nof some medications including some antibiotics, and a high-\nprotein diet.\nThe BUN can be used in conjunction with the creatinine level \nand is usually between a ratio of 10 to 1 and 20 to 1. A ratio \nof greater than 20 can indicate dehydration or GI bleeding. This \ncondition is referred to as prerenal and can also be a result of \nhypoperfusion of the kidney. When the ratio is less than 10 to 1, \nit can indicate polyuria such as in diabetes insipidus or Cushing \ndisease and liver disease or failure (Table 10.4). \nSystemic Disease and Oral Implants\nSystemic diseases play a vital role in treatment planning and \nimplant therapy for patients. There are specific systemic diseases \nand conditions that undeniably affect bone metabolism, wound \n  \u0007Diagnostic Laboratory Test Summary\nTest Name\nDescription\nElevated Levels\nDecreased Levels\nAlbumin \n(blood)\nIs produced by liver and most abundant protein in \nblood; can be used to judge changes in overall \nhealth, liver, or kidney function\nDehydration\nInflammation, liver disease, malnutrition, \nkidney disease, malabsorption\nAlkaline \nphospha-\ntase\nProduced by several organs including liver, bone, and \nkidney\nBone disease such as metastatic cancer, \nPaget disease, multiple myeloma, liver \ndisease\nMalnutrition, hypophosphatemia, hypothy-\nroid, B12 deficiency\nALT (SGPT)\nUsed to access function of the liver\nLiver disease (hepatitis, necrosis, cirrhosis, \ntumor); medications (statins, antibiotics, \nchemotherapy, narcotics); mononucleo-\nsis, obesity (fatty liver)\nN/A\nAmylase\nEnzyme produced by pancreas and used to detect \nissues with pancreas\nPancreatitis\nN/A\nANA\nUsed as a screen for connective tissue disease; \npositive test occurs in some individuals without \nspecific disease\nRequires further specific tests to confirm \nlupus, scleroderma, Sjögren syndrome, \nor myositis\nN/A\nAST (SGOT)\nUsed to detect liver disease and provide assessment \nof liver function\nLiver disease, medications, mononucleosis, \nobesity (similar to AST)\nAST:ALT >2:1 shows alcoholic liver\nAcute renal disease, beriberi, diabetic \nketoacidosis, pregnancy, chronic renal \ndialysis\nBMP\nBlood panel that measures sodium, potassium, \nglucose, BUN, creatinine, chloride, CO2\nN/A\nDependent on test (refer to each compo-\nnent)\nBilirubin \nindirect\nLevel of bilirubin that is product of liver that is not \nconjugated (have sugar molecules attached)\nHemolytic anemia, cirrhosis, transfusion \nreaction, Gilbert disease (lack enzyme \nto conjugate)\nN/A\nBilirubin \ndirect\nLevel of bilirubin that is conjugated with a sugar \nmolecule but cannot be secreted through blocked \nbile ducts\nViral hepatitis, drug reactions, alcoholic \nliver disease, gallstones, tumors, bile \nduct scarring\nN/A\nBleeding time\nMeasure clot time focused on function of platelets\nvon Willebrand disease, thrombocytopenia, \nDIC, medications\nN/A\nBUN\nMeasure urea nitrogen formed when protein is bro-\nken down; help measure kidney and liver function\nKidney dysfunction, GI bleed, dehydration, \nshock, medications, CHF, or urinary \noutlet obstruction\nLiver disease, SIADH, malnutrition\nBUN/creati-\nnine ratio\nRatio of BUN to creatinine, usually between 10:1 \nand 20:1\nDehydration, acute kidney failure or injury, \ndiet high in protein (ratio can be normal \nin chronic kidney disease)\ndiet low in protein, muscle injury  \n(rhabdomyolysis), pregnancy, cirrhosis, \nor (SIADH)\nTABLE \n10.4\n(text continues on p. 19)"
  },
  {
    "page": 17,
    "content": "225\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nTest Name\nDescription\nElevated Levels\nDecreased Levels\nCalcium\nChecks blood level calcium not in bones and para-\nthyroid function\nHyperparathyroidism, lung/breast cancer \nmetastasis to bone, Paget disease, \nexcessive intake of vitamin D\nChronic renal failure, vitamin D deficiency, \nmagnesium deficiency, bisphosphonate \ntherapy\nCarbon \ndioxide\nLevel of carbon dioxide in the blood and important \nbuffer of acid/base regulation\nVomiting, COPD, anorexia, dehydration, \nhypoventilation\nDiarrhea, hyperventilation, kidney or liver \ndisease\nChloride\nImportant in the monitoring of acid/base disorders\nDehydration, diarrhea, renal tubular acido-\nsis, diuretics, hyperparathyroidism\nOverhydration (SIADH), Addison disease, \nchronic vomiting, heart failure\nCreatinine\nImportant measurement of kidney function\nKidney disease, dehydration, diuresis, \nmedication, radiocontrast induced, \nhypertensive kidney disease\nDecreased muscle mass\nCreatinine \nclearance\nUsed to estimate glomerular filtration rate and \noverall kidney function\n90+: stage 1 (normal kidney function)\n60–89: stage 2 (mildly reduced kidney \nfunction)\n30–59: stage 3 (moderately reduced \nkidney function)\n15–29: stage 4 (severe kidney disease)\n<15: end-stage kidney disease\nESR\nNonspecific marker for inflammation\nCollagen vascular disease (lupus, rheu-\nmatoid arthritis), vasculitis, infections, \nmalignancy, renal failure, inflammatory \nbowel disease, anemias\nPolycythemia, sickle cell anemia, sphero-\ncytosis\nFerritin\nMeasures amount of iron stored in body\nHemochromatosis, porphyria, liver disease, \nmultiple blood transfusions, liver dis-\nease, Hodgkin lymphoma\nHemodialysis, iron deficiency anemia\nGlucose\nMeasurement of blood sugar level that is best inter-\npreted fasting <100\nDiabetes, nonfasting level, illness, infec-\ntion, stress response\nExcess insulin secretion, excessive \nalcohol, Addison’s disease (adrenal \ninsufficiency), reactive hypoglycemia\nHematocrit\nRatio of red blood cell volume to the total volume of \nthe blood\nDehydration, diuresis, polycythemia vera, \nhigh altitude exposures\nAnemia, pregnancy, excessive blood loss\nHemoglobin\nCarries oxygen to tissues\nPolycythemia, high altitude exposure, \nextreme exercise program\nAnemia, hemolysis, excessive blood loss\nHemoglobin \nA1c\nMeasurement of percentage of hemoglobin coated \nwith sugar and provides average of blood sugar \nover a 3-month period\nPoorly controlled diabetes, iron deficiency \nanemia, vitamin B12 deficiency, uremia, \nalcoholism\nHemolysis, recent blood transfusion, \nchronic liver disease, excess treatment \nof diabetes, hypertriglyceridemia\nIron level\nMeasures amount of iron in blood\nHemochromatosis, hemolysis, liver necro-\nsis, hepatitis, vitamin B12 deficiency, \nexcessive blood transfusions\nLow dietary intake, heavy menstrual \nbleeding, GI blood loss, intestinal \nmalabsorption, pregnancy\nLPL\nEnzyme produced by pancreas to help break down \nfats and used to help determine disease of the \npancreas\nPancreatitis, tumors of pancreas, gallblad-\nder infection, high triglycerides, exces-\nsive alcohol, gallstones or infection of \ngallbladder\nMay indicate chronic damage to pancreas\nLFTs\nMeasurement of liver functioning (AST, ALT, bilirubin, \nalbumin, alkaline phosphatase)\nSee Individual Tests\nSee Individual Tests\nMCV\nRed blood cell average size\nVitamin B12 or folic acid deficiency, ETOH \nabuse, liver disease, bone marrow \ndysfunction, hypothyroidism\nAnemias, iron deficiency, chronic disease, \nsideroblastic, chronic renal failure, lead \npoisoning, thalassemia\nPTT\nMeasures time for blood to clot for intrinsic pathway \n(factors IX, X, XI, and XII)\nSimilar to PT\nSimilar to PT\nPlatelets\nNumber of circulating platelets\nAcute bleeding, cancer, renal failure, \ninfections, iron deficiency, splenectomy, \ninflammatory bowel disease, lupus\nHemolytic uremic syndrome, autoimmune \ndisease, pregnancy, ITP, TTP\n  \u0007Diagnostic Laboratory Test Summary—cont’d\nTABLE \n10.4\nContinued"
  },
  {
    "page": 18,
    "content": "226\nPART III     Fundamental Science\nTest Name\nDescription\nElevated Levels\nDecreased Levels\nPotassium\nMeasure level of potassium in blood, essential for \nproper function of organs and all cells\nAcute/chronic kidney disease, Addi-\nson’s disease (adrenal insufficiency) \nrhabdomyolysis (breakdown of muscle), \nHTN medications (ACE/ARB), excessive \nintake, burn injury\nDiabetic ketoacidosis, diarrhea, excessive \nalcohol or laxative use, hyperhidrosis \n(excessive sweating), diuretics, folic \nacid deficiency, primary aldosterone \ntumor, vomiting\nPSA\nMeasure blood level of PSA released by prostate \ngland; PSA normally increases with age as \nprostate enlarges\nProstate cancer, prostatitis, catheter inser-\ntion, BPH, UTI, age-related, prolonged \nbike riding\n<0.1 in patients treated for prostate \ncancer\nPT\nMeasures time for blood to clot by the extrinsic path-\nway (tissue factor, Xa); INR is standard measure\nLiver disease, alcohol abuse, DIC, vitamin \nK deficiency, clotting factor deficiency, \nmedication induced\nVitamin K supplementation, estrogen \ntherapy, thrombophlebitis\nRBC\nMeasures number of RBCs\nThalassemia trait, altitude exposure, ciga-\nrette use, polycythemia\nAnemia (including hemolytic), acute blood \nloss, bone marrow dysfunction\nRF\nMeasures Rheumatoid Factor (RF antibody) level \nwhich are proteins  that attack healthy tissue\nRheumatoid arthritis, cancer, chronic infec-\ntions or liver disease, lupus, sclero-\nderma, Sjögren syndrome; also found in \nindividuals with no disease\nN/A\nSodium (Na)\nMeasure level of circulating sodium (important \nfor fluid balance and functioning of nerves and \nmuscles)\nIncreased dietary intake, Cushing syn-\ndrome\nMedications (diuretics), CHF, liver disease, \nSIADH, chronic vomiting, adrenal insuf-\nficiency, drinking too much water\nTSH\nReleased by pituitary and causes thyroid gland to \nrelease T4 and T3; used to diagnosis thyroid disease\nHypothyroidism, Hashimoto’s thyroiditis \n(antibody attach thyroid), lithium, \namiodarone\nHyperthyroidism, subacute thyroiditis \n(inflammation thyroid), excess thyroid \nreplacement therapy, thyroid cancer \n(low normal)\nT4 free or \ntotal\nTotal T4 measures the amount of T4 in blood \nreleased by thyroid and used to diagnose hyper/\nhypothyroid disease and respond to thyroid \nreplacement; total T4 is protein bound and can be \nabnormal because of protein levels; free T4 more \naccurate and not influenced by protein levels\nHyperthyroidism (Graves’ disease), pituitary \nadenoma, excessive thyroid replace-\nment therapy, thyroiditis, birth control \npills, pregnancy, excessive iodine intake\nHypothyroidism, pituitary insufficiency, \nmalnutrition, chronic illness, low intake \nof iodine\nT3 free or \ntotal\nMeasure the amount of circulating T3 produced by \nthyroid; T3 is bound to thyroxine binding globulin; \nT3 not bound to protein is free T3 and this is \nthought to be responsible for biologic activities in \nthe body\nHyperthyroidism (Graves’ disease), pituitary \nadenoma, excessive thyroid replace-\nment therapy, thyroiditis, birth control \npills, pregnancy, excessive iodine intake; \nfree T3 levels stable in pregnancy and \nwith birth control pills\nHypothyroidism, pituitary insufficiency, \nmalnutrition, illness, medications \n(amiodarone, phenytoin)\nWBC\nMeasures total number of white blood cells\nBacterial infection, sepsis, steroids very \nhigh in CLL\nImmunosuppression, viral infections, che-\nmotherapy, antibiotics\nTypes of WBCs\nNeutrophils\nMost abundant type of white blood cell\nBacterial infections, “shift to left,” more \nneutrophils, acute infection\nMalignancies, aplastic anemia, severe \ninfections\nLymphocytes\nMade up of B cells that produce antibodies and T \ncells produced in thymus and are part of immune \nresponse\nViral infections including mononucleosis \nand hepatitis\nBone marrow dysfunction, chemotherapy, \nTB, lupus, rheumatoid arthritis, drug \ninduced\nMonocytes\nParticipate in phagocytosis; produce macrophages to \nhelp fight bacteria, fungi, and viruses\nTB, chronic inflammatory disorders such as \nCrohn disease, ulcerative colitis, lupus\nVitamin B12 deficiency, bone marrow dys-\nfunction, certain leukemias\nEosinophils\nProduced in response to allergens and diseases\nAllergic reactions, parasites\nCushing disease, treatment with steroids, \nstress reactions\nBasophils\nLeast abundant WBC; contain heparin and histamine \nrelated to hypersensitivity reactions\nViruses, lymphoma, hypothyroidism, \ninflammatory bowel disease\nPregnancy, steroid use, hyperthyroidism\nACE, Angiotensin-converting enzyme; ALT, alanine transaminase; ANA; antinuclear antibody; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BMP, basic metabolic profile; BPH, benign \nprostatic hypertension; BUN, blood urea nitrogen; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DIC, disseminated intravascular coagulation; ESR, erythrocyte sedimentation \nrate; ETOH, alcohol; GI, gastrointestinal; HTN, hypertension; INR, international normalized ratio; ITP, idiopathic thrombocytopenic purpura; LFTs, liver function tests; LPL, lipase; MCV, mean corpuscular \nvolume; PSA, prostatic-specific antigen; PT, prothrombin time; PTT, partial thromboplastic time; RBC, red blood cell; RF, rheumatoid factor; SIADH, syndrome of inappropriate antidiuretic hormone secretion; \nT3, triiodothyronine; T4, thyroxine; TB, tuberculosis; TSH, thyroid-stimulating hormone; TTP, thrombotic thrombocytopenic purpura; UTI, urinary tract infection; WBC, white blood cell.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \n  \u0007Diagnostic Laboratory Test Summary—cont’d\nTABLE \n10.4"
  },
  {
    "page": 19,
    "content": "227\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nhealing, and ultimately the success of implant therapy. The \nimplant clinician should use the specific systemic disease informa-\ntion with the planning and management phases of treatment. It is \nthe responsibility of the implant dentist to understand the inter-\nrelationship of systemic diseases and implant dentistry. Common \nconditions that may affect the implant treatment are discussed in \nthree steps. The first section describes the entity in general. The \nsecond section discusses dental implant treatment implications. \nThe last section reviews dental implant management.\nAmerican Society of Anesthesiologists Physical \nStatus Classification\nSystemic diseases have a wide range of effects on a patient, depend-\ning on the severity of the disease. There are relatively few systemic \ndiseases that always contraindicate implant surgery or prosthetic \nrehabilitation. However, several metabolic disorders have con-\ntraindications when the conditions are uncontrolled or severe. \nIn 1962, the ASA adopted a classification system for the severity \nof disease, and the system still is widely used today in medicine. \nThe classification system was designed to estimate the medical risk \npresented by a patient receiving general anesthesia for a surgical \nprocedure. However, the classification system is valuable for deter-\nmining any medical risk, regardless of the method of anesthesia or \ntype of surgery (Box 10.2).\nThe systemic conditions listed in this chapter are those most \ncommonly observed in an implant practice; it is not the intent \nof this chapter to include all conditions. The diseases discussed \nare classified as mild, moderate, or severe. A disease entity affects \nthe host with varied intensity. For example, mild diabetes may \npermit implant treatment, but the same disease in the severe form \nmay contraindicate most implant therapy. As a result, a mild dia-\nbetic patient should be treated differently from the severe diabetic \npatient.\nIn addition to the range of disease expression, the authors have \npresented a variety of implant treatments delivered to a patient.21 \nIn Table 10.5, four levels of surgical and prosthetic dental treat-\nments are established. A systemic condition may contraindicate \none class of treatment, yet a more simplified implant procedure \ncan still be performed. The four levels of treatment range from \nnoninvasive procedures with little or no risk of gingival bleeding \nto those that are most complicated and invasive.\nType 1 procedures can be performed on most patients regard-\nless of systemic condition. Type 2 procedures are more likely to \ncause gingival bleeding or bacterial invasion of the bony struc-\ntures. Type 3 procedures are surgical procedures that require more \ntime and technique. Type 4 procedures are advanced surgical pro-\ncedures with more bleeding and greater risk of postoperative infec-\ntion and complications.\nA relationship can be established between the severity of \nthe disease (mild to severe) and the maximum involvement \nof the dental implant procedure (Table 10.6). For the more \nextensive procedure, the patient should be healthier; for a more \nsevere form of the disease, the surgical procedure should be less \ninvasive. \nCardiovascular Diseases\nHypertension\nHypertension is the most common primary diagnosis in the \nUnited States and accounts for more than 35 million health care \nvisits per year. In 2018, new statistics from the AHA showed that \nthere is an estimated 103 million adults, or almost half (46%) of \nthe entire adult population, in the United States that have high \nblood pressure. The death rate from high blood pressure contin-\nues to rise each year and still remains the most common cause of \ncardiovascular deaths.22\nUntreated, undiagnosed, and uncontrolled hypertension is a \nserious problem in society today. With increasing age, the prev-\nalence of hypertension increases. More than half of people aged \n60 to 69 years and approximately three-quarters of those age \n70 and older are affected with hypertension.2 A recent study \nshowed that the lifetime risk of hypertension is 90% for men \nand women who were nonhypertensive at age 55 to 65 and live \nto age 80. Failure to diagnose and detect hypertensive patients \ncan result in life-threatening conditions such as stroke or MI.\nBecause implant dentists treat a high percentage of elderly \npatients and there is such a high prevalence in the general popula-\ntion, the incidence of treating dental patients with uncontrolled \nor undiagnosed hypertension is very high. This places the implant \nclinician at risk because intraoperative hypertensive episodes may \nresult in cardiac arrhythmias with possible myocardial ischemia \nissues, which may lead to cardiovascular events such as MI or cere-\nbrovascular events.\nASA I: A normal, healthy patient, without systemic disease.\nASA II: A patient with mild to moderate systemic disease.\nASA III: A patient with severe systemic disease, which limits or alters activity \nbut is not incapacitating.\nASA IV: A patient with severe systemic disease, which is incapacitating and \nis a constant threat to life.\nASA V: A moribund patient not expected to live more than 24 hours without \nan operation.\naElective implant surgeries are not indicated for ASA IV or V patients.\nASA, American Society of Anesthesiologists.\naOwens WD, Felts JA, Jr EL Spitznagel. ASA physical status classifications: a study of consistency \nof ratings. Anesthesiology. 1978;49(4):239–243.\n\t • BOX 10.2\t       \u0007American Society of Anesthesiologists \nClassifications\n  \u0007Classifications of Dental Treatment\nClassification \nType\nTreatment\n1\nExaminations, radiographs, study cast impressions, \ntreatment planning, oral hygiene instruction, stage \n2 uncovery with minimum tissue reflection, simple \nrestorative dentistry\n2\nExtractions, single-tooth implants, multiple implants \nwith minimum tissue reflection, minor augmenta-\ntion procedures\n3\nDifficult extractions, multiple implants with more \nextensive reflection, ridge augmentation, unilateral \nsinus graft\n4\nFull-arch implants, autogenous block bone augmen-\ntation, large membrane grafts, bilateral sinus graft\n   \nTABLE \n10.5"
  },
  {
    "page": 20,
    "content": "228\nPART III     Fundamental Science\nClassification Guidelines. In late 2017, the American College \nof Cardiology (ACC) and the AHA released new guidelines for \nthe diagnosis and treatment of high blood pressure. These recom-\nmendations show that blood pressure readings greater than 130 \nmm Hg systolic or 80 mm Hg diastolic should be treated earlier \nwith lifestyle changes and, in some patients that have associated \nrisk factors, with medication. This is a change from the previ-\nous guidelines that recommended intervention at blood pressure \ngreater than 140/90. By lowering the definition of high blood \npressure, the new guidelines account for complications that can \nbegin with lower readings and now allow for earlier intervention. \nAlthough the number of patients now classified as having hyper-\ntension will increase, there will be a relatively smaller increase in \nthe need to medicate these patients as opposed to instituting diet, \nexercise, cholesterol therapy, and other treatment recommenda-\ntions earlier to prevent future complications from high blood \npressure.\nThe new guidelines define normal blood pressure as less than \n120/80 mm Hg. The category of prehypertension has been \neliminated; instead these patients are now classified as having \nelevated blood pressure at 120 to 129/80 mm Hg or stage 1 \nwith a blood pressure between 130 and 139 systolic or 80 and \n89 diastolic. In previous guidelines, stage 1 hypertension was \nclassified as 140/90 mm Hg, but in the new classification, this is \nnow stage 2 hypertension. Hypertensive crisis has been redefined \nas a blood pressure systolic over 180 and/or diastolic over 120 \nmm Hg. If medically stable, these patients require immediate \nintervention via consultation with their physician and change \nof medication. Those patients with chest pain, headache, visual \nchanges, or other somatic complaints may require immediate \nhospitalization.\nAlways ensure that proper technique is used to measure blood \npressure and use home monitoring with devices that can be vali-\ndated. White coat hypertension in a medical office is still a con-\ncern and should be confirmed by having the patient obtain a \nblood pressure outside the medical office (i.e., pharmacy, grocery \nstore, home).\nAlthough the definition of Stage 1 hypertension has changed, \nmedication is usually not required for many individuals. The rec-\nommendations state that only those individuals that have already \nhad a cardiovascular event like a stroke or heart attack or those at \nhigh risk for stroke or heart attack based on factors such as age, \npresence of diabetes, CKD, or at higher risk for atherosclerotic \ndisease with elevated low-density lipoprotein (LDL) cholesterol \nor low high-density lipoprotein (HDL) cholesterol should begin \nmedications. Stage 2 hypertension in most cases should be treated \nwith medications.\nHypertension is usually asymptomatic and is the major risk \nfactor for coronary heart disease and CVAs leading to cardiovas-\ncular morbidity and mortality for people older than 50 years of \nage. The medical history should focus on predisposing factors \nto hypertension such as excessive alcohol intake, history of renal \ndisease, stroke, other cardiovascular diseases, diabetes, increased \ndietary sodium intake, obesity, and smoking.\nSpecial attention should be given to patients with a history of \nobstructive sleep apnea (OSA). Sleep apnea has been associated \nwith a number of cardiovascular diseases including dysthymias, \nMI, and stroke.23 Greater than 50% of patients with sleep apnea \nalso have hypertension.24 In contrast to past knowledge that dia-\nstolic pressure is more important than systolic pressure, studies \nhave shown that with the aging population, uncontrolled systolic \nhypertension causes increased rates of cardiovascular and renal \ndiseases.7\nThe side effects of blood pressure medications may alter treat-\nment or require special precautions. For example, orthostatic \nhypotension affects a patient brought from a supine to an upright \nposition, which can result in syncope and falling, with possible \ninjuries. The patient may feel lightheaded or even faint; these \nsymptoms can be avoided by allowing patients to sit upright \nfor several minutes after the completion of their dental proce-\ndure. Patients at high risk include the elderly, those with anxiety, \npatients taking multiple medications, and those who have under-\ngone lengthy dental procedures.\nPatients with difficult-to-control blood pressure may be pre-\nscribed multiple classes of antihypertensive medications. Even \nthough these patients are being treated with various antihyperten-\nsive medications, they are prone to possible elevation and spikes \nin blood pressure. With these patients, the clinician should seek \nmedical evaluation and consultation, which may include a postop-\nerative blood pressure–monitoring plan.\nSevere hypertension or elevation in blood pressure may lead to \nangina pectoris, CHF, MI, retinal hemorrhage, or even a cerebro-\nvascular episode. These conditions may be precipitated by a rapid \nincrease in blood pressure during a local anesthetic injection or \nthe inherent stress associated with the surgical procedure. A stress \nreduction protocol is paramount with hypertensive patients. \n  \u0007Evaluation of Risk in Systemic Diseases\nRisk (Disease)\nASA Category\nType 1\nType 2\nType 3\nType 4\nNormal (disease)\nI\n+\n+\n+\n+\nMild\nII\n+\nSRP\nSedation, SRP\nSedation, SRP\nModerate\nII\n+\nMedical consult\nMedical consult\nMedical consult\nSevere\nIII\nMedical consult\nPostpone all elective procedures\nPostpone all elective \nprocedures\nPostpone all elective \nprocedures\n+, Procedure may be performed with regular protocol ASA, American Society of Anesthesiologists; SRP, stress reduction protocol.\nNote: ASA IV patients: no treatment.\n   \nTABLE \n10.6"
  },
  {
    "page": 21,
    "content": "229\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nDental Implant Management. Because a high percentage of \npatients have hypertension, the implant clinician and staff mem-\nbers must be knowledgeable about the measurement, detection, \nand treatment of hypertension. The accurate measurement of \nblood pressure, along with a review of all medications including \nherbal and OTC medications, should be an integral part of the \nimplant consultation and examination (Box 10.3).25\nAn elevated blood pressure is common in the dental office set-\nting because stress associated with treatment (i.e., white coat syn-\ndrome) leads to increased levels of catecholamine, which causes \nan increase in blood pressure and heart rate. Two important steps \nto decrease the stress in the dental office are a well-monitored \nstress reduction protocol and proper management of pain and \ndiscomfort. Stress reduction protocol may include premedication \nthe night before the appointment with diazepam [Valium] 5 to \n10 mg, oral or conscious sedation for the procedure, setting an \nearly morning appointment, minimizing waiting room time, and \nensuring the duration of treatment does not exceed the patient’s \nlimits. Adequate pain control is also important, including pre-\nemptive analgesia, profound anesthesia during the procedure, and \nsufficient postoperative pain control including long-acting anes-\nthetics. A resting systolic pressure greater than 180 or a diastolic \npressure greater than 110 should indicate that all elective proce-\ndures be delayed until blood pressure can be reduced to a safer \nlevel (Box 10.4).\nThe use of NSAIDs has been shown to lessen the effective-\nness of various antihypertensive medications by inhibiting \nprostaglandin production, leading to intraoperative hyperten-\nsive episodes. Blood pressure regulation is highly prostaglandin \ndependent, especially as it relates to kidney function through the \nvasodilatory effects. NSAIDs possess a higher degree of inter-\naction with diuretics angiotensin-converting enzyme (ACE) \ninhibitors, angiotensin receptor blocker (ARB) inhibitors, and \nbeta-blockers, which may modify prostaglandin-dependent \npathways more than drugs that alter non–prostaglandin-sensitive \npathways such as calcium channel blockers and central-acting \ndrugs. Therefore the interaction with hypertensive medications \nand NSAIDs results in a higher propensity to increase blood \npressure.26 Studies have shown that approximately 50 million \npatients are being treated with antihypertensive therapy, and 12 \nmillion use NSAIDs concomitantly. However, the short-term \nuse of NSAIDs has not been shown to have a clinically signifi-\ncant effect.27\nThe implant clinician must take into consideration that beta-\nblockers may potentiate the cardiovascular effects of epinephrine \nused in local anesthetics. The nonselective beta-adrenergic drugs, \nsuch as propranolol (Inderal) and nadolol, pose the greatest risk of \nadverse interactions.10 The cardioselective beta-blockers (Lopres-\nsor, Tenormin, and Bystolic) carry less risk of adverse reactions; \nhowever, there is competitive clearance through the liver between \nboth classes of beta-blockers and the local anesthetic. This may \nlead to an increase in serum levels of the local anesthetic.28 To \navoid intraoperative hypertensive episodes, decreasing the dose \nand increasing the time interval between epinephrine-containing \ninjections is recommended.29\nCalcium channel blockers (amlodipine, nifedipine, and dil-\ntiazem) used to treat hypertension or CHF may lead to gin-\ngival hyperplasia around natural teeth or implants (similar to \nDilantin). Additionally, this drug classification has been associ-\nated with erythema multiforme (a benign rash characterized by \npatches of red raised skin) and other types of oral ulceration. \nGingival overgrowth can result in pain, gingival bleeding, and \ndifficulty in mastication, especially around implant prostheses. \nThe incidence of gingival hyperplasia is approximately 1.7% to \n3.8% of patients taking calcium channel blockers30 (Tables 10.7 \nand 10.8). \nAngina Pectoris\nAngina is chest pain that is a result of decreased blood flow to the \nheart. Atherosclerotic disease of the heart blood vessels is usually \nresponsible for the interruption of blood flow to the heart muscle. \nThere are some other causes of angina including coronary artery \nspasm and severe aortic valve disease. The classic symptoms are \na crushing pain in the substernal area that can radiate across the \nchest or into the neck or jaw. It can be accompanied by shortness \nof breath, nausea, diaphoresis, and fatigue. Pain is usually relieved \nwith rest and caused by an imbalance between the amount of oxy-\ngen the heart requires and the amount delivered by the coronary \narteries, especially with exertion or physical activity.\nMen tend to develop coronary disease in the larger vessels and \nhave more classic symptoms. Women tend to develop coronary \ndisease in the smaller vessels, which can lead to variations of the \nclassic symptoms. Women may still experience chest pain but can \nhave the other symptoms of pain into the jaw or neck, fatigue, and \nshortness of breath.\nAngina can be classified as stable, unstable, or Prinzmetal. Sta-\nble angina is triggered by exertion such as exercise (i.e., climbing \nstairs), which results in chest pain that is relieved by resting and/\nor taking nitroglycerin. Unstable angina is the typical substernal \nchest pain that is not brought on by exertion or exercise, occurs \nat rest, can last longer, and sometimes may not be relieved by rest \n • \u0007Premedication the night before a procedure (longer-acting \nbenzodiazepine [diazepam 5–10 mg])\n • \u0007Early morning appointment\n • \u0007Explain entire procedure in detail\n • \u0007Sedation (oral/IV)\n • \u0007Minimize waiting-room time\n • \u0007Duration of treatment not to exceed patient’s tolerance\n • \u0007Profound local anesthesia\n • \u0007Slow/aspiration LA administration\n • \u0007Sufficient postoperative pain management\nIV, Intravenous; LA, local anesthetic.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; \n2018.\n\t• BOX 10.4\t      \u0007Stress Reduction Protocol\n• \u0007Celery\n• \u0007Dandelion\n• \u0007Elder\n• \u0007Goldenseal\n• \u0007Guaiacum\n• \u0007Juniper\n\t • BOX 10.3\t       \u0007Supplements Associated With Increased \nSwelling and Increased Blood Pressure"
  },
  {
    "page": 22,
    "content": "230\nPART III     Fundamental Science\nTABLE \n10.7a   Common Antihypertensive Medications\nThiazides Diuretics\nMechanism of Action\nAce Inhibitors\nMechanism of Action\nCalcium Channel \nBlockers \nNondihydropyridines\nMechanism of Action\nHydrochlorothiazide\nDecrease BP by Decrease \nBlood Volume\nCaptopril, Enalapril, Quinapril, Lisinopril, \nRamipril\nDecrease BP by decreasing periph-\neral vascular resistance, Blocks \nAngiotension Converting enzyme in \nkidney, Results in decrease level of \nangiotensin which decreases levels \nof aldosterone, Lower levels of \naldosterone result in less sodium and \nwater retention which lowers BP, Can \ncause dry cough or angioedema\nDiltiazem, Verapamil\nActs to vasodilate peripheral \nvascular system through \nsmooth muscle relaxation \nDecreases heart rate and \nstroke volume of heart and \ncan cause blockade of AV \nnode in heart resulting in \nsymptomatic bradycardia\nChlorthalidone\nDecrease reabsorption of \nSodium in Distal Kidney\nEnalapril\nBlocks Angiotension Converting enzyme \nin kidney\nVerapamil\nDecreases heart rate and \nstroke volume of heart and \ncan cause blockade of AV \nnode in heart resulting in \nsymptomatic bradycardia\nMetolazone\nCan cause hypokalemia \nand hypomagnesemia\nQuinapril\nResults in decrease level of angiotensin \nwhich decreases levels of aldosterone\nLisinopril\nLower levels of aldosterone result in \nless sodium and water retention \nwhich lowers BP\nRamipril\nCan cause dry cough or angioedema\nLoop Diuretics\nAngiotensin II Receptor Antagonist (ARB)\nCalcium Channel Blockers  \nDihydropyridines\nBumetanide (Bumex)\nInhibits absorbtion of \nSodium in Loop of \nHenle\nCandesartan (Atacand), Losartan (Cozaar), \nOlmesartan (Benicar), Telmisartan (Micar-\ndis), Valsartan (Diovan)\nlowers BP by vasodilation produced by \ninhibiting aldosterone production In \nrenal insufficiency can cause worsen-\ning renal function and hyperkalemia In \nrenal insufficiency can cause worsen-\ning renal function and hyperkalemia \nCan cause cough or angioedema \nDecrease Aldosteron decreases sodium \nabsorption and water reabsorption\nAmlodipine (Norvasc)\nBlock movement of calcium in \nsmooth muscle heart and \nperipheral smooth muscle\nFurosemide (Lasix)\nCan cause hypokalemia \nand hypomagnesemia\nLosartan (Cozaar)\nDecrease Aldosteron decreases sodium \nabsorption and water reabsorption\nFelodipine (Plendil)\nLowers BP through smooth \nmuscle relaxation and \nvasodilation\nTorsemide\nIncrease Prostaglandin \nsynthesis (NSAIDS can \ninterfere and decrease \neffectiveness of loop \ndiuretics)\nOlmesartan (Benicar)\nCan cause cough or angioedema\nNifidipine (Procardia)\nCan make heart failure worse \nand cause leg and periph-\neral edema"
  },
  {
    "page": 23,
    "content": "231\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nDemadex\nTelmisartan (Micardis)\nIn renal insufficiency can cause worsen-\ning renal function and hyperkalemia\nValsartan (Diovan)\nBeta Blocker\nVasodilators\nNonselective : Block beta receptor at both B1 \n(heart) and B2 (lungs) receptors\nHydralazine  \n(Apresoline)\nProduce Relaxation of Vas-\ncular Smooth Muscle\nPropranolol\nDecrease Cardiac output which \ndecreases cardiac O2 con-\nsumption by blockade of B1 \nreceptors and lowers BP\nMinoxidil\nCauses decrease in \nperipheral vascular \nresistance lowering BP\nTimolol\nCauses Peripheral Vasocon-\nstriction and Bronchocon-\nstriction\nCan cause reflex stiuma-\ntion of heart increasing \nheart rate, cardiac \ncontractility and O2  \nconsumption\nNadolol\nBlocks effects of epinephrine \n(adrenaline)\nMinoxidil reserved for \nsevere hypertension\nCarvdilol\nDecrease Heart Rate and \nsexual dysfunction\nLabetalol\nCan cause disturbances in \nglucose metabolism:\nCentral alpha-\nAgonist in brain\nCardio selective Beta blockers block only  \nB1 (heart) receptors\nClonidine (Catapress)\nStimulate alpha receptors \nin brain\nAcebutolol\nMethyldopa \n(Aldomet)\nResults in decrease \nvasoconstriction, heart \nrate, systemic vascular \nresistance which then \nlowers BP\nAtenolol\nWorks specifically on Beta \nreceptors in heart\nEsmolol\nBP decreases because of \nlower Heart Rate and \nDecrease in cardiac \ncontractility and force of \nblood flow\nMetoprolol Succinate\nCardiovil (Coreg)\nNebivolol (Bystolic)\nCoreg and Bystolyic are 3rd \ngeneration beta blockers\nMuch more specific for work-\ning only on beta receptors \nin heart"
  },
  {
    "page": 24,
    "content": "Thiazides Diuretics\nMechanism of Action\nHydrochlorothiazide\nChlorthalidone\nMetolazone\nDecrease BP by Decrease Blood Volume\nCan cause hypokalemia and hypomagnesemia\nDecrease reabsorption of Sodium in Distal Kidney\nLoop diuretics\nMechanism of Action\nBumetanide (Bumex)\nFurosemide (Lasix)\nTorsemide(Demadex)\nInhibits absorbtion of Sodium in Loop of Henle\nCan cause hypokalemia and hypomagnesemia\nIncrease Prostaglandin synthesis (NSAIDS can interfere and decrease effectiveness of loop diuretics)\nAce Inhibitors\nMechanism of Action\nCaptopril\nEnalapril\nQuinapril\nLisinopril\nRamipril\nDecrease BP by decreasing peripheral vascular resistance,\nBlocks Angiotension Converting enzyme in kidney,\nResults in decrease level of angiotensin which decreases levels of aldosterone,\nLower levels of aldosterone result in less sodium and water retention which lowers BP,\nCan cause dry cough or angioedema\nAngiotensin II Receptor Antagonist (ARB)\nMechanism of Action\nCandesartan (Atacand)\nLosartan (Cozaar)\nOlmesartan (Benicar)\nTelmisartan (Micardis)\nValsartan (Diovan)\nBlocks the binding of of angiotension II on muscle receptors surrounding blood vessels\nResults in lowers BP by vasodilation and inhibition of aldosterone production\nIn renal insufficiency can cause worsening renal function and hyperkalemia\nIn renal insufficiency can cause worsening renal function and hyperkalemia\nCan cause cough or angioedema\nDecrease Aldosteron decreases sodium absorption and water reabsorption\nCalcium Channel Blockers \nNondihydropyridines\nMechanism of Action\nDiltiazem (Cardiazem)\nVerapamil (Calan)\nActs to vasodilate peripheral vascular system through smooth muscle relaxation\nDecreases heart rate and stroke volume of heart\nCan cause blockade of AV node in heart resulting in symptomatic bradycardia\nCalcium Channel Blockers Dihydropyridines\nMechanism of Action\nAmlodipine (Norvasc)\nFelodipine (Plendil)\nNifidipine (Procardia)\nBlock movement of calcium in smooth muscle heart and peripheral smooth muscle\nLowers BP through smooth muscle relaxation and vasodilation\nCan make heart failure worse and cause leg and peripheral edema\nBeta blocker Non-Selective\nBlock beta receptor at both B1 (heart) and B2 \n(lungs) receptors\nMechanism of Action\nCardiovil (Coreg)\nLabetalol (Normodyne)\nNadolol (Corgard)\nPindolol (Visken)\nPropranolol (Inderol)\nSotolol (Betapace)\nTimolol (Blocardren)\nDecrease Cardiac output which decreases cardiac O2  consumption by blockade of B1 receptors \nand lowers BP\nCauses Peripheral Vasoconstriction\nBlocks effects of epinephrine (adrenaline)\nDecrease Heart Rate and can cause sexual dysfunction\nCan cause disturbances in glucose metabolism\nCan Cause Bronchorestriction as these agents block Beta 2 receptors in lungs\nCardio selective Beta blockers block only B1 \n(heart) receptors\nMechanism of Action\nAcebutolol (Sectral)\nAtenolol (Tenormin)\nBisoprolol (Zebeta)\nEsmolol (Brevibloc)\nMetoprolol Succinate (Toprol)\nNebivolol (Bystolic)\nWorks specifically on Beta 1 receptors in heart\nBP decreases because of lower Heart Rate and Decrease in cardiac contractility and force of blood flow\nReduce systolic pressure and heart rate\nDecrease contractility of heart which decrease cardiac output and reduces oxygen demand by the \nheart\nCan cause some sexual dysfunction and less likely to cause bronchocontriction\nVasodilators\nMechanism of Action\nHydralazine (Apresoline)\nMinoxidil\nProduce Relaxation of Vascular Smooth Muscle\nCauses decrease in peripheral vascular resistance lowering BP\nCan cause reflex stiumation of heart increasing heart rate, cardiac contractility and O2  consumption\nMinoxidil reserved for severe hypertension\nCentral alpha-Agonist in brain\nMechanism of Action\nClonidine (Catapress)\nMethyldopa (Aldomet)\nStimulate alpha receptors in brain\nResults in decrease vasoconstriction, heart rate, systemic vascular resistance which then lowers BP\n  \u0007Common Antihypertensive Medications\nTABLE \n10.7b"
  },
  {
    "page": 25,
    "content": "233\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\n  \u0007Blood Pressure Treatment Guidelines\nCategory\nSystolic (mm Hg)\nDiastolic (mm Hg)\nTREATMENT\nPreoperative\nIntraoperative\nIdeal\n<120\n<80\nNone\nNone\nPrehypertension\n120–139\n80–89\nRecheck, possible medical consultation\nRecheck, stress reduction protocol\nGrade 1 hypertension\n140–159\n90–99\nRecheck, possible medical consultation, \n(relative)\nMonitor, stress reduction protocol\nGrade 2 hypertension\n160–179\n100–109\nRecheck, medical consultation, (absolute)\nMonitor, discontinue procedure, pos-\nsible emergency room referral\nHypertensive crisis\n>180\n>110\nRecheck, emergency care, (absolute)\nMonitor, abort immediately, emer-\ngency care\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \nTABLE \n10.8\nor nitroglycerin. This indicates more advanced coronary disease \nthat requires immediate attention. Prinzmetal angina is caused by \ncoronary artery spasm. Stress and drug use, especially cocaine, are \nthe main causes of this type of angina.\nTreatment of angina involves many different medications. \nBeta-blockers are used to reduce the workload of the heart. Nitro-\nglycerin works to dilate coronary blood vessels, which decrease \nmyocardial oxygen consumption and also reduce the workload \nof the heart. Aspirin and other antiplatelet agents are critical to \nprevent thrombus formation. Progressive angina requires cardiac \ncatheterization. If there is significant narrowing, an angioplasty \nand stent may be used to relieve the blockage and improve symp-\ntoms. If the blockage is more severe or not amenable to angio-\nplasty, then bypass surgery may be indicated.\nRisk factors for angina pectoris are smoking, hypertension, \nhigh cholesterol, obesity, and diabetes. Patients with a history of \nangina may be taking long-acting nitrates to prevent the occur-\nrence of acute episodes. Sublingual or spray nitroglycerin is rec-\nommended for the treatment of acute episodes. It is important \nto ask any patient with angina about their most recent symptoms \nincluding frequency, exacerbating factors, worsening symptoms, \nhow long the chest pain lasts, and what relieves the chest pain. \nPatients with increased symptoms or more frequent or longer-\nlasting attacks should be referred to the physician for evaluation. \nPatients with pain at rest should be immediately referred to their \nphysician.\nDental Implant Management. The major concern for the \nimplant clinician is the precipitation or management of the actual \nangina attack. Precipitating factors are exertion, cold, heat, large \nmeals, humidity, psychological stress, and dental-related stress. All \nof these factors cause catecholamine release, which in turn increases \nthe heart rate, blood pressure, and myocardial oxygen demand.31\nThe dental emergency kit should include nitroglycerin tablets \n(0.3–0.4 mg) or sublingual nitroglycerin spray, which are replaced \nevery 6 months because of their short shelf-life. During an angina \nattack, all dental treatment should be stopped immediately. Nitro-\nglycerin is then administered sublingually, and 100% oxygen is given \nat 6 L/min, with the patient in a semisupine or 45-degree position.\nVital signs should be monitored after nitroglycerin is admin-\nistered because transient hypotension may occur. If the systolic \nblood pressure falls below 100 mm Hg, then the patient’s feet \nshould be elevated. If the pain is not relieved in 8 to 10 minutes \nwith the use of nitroglycerin at 5-minute intervals, emergency \nmedical assistance should be initiated.\nPatients with mild angina (up to one attack per month) may \nundergo most nonsurgical dental procedures performed with the \nnormal protocol (type 1). General cardiac precautions are advised, \nsuch as vital signs monitoring, and patients are instructed to bring \ntheir own nitroglycerin. Advanced restorative procedures and \nminor implant surgery (type 2) are performed with nitrous oxide \nor oral sedation. For more advanced implant procedures (types 3 \nand 4), appropriate sedation techniques should be used. Appoint-\nments should be as short as possible. This may require more than \none surgical or restorative appointment. Use of vasoconstrictors \nshould be limited to a maximum of 0.04 to 0.05 mg epinephrine, \nand concentrations greater than 1/100,000 should be avoided.\nPatients with moderate angina (up to one attack per week) \ntolerate examination and most simple operative procedures (type \n1). Prophylactic nitroglycerin (0.3–0.4 mg) or long-acting nitrates \nare given sublingually just before advanced operative or simple to \nmoderate implant surgery (types 2 and 3). Antianxiety sedation \nwith supplemental oxygen is required. Advanced surgical proce-\ndures may require a hospital setting (type 4).\nPatients with unstable angina (daily episodes) are limited to \nexamination procedures performed under normal protocol. Medi-\ncal consultation is recommended for any additional treatment. \nThis form of angina has been represented as an absolute contrain-\ndication for elective dental surgery (ASA IV).\nThe side effects of nitroglycerin are important to recognize \nbecause prophylactic administration is in order for the patient \nwith moderate to severe angina because there is a decrease in \nblood pressure, which causes a decrease of the blood flow to \nthe brain. Fainting is often a possibility; therefore the patient \nshould be sitting or lying down during nitroglycerin administra-\ntion. The heart attempts to compensate for the decreased blood \npressure, and the pulse rate may increase to as much as 160 \nbeats/min. Flushing of the face and shoulders is common after \nadministration of nitroglycerin. If the patient has been taking \nlong-acting nitrates, tolerance to the drug may occur; therefore \ntwo tablets may be needed at a time. A headache may occur \nafter administration, which may be treated with OTC analgesics \n(Table 10.9)."
  },
  {
    "page": 26,
    "content": "234\nPART III     Fundamental Science\nMyocardial Infarction\nAn MI is a prolonged ischemia or lack of oxygen resulting from a \ndeficiency in the coronary arterial blood supply that causes injury \nto the myocardium or heart muscle. The end result is cellular \ndeath and necrosis of the heart muscle.\nAbout every 40 seconds someone in the United States has a \nheart attack. Just under 800,000 individuals suffer a heart attack \neach year in the United States, and three of every four heart \nattacks are an initial event.32 One in five heart attacks are silent \nand there is heart muscle loss, but the individual is unaware of \nthe event.\nAn acute MI may be precipitated when the patient undergoes \nunusual stress, either physical (painful stimuli) or emotional (anxi-\nety). The patient usually has severe chest pain in the substernal or \nleft precordial area during an MI episode. The pain may radiate to \nthe left arm or mandible, and is similar to angina pectoris but more \nsevere. Cyanosis, diaphoresis, weakness, nausea or vomiting, and \nirregular and increased pulse rate are all signs and symptoms of MI.\nThe complications of MI include arrhythmias and Congestive \nHeart Failure (CHF), and if a complete occlusion or malignant \narrhythmia occurs, then sudden death results. The larger the isch-\nemic area, the greater the risk of heart failure or life-threatening \narrhythmias. Any history of MI indicates significant problems \nin the coronary vessels. Recent infarctions correspond to higher \nmorbidity and death rates with even simple elective surgery.\nThe risk of MI is less than 1% in the general population in \na perioperative setting. Approximately 18% to 20% of patients \nwith a recent history of MI will have an increase of complications, \nwhich have a high mortality rate of 40% to 70%. If general anes-\nthesia and surgery are performed within 3 months of MI, the risk \nof another MI is 30%, and if performed within 3 to 6 months, the \nrisk is 15%. After 12 months, the incidence of recurrent MI sta-\nbilizes at about 5%.33 Acute coronary syndrome consists of three \ndifferent types of coronary blockages that can result in sudden \nrupture of plaque inside one of the coronary arteries. When the \nplaque ruptures, it causes exposure of the soft fatty tissue, which \nthen causes platelets to migrate to the area of rupture and form \na clot around the plaque to cover the fatty tissue. When the clot \nblocks the entire blood supply to the heart muscles, there is coro-\nnary occlusion. This can result in one of three scenarios that result \nin ischemia: unstable angina (as previously described), non-ST \nsegment elevation MI (NSTEMI), or ST elevation MI (STEMI).\nThere are several variables that determine the type of acute \ncoronary syndrome: length of time blood flow is blocked, and \nlocation of the blockage. Unstable angina is a change from sta-\nble angina when the pain starts occurring at rest as opposed to \noccurring with exertion. If the MI does not cause ST-elevation \n(classic electrocardiogram [ECG] finding of MI) on the ECG but \nthe clinical markers in blood enzymes demonstrate damage has \noccurred, then this is considered an NSTEMI. The blockage is \npartial or temporary, so the damage done to heart muscle is usu-\nally much smaller. This is still considered a heart attack or MI. \nSerial troponin and or creatine-kinase (CK)-MB blood levels are \ndrawn and repeated over several hours. Both of these markers \nindicate damage to the myocardial muscle. Troponin levels may \nbe the earliest indicator of an MI.\nIf the interruption to the blood supply is more abrupt and \nprolonged, it will affect a much larger area of the heart and dem-\nonstrate ST-segment elevation on the ECG and damage by the \nserum chemical makers.\nDental Implant Management\nMedical Consultation. A medical consultation should pre-\ncede any extensive restorative or surgical procedure. Even though \nthere are recommendations based solely on the length of time \nafter an MI, the deciding factor on elective dental implant treat-\nment is not only time but also the amount of myocardial dam-\nage. The implant clinician should follow the recommendation of \nthe physician concerning treatment options, modifications, or \ncontraindications. \nStress Reduction Protocol. Dental implant surgery after \nMI may induce arrhythmias or aggravate cardiac ischemia. An \nincreased blood pressure is common in the dental office setting, \nbecause stress associated with treatment (i.e., white coat syn-\ndrome) leads to increased levels of catecholamine, which cause an \nincrease in blood pressure and heart rate. The most important step \nin decreasing stress in the dental office is to integrate a compre-\nhensive stress reduction protocol. \nReduction in the Use of Vasoconstrictors. Epinephrine and \nother vasoconstrictors have several properties that can potentially \nresult in adverse outcomes in patients that have not fully recovered \nfrom a recent MI. Epinephrine is chronotropic, which results in \nan increased heart rate and force of contraction. Both of these \nresult in an increased oxygen demand and could potentiate isch-\nemia. Epinephrine does have some arrhythmogenic properties \nthat could provoke ventricular fibrillation or tachycardia in recov-\nering myocardial muscle. It is best to minimize complications by \nconsulting the patient’s treating physician and closely monitoring \nvital signs when vasoconstrictors are used. \nMyocardial Infarction Treatment Summary. The patient’s \nphysician should be consulted before elective dental implant \ntreatment to verify the patient’s current cardiac status (Table \n10.10).\n   \n  \u0007Dental Implant Management in Patients with Angina Pectoris\nRisk\nSymptoms\nType 1\nType 2\nType 3\nType 4\nMild\n≤1/month; ASA II\n+\n+\nSedation, supplemental oxygen\nSedation, supplemental oxygen\nModerate\n≤1/week; ASA III\n+\nSedation, premedication, \nnitrates, supplemental \noxygen\nSedation, premedication, \nnitrates, supplemental \noxygen\nPremedication, sedation, outpa-\ntient hospitalization\nSevere\nDaily/more; ASA IV; \nunstable\n+\nPhysician consultation\nElective procedures contrain-\ndicated\nElective procedures contraindi-\ncated\n+, Procedure may be performed with regular protocol; ASA, American Society of Anesthesiologists.\n   \nTABLE \n10.9"
  },
  {
    "page": 27,
    "content": "235\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nAbsolute (surgical): Recent MI (depending on doctor’s recom-\nmendation).\nRelative (surgical): History of MI (depending on doctor’s recom-\nmendation). \nCongestive Heart Failure\nCHF is a pathophysiologic state in which an abnormality in \ncardiac function is responsible for failure of the heart to pump \nblood in adequate volume to meet the needs of the metaboliz-\ning tissues.34 Over the past 10 years the number of adults living \nwith heart failure has increased significantly. The most recent data \nfrom the AHA’s “2017 Heart Disease and Stroke Statistics” update \nstates that about 6.5 million Americans were living with heart fail-\nure by the end of 2014. That number may jump to 8 million in \nthe next 10 to 12 years because more people are now surviving \nheart attacks, leaving the heart weaker and more susceptible to \nheart failure.35\nTotal direct medical costs for heart failure were over $21 bil-\nlion in 2012, and it is expected that by 2030 we could see that \ncost rise to over $53 billion. The overwhelming majority of the \ncost for health failure is in patients aged 65 years and older; these \npatients currently account for over 80% of costs related to heart \nfailure and are projected to be responsible for 88% or more of the \ntotal costs by 2030.36\nCHF usually develops over time because the muscles in the \nheart wall lose their ability to generate appropriate contractile \nforces and can continue to deteriorate with continuous expo-\nsure to volume overload. This results in high levels of pressure \nin the heart and eventual weakening of the stretched contrac-\ntile muscles in the heart. Because of the diminished output of \nthe heart, the body responds by increasing vascular resistance \n(increased blood pressure) throughout the circulatory system, \nwhich is initially beneficial to the peripheral tissues. However, \nthis leads to further reductions in cardiac output, because the \nweakened heart must pump against this increased pressure. The \nkidney acts to retain sodium and fluid, which continues to exac-\nerbate the problem.\nThere are many acceptable pharmacologic interventions includ-\ning diuretics, inotropic drugs, beta-blockers, and ACE/ARB blood \npressure medications, among others. Spironolactone has now \nbecome the diuretic of choice in treating heart failure. Digoxin \nwas one of the most common drugs used for years to treat heart \nfailure; however, recent CHF treatment algorithms have been \nupdated and digoxin has been replaced by the use of beta-blockers \nand spironolactone. Digoxin is appropriate for some patients, so \nimplant dentists should be aware of the more common side effects \nof elevated levels like nausea, vomiting, anorexia, headaches, con-\nfusion, and visual changes including halos around objects. Patients \non digoxin should be questioned about their most recent blood \nlevel and stability of blood level over the past several months.\nOne of newest and most revolutionary treatments for CHF \nis the medication Entresto. Entresto contains a combination of \nsacubitril and valsartan. Valsartan (which is classified as an ARB) \nis used as a single agent to treat hypertension. The drug works \nin the kidney to block receptors that cause constriction resulting \nin dilatation of blood vessels, which lowers the resistance against \nwhich the heart must pump. Sacubitril is a neprilysin inhibitor \nthat improves blood flow to the kidneys and helps in diuresis and \nremoval of excess volume in the bloodstream.\nSymptoms of CHF are listed in Box 10.5, and they include \nabnormal tiredness or shortness of breath (dyspnea) brought \non by slight activity or even occurring at rest (these symptoms \nare caused by excess fluid in the lungs and partly caused by the \nexcess work required of the heart); wheezing caused by fluid in \nthe lungs (pulmonary edema); peripheral edema or swelling of \nthe ankles (pedal edema) and lower legs; frequent urination at \nnight; jugular venous distension; sounds at auscultation (S3 gal-\nlop); and paroxysmal nocturnal dyspnea (the sensation of being \n  \u0007Dental Implant Management in Patients With Myocardial Infarction\nRisk\nType 1\nType 2\nType 3\nType 4\nMild (>12 months)\n+\n+\nPhysician\nPhysician hospitalization if general \nanesthesia required\nModerate (6–12 \nmonths; ASA III)\n+\nPostpone all elective pro-\ncedures\nPostpone all elective \nprocedures\nPostpone all elective procedures\nSevere (<6 months; \nASA IV)\nPhysician consultation\nPostpone all elective pro-\ncedures\nPostpone all elective \nprocedures\nPostpone all elective procedures\n+, Procedure may be performed with regular protocol; ASA, American Society of Anesthesiologists.\n   \nTABLE \n10.10\n • \u0007Paroxysmal nocturnal dyspnea or orthopnea\n • \u0007Neck vein distention\n • \u0007Rales\n • \u0007Cardiomegaly\n • \u0007Acute pulmonary edema\n • \u0007S3 gallop\n • \u0007Increased venous pressure >16 cm of water\n • \u0007Hepatojugular reflux.\nMinor Criteria:\n • \u0007Ankle edema\n • \u0007Night cough\n • \u0007Dyspnea on exertion\n • \u0007Hepatomegaly\n • \u0007Pleural effusion\n • \u0007Vital capacity reduced one third from maximum\n • \u0007Tachycardia (≥120 bpm) \nMajor or Minor Criteria:\n • \u0007Weight loss of 4.5 kg or more in 5 days in response to treatment.\n\t • BOX 10.5\t      \u0007Diagnostic Criteria for Congestive Heart \nFailure"
  },
  {
    "page": 28,
    "content": "236\nPART III     Fundamental Science\nunable to breath), which may interrupt sleep. This symptom is \ncaused by the effect of gravity on fluid that has spent the day \ndown at the feet. As the fluid flows back up, it may pool in the \nlungs, causing a feeling of suffocation. Excessive weight gain, as \nmuch as 20 to 30 pounds, with no change in diet, is also a symp-\ntom. This increase, purely from fluid retention, gives some indi-\ncation of how poorly the heart is pumping. The most common \nway to make the diagnosis is by using the Framingham criteria. \nCHF can be diagnosed in patients with two major or one major \nand two minor criteria.\nThe most common classification system for heart failure is the \nNew York Heart Association (NYHA). Class 1 is asymptomatic, \nclass II has mild symptoms with moderate exertion, class III has \nsymptoms with minimal activity, and class IV failure has symp-\ntoms at rest37 (Box 10.6).\nThere are several types of heart failure. Left-sided heart failure \ninvolves dysfunction of the left atrium and left ventricle. The left \nventricle must function correctly to pump blood to the rest of the \nbody. Left-sided heart failure can be divided into two different \nsubtypes. Systolic failure is when the left ventricle loses its ability \nto contract fully. This is referred to as heart failure with reduced \nejection fraction (HFrEF). Diastolic failure or dysfunction is when \nthe left ventricle cannot relax properly because with the increased \npressure and volume the muscle is very stiff. This limits the heart’s \nability to fill properly between beats, confining the amount of \nblood that can be pumped out with each beat. Drug treatments \nare not the same for these two types and are directed at the issue \ncausing the heart failure.\nAs blood returns to the heart from the venous system in the \nbody, it needs to be reoxygenated. It is collected on the right side \nof the heart and pumped into the lungs before returning to the left \nside of the heart. Right-sided heart failure usually occurs as a result \nof left-sided failure. As the left side increases pressure, the pres-\nsure is transferred back through lungs to right side of the heart. \nEventually the right side loses contractile power and then backs up \ninto the veins of the body. This results in venous congestion and \nswelling in the neck or jugular vein distention (JVD). This also \ncauses swelling in the legs, feet, ankles, abdomen, and even in the \nliver, causing ascites.\nIn CHF, as the left side of the heart becomes overloaded with \nfluid, this pressure will be transferred to the lungs, resulting in \nshortness of breath, dyspnea on exertion, and orthopnea (diffi-\nculty breathing when lying down). Heart failure affects the kid-\nney’s ability to dispose of sodium and water, leading to edema of \nthe extremities.\nAn echocardiogram of the heart is the preferred test to gauge \nthe actual output capacity of the heart. Patients with more \nadvanced levels of heart failure such as NYHA class III or class IV \nmay require an implantable defibrillator to prevent sudden death \nfrom heart arrhythmias. Most of these patients have heart ejection \nfractions of less than 30%.\nIn heart failure there are two proteins, B-brain natriuretic \npeptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP), which \ngo up when heart failure worsens and down when heart failure \nimproves. BNP (not to be confused with BMP blood panels) lev-\nels can be used to monitor the severity of heart failure. Levels <100 \nare usually not associated with heart failure. In conditions such as \nsepsis, cirrhosis, and hyperthyroid disorders there is increased or \nhigh cardiac output. This can increase levels of BNP and make \nthe test less reliable in gauging the degree of heart failure. Before \nany dental surgery in a patient with a history of heart failure who \nis having symptoms, it would be good to review the most recent \nBNP compared with the patient’s baseline. Elevated levels may \nindicate acute worsening of symptoms and warrant consultation \nwith the patient’s physician.\nDental Implant Management. In patients classified as NYHA \nI and II, no medical consultation is indicated unless there exist \nadditional systemic diseases. In NYHA III and IV, medical con-\nsultation is highly recommended for all implant type 3 and 4 pro-\ncedures. A comprehensive stress reduction protocol is indicated \nfor all patients with CHF. Intraoperatively and postoperatively, \npain and anxiety control is important because increased stress can \nproduce an increased myocardial workload with an increase in the \ndegree of heart failure.\nIntraoperative Complications. CHF patients are very sus-\nceptible to intraoperative cardiovascular morbidity issues. Stress \nreduction protocol and strict monitoring should be followed. \nIt is advisable to discuss the current condition of the patient \nwith their treating physician. Patients with CHF can be clas-\nsified as compensated or uncompensated. In uncompensated \nheart failure, the pulmonary circulation is expanded and con-\ngested because the heart is unable to fully compensate. The \nclassic symptoms are seen including shortness of breath, espe-\ncially with exertion; fatigue; or lying supine. When the CHF \npatient is treated for heart failure through medical management \nand the symptoms are controlled, the patient is referred to as \ncompensated. \nPatient Positioning. CHF patients should be positioned in the \nmost recumbent position in which they can breathe comfortably \nand efficiently. This is usually a semireclined or sitting upright \nposition. Usually, the more upright the patient is, the easier it is \nfor the patient to breathe. \nOxygen Supplementation. Oxygen supplementation (≈2 L/\nmin) during implant procedures is highly recommended to mini-\nmize the possibility of hypoxia. The use of nitrous oxide in these \npatients is not advised. \nStress Reduction Protocol. A stress reduction protocol should \nbe implemented prior to the procedure to prevent increased myo-\ncardial workload with a damaged heart \nSubacute Bacterial Endocarditis and Valvular Heart \nDisease\nBacterial endocarditis is an infection of the heart valves or the \nendothelial surfaces of the heart. The infection is the result of the \ngrowth of bacteria on damaged or altered cardiac surfaces. The \nmicroorganisms most often associated with endocarditis after den-\ntal treatment are alpha-hemolytic Streptococcus viridans and less \nfrequently staphylococci and anaerobes. The disorder is serious, \nwith a mortality rate of approximately 11%.38 Dental procedures \ncausing transient bacteremia has been shown to be an etiologic \nfactor of bacterial endocarditis. Patients with gingivitis and cer-\ntain cardiac conditions are at highest risk. When inflamed gums \nbleed during dental procedures, bacteria can be introduced into \n I. \u0007No symptoms and no limitation in ordinary physical activity.\n II. \u0007Mild symptoms and slight limitation during ordinary activity. Comfortable \nat rest.\n III. \u0007Marked limitation in activity caused by symptoms, even during less than \nordinary activity. Comfortable only at rest.\n IV. \u0007Severe limitations. Experiences symptoms even while at rest.\n\t• BOX 10.6\t      \u0007Classification of Congestive Heart \nFailure (New York Heart Association)"
  },
  {
    "page": 29,
    "content": "237\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nthe bloodstream and infect heart valves and the lining of the heart. \nThese bacteria continue to replicate at the infected site. Depend-\ning on the type of bacteria infecting the heart tissue, endocardi-\ntis can develop quickly or more slowly. Some symptoms include \nfever, chills, fatigue, muscle aches, night sweats, shortness of \nbreath, edema, and chest pain with inspiration. As a result, the \nimplant dentist should identify the patient at risk for endocarditis \nand implement prophylactic procedures.\nHowever, endocarditis after a dental procedure is not as com-\nmon as once believed. New guidelines suggest prophylactic antibi-\notics for patients only at the highest risk levels. Scientific evidence \nhas shown that the risk of adverse reactions to antibiotics may \nexceed any benefit for prophylactic treatment based on previous \nguidelines. This can also increase the likelihood of drug-resistant \nbacteria.39\nIn 2007, several organizations including the American Dental \nAssociation (ADA) and the AHA released updated guidelines for \nthe prevention of infective endocarditis. In 2017, these guidelines \nwere confirmed by a joint review by the AHA and ACC. These \ngroups published a new update to their 2014 guidelines on the \nmanagement of valvular heart disease.40\nThe updated recommendation states that patients who have \nroutinely taken prophylactic antibiotics in the past are no \nlonger required to do so. The more specific updated infective \nendocarditis prophylaxis recommendations for dental proce-\ndures are only for patients with underlying cardiac conditions \nthat have been linked to the highest risk for developing an \nadverse outcome. These include patients with prosthetic heart \nvalves, prosthetic material used for cardiac valve repair, a his-\ntory of endocarditis, a cardiac transplant with abnormal valves, \nand certain congenital defects of the heart including cyanotic \nheart disease with shunts and any repaired defects with residual \nshunts, or other defects that remain at the site of the prosthetic \npatch.41\nThe risk of bacterial endocarditis increases with the \namount of intraoral soft tissue trauma. There is a correlation \nbetween the incidence of endocarditis and the number of teeth \nextracted or the degree of a preexisting inflammatory disease \nof the mouth.42 An incidence of bacteremia is six times higher \nin patients with severe periodontal disease.43 However, if scal-\ning and root planing are performed before subsequent soft \ntissue surgery, the risk of endocarditis is greatly reduced. Bac-\nteremia after traumatic tooth brushing, endodontic treatment, \nand paraffin chewing has also been reported.44 Endocarditis \nmay even occur in an edentulous patient with denture sores.45 \nChlorhexidine use on isolated gingiva or irrigation of the sul-\ncus 3 to 5 minutes before tooth extraction reduces postextrac-\ntion bacteremia.\nHowever, these new guidelines suggested that preventative \ntreatment should be initiated in patients with the listed cardiac \nconditions but not for all dental procedures. The guidelines sug-\ngested prophylactic antibiotics only for dental procedures that \ninvolve manipulation of gingival tissue and bleeding. Antibiotics \nare not recommended for routine anesthesia through noninfected \ntissues or placement or adjustment of removable prosthodontic or \northodontic appliances.\nThe oral regimen in adults is 2 g amoxicillin orally, 60 \nminutes before the procedure. A second dose is not neces-\nsary because of the prolonged serum levels above the mini-\nmal inhibitory concentration of most oral streptococci46 and \nthe prolonged serum inhibitory activity induced by amoxicil-\nlin against such strains (6–14 hours).47 For patients unable to \ntake oral medications, 2 g ampicillin is administered intramus-\ncularly (IM) or IV 30 minutes before the procedure. If the \npatient is allergic to penicillin, clindamycin 600 mg or cepha-\nlexin (or cefadroxil) 2 g are administered orally l hour before \nthe procedure. For patients allergic to penicillin and not able \nto take oral medications, clindamycin 600 mg IV within 30 \nminutes of the procedure or cefazolin 1 g IM or IV 30 minutes \nbefore the procedure are the recommended regimens for oral \nprocedures.48 Erythromycin is no longer included because GI \nupset and complicated pharmacokinetics of various formula-\ntions make its use problematic.\nIn patients who are classified in the high-risk category for \ndevelopment of endocarditis, elective implant therapy may be \ncontraindicated. Edentulous patients restored with implants \nmust contend with transient bacteremia from chewing, brushing, \nor peri-implant disease. Endosteal implants, with an adequate \nwidth of attached gingiva, are the implants of choice for patients \nin this group who need implant-supported prostheses. Implants \nmay be contraindicated for patients with a limited oral hygiene \npotential and for those with a history of multiple endocarditis \nevents.\nImplant surgery in patients with aortic stenosis is usually \ncontraindicated until after aortic valve replacement. It has been \nrecommended that patients with valve replacements postpone \nany elective implant surgery until 15 to 18 months after surgical \ncompletion because these patients are at high risk for bacterial \nendocarditis and because of the use of high doses of anticoagu-\nlants.49 Special precautions should always be adhered to in valve \nreplacement patients because their therapeutic bleeding times are \nusually high (INR 2.5–3.5).\nDental Implant Management. The implant clinician must be \nfamiliar with the antibiotic regimens for heart conditions requir-\ning prophylaxis. A similar regimen is suggested for any person \nrequiring antibiotic coverage. There may be future updates, but \ncurrently the 2017 AHA and ACC guidelines for endocarditis \nprophylaxis should be used (Box 10.7).50 \nThe American Dental Association, American Medical Association, and the \nAmerican Heart Association have recommended antibiotic coverage in patients \nwith the following conditions receiving elective surgery:\n • \u0007Artificial heart valves\n • \u0007Past history of infectious endocarditis\n • \u0007Cardiac transplant that develops a heart valve problem\n • \u0007Congenital heart disease with shunts or conduitsa repaired\n • \u0007Congenital heart defect with residual defect\n \n• \u0007Able to take oral medication: Amoxicillin 2 g (50 mg/kg)\n \n• \u0007Unable to take oral medication: Ampicillin 2 g IM or IV (50 mg/kg IM \nor IV); cefazolin or ceftriaxone 1 g IM or IV (50 mg/kg IM or IV)\n \n• \u0007Allergic to penicillin or ampicillin: Cephalexin 2 g (50 mg/kg); \nclindamycin 600 mg (20 mg/kg); azithromycin or clarithromycin 500 \nmg (15 mg/kg)\n \n• \u0007Allergic to penicillin or ampicillin and unable to take oral medication: \nCefazolin or ceftriaxone 1 g IM or IV (50 mg/kg IM or IV); clindamycin \n600 mg IM or IV (20 mg/kg IM or IV)\na\u0007Functional murmurs and organic heart murmurs do not require prophylactic antibiotic.\nIM, intramuscular; IV, intravenous.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; \n2018.\n\t • BOX 10.7\t       \u0007Endocarditis Prophylaxis \nRecommendation"
  },
  {
    "page": 30,
    "content": "238\nPART III     Fundamental Science\nCerebrovascular Accident\nA stroke is a CVA characterized by a sudden interruption of \nblood flow to the brain, causing oxygen deprivation. It is most \nfrequently seen in patients with current cardiovascular diseases \nand is the fourth leading cause of death in the United States \nand a major cause of adult disability. The majority of strokes \nare ischemic, resulting from narrowing or blocking of the \nblood supply to the brain. The etiology of ischemic strokes is \nembolic and thrombotic. Thrombotic strokes are the result of \nclots that form inside one of the brain’s arteries. The clot blocks \nblood flow to the brain, causing cell death. Usually, these clots \nresult from plaque or other fatty deposits from atherosclero-\nsis, which break off and become lodged in the blood vessel. \nEmbolic strokes are the results of clots that form in other parts \nof the body and travel to the brain via the bloodstream. The \nclot eventually will lodge in a blood vessel and block flow of \nblood to the brain.\nIt is important to ask patients if they have ever been diagnosed \nor treated for “ministrokes” or transient ischemic attacks (TIAs). \nThese attacks are the result of brief (usually less than 24 hours) \ninterruptions in blood flow causing strokelike symptoms. These \nepisodes can be a precursor for a much larger stroke. Unlike a \nCVA, the blockage is temporary and the clot may dissolve or get \ndislodged in a very brief time causing the temporary symptoms. \nTIAs usually cause symptoms for less than 10 minutes and should \ncompletely resolve within 24 hours. Unlike a CVA, there is no \npermanent injury to the brain.\nDental Implant Implications\nBleeding. Although it is important to control blood pressure \nand treat elevated cholesterol in the management of individu-\nals with a history of strokes, caution should be taken because \nmost patients are on blood-thinning medication. Antiplatelet \nagents such as aspirin or clopidogrel may be used as single \nagents or in combination as part of a stroke prevention treat-\nment. Both of these medications irreversibly affect platelets’ \nclotting ability and have been shown to cause increased bleed-\ning. In some cases, warfarin (Coumadin) may also be used, \nwhich directly interferes with the body’s clotting mechanisms. \nEvaluation and bleeding control are essential in these types of \npatients. \nLimited Dexterity. Patients who have suffered a compromise \nin dexterity as the result of a stroke require alternative treatment \nplanning for their final prostheses. A fixed prosthesis is usually \nthe best solution for these patients, because an implant-retained \nprosthesis may lead to the inability to remove for routine hygiene. \nAdditionally, poor oral hygiene, when combined with xerostomia, \ncauses additional oral problems such as candidiasis, dental caries, \nperiodontal issues, and mucositis lesions, which increase implant \nprostheses morbidity. \nCurrent Anticoagulant Medications. The goal of anticoagula-\ntion medication is to keep the blood thinned so clotting is more \ndifficult. However, it is important to understand these medica-\ntions work by various pathways and can affect clotting at dif-\nferent points in the clotting cascade or by directly inhibiting \nplatelet function. The antiplatelet agents such as aspirin or clopi-\ndogrel have been shown to have a minimal effect on bleeding, \nboth intraoperatively and postoperatively.19 A number of studies \nhave found no increased risk of bleeding during dental proce-\ndures when patients on Coumadin have a therapeutic treatment \nrange INR (below 3.0). In patients with mechanical heart valves, \nthe upper limit of the therapeutic range can reach 3.5 to 4.0. In \npatients with artificial valves, the INR may be checked 24 hours \nbefore the implant surgery. Under no circumstances should \na patient with a mechanical valve on Coumadin be instructed \nto stop or hold a dose without input from the patient’s treating \nphysician. \nHemostatic Agents/Surgical Technique. Ideal surgical tech-\nnique should be followed, which consists of nontraumatic incision \nand reflection of tissue. The surgical procedures should be mini-\nmized with a decreased surgical duration. The implant clinician \nmust have experience with the use of active and passive hemostatic \nagents. \nTreatment Summary\nAbsolute (surgical): Recent CVA incident (medical consult)\nRelative (surgical): History of CVA + anticoagulants (medical \nconsult)\nAdditional Cardiovascular Disorders\nSee Table 10.11. \nEndocrine Disorders\nDiabetes Mellitus\nThe most recent Diabetes Statistics Report of 2017 from the \nCenters for Disease Control and Prevention (CDC) estimated \nthat over 30 million Americans (1 in 10) now have diabetes, \nwith another 84 million (1 in 3) with prediabetes. The majority \nof new cases of diabetes are in adults 45 to 64 years of age, and \nthere also has been an increase in diabetes in the American youth \npopulation. New cases were more prevalent in African Americans. \nAlmost 90% of adults diagnosed were overweight and 40% were \nnot physically active. The diagnosis of diabetes usually involves \nhaving an HbA1c (glycosylated Hb) of >6.4%. Glucose tolerance \ntests have been used previously and still have utility in the diag-\nnosis of gestational diabetes. Using the Hba1c in combination \nwith random fasting an post-prandial sugars has now become the \naccepted standard of care.51\n  \u0007Additional Cardiovascular Issues and \nTreatment Implications\nPositive Response\nTreatment Implications\nAbdominal aneurysm\nRupture leading to high mortality, medical \nconsultation (absolute)\nAtrial fibrillation\nThrombin inhibitors, hemostatic measures\nProsthetic heart valve\nMaintained at high INR, hemostatic  \nmeasures\nPacemaker\nCardiovascular issue, stress reduction \nprotocol, no electrosurgery\nFainting/lightheadedness\nOrthostatic hypotension\nCongenital heart defect\nCardiovascular issue, medical consult to \ndetermine extent\nAnkle edema\nCongestive heart failure, possible varicose \nveins\nINR, International normalized ratio.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Else-\nvier; 2018.\n   \nTABLE \n10.11"
  },
  {
    "page": 31,
    "content": "239\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nThe most current classification of diabetes includes three \ngeneral clinical categories: type 1 diabetes, type 2 diabetes, \nand gestational diabetes (pregnancy). In type 1 diabetes, insu-\nlin is not produced from the pancreas. This type of diabetes \ndevelops most frequently in children or before age 21. How-\never, there is now a form of type 1 diabetes that develops a bit \nlater in life in which the pancreas does not produce insulin. \nThe incidence of type 2 diabetes in the older population is \nincreasing. This type is much more common and accounts for \napproximately 95% of the diabetic cases and almost always \noccurs in adults. Initially the defect is coming from the body’s \ninability to respond properly to the action of insulin, which is \nproduced from the pancreas. The incidence of type 2 diabe-\ntes is estimated to double by the year 2025 because of aging, \nunhealthy diets, and obesity.52 An increased body mass index \n(BMI) and advanced age can be predictors of undiagnosed \ndiabetes. In patients for whom the clinician has a higher sus-\npicion of diabetes, questions concerning frequent urination \n(polyuria) or excessively thirst (polydipsia) may be appropri-\nate (Box 10.8). \nDiabetes and Dental Implant Healing\nStudies have shown that hyperglycemia has a negative effect on \nbone metabolism, reducing bone mineral density, affecting bone \nmechanical properties, and impairing bone formation, leading \nto poor bone microarchitecture.53 There is a direct correlation \nbetween implant osseointegration and glycemic control.54 Osseo-\nintegration is more predictable in anatomic areas with abundant \ncortical bone, which is why the mandible has shown a greater \nbone formation than the maxilla.55\nImplant Failure\nHuman clinical studies have indicated that no contraindications \nexist for patients who are well controlled by diet and oral hypo-\nglycemic. However, for insulin-controlled patients, a contraindi-\ncation for implants may exist depending on the state of control. \nResearchers have concluded that implants have a high success rate \nprovided the diabetes is controlled (monitor to ensure that gly-\ncosylated Hb [HbA1c] < 7.0). An increased failure rate of dental \nimplants has been associated with poor metabolic control.56 It is \nimperative that uncontrolled diabetics or patients exhibiting an \nelevated HbA1c are treated before and during the implant surgery \nhealing period.\nDental Implant Management\nHypoglycemia. The most serious intraoperative complication \nfor diabetic patients is hypoglycemia, which usually occurs as a \nresult of an excessive insulin level, hypoglycemic drugs, or inad-\nequate food intake. Weakness, nervousness, tremor, palpitations, \nor sweating are all signs of acute hypoglycemia. Mild symptoms \ncan be treated with sugar in the form of orange juice or candy. \nIf the symptoms are not addressed, then they may evolve from \nminor warning signs to seizure, coma, and, in rare cases, death. \nIn these severe cases, patients may become unconscious or barely \narousable. For these symptoms, the emergency administration \nof 50% IV dextrose should be completed. Additionally, gluca-\ngon should be available because this hormone may raise blood \nsugar through a direct effect on the liver. Glucagon may also \nbe administered IM in a dose of 1 mg for adults over 20 kg. \nPatients taking sulfonylurea medications for diabetes (including \nglyburide, glipizide, and glimepiride) who do not have adequate \ncarbohydrate intake before their procedure are at an increased \nrisk of hypoglycemia. It is important that patients on these med-\nications follow their regularly prescribed diet before the dental \nprocedure. \nHyperglycemia. The stress of surgery may provoke the release \nof counterregulatory hormones that will impair insulin regulation \nand may result in hyperglycemia and a catabolic state. The cause \nof hyperglycemia is multifactorial and may include any of several \nmedications such as corticosteroids, beta-blockers, epinephrine, \ndiuretics, and some antipsychotic drugs. Hyperglycemia is usu-\nally slower to develop and may not necessarily demonstrate any \nphysical symptoms. Patients should be instructed to monitor their \nblood sugars in the postsurgical period and contact their physi-\ncian if their readings remain elevated from their normal baseline. \nIn the acute setting, hyperglycemia can be treated with insulin \nor by increasing fluids in noncardiac patients. Emergency services \nshould be called for patients who experience erratic breathing and/\nor fluctuating levels of consciousness associated with high blood \nsugar levels. \nInfection. Diabetic patients are prone to developing infec-\ntions and vascular complications. The healing process is affected \nby the impairment of vascular function, chemotaxis, and neu-\ntrophil function, as well as an anaerobic milieu. Protein metabo-\nlism is decreased, and healing of soft and hard tissue is delayed, \nwhich may lead to the susceptibility to infection. Neuropa-\nthy and impaired nerve regeneration may be altered as well as \nangiogenesis.57 \nDetermine Glycemic Control. The glycemic control should \nbe evaluated via an HbA1c test (HbA1c, glycated Hb, A1c, or \nHbA1c) in conjunction with a consultation with the patient’s \nphysician. Ideally, the A1c should be maintained at less than \n7% when appropriate. The HbA1c test is ideal for evaluation \nof glycemic control because it will show the glycemic control \nBiguanides: These drugs decrease glucose release from liver and act to \nblock intestinal absorption of glucose. They are in the peripheral system \nto improve insulin sensitivity by increasing glucose uptake. They are \nconsidered euglycemic and should not cause hypoglycemia. Example: \nMetformin (Glucophage). Many newer medications combine metformin \nwith one of the following categories of medications:\n \n• \u0007Sulfonylureas (SFUs). These drugs increase insulin secretion from \nthe pancreas and can cause hypoglycemia. Skipping meals will \nsignificantly increase the risk of hypoglycemia. Examples: Amaryl \n(glimepiride), Glucotrol (glipizide), Micronase (glyburide), Prandin \n(repaglinide), and Starlix (nateglinide)\n \n• \u0007Thiazolidinediones (glitazones or TZDs): These drugs work to \ndecrease insulin resistance in the muscle and fat tissues creating \nincreased utilization of blood glucose. Examples: Actos (pioglitazone), \nAvandia (rosiglitazone)\nGLP-1 Analogs: These drugs work on several systems to increase insulin \nsecretion and inhibit the release of glucose from the liver after eating. \nThey also can delay emptying of food from the stomach, creating a \nfeeling of satiety. They have been shown to also promote weight loss. \nThese medications require injections and are not oral. Examples: Byetta \n(exenatide), Victoza (liraglutide), and Trulicity (dulaglutide).\nDPP-4 Inhibitors: These drugs also increase insulin secretion and \nlimit glucose release from the liver after eating. Examples: Januvia \n(sitagliptin), Onglyza (saxagliptin), and Trajenta (linagliptin).\nSGLT2 inhibitors: These drugs work specifically in the kidney in patients \nwith normal renal function to increase glucose excretion in the urine. \nPatients on these medications will usually show levels of glucose on a \nurinalysis. Examples: Invokana (canagliflozin), Farxiga (dapagliflozin), \nand Jardiance (empagliflozin).\n\t • BOX 10.8\t   \u0007Medication Management of Diabetes"
  },
  {
    "page": 32,
    "content": "240\nPART III     Fundamental Science\nover the past 3 months. The HbA1c measures the glucose \nbound to Hb within the RBCs. The test is a weighted average \nof blood glucose levels during the life of the RBCs (120 days). \nThis test is more accurate in the assessment of diabetic control \ncompared with a fasting blood glucose, which can give a false-\npositive or false-negative result. It is important to note that \ntarget levels for diabetic patients are now individualized rather \nthan generalized. Many times diabetics can be maintained at \nHbA1c levels greater than 7.0% but less than 8%. The new \nMedicare quality guidelines consider diabetics less than 9.0% \nas controlled and greater than 9.0% as uncontrolled. However, \nit is important to understand studies show that the healing \nprocess is much better and complication rate lower in patients \nwith an HbA1c < 7.0%. Because this is an elective procedure, \nproceeding with surgery in patients with an HbA1c > 7% \nand ≤8% should be individualized and discussed with their \nphysician and the patient with full disclosure of the increased \nrisks of infection, implant failure, and other complications. \nPatients with HbA1c > 8% should probably not undergo elec-\ntive implant surgery because of the higher risk of infection and \ncomplications (Table 10.12). \nMedication Prophylaxis. Because of the reciprocal relation-\nship between infection and glycemic control, the use of antibiotic \nprophylaxis is highly recommended. Ideally, a β-lactam antibiotic \nshould be used preoperatively and postoperatively. When antibi-\notic prophylaxis is administered to diabetic patients, studies have \nshown a 10.5% reduction in failure rate. Further reduction is \nachieved by maintaining a strict aseptic technique in combination \nwith good surgical technique. Additionally, it has been reported \nthat the use of a chlorohexidine gluconate (0.12%) rinse at the \ntime of implant placement reduced the failure rate from 13.5% \nto a remarkable 4.4% in type 2 diabetic patients.58 A preoperative \nand postoperative chlorohexidine regimen will decrease morbidity \nwith implants in diabetics. These patients must practice meticu-\nlous oral hygiene and be recalled at regular intervals to minimize \nthe possibility of peri-implantitis. \nSteroids. Oral steroids like dexamethasone, prednisone, and \nmethylprednisolone will increase blood sugar and should be \nused with extreme caution in diabetics. A physician consult is \nrecommended for patients under treatment for oral hypoglycemic \nor insulin-related medications. \nTreatment Summary (Diabetes)\nDiet-controlled diabetic: Determine/maintain diabetic control.\nHypoglycemic-controlled diabetic: Determine/maintain dia-\nbetic, stress reduction protocol; HbA1c < 7%; and individu-\nalized treatment recommendations of HbA1c > 7.0% and \n≤ 8.0%.\nInsulin-controlled diabetic: Determine diabetic control, stress \nreduction protocol; HbA1c < 7%; individualized treatment \nrecommendations of HbA1c > 7.0% and ≤ 8.0%.\nThyroid Disorders\nThyroid disorders are the second most common endocrine prob-\nlem, affecting approximately 1% of the general population, prin-\ncipally women. Synthroid (levothyroxine), is one of the most \ncommonly prescribed drugs in the United States.59,60 Because the \nmajority of patients in implant dentistry are women, a slightly \nhigher prevalence of this disorder is seen in the dental implant \npractice.\nThe thyroid gland is one of the larger endocrine glands in the \nbody and is situated at the level of C5 and T1 vertebral bodies, just \nbelow the laryngeal prominence. The main function of the thyroid \ngland is to produce hormones, and the most common are thyrox-\nine (T4) and triiodothyronine (T3). Thyroxine is responsible for \nthe regulation of carbohydrate, protein, and lipid metabolism. In \naddition, the hormone potentiates the action of other hormones \nsuch as catecholamines and growth hormones.\nAbnormalities in the anterior pituitary gland or the thyroid can \nresult in disorders of thyroxine production. Excessive production \nof thyroxine results in hyperthyroidism. Symptoms of this disor-\nder include increased pulse rate, nervousness, intolerance to heat, \nexcessive sweating, weakness of muscles, diarrhea, increased appe-\ntite, increased metabolism, and weight loss. Excessive thyroxine \nmay also cause atrial fibrillation, angina, and CHF. Palpation of \nthe patient’s neck often reveals an enlarged thyroid gland (goiter) \nbetween the cricoid cartilage and the suprasternal notch.\n  \u0007Hemoglobin–Blood Glucose Treatment Regimen\nRisk\nHemoglobin \n(A1c)\nBlood Sugar Level \n(mg/dL)\nTreatment Plan\nLow\n<6.0\n<140\nStress reduction protocol, maintain glycemic control\nLow/\nmedium\n6.0–7.0\n140–180\nStress reduction protocol, maintain glycemic control\nPatients with neuropathy, nephropathy, peripheral vascular disease, history of  \ncoronary disease, or ophthalmologic manifestation of diabetes (retinopathy) may  \nbe at higher risk despite controlled HbA1c.\nMedical consultation may be appropriate (relative contraindication)\nMedium \nhigh\n7.0–8.0\n180–215\nPatients without any secondary manifestations of diabetes such as neuropathy,  \nnephropathy, peripheral vascular disease, or ophthalmologic (retinopathy),  \nmedical consult may be obtained (relative)\nPatients with coronary disease or other diabetic related conditions require medical  \nconsult (relative/absolute)\nHigh risk\n>8.0\n>215\nMedical referral and better glycemic control (absolute contraindication)\nHbA1c, Glycosylated hemoglobin.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \nTABLE \n10.12"
  },
  {
    "page": 33,
    "content": "241\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nThe most common form of hypothyroidism is Hashimoto’s \nthyroiditis, which is an autoimmune disease where by the immune \nsystem produces antibodies that attack the thyroid gland and cre-\nate chronic inflammation, which in turn leads to insufficient levels \nof circulating thyroxine. The related symptoms are a result of a \ndecrease in metabolic rate. The patient complains of cold intoler-\nance, constipation, dry skin, fatigue, and weight gain. In severe \ncases the patient can develop hoarseness or enter what is termed a \nmyxedema coma. This is a medical emergency with compromised \nmental activity and hypothermia.\nThyroid function tests are used to confirm the diagnosis of \nhypothyroidism. The best screening test for thyroid function \nis to measure the thyroid-stimulating hormone (TSH) level. \nAn increased level indicates underactivity of the thyroid gland, \nwhereas decreased or very low levels indicate over activity of \nthe thyroid. An overactive thyroid gland can cause palpitations, \nweight loss, tremor, nervousness, and diarrhea. If the TSH level is \nabnormal, then a free T3 and free T4 can help determine further \nfunctioning of the thyroid. T4 and T3 both circulate in the blood, \nand T4 is converted in the more active form of thyroid hormone \nT3 in multiple tissues in the body. High levels of T3 and/or T4 \nindicate an overactive thyroid gland, and low levels indicate an \nhypofunctioning thyroid gland.\nMost people with hypothyroidism are treated with synthetic \nthyroid replacement medications such as levothyroxine (Syn-\nthroid), and the TSH is the best way to monitor this therapy. \nSome individuals are treated with animal versions of thyroid hor-\nmone (Armour Thyroid). The TSH can be artificially low in treat-\nment with Armour Thyroid; therefore a measurement of free T3/\nT4 is the better way to monitor adequate levels of this treatment. \nDental Implant \t Management\nHyperthyroidism\nCatecholamine Sensitivity. Patients with hyperthyroidism \nare especially sensitive to catecholamines such as epinephrine in \nlocal anesthetics. When exposure to catecholamines is coupled \nwith stress (often related to dental procedures) and tissue dam-\nage (dental implant surgery), an exacerbation of the symptoms of \nhyperthyroidism may occur. This can result in a condition termed \nthyrotoxicosis or thyroid storm, which is an acute, life-threatening \nhypermetabolic state clinically presenting with symptoms of fever, \ntachycardia, hypertension, and neurologic and GI abnormalities. \nTreatment of thyroid storm in the dental setting includes immedi-\nate medical attention. If left untreated, these symptoms may result \nin CHF and life-threatening cardiac arrhythmias. \nBleeding. The increased blood pressure and heart rate that \naccompany hyperthyroidism may increase bleeding at the surgical \nsite and require additional hemostatic techniques. It is also impor-\ntant to note that propylthiouracil (PTU) is used to treat hyper-\nthyroidism. This drug is an antagonist of vitamin K, which has an \nadverse effect on the clotting cascade and may result in significant \nbleeding or postoperative hemorrhage. \nAspirin/Nonsteroidal Antiinflammatory Drug Use. Use of \naspirin or NSAIDs requires extreme caution in the hyperthyroid \npatient. Aspirin can increase free levels of the T4 hormone because \nof an interaction with protein binding. Additionally, many hyper-\nthyroid patients are on beta-blockers for heart rate and blood pres-\nsure control, and the use of NSAIDs can decrease the efficacy of \nbeta-blockers. Alternative pain medications should be considered \nin patients with hyperthyroidism (e.g., Ultram). \nHypothyroidism\nCentral Nervous System Depressants Use. The hypothyroid \npatient is particularly sensitive to central nervous system (CNS)–\ndepressant drugs, especially narcotics and sedative drugs, such as \ndiazepam or barbiturates. The risk of respiratory depression, car-\ndiovascular depression, or collapse must be considered. Patients \nwith long-standing hypothyroidism may have prolonged bleeding \nrequiring hemostatic control for excessive bleeding. Additionally, \nhypothyroid patients may exhibit delayed wound healing and pre-\ndisposition to postoperative infection. \nBone Healing. T4 affects bone metabolism by decreasing \nrecruitment and maturation of bone cells and reducing the bone \ngrowth factor of insulin-like growth factor. Studies have shown \nthat medically treated hypothyroid patients exhibit greater bone \nloss and a less favorable soft tissue response after stage I surgery \nbut with no significant increased risk of failure59 (Table 10.13). \nAdrenal Gland Disorders\nThe adrenal glands are endocrine organs located just above the \nkidneys. Epinephrine and norepinephrine are produced by chro-\nmaffin cells in the adrenal medulla, which forms the central por-\ntion of the gland. These hormones are largely responsible for the \ncontrol of blood pressure, myocardial contractility and excitabil-\nity, and general metabolism.61 The outer portion of the gland or \nadrenal cortex produces three different types of hormones. Glu-\ncocorticoids regulate carbohydrate, fat, and protein metabolism \nand also help decrease inflammation. Synthetic glucocorticoid \nmedications may be used by the implant dentist to decrease swell-\ning and pain. The mineralocorticoids maintain sodium and potas-\nsium balance. A third category of hormones is produced that are \n  \u0007Dental Implant Management in Patients With Thyroid Disorders\nRisk\nType 1\nType 2\nType 3\nType 4\nMild\nMedical examination <6 \nmonths normal Fct last 6 \nmonths\n+\n+\n+\n+\nModerate\nNo symptoms\nNo medical examination\nNo Fct test\n+\nDecrease epinephrine, ste-\nroids, CNS depressants\nPhysician consultation\nPhysician consultation\nSevere\nSymptoms\nPhysician consultation\nPostpone all elective \nprocedures\nPostpone all elective \nprocedures\nPostpone all elective \nprocedures\n+, Procedure may be performed with regular protocol; CNS, central nervous system; Fct, function.\n   \nTABLE \n10.13"
  },
  {
    "page": 34,
    "content": "242\nPART III     Fundamental Science\nmainly sex hormones (testosterone and dehydroepiandrosterone \n[DHEA]). The hypothalamus stimulated the anterior pituitary \ngland to produce adrenocorticotropic hormone (ACTH), which \nthen stimulates the adrenal glands to produce cortisol.\nCortisol is one of the most important glucocorticoids secreted \nby the adrenal cortex. Insufficient production and secretion of \ncortisol leads to primary adrenocortical insufficiency, also termed \nAddison’s disease. A patient with Addison’s disease shows symp-\ntoms of weakness, weight loss, orthostatic hypotension, nausea, \nand vomiting. The physical signs of primary insufficiency do not \nmanifest until 90% of the gland is destroyed. Signs and symptoms \ndevelop insidiously over months. When these signs are noted, \nthe implant dentist should require a medical consultation. These \npatients cannot increase their steroid production in response to \nstress and in the midst of surgery or long restorative procedures \nmay have cardiovascular collapse. During the physical examina-\ntion, the dentist can notice hyperpigmented areas on the face, \nlips, and gingiva.62 An increase in serum potassium level (hyper-\nkalemia) and decrease in serum glucose level are characteristic of \nAddison’s disease.\nWhen adrenal hypersecretion of cortisol is present, patients will \nshow signs of Cushing syndrome. The characteristic changes asso-\nciated with this disease are moon facies, truncal obesity or “buffalo \nhump,” muscle wasting, and hirsutism. Patients are hypertensive, \nand long-term excess function of the cortex decreases collagen \nproduction. These patients bruise easily, have poor wound healing, \nexperience osteoporosis, and are also at increased risk for infec-\ntion. These elements are especially noteworthy to the implant den-\ntist. Laboratory studies show an increase in blood glucose related \nto an interference with carbohydrate metabolism. The CBC often \nshows a slight decrease in eosinophil and lymphocyte counts.\nCorticosteroids are potent antiinflammatory drugs used to \ntreat a number of systemic diseases and are one of the most pre-\nscribed drugs in medicine. Steroids are used for more than 80 con-\nditions such as arthritis, collagen and vascular disorders, kidney \ndiseases, asthma, and dermatologic disorders. However, the con-\ntinued administration of exogenous steroids suppresses the natural \nfunction of the adrenal glands and causes a condition equivalent \nto Cushing disease. As a result, patients under long-term steroid \ntherapy are placed on the same protocol as patients with hypo-\nfunction of the adrenal glands.\nAldosterone is the main mineralocorticoid produced by the \nadrenal gland and it is essential for sodium conservation by the \nbody. It is regulated by the renin angiotensin system in the kidney. \nRenin is secreted in response to variations in blood pressure, vol-\nume, and sodium and potassium levels by the kidney. Aldosterone \nworks to enhance the reabsorption of sodium and water in the \nkidneys and secrete potassium, which increases blood pressure. \nARB and ACE inhibitor high blood pressure medications block \nthe production of the angiotensin–renin system in the kidneys, \nthus lowering aldosterone production and sodium retention and \nleading to the lowering of blood pressure. Overproduction of \naldosterone can lead to low levels of potassium and uncontrolled \nhypertension\nDental Implant Management. Patients with a history of adre-\nnal gland disease, whether hyperfunctioning or hypofunctioning, \nface similar problems related to dentistry and stress. The body \nis unable to produce increased levels of steroids during stressful \nsituations, and cardiovascular collapse may occur. As a result, \nadditional steroids are prescribed for the patient just before the \nstressful situation. These doses are stopped within 3 days. The \nhealthy patient will accelerate steroid production three to five \ntimes higher than regular levels to respond to the stress of surgery \nor dental procedures. Therefore for patients with known adrenal \ndisorders, the physician should be contacted for consultation. The \nnature of the disorder and the recommended treatment should be \nevaluated.\nThe patient on regular maintenance doses of steroid in excess \nof prednisone 5 mg/day is at high risk of adrenal suppression. \nAdrenocortical suppression should be suspected if a patient has \nreceived a dose of 20 mg or more of cortisone or equivalent daily \nvia the oral or parenteral route for a continuous period of 2 weeks \nor longer, within 2 years of dental treatment.63 Consultation \nwith the patient’s physician is indicated, and any modification \nof medication should only be adjusted by the patient’s physician. \nFor simple to advanced operative procedures and simple extrac-\ntions, and for periodontal or implant surgery (types 1 and 2), the \nsteroid dose should be doubled up to 60 mg of prednisone or \nequivalent (10 mg dexamethasone). The day after the procedure, \nthe maintenance dose is returned to normal. Oral or IV con-\nscious sedation is used to reduce stress. For moderate to advanced \nimplant surgery or the very anxious patient, general anesthesia \nmay be indicated. The day of the procedure, 60 mg prednisone \nis administered. This dose is reduced by 50% each day over a \n2- to 3-day period to the maintenance dose. Antibiotics are also \nadministered for 3 to 5 days.\nPatients at significant or moderate risk for adrenal suppres-\nsion are those formerly on steroid therapy of 20 mg prednisone \nor more for longer than 7 days within the preceding year. Simple \nto complex restorative procedures or simple surgery (types 1 and \n2) suggest administration of 20 to 40 mg of prednisone the day of \nthe procedure. Sedation techniques and antibiotics for 3 to 5 days \nare suggested. The next day the steroid dose is reduced by 50%, \nand by the third day the dosage is reduced by an additional 50% \nor returned to normal. For types 3 and 4, moderate to advanced \nsurgical procedures, the protocol is further modified. Prednisone \n60 mg or equivalent is administered the day of the surgery. This \ndose is reduced 50% the next day, and another 50% on the third \nday. General anesthesia may be used to reduce anxiety in the \napprehensive patient.\nPatients at low risk for adrenal suppression are those on alter-\nnate-day steroid therapy or those whose steroid therapy ended \n1 year or more before the implant procedure. For these, dental \nprocedures are scheduled the day steroids are taken or up to 60 \nmg of prednisone is administered. On the second day the dose is \nreduced 50%; on the third day, the patient resumes the alternate-\nday schedule. Sedation and antibiotics are also used.\nSteroids act in three different ways that affect implant sur-\ngery. They decrease inflammation and are useful in decreasing \nswelling and related pain. However, steroids also decrease protein \nsynthesis and therefore delay healing. In addition, they decrease \nleukocytes, reducing the patient’s ability to fight infection. There-\nfore whenever steroids are given to patients for surgery, it may be \nreasonable to prescribe antibiotics. After a loading dose, amoxi-\ncillin or clindamycin are given three times per day for 3 to 5 days \n(Table 10.14). \nHyperparathyroidism\nHyperparathyroidism is an excess of PTH in the bloodstream \ncaused by overactivity of one or more of the parathyroid glands \nthat maintain calcium balance. The clinical manifestations of this \ndisease vary widely depending on the severity. Mild forms may"
  },
  {
    "page": 35,
    "content": "243\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nbe asymptomatic, whereas severe hyperparathyroidism can cause \nbone, renal, and gastric disturbance. It has been noted that skeletal \ndepletion occurs as a result of stimulation by the parathyroid gland, \nwhich results in alveolar bone being affected before bones such as \nthe ribs, vertebrae, or long bones. In the oral and maxillofacial \nregions, altered trabecular bone patterns may be present that result \nin mobility of the teeth and compromised bone density. Hyper-\nparathyroidism falls into three categories: primary, secondary, and \ntertiary. Primary hyperparathyroidism involves one of the parathy-\nroid glands becoming overactive and releasing excess parathyroid \nhormone. This results in high levels of calcium being released into \nthe bloodstream from the bone, which leads to osteoporotic bones.\nSecondary hyperparathyroidism is a chronic condition in \nwhich the parathyroid glands release an excess amount of para-\nthyroid hormone because of chronically low blood calcium levels. \nSecondary hyperparathyroidism is usually caused by conditions \nsuch as CKD, vitamin D deficiency, and some GI issues that affect \ncalcium absorption.\nTertiary hyperparathyroidism can occur when the condition \ncausing secondary hyperparathyroidism is treated. This is similar \nto vitamin D deficiency; however, the parathyroid glands continue \nto produce excess parathyroid hormone.\nDental Implant Management\nBone Involvement. Dental implants are contraindicated (abso-\nlute) in areas of active bony lesions; however, implant placement \nmay be initiated after treatment and healing of the affected areas. \nAltered trabecular bone pattern with the appearance of ground \nglass may also occur. In animal studies, secondary hyperparathy-\nroidism affects alveolar bone more than any other bone of the \nskeleton, and central or peripheral giant cell tumors may be pres-\nent in active lesion areas.64 \nParathyroid Control. When the PTH is elevated, a serum \ncalcium level is obtained to determine whether the hyperpara-\nthyroidism is primary or secondary, and the condition is usually \ntreated with surgery or medication. In advanced disease, there are \ncertain oral changes that can be present to suggest hyperparathy-\nroidism. These patients have an increased risk for tori, and reduc-\ntion in the radicular lamina dura is evident on dental radiographs. \nMany patients with higher levels of PTH develop loose teeth and \nwidening of the periodontal ligament space surrounding the teeth. \nAdditionally, cortical bone loss at the angle of the mandible has \nbeen noted in this disorder. \nXerostomia\nXerostomia (dry mouth) may directly or indirectly have effects \non dental implants. A decrease in salivary flow is also accompa-\nnied by a change in its composition. An increase in mucin and a \ndecrease in ptyalin result in a more viscous and ropy saliva. Plaque \nformation is increased, and the reduced antibacterial action of \nthe saliva results in a favorable environment for bacteria growth \n(Box 10.9).\nDental Implant Management\nOral Complications. Dental implants are not contraindicated \nin patients suffering from xerostomia. Case reports have been \ndocumented with successful implant placement with no increase \nin failure rate.65 However, with the lack of saliva, implant patients \nmay be susceptible to more oral lesions and the possibility of irrita-\ntion from tissue-borne implant prostheses. Additionally, patients \nare at higher risk for incision line opening. \nOral Bacterial Infections. Patients with xerostomia are at a \nhigher risk for oral infections such as periodontitis, caries, and \nfungal infections. A comprehensive oral and periodontal exami-\nnation must be completed with emphasis on a low periodontal \n  \u0007Dental Implant Management in Patients With Adrenal Disorders\nRisk\nDosage\nType 1\nType 2\nTypes 3 and 4\nMild\nEquivalent of prednisone on alternate \ndays for >1 year\n+\nSurgery on day of steroids\nSedation and antibiotics steroids:\n<60 mg prednisone on day 1\nDose x/2 on day 2 Maintenance dose \non day 3\nModerate\nEquivalent of prednisone >20 mg or \n>7 days in past year\n+\nSedation and antibiotics:\n20–40 mg day 1\nDose x2 on day 2\nDose x4 on day 3\nSedation and antibiotics:\n60 mg day 1\nDose x2 on day 2\nDose x4 on day 3\nSevere\nEquivalent of prednisone 5 mg/day\nPhysician consultation\nElective procedures contrain-\ndicated\nElective procedures contraindicated\n+, Procedure may be performed with regular protocol.\n   \nTABLE \n10.14\n • \u0007Drink water frequently: Helps moisten mucosa and loosen mucus.\n • \u0007Gum/candy: The use of sugarless gum or candy helps stimulate saliva \nflow.\n • \u0007Avoid commercial mouth rinses containing alcohol or peroxide: Further \ndesiccates the mucosa.\n • \u0007Avoid salty foods, dry foods (for example, crackers, toast, cookies, dry \nbreads, dry meats/poultry/fish, dried fruit, bananas), and foods and \nbeverages with high sugar content.\n • \u0007Avoid drinks containing alcohol or caffeine. Alcohol and caffeine \nincrease urination and desiccate the mucosa.\n • \u0007Over-the-counter saliva substitutes: Products containing xylitol (e.g., \nMouth Kote, Oasis Moisturizing Mouth Spray, or ones containing \ncarboxymethylcellulose).\n • \u0007Prescription medications, after physician consultation (Evoxac \n[cevimeline], Salagen [pilocarpine]).\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds, Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; \n2018.\n\t • BOX 10.9\t      \u0007Xerostomia Treatment Regimens"
  },
  {
    "page": 36,
    "content": "244\nPART III     Fundamental Science\npathogen bacterial count to reduce possible postoperative \ncomplications. \nIncrease Saliva Flow. Stimulation of salivary flow may be \nachieved either by physiologic or pharmacologic means. Mouth \nrinses, chewing gum, or salivary substitutes may be used. \nFinal Prosthesis. When planning treatment for patients \nwith xerostomia, a final prosthesis that is not tissue borne is \nrecommended. A fixed-detachable (FP-3) prosthesis is highly \nrecommended because of the lack of soft tissue coverage. If a \nremovable prosthesis is warranted, an RP-4 is recommended \nbecause of the lack of soft tissue coverage. Additionally, \nremovable prostheses worn in patients with xerostomia are \nassociated with a high prevalence of fungal infections. If fun-\ngal infection is diagnosed, the use of a Nystatin medication is \nwarranted. \nPregnancy\nElective dental implant surgery procedures are contraindicated \nfor the pregnant patient. Not only is the mother the responsibility \nof the dentist, but so is the fetus. The radiographs or medications \nthat may be needed for implant therapy and the increased stress \nare all reasons the elective implant surgical procedure should be \npostponed until after childbirth. However, after implant surgery \nhas occurred, the patient may become pregnant while waiting \nfor the restorative procedures, especially because modalities may \nrequire 3 months to 1 year of healing. Periodontal disease is often \nexacerbated during pregnancy. All elective dental care, with the \nexception of dental prophylaxis, should be deferred until after \nthe birth. The only exceptions to this are caries control or emer-\ngency dental procedures. In these instances, medical clearance \nshould be given for all drugs, including anesthetics, analgesics, \nand antibiotics to be administered to the patient. In most cases, \nphysicians will approve the use of lidocaine, penicillin, eryth-\nromycin, and acetaminophen (Tylenol). Aspirin, vasoconstric-\ntors (epinephrine), and drugs that cause respiratory depression \n(e.g., narcotic analgesics) are usually contraindicated. Diazepam \n(Valium), nitrous oxide, and tetracycline are almost always \ncontraindicated.\nDental Implant Management. Elective dental implant ther-\napy should be delayed until after pregnancy. A medical clearance \nshould be obtained before any invasive treatment. \nAdditional Endocrine Disorders and Treatment \nImplications\nSee Table 10.15. \nHematologic System\nErythrocytic (Red Blood Cell) Disorders\nIn a healthy patient, 4 to 6 million RBCs per millili-\nter of blood are in circulation. RBCs make up the larg-\nest portion of the formed elements in blood. There are \ntwo main categories of erythrocyte disorders: polycythe-\nmia (increased erythrocyte count) and anemia (decrease in \nHb).\nPolycythemia. Polycythemia is defined as an increased con-\ncentration of Hb in body. It is either the result of increased RBC \nproduction or can it be caused by reduction in plasma volume. \nMost cases of polycythemia are the result of other underlying \nmedical conditions or medications and referred to as secondary \npolycythemia. Hb levels >16.5 g/dL in women or 18.5 g/dL in \nmen can suggest a diagnosis of polycythemia. Any condition that \ncauses chronic hypoxemia like COPD or even sleep apnea can be \na secondary cause of polycythemia. Patients undergoing testos-\nterone replacement can also develop a secondary polycythemia. \nComplicated implant or reconstruction procedures are usu-\nally contraindicated. Very high concentrations of Hb can cause \ninfarcts in tissue such as the heart and stroke. Any patient with \nan elevated Hb having chest pain or any neurologic symptoms \nincluding headache, visuals issues or numbness, and weakness \nor tingling of extremities should be referred to their physician \nimmediately. \nDental Implant Implications\nThrombus Formation. Because of the higher viscosity of the \nblood in polycythemic patients, an increased possibility of stroke, \nMI, or pulmonary embolism may occur. \nBleeding. Excessive bleeding and clotting issues are common \nwith polycythemia patients; good surgical technique and strict \nhemostatic control measures must be followed to minimize intra-\noperative and postoperative bleeding episodes. \nTreatment Summary\nUnless cleared by a physician, polycythemia is an absolute contra-\nindication for dental implant treatment.\nAnemia\nAnemia is the most common hematologic disorder. Almost all \nblood dyscrasias may at one time or another be associated with \n  \u0007Additional Endocrine Issues and Treatment \nImplications\nPositive Response\nTreatment Implications\nFrequent urination\nDiabetes (undiagnosed)\nIncreased thirst\nDiabetes (undiagnosed)\nRecent weight loss\nAnxiety, depression, GI disease, diabetes, \nhyperthyroidism\nRecent weight gain\nHeart failure (water retention), corticoste-\nroids, Cushing syndrome, hypothyroidism\nIncreased appetite\nDiabetes, hyperthyroidism\nFatigue\nAnxiety, depression, anemia, vitamin B \ndeficiency, hyper/hypothyroidism, chronic \npulmonary/cardiovascular disease\nFrequent kidney stones\nHypercalciuria from hyperparathyroidism\nIncreased head/hand \nshoe size\nPaget disease\nNontraumatic bone \nfractures\nOsteoporosis, hyperparathyroidism, myeloma\nSlow healing infec-\ntions/sores\nUndiagnosed diabetes, Cushing syndrome, \ncoagulation factor deficiency, vitamin C \ndeficiency, adrenal insufficiency\nPigment changes in \nskin (dark spots)\nUndiagnosed diabetes, Addison disease, \nmelanoma, hemochromatosis\nGI, Gastrointestinal.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Else-\nvier; 2018.\n   \nTABLE \n10.15"
  },
  {
    "page": 37,
    "content": "245\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nanemia. Anemia is not a disease entity; rather, it is a symptom \ncomplex that results from a decreased production of erythro-\ncytes, an increased rate of their destruction, or a deficiency in \niron. It is defined as a reduction in the oxygen-carrying capacity \nof the blood and results from a decrease in the number of eryth-\nrocytes or the abnormality of Hb. Hb levels <13.5 g/dL in men \nor <12.0 g/dL in women can be indicative of anemia. Levels less \nthan 10 g/dL require immediate attention, especially in patients \nthat are symptomatic with shortness of breath, extreme fatigue, \nor dizziness.\nThere are a number of different types of anemia, and the most \ncommon type is iron-deficiency anemia and relative bone mar-\nrow failure. Iron-deficiency anemia may be caused by a decreased \nintake of iron, a decreased absorption of iron, or an increase in \nbleeding. Vitamin C increases the absorption of iron. The female \npatient may normally be anemic in menses or pregnancy. Mild \nanemia in a man, however, may indicate a serious underlying \nmedical problem. The most common causes of anemia in men are \npeptic ulcers or carcinoma of the colon. These serious complica-\ntions warrant medical evaluation of any male patient found to be \nanemic.\nOther forms of anemia include sickle cell anemia (predomi-\nnant in African Americans), pernicious anemia (low B12 or folate \nlevels), and thalassemia (chronic hereditary hemolytic anemia as \na result of defective Hb production). These types of anemia are \nchronic and many patients are well adapted to lower levels of Hb \nwithout many symptoms. Sickle cell anemia has different levels of \nseverity, which requires a thorough history and consultation with \nthe patient’s physician may be warranted.\nThe general symptoms and signs are all a consequence of either \na reduction of oxygen reaching the tissues or alterations of the \nRBC. The symptoms of mild anemia include fatigue, anxiety, \nand sleeplessness. Chronic anemia is characterized by shortness \nof breath, abdominal pain, bone pain, tingling of extremities, \nmuscular weakness, headaches, fainting, change in heart rhythm, \nand nausea. The general signs of anemia may include jaundice, \npallor, spooning or cracking of the nails, hepatomegaly and sple-\nnomegaly, and lymphadenopathy. The oral signs of anemia affect \nthe tongue; symptoms include a sore, painful, smooth tongue; loss \nof papillae; redness; loss of taste sensation; and paresthesia of the \noral tissues.\nComplications associated with implant patients with anemia \nmay affect both short-term and long-term prognoses. Bone matu-\nration and development are often impaired in the long-term ane-\nmic patient. A faint, large trabecular pattern of bone may even \nappear radiographically, which indicates a 25% to 40% loss in tra-\nbecular pattern. Therefore the initial character of the bone needed \nto support the implant can be affected significantly. The decreased \nbone density affects the initial placement and may influence the \ninitial amount of mature lamellar bone forming at the interface of \nan osteointegrated implant. The time needed for a proper inter-\nface formation is longer in poor density bone.66 However, after the \nimplant is loaded successfully, the local strain environment will \nimprove the bone density at the interface.\nAbnormal bleeding is also a common complication of anemia; \nduring extensive surgery, a decreased field vision from the hem-\norrhage may occur. Increased edema and subsequent increased \ndiscomfort postsurgically are common consequences. In addi-\ntion, the excess edema increases the risk of postoperative infec-\ntion and its consequences. Not only are anemic patients prone to \nmore immediate infection from surgery; they are also more sensi-\ntive to chronic infection throughout their lives. This may affect \nthe long-term maintenance of the proposed implant or abutment \nteeth.\nApproximately 0.15% of the African American population has \nsickle cell anemia.67 Patients with such a disorder usually show \nmarked clinical manifestations and often die before the age of 40. \nSecondary infections are a common consequence with frequent \nhistory of osteomyelitis and bone infection. Because of these com-\nplications, implants are contraindicated in patients with sickle cell \nanemia.\nThe laboratory tests that diagnose anemia or polycythemia are \nin the CBC. An accurate test for anemia is the hematocrit, fol-\nlowed by the Hb; the least accurate is the RBC count. The hema-\ntocrit indicates the percentage of a given volume of whole blood \ncomposed of erythrocytes. The normal values for men range from \n40% to 50%, and those for women from 35% to 45%. Hb com-\nposes almost 95% of the dry weight of RBCs. Abnormal Hb may \nresult from its combination with substances other than oxygen \n(e.g., carbon monoxide) or genetic diseases (e.g., sickle cell dis-\neases). Normal values for men are 13.5 to 18 g/dL, and those for \nwomen are 12 to 16 g/dL. The minimum baseline recommended \nfor surgery is 10 mg/dL, especially for elective implant surgery. \nFor the majority of anemic patients, implant procedures are not \ncontraindicated. However, preoperative and postoperative antibi-\notics should be administered, and the risk of bleeding in anemic \npatients should not be potentiated by the prescription/use of aspi-\nrin. Hygiene appointments should be scheduled more frequently \nfor these patients.\nDental Implant Implications\nBleeding. Some anemias are associated with abnormal bleed-\ning. During extensive surgery, the increased bleeding may cause \na decreased field of view for the clinician and possible postopera-\ntive issues. Most often iron-deficiency anemia and other vitamin-\ndependent anemias are associated with increased bleeding. \nEdema. Increased edema and subsequent increased discomfort \npostsurgically are common consequences. In addition, the excess \nedema increases the risk of postoperative infection and morbid-\nity. Anemic patients are prone to more immediate infection from \nsurgery, and they are also more sensitive to chronic infection \nthroughout their lives. This may affect the long-term maintenance \nof the proposed implant or abutment teeth. \nOral soft tissue issues. The oral signs of anemia affect the \ntongue. Symptoms include a sore, painful, smooth tongue; loss \nof papillae; redness; loss of taste sensation; and paresthesia of the \noral tissues. \nBone Healing. Bone maturation and development are often \nimpaired in the long-term anemic patient. A faint, large trabecu-\nlar pattern of bone may even appear radiographically, which indi-\ncates a 25% to 40% loss in trabecular pattern. Therefore the initial \nquality of the bone required to support the implant can be affected \nsignificantly. The decreased bone density affects the initial place-\nment and may influence the initial amount of mature lamellar \nbone forming at the interface of an osseointegrated implant. The \ntime needed for a proper interface formation is longer in poor \ndensity bone.68 However, after the implant is loaded successfully, \nthe local strain environment will improve the bone density at the \ninterface. \nLeukocytic Disorders\nLeukocyte disorders are an important consideration in hemato-\nlogic diseases. The WBC count normally ranges from 4500 to \n11,000/mm3 in the adult. Leukocytosis is defined as an increase \nin circulating WBCs in excess of 11,000/mm3. The most common"
  },
  {
    "page": 38,
    "content": "246\nPART III     Fundamental Science\ncause of leukocytosis is infection. Leukemia, neoplasms, acute \nhemorrhage, and diseases associated with acute inflammation or \nnecrosis (e.g., infarction, collagen diseases) are more serious causes \nof leukocytosis. Physiologic conditions such as exercise, pregnancy, \nand emotional stress can also lead to leukocytosis. Any patient \nreceiving recent or continuous oral steroids will most likely have \nan elevated WBC count.\nMost oral implant procedures are contraindicated for the \npatient with acute or chronic leukemia. Acute leukemia can be \na fatal disease, but some patients with aggressive therapy includ-\ning stem cell transplants do have more favorable outcomes. \nThese patients experience serious oral problems, either second-\nary to the disease process or as complications after chemotherapy. \nThe patient with chronic leukemia will experience anemia and \nthrombocytopenia. Although the infection is less severe than in \nacute leukemia, radiolucent lesions of the jaws, oral ulcerations, \nhyperplastic gingiva, and bleeding complications develop in these \npatients\nLeukopenia is a reduction in the number of circulating WBCs \nto less than 4500/mm3. Many times, a low WBC count can be \ncaused by a recent viral infection; however, this should be tem-\nporary and past WBC counts should have been normal. Cancer, \ncertain autoimmune diseases (lupus and rheumatoid arthritis \n[RA]), severe infections, and even some antibiotics can cause a \nlow WBC. There is a subset of patients that have a chronically low \nWBC count and are otherwise completely healthy. However, these \npatients require additional testing to confirm that the decrease is \nin WBCs is benign. These patients should be evaluated by a hema-\ntology specialist.\nIn the potential implant candidate with leukocytosis or leu-\nkopenia, many complications can compromise the success of \nthe implants and prosthesis. The most common is infection, \nnot only during the initial healing phase but also long term. \nDelayed healing is also a consequence of WBC disorders. For \nmost implant procedures, the first few months are critical for \nlong-term success. Delayed healing may increase the risk of \nsecondary infection. Treatment-planning modifications should \nshift toward a conservative approach when dealing with leu-\nkocyte disorders. Complications are more common than in \nerythrocyte disorders. If the condition is temporary, such as an \nacute infection, surgical procedures should be delayed until the \ninfection has been controlled and the patient has returned to a \nnormal condition. \nPlatelet Disorders\nA normal platelet count is between 150,000 and 450,000/μL. \nThrombocytopenia is a lower than normal platelet count \ncaused by decreased production, increased destruction, or \nsequestration of platelets in the spleen, which results in \npotential bleeding complications during surgery. A platelet \ncount should always be obtained in patients with this history, \nand a value lower than 50,000 U/L contraindicates elective \ndental surgery because of a significant risk of postoperative \nbleeding.69\nIt should also be noted that platelet counts can be reduced or \nnormal but bleeding time can be prolonged in the presence of \nplatelet dysfunction. Acquired platelet dysfunction can be the \nresult of a systemic illness like liver or connective tissue disease. \nDrugs like aspirin or clopidogrel cause an acquired platelet dys-\nfunction that can last 7 days or longer, and concurrent use in \nthe presence of lower than normal platelet counts can prolong \nbleeding. Consultation with the patient’s physician is indicated in \nthis situation.\nIdiopathic thrombocytopenic purpura is a platelet disorder \nthat may present with a number of findings including petechiae, \nblood in the urine, ecchymosis, and spontaneous prolonged bleed-\ning. Implant dentists need to recognize this condition because it \nmay create prolonged life-threatening bleeding. Oral manifesta-\ntions include spontaneous gingival bleeding. There may be scat-\ntered petechiae on the palate tongue or oral mucosa. There should \nbe consultation with the patient’s physician before any dental \nimplant surgery.\nThrombotic thrombocytopenic purpura (TTP) is a rare \nblood disorder characterized by anemia, neurologic dysfunc-\ntion, and thrombocytopenia. Neurologically patients will have \nchanges in vision, speech, and mental status as well as fatigue \nfrom the anemia and bleeding from the low platelet counts. \nTTP can be the result of certain medications, including che-\nmotherapy. Any patient with a history of TTP should not \nundergo any dental implant procedure without clearance from \ntheir physician.\nEssential thrombocythemia is a condition when the body pro-\nduces too many platelets. This condition can result in abnormal \nblood clotting, but because many times the overproduced plate-\nlets are dysfunctional, it can also cause abnormal bleeding. Plate-\nlet counts can also be elevated from inflammation and caused by \nseveral conditions including recent blood loss, infections, pan-\ncreatitis, splenectomy, and certain anemias. The platelet counts \nin these conditions usually resolve as the underlying condition \nis treated.\nIt is recommended that patients that have a history of low \nor high platelet counts be closely evaluated for elective implant \nsurgery.\nDental Implant Management. When treating patients with \nany hematologic disease, a medical consultation and clearance is \nwarranted, including those with current or past history of reduced \nor elevated platelet counts because many times there may be an \nassociated platelet dysfunction, which could lead to issues with \nperioperative and postoperative bleeding. The patient’s physician \nshould be presented with a comprehensive summary of the pro-\nposed procedure, medications to be prescribed, and the extent of \nanticipated bleeding. \nAdditional Hematologic Disorders and Treatment \nImplications\nSee Table 10.16. \nPulmonary System\nChronic Obstructive Pulmonary Disease\nCOPD refers to a group of pulmonary diseases that block airflow, \nresulting in breathing difficulties. The two most common condi-\ntions that make up COPD are chronic bronchitis and emphysema. \nChronic bronchitis is an inflammation of the bronchial tubes that \nproduces an increase in mucous production and coughing.\nThere are close to 15 million American adults that have been \ndiagnosed with COPD and about 10 million of them have \nchronic bronchitis with about 5 million with emphysema. COPD \nis now the third most common cause of death behind only cancer \nand heart disease in the United States. The annual costs to our \nhealth care system for COPD-related illness is over $30 billion \neach year.70"
  },
  {
    "page": 39,
    "content": "247\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nEmphysema occurs when the alveoli in the bronchioles of the \nlungs become damaged or destroyed, creating symptoms of dys-\npnea (shortness of breath) that may worsen with mild activity. \nPatients with COPD may have a combination of both conditions. \nThese patients usually present with fatigue, history of recurrent \nrespiratory infections, wheezing, and shortness of breath. In \nadvanced disease states, patients may become oxygen dependent \nwith tachypnea being present with some audible wheezing and \nshortness of breath even at rest. The various levels of COPD are \nclassified via the Global Initiative for Chronic Obstructive Lung \nDisease (GOLD), which classifies patients on their degree of air-\nflow limitation. The airflow limitation is measured during pul-\nmonary function tests (PFTs) and measured as forced expiratory \nvolume (FEV1).\nThese guidelines use an ABCD grading system with A being \nbetter and D being worse. Treatment involves using long-acting \nbronchodilators that are beta-agonists (LABA) or muscarinic \nantagonist (LAMA) and work directly on the lung to improve \noxygenation through dilation of the bronchioles. Inhaled cortico-\nsteroids (ICS) are not usually used as a single therapy, but many \ntimes are used in combination with bronchodilators. More com-\nmon LABA/IC combinations include Advair, Dulero, Breo, and \nSymbicort. Common LAMA drugs include Spiriva and Incrusel. \nAlbuterol is a short-acting bronchodilator and is not indicated \nfor continuous monotherapy. It is used as a “rescue” to help treat \nacute symptoms or exacerbations. Short-acting bronchodilators \ncan have a profound effect on increasing heart rate, especially if \nused just before an elective dental surgery. Any COPD patient \nusing a long- or short-acting bronchodilator is considered grade \nA. Patients using a long-acting bronchodilator LABA or LAMA, \nor both, with persistent symptoms are considered grade B. Grade \nC is the addition of a LAMA or switching to a LABA and LAMA \ncombination or adding an inhaled corticosteroid to control exacer-\nbations. Grade D patients are the more complex patients requiring \nmore specialized treatment because they do not respond to con-\nventional combinations. Although it is important to get a detailed \nhistory of a patient with COPD, there should be specific focus on \ntheir current use of medications to control symptoms because they \ncan vary seasonally and under other situations. Patients with grade \nD symptoms should always get clearance from their physician for \nelective dental surgery. However, there should be consideration \nfor physician consultation for any grade C or recent worsening of \nrespiratory symptoms in patients with COPD.\nDental Implant Management. Patients with difficulty breath-\ning only on significant exertion and who have normal laboratory \nblood gases are at minimal risk and may follow all restorative or \nsurgical procedures with normal protocols (types 1–4). Dental \nmanagement of COPD patients may require repositioning the \npatient from the normal supine position. Depending on the sever-\nity of the disease, orthopnea may result. The patient can be placed \nin the most recumbent position so that breathing is comfortable. \nSupplemental oxygen (2–3 L) should be administered throughout \nthe dental procedures.\nPatients with difficulty breathing on exertion in general are at \nmoderate risk, as are patients on chronic bronchodilator therapy or \nwho have recently used corticosteroids. These patients may follow \nexamination procedures with normal protocol (type 1). A recent \nmedical examination is recommended for all other procedures. \nType 2 procedures should be performed in a hospital setting. If \nthe patient is on bronchodilators, no epinephrine or vasoconstric-\ntors should be added to the anesthetics or gingival retraction cord. \nAdrenal suppression should be evaluated for any patient on steroid \ntherapy within the past year.\nPatients at high risk are those with previously unrecognized \nCOPD, acute exacerbation (e.g., respiratory infection), dyspnea at \nrest, or a history of carbon dioxide retention. Dental management \n  \u0007Additional Hematologic Issues and Treatment \nImplications\nPositive Response\nTreatment Implications\nSickle cell anemia\nSecondary infections are a common consequence \nwith frequent history of osteomyelitis and bone \ninfection (absolute contraindication)\nLeukemia\nExperience anemia and thrombocytopenia.\nAlthough the infection is less severe than in acute \nleukemia, radiolucent lesions of the jaws, oral \nulcerations, hyperplastic gingiva, and bleeding \ncomplications develop in these patients (abso-\nlute contraindication)\nThalassemia\nMultiple types (alpha, beta) and degrees of severity \n(major, minor)\nMore severe forms can present some issues such \nas erythroid mass expansion directly into facial \nbones causing malocclusions\nMedical consultation is recommended to deter-\nmine severity of disease\nMajor (severe forms): absolute contraindication\nMinor (less severe): relative contraindication\nFrequent nosebleeds \n(epistaxis)\nHypertension, sinus disease, bleeding disorders \nsuch as von Willebrand\nSpontaneous or frequent nosebleeds should have \nbleeding time and INR\nEasy bleeding gums\nGingival disease, bleeding disorder, thrombocyto­\npenia, leukemia, liver disease\nFurther investigation may be warranted with  \nplatelet, CBC, bleeding time, PT, PTT\nHeavy menstrual \nperiods\nThyroid disease, dysfunctional uterine bleeding \n(fibroid, polyps, and hormone imbalance),  \nbleeding disorders, platelet dysfunction\nIf no obvious medical reason, check CBC, INR, \nbleeding time\nFamily history of \nbleeding disorder\nIf family history of bleeding issues, check CBC, \nINR, PTT, bleeding time to rule out hereditary \nbleeding disorders such as von Willebrand, \nhemophilia, and coagulation factor deficiencies\nProlonged bleeding \nafter cuts\nRule out coagulation defect, hereditary bleeding \ndisorder, or platelet dysfunction; check CBC, \nINR, PTT, bleeding times\nEasy bruising or \nspontaneous \nbruising\nPlatelet deficiency, coagulation factor issue, \nleukemias, vitamin K deficiency, chemotherapy, \nanticoagulation medication\nHistory of excessive \nbleeding after \ndental surgery\nIf no definitive diagnosis correlates with prolonged \nbleeding, check CBC, INR, PTT, bleeding time\nCBC, Complete blood count; INR, international normalized ratio; PT, prothrombin time; PTT, \npartial thromboplastin time.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, \nMisch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \nTABLE \n10.15"
  },
  {
    "page": 40,
    "content": "248\nPART III     Fundamental Science\nof patients with COPD is staged according to the severity of the \ndisease. If a patient has been hospitalized for respiratory difficul-\nties, then a medical consultation is warranted. The dentist should \ninquire regarding the carbon dioxide retention capability of these \npatients. Patients who retain carbon dioxide have a severe con-\ndition and are prone to respiratory failure when given sedatives, \noxygen or nitrous oxide, and oxygen analgesia.\nExamination procedures may be performed under normal pro-\ntocol (type 1). Elective moderate procedures or advanced surgical \nor prosthetic procedures are usually contraindicated. However, \nif surgery or prosthetic procedures are needed to repair a previ-\nously inserted implant, then they should be performed in the \nhospital. The use of epinephrine should be limited. Drugs that \ndepress respiratory function, such as sedatives (including nitrous \noxide), tranquilizers, and narcotics, should be discussed with the \nphysician.\nAnesthetic selection. In rare instances, patients with COPD \nreceiving local anesthetics have exhibited adverse reactions. \nIncreased doses of anesthetic solutions that contain sulfites may \nincrease the risk of bronchospasm or allergic reactions. Most local \nanesthetics that are vasopressor anesthetics (e.g., epinephrine, \nlevonordefrin) will contain the antioxidant sodium (meta) bisul-\nfite. For COPD patients with a known allergy to bisulfites, a local \nanesthetic without a vasopressor (e.g., mepivacaine HCL 3%, pri-\nlocaine HCL 4%) should be used. \nAdrenal Suppression. Adrenal suppression may occur with \nlong-term corticosteroid treatment, which is common with more \nadvanced COPD patients. \nCardiovascular Event. For patients who have had a cardiovas-\ncular event, the patient’s functional capacity should be ascertained \n(physician consultation) and a stress reduction protocol imple-\nmented. The implant clinician should avoid long or extensive sur-\ngical procedures. \nOxygen Supplementation. High flow rates of oxygen can \nresult in respiratory depression in patients that are oxygen depen-\ndent or have more severe COPD disease. However, there is now \nsupporting evidence that titration of oxygen therapy to main-\ntain saturations between 88% and 92% is the correct approach. \nAvoid using higher levels of oxygen that would increase pulse \noximetry levels to >92%, creating hyperoxia in a COPD patient, \nwhich could result in hypercapnia (retention of COPD which \ncan diminish respiratory rate). Nitrous oxide is also contrain-\ndicated because of the negative affect on the respiratory drive. \nLow–flow rate oxygen supplementation (<2 L/min) during \nimplant procedures is highly recommended to minimize the pos-\nsibility of hypoxia. \nBronchodilators/Inhaled Corticosteroids. Bronchodilators and \ninhaled corticosteroids are the hallmark of treatment for COPD; \nhowever, they have been associated with an adverse effect on oral \ntissues. β2-agonists such as albuterol have been associated with a \ndecrease in saliva production and subsequent secretion resulting \nin xerostomia. Patients should always be instructed to bring their \nrescue inhaler (usually albuterol) to the procedure or, for more \nadvanced COPD patients, their nebulizer and albuterol solution \nin case of an emergency. \nUse of Sedation. Sedation should be carefully evaluated in \npatients with COPD, and discussion with their treating phy-\nsician is recommended. Potent sedatives such as narcotics and \nbarbiturates should be avoided unless approved by the treating \nphysician. These drugs can further depress the respiratory drive \nin more advanced COPD patients. Antihistamines may desic-\ncate respiratory secretions, which may lead to compromised air-\nflow. Additionally, nitrous oxide should not be used in COPD \npatients because it can lead to further respiratory depression \n(Table 10.17). \nAdditional Pulmonary Disorders and Treatment \nImplications\nSee Table 10.18. \nDigestive System\nLiver Disease (Cirrhosis)\nCirrhosis of the liver is characterized by irreversible scarring and \nis usually caused by excessive alcohol intake, viral hepatitis B and \nC, and certain medications. Although patients with advanced dis-\nease can present with jaundice and itching, the diagnosis is usually \nconfirmed by liver biopsy and blood tests. Cirrhosis may cause \nexcessive bleeding, mental confusion, kidney failure, and accumu-\nlation of fluid in the abdomen (ascites). Cirrhosis is irreversible, \nand transplantation is becoming the most successful treatment for \nadvanced disease states.\nCirrhosis is the third leading cause of death in young men \nbetween the ages of 35 and 54 years. It occurs as a result of injury \nto the liver with resultant loss of liver cells and progressive scar-\nring. The major cause of cirrhosis is alcoholic liver disease. In \n2015, approximately 6.2% of the population met the diagnostic \ncriteria for alcohol abuse and alcohol dependence, but as many as \n15 to 20 million may be considered alcoholics. More than 25 mil-\nlion Americans have alcohol-related liver or gallbladder disease, \nand an estimated 900,000 Americans have cirrhosis.71,72\nPatients with cirrhosis have several significant issues that can \naffect dental treatment, including dysfunctional synthesis of clot-\nting factors and the inability to detoxify drugs. Hemostatic defects \nof liver disease cause not only reduced synthesis of clotting factors \nbut also an abnormal synthesis of fibrinogen and clotting proteins, \nvitamin K deficiency, enhanced fibrinolytic activity, and quantita-\ntive and qualitative platelet defects. Of patients with liver disease, \n  \u0007Dental Implant Management in Patients With Chronic Obstructive Pulmonary Disease\nRisk\nType 1\nType 2\nType 3\nType 4\nMild (ASA II)\n+\n+\n+\n+\nModerate (ASA III)\n+\nPhysician\nPhysician/moderate treatment\nPhysician/moderate treatment\nSevere (ASA IV)\nPhysician consultation\nPostpone (hospitalization)\nElective procedures contraindicated\nElective procedures contrain-\ndicated\n+, Procedure may be performed with regular protocol; ASA, American Society of Anesthesiologists.\n   \nTABLE \n10.17"
  },
  {
    "page": 41,
    "content": "249\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\n50% have a prolonged PT and possible significant clinical bleed-\ning. The inability to detoxify drugs may result in oversedation or \nrespiratory depression. The laboratory evaluation of the implant \ncandidate gives much insight into hepatic function. A basic panel \nof LFTs or a CMP can provide the needed information. In most \npatients with liver disease, it is recommended that a CBC, LFT, \nBMP, bleeding time, and an INR/PT test should be performed.\nOf special note, patients with normal LFTs can present with \nconstant itching or pruritus. This may be the first symptom of \nearly liver disease, especially primary biliary cirrhosis. This is a pro-\ngressive disease that causes cholestasis (buildup of bile in the liver) \nand damages the small bile ducts and over time destroys the ducts, \nresulting in liver damage. Because this is a progressive disease, it can \nbe fatal, but early diagnosis of the disease can have more favorable \noutcomes. For baby boomers, hepatitis C has been a significant \nissue, and until recently many chronic hepatitis C patients were \nundiagnosed until new screening protocols were instituted. Risk \nfactors include transfusions of blood products (mostly from the \n1970s and 1980s), IV drug use, sexual transmission, and tattoos. \nBecause of the opioid and injection drug use epidemic, hepatitis C \ninfections have increased dramatically since 2005. Many infected \nindividuals can have spontaneous resolution of their infection, but \nalmost 50% of persons with hepatitis C infections are unaware \nthey have or have had the disease. Seventy-five percent of indi-\nviduals currently with hepatitis C were born between 1945 and \n1965 and may be current candidates for elective dental implant \nsurgery. Asking patients at risk, or in this age group, about previ-\nous screening through a blood test for hepatitis C is recommended. \nNewer treatments have now essentially cured this disease for many \npatients. Individuals affected by hepatitis C can have normal or \nslightly elevated LFTs, but screening with a hepatitis C antibody \nblood test should be considered for patients at risk.\nDental Implant Management. Patients with no abnormal \nlaboratory values on CMP, CBC, PTT, and PT are at low risk, \nand a normal protocol is indicated for all procedures (types 1–4). \nPatients with an elevated PT of less than 1.5 times the control \nvalue, or bilirubin slightly affected, are at moderate risk. These \npatients should be referred to their physician for evaluation and \ntreatment. The use of sedatives may require physician clearance. \nNonsurgical and simple surgical procedures may follow normal \nprotocols (types 1 and 2). However, strict attention to hemostasis \nis indicated. Bovine collagen such as CollaTape, topical thrombin, \nor additional sutures may be indicated. Moderate to advanced sur-\ngical procedures may require hospitalization (types 3 and 4). Post-\nsurgical close surveillance is indicated. Elective implant therapy is \na relative contraindication in the patient with symptoms of active \nalcoholism.\nPatients with a PT greater than 1.5 times the control value, \nmild to severe thrombocytopenia (platelets lower than 140,000/\nmL), or several liver-related enzymes or chemicals affected (biliru-\nbin, albumin, ALP, SGOT, and SGPT) are at high risk.\nElective dental procedures such as implants are usually contra-\nindicated. If surgical procedures must be performed on a preexist-\ning implant, hospitalization is recommended. Platelet transfusion \nmay be required for even scaling procedures and administration \nof mandibular nerve blocks. Fresh frozen plasma may be used to \ncorrect PT to under half the control value.\nMedications. Many drugs such as local anesthetics (lidocaine, \nprilocaine, mepivacaine, and bupivacaine), sedatives (lorazepam, \nvalium, and alprazolam), and antibiotics (erythromycin and \nclindamycin) are metabolized primarily in the liver. Therefore in \nsome patients a dosage reduction may be warranted based on the \ncurrent liver functioning. \nNonsteroidal Antiinflammatory Drugs. In patients with cir-\nrhosis, NSAIDs have been associated with renal failure and should \nbe avoided. In patients with chronic liver disease, NSAIDs and \nopioids may be used at reduced doses but only after consultation \nwith the patient’s physician. Acetaminophen at a reduced dosage \nis a possible alternative consideration. New FDA recommenda-\ntions suggested a maximum dosage of 2 g/day is reasonable. An \naccepted school of thought is that codeine and opioids should not \nbe used or, if so, used at very infrequent and lower dosages to \navoid hepatic encephalopathy.73 Additionally, tetracycline, eryth-\nromycin, and metronidazole should never be used in patients with \nadvanced liver disease. \nStomach Ulcers\nApproximately 1 in 10 Americans will suffer from a version of \ngastritis or ulcer disease during their lifetime. Ulcers form when \nthere is a break or breach of the lining of the stomach or intestine.\nPeptic ulcers form in the duodenum of the small intestine \nfrom being in contact with stomach acids. Duodenal ulcers are \n  \u0007Additional Pulmonary Issues and Treatment \nImplications\nPositive Response\nTreatment Implications\nAsthma\nInflammatory process in lung is IgE/\nallergen mediated\nDetermination of trigger: asthma or  \nbronchospasm, including anxiety\nAlbuterol on hand for surgery\nApproximation of severity determined by \nnumber of medications and frequency  \nof use of albuterol rescue inhaler\nShortness of breath  \n(dyspnea)\nAsthma, COPD, heart disease, cardio-\nmyopathy, CHF, arrhythmias, anemia, \nobesity, heart valve disease\nWheezing\nAllergies, asthma, bronchitis, GERD, vocal \ncord dysfunction\nHemoptysis (blood in sputum) Bronchitis, pulmonary embolism, CHF,  \nlung cancer, blood thinners, TB\nCough\nPostnasal drainage, asthma, GERD, ACE/\nARB blood pressure medications, \nchronic bronchitis in COPD, other respi­\nratory processes like bronchiectasis\nChange in exercise tolerance\nAny changes walking upstairs or walking \nmore than 50 yards\nCardiovascular, pulmonary, poor condi-\ntioning\nWeight loss\nPoorly controlled COPD, malignancy, TB, \nhyperthyroid, ethyl alcohol abuse\nDysphagia from stroke or \nother neuromuscular \ndiseases\nRisk of aspiration during dental proce-\ndure\nACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CHF, congestive \nheart failure; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux \ndisease; IgE, immunoglobulin E; TB, tuberculosis.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Else-\nvier; 2018.\n   \nTABLE \n10.18"
  },
  {
    "page": 42,
    "content": "250\nPART III     Fundamental Science\nthe most common type of ulcer. Ulcers that occur in the stomach \nare referred to as gastric ulcers. In rare cases, esophageal reflux can \ncause esophageal ulcers. There are several main causes for ulcer \ndisease, including excessive alcohol intake, stress, medications \n(NSAIDs and aspirin), and a bacterium (Helicobacter pylori).\nAlthough there are no direct contraindications to the use of \nprophylactic antibiotics in patients with ulcer disease (except aller-\ngies), some patients may be more sensitive to certain types of anti-\nbiotics that may irritate their stomach. Pain management may be \nhampered by the inability to use NSAIDs or certain narcotics. To \nprevent bleeding from stomach ulcers, analgesics and antibiotics \nshould be cautiously used (medical clearance) in the treatment of \nimplant surgical patients. \nInflammatory Bowel Disease\nIBD is a chronic inflammation of all or part of the digestive tract. \nThe number of people afflicted with this condition continues to \nincrease. The two major forms of IBD are ulcerative colitis and \nCrohn’s disease. Patients will usually have symptoms of chronic \nor severe diarrhea, fatigue, rectal bleeding, and anemia. Ulcerative \ncolitis is characterized as an inflammatory disease of the rectum \nand large intestine mainly affecting the mucosal lining. Crohn’s \ndisease is an inflammatory disease of the entire digestive tract from \nmouth to anus, resulting in lesions of healthy tissue in between \nareas of inflammation. Most cases of Crohn’s disease originate \nwithin the terminal ileum.\nPatients with a history of stomach ulcers are susceptible to \ninfections and healing issues usually associated with the immuno-\nsuppressive drugs. Also, their dietary restrictions may affect both \nof these issues, and postoperative antibiotics are usually indicated.\nDuring dental procedures, stress reduction protocol is essential. \nExcess stress can affect adrenal function and require additional \ncorticosteroid augmentation. Postoperative pain episodes may \nincrease stress on the adrenal gland, resulting in possible adrenal \nsuppression complications.\nMany digestive disorder patients are anemic and, because of \nmalabsorption, may not absorb all the necessary components of \nclotting factors and certain vitamins. Care should be taken to \nminimize bleeding.\nThere are many differences in the oral lesions that manifest \nin patients with Crohn’s disease and those with ulcerative colitis. \nMany of these patients present with a glossitis, aphthous ulcer-\nations, or a more classic marker of ulcerative colitis, pyostomatitis \nvegetans. This condition is characterized by pustules with thick-\nened oral mucosa and surrounding erythema with some erosions. \nUlcerative colitis has extra GI manifestations that have been asso-\nciated with erosive temporomandibular joint disease. Crohn’s dis-\nease has been shown to have oral symptoms such as cobblestoning \nof the oral mucosa accompanied by ulcerations usually in a lin-\near pattern along with hyperplastic folds of the buccal vestibules \n(mucosal tags).\nA physician consultation is recommended to determine the \nextent of the patient’s digestive disorder along with the current \nimmune status. Most notably, an evaluation of delayed wound \nhealing and postoperative infection susceptibility should be \nascertained.\nAntibiotics that have a high incidence of antibiotic-associated \ndiarrhea or pseudomembranous colitis should be avoided \n(e.g., amoxicillin/clavulanic acid, erythromycin, clindamycin). \nPatients with IBD, especially those with ulcerative colitis, may \nbenefit from the use of probiotics, especially when antibiotics are \nprescribed. Probiotics are live microorganisms that are added to \nfood to change the intestinal microbial balance. The mechanism \nof action is controversial; however, theories include strengthen-\ning of the gut barrier, pathogen growth inhibition, and enhance-\nment of mucosal and systemic immune responses. Most NSAIDs \nmay precipitate these disease states and should be avoided unless \nauthorized by a physician. \nAdditional Digestive Disorders and Treatment \nImplications\nSee Table 10.19. \nBone Diseases\nDiseases of the skeletal system and specifically the jaws often influ-\nence decisions regarding treatment in the field of oral implants. \nBone and calcium metabolisms are directly related. Approximately \n99% of the calcium in the body is held in the bones and teeth. \nCalcium equilibrium is influenced by several different processes \nin the body, which then could directly affect bone health. PTH \nhas the most important influence on calcium by impacting the \nstorage of calcium on bones. Even though vitamin D is impor-\ntant for small intestine absorption of calcium, the renal tubules in \n  \u0007Additional Digestive Issues and Treatment \nImplications\nPositive Response\nTreatment Implications\nJaundice\nHepatitis, bile duct disorders, sickle cell \nanemia, autoimmune hemolytic disease \npancreatic cancer\nHepatitis\nMedical consultation, aseptic technique, \npreventive measures\nEsophageal reflux\nInfection, increased tooth decay/erosion\nHiatal hernia\nAppointment duration not to exceed \npatient’s tolerance\nNocturnal cough\nGastric reflux disease, chronic sinusitis, \nallergies\nDark, tar-colored stools\nGI bleeding (avoid anticoagulants, NSAIDs; \nneed GI evaluation)\nFrequent foul-smelling \nstools\nCrohn disease, pancreatic cancer (gum \ndisease), lactose intolerance (tooth \ndecay, bone demineralization), celiac \n(gluten intolerance) disease (enamel \nerosion, aphthous ulcers)\nDysphagia (solid/liquid)\nReflux, esophageal spasm, stricture, \nesophageal mass, multiple sclerosis, \nParkinson disease, stroke, poor oral \nclearance, high-volume suction, aspira-\ntion during treatment, protect airway \nrubber dam\nPersistent pruritus (itching)\nCeliac disease, liver disease, biliary \ndisease (sclerosing cholangitis)\nAll can lead to coagulopathy and exces-\nsive bleeding\nGI, gastrointestinal; NSAIDs, nonsteroidal antiinflammatory drugs.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Else-\nvier; 2018.\n   \nTABLE \n10.19"
  },
  {
    "page": 43,
    "content": "251\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nthe kidneys reabsorb 95% of the calcium. In the elderly there is \nincreasing evidence to support that lower levels of vitamin D have \nthe most influence on calcium levels.74\nThere exist many diseases that directly affect the dental implant \ntreatment.\nOsteoporosis\nThe most common disease of bone metabolism the implant cli-\nnician will encounter is osteoporosis, which is an age-related \ndisorder characterized by a decrease in bone mass, increased \nmicroarchitectural deterioration, and susceptibility to fractures. \nThe WHO defines osteoporosis as a bone mineral density level \nmore than 2.5 standard deviations below the mean of normal \nyoung women.75 Forty percent of postmenopausal women in the \nUnited States have bone mineral density levels denoting osteo-\npenia, and 7% have scores correlated with osteoporosis.76 As the \npopulation ages, the incidence of osteoporosis will continue to \nincrease in both women and men. Women with osteoporosis are \nthree times more likely to experience tooth loss than those who do \nnot have the disease. It has been shown that dental x-rays may be \nused as screening for osteoporosis.77\nAfter age 60, almost one-third of the population has osteopo-\nrosis; it occurs in twice as many women as men. This condition is \ncommon in postmenopausal women or those with a history of a \npremenopausal oophorectomy. The lack of estrogen increases the \nlikelihood of osteoporosis; the addition of estrogen is the single \nmost effective treatment to increase calcium absorption in these \nwomen. However, current concerns about the development of \nbreast, ovarian, or endometrial cancer and an increased incidence \nof stroke, heart attack, and blood clots in these patients have \nalmost eliminated the use of supplemental estrogen.\nMany times, if estrogen therapy is initiated, it is at much lower \ndoses and for shorter duration. Half of all women present with \nbone mineral density below the normal fracture threshold of a \n20-year-old woman by the age of 65 years. It is estimated that \n1.3 million fractures overall and 133,000 hip fractures occur \nevery year as a result of osteoporosis. Most patients fail to recover \nnormal activity; 24% die of complications related to the fracture \nwithin the first year.78\nThe osteoporotic changes in the jaws are similar to other \nbones in the body. The structure of the bone is normal; however, \nbecause of the uncoupling of the bone resorption and forma-\ntion processes with emphasis on resorption, the cortical plates \nbecome thinner, the trabecular bone pattern becomes more \ndiscrete, and advanced demineralization occurs. The bone loss \nrelated to osteoporosis may be expressed in both the dentate and \nedentulous patient. In one study of osteoporotic women who \nhad their teeth at age 50, 44% had a complete denture by the \nage of 60, whereas only 15% of nonosteoporotic women had \ndentures.79 A strong correlation was shown between periodontal \ndisease and skeletal osteoporotic changes. In addition, women \nrepresent a greater percentage of patients with residual ridge \nresorption than do men.80 The loss of trabecular bone is acceler-\nated in the edentulous patient because the factors involved in \nresorption are already established.\nBone remodeling is a continuous process; however, bone mass \nincreases during youth and diminishes with aging. The peak \nbone mass is usually reached by the age of 35 to 40 years and \nis usually 30% higher in men than in women. In the first 3 to \n10 years after menopause, bone loss is rapid. Trabecular bone \nloss in a women 80 years old reaches 40%, but is only 27% in \nmen of the same age. Persons most at risk of osteoporosis are \nthin, postmenopausal, Caucasian women with a history of poor \ndietary calcium intake, cigarette smoking, and British or North-\nern European ancestry.\nEstrogen therapy can halt or retard severe bone demin-\neralization caused by osteoporosis and can reduce fractures \nby about 50% compared with the fracture rate of untreated \nwomen. For those patients taking an estrogen supplement, \nthere have been studies to evaluate the effect of estrogen \nreplacement therapy on dental implant failures. Osteoporotic \npatients not taking estrogen have nearly twice the failure rate of \nmaxillary implants in comparison to patients who were receiv-\ning estrogen therapy.81\nRecent advances in radiology, such as dual-energy x-ray absorp-\ntiometry, can measure as little as 1 mg of bone mass change at \nsuch sites as the hip, spine, and wrist. Such measurements may \naccurately predict future fracture risk and identify the patients at \nrisk. The actual diagnosis and treatment of osteoporosis should be \nattained by the patient’s physician. The implant dentist can best \nassist the patient by noting the loss of trabecular bone and early \nreferral.\nTreatment of osteoporosis remains controversial. Its manage-\nment concentrates on prevention. Regular exercise has shown to \nhelp maintain bone mass and increase bone strength. Adequate \ndietary calcium intake is essential. The advanced demineralization \nand consequent increase in bone loss of the completely edentulous \nmay become a vicious circle. The denture is less secure, and the \npatient may not be able to follow the diet needed to maintain \nproper calcium absorption levels.\nThe recommended calcium intake is 800 mg/day. The aver-\nage person in the United States ingests 450 to 550 mg. In post-\nmenopausal women, 1500 mg may be required to maintain a \npositive calcium balance.82 Calcium supplements of 1 to 2 g \nof elemental calcium per day have been shown in several stud-\nies to reduce the rate of bone loss. However, there is no evi-\ndence that these supplements lead to recovery of bone mass. \nPlain calcium carbonate tablets contain the greatest fraction of \nelemental calcium and are relatively inexpensive. It is insolu-\nble and is absorbed after conversion into calcium chloride by \ngastric hydrochloric acid. Patients with achlorhydria (lack of \nhydrochloric acid) should be given salts other than calcium \ncarbonate. If the patient has a lactate deficiency, lactate salts \nare contraindicated. Several food–drug interactions have been \nreported. Tetracycline and iron do not work effectively with \ncalcium doses. Patients should also avoid phosphate (found in \nsome dairy products or diet soda) or oxalic acid (in spinach and \nrhubarb) and the phytic acid in bran and whole grains because \nthese decrease calcium absorptions. Patients with a history of \nrenal calculi should avoid calcium supplements. Patients with \nrenal dysfunction need periodic serum and urine calcium level \nchecks, and their serum pH should be monitored to avoid \nhypercalcemia and metabolic alkalosis.\nVitamin D is also important in treating and preventing osteo-\nporosis because it is required for proper calcium absorption. \nWithout proper levels of vitamin D calcium supplementation \nmay have no effect on bone health; this is especially true in older \npatients. Calcium and vitamin D supplements may help prevent \ntooth loss in older adults. Vitamin D is normally made in the \nskin after exposure to sunlight; however, given the concerns for \nskin cancer, most individuals are now avoiding direct sun expo-\nsure or overexposure. At least 800 IU of vitamin D per day are \nrecommended for postmenopausal women or men over age 70. \nFor more severe cases of vitamin D deficiency higher daily doses"
  },
  {
    "page": 44,
    "content": "252\nPART III     Fundamental Science\nof one to several thousand international units of vitamin D may \nbe required. For patients with established osteoporosis, treat-\nment options include bisphosphonates and calcitonin. Bisphos-\nphonates are inhibitors of bone resorption. Calcitonin, which is \nnormally secreted by the thyroid gland, inhibits bone resorption \nand alters calcium metabolism.\nDental Implant Implications\nSurgical Technique. Underpreparation of the osteotomy site \n(or use of osteotomes) will result in the implant having more \nbone at the implant interface. Although not contraindicated, \nimmediate stabilization of dental implants is a common concern \nbecause of decreased trabecular bone mass. Healing periods and \nimplant surface characteristics should be selected for poorer-\nquality bone. \nBisphosphonates Use. Oral/IV bisphosphonates are common \nmedications for osteoporosis. (See the section “Bisphosphonates.”)  \nLength of Healing. In osteoporotic patients, there is a \ndecrease in cortical and trabecular bone; the repair process \n(implant healing) may be compromised. Sufficient time for \nhealing should be adhered to with progressive prosthetic bone \nloading is highly recommended. \nPeri-implantitis. A strong correlation has been shown \nbetween periodontal disease and skeletal osteoporotic changes. \nStrict postoperative recall and periodontal evaluation should be \nadhered to. \nProgressive Bone Loading. Because of poorer bone quality, \nhealing is compromised, necessitating progressive bone loading \nthroughout the prosthetic rehabilitation. The poorer-quality bone \nis progressively increased to better-quality bone, which results in \nbetter bone quality at the implant interface. \nImplant Design. Implant design should include greater- \nwidth implants. Surface conditions of implant bodies should be \ndesigned to increase bone contact and density. Bone stimulation \nto the healed interface will increase bone density, even in advanced \nosteoporotic changes (Box 10.10). \nFibrous Dysplasia\nFibrous dysplasia (FD) is a rare, nonheritable, genetic disorder \ncharacterized by normal bone being replaced by immature, hap-\nhazardly distributed bone and fibrous tissues. The etiology of \nthis bone disease is a gene mutation that prevents the differ-\nentiation of cells within the osteoblastic formation. FD can be \nfurther classified to involve one site (monostotic FD [MFD]), \nmultiple sites (polyostotic FD [PFD]), or multiple locations \n(craniofacial FD [CFD]). CFD lesions are usually unilateral and \noccur twice as often in the maxilla versus mandible. The diag-\nnosis of CFD should be determined from the clinical evidence, \nhistopathologic analysis of the biopsy specimen, and radiologic \nfindings.55 Most individuals with this disorder are diagnosed \nearly in childhood.\nThe radiographic appearance is highly variable because of \nthe disproportionately mineralized tissue and fibrous tissue \nin the lesion. This variability results in radiographic images \ndepicting the typical “ground glass” appearance to early-stage \nradiolucencies and late-stage radiopacities.83 Additionally, \nsevere malocclusion, dental abnormalities, and facial asymme-\ntry have been shown to be highly prevalent in CFD patients, \nwhich further complicates the prosthetic rehabilitation of \nthese patients.84\nDental Implant Implications\nPostoperative Healing. Healing after trauma in patients with \nFD is much different than for those with normal bone. The tissue \nis hypocellular, which leads to slow healing and an increased infec-\ntion rate. These local infections may spread through the bone and \nresult in more advanced complications. \nInformed Consent. Because of the lack of research and stud-\nies, patients need to be well informed of possible morbidity and \ncomplications. \nTreatment Summary\nActive lesion areas: Absolute contraindication\nNonlesion areas: Relative contraindication\nVitamin D Disorders (Osteomalacia)\nOsteomalacia results in softer than normal bones and is directly \nrelated to calcium deficiencies. Lack of vitamin D is the most \ncommon cause of osteomalacia. Vitamin D is synthesized by \nthe body in several steps involving the skin, liver, kidney, and \nintestine. The kidney, in conjunction with PTH, activates \nvitamin D. With this deficiency, the intestinal uptake and \nmobilization of calcium from the bone is altered, resulting in \nhypocalcemia. This will lead to an increased PTH secretion, \nwhich increases the clearance of phosphorus from the kidneys. \nThis resultant decrease in the concentration of phosphorus pre-\nvents a normal mineralization process. Anticonvulsant drugs, \nespecially diphenylhydantoin and phenobarbital, may cause \ndrug-induced osteomalacia. Many GI disorders also may result \nin osteomalacia. Osteoporosis is different from osteomalacia. \nIn osteoporosis the bones become more porous and brittle, \nwhereas in osteomalacia the bones are just softer because of \nBisphosphonates\n• \u0007Alendronate (Fosamax, Fosamax Plus D)\n• \u0007Alendronate (Binosto)\n• \u0007Denosumab (Prolia)\n• \u0007Ibandronate (Boniva)\n• \u0007Risedronate (Actonel)\n• \u0007Risedronate (Atelvia)\n• \u0007Zoledronic acid (Reclast) \nCalcitonin\n• \u0007Calcitonin (Fortical, Miacalcin)\n• \u0007Calcitonin (Miacalcin injection) \nEstrogen (Hormone Therapy)\n• \u0007Estrogen (multiple brands) \nEstrogen Agonists/Antagonists (Also Called Selective Estrogen \nReceptor Modulators)\n• \u0007Raloxifene (Evista)\n• \u0007Bazedoxifene (Duavee) \nAnabolic Agents Parathyroid Hormone (Anabolic Agent)\n• \u0007Teriparatide (Forteo) \nParathyroid Hormone-Related Protein Analog (Anabolic Agent)\n• \u0007Abaloparatide (Tymlos injection) \nRank Ligand Inhibitor\n• \u0007Denosumab (Prolia injection)\n\t• BOX 10.10\t      \u0007Common Medications and Implications \nfor Treatment of Osteoporosis"
  },
  {
    "page": 45,
    "content": "253\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\ndemineralization caused by the lower levels of phosphorus and \ncalcium.\nThe oral findings of osteomalacia are usually not dramatic. A \ndecrease in trabecular bone, indistinct lamina dura, and an increase \nin chronic periodontal disease have been reported. The treatment \nfor osteomalacia is supplemental oral vitamin D (50,000 IU) usu-\nally at weekly doses.\nDental Implant Implications. Treatment for osteomalacia \nis usually successful, with radiographic changes seen months \nafter treatment. There are no known reports of implant \ncomplications in osteomalacia patients; however, there is no \ncontraindication as long as the disease is not active and well \ncontrolled. \nHyperparathyroidism\nHyperparathyroidism is caused by overactivity of the parathyroid \nglands. There are four of these tiny glands located just behind/\nbeside the thyroid gland. Primary hyperparathyroidism results \nwhen one or more of the glands become hyperactive, which \nleads to increased levels of PTH. Surgical intervention is usually \nrequired. Vitamin D deficiency, kidney failure, and other disease \nthat results in lower calcium levels will cause a secondary hyper-\nparathyroidism. The treatment for this condition is targeted at the \nsecondary cause. The diagnosis is confirmed with an elevated level \nof intact PTH.\nThe clinical manifestations of this disease vary widely, depend-\ning on the severity. Mild forms may be asymptomatic. Renal colic \ndisorders often occur with moderate disease. Severe hyperparathy-\nroidism can cause bone, renal, and gastric disturbance. It has been \nnoted that when skeletal depletion occurs as a result of stimulation \nby the parathyroid gland, alveolar bone may be affected before \nthat of the rib, vertebrae, or long bones.\nOral changes related to this disorder occur only with advanced \ndisease. The loss of lamina dura is the most significant find-\ning. Clinically, patients with this disorder develop loose teeth. \nAltered trabecular bone pattern with the appearance of ground \nglass may also occur. In animals, secondary hyperparathyroidism \naffects alveolar bone loss greater than any other bone of the skel-\neton.85 Central or peripheral giant cell tumors may also develop.\nDental Implant Implications. Dental implants are contraindi-\ncated in areas of active bony lesions. However, implant placement \nmay be initiated after treatment and healing of the affected areas. \nMedical consultation is highly recommended. \nOsteitis Deformans (Paget Disease)\nOsteitis deformans, or Paget disease, is a common metabolic dis-\nease characterized by slow, progressive, uncontrolled resorption \nand deposition of bone. This disease is usually seen in Caucasian \nmen older than 40 years. It is estimated that the rates of Paget \ndisease in the United States are approximately 2% to 3% among \npatients 55 years and older.86\nThe etiology is unknown and usually affects the maxillary alve-\nolar ridge twice as frequently as the mandibular ridge. Because of \nthe enlargement of the middle one-third of the face, the appear-\nance of a “lionlike” deformity is often noted. Diastemas, tooth \nmobility, and bone pain are additional characteristics. Radio-\ngraphically, a decreased radiodensity, large circumscribed radio-\nlucencies, patchy areas of coalesced sclerotic bone (cotton-wool \nappearance), and marrow spaces that are replaced by fibrous tis-\nsue are observed. During the active phases of this disease, bone is \nhighly vascular with the possibility of arteriovenous shunts, which \nmay cause hemorrhagic complications.\nPaget disease is marked by high elevations of serum ALP, nor-\nmal or elevated calcium, and normal phosphate levels. Radionu-\nclear bone scans are used to determine the extent of the disease \nthroughout the body. Edentulous patients are often unable to \nwear their prostheses without discomfort. There is no specific \ntreatment for Paget disease, and these patients are predisposed to \ndevelop osteosarcoma and possibly osteomyelitis.\nThis disease has a wide spectrum of treatment ranging from \nno treatment to the use of bisphosphonates. For patients who are \nsymptomatic, IV bisphosphonates are usually the preferred treat-\nments. These drugs help decrease further bone breakdown, forma-\ntion, and remodeling.\nDental Implant Implications\nBleeding. During the active phases of this disease, bone is \nhighly vascular with the possibility of arteriovenous shunts, which \nmay cause hemorrhagic complications. \nInfection. Bone areas that are affected by this disor-\nder are predisposed to develop osteosarcoma and possible \nosteomyelitis. \nTreatment Summary\nOral implants are contraindicated in the regions affected by this \ndisorder or in patients on IV bisphosphonates for the treatment of \ntheir Paget symptoms.\nMultiple Myeloma\nMultiple myeloma is a plasma cell neoplasm that originates in \nthe bone marrow and is characterized by the abnormal prolifera-\ntion of B cells. Multiple myeloma causes severe hypercalcemia, \nimmune suppression, anemia, and thrombocytopenia because it \ncauses widespread bone destruction. The disease is usually found \nin patients between 40 and 70 years of age. Usually it affects \nseveral bones in the body, with symptoms of skeletal pain. Patho-\nlogic fractures may occur. Punched-out lesions appear radio-\ngraphically. Some patients with early disease may not have any \nsymptoms, but there are increasing examples of the first manifes-\ntation of multiple myeloma being an oral gingival or mandibular \nsoft mass.87\nSecondary oral manifestations of the disease are common \n(80%) and may affect both the maxilla and the mandible. Par-\nesthesia, swelling, tooth mobility, and tooth movement may \noccur. Gingival enlargements are also possible. The diagnosis \nis usually determined through both a urine and serum pro-\ntein electrophoresis test. The presence of light-chain proteins \n(Bence-Jones) can also be found. In the past the disease was \nalmost always fatal within a short time after being diagnosed. \nHowever, there are now more aggressive treatments including \nimproved chemotherapy and stem cell transplants that have \nprolonged survival. Although it is rarely curable, the disease is \nnow more manageable.\nDental Implant Implications. Dental implants are usually \nan absolute contraindication in patients with multiple myeloma \nbecause of the severity of this disease; however, a case report has \ndescribed successful implant placement in a patient with this \ndisease.88 Although the disease is rarely curable, it is now more \nmanageable, and in just the past few years the 5-year survival \nrate for these patients has doubled. Given the recent success in \ntreating this disease and the longer survival time, new studies will \nmost likely be done to evaluate the use the of dental implants in \npatients that have undergone successful treatment for multiple \nmyeloma."
  },
  {
    "page": 46,
    "content": "254\nPART III     Fundamental Science\nOsteomyelitis\nOsteomyelitis is an infection with or without inflammation of the \nbone. Most always the infection is caused by a bacteria or fungi \nentering the bone. Open wounds or recent surgery around a bone \nare the most common sources, but an abscessed tooth is also a \npotential source for the infection. The radiographic appearance \nis a poorly defined, radiolucent area with isolated fragments of \nbone (sequestra) that can exfoliate or become surrounded by bone \n(involucrum). Osteomyelitis in the oral cavity is usually in the \nmandible and rarely in the maxilla, most likely because of the \nincreased vascularization. This disorder can also be caused by \nodontogenic and periodontal infections, trauma, dental implants, \nimmunocompromised states, and hypovascularized bone. The \ntreatment includes aggressive surgical drainage, with possible IV \nantibiotic intervention.\nDental Implant Implications\nImplant Placement. Implant placement in surgical sites that \nhave been previously affected with osteomyelitis leads to an \nincreased morbidity. Because of the lack of vascularity, endosseous \nimplants have a greater chance of bone loss, infection, and failure. \nTreatment Summary\nOsteomyelitis is usually an absolute contraindication unless the \netiologic factors are corrected and adequate blood supply to the \naffected area is restored. A physician clearance should be obtained \nalong with a comprehensive informed consent on the possible \ncomplications that may arise from implant placement into these \nsites.\nOsteogenesis Imperfecta\nThis is a genetic disorder in which bones break with ease many \ntimes with almost no apparent cause. Bone quality is poor, with a \nthin cortical bone and thin, fine trabeculae. Bones are extremely \nfragile. Some forms are more severe, but overall the disease is rela-\ntively rare. However, osteogenesis imperfecta is the most common \ninherited bone disease. Bone fractures along with skeletal defor-\nmities are common, with very poor healing. Histologically, defec-\ntive osteoblasts lead to a reduction in bone matrix and abnormal \ncollagen.\nDental Implant Implications. Dental implants are not contra-\nindicated; however, caution should be given to the very poor bone \nquality and questionable osseous healing. \nCemento-Osseous Dysplasia\nThis disease usually manifests with lesions in the upper and or \nlower jaw. Normal bone is replaced with bone that is mixed with \nconnective tissue and abnormal bone. Cemento-osseous dyspla-\nsia seems to be more common in middle-aged women, with a \nhigher incidence in African American and Asian women. Most of \nthe time, the lesions are symmetric on both sides of jaw. There is \nvariability in shape, size, and number of lesions. The lesions can \nexpand and may cause some pain, but for the most part the disease \nis asymptomatic. Many times, the diagnosis is found by accident \non a radiograph. There are three types of cemento-osseous dyspla-\nsia (i.e., focal, periapical cementoma, florid) that can vary radio-\ngraphically as radiolucent, radiopaque, or a combination. The \nlesions are usually associated with the mandibular anterior teeth.\nDental Implant Implications. Dental implants are not contra-\nindicated unless in the sclerotic phase of the disease in which the \nbone is hypovascular. This bone has the ability to become infected \neasily, with questionable healing. Special attention must be given \nso that the disease does not progress to osteomyelitis. \nEctodermal Dysplasia\nEctodermal dysplasia (ED) is a genetically inherited disorder that \noccurs in 1 per 100,000 live births.89 Clinically, ED has been \ndivided into two broad categories: an X-linked hypohidrotic form \n(Christ–Siemens–Touraine syndrome) characterized by the classi-\ncal triad of hypodontia, hypohidrosis, and hypotrichosis, and by \ncharacteristic facial features such as prominent supraorbital ridges \nand a depressed nasal bridge; and an autosomal inherited hidrotic \nform (Clouston syndrome), which usually spares the sweat glands \nbut affects teeth, hair, and nails.90\nIn this condition, there is abnormal development of the skin, \nhair, nails, sweat glands, or teeth. The most common intraoral \nfeature of ED is hypodontia or anodontia. In these patients, \nconventional prosthodontic procedures often are not successful \nbecause of anatomic abnormalities that result in poor retention \nand stability. Because of this, dental implant therapy aimed at \nrestoring function, esthetics, and psychological rehabilitation is \nan integral part in the management of adolescent patients with \nED. Numerous studies have been completed on dental implants \nin patients with ED. A 3-year study showed impressive suc-\ncess rates in preadolescents (ages 7–11, 87%), adolescents (ages \n12–17, 90%), and adults (older than 17, 97%). Other positive \ncase reports have shown dental implants as a successful adjunct to \noral rehabilitation.91,92\nDental Implant Implications. Dental implants are not contra-\nindicated in patients with ED. Although not ideal, implants may \nbe placed in preadolescents (i.e., usually anterior mandible), with \nwith functional, esthetic, and psychological advantages. Alveolar \nbone has been shown to continue to grow after implants have \nbeen placed in edentulous ridges of children with ED. Transverse \nand sagittal growth is not restricted; however, vertical growth may \nresult in submersion of the implants, necessitating prosthetic revi-\nsion or possible use of longer abutments. \nRadiation\nAlthough the survival rate of patients with head and neck cancer \nhas increased over the last 20 years, it still remains one of the \ndeadliest forms of cancer. Aggressive treatment includes surgery, \nradiation, chemotherapy, or a combination therapy that inevita-\nbly leaves the patient with compromised anatomy and physiologic \nfunctioning. Patients are left with many deficits including oral \nmucositis, xerostomia, compromised healing, and reduced angio-\ngenesis. This is a direct result of changes in the vascularity and \ncellularity of hard and soft tissue, damage to the salivary glands, \nand increased collagen synthesis that results in fibrosis. Because of \nthese detrimental effects on the bone, wound repair and healing \nare significantly reduced after surgical procedures. When exposed \nto high levels of radiation, bone undergoes irreversible physiologic \nchanges that include narrowing of the vascular channels (endar-\nteritis), diminished blood flow, and loss of osteocytes. In time the \nbone becomes nonvital, which leads to limited remodeling and \nhealing potential.\nDental Implant Implications\nOsteoradionecrosis. The most significant risk in placing \nimplants into irradiated bone is osteoradionecrosis (ORN), \nwhich is an irreversible devitalization of irradiated bone char-\nacterized by necrotic, soft bone that fails to heal properly. The \npathophysiologic mechanism is an imbalance in oxygen demand"
  },
  {
    "page": 47,
    "content": "255\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nand oxygen availability, which is caused by endarteritis of the \nblood vessels. Clinical symptoms include pain, exposed necrotic \nbone, pathologic fractures, and suppuration. Studies have shown \nthe overall incidence of ORN after radiotherapy to be from 3% \nto 22%.93 \nRadiotherapy to Previously Placed Implants. There are very \nfew studies on the effects of radiotherapy on preexisting dental \nimplants. Short-term data show very minimal complications and \nfailures. However, in longer-term studies, failure rates seem to be \nhigher.74 At this time, more studies need to be conducted for con-\nclusive results. \nImplant Placement After Radiotherapy. The time between \nradiotherapy to implant placement seems to affect the prognosis \nof implants. Most studies have shown that the longer the period \nfor implant placement after radiotherapy, the higher the success \nrate and the lower the risk of ORN (Box 10.11).94 \nIrradiation Patient Prosthetics. Because of the oral effects of \nradiotherapy (mucositis and xerostomia), an implant-supported \nprosthesis (FP-1, FP-2, and FP-3) is recommended over a soft tis-\nsue prosthesis (RP-4 and RP-5). This will reduce the possibility \nof soft tissue irritation associated with postradiotherapy patients \nwearing removable prostheses. \nPast Radiation Treatment. Caution must be emphasized to \npatients with past radiation therapy because earlier forms of radia-\ntion therapy (pre-1980s) were of lower energy, in contrast to cur-\nrent higher energy levels that are less destructive. Because of this \nlower-energy radiation and associated higher destructive radio-\ntherapy, progressive endarteritis has been shown to take place, \nwhich increases over time.95 \nAmount of Radiation Exposure. The presently available lit-\nerature states that implant placement surgery may be completed \non patients who have been irradiated at doses lower than 50 \nGy.96 Unfortunately, very few patients receiving doses greater \nthan 50 Gy have been rehabilitated with implants. Studies have \nshown that implants placed in patients with a cumulative radia-\ntion effect of 18 to 20 (approximately 48–65 Gy standard frac-\ntionation) have a rather high success rate. Other reports have \nshown that doses greater than a cumulative radiation effect of \n40 (approximately 120 Gy standard fractionation) exhibit a high \ndegree of failure.97 \nHyperbaric Oxygen. One treatment proposed to minimize the \npossibility of ORN is the use of hyperbaric oxygen. Prophylactic \nhyperbaric oxygen has been advocated to increase oxygen tension \nin irradiated bone, which will promote capillary angiogenesis and \nbone formation. Recent data show that oxygen under hyperbaric \nconditions acts synergistically with growth factors, which stim-\nulates bone growth and turnover and also may act as a growth \nfactor itself. Hyperbaric oxygen also has been shown to act as a \nstimulator of osseointegration by increasing new bone formation, \nincreasing bone turnover, and increasing the vascular supply to \nirradiated bone.98 \nAdditional Bone Diseases\nSee Table 10.20. \nSystemic Autoimmune Diseases\nAutoimmune diseases refer to a group of more than 80 serious, \nchronic illnesses that can affect almost any organ in the body. \nApproximately 75% of autoimmune diseases occur in women; \nthese diseases are thought to have a genetic predisposition. How-\never, autoimmune diseases are among the most poorly understood \ndiseases, with symptoms extremely variable among individuals.\nSjögren Syndrome\nSjögren syndrome is an autoimmune disease in which immune \ncells attack and destroy exocrine glands that produce saliva and \ntears. This disorder affects an estimated 4 million people in the \nUnited States (90% are female), with an average age of onset in the \nlate 40s. The classic symptoms of Sjögren syndrome are xerostomia \nand xerophthalmia (dry eyes). Because of the xerostomia, patients \nare more susceptible to decay and the mucous membranes become \natrophic and friable. Because of the lack of salivary secretions, \ncomplications may arise with the use of a tissue-borne prosthesis.\nThe healing response and integration of implants has been \nshown to be successful in patients with Sjögren syndrome.99 These \nimplant-supported prostheses decrease soft tissue–borne pros-\nthetic sore spots and discomfort.\n • \u0007For sites that have been previously treated with radiotherapy, the \nauthors recommend referral to a dental school, hospital, or clinic that \nhas experience in treating radiotherapy patients.\n • \u0007If the clinician has experience or can treat the associated complications, \nthe following is recommended.\nIdeal Implant Placement\n • \u0007Preradiation: More than 14 days before radiation\n • \u0007During radiation: Absolute contraindicationa\n • \u0007Postradiation: <6 month or >24 months—relative/absolute \ncontraindication\n • \u00076 to 24 months: Relative contraindicationb\naRadiation therapy medical consultation, possible >20 years ago referral to cancer institution or \nhospital treatments, for 90 minutes before placement followed by 10 minutes after placement.\nbMedical consultation, hyperbaric oxygen, informed consent, aseptic technique (<20 Gy \ncumulative, approximately <50 Gy technique fractionation).\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; \n2018.\n\t • BOX 10.11\t      \u0007Treatment Protocol for Implant \nPlacement in Radiation Sites\n  \u0007Additional Bone Disease Responses and \nTreatment Implications\nPositive Response\nTreatment Implications\nOrthopedic prosthetic device\nAntibiotic prophylaxis\nEctodermal dysplasia\nMany studies completed showing \nsuccessful treatment in ectodermal \ndysplasia patients\nCemento-osseous dysplasia \n(periapical cemental \ndysplasia)\nBone quality is questionable because \nof avascular cementum–like lesions \n(relative contraindication)\nOsteomalacia\nHypomineralized bone, questionable \nbone quality (relative contraindication)\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Else-\nvier; 2018.\n   \nTABLE \n10.20"
  },
  {
    "page": 48,
    "content": "256\nPART III     Fundamental Science\nDental Implant Implications\nThere are no contraindications for dental implants in patients with \na history of Sjögren syndrome. However, it is advantageous for the \nprosthesis to be non–tissue-borne (FP-1, FP-2, FP-3, and RP-4) \nto minimize soft tissue complications associated with xerostomia. \nSystemic Lupus Erythematosus\nSystemic lupus erythematosus is a chronic, potentially fatal \nautoimmune disease in which the immune system attacks cells \nand tissue in almost any part of the body. There are three main \ntypes of lupus in adults. The majority of patients have systemic \nlupus (eight times higher incidence than other forms) in which \nthe immune system attacks cells and tissue in several areas of \nthe body. In the United States, over 50% of the time, patients \nwith systemic lupus have a major organ such as the heart, lung, \nkidney, or brain affected. Cutaneous lupus affects only the skin \nand accounts for a small number of cases (1 of 8). Certain drugs \nproducing symptoms similar to systemic lupus can induce lupus. \nThis category is referred to as drug-induced lupus, and the major \ncontributors are hydralazine, procainamide, and isoniazid. The \nremaining cases of lupus are neonatal lupus. Lupus occurs in both \nmen and women, but almost 90% of the cases are in women, and \nmost of those cases are women of childbearing age between 14 \nand 45.100\nThere is no one test to diagnosis lupus. The antinuclear anti-\nbody (ANA) test provides some suggestion of lupus; it important \nto realize that most people with lupus have a positive ANA test, \nbut most people with a positive ANA test do not have lupus. \nPositive ANA can occur with certain drugs, cancer, and a viral \ninfection. It is interesting to note that those with a positive ANA, \nbut no signs of lupus, may have a false positive test for other \ndiseases like Lyme disease. A positive ANA blood test requires a \nmore sophisticated panel of antibody testing to further differenti-\nate the etiology of the positive ANA and help confirm a diagnosis \nof lupus. There is no cure for lupus, but symptoms can be con-\ntrolled in many cases with corticosteroids and immunosuppres-\nsive drugs.\nDental Implant Implications\nThere is no direct contraindication to dental implant treatment in \nsystemic lupus erythematosus patients. However, caution should \nbe taken for possible associated organ damage and the use of high \ndoses of corticosteroids and immunosuppressive drugs, which \nmay contraindicate dental implants in those individuals. \nScleroderma\nScleroderma is a rare, chronic disease characterized by excessive \ndeposits of collagen that causes musculoskeletal, pulmonary, and \nGI involvement. There are about 75,000 to 100,000 people in \nthe United States that have this disease. The disease is most com-\nmon in women between the ages of 30 and 50. There are two \nmain types, localized and systemic. Localized scleroderma usu-\nally attacks the skin and on occasion the muscle and joints, but it \nspares the internal organs. These patients usually have discolored \npatches on the skin (morphea). They can have streaks or bands of \nthick, hard skin. This is called linear scleroderma and it affects the \narms and legs. The more serious type is systemic scleroderma. This \nform attacks the skin, joints, blood vessels, lungs, kidneys, heart, \nand other organs and in many cases significantly shortens one’s \nlife span. CREST syndrome is a version of systemic scleroderma \nthat manifests as skin thickening in fingers and toes and as calci-\nfied nodules under the skin. Raynaud phenomenon is also associ-\nated with CREST, as are esophageal motility issues. A blood test \nfor anticentemere antibodies is usually positive in CREST syn-\ndrome. There is no cure for scleroderma. Treatment is aimed at \nthe affected organs, including NSAIDs and immunosuppressant \ndrugs. ACE inhibitors are a mainstay of scleroderma affecting the \nkidney.101\nDental Implant Implications\nNumerous reports have discussed the successful treatment of \nscleroderma patients with dental implants. A fixed prosthesis is \nrecommended because of the inability to retrieve a removable \nprosthesis due to possible dexterity problems. However, a high \npercentage of these patients are being treated with immunosup-\npressive drugs, which may contraindicate the implant therapy. \nRheumatoid Arthritis\nRA is a chronic, inflammatory autoimmune disease that causes the \npatient’s immune system to attack the muscles and joints of the \nbody. It is more prominent in the early stages in the fingers, wrist, \nfeet, and ankles rather than the larger joints such as the shoulder, \nhip, or knee. RA is different from osteoarthritis, which is caused \nby wear and tear and previous injuries. In RA, the disease affects \nthe lining of the joints, which increases pain and swelling and \nresults in significant bone erosion and deformity of the joints. The \ninflammation in RA can affect other organs in the body. In most \ncases the affected joints are symmetric, so if one side of the body \nis affected, then the other side usually will demonstrate similar \nmanifestations. Life expectancy of patients with RA is shortened \nby approximately 5 to 10 years.102\nRA is treated with a wide range of medications including dis-\nease-modifying antirheumatic drugs, antiinflammatory drugs, and \nanalgesic medications.\nMethotrexate, a drug used to treat cancer, is commonly used to \ntreat RA. Studies have shown the detrimental effect of this medi-\ncation on bone by delaying bone healing. However, other studies \nhave concluded that that low-dose methotrexate treatment does \nnot affect titanium implant osseointegration.103\nDental Implant Implications\nThere is no direct contraindication for dental implants in patients \nwho have RA. Because of the lack of mobility and dexterity, a \nfixed-implant restoration is indicated. Special attention should be \ngiven to the treatment medications because immunosuppressive, \nglucocorticoid therapy and biologics may contraindicate implant \ntreatment. \nHuman Immunodeficiency Virus\nHuman immunodeficiency virus (HIV) is a retrovirus that is \nresponsible for acquired immunodeficiency syndrome (AIDS), \nwhich causes the immune system to be depressed, leading to life-\nthreatening opportunistic infections. According to the US govern-\nment (https://www.hiv.gov), there are more than 1.1 million in \nthe United States living with HIV and almost 1 in 7 may not be \naware they have the disease. Just less than 40,000 individuals were \ndiagnosed with HIV in 2016. The number of new HIV infections \ndid decline between 2008 to 2014, but over the past several years \nan increase in new cases has been seen. It is most common in \nhomosexual and bisexual men."
  },
  {
    "page": 49,
    "content": "257\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nInitially, most diagnosed with HIV died from the disease, but \na lot has changed in the past 20 years. In 1996, the life expectancy \nfor a 20-year-old with HIV increased to almost 39 years. In 2011, \nthe total life expectancy increased to almost 70 years.104\nThere is no cure for either HIV or AIDS; however, revolutionary \nnew antiretroviral medication and protease inhibitors developed \nsince 1996 have now been able to eliminate active viral load titers \nfrom the bloodstream. Many patients demonstrate complete sup-\npression of the virus while taking the medication. Although not a \ncure, the inactivity improves survival and limits the effect on other \norgans. These newer medications have slowed or even stopped the \ndamage caused by the HIV infection. They also prevent the virus \nfrom developing into more virulent forms and attacking other \norgans in the body. A postexposure prophylaxis (an antiretroviral) \nhas been shown to reduce the risk of infection after exposure.\nDental Implant Implications\nNumerous reports have shown successful dental implant therapy \nin HIV patients.105,106; however, there is insufficient data to deter-\nmine the association between HIV infection and the success of \ndental implants. Special care must be taken to evaluate the current \nstatus of the patient’s immune system and the potentially toxic \nmedications the patient is taking. \nMiscellaneous\nSleep Apnea\nObstructive sleep apnea (OSA) occurs when there is partial or \ncomplete obstruction of the upper airway during sleep. This in \nturn causes the chest wall muscles and diaphragm to work harder \nto clear the obstruction. OSA has both significant medical and \ndental implications. During the period of obstruction, the oxygen \nlevels in the bloodstream decrease, resulting in diminished delivery \nof oxygen to vital organs, which can precipitate an MI or stroke.\nPatients that are obese, have a larger, thicker neck, deviated \nseptum or smaller nasal canals, enlarged tonsils, large uvula, or \nlarge tongue may be at increased risk during surgery, especially if \nsedation is used. There are many symptoms that can be associated \nwith OSA. Daytime sleepiness, early morning headaches, restless \nsleep, loud snoring, and waking up feeling like one is choking or \ngasping are some of the more common ones.\nOne study demonstrated that “among the associated sleep \nsymptoms and disorders OSA was the highest risk factor for tooth \ngrinding during sleep and was reduced with proper treatment.”107 \nUntreated patients will most likely have increased morbidity, and \nimplants will be subject to higher related mechanical force issues.\nThe diagnosis of OSA is made through the use of a sleep study. \nSleep studies can be done at home or in a sleep clinic. Home sleep \nstudies are better used as screening tools to confirm the diagno-\nsis. To fully evaluate the potential treatment options, a titration \nstudy in a sleep laboratory may be required. The test records the \nnumber of slower or apneic (stopped breathing) episodes and oxy-\ngen saturation in the bloodstream. The test also monitors arm and \nleg movements. A sleep specialty physician evaluates the test and \nmakes the diagnosis and recommendations for treatment.\nTreatment options include continuous positive airway pres-\nsure (CPAP). The CPAP machine uses a hose and mask to deliver \nconstant steady air pressure. Newer devices are much more com-\npact, including Federal Aviation Administration (FAA) travel \nsizes, and are much quieter. Some individuals find these devices \ncumbersome and uncomfortable and sometimes give up on this \ntreatment method. It is important to ask patients diagnosed with \nsleep apnea if they are using their CPAP or other treatment on a \nregular basis. A variation of the CPAP is bilevel positive airway \npressure (BiPAP). This machine supplies BiPAP and coordinates \nmore pressure during inhalation versus exhalation. In less severe \ncases, oral appliances may be a reasonable option and are much \neasier to use than CPAP. Most open the airway by bringing the \njaw more forward. CPAP machines may place an increased force \non the implant-related area. Oral airway devices may not be \nappropriate for patients with more significant apnea.\nIt is important to remember that OSA is a medical condition \nthat has a complex pathophysiology. It can be seen as a factor in \nother medical conditions including CHF and asthma. OSA is not \nlimited to just maxillofacial structural abnormalities. The diag-\nnosis goes beyond just a test on the number of apnea-hypopnea \nspells. The diagnosis must be considered in conjunction with \nother of the patient’s comorbid conditions. OSA should be diag-\nnosed and treated by a physician, and preferably by a sleep medi-\ncine specialist.108\nOSA has been shown to be a secondary cause of hypertension. \nApnea creates significant increases in systolic and diastolic pres-\nsure, which creates higher blood pressure levels at night. However, \nthis elevation can continue into the daytime. It has been shown \nthat 50% of patients with hypertension may have OSA (p. 20). \nMore important OSA causes more secondary hypertension than \nany other source. This same study implies that OSA may be one \nof the modifiable factors to help prevent hypertension. It is rea-\nsonable to consider that patients with resistant hypertension may \nhave untreated sleep apnea.109 \nElderly (Increased Age)\nAccording to WHO, most developed countries have accepted the \nchronologic age of 65 years as the definition of an elderly or older \nperson. The treatment of elderly patients is definitely challenging, \nand because more patients are living longer and are more socially \nactive, they will continue to be a significant part of the implant \ndentist’s practice. Studies have shown that elderly patients are \nmore prone to systemic diseases, more medically compromised, \nhave potentially longer healing periods, more challenging bone \nconditions (quality and quantity), increased susceptibility to drug \ninteractions, and increased dental implant morbidity.\nDental Implant Implications\nDecreased Renal Function. There is an age-related decline \nin renal functions accelerated by comorbid conditions such as \nhypertension, heart disease, and diabetes. The age-related decline \nis more physiologic, whereas the pathologic decline is associated \nwith many medical conditions. In elderly patients, the glomer-\nular filtration rate (GFR) and creatine will give insight into the \npatient’s kidney function. As kidney function declines, especially \nin stage 3 (GFR 30–59) and above, there is a decreased metabo-\nlism and excretion of drugs. Therefore the intervals between drug \nadministration should be longer and dosages should be decreased, \nexcept for lipid-soluble drugs and antibiotics, to compensate for \nthe increase in body fat and the reduced immune response. In the \npresence of significant kidney disease (stage 4 or above), antivirals \n(acyclovir), β-lactams (amoxicillin), and cephalosporins should be \nreduced. Nonsteroidal analgesics should not be prescribed in those \nwith stage 3 or greater impairment without consultation with the \npatient’s physician. Caution should be exercised with the use of \nsedation drugs because they can have more pronounced and lon-\nger-lasting effects. \nDecreased Gastric Motility. The decreased gastric motility \nof the elderly patient affects the use of oral analgesics such as"
  },
  {
    "page": 50,
    "content": "258\nPART III     Fundamental Science\nhydrocodone and oxycodone. In addition, the use of narcotics in \nthe elderly can cause significant changes in bowel habits, especially \nconstipation. If not contraindicated, a stool softener may be rec-\nommended concurrently with use of analgesics. Also, when using \nantibiotics for any prolonged period, the use of probiotics may \nhelp maintain normal gut flora. \nMedications. Medications and the number of prescribed drugs \nusually increase with age, with over 75% of patients 65 years and \nolder taking medications. Many of these drugs are often the cause \nof adverse or significant drug reactions. Studies have shown more \nthan 70% of drugs taken by elderly patients have potentially \nadverse effects in the dental practice.29 Although the incidence of \nsevere drug interactions with commonly prescribed pain medica-\ntions is relatively low, caution should be used in reviewing the \nelderly patient’s complete medication history before prescribing \nany analgesics. \nIsolated Systemic Hypertension. A major cardiovascular health \nissue with the elderly is isolated systolic hypertension (ISH). In \nISH, systolic blood pressure elevates above 140 mm Hg while \nthe diastolic pressure remains below 90 mm Hg. The differ-\nence between the systolic and diastolic is termed the pulse pres-\nsure, which is a significant risk factor for stroke and heart disease. \nRecent meta-analysis studies have shown a 10-mm Hg increase in \npulse pressure will increase the risk of major cardiovascular events \nby 20%.110 \nBone Healing. Clinical studies have shown a direct correlation \nbetween delayed bone healing with increasing age. Most likely the \netiology results from a reduced number of osteogenic cells and \nreduced systemic and localized blood flow to the healing site. \nTherefore longer healing periods along with progressive loading \nare recommended in older patients. \nBone Quality/Quantity. Both the quality and quantity of \nbone is affected by aging. Histomorphometric and microradio-\ngraphic studies have shown that after the age of 50, a marked \nincrease in the cortical porosity leading to decreased bone mass \nis present. Loss of bone mineral content has been estimated \nto be approximately 1.5% per year in females and 0.9% in \nmales.111 \nIncreased Implant Failure Rate. Studies have shown an \nincreased risk of implant failure as a result of many age-related fac-\ntors including compromised bone quality and quantity, implant \nlength, treatment protocol, and edentulous locations. Other stud-\nies have shown patients older than 60 years were twice as likely to \nhave adverse outcomes.112 \nProsthetic Treatment. Elderly patients have been shown to have \nincreased difficulty in adapting to the final implant prostheses. \nPostinsertion issues such as general adaptation, muscle control, \nhygiene difficulty, tissue inflammation, and overdenture seating \nwere significant in the older population study. Patient education \nand final expectations should be discussed in detail before initiat-\ning treatment.113 \nTreatment Summary. The implant clinician must understand \nthe physical, metabolic, and endocrine changes and the effects \nassociated with the elderly patient before initiating implant treat-\nment. Age is most certainly a prognostic factor in implant failure \nand morbidity. However, advanced age is not an absolute contra-\nindication to implant therapy. It is imperative that the clinician \nobtain a detailed medical history and list of medications before \ndevising the dental treatment plan. Patient education along with \nmodification in medication use, surgical technique, soft and hard \ntissue healing times, and careful assessment of postoperative com-\nplications must be strictly enforced. \nAdolescent (Decreased Age)\nDental implants are commonly used to correct the congenital \nabsence of teeth in adolescents, and studies have shown this to be \na very reliable and predictable treatment option. When a clinician \nis presented with an adolescent patient, there must be a degree \nof caution as to the ideal time that implant therapy should be \ncommenced. The concern is that placement of implants too early \nmay lead to the implants interfering with normal growth develop-\nment and potential esthetic issues. No age-related surgical issues \nexist unless there are systemic contraindications or psychological \nissues. If placement of an implant is completed before craniofa-\ncial growth is complete, possible interruption of facial growth and \nesthetic (infraocclusion or labioversion) issues can result.\nDental Implant Implications\nEarly Consultation. In determining the ideal time for implant \nplacement, the patient/family must be educated on craniofacial \ngrowth compared with chronologic age. Chronologic age is a poor \nindicator of dental development/facial growth; timing of implant \nplacement should coincide with growth cessation. \nDetermination of Growth Cessation. In the literature, there \nexist many methods of determining completion of craniofacial/\nskeletal growth: chronologic age, complete dental development, \nvoice changes, hand–wrist radiographs, cervical vertebral matura-\ntion, and superimposition of lateral cephalometric radiographs. \nThe most reliable and safest (no radiation exposure) method has \nbeen shown to be when the patient begins to exhibit a lack of \ngrowth in stature (0.5 cm/year). When implants are treatment \nplanned in adolescents, clinicians must take into consideration the \ntiming, site development, esthetics, and possible prosthetic limi-\ntations including malposition that may develop with age. Most \nimportantly, the determination of growth cessation should be \ndetermined by the lack of growth in stature. This method involves \nno radiographs (decreased radiation exposure) and is the most \nbenign method. The patient’s pediatrician should be consulted in \nthe determination of growth cessation (Fig. 10.3). \nSmoking\nIn the United States, an estimated 42.1 million people, or 18.1% \nof all adults (age 18 years or older), smoke cigarettes. Overall, \nsmoking prevalence has declined from 2005 (20.9%) to 2012 \n(18.1%); however, tobacco is still the most preventable cause of \ndeath and disease in the United States.\nSmoking has been directly related to many oral diseases includ-\ning periodontal disease, malignancies, and dental implant–related \ncomplications. Studies have shown that over 7000 different gases and \nchemicals are found in cigarette smoke (e.g., nitrogen, carbon monox-\nide, carbon dioxide, ammonia, hydrogen cyanide, benzene, nicotine). \nIn tissues, carbon monoxide displaces oxygen from Hb molecules \nbecause of its stronger affinity.114 Hydrogen cyanide has been shown \nto cause hypoxia in tissues. The adverse effects that smoking has on \nsuccessful outcomes in implant surgery are well documented. Multi-\nple retrospective studies have shown that smokers experienced almost \ntwice as many implant failures compared with nonsmokers.115\nDental Implant Implications\nIncreased Incision Opening. Studies have shown that \nsmoking is directly related to increased incision line open-\ning. Possible mechanisms for poor wound healing include the \nvasoconstrictive nature of nicotine; increased levels of fibrino-\ngen, Hb, and blood viscosity; increased platelet aggregation; \nand impaired polymorphonuclear neutrophil leukocyte func-\ntion.116 Therefore additional sutures along with tension-free \nclosure are recommended."
  },
  {
    "page": 51,
    "content": "259\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nInfection. Tobacco smoke decreases polymorphonuclear leuko-\ncyte activity, resulting in lower motility, a lower rate of chemotactic \nmigration, and reduced phagocytic activity. These conditions con-\ntribute to a decreased resistance to inflammation and infection.117 \nImplant/Bone Grafting Failure. Meta-analysis studies have \nshown a definite correlation between smoking and failure rates of \nimplants and bone grafts. \nPeri-implantitis. Studies have shown in smokers a strong cor-\nrelation between peri-implantitis and dental implants. \nInformed Consent. With the possible detrimental effects of \nsmoking on implants, it is recommended that patients be informed \nin detail about the risks of smoking. These possible consequences \ninclude increased marginal bone loss after implant placement and \nthe presence of peri-implantitis. Additionally, there is a direct effect \non the success rates of bone grafts, with almost double the failure \nrate in implants placed in grafted maxillary sinuses. \nSmoking Cessation. A strong recommendation on smok-\ning cessation before and after implant surgery is recommended \nbecause it has been shown to decrease implant morbidity.118 \nIdeally, the patient is instructed to cease smoking for 2 weeks \nbefore surgery to allow for reversal of increased blood viscos-\nity and platelet adhesion. Smoking cessation is continued for 8 \nweeks after implant surgery, which coincides with the osteoblas-\ntic phase of bone healing.119 This has been shown to increase \nwound healing capabilities and reverse subgingival microflora120 \n(Table 10.21).\nIdeally, smoking cessation should be a gradual process because \nwithdrawal symptoms are less severe in patients who quit slowly. \nThere exists the concept of the “five As” in smoking cessation:\n\t1.\t \u0007Ask: All patients should be asked about possible tobacco use.\n\t2.\t \u0007Assess: Determine whether the patient has ever quit smoking \nor is interested in smoking cessation.\n\t3.\t \u0007Advise: Every smoking patient should be advised of complica-\ntions that may arise from continued smoking.\n\t4.\t \u0007Assist: The smoking patient must be instructed on ways to quit \nsmoking or be given a relevant physician referral.\n\t5.\t \u0007Arrange: Make arrangements to evaluate the success of the \nsmoking cessation.121 \nTreatment Summary\nAny amount of smoking: Relative contraindication\nExcessive smoking (>1.5 packs/day): Absolute contraindication \nuntil smoking sessation\nAlcohol\nEthyl alcohol is one of the most widely used mood-altering \ndrugs in the world. Approximately 17 million adults aged 18 \nand older have an alcohol use disorder. This is more common \nin men than women. Many with alcohol dependence disorders \ngo undiagnosed. Because of the adverse effect of alcohol on den-\ntal implants, screening for undiagnosed alcohol-related disorders \n180\n170\n160\n150\n140\n130\n120\n110\n100\n90\n80\n70\n60\n50\n40\n0\n1\n2\n3\n4\n5\n6\n7\n8\nAge, years\n97\n90\n75\n50\n25\n10\n3\ncm\n9 10 11 12 13 14 15 16 17 18\n190\n180\n170\n160\n150\n140\n130\n120\n110\n100\n90\n80\n70\n60\n50\n40\n0\n1\n2\n3\n4\n5\n6\n7\n8\nAge, years\nHEIGHT        Boys\n97\n90\n75\n50\n25\n10\n3\ncm\n9 10 11 12 13 14 15 16 17 18\nHEIGHT        Girls\n• Fig. 10.3  Growth cessation chart. Consultation with the patient’s pediatrician should be completed to \nascertain growth cessation, which usually coincides with <0.5 cm of growth in stature (arrows)."
  },
  {
    "page": 52,
    "content": "260\nPART III     Fundamental Science\nis beneficial. Excessive alcohol intake has been associated with \nsurgical and dental implant-related issues such as liver and meta-\nbolic dysfunction, bone marrow suppression resulting in bleeding \ncomplications, predisposition to infection, and delayed soft tissue \nhealing.122\nDental Implant Implications\nBleeding Problems. Alcohol interferes with coagulation \non multiple levels, leading to decreased platelet production \n(thrombocytopenia), impaired platelet function (thrombo-\ncytopathy), and diminished fibrinolysis. Patients who abuse \nalcohol are more susceptible to intraoperative and postopera-\ntive bleeding complications associated with dental implant \nsurgery. \nInfection. Alcohol use leads to significant alterations of \ncell-mediated immune systems. Alcohol-induced immunosup-\npression results in a decrease in delayed-type hypersensitivity \n(DTH), which is a preoperative indicator for postoperative \ninfectious complications.123 Therefore patients consuming \nalcohol (especially those who consume it immediately after \nsurgery) are more susceptible to incision line opening and \ninfection. \nIncreased Bone Loss. Alcohol use also leads to decreased \nbone formation, increased resorption, and decreased osteo-\nblast function, resulting in decreased bone density and \nintegration issues. The use of alcohol has a direct effect on \ndental implant healing; studies have shown greater mar-\nginal bone loss and implant failure associated with alcohol \nconsumption. \nInformed Consent/Decrease Comorbidities. The patient must \nbe well informed of potential consequences of alcohol use, espe-\ncially immediately after implant surgery. \nCessation Program. Abstinence can reverse many of alco-\nhol’s effects on hematopoiesis and blood cell functioning; the \npatient should be instructed on possible cessation treatments \nand programs. Ideally, patients should refrain from using alco-\nhol for a minimum of 2 weeks or after incision line closure \noccurs. \nPsychological\nProviding dental implant care to patients with psychologi-\ncal problems is very challenging for clinicians. This group of \npatients is prone to oral health issues because of poor oral \nhygiene, poor compliance, and adverse medication effects. Pro-\nviding comprehensive dental implant care to patients requires \ngood communication skills, perseverance, and flexibility in \nboth the surgical and prosthetic phases of treatment. Addition-\nally, many of the drugs used to treat these patients, including \ntricyclic antidepressants, selective serotonin reuptake inhibitors \n(SSRIs), and monoamine oxidase inhibitors, are associated with \nmany drug interactions. Oral manifestations of these diseases \nand medications include an increase in caries and periodon-\ntal disease, increased smoking, xerostomia, chronic facial pain, \nparafunction (bruxism/clenching), and temporomandibular \njoint dysfunction.\nDental Implant Implications. Many psychotherapeutic \ndrugs interact with medications that are commonly prescribed \nin implant dentistry. Clinicians must be aware of drug–drug and \ndrug–disease interactions with respect to the patient’s medical \nhistory. Most interactions are related to the potentiation of the \nsedative and anticholinergic actions of the psychotherapeutic \ndrugs. It is important to identify patients taking monoamine \noxidase inhibitors or tricyclic antidepressants. Although these \nare no longer the mainstay of treatment for psychiatric illness, \nmany patients will be placed on these medications to potenti-\nate the effect of other medications. Common examples include \namitriptyline, doxepin, nortriptyline, and imipramine. These \nmedications are also being used to treat nonpsychiatric illnesses \nsuch as chronic pain and sleep disorders. The main concern is \n  \u0007Smoking Cessation Techniques\nTechnique\nInstructions\nPossible Side Effects\nNicotine gum (Nicorette)\nChewing gum that releases nicotine\nTMJ, gastric irritation, difficulty for patients wearing removable prostheses\nNicotine inhaler (Nicotrol inhaler)\nPuffing for approximately 20 minutes/hour\nDizziness, nausea/vomiting, confusion, blurred vision, palpitations\nNicotine lozenge (Nicorette)\nDissolving\nDizziness, nausea/vomiting, confusion, blurred vision, palpitations\nNicotine nasal spray (Nicotrol)\n1–2 doses per hour for 2 months\nNasal mucosa irritation, dizziness, nausea/vomiting, confusion, blurred \nvision, palpitations\nNicorette microtab sublingual \ntablets\n1–2 tabs hourly\nDizziness, nausea/vomiting, confusion, blurred vision, palpitations\nNicotine patch (Nicoderm CQ)\nWorn during day\nSkin irritation, dizziness, nausea/vomiting, confusion, blurred vision, \npalpitations\nRx medication: bupropion SR \n(Zyban), varenicline tartrate \n(Chantix)\nAs directed\nBupropion SR: dry mouth, nausea, headache, dizziness, changes in  \nappetite, weight loss or gain, worsening of anxiety, insomnia\nVarenicline tartrate: chest pain, dizziness, severe headache, easy  \nbruising, vivid nightmares, sleep disturbance\nHypnosis\nMixed results supporting effectiveness\nN/A\nAcupuncture\nMixed results supporting effectiveness\nN/A\nTMJ, Temporomandibular joint dysfunction.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \nTABLE \n10.21"
  },
  {
    "page": 53,
    "content": "261\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nthe interaction of tricyclic medications and epinephrine because \nthey produce anticholinergic effects on the heart. There is no \ncontraindication to using them together, but patients should \nbe followed more closely for adverse interactions. A physician \nconsult and the implementation of a stress reduction protocol \nare recommended steps to follow when initiating treatment with \nthese patients. \nMedications of Interest to Implant Dentistry\nBisphosphonates\nSince the first reported cases of necrotic, exposed bone in \npatients taking bisphosphonates, there has been much debate \nover treatment implications regarding dental implants. Bisphos-\nphonates are a group of drugs that are widely used for several \nbone disorders and have been approved by the FDA for treat-\nment of osteoporosis, metastatic bone cancer, and Paget disease. \nHowever, what was once termed bisphosphonate osteonecrosis \nhas now been renamed drug-induced or medication-induced \nosteonecrosis of the jaws (DIONJ) by the American Medical \nAssociation. This has been renamed because of the incidence of \nosteonecrosis cases involving additional drug classifications such \nas monoclonal antibody drugs, antiangiogenic drugs, and tyro-\nsine kinase inhibitors (Table 10.22).\nBisphosphonates are mainly used for the treatment of \nosteoporosis (oral form) and metastatic cancer (IV form) by \ninducing osteoclastic death or apoptosis at the cellular level. \nAs an osteoporosis drug, bisphosphonates reduce bone resorp-\ntion via a direct effect on the osteoclast. In osteoporotic \npatients undergoing bisphosphonate treatment, old bone is \nretained because bone turnover is suppressed, preventing nor-\nmal remodeling in this area, which results in the formation \nof brittle bone. Additionally, bisphosphonates kill functionally \nresorbing osteoclasts not only at the peripheral sites but also \nin the bone marrow.\nDiagnosis of Drug-Induced Osteonecrosis of the Jaw\nMarx has defined characteristics of patients who are diagnosed \nas having drug-induced osteonecrosis of the jaw (DIONJ). These \ncharacteristics include (1) current or previous treatment with a \nsystemic drug that affects bone homeostasis, (2) exposed alveolar \nbone in the jaws that persists for more than 8 weeks, (3) no his-\ntory of radiotherapy to the jaws, and (4) no known diagnosis of \nosteopetrosis or cemento-osseous dysplasia. The definitive symp-\ntom of DIONJ is bone exposure in the mandible or maxilla that \ndoes not heal. Pain and inflammation are present, with possible \nsecondary infection of the soft tissue. In severe cases, drainage \nand progressive extension of bone involvement or sequestration \nresult.124 \nActive Lesions\nOsteonecrosis may remain asymptomatic for weeks and possibly \nmonths. Lesions usually develop around sharp, bony areas and \nprevious surgical sites, including extractions, retrograde apicoecto-\nmies, periodontal surgery, and dental implant surgery. Symptoms \ninclude pain, soft tissue swelling, infection, loosening of teeth, \nand drainage. Radiographically, osteolytic changes are seen, and \ntissue biopsy has shown the presence of actinomyces, which is pos-\nsibly caused by secondary infection. \nTesting\nC-Terminal Telopeptide Test (CTx). It has been proposed that \nassays to monitor markers of bone turnover may help in the diag-\nnosis and risk assessment of developing bisphosphonate-associ-\nated osteonecrosis. CTx are fragments of collagen that are released \nduring bone remodeling and turnover. Because bisphosphonates \nreduce CTx levels, it is believed that serum CTx levels can be a \nreliable indicator of risk level. The CTx test (also called C-terminal \ntelopeptide and collagen type 1 C telopeptide) is a serum blood \ntest obtained by laboratories or hospitals (ICD-9 diagnostic code \n733.40). However, today, the use of the CTx test to determine the \npossibility of osteonecrosis is controversial.125,126\n  \u0007Medications Linked to Drug-Induced Osteonecrosis of the Jaw\nDrug\nClassification\nUse\nDose\nRoute\nAlendronate (Fosamax)\nBisphosphonate\nOsteoporosis\n70 mg/week\nOral\nRisedronate (Actonel)\nBisphosphonate\nOsteoporosis\n35 mg/week\nOral\nIbandronate (Boniva)\nBisphosphonate\nOsteoporosis\n150 mg/month\nOral\nZoledronate acid (Reclast)\nBisphosphonate\nOsteoporosis\n5 mg/year\nIV\nZoledronate acid (Zometa)\nBisphosphonate\nOsteoporosis\n4 mg/month\nIV\nPamidronate (Aredia)\nBisphosphonate\nOsteoporosis\n90 mg/month\nIV\nDenosumab (Prolia, Xgeva)\nMonoclonal antibody\nOsteoporosis, cancer\n60 mg/6 months\nSubcutaneous\nBevacizumab (Avastin)\nMonoclonal antibody\nMetastatic cancer\n100–400 mg/14 days\nIV\nSunitinib (Sutent)\nTyrosine kinase inhibitor\nCancer\n5 mg/year\nIV\nEtidronate (Didronel)\nBisphosphonate\nPaget disease\n300–750 mg/6 months\nOral\nTiludronate (Skelid)\nBisphosphonate\nPaget disease\n400 mg daily/3 months\nOral\nIV, Intravenous.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \nTABLE \n10.22"
  },
  {
    "page": 54,
    "content": "262\nPART III     Fundamental Science\nCTx Value\nRisk for Drug-Induced  \nOsteonecrosis of the Jaw\n300–600 pg/mL (normal)\nNone\n150–299 pg/mL\nNone to minimal\n101–149 pg/mL\nModerate\nLess than 100 pg/mL\nHigh\n Drug Holiday. Marx has suggested a preoperative protocol for \nadministering possible DIONJ drugs to patients who are under-\ngoing oral surgical procedures. This protocol takes into consid-\neration the type and duration of drug use and radiographic and \nclinical risk factors. Depending on the laboratory values obtained, \na “drug holiday” may be indicated, which includes temporary \ninterruption of bisphosphonate treatment. However, improve-\nment of bisphosphonate levels may not be observed, because mea-\nsurable levels have been shown to persist in bone for up to 12 years \nafter cessation of therapy. \nDrug Holiday Recommendation125    \nPresurgical: Medication stoppage 9 months before surgery\nPostsurgical: Medication stoppage 3 months after surgery \nAdditional Recommendations\nMedical History. A comprehensive medical history is \nessential before any elective treatment is initiated. The most \nimportant history of bisphosphonates is the use of IV nitro-\ngen-containing bisphosphonates such as pamidronate (Aredia) \nand zoledronic acid (Zometa) and new osteoporotic drugs, \nwhich have very limited data on the association with DIONJ. \nIn the dental setting, the most common bisphosphonates that \nimplant dentists are exposed to will most likely belong to the \nfamily of oral nitrogen-containing bisphosphonates such as \nrisedronate, ibandronate, and alendronate. The latest studies \nshow that oral bisphosphonates have a very low probability of \ncausing osteonecrosis.127 However, because of the long half-\nlife and short duration of the studies, future long-term com-\nplications may become problematic. With this in mind, the \nimplant dentist should be cautioned regarding the possibility \nof developing osteonecrosis side effects. The risks versus ben-\nefits of dental treatment must be discussed with the patient in \ndetail. A well-documented consent form is recommended with \npossible medical consultation if the patient has been on this \nmedication for more than 3 years. \nReclast. As stated previously, most drugs used to treat osteo-\nporosis are oral, nitrogen-containing bisphosphonate drugs. \nReclast (IV: Zoledronate) is given in 5-mg IV doses once a \nyear. Studies have shown that a significant risk occurs after the \nfourth yearly dose, which is caused by the accumulation of the \nmedication and its 11-year half-life. Elective dental implant \nsurgery or bone graft surgery are best scheduled 9 months \nafter the most recent Reclast dose and 3 months before the \nnext planned dose. However, at this time, very little research \nhas been conducted on the relationship between Reclast and \nDIONJ. The FDA has placed a warning on the Reclast pack-\nage inserts that states, “avoid having any type of dental surgery \nwhile you are being treated with Reclast.” Therefore patients \nunder treatment with Reclast should not be considered for \nelective dental implant surgery. \nComorbidities. Comorbidities are systemic diseases, medical \nconditions, medications, gender, and age, all of which can pre-\ndispose the patient to a greater chance of developing DIONJ. \nMany chemotherapeutic drugs, diabetes, immune diseases, ane-\nmia, smoking, obesity, female gender, and renal dialysis have \nbeen noted as comorbidities for DIONJ. Additionally, the use \nof glucocorticosteroids may be contraindicated in patients tak-\ning the DIONJ medications discussed previously because these \ndrugs have been associated with an increased occurrence of \nosteonecrosis. \nTreatment Summary\nOral bisphosphonates: Relative contraindication (informed con-\nsent, good surgical technique, CTx test, drug holiday)\n\tIV\t\u0007bisphosphonates: Absolute contraindication (Reclast: abso-\nlute/relative contraindication depending on physician clear-\nance) (Box 10.12). \nNew Therapies for Osteoporosis\nMonoclonal Antibodies\nMonoclonal antibodies work by inhibiting receptor activator of \nnuclear factor κ-B (RANK) ligand, which is a type II membrane \nprotein that acts as a primary signal for bone removal. Mono-\nclonal antibodies have a direct effect on the immune system and \nORAL BISPHOSPHONATE\nUse <3 Years:\n 1. \u0007Proceed with surgery with detailed oral and written informed consent \nfor bisphosphonate-associated osteonecrosis and possible decreased \nimplant healing.\n 2. \u0007Decrease co-morbidities: periodontal disease, infections, smoking, etc.\n 3. \u0007Strict adherence to antibiotic prophylaxis and antimicrobial use (0.12% \nchlorhexidine)\n 4. \u0007No prophylactic corticosteroids \n 5. \u0007Elective: CTx Test or Drug Holiday \n*Early learning curve: Referral\nUse >3 Years \n 1. \u0007Proceed with surgery with detailed oral and written informed consent \nfor bisphosphonate-associated osteonecrosis and possible decreased \nimplant healing.\n 2. \u0007Decrease co-morbidities: periodontal disease, infections, smoking, etc.\n 3. \u0007Medical Clearance\n 4. \u0007Strict adherence to antibiotic prophylaxis and antimicrobial use (0.12% \nchlorhexidine) \n 5. \u0007No prophylactic corticosteroids \n 6. \u0007CTx Test (>150 pg/mL) or Drug Holiday \n*Early learning curve: Referral\nDrug Holiday (by physician only)\n9-month presurgical + 3 month post-surgical\nLaboratory Risk Assessment\nCTx Value (pg/mL)\nRisk for Osteonecrosis \n300–600 (normal) \nNone \n150–299 \nNone to minimal \n101–149 \nModerate \n<100 \nHigh \nIV BISPHOSPHONATE\nAbsolute Contraindication\na \u0007Marx RE: Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, \netiology, prevention, and treatment. Chicago, IL: Quintessence; 2007.\n\t• BOX 10.12\t      \u0007Bisphosphonate Protocol and \nSuggestionsa"
  },
  {
    "page": 55,
    "content": "263\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\ncontrol bone regeneration and remodeling. These drug molecules \nirreversibly bind to mineral matrix in bone and have a half-life of \napproximately 26 days, which is much shorter than bisphospho-\nnates (11 years).\nDenosumab (Prolia) is a biyearly subcutaneous injection \nfor the treatment of osteoporosis. This is a human monoclonal \nantibody that functions as a RANK ligand inhibitor. Inhibition \nof the RANK ligand results in diminished osteoclast functional \nand bone resorption. Denosumab recognizes the specific protein \nthat normally activates osteoclasts, inhibiting their activation \nand preventing them from breaking down bone. Denosumab \nhas also been used to treat metastatic bone disease. These inhibi-\ntors do not bind to bone, and their effect on bone remodeling \ndecreases after treatment is stopped. Prolia has a short half-life \n(26 days) and does not accumulate in the bone like bisphos-\nphonates. It has been shown to be completely inert within 6 \nmonths of administration.128 Osteonecrosis of the jaw has been \nobserved in patients receiving denosumab, and all patients \nshould receive an oral examination before therapy. The risk of \ndeveloping osteonecrosis of the jaw is less studied compared \nwith the bisphosphonates; however, this has been shown to be a \nrelevant concern.129 \nImmunosuppressive Drugs\nImmunosuppressive drugs are medications that are used to inhibit \nor prevent activity of the immune system. They are usually used \nto minimize rejection of transplanted organs and tissues and for \ntreatment of autoimmune diseases. These drugs have many side \neffects, with the majority of them acting nonselectively (acting on \nnormal cells also). There are many classes of immunosuppressive \ndrugs including corticosteroids, calcineurin inhibitors, mTOR \ninhibitors, IMDH inhibitors, biologics, monoclonal antibodies \n(Box 10.13).\nGlucocorticoids (Long-Term Use)\nGlucocorticoids have potent antiinflammatory and immunosup-\npressive properties. Because these drugs are widely used in the \ntreatment of inflammatory and autoimmune diseases, special \nattention must be given to patients who are on long-term high \ndoses of glucocorticoids. These drugs impair many healthy ana-\nbolic processes in the body and suppress the immune system, \nwhich can lead to severe complications in dental implant patients. \nThe long-term use has been shown to have deleterious effects on \nbone remodeling and repair. \nCytostatics\nCytostatics are common medications in the treatment of malig-\nnant disease. These drugs cannot discriminate between malignant \nand normal tissues and become cytotoxic to normal tissue. Most \nchemotherapeutic agents are known to have cytotoxic effects \non bone, especially on grafted bone in which the blood supply \nis compromised. Because chemotherapeutic agents have a high \naffinity for cells that have a high turnover rate, the oral mucosa is \noften affected. These mucosal ulcerations can become secondarily \ninfected.\nSeveral studies have shown that cyclosporin may negatively \ninfluence bone healing around dental implants and may even \nimpair the mechanical retention of dental implants previously \nintegrated in bone.130\nTamoxifen\nTamoxifen is a standard treatment for hormone receptor–posi-\ntive breast cancer in premenopausal women. Because tamoxifen \nmimics the effects of estrogen, it has a very beneficial side effect \nthat preserves bone mass and prevents bone loss. However, there \nexist drug-induced osteonecrosis concerns with the administra-\ntion of this drug, even though there is a very low prevalence.131 \nAromatase Inhibitors\nIn postmenopausal women diagnosed with estrogen recep-\ntor–positive breast cancer, aromatase inhibitors (AIs) are the \nmainstay of adjuvant therapy. These medications inhibit the \nconversion of androgens to estrogens, which results in estro-\ngen deficiency and may accelerate bone loss. There has been \nan association with an increase in drug-related osteonecrosis of \nthe jaws with this class of medications.132 However, in patients \non AIs, the incidence of osteonecrosis is still significant, and \nconsultation with the treating physician should be considered \nin these patients. \nTreatment Summary of Immunosuppressive Drugs\nMost immunosuppressive medications affect the entire immune \nsystem, having a higher incidence of adverse effects (e.g., bone \nCorticosteroids\n • \u0007Prednisone (Deltasone, Orasone)\n • \u0007Budesonide (Entocort EC)\n • \u0007Prednisolone (Millipred) \nCalcineurin Inhibitors\n • \u0007Cyclosporin (Neoral, Sandimmune, SangCya)\n • \u0007Tacrolimus (Astagraf XL, Envarsus XR, Prograf) \nmTOR Inhibitors\n • \u0007Sirolimus (Rapamune)\n • \u0007Everolimus (Afinitor, Zortress) \nIMDH Inhibitors\n • \u0007Azathioprine (Azasan, Imuran)\n • \u0007Leflunomide (Arava)\n • \u0007Mycophenolate (CellCept, Myfortic) \nBiologics\n • \u0007Humira (Adalimumab): Rheumatoid arthritis, Crohn’s disease, ulcerative \ncolitis, psoriatic arthritis, ankylosing spondylitis\n • \u0007Remicade (Infliximab): Rheumatoid arthritis, Crohn’s disease, ulcerative \ncolitis, psoriatic arthritis, ankylosing spondylitis\n • \u0007Enbrel (Etanercept): Rheumatoid arthritis, psoriatic arthritis\n • \u0007Herceptin (Trastuzumab): HER2+ breast cancer\n • \u0007Lucentis (Ranibizumab): Age-related macular degeneration\n • \u0007Avonex (Interferon beta-1a): Multiple sclerosis\n • \u0007Glatiramer acetate (Copaxone): Multiple sclerosis\n • \u0007Brodalumab (Siliq): Psoriatic arthritis\n • \u0007Ixekizumab (Taltz): Psoriatic arthritis\n • \u0007Secukinumab (Cosentyx): Psoriatic arthritis, ankylosing spondylitis\n • \u0007Ustekinumab (Stelara): Psoriatic arthritis, Crohn’s disease \nMonoclonal Antibodies\n • \u0007Basiliximab (Simulect)\n • \u0007Daclizumab (Zinbryta)\n • \u0007Muromonab (Orthoclone OKT3)\n  • BOX 10.13\t      \u0007Immunosuppressive Drugs"
  },
  {
    "page": 56,
    "content": "264\nPART III     Fundamental Science\nmarrow suppression leukopenia, thrombocytopenia, anemia). \nTherefore patients are susceptible to increased infectious episodes, \nintraoperative bleeding, and compromised bone healing. A medi-\ncal consult and evaluation are highly recommended before any \nproposed implant treatment. For most immunosuppressive drugs, \nconcurrent use and the placement of implants are an absolute \ncontraindication. Additionally, patients on long-term cortico-\nsteroid use should be evaluated for possible adrenal insufficiency \nsymptoms.\n   \nPast immunosuppressive therapy: Relative contraindication af-\nter medical consultation\nConcurrent immunosuppressive therapy + implant therapy: \nAbsolute contraindication \nBiologics\nA newer class of therapeutic drugs is termed biologics, and it is \nused to treat an array of medical conditions such as autoimmune \ndiseases and cancers. Biologics use living organisms (genes) and \nare manufactured by using recombinant DNA technology in the \nform of vaccines, antitoxins, growth hormones, gene therapy, \nand recombined proteins and allergens. Biologic medications \nare advantageous because they specifically target cells that are \ninvolved in the pathogenesis of the disease. Some of the most \ncommon biologics used today are tumor necrosis factor-α \n(TNF-α) inhibitors Cimzia (certolizumab pegol), Enbrel (etan-\nercept), Humira (adalimumab), Remicade (infliximab), and \nSimponi (golimumab). These drugs block the protein TNF-α \nthat stimulates the body to initiate the inflammation process. \nIn conditions such as psoriasis and psoriatic arthritis, TNF-α \nis produced in excess in the skin and joints, which stimulate \naccelerated growth of skin cells and may damage joint tissue. \nBlocking TNF-α stops the inflammatory cycle. Other biologics \ninclude the following:\n   \nInterleukin (IL)-12 and IL-23 inhibitors Stelara (ustekinumab): \nThese drugs work by specifically targeting IL-12 and IL-23, \nwhich create inflammation.\nIL-17 inhibitors Cosentyx (secukinumab) and Taltz (ixekizumab): \nThese drugs block IL-17, which is involved in inflammatory \nand immune responses; Siliq (brodalumab) blocks the recep-\ntor for IL-17, which then inhibits the inflammatory process \ncreated by IL-17.\nT-cell inhibitors Orencia (abatacept): These drugs target T cells, \nwhich are involved in the immune and inflammatory response. \nBlocking T-cell activation leads to reduced inflammation. \nCommon Disorders Using Biologics for \nTreatment\nAge-Related Macular Degeneration\nAge-related macular degeneration (AMD) is an incurable disease \nthat is the most common cause for blindness in the United States. \nThe macula is the central portion of the eye, which is respon-\nsible for the central vision in reading, driving, recognizing color, \nand seeing objects in fine detail. Over 11 million people in the \nUnited States have some form of AMD. This number is expected \nto double to nearly 22 million by 2050. Worldwide the num-\nber may exceed 200 million by 2020 and approach 300 million \nby 2040. Advancing age is the greatest risk factor. In those less \nthan 59, the risk is only about 2%, but the risk is 30% for those \nover age 75.133 A newer, more aggressive treatment option to slow \nthe progression of AMD is to inject medications that block vas-\ncular endothelial growth factors (VEGFs). With AMD, abnor-\nmally high levels of VEGF may be found that can be reduced by \ninjections with anti-VEGF medications such as Lucentis (ranibi-\nzumab). These intraocular injections, which may be administered \nmultiple times a month, have been linked to a significant increase \nin nonocular hemorrhagic events. This may include bruising, GI \nhemorrhages, formation of hematomas, and subdural hematomas. \nDespite being injected directly into the eye intravitreally, anti-\nVEGF agents have demonstrated high levels in the bloodstream. \nThis provides the basis for the potential occurrence of significant \nsystemic adverse events.134 \nPsoriatic Arthritis\nPsoriasis is an autoimmune disease that usually affects the skin. \nApproximately 33% of patients with psoriasis may develop a \nvery painful form of debilitating inflammatory autoimmune \narthritis called psoriatic arthritis. The body’s immune system \nattacks healthy tissue mostly in the skin as well as the joints. \nThis defective process creates inflammation that leads to joint \npain with swelling and stiffness. Psoriatic arthritis is usually \ntreated very aggressively to avoid permanent joint damage. In \nmost patients, skin symptoms develop before joint problems. \nThis disease most prevalently affects people who have psoriasis \nand are 30 to 55 years of age. There exist multiple forms includ-\ning the following:\n   \nSymmetric psoriatic arthritis: This makes up about half of the \ncases of psoriatic arthritis. This creates symptoms in the same \njoints on both sides of the body simultaneously. This type is \nvery similar to RA.\nAsymmetric psoriatic arthritis: A milder form that affects about \n35% of patients with psoriatic arthritis but does not appear in \nthe same joints on both sides of body.\nSpondylitis: This form creates pain and stiffness in neck and spine.\nDistal psoriatic arthritis: The inflammation in this form occurs \nnear distal portion of fingers and toes, and there can be changes \nin the toenails and fingernails, including lifting from the nail \nbed and pitting.\nArthritis mutilans: This is only about 5% of the cases and is the \nmost severe. In this form, the inflammation is more aggressive, \ncausing destruction and deformities of the distal joints in the \nfinger and toes.\nAnkylosing spondylitis (AS): This is a form of arthritis that \nprimarily creates pain in the lower lumbosacral area of the \nspine, but it can also affect the ribs, hips, knees, feet, eyes, \nand bowel. There is a genetic predisposition to development \nof this disease, and the main gene associated with this condi-\ntion is HLA-B27. Frequently, patients are given steroids and/\nor methotrexate to treat the symptoms. New treatment op-\ntions include biologics. \nRheumatoid Arthritis\nSee “Autoimmune” section. \nPolymyalgia Rheumatica\nPolymyalgia rheumatica (PMR) is an autoimmune inflammatory \ndisease that directly affects the muscles and joints, mainly in the \nshoulders and hips. The disease also causes muscle pain and stiff-\nness in the neck, buttocks, and arms. Most of patients diagnosed"
  },
  {
    "page": 57,
    "content": "265\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nwith PMR are over 50, and the average age is about 70. Onset of \nsymptoms can be abrupt without warning and is usually bilat-\neral. One of the most common complaints is that patients have \ntrouble raising their arms above their shoulders and have aching \nin joints including the hands and wrists. The stiffness is always \nworse after prolonged sitting, sleeping, or inactivity. There is no \njoint swelling. There is no specific test that confirms the diagnosis. \nAlmost all patients with the shoulder and other symptoms have \nelevated inflammatory markers including elevated sedimentation \nrate and C-reactive protein. Treatment many times includes ste-\nroids, methotrexate, and various biologics. \nEczema (Atopic Dermatitis)\nEczema is a dermatitis that causes dry, itchy, inflamed patches \nof skin. The etiology of eczema is not fully understood, but it is \nrelated to an overactive immune system that many times can be \nassociated with other allergy type symptoms and asthma. There \nare several types of eczema. (1) Contact dermatitis is caused by \ncontact with chemicals, soaps, plants, or other irritants. (2) Dys-\nhidrotic dermatitis, which is more common in women, affects fin-\ngers, the bottom of the feet, and palms. This condition causes itchy, \ninflamed patches of skin that become erythematous, cracked, and \neventually painful. (3) Nummular dermatitis is more prevalent in \nthe winter, with round dry patches mostly on the legs. (4) Sebor-\nrheic dermatitis causes scaly, red flaky rashes mostly in the scalp \nor around the eyes. It can also be seen on the sides of the nose or \nbehind the ears.\nFor the most part, eczema has been treated with topical ste-\nroids, which have very little effect on dental implant surgery. \nHowever, recently new biologics have been introduced to treat \neczema. Dupixent (dupilumab) is the first biologic medication \nused to treat eczema. Dupixent works by blocking interleukins \nfrom attaching to cell receptors. Interleukins help the immune \nsystem combat infection, but when the immune system becomes \ndysfunctional, the interleukins can cause immune disorders such \nas eczema. The injection schedule for Dupixent is usually every 2 \nweeks. \nMultiple Sclerosis\nMultiple sclerosis (MS) is a chronic disease of the CNS that results \nin damage to the nerves in the brain, spinal cord, and optic nerves. \nSymptoms can be mild to severe, from numbness in extremities to \ncomplete paralysis or even vision loss. There are over 400,000 peo-\nple in the United States that have MS. Each year approximately \n10,000 new cases are diagnosed. It is over twice as prevalent in \nwomen as men, and the diagnosis is usually made after age 20 and \nbefore age 50.\nNerves rely on myelin to successfully transmit electrical \nimpulses. MS attacks the myelin sheath, resulting in damage to \nthe nerves and resulting in plaques or lesions that can show up on \nimaging such as magnetic resonance imaging (MRI). As the nerves \nlose myelin, impulses from the brain are no longer transmitted to \nthe muscle, causing the symptoms of MS.\nMost of the cases of MS are relapse–remitting, which results \nin new attacks with increasing symptoms, but there are periods of \nremittance with the periods of relapse. Progressive MS does not \nhave any relapse or remissions; symptoms worsen progressively. \nThese symptoms include muscle weakness, vision problems, \ncoordination and balance issues, memory issues, and numbness \nin extremities. Difficulty emptying the bladder, constipation, \nfatigue, dizziness, and muscle spasms are also common symp-\ntoms. The exact cause in unknown, but MS is thought to be an \nautoimmune disorder. There are almost a dozen drugs approved \nto treat MS, and the most common biologics are Avonex (inter-\nferon beta-1a) and glatiramer acetate (Copaxone). \nFibromyalgia\nFibromyalgia causes diffuse musculoskeletal pain accompanied \nby exhaustion/fatigue, sleep disturbances, mood swings, and \nsometimes memory issues. Although the etiology of fibromy-\nalgia is unclear, many researchers believe there exists a dysfunc-\ntional amplification of pain sensation by the brain, which results \nin the patient being more sensitive to pain. The disease is much \nmore common in women than men and there is no real cure; \nhowever, the symptoms may be treated. Most of the treatment \ninvolves relaxation, stress reduction techniques, and exercise. In \nthe United States, fibromyalgia affects about 4 million, or about \n2% of the adult population. Although there is no specific test \nfor fibromyalgia, the diagnosis is usually made by combining \na detailed history and physical with laboratory and radiologic \nevaluation.135 Duloxetine (Cymbalta) and other SSRIs are com-\nmon treatment options for fibromyalgia. Tricyclic antidepres-\nsants like amitriptyline (Elavil) and nortriptyline (Pamelor) are \nused to help treat fatigue and sleep disturbances. The greatest \nconcern regarding tricyclic antidepressants in implant dentistry \nis the production of anticholinergic actions on the heart. Epi-\nnephrine and levonordefrin are not contraindicated in these \npatients, but they should be used cautiously. For example, heart \nrate and blood pressure should be reassessed after each 20- to \n40-μg dose of epinephrine administered.136 Muscle relaxants \nlike cyclobenzaprine, tizanidine, or carisoprodol (Soma) are \nused to help relieve the muscle pain. These drugs can cause xero-\nstomia. Of greatest concern for dental implant patients is the \npotential for chronic pain after the implant surgery. There are \nnumerous studies demonstrating chronic persistent pain after \ndental implant surgery without any neurosensory deficits or \nevidence of an organic cause. Dental implant surgeons need to \ntake this potential postsurgical complication into consideration \nwhen determining whether patients are candidates for implant \ntreatment.137 \nBreast Cancer\nThe American Cancer Society estimates just over 250,000 new \ncases of invasive breast cancer will be diagnosed in the United \nStates in 2018. In addition, about 64,000 cases of carcinoma \nin situ (CIS), which is the earliest form of breast cancer, will be \nalso diagnosed. About 41,000 women will die of breast cancer \nthis same year. The incidence of breast cancer has been stable \nover the past couple of years, but it remains more common in \nAfrican American women. Breast cancer remains the second \nleading cause of cancer death in women, and rates from 1989 \nto 2015 have dropped almost 40%. Since 2007, deaths from \nbreast cancer have continued to drop in women over age 50. \nThere are currently about 3.1 million breast cancer survivors in \nthe United States, including those that are still being treated.138\nIt is important to recognize that women with breast cancer may \nbe considered cancer free after treatment but, for up to 10 years \nafter the diagnosis, patients may be taking adjuvant therapy (treat-\nment given after chemotherapy and surgery) with medications that \ncould affect dental implant success. This therapy is targeted for \nhormone receptor–positive breast cancer (the most common type \nof breast cancer). Approximately 75% of breast cancers express \nthe estrogen and/or progesterone receptors (ERs, PRs).139 Certain \nbreast cancer cells are stimulated by progesterone and/or estrogen"
  },
  {
    "page": 58,
    "content": "266\nPART III     Fundamental Science\nto grow. Medications such as tamoxifen or other similar drugs clas-\nsified as Aromatase Inhitibitors block the hormones from getting to \nthese cells. AIs stop tissues and organs other than the ovaries from \nmaking estrogen and are used in postmenopausal women only. \nIn premenopausal women, the AI medications actually stimulate \nestrogen production from the ovary. Tamoxifen, on the other hand, \nblocks a cell’s ability to use estrogen so it can be used in premeno-\npausal and postmenopausal women. Women that have hormone \nreceptor–positive cancer and are premenopausal will take tamoxi-\nfen for 5 years. If they have not entered menopause after 5 years, \nthen they can continue tamoxifen for up to 10 years total. Women \nthat go through menopause while on Tamoxifen can switch to an \nAI for 5 more years or a total of 10 years of hormone treatment.\nThe oral cavity can be directly affected by estrogen. Antiestrogen \ntherapies can create issues that can influence dental implant success. \nThere are associated side effects with these types of prolonged hor-\nmonal therapies. The complications include oral/pharyngeal muco-\nsitis, pain, xerostomia, and dental caries. Of increased concern is \nthe risk for opportunistic bacterial, fungal, and viral infections from \nthe immunosuppressive effect of these drugs as a result of chemo-\ntherapy-induced immune suppression.140 Patients are also at risk for \nosteonecrosis and the therapies may affect the periodontal tissue, \ncausing gingivitis, gingival bleeding, and periodontal infection.141 \nTreatment Summary for Biologic Medications\nAlthough biologic medications have become very popular in the \ntreatment of many systemic disorders, caution must be exercised \nin patients that have been treated in the past or are currently being \ntreated. Patients may be susceptible to increased infectious epi-\nsodes, intraoperative bleeding, and compromised bone healing. A \nmedical consult and evaluation are highly recommended before \nany proposed implant treatment. For most biologic drugs, con-\ncurrent use and the placement of implants is an absolute contra-\nindication. Because of the lack of history and studies with these \ntypes of medications, severe caution must be exercised with past \nbiologic use and future implant treatment. Physician consultation \nand approval is highly recommended.\n   \nPast biologic therapy: Relative contraindication after medical \nconsultation\nConcurrent biologic therapy + implant therapy: Absolute con-\ntraindication \nOral Antithrombotic Medications\nOral antithrombotic medications have been used successfully to \ntreat a variety of thrombotic diseases such as MI, stroke, and deep \nvenous thrombosis, and are frequently used in the prevention of \ncardiovascular diseases. For decades, clinicians and patients have \nbeen conscious of the adverse side effects of these medications, \nprimarily spontaneous bleeding or perioperative bleeding. Many \nhave advocated for years to temporarily discontinue these medica-\ntions before invasive dental treatments such as dental implant sur-\ngery. However, because discontinuation of these drugs may result \nin serious thrombus complications, a thorough knowledge of the \nmechanism of action needs to be understood (Table 10.23).\nWarfarin Sodium\nWarfarin sodium (Coumadin) is used as an anticoagulant in a \nwide range of conditions such as ischemic heart disease, deep \nvenous thrombosis, pulmonary emboli, and artificial heart \nvalves. Warfarin sodium has a half-life of 40 hours, which has \nbeen known to vary from 20 to 60 hours in some individuals. \nThe mode of action of warfarin sodium is the interference of \nthe synthesis of vitamin K, which is a cofactor in many reac-\ntions within the coagulation cascade. Coumadin has been the \nmainstay of anticoagulant treatment options; however, in the \npast 3 years there has been a shift to a new class of blood thin-\nners in the treatment of nonvalvular atrial fibrillation and deep \nvenous thrombosis. With an aging population, the number of \nindividuals diagnosed with nonvalvular atrial fibrillation contin-\nues to climb, with over 2 million Americans now undergoing \ntreatment. The major concern of atrial fibrillation is the forma-\ntion of blood clots, so most of these patients will be maintained \non blood-thinning medications.\nMedication Modification\nUntil recently, most medical practitioners have believed that \nanticoagulants should be discontinued before dental surgery \nto prevent possible bleeding problems. However, there exist \nmany documented cases of embolic complications in patients \nwho discontinue the use of warfarin sodium and develop \nthrombosis from rebound hypercoagulability. In addition, \nstudies have shown that dental surgery may be performed \nsafely on patients receiving anticoagulant therapy as long as \ntheir INR values are within the therapeutic range (2.0–3.5). \nA brief periprocedural interruption of warfarin therapy is \nassociated with a low risk of thromboembolism (0.7%) and \nrisk of clinically significant bleeding (1.7%); however, the \nrisk versus benefit of interruption is not warranted in most \ncases.142 \nMedical Consultation\nPractitioners should consult with the patient’s physician to \ndetermine the most recent INR before the surgery (ideally \n24–48 hours before surgery). If the INR values are within the \ntherapeutic range (2–3.5) then there is no need to discontinue \nuse of the anticoagulant. If the INR value is higher the therapeu-\ntic range (especially higher than 3.5), the physician should take \nappropriate steps to lower the INR to a safer level or possibly \ndiscontinue the warfarin and supplement with heparin therapy \nor vitamin K. It is important to remember with all anticoagulant \npatients that special attention should be given to good surgi-\ncal technique and use of appropriate local measures to control \nbleeding (hemostatic agents). In addition, many antibiotics can \nincrease the effect of Coumadin thus increasing the chance of \nbleeding. In general cephalosporins, penicillins, quinolones, and \nmacrolides can increase INR and have a moderate class C rating, \nwhich means patient should have their INR checked a bit more \nfrequently while on these antibiotics. Sulfonamides and met-\nronidazole are considered to have more severe interactions and \nare considered as class D drugs, which usually require reduction \nin Coumadin dosages. Consultation with a physician for use of \nany class D drug is absolutely indicated. For class C drugs it is \nsuggested but imperative that the patient also understand the \nrelative increased risk. NSAIDs should not be used in patients \non Coumadin. \nAspirin\nAspirin or salicylic acid has been used as an antiinflammatory, \nanalgesic, and antipyretic medication. However, in the 1980s, it"
  },
  {
    "page": 59,
    "content": "267\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nwas discovered that aspirin also had an antiplatelet effect at very \nlow doses (0.5–1 mg/kg) versus higher doses needed for an anti-\npyretic effect (5–10 mg/kg) and antiinflammatory response (30 \nmg/kg). Because of this research, low-dose aspirin has become a \nsecondary preventive drug for patients who have cardiovascular \nand peripheral vascular disease. Aspirin works by inhibiting the \nformation of prostaglandin thromboxane A2 within the platelet, \naffecting thrombus formation by irreversibly decreasing platelet \naggregation.\nStudies\nAspirin inhibits platelet function and can be much more severe \nin the presence of decreased platelet counts. Studies have shown \nthat this risk is minimal unless a 325-mg aspirin is being used. In \na study of tooth extractions, 36 patients were randomized to 325 \nmg of aspirin or placebo for 2 days before and 2 days after. There \nwas no significant association between those that took the aspirin \nand perioperative or postoperative bleeding.143 \nRecommendations\nLow-Dose (81 mg) Aspirin. There exists no study supporting \nthe recommendation of low-dose aspirin discontinuation for rou-\ntine dental implant procedures. In most patients, interruption is \nnot warranted because it may expose the patient to the risk of \ndeveloping thromboembolism, MI, or CVA. \nHigh-Dose (325 mg) Aspirin. When patients are advised by \ntheir physician to take 325 mg of aspirin or doses higher than \n100 mg, a physician consultation is recommended. This is espe-\ncially true of patients on aspirin (any dose) with other antico-\nagulants such as clopidogrel or dipyridamole. Bleeding times \nmay be appropriate in these patients in combination with physi-\ncian consultation. Usually aspirin is stopped 7 to 10 days before \n  \u0007Common Anticoagulant Medications\nDrug\nASA (81 mg)\nASA (325 mg)\nClopidogrel \n(Plavix)\nCoumadin \n(Warfarin)\nDabigatran \n(Pradaxa)\nRivaroxaban \n(Xarelto)\nApixaban \n(Eliquis)\nTest to determine \ncoagulation \nstatus\nSerum thrombin \ntime, bleeding \ntime\nSerum thrombin \ntime, bleed-\ning time\nSerum thrombin \ntime, bleeding \ntime\nINR\nNo testing \nneeded\nNo testing \nneeded\nNo testing \nneeded\nMechanism of \naction\nInhibiting platelet \ngeneration of \nthromboxane \nA2 results \nin inhibition \nof thrombus \nformation\nInhibiting plate-\nlet generation \nof thrombox-\nane A2 results \nin inhibition \nof thrombus \nformation\nInhibits platelet \naggregation \nand activation\nInhibits production \nof vitamin \nK–dependent \nclotting factors \n(II, VII, IX, and X)\nDirect throm-\nbin inhibitor\nFactor Xa \ninhibitor\nFactor Xa \ninhibitor\nDietary restric-\ntions\nNone\nNone\nNone\nVitamin K\nNone\nNone\nNone\nDosing difficulty\nNone\nNone\nNone\nDifficult\nReduce dose\nCrCl < 30\nReduction CrCl \n< 50 dosing \ndifferent for \ndifferent \nindications\nReduction CrCl \n< 50 dosing \ndifferent for \ndifferent \nindications\nNeed for reduc-\ntion/interrup-\ntion\nUsually not rec-\nommended\nCase specific\nCase specific, \nusually not \nrecom-\nmended, can \nprecipitate, \nsignificant \nmedical clot-\nting issues\nCase specific, \nusually not \nrecommended, \ncan precipitate, \nsignificant \nmedical clot-\nting issues\nYes, medical \nconsult, \nusually \n48–72 \nhours\nYes, medical \nconsult\nYes, medical \nconsult\nDays of \ndiscontinu-\nation before \nprocedures\nNot required in \nmost cases, \nplatelet func-\ntion inhibited \n10–14 days\n10 days or \nmore, medi-\ncal consult\nMedical consult, \nespecially if \ngiven with \nASA\nMedical consult, \nusually 5 days \nor more\nYes, usually \n48–72 \nhours\nYes, usually \n48–72 hours\nYes, usually \n48–72 \nhours\nRestarting medi-\ncation\nIf discontinued, \nafter hemosta-\nsis\nIf discontinued, \nafter hemo-\nstasis\nIf discontinued, \ndependent \non medical \nrecommenda-\ntion\nIf discontinued, \ndependent on \nmedical recom-\nmendation\nUsually 24–48 \nhours and \ndiscussion \nwith physi-\ncian\nUsually 24–48 \nhours and \ndiscussion \nwith physi-\ncian\nUsually 24–48 \nhours and \ndiscussion \nwith physi-\ncian\nASA, American Society of Anesthesiologists; CrCl, creatinine clearance; INR, international normalized ratio.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; 2018.\n   \nTABLE \n10.23"
  },
  {
    "page": 60,
    "content": "268\nPART III     Fundamental Science\nsurgery and can be continued after adequate hemostasis has been \nconfirmed.144 \nPlavix (Clopidogrel)\nClopidogrel is a platelet inhibitor that is approved for the reduc-\ntion of atherosclerotic events in patients with recent stroke, MI, \nor peripheral arterial disease. The recent literature has supported \nlonger treatment times for patients with coronary stents and acute \ncoronary syndrome from 3 to 12 months or more in combination \nwith aspirin. The literature does not support the routine discon-\ntinuation of this medication in relation to dental implant treat-\nment, but it is important to remember that many patients treated \nwith clopidogrel will be on aspirin or another antiplatelet medica-\ntion, especially those with cardiac stents.\nRecommendation: This regimen should never be discontinued \nunless under the recommendation of a physician. \nNovel Oral Anticoagulants\nPradaxa, Xarelto, and Eliquis are a class of medications termed \nNovel Oral Anticoagulants (NOAC). NOACs. Orally adminis-\ntered anticoagulants have recently been developed to eliminate \nthe disadvantages associated with warfarin. Dabigatran etexilate \n(Pradaxa) and rivaroxaban (Xarelto) have been shown to have a \nmore favorable (wider) therapeutic index, fewer drug–drug and \ndrug–food interactions, and a predictable anticoagulant response \nwithout the need for anticoagulants. Dabigatran reversibly inhib-\nits thrombin, so the duration of action is predictable and corre-\nlates well with plasma drug concentrations. Rivaroxaban is an FXa \ninhibitor that produces reversible inhibition of FXa activity.145\nBleeding\nIn contrast to the many studies on oral surgery and the use of \nwarfarin, no clinical trials have been completed to offer recom-\nmendations on the management of patients on these newer anti-\ncoagulants with relation to dental implant surgery. However, there \nexist several case studies suggesting that, with physician consulta-\ntion, these drugs can be temporarily discontinued 24 hours before \nelective oral surgery and restarted the following day, resulting in \nminimal complications. Because these drugs have a short half-life, \nbrief interruption of usage is usually acceptable. It is imperative \nthat physician consultation be obtained prior to any of these med-\nications being temporarily discontinued. Good surgical technique \nand the use of hemostatic agents should be adhered to during oral \nsurgery. Currently Praxbind is available to help reverse the effects \non Pradaxa and control excessive bleeding. AndrexXA is await-\ning final approval to help reverse the excessive or uncontrollable \nbleeding that may occur from the FXa inhibitors (Xarelto, Eliquis, \nand Savaysa). Currently there is no approved treatment to control \nexcessive bleeding caused by the FXa inhibitors. \nTreatment Summary\nCurrently there is no accepted reduction protocol for NOACs. \nBased on the information available, the clinician should consult \nthe patient’s physician concerning the proposed implant proce-\ndure and the invasiveness of the surgery, anticipated hemostasis \ncomplications, and amount of bleeding to be expected. If phy-\nsician recommendation is for the temporary discontinuation of \nthese drugs, then the typical discontinuation recommendation is \nfor 24 hours before surgery, and the drug should not be restarted \nuntil the risk of postoperative bleeding is minimal (usually within \n24 hours of surgery).146 Patients should be closely monitored \npostoperatively because bleeding may reoccur after initial hemo-\nstasis and continuation of the medication. \nHerbal Supplements\nOTC herbal and dietary supplements are being consumed at a \nrecord pace for general health improvement and treatment of \nchronic conditions. It is an important part of taking a medical his-\ntory that you specifically ask about any OTC supplements, herbal \nmedications, or any pills a patient may be taking that are not pre-\nscribed by a physician.\nHerbs have been known to be associated with unwanted side \neffects and can cause drug interactions, as well as being associated \nwith surgical complications. Many of these supplements contain \nactive ingredients that exhibit strong biologic effects. The doses are \nusually unregulated and variable among patients. The Journal of \nthe American Medical Association estimates that 15 million adults \nare at risk for adverse interactions between herbs and prescription \nmedications.147 The risks of these medications associated with \ndental implant surgery are increased bleeding, drug interactions, \nand possible infection.\nRecommendation: Patients should discontinue the use of these \nherbal supplements for at least 2 weeks before implant surgery \n(Box 10.14). \nSelective Serotonin Reuptake Inhibitors\nDepression is a prevalent mental illness disorder that is a signifi-\ncant disability with a reduced quality of life. Low levels of sero-\ntonin (chemical and neurotransmitter) have been associated with \ndepression. SSRIs have been used to successfully treat depression.\nSSRIs have a very low adverse-effect profile because they do \nnot affect blood pressure or heart rate. SSRIs inhibit serotonin \nreuptake from the synaptic cleft into presynaptic nerve terminals, \nincreasing serotonin neurotransmission. However, SSRIs have \nbeen directly associated with lower bone mineral density.148\nSerotonin found in bone cells (osteocytes, osteoblasts, and \nosteoclasts) can be activated by SSRIs, which results in altered \nfunction. Wu and colleagues stated that SSRIs might have a nega-\ntive effect on dental implant healing. Their data demonstrate an \nincreased risk of failure with most complications occurring from \nthe anabolic response, which inhibits the bone-remodeling pro-\ncesses triggered by mechanical loading.149 \nTreatment Summary\nThe concomitant use of SSRIs and dental implants is a relative \ncontraindication. A medical consult and evaluation should ideally \nbe completed before dental implant treatment. \nAllergies\nHypersensitivity to titanium is an ever-increasing reportable com-\nplication in medicine today that has been associated with a wide \nrange of situations. In orthopedic medicine, there exist many \ncase reports of titanium alloy hypersensitivity. Witt and Swann \nreported 13 cases of failed total hip prostheses and concluded the \ntissue reaction in response to metal-wear debris may have been \nthe etiology of the failed implants. This process has been termed \nrepassivation and may produce an oxide that surrounds and turns \nthe peri-implant tissues black.150\nYamauchi and colleagues reported a titanium-implanted \npacemaker developing an allergic reaction. The patient devel-\noped a distinct erythema over the implantation site, which"
  },
  {
    "page": 61,
    "content": "269\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nresulted in a generalized eczema. Titanium sensitivity was \nconfirmed by intracutaneous and lymphocyte stimulation test-\ning.151 In the dental literature, allergic reactions to pure tita-\nnium are rare. However, many authors have suggested there is a \nhigher incidence of titanium alloy allergy with respect to dental \nimplants, and it is most likely underreported because of a poor \nunderstanding of failure or allergy.152 du Preez and colleagues \nhave reported a case of implant failure caused by a suspected \ntitanium hypersensitivity reaction around a dental implant. \nHistologic results showed a chronic inflammatory reaction \nwith concomitant fibrosis.153 Egusa and colleagues reported \na titanium implant overdenture case that resulted in general-\nized eczema that fully resolved after implant removal.154 Sicilia \nand colleagues, in a clinical study of 1500 consecutive implant \npatients, reported approximately nine implants with a positive \nreaction to titanium allergy.155\nSensitivity to titanium has been shown to be a result of the pres-\nence of macrophages and T-lymphocytes with the presence of B-lym-\nphocytes, which results in a type IV hypersensitivity reaction.156 All \nmetals, when in a biologic environment, undergo corrosion, which \nmay lead to the formation of metallic ions that trigger the immune \nsystem complex with endogenous proteins.157 Titanium alloy dental \nimplants have been shown to contain many “impurities” that may \ntrigger type IV hypersensitivity reactions. Harloff used spectral anal-\nysis to investigate various Ti alloy implants. The results showed that \nall the Ti alloy samples contained small amounts of other elements \nsuch as beryllium (Be), cobalt (Co), chromium (Cr), copper (Cu), \niron (Fe), nickel (Ni), and palladium. These impurity elements have \nbeen shown to be the etiology of the hypersensitivity reactions.158\nTreatment Summary\nWhen titanium hypersensitivity is suspected, the implants should \nbe removed and the patient should be referred to their physi-\ncian for appropriate testing. Case reports have shown that, after \ncomplete removal of the implants, complete resolution results.154 \nMetal sensitivity is usually diagnosed using a “patch-test,” which \ninvolves placement of titanium (allergen) to the skin for approxi-\nmately 3 to 4 days. A positive test would include the appearance \nof an erythematous reaction. However, there is a possibility of false \nnegatives because the sealing qualities of the skin against direct \ncontact, which may make the test unreliable (Fig. 10.4). \nMedical Consultation and Clearance\nOral implantology is a complex specialty with many factors that \nmust be taken into consideration to decrease morbidity and \nincrease the probability of successful treatment. Medical clearance \nis a necessity with respect to patients who present with compli-\ncated systemic conditions, medications, and predisposing factors \nthat may lead to complications. The implant clinician must relay \nto the physician all necessary information, including\n\t1.\t \u0007A detailed summary of what the patient related as their medical \nhistory\n\t2.\t \u0007A list of all current and recent medications\n\t3.\t \u0007A list of all allergies\n\t4.\t \u0007Any medications that will be prescribed by the implant dentist\n\t5.\t \u0007The invasiveness of the intended procedure\nThe physician will provide with the following:\n\t1.\t \u0007Most recent physical examination: To determine whether the \npatient is compliant with keeping up with their medical health\n\t2.\t \u0007Documentation of medical health: Very important to deter-\nmine whether there exists any misinformation or missing \nhealth issues that the patient failed to represent on the medical/\ndental history\n\t3.\t \u0007Medication modification: The physician will recommend any \nmodifications to physician-prescribed medications or dental \nsurgery proposed medications.\n\t4.\t \u0007Acceptable candidate: The physician will clear the patient for \ndental implant treatment in writing.\n\t5.\t \u0007Contacting the physician: The physician will document \nwhether their recommendation is for the implant dentist to \ncontact them before treatment and, last, to make sure the phy-\nsician signs and dates the form (Fig. 10.5).\nIncreased Bleeding\n• \u0007Arnica\n• \u0007Barberry\n• \u0007Bilberry\n• \u0007Bromelain\n• \u0007Cat’s claw\n• \u0007Cayenne\n• \u0007Chamomile\n• \u0007Chestnut\n• \u0007Cinnabar root\n• \u0007Devil’s claw\n• \u0007Dong quai\n• \u0007Fennel\n• \u0007Feverfew\n• \u0007Garlic\n• \u0007Ginger\n• \u0007Ginkgo biloba\n• \u0007Ginseng\n• \u0007Grape seed\n• \u0007Green tea\n• \u0007Kudzu\n• \u0007Primrose\n• \u0007Red clover\n• \u0007Turmeric\n• \u0007Sweet woodruff\n• \u0007Vitamin E \nIncreased Inflammation\n• \u0007Celery\n• \u0007Dandelion\n• \u0007Elder\n• \u0007Goldenseal\n• \u0007Juniper \nInteractions With Nonsteroidal Antiinflammatory Drugs\n• \u0007Feverfew\n• \u0007Gingko\n• \u0007Ginseng\n• \u0007St. John’s Wort\n• \u0007Uva-Ursi \nInteractions With Anesthesia\n• \u0007Green tea: Decreases effect of oral atropine\n• \u0007Dong quai: Increases sedation and lowers seizure threshold\n• \u0007Kava: Increases sedation\n• \u0007Valerian: Increases sedation, interacts with opioids\n• \u0007Vitamin C: In large doses can weaken anesthesia\n• \u0007Yohimbe: Can interact with some analgesics like morphine\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In Resnik \nRR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St Louis, MO: Elsevier; \n2018.\n  • BOX 10.14\t      \u0007Herbal Supplement and Adverse Effects"
  },
  {
    "page": 62,
    "content": "270\nPART III     Fundamental Science\nA\nB\nC\n• Fig. 10.4  Titanium dental implant allergy. (A) Facial eczema after implant placement. (B) Intraoral view \nof type IV hypersensitivity reaction. (C) Complete resolution after implant removal. (From Egusa H, Ko N, \nShimazu T, Yatani H. Suspected association of an allergic reaction with titanium dental implants: a clinical \nreport. J Prosthet Dent. 2008;100(5):344–347.)\nPatient:\nMedical History:\nCurrent Medications:\nAllergies to Medications:\nTHE FOLLOWING MEDICATIONS ARE PROPOSED FOR THE DENTAL IMPLANT SURGERY:\nPLEASE PROVIDE ANSWERS TO THE FOLLOWING QUESTIONS\nThe above patient is tentatively scheduled for dental implant surgery. The outpatient surgery will be performed in\nmy office under intravenous conscious sedation. The following information has been provided by the patient.\nANTIMICROBIAL\nANTI-INFLAMMATORY\nANALGESIC\nANESTHESIA\nSEDATION\nAmoxicillin\nCephalosporin\nIbuprofen\nHydrocodone\n2% Lidocaine 1/100k Epi.\nHalcion\nValium\nN20\nIV Rx”s\n(Versed,Fentanyl)\n2% Carbocaine 1/20k Neo.\n3% Carbocaine\n.5% Marcaine 1/200k Epi\n4% Articaine 1/100k Epi\nCodeine\nAcetaminophen\nPercocet\nUltram\nDexamethasone\nClindamycin\nAugmentin\n1. Date of most recent physical exam:\n2. Significant medical condition, treatment, disease, injury or comments:\n3. Any Recommendations or Modifications of Medications\n4. The above patient is an acceptable candidate for outpatient dental implant surgery\n5. Please contact me prior to treating this patient\nCurrent Medications\nProposed Medications (Listed Above)\nYES\nYES\nNO\nNO\nYES\nSignature of Physician\nDate\nNO\nDate:\nMEDICAL CONSULTATION FOR DENTAL IMPLANT SURGERY\n• Fig. 10.5  Medical consultation form."
  },
  {
    "page": 63,
    "content": "271\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\nReferences\n\t 1.\t \u0007Weijant RJ. Characteristics associated with the loss and perio \nimplant tissue health of endosseous dental implants. Int J Oral \nMaxillofac Implants. 1992;7:367–372.\n\t 2.\t \u0007Scully C. Scully’s Medical Problems in Dentistry. 7th ed. London: \nChurchill Livingstone; 2014. 231–231.\n\t 3.\t \u0007https://www.wsj.com/articles/when-patients-take-too-many-pills-\ndoctors-deprescribe-1476122784.\n\t 4.\t \u0007Dycht K. Age Wave: The Challenges and Opportunities of an Aging \nAmerica. New York: St Martin’s Press; 1988.\n\t 5.\t \u0007US Bureau of the Census. Population reports. Population Estimates. \n1988;25:1024.\n\t 6.\t \u0007McCarthy FM. Vital signs—the six minute warning. J Am Dent \nAssoc. 1980;100:682–691.\n\t 7.\t \u0007Chobanian AV, Bakris GL, Black HR, et al. The seventh report of \nthe joint national committee on prevention, detection, evaluation, \nand treatment of high blood pressure. JAMA. 2003;289(19):2560–\n2571. https://doi.org/10.1001/jama.289.19.2560.\n\t 8.\t \u0007Muntner P, Carey RM, Gidding S, et al. Potential U.S. population \nimpact of the 2017 ACC/AHA high blood pressure guideline. J Am \nColl Cardiol. 2018;71(2):109–118.\n\t 9.\t \u0007Gilbert GH, Minaker KL. Principles of surgical risk assessment of \nthe elderly patient. J Oral Maxillofac Surg. 1990;48:972–979.\n\t10.\t \u0007Sabes WR, Green S, Craine C. Value of medical diagnostic screen-\ning tests for dental patients. J Am Dent Assoc. 1970;80:133–136.\n\t11.\t \u0007Sones ST, Fazio R, Setkowicz A, et al. Comparison of the nature \nand frequency of medical problems among patients in general spe-\ncialty and hospital dental practices. J Oral Med. 1985;38:58.\n\t12.\t \u0007Misch CE. Medical evaluation of the implant candidate. Part II: \ncomplete blood count and bleeding disorders. Int J Oral Implant. \n1982;10:363–370.\n\t13.\t \u0007Corman L, Bolt RJ, eds. Medical evaluation of the pre-operative \npatient. Med Clin North Am. 1979;63:6.\n\t14.\t \u0007https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340464/.\n\t15.\t \u0007Hirsch J, Dalan JE, Deykin D, et al. Oral anticoagulants: mecha-\nnism of action, clinical effectiveness, and optimal therapeutic \nrange. Chest. 1992;102(suppl):312–326.\n\t16.\t \u0007Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory mea-\nsurement of the anticoagulant activity of the non-vitamin K oral \nanticoagulants. J Am Coll Cardiol. 2014;64:1128–1139.\n\t17.\t \u0007Cuker A, Husseinzadeh H. Laboratory measurement of the antico-\nagulant activity of edoxaban: a systemic review. J Thromb Throm-\nbolysis. 2015;39:288–294.\n\t18.\t \u0007Lab Tests Online. Comprehensive Metabolic Panel; 2005. Available \nat: \nhttp://www.labtestsonline.org/understanding/analytes/cmp/\nglance.html.\n\t19.\t \u0007Misch CE. Medical evaluation of the implant candidate. Part III. \nSMA 12/60. J Oral Implant. 1981;9:556–570.\n\t20.\t \u0007Raslavicus PA, Mei Shen E. Laboratory diagnosis by chemical \nmethods. Dent Clin North Am. 1974;18:155–170.\n\t21.\t \u0007Misch CE. Medical evaluation. In: Misch CE, ed. Contemporary \nImplant Dentistry. St Louis: Mosby; 1993.\n\t22.\t \u0007Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and \nstroke statistics—2018 update: a report from the american heart \nassociation. Circulation. 2018;137(12):e67–e492.\n\t23.\t \u0007Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am \nJ Respir Crit Care Med. 2001;164:2147–2167.\n\t24.\t \u0007Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syn-\ndrome as a risk factor for hypertension: population study. BMJ. \n2000;320(7233):479–482.\n\t25.\t \u0007Gordy FM, LeJeune RC, Copeland LB. The prevalence of hyper-\ntension in a dental school patient population. Quintessence Int. \n2001;32:691–695.\n\t26.\t \u0007Zamost B, Benumof JL. Anesthesia in geriatric patients. In: Katz \nJ, Benumof JL, Kadis LB, eds. Anesthesia and Uncommon Diseases: \nPathophysiologic and Clinical Correlation. 2nd ed. Philadelphia: WB \nSaunders; 1976.\n\t27.\t \u0007Alder M, Kitchen S, Jrion A. Data Book on the Elderly: A Statistical \nPortrait. Washington, DC: US Department of Health and Human \nServices; 1987.\n\t28.\t \u0007Levy SM, Baker KA, Semla TP, et al. Use of medications with den-\ntal significance by a noninstitutionalized elderly population. Ger-\nodontics. 1988;4:119–125.\n\t29.\t \u0007Heeling DK, Lemke JH, Semla TP, et al. Medication use character-\nistics in the elderly. The Iowa 65+ rural health study. J Am Geriatr \nSoc. 1987;35:4–12.\n\t30.\t \u0007Ellis JS, Seymour RA, Steele JG, et al. Prevalence of gingival over-\ngrowth induced by calcium channel blockers: a community-based \nstudy. J Periodontol. 1999;70:63–67.\n\t31.\t \u0007Herman WW, Konzelman JL. Angina, an update for dentistry. \nJ Am Dent Assoc. 1996;127:98–104.\n\t32.\t \u0007Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo \nR, et al. Heart disease and stroke statistics—2017 update: a report \nfrom the American Heart Association. 135:e1–e458. https://doi.\norg/10.1161/CIR.0000000000000485.\n\t33.\t \u0007Pell S, D’Alonzo CA. Immediate mortality and five year survival \nof employed men with a first myocardial infarction. N Engl J Med. \n1964;270:915.\n\t34.\t \u0007Malamed SF. Sedation: A Guide to Patient Management. 2nd ed. St \nLouis: Mosby; 1989.\n\t35.\t \u0007Heart disease and stroke statistics—2018 update. A report from the \nAmerican heart association. Circulation. 2018. [Epub ahead of print].\n\t36.\t \u0007Heidenreich PA, Albert NM, et al. Forecasting the impact of heart \nfailure in the US. A statement policy from the American Heart \nAssociation. Circ Heart Fail. 2013;6(3):606–619.\n\t37.\t \u0007Yancy CW, Jessup M, Bozkurt B, et  al. 2013 ACCF/AHA \nguideline for the management of heart failure: a report of the \nAmerican College of Cardiology Foundation/American Heart Asso-\nciation Task Force on Practice Guidelines. Circulation. 2013;128: \ne240–319.\n\t38.\t \u0007Smith MJ, So, RR, Engel AM. Clinical predictors of mortality \nfrom infective endocarditis. IJS. 2007;5(1):31–34. https://doi.\norg/10.1016/j.ijsu.2006.06.008.\n\t39.\t \u0007Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective \nendocarditis: guidelines from the American Heart Association: a \nguideline from the American Heart Association Rheumatic Fever, \nEndocarditis, and Kawasaki Disease Committee, Council on Car-\ndiovascular Disease in the Young, and the Council on Clinical \nCardiology, Council on Cardiovascular Surgery and Anesthesia, \nand the Quality of Care and Outcomes Research Interdisciplinary \nWorking Group. Circulation. 2007;116(15):1736–1754.\n\t40.\t \u0007Nishimura RA, Otto CM, Bonow RO, et  al. 2017 AHA/ACC \nFocused Update of the 2014 AHA/ACC guideline for the manage-\nment of patients with valvular heart disease: a report of the Ameri-\ncan College of Cardiology/American Heart Association Task Force \non Clinical Practice Guidelines. Circulation. 2017;135:e1159–\ne1195. Accessed June 19, 2017.\n\t41.\t \u0007Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective \nendocarditis: guidelines from the American Heart Association: \na guideline from the American Heart Association Rheumatic \nFever, Endocarditis, and Kawasaki Disease Committee, Coun-\ncil on Cardiovascular Disease in the Young, and the Council on \nClinical Cardiology, Council on Cardiovascular Surgery and \nAnesthesia, and the Quality of Care and Outcomes Research \nInterdisciplinary Working Group. Circulation. 2007;116(15): \n1736–1754.\n\t42.\t \u0007Burkett LW, Burn CG. Bacteremias following dental extraction: \ndemonstration of source of bacteria by means of a non-pathogen \n(Serratia marcescens). J Dent Res. 1937;16:521.\n\t43.\t \u0007Korn VA, Schaffer EM. A comparison of the postoperative bacte-\nremias induced following different periodontal procedures. J Peri-\nodontol. 1962;33:226.\n\t44.\t \u0007Grant BF, Harforf TC, Dawson DA, et al. Prevalence of DSM IV \nalcohol abuse and dependence. United States:1992. Alcohol Health \nRes World. 1994;18:243–248."
  },
  {
    "page": 64,
    "content": "272\nPART III     Fundamental Science\n\t45.\t \u0007Cameron IW. SBE in an edentulous patient: a case report. Br Med \nJ. 1971;1:821.\n\t46.\t \u0007Dajani AS, Bawdon RE, Berry MC. Oral amoxicillin as prophy-\nlaxis for endocarditis: what is the optimal dose? Clin Inject Dis. \n1994;18:157–160.\n\t47.\t \u0007Fluckiger U, Franciolo P, Blaser J, et al. Role of amoxicillin serum \nlevels for successful prophylaxis of experimental endocarditis due to \ntolerant streptococci. J Inject Dis. 1994;169:397–400.\n\t48.\t \u0007Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial \nendocarditis. Recommendations by the American Heart Associa-\ntion. J Am Med Assoc. 1997;277:1794–1801.\n\t49.\t \u0007Chanavaz M. Patient screening and medical evaluation for implant \nand preprosthetic surgery. J Oral Implantol. 1998;24:222–229.\n\t50.\t \u0007Nishimura RA, Otto CM, Bonow RA, et  al. 2017 AHA/ACC \nfocused update of the 2014 AHA/ACC guideline for the man-\nagement of patients with valvular heart disease: a report of the \nAmerican College of Cardiology/American Heart Association Task \nForce on Clinical Practice Guidelines. Circulation. 2017;135(25): \ne1159–e1195.\n\t51.\t \u0007https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-\nstatistics-report.pdf.\n\t52.\t \u0007Gilbert GH, Minaker KL. Principles of surgical risk assessment of \nthe elderly patient. J Oral Maxillofac Surg. 1990;48:972–979.\n\t53.\t \u0007Retzepi M, Donos N. The effect of diabetes mellitus on osseous \nhealing. Clin Oral Implants Res. 2010;21:673–681.\n\t54.\t \u0007Mellado-Valero A, Ferrer Garcia JC, Herrera Ballester A, et  al. \nEffects of diabetes on the osseo-integration of dental implants. Med \nOral Patol Oral Cir Bucal. 2007;12:E38–E43.\n\t55.\t \u0007McCracken M, Lemons JE, Rahemtulla F, et al. Bone response to \ntitanium alloy implants placed in diabetic rats. Int J Oral Maxillofac \nImplants. 2000;15:345–354.\n\t56.\t \u0007Javed F, Romanos GE. Impact of diabetes mellitus and glycaemic \ncontrol on the osseointegration of dental implants: a systematic lit-\nerature review. J Periodontol. 2009;80:1719–1730.\n\t57.\t \u0007Marchand F, Raskin A, Dionnes-Hornes A, et al. Dental implants \nand diabetes: conditions for success. Diabetes Metab. 2012;38:14–19.\n\t58.\t \u0007Jolly DE. Interpreting the clinical laboratory. Cal Dent Assoc J. \n1995;23:32–40.\n\t59.\t \u0007Attard NJ, Zarb GA. A study of dental implants in medically treated \nhypothyroid patients. Clin Implant Dent Relat Res. 2002;4:220–\n231.\n\t60.\t \u0007Biron CR. Patients with thyroid dysfunctions require risk manage-\nment before dental procedures. RDH. 1996;16(4):42–44.\n\t61.\t \u0007Liddle GW, Melmon KC. The adrenals. In: Williams RH, ed. Text-\nbook on Endocrinology. 5th ed. Philadelphia: WB Saunders; 1974.\n\t62.\t \u0007Dummett CO, Barens C. Oromucosal pigmentation: an updated \nliterary review. J Periodontol. 1971;42:726.\n\t63.\t \u0007McCarthy FM. Adrenal insufficiency. In: McCarthy FM, ed. Essen-\ntials of Safe Dentistry for the Medically Compromised Patient. Phila-\ndelphia: WB Saunders; 1989.\n\t64.\t \u0007Henrikson P. Periodontal disease and calcium deficiency: an \nexperimental study in the dog. Acta Odontol Scand. 1968;26(suppl \n50):1–132.\n\t65.\t \u0007Johnson BS. Altered hemostasis: considerations for dental care. Cal \nDent Assoc J. 1995;23:41 54.\n\t66.\t \u0007Misch CE. Density of bone: effect on treatment plans, surgical \napproach, healing and progressive bone loading. Int J Oral Implant. \n1990;6:23–31.\n\t67.\t \u0007Konotey Ahuke FI. The sickle cell diseases. Arch Intern Med. \n1974;133:611.\n\t68.\t \u0007Bennett B. Coagulation pathways: inter-relationships and control \nmechanisms. Semin Hematol. 1977;14:301.\n\t69.\t \u0007Marder MZ. Medical conditions affecting the success of dental \nimplants. Compendium. 2004;25:739–764.\n\t70.\t \u0007https://www.cdc.gov/copd/data.html.\n\t71.\t \u0007Grant BF, Harforf TC, Dawson DA, et al. Prevalence of DSM IV \nalcohol abuse and dependence. United States:1992. Alcohol Health \nRes World. 1994;18:243–248.\n\t72.\t \u0007Lieber CS. Medical disorders of alcoholism. N Engl J Med. \n1995;333:1058–1065.\n\t73.\t \u0007Chandok N, Watt K. Pain management in the cirrhotic patient: the \nclinical challenge. Mayo Clin Proc. 2010;85:451–458.\n\t74.\t \u0007Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vita-\nmin D, calcium homeostasis and aging. Bone Res. 2016;4:16041. Pub­\nlished online 2016 Oct 18 . https://doi.org/10.1038/boneres.2016.41. \nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068478/.\n\t75.\t \u0007Bone Health and Osteoporosis: a report of the Surgeon General. Rock-\nville, MD: Department of Health and Human Services; 2004.\n\t76.\t \u0007Chestnut CH. Osteoporosis an undiagnosed disease. JAMA. \n2001;286:2865–2866.\n\t77.\t \u0007Darcy J, Homer K, Walsh T, et al. Tooth loss and osteoporosis: to \nassess the association between osteoporosis status and tooth num-\nber. Br Dent J. 2013;214(4).\n\t78.\t \u0007National Osteoporosis Foundation: Boning up on Osteoporosis, A \nGuide to Prevention and Treatment. Washington, DC: National \nOsteoporosis Foundation; 1991.\n\t79.\t \u0007Heasman PA. The role of nonsteroidal antiinflammatory drugs in the \nmanagement of periodontal disease. J Dent Res. 1988;16:247–257.\n\t80.\t \u0007Ortman LF, Hausman E, Dunford RG. Skeletal osteopenia and \nresidual ridge resorption. J Prosthet Dent. 1989;61:321–325.\n\t81.\t \u0007August M, Chung K, Chang Y, et al. Influence of estrogen sta-\ntus on endosseous implant integration. J Oral Maxillofac Surg. \n2001;59:1285–1289.\n\t82.\t \u0007Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates \nproliferation and alkaline phosphatase activity of bone forming \ncells. Science. 1983;222:330.\n\t83.\t \u0007Bajwa MS, Ethunandan M, Flood TR. Oral rehabilitation with \nendosseous implants in a patient with fibrous dysplasia (McCune-\nAlbright syndrome): a case report. J Oral Maxillofac Surg. \n2008;66:2605–2608.\n\t 84.\t \u0007Ricalde P, Magliocca KR, Lee JS. Craniofacial fibrous dysplasia. \nOral Maxil Surg Clin. 2012;24:427–441.\n\t 85.\t \u0007Padbury Jr AD, Tözüm TF, Taba Jr M,  Ealba EL, West BT, Burney \nRE, et al. The impact of primary hyperparathyroidism on the oral \ncavity. J Clin Endocr Metab. 2006;91(9):3439–3445.\n\t 86.\t \u0007Singer FR, Bone 3rd HG, Hosking DJ, et al. Paget’s Disease of \nBone: an endocrine society clinical practice guideline. J Clin Endo-\ncrinol Metab. 2014;99(12):4408–4422.\n\t 87.\t \u0007https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244103/.\n\t 88.\t \u0007Sager RD, Thesis RM. Dental implants placed in a patient with \nmultiple myeloma. Report of case. J Am Dent Assoc. 1990;121: \n699–701.\n\t 89.\t \u0007Clarke A. Hypohidrotic ectodermal dysplasia. J Med Genet. \n1987;24:659–663.\n\t 90.\t \u0007Bergendal B, Bergendal T, Hallonsten AL, et al. A multidisciplinary \napproach to oral rehabilitation with osseointegrated implants \nin children and adolescents with multiple aplasia. Eur J Orthod. \n1996;18:119–129.\n\t 91.\t \u0007Smith RA, Vargervik K, Kearns G, et al. Placement of an endosse-\nous implant in a growing child with ectodermal dysplasia. Oral Surg \nOral Med Oral Pathol. 1993;75:669–673.\n\t 92.\t \u0007Davarpanah M, Moon JW, Yang LR, et  al. Dental implants in \nthe oral rehabilitation of a teenager with hypohidrotic ectoder-\nmal dysplasia: report of a case. Int J Oral Maxillofac Implants. \n1997;12:252–258.\n\t 93.\t \u0007Altasalo K. Bone tissue response to irradiation and treatment model \nof mandibular irradiation injury. Acta Otolaryngol. 1986;428: \n1–54.\n\t 94.\t \u0007Granstrom G. Hyperbaric oxygen as a stimulator of osseointegra-\ntion. In: Yanagita N, Nakashima T, eds. Hyperbalic Oxygen Therapy \nin Otorhinolaryngology. 54. ; 1998:33–49. Adv Otorhinolaryngol.\n\t 95.\t \u0007Jacobsson M. On Behavior After Irradiation (Master’s Thesis). Gote-\nborg: Sweden: University of Goteborg; 1985.\n\t 96.\t \u0007Keller EE. Placement of dental implants in irradiated mandible. A \nprotocol without adjunctive hyperbaric oxygen. J Oral Maxillofac \nSurg. 1997;55:972."
  },
  {
    "page": 65,
    "content": "273\nCHAPTER 10  Medical Evaluation of the Dental Implant Patient\n\t 97.\t \u0007Granstrom G. Osseointegration in irradiated tissues. Experi-\nence from our first 100 treated patients. J Oral Maxillofac Surg. \n1996;63:579–585.\n\t 98.\t \u0007King MA, Casarett GW, Weber DA. A study of irradiated \nbone: I. histopathologic and physiologic changes. J Nucl Med. \n1979;20:1142–1149.\n\t 99.\t \u0007Almeida D, Vianna K, Arriaga P, Moraschini V. Dental implants \nin Sjögren’s syndrome patients: a systematic review. PloS one. \n2017;12(12):e0189507.\n\t100.\t \u0007Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epi-\ndemiology and progression of systemic lupus erythematosus. Semin \nArthritis Rheum. 2010;39(4):257–268. https://doi.org/10.1016/j.\nsemarthrit.2008.10.007. Epub 2009 Jan 10.\n\t101.\t \u0007https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Dis-\neases-Conditions/Scleroderma.\n\t102.\t \u0007Vital EM, Emery P. Advances in the treatment of early rheumatoid \narthritis. Am Fam Physician. 2005;72:1002–1004.\n\t103.\t \u0007Friedlander GE, Tross RB, Doganis AC, et al. Effects of chemo-\ntherapeutic agents on bone: I. short-term methotrexate and doxo-\nrubicin (adriamycin) treatment in a rat model. J Bone Joint Surg \nAm. 1984;66(4):602–607.\n\t104.\t \u0007http://www.natap.org/2016/CROI/croi_25.htm.\n\t105.\t \u0007Shetty K, Achong R. Dental implants in the HIV-positive patient—\ncase report and review of the literature. Gen Dent. 2005;53:434–437.\n\t106.\t \u0007Achong RM, Shetty K, Arribas A, et  al. Implants in HIV-\npositive patients: 3 case reports. J Oral Maxillofac Surg. 64: \n1199–1203.\n\t107.\t \u0007Oksenberg A, Aarons E. Reduction of sleep bruxism using a man-\ndibular advancement device: an experimental controlled study. \nSleep Med. Nov. 2002;3(6):513–515.\n\t108.\t \u0007Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep \napnoea. Lancet. 2014;383(9918):736–747.\n\t109.\t \u0007Hypertension. 2014;63:203–209. https://doi.org/10.1161/HYPER-\nTENSIONAHA.113.00613.\n\t110.\t \u0007McCracken M, Lemons JE, Rahemtulla F, et al. Bone response to \ntitanium alloy implants placed in diabetic rats. Int J Oral Maxillofac \nImplants. 2000;15:345–354.\n\t111.\t \u0007Peled M, Ardekian L, Tagger-Green N, et al. Dental implants in \npatients with type 2 diabetes mellitus: a clinical study. Implant \nDent. 2003;12:116–122.\n\t112.\t \u0007Balshi TJ, Wolfinger GJ. Dental implants in the diabetic patient: a \nretrospective study. Implant Dent. 1999;8:355–359.\n\t113.\t \u0007Jemt T. Implant treatment in elderly patients. Int J Prosthodont. \n1993;6:456–461.\n\t114.\t \u0007Leow YH, Maibach HI. Cigarette smoking, cutaneous vasculature, \nand tissue oxygen. Clin Dermatol. 1998;16:579–584.\n\t115.\t \u0007Cavalcanti R, Oreglia F, Manfredonia MF, et  al. The influence \nof smoking on the survival of dental implants: a 5-year pragmatic \nmulticenter retrospective cohort study of 1727 patients. Eur J Oral \nImplantol. 2011;4:39–45.\n\t116.\t \u0007van Steenberghe D, Jacobs R, Desnyder M, et  al. The relative \nimpact of local and endogenous patient-related factors on implant \nfailure up to the abutment stage. Clin Oral Implants Res. 2002;13: \n617.\n\t117.\t \u0007Jones JK, Triplett RG. The relationship of cigarette smoking \nto impaired intra-oral wound healing. J Oral Maxillofac Surg. \n1992;50:237–239.\n\t118.\t \u0007Bain CA. Smoking and implant failure—benefits of a smoking \ncessation protocol. Int J Oral Maxillofac Implants. 1996;11:1667–\n1674.\n\t119.\t \u0007Bain CA, Moy PK. The association between the failure of den-\ntal implants and cigarette smoking. Int J Oral Maxillofac Impl. \n1993;8:609–615.\n\t120.\t \u0007Grossi SG, Zambon J, Machtei EE. Effects of smoking and smok-\ning cessation on healing after mechanical periodontal therapy. J Am \nDent Assoc. 1997;128:599–607.\n\t121.\t \u0007Scully C. Scully’s Medical Problems in Dentistry. 7th ed. London: \nChurchill Livingstone; 2014.\n\t122.\t \u0007Rees TD. Oral effects of drug abuse. Crit Rev Oral Biol Med. \n1992;3:163–184.\n\t123.\t \u0007Tonnesen H. Alcohol abuse and postoperative morbidity. Dan Med \nBull. 2003;50:139–160.\n\t124.\t \u0007Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecro-\nsis of the Jaws. Hanover Park, IL: Quintessence; 2007.\n\t125.\t \u0007Greenspan SL, Rosen HN, Parker RA. Early changes in serum \nN-telopeptide and C-telopeptide cross-linked collagen type 1 pre-\ndict long-term response to alendronate therapy in elderly women. \nJ Clin Endocrinol Metab. 2000;85:3537–3540.\n\t126.\t \u0007Marx RE. Bisphosphonates and bisphosphonate-induced osteone-\ncrosis of the jaws. In: Bagheri SC, Bell RB, Kahn HA, eds. Current \nTherapy in Oral and Maxillofacial Surgery. St Louis: Saunders; 2012.\n\t127.\t \u0007Jeffcoat MK. Safety of oral bisphosphonates: controlled stud-\nies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21: \n349–353.\n\t128.\t \u0007Damm DD, Jones DM. Bisphosphonate-related osteonecrosis \nof the jaws: a potential alternative to drug holidays. Gen Dent. \n2013;61(5):33–38.\n\t129.\t \u0007Aljohani S, Gaudin R, Weiser J, et al. Osteonecrosis of the jaw in \npatients treated with denosumab: a multicenter case series. J Cra-\nniomaxillofac Surg. 2018;46(9):1515–1525.\n\t130.\t \u0007Blanchaert RH. Implants in the medically challenged patient. Dent \nClin N Am. 1998;42:1.\n\t131.\t \u0007Hess LM, Jeter J, Benham-Hutchins M, et al. Factors associated \nwith osteonecrosis of the jaw among bisphosphonate users. Am J \nMed. 2009;121:475–483. e3.\n\t132.\t \u0007Shapiro CL. Bisphosphonate-related osteonecrosis of jaw in the \nadjuvant breast cancer setting: risks and perspective. J Clin Oncol. \n2013;31:2648.\n\t133.\t \u0007https://nei.nih.gov/health/maculardegen/armd_facts.\n\t134.\t \u0007Tolentino M. Systemic and ocular safety of intravitreal anti-\nVEGF therapies for ocular neovascular disease. Sur Ophthalmol. \n2011;56(2):95–113.\n\t135.\t \u0007https://www.cdc.gov/arthritis/basics/fibromyalgia.htm.\n\t136.\t \u0007Becker DE. Psychotropic drugs: implications for dental practice. \nAnesth Prog. 2008;55(3):89–99.\n\t137.\t \u0007Devine M, Taylor S, Renton T. Chronic post-surgical pain follow-\ning the placement of dental implants in the maxilla: a case series. \nEur J Oral Implantol. 2016;9(suppl 2, [1]):179–186.\n\t138.\t \u0007https://www.cancer.org/cancer/breast-cancer/about/how-common- \nis-breast-cancer.html.\n\t139.\t \u0007Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen recep-\ntor status by immunohistochemistry is superior to the ligand-bind-\ning assay for predicting response to adjuvant endocrine therapy in \nbreast cancer. J Clin Oncol. 1999;17(5):1474–1481.\n\t140.\t \u0007Sadler GR, Stoudt A, Fullerton JT, et  al. Managing the oral \nsequelae of cancer therapy. Med surg Nurs. 2003;12(1):28–36.\n\t141.\t \u0007Watters AL, Epstein JB, Agulnik M. Oral complications of tar-\ngeted cancer therapies: a narrative literature review. Oral Oncol. \n2011;47(6):441–448. [PubMed].\n\t142.\t \u0007Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism \nwith short-term interruption of warfarin therapy. Arch Intern Med. \n2008;168:63–69.\n\t143.\t \u0007Brennan MT, et al. Aspirin use and post-operative bleeding from \ndental extractions. J Dent Res. 2008;87:740–744.\n\t144.\t \u0007Gulpinar K, Suleyman O, Erpulat O, et al. A preliminary study: \naspirin discontinuation before elective operations; when is the opti-\nmal timing? J Korean Surg Soc. 2013;85(4):185–190.\n\t145.\t \u0007Gomez-Moreno G, Aguilar-Salvaterra A, Martin-Piedra MA, \net al. Dabigatran and rivaroxaban, new oral anticoagulants, new \napproaches in dentistry. J Clin Exp Dent. 2010;2:e1–e5.\n\t146.\t \u0007Firriolo JF, Hupp WS. Beyond warfarin: the new generation of \noral anticoagulants and their implications for the management \nof dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. \n2012;113(4):431–441.\n\t147.\t \u0007Phillips KA, Veenstr DL. Potential role of pharmocogenics in \nreducing adverse drug reactions. JAMA. 2001;286:2270–2279."
  },
  {
    "page": 66,
    "content": "274\nPART III     Fundamental Science\n\t148.\t \u0007Haney EM, Chan BKS, Diem SJ, et al. Association of low bone \nmineral density with selective serotonin reuptake inhibitor use by \nolder men. Arch Intern Med. 2007;167(12):1246–1251.\n\t149.\t \u0007Wu X, Al-Abedalla K, Rastikerdar E, et al. Selective serotonin reup-\ntake inhibitors and the risk of osseointegrated implant failure: a \ncohort study. J Dent Res. 2014;93(11):1054–1061.\n\t150.\t \u0007Witt JD, Swann M. Metal wear and tissue response in failed \ntitanium alloy total hip replacements. J Bone Joint Surg Br. \n1991;73:559–563.\n\t151.\t \u0007Yamauchi R, Morita A, Tsuji T. Pacemaker dermatitis from tita-\nnium. Contact Dermatitis. 2000;42:52–53.\n\t152.\t \u0007Siddiqi A, Payne AG, De Silva RK, et al. Titanium allergy: could \nit affect dental implant integration? Clin Oral Implants Res. \n2011;22:673–680.\n\t153.\t \u0007du Preez LA, BÜtow KW, Swart TJ. Implant failure due to titanium \nhypersensitivity/allergy? Report of a case. SADJ. 2007;62:24–25.\n\t154.\t \u0007Egusa H, Ko N, Shimazu T, Yatani H. Suspected association of an \nallergic reaction with titanium dental implants: a clinical report. \nJ Prosthet Dent. 2008;100:344–347.\n\t155.\t \u0007Sicilia A, Cuesta S, Coma G, et  al. Titanium allergy in dental \nimplant patients: a clinical study on 1500 consecutive patients. \nClin Oral Implants Res. 2008;19:823–835.\n\t156.\t \u0007Holgers KM, Roupe G, Tjellström A, Bjursten LM. Clinical, \nimmunological and bacteriological evaluation of adverse reactions \nto skin-penetrating titanium implants in the head and neck region. \nContact Dermatitis. 1992;27:1–7.\n\t157.\t \u0007Hallab N, Merritt K, Jacobs JJ. Metal sensitivity in patients \nwith orthopaedic implants. J Bone Joint Surg Am. 2001;83A: \n428–436.\n\t158.\t \u0007Harloff T, Hönle W, Holzwarth U, et al. Titanium allergy or not? \n“Impurity” of titanium implant materials. Health. 2010;2:306–\n310."
  },
  {
    "page": 67,
    "content": "275\n11\nRadiographic Evaluation in \nOral Implantology\nRANDOLPH R. RESNIK\nA\ndvances in radiologic imaging technology have had a sig-\nnificant impact on the surgical and prosthetic phases of \noral implantology. Comprehensive and accurate radio-\ngraphic assessment is crucial and one of the most important \naspects of dental implant treatment planning. In the past, vari-\nous imaging techniques have been used to evaluate bone quality, \nquantity, and location of anatomic structures in relation to pro-\nposed implant sites. Traditionally, implant clinicians have relied \non two-dimensional (2D) conventional radiographic modalities \nin implant dentistry that have inherent shortcomings. How-\never, with the advent of computed tomography (CT) and cone \nbeam computed tomography (CBCT), a new era in all phases \nof the radiographic imaging survey of implant patients has \nbecome available to the implant clinician. These technological \nadvances have significantly increased the level of detailed infor-\nmation available to implant clinicians in the diagnosis, treat-\nment planning, surgical, and prosthetic phases of dental implant \ntreatment. This chapter will comprehensively review the use of \nvarious radiographic modalities and technology in the presurgi-\ncal evaluation, treatment planning, and surgical, prosthetic, and \npostoperative assessments of implant treatment.\nImaging Objectives in Oral Implantology\nThe objectives of diagnostic imaging depend on a number of fac-\ntors, including the amount and type of information required and \nthe anatomic location of interest. The decision of when to image, \nalong with which imaging modality to use, depends on the inte-\ngration of these factors and can be organized into three phases.\nPhase 1\nPhase 1 is termed presurgical implant imaging assessment and \ninvolves all past radiologic examinations and new radiologic \nexaminations selected to assist the implant team in determining \nthe patient’s final and comprehensive treatment plan. The objec-\ntives of this phase of imaging include all necessary surgical and \nprosthetic information to determine the quantity, quality, and \nangulations of bone; the relationship of critical structures to the \nprospective implant sites; and the presence or absence of disease at \nthe proposed surgery sites. \nPhase 2\nPhase 2 consists of surgical and intraoperative implant imaging, \nand is focused on assisting in the surgical and prosthetic phases of \nintervention of the patient. The objectives of this phase of imag-\ning are to evaluate the surgery sites during and immediately after \nsurgery, assist in the optimal position and orientation of dental \nimplants, evaluate the healing and integration phase of implant \nsurgery, and ensure that abutment position and prosthesis fabrica-\ntion are correct. \nPhase 3\nPhase 3 is the final phase comprising the postprosthetic implant \nimaging. This phase commences just after the prosthesis place-\nment and continues as long as the implants remain in the jaws. \nThe objectives of this phase of imaging are to evaluate the long-\nterm maintenance of implant rigid fixation and function, includ-\ning the crestal bone levels around each implant, and to evaluate \nthe implant prosthesis. \nPresurgical Imaging (Phase 1)\nIn the field of oral implantology numerous radiographic imaging \nmodalities are available for the presurgical assessment of patients \nwith dental implants. Before cone beam computerized tomogra-\nphy, intraoral radiographs, along with 2D panoramic images, were \nused as the sole determinants of implant diagnosis and treatment \nplanning. With the advancement of radiographic technology, vari-\nous three-dimensional (3D) imaging systems are now common \nplace in the dental profession, allowing an unlimited amount of \ndiagnostic information to be available to the implant team.\nThe presurgical imaging phase of treatment is one of the most \nimportant in the implant process. The goal of presurgical radio-\ngraphic evaluation is to assess the available bone quality and \nquantity, angulation of bone, and selection of potential implant \nsites, and to verify the absence of pathology. With the popular use \nof CBCT, the presurgical phase has become more user-friendly \nand allows a comprehensive evaluation of the patient. In com-\nparison with CBCT, other types of radiographic modalities (e.g., \npanoramic, periapical, cephalometric, conventional tomography)"
  },
  {
    "page": 68,
    "content": "276\nPART III    Fundamental Science\nhave inherent advantages and disadvantages, and have been shown \nto exhibit false-negative and false-positive results.1\nIn dental and medical radiology a recommended principle when \nselecting the appropriate radiographic modality is based on radia-\ntion dosage. Dental professionals should always adhere to the “as \nlow as reasonably achievable” (ALARA) principle. ALARA basically \nstates that the diagnostic imaging technique selected should include \nthe lowest possible radiation dose to the patient. The American \nAcademy of Oral and Maxillofacial Radiology published guidelines \nstating that all implant site surveys should be evaluated with a 3D \nimaging technique such as CBCT or CT.2 This phase of implant \nimaging is intended to evaluate the current status of the patient’s \nteeth and bony anatomy, and to develop and refine the patient’s \ntreatment plan. Evaluation of the patient by members of the dental \nimplant team is accomplished with a review of the patient’s history, \na thorough clinical examination, and a review of the patient’s radio-\nlogic examinations. At this point the clinician should be able to rule \nout dental or bone disease, and establish a tentative clinical objective \nthat meets the patient’s functional and esthetic needs. If the dentist \ncannot rule out dental or bone disease, then a further clinical or \nradiologic examination is necessary. The ideal objective of this phase \nof treatment is to develop and implement a treatment plan for the \npatient that enables restoration of the patient’s function and esthet-\nics by the accurate and strategic placement of dental implants. The \npatient’s functional and esthetic needs can be transformed physi-\ncally into a 3D diagnostic template that allows the implant team to \nidentify the specific sites of prospective implant surgery in the imag-\ning examinations. The specific objectives of preprosthetic imaging \nare listed in Box 11.1.\nAll of the modalities identified in Box 11.2 have been used in the \nfirst diagnostic phase of treatment in oral implantology.3,4 However, \ndental implant cases are inherently 3D with respect to the final pros-\nthetics, occlusion, and function of the patient’s 3D anatomy. A 3D \ntreatment plan ideally identifies at each prospective implant site the \namount of bone width, the ideal position and orientation of each \nimplant, its optimal length and diameter, the presence and amount \nof cortical bone on the crest, the degree of mineralization of tra-\nbecular bone, and the position or relationship of critical structures \nto the proposed implant sites. Therefore the modalities of choice \nfor presurgical implant treatment planning most commonly utilize \nCBCT which provides high-resolution and dimensionally accurate \n3D information about the patient at the proposed implant sites. \nRadiographic Modalities Used in Oral \nImplantology\nPeriapical Radiograph\nPeriapical radiography (digital), one of the most commonly used \nradiographic modalities in dentistry, has many advantages, such as \nhigh resolution, low radiation, convenience, and image modifica-\ntion via digital software capability. However, the implant clini-\ncian must understand the inherent disadvantages of this radiologic \ntechnique when used in oral implantology.\n\t1.\t \u0007Image distortion: Intraoral radiographs are inherently suscep-\ntible to image distortion and magnification because the object \nof interest does not have the same focal spot-to-object distance. \nWhen determining the location of anatomic structures the \nclinician should note that the image may contain distortion, \nand relying on exact measurements from these images should \nbe cautioned. If the x-ray beam is perpendicular to the image \nreceptor (film or sensor), but the object is not perpendicular to \nthe image receptor and object, then dimensional changes such \nas foreshortening and elongation will occur (Fig. 11.1). Eden-\ntulous sites/quadrants are especially predisposed to these errors \nbecause flat maxillary palatal vaults, along with high muscle \n • \u0007Identify normal versus abnormal anatomy.\n • \u0007Identify anatomic variants.\n • \u0007Determine bone quality.\n • \u0007Determine bone quantity.\n • \u0007Identify ideal implant positioning.\n • \u0007Use for surgical templates.\n\t • BOX 11.1\t    \u0007Objectives of Preprosthetic Imaging\n • \u0007Periapical\n • \u0007Panoramic\n • \u0007Occlusal\n • \u0007Cephalometric\n • \u0007Medical computerized technology\n • \u0007Cone beam computerized technology\n • \u0007Magnetic resonance imaging\n\t • BOX 11.2\t    \u0007Types of Imaging Modalities\nCollimated\nbeam\nCentral ray\nCentral ray\nFilm\nFilm\nImage\n5\n5\n10\nFilm\nImage\n5 10 15\n5\n10\nA\nB\nC\n• Fig. 11.1  Film Positioning.  (A) Ideally the central ray is perpendicular to the bone, object, and film, which \nresults in minimal distortion. (B) The central ray is perpendicular to the film, but not to the implant, resulting \nin foreshortening. (C) The central ray is perpendicular to the object, but not the film, resulting in elongation. \n(From Resnik RR, Preece JW. Radiographic complications and evaluation. In: Resnik RR, Misch CE, eds. \nMisch’s Avoiding Complications in Oral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 69,
    "content": "277\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nattachments in the mandible, make accurate positioning of the \nimage receptor difficult.\n\t2.\t \u0007Two-dimensional radiographic modality: A true evaluation and \ndetermination of the buccal-lingual available bone must be \nascertained to evaluate the osseous contours of the existing \nbone. Because periapical radiography is 2D, vital information \non the width of available bone is not obtained. Therefore when \nattempting to estimate width distances in close approxima-\ntion to maxillary and mandibular anatomic structures with 2D \nradiographs, the implant clinician must be conscious of the \ninherent inaccuracies associated with 2D images.\n\t3.\t \u0007Poor identification of vital structures: When evaluating the posi-\ntion of vital structures with intraoral radiographs, extreme cau-\ntion should be exercised. In the evaluation of the true location \nof the mental foramen, studies have shown less than 50% of \nperiapical radiographs depict the correct location of the men-\ntal foramen.5 Other studies have concluded that because of \ninsufficient cortical bone around the mandibular canal (MC), \nonly 28% of periapical radiographs will accurately identify the \nMC.3 Therefore periapical radiographs exhibit relatively high \nfalse-positives and false-negatives with respect to the identifica-\ntion of vital anatomic structures.\nUses in Oral Implantology\nPeriapical radiographs have many inherent disadvantages, most \nnotably providing only a 2D image of a 3D object. The inabil-\nity to determine the buccal-lingual bony dimensions is a major \nshortcoming with respect to implant treatment planning. These \nradiographs are of little value in determining quantity and qual-\nity of bone, identifying vital structures, and depicting the spatial \nrelationship between structures within proposed implant sites. In \nsummary, periapical radiographs should be limited to an initial \nevaluation of a proposed implant site, intraoperative evaluation, \nand postoperative assessment.\nIn terms of the objectives of presurgical imaging, periapical \nradiography is:\n • \u0007a useful high-yield modality for ruling out local bone or dental \ndisease;\n • \u0007limited value in determining quantity because the image is \nmagnified, may be distorted, and does not depict the third \ndimension (bone width);\n • \u0007limited value in determining bone density or mineralization \n(the lateral cortical plates prevent accurate interpretation and \ncannot differentiate subtle trabecular bone changes); and\n • \u0007has poor ability in depicting the spatial relationship between \nthe anatomic structures and the proposed implant site. \nPanoramic Radiograph\nPanoramic radiography is a curved plane tomographic radio-\ngraphic technique used to depict the body of the mandible, max-\nilla, and the maxillary sinuses in a single image. Its convenience, \nspeed, and ease have made this type of radiography a popular \ntechnique in evaluating the gross anatomy of the jaws. However, \nthe implant clinician must understand the inherent fundamental \nlimitations characteristic of this type of radiograph.\n\t1.\t \u0007Magnification/Distortion: All panoramic radiographs exhibit \nvertical and horizontal magnification, together with a tomo-\ngraphic section thickness that varies according to the ana-\ntomic position. Because the x-ray source exposes the jaws \nusing a negative angulation (∼8%) to avoid superimposing the \noccipital bone/base of the skull over the anterior dental region, \nvariable magnification will always be present on panoramic \nradiographs. Increased magnification stems from variances in \npatient positioning, focal object distance, the relative location \nof the rotation center of the x-ray system, and variations in \nnormal anatomic form and size from one patient to the next. \nZarch et al.4 have shown that 83% of panoramic measurements \nare underestimated, with the greatest magnification being pres-\nent in the anterior region (Fig. 11.2).\n\t\na.\t \u0007Horizontal magnification is determined by the position of \nthe object within the focal trough. The degree of horizontal \nmagnification depends on the distance of the object from \nthe focal trough center and is influenced by the patient’s \nanatomy and positioning within the panoramic machine. \nIn the anterior region the horizontal magnification will \nincrease significantly as the object moves away from the \nfocal trough. This results in anterior magnification being \nfar greater and more variable than posterior magnification.\n\t\nb.\t \u0007Vertical magnification is determined by the differences \nbetween the x-ray source and object. Because the beam \nangle is directed at a negative [upward] angulation, struc-\ntures positioned closer to the source are projected higher \nwithin the image in relation to structures positioned farther \nfrom the x-ray source. Therefore the vertical plane spatial \nrelationships between objects projected on a panoramic \nradiograph are inaccurate.\n\t2.\t \u0007Two-dimensional radiographic modality: The panoramic radio-\ngraph is a 2D image depicting 3D structures. Accordingly, it \ndoes not demonstrate the buccal-lingual dimension of max-\nillofacial structures; therefore bone width and vital structures \ncannot be determined. In addition, it produces a flattened, \nspread-out image of curved structures, which results in signifi-\ncant distortion of the vital structures and their relationship in \nspace.\n\t3.\t \u0007Identification of vital structures: Panoramic radiography does \nnot exhibit an accurate assessment of bone quality/mineraliza-\ntion and the true identification and location of vital structures.\n\t\na.\t \u0007Visibility of Mental Foramen: Caution must be exercised in \nusing panoramic images as the definitive diagnostic modal-\nity in evaluating the location and visibility of the MC. \n• Fig. 11.2  All two-dimensional panoramic radiographs exhibit magnifica-\ntion, distortion, overlapping of images, and ghost images, making these \nimages inaccurate as the sole determination for dental implant diagnosis. \nTherefore panoramic radiographs should not be used for final measure-\nments or determination of vital structures."
  },
  {
    "page": 70,
    "content": "278\nPART III    Fundamental Science\nLindh et al.6 have shown that the MC cortical walls were \nvisible in only 36.7% of panoramic radiographs.\n\t\nb.\t \u0007Mental foramen location: The location of the mental fora-\nmen has high patient variability. Yosue and Brooks,7 in eval-\nuation of the mental foramen, concluded that more than \n50% of radiographs will not depict the true location of the \nmental foramen.\n\t\nc.\t \u0007Linear measurements: Because of the inherent panoramic \nmagnification and distortion disadvantages, calculating lin-\near measurements on panoramic images is inaccurate. Sonic \net al.8 reported in determination of linear measurements for \nbone assessment with respect to vital structures, an inaccu-\nracy rate of 24% has been shown.\n\t\nd.\t \u0007Anterior loops: The anterior course of the mental nerve in \nrelation to the mental foramen must be identified to pre-\nvent neurosensory impairment. Studies completed by \nKuzmanovic et al.9 of anterior loops (mental nerve courses \nanteriorly to the mental foramen) concluded panoramic \nradiographs exhibit a high incidence of false-positives and \nfalse-negative results, thus being totally inaccurate.\n\t\ne.\t \u0007Location of septa: Septum in the maxillary sinus compli-\ncate bone grafting and implant placement. In evaluation \nof maxillary sinus floor bony septa by Krennmair et al.,10 \ncorrect identification and location have been shown to be \napproximately 21.3%.\n\t\nf.\t \u0007Identification of accessory foramina: A common anatomic \nvariant in the mandible is the presence of two mental fora-\nmen. Accessory (double) foramina have been shown to be \nidentified accurately in less than 50% of panoramic radio-\ngraphs.11\nUse in Oral Implantology\nAlthough panoramic radiographs have historically been the gold \nstandard in evaluating potential implant sites, many disadvantages \nare associated with these types of radiographs. A lower resolu-\ntion prevents evaluation of the fine detail that is required for the \nassessment of osseous structures and anatomy. The magnification \nin the horizontal and vertical planes are nonuniform; thus linear \nmeasurements are inaccurate. Often the image has superimposi-\ntion of real, double, and ghost images, which result in difficulty \nin visualizing anatomic and pathologic details. The true positions \nof important vital structures, which are crucial in dental implant \ntreatment, are not easily seen or incorrectly depicted. Therefore \npanoramic radiographs have value for initial evaluation; however, \ncaution should be exercised when using these types of radiographs \nfor the sole determinant of implant placement because they pre-\ndispose the implant clinician to many surgical, prosthetic, and \nmedical-legal complications (Fig. 11.3). \nMagnetic Resonance Imaging\nMagnetic resonance imaging (MRI) is a cross-sectional imag-\ning technique that produces images of thin slices of tissue with \nexcellent spatial resolution. This imaging modality developed by \nLauterbur12 in 1972 uses a combination of magnetic fields that \ngenerate images of tissues in the body without the use of ionizing \nradiation. MRI allows complete flexibility in the positioning and \nangulation of image sections and can reproduce multiple slices \nsimultaneously. Digital MRI images are characterized by voxels, \nwith an in-plane resolution measured in pixels and millimeters, \nand a section thickness measured in millimeters (2–3 mm) for \nhigh-resolution imaging acquisitions. The image sequences used \nto obtain magnetic resonance images can be varied to obtain fat, \nwater, or balanced imaging of the patient’s anatomy. The images \ncreated by MRI are the result of signals generated by hydrogen \nprotons in water or fat such that cortical bone will appear black \n(radiolucent) or as having no signal. Cancellous bone will gener-\nate a signal and will appear white because it contains fatty mar-\nrow. Metal restorations will not produce scattering and thus will \nappear as black images. Therefore MRI has been shown to be less \nprone to artifacts from dental restorations, prostheses, and dental \nimplants than CT or CBCT scans.13 As with CT, MRI is a quan-\ntitatively accurate technique with exact tomographic sections and \nno distortion.\nNumerous authors have suggested the use of MRI for dental \nimplant evaluation and treatment planning.14 Vital structures are \neasily viewed, such as the inferior alveolar canal and the maxillary \nsinus. In cases where the inferior alveolar canal cannot be differ-\nentiated by conventional tomography or CT, MRI would be a \nviable alternative because the trabecular bone is easily differenti-\nated with the inferior alveolar canal. In cases of nerve impairment \nor infection (osteomyelitis), MRI may be used because of added \nadvantages including differentiation of soft tissue with respect to \nCT. Studies have shown that the geometric accuracy of the man-\ndibular nerve with MRI is comparable with CT and is an accurate \nimaging method for dental implant treatment planning.15 MRI \nmay be used in implant imaging as a secondary imaging technique \nwhen primary imaging techniques such as complex tomography \nor CBCT fail. Complex tomography fails to differentiate the infe-\nrior alveolar canal in 60% of implant cases, and CT fails to dif-\nferentiate the inferior alveolar canal in about 2% of implant cases. \nFailure to differentiate the inferior alveolar canal may be caused by \nosteoporotic trabecular bone and poorly corticated inferior alveo-\nlar canal.16 MRI visualizes the fat in trabecular bone and differen-\ntiates the inferior alveolar canal and neurovascular bundle from \nthe adjacent trabecular bone. Double-scout MRI protocols with \nvolume and oriented cross-sectional imaging of the mandible pro-\nduce orthogonal quantitative contiguous images of the proposed \nimplant sites. Oriented MRI of the posterior mandible is dimen-\nsionally quantitative and enables spatial differentiation between \ncritical structures and the proposed implant site. Recent advances \nin MRI have allowed for higher image resolution, similar to the \nresolution produced on CBCT scans, with voxel sizes of 300 to \n400 μm3. In addition, technology has allowed for shorter image \nacquisition times of only 3 to 4 minutes.17 However, there exist \nnumerous disadvantages for the use of MRI for implant dentistry. \n12%\n~20–45%\n~10–70%\n40%\n20% 50%\n• Fig. 11.3  Panoramic showing nonuniform magnification in the vertical \nand horizontal plane depicting inaccurate measurements. Magnification is \nhighly variable, especially in the horizontal plane. (From Resnik RR, Preece \nJW. Radiographic complications and evaluation. In: Resnik RR, Misch CE, \neds. Misch’s Avoiding Complications in Oral Implantology. St. Louis, MO: \nElsevier; 2018.)"
  },
  {
    "page": 71,
    "content": "279\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nMRI is not useful in characterizing bone mineralization or as a \nhigh-yield technique for identifying bone or dental disease. In \naddition, no commercially available reformatting programs are \navailable to use as reference points.\nUse in Oral Implantology\nIn oral implantology, because of the imaging artifacts associated \nwith CBCT scans, MRI is a possible alternative for the postopera-\ntive evaluation of dental implants, especially if associated with a \nneurosensory impairment (Fig. 11.4). \nCone Beam Tomography (CBCT)\nWith the advent of cone beam computerized tomography, many \nof the disadvantages of 2D radiographs and conventional medi-\ncal CT scanners have been overcome. CBCT has been one of \nthe most significant technological breakthroughs in oral implan-\ntology today. Because of the low radiation dose inherent with \ncone beam technology, the limitations of medical computerized \ntomography have been overcome. This scanning technology has \nmany advantages, including “in-office” installation and use, \nwhich allow the clinician and patient the convenience of on-site \nscanning capabilities and treatment planning. In addition, the \nscanning speed (<5 seconds) and integration of interactive soft-\nware programs have brought an unparalleled advantage to the \nimplant clinician for the evaluation and assessment of potential \nimplant sites.\nToday CBCT imaging has become the gold standard for dental \nimplant treatment planning. However, many implant clinicians \nlack the background and knowledge in evaluating and treat-\nment planning with CBCT, thus predisposing to possible com-\nplications. Therefore the implant clinician must have a thorough \nunderstanding of inherent disadvantages of CBCT scans, together \nwith knowledge of applied head and neck anatomy, anatomic vari-\nants, incidental findings, and pathologic conditions with respect \nto implant treatment planning.\nCBCT images are a result of data collected by numerous detec-\ntors and ionizing chambers in the CBCT unit. The data collected \nby the detectors correspond to a composite of the absorption char-\nacteristics of the tissues and structures imaged. This information \nis transformed into images (raw data) that are reformatted into a \nvoxel (digital) volume for evaluation and analysis. The integration \nof digital imaging systems in the field of implant dentistry has sig-\nnificantly increased clinicians’ diagnostic capabilities. A digital 2D \nimage is described by an image matrix that has individual picture \nelements called pixels. A digital image is described by its width, \nheight, and pixels (i.e., 512 Å∼ 512). For larger digital images (i.e., \n1.2 M Å∼ 1.2 M, where M is megapixels), the image is alterna-\ntively described as a 1.5-M image. Each picture element, or pixel, \nhas a discrete digital value that describes the image intensity at \nthat particular point. The value of a pixel element is described \nby a scale, which may be as low as 8 bits (256 values) or as high \nas 12 bits (4096 values) for black and white imaging systems, or \n36 bits (65 billion values) for color imaging systems. Nine to 11 \nImplant body\nInferior alveolar nerve\ncancellous bone\ncortical bone\nA\nB\nC\n• Fig. 11.4  Acquired magnetic resonance images—(A) sagittal, (B) axial, and (C) coronal)—for three-\ndimensional assessment of bone after implant placement, with a display of the implant located in the \ninferior alveolar canal. (From Wanner L, et al. Magnetic resonance imaging—a diagnostic tool for post-\noperative evaluation of dental implants: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. \n2018;125:e103-e107.)"
  },
  {
    "page": 72,
    "content": "280\nPART III    Fundamental Science\nblack and white digital images are displayed optimally on a dedi-\ncated black and white monitor. Generally 8 bits, or 256 levels, \ncan be displayed effectively on a monitor. A digital 3D image is \ndescribed by an image matrix that has individual image or picture \nelements called voxels. A digital 3D image is described not only \nby its width and height of pixels (i.e., 512 Å∼ 512) but also by its \ndepth and thickness. An imaging volume or 3D characterization \nof the patient is produced by contiguous images, which produce a \n3D structure of volume elements (i.e., CT, MRI, and interactive \ncomputed tomography [ICT]).\nEach volume element has a value that describes its intensity \nlevel. Typically 3D modalities have an intensity scale of 12 bits, or \n4096 values. The 2D digital images are composed of pixels (2D) \nand voxels (3D) picture elements. Pixels and voxels possess attri-\nbutes of size, location, and grayscale value. Each voxel and pixel \ndisplayed is characterized by a numerical value that represents the \ndensity of the tissues. This is termed the CT number. A specific \nshade of gray or density value is assigned to each CT number that \ncomprises the images (Fig. 11.5).\nCT images are inherently 3D images that are typically 512 Å∼ \n512 pixels with a thickness described by the slice spacing of the \nimaging technique. Each voxel has a value, referred to in Houn-\nsfield units (HUs), that describes the density of each image. The \nrange of these units is −1000 (air) to +3000 (enamel) HUs (Box \n11.3). Most CT scanners are standardized with a Hounsfield value \nof 0 for water. The CT density scale is quantitative and meaning-\nful in identifying and differentiating structures and tissues (Box \n11.4).\nTypes of Computed Tomography Scanners\nMedical\nIn medical radiology departments the CT scan is the most com-\nmon diagnostic imaging modality to evaluate hard and soft tissues. \nPixel\nThe smallest component of\nan image, which reflects\ncolors in 2D\nVoxel\nVoxel \u001f volumetric pixel,\ni.e., a 3-dimensional\npixel. It is the smallest\nvolumetric element of a\n3-dimensional volume.\nPixel\n• Fig. 11.5  The final computed tomography image depends on the pixel (two-dimensional [2D]) and the \nvoxel (three-dimensional) size. (From Resnik RR, Misch CE. Radiographic imaging in implant dentistry. In: \nMisch CE, ed. Dental Implant Prosthetics. 2nd ed. St. Louis, MO: Elsevier; 2015.)"
  },
  {
    "page": 73,
    "content": "281\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nAdvances in speed and image quality were apparent in the early 1990s \nwith the advent of spiral and helical CT scanners. However, since its \nintroduction in 1998, multislice (multirow detector CT) has revolu-\ntionized the ﬁeld of medical CT. These CT scanning units are tomo-\ngraphic machines that are classiﬁed as 4-, 8-, 12-, 16-, 32-, or 64-slice \nmachines. The number of slices corresponds to the number of times \nthe x-ray beam rotates around the patient’s head to acquire the CT \ndata. The CT numbers, or Hounsﬁeld units, are then reconstructed \nmathematically and formatted into images. However, because these \nimages consist of a series of incremental images grouped together, CT \nspiral slices produce “average” reconstructed images based on mul-\ntiple x-rays transversing the scanning area. With this reconstruction \nof images, a small gap between each slice is present, which contributes \nto an inherent error within medical scanners.\nIn the 1980s cross-sectional reconstruction of the CT images \ndramatically improved the diagnosis and treatment planning in \noral implantology. These reformatted images allowed 3D evalu-\nation of vital structures and related oral anatomy. However, even \nthough these advances enhanced diagnostic skills, there were \ninherent shortcomings to medical scanners used for dental pur-\nposes. Because medical scanners were not developed for dental \nreformatting, there existed inherent errors such as distortion, \nmagniﬁcation, and positioning problems that led to inaccuracies \nwhen reformatted. In addition, no prosthetic information could \nbe gathered to predict the ﬁnal prosthetic outcome. This was \novercome with the advent of sophisticated scanning appliances, \nstereolithographic resin bone models, virtual teeth technology, \ninteractive software, computer-generated surgical guides, and CT-\nbased image-guided navigation systems, which allowed for ideal \nplacement and prosthetic outcome to be established.\nAlthough the clinical problems of medical scanners have been \nremedied, numerous disadvantages remain, including radiation \nexposure and availability. The amount of radiation exposure of \nmedical scans has been a controversial topic for many years and \nhas been shown to be excessive. The availability has dramatically \nimproved over the years with the advent of cone beam computed \ntechnology (Fig. 11.6A).\nTo overcome some of the disadvantages of conventional medi-\ncal CT scanners, CBCT has become extremely popular (Table \n11.1 and Fig. 11.6B). Because conventional CT is associated with \nhigh radiation doses, this medical imaging technique has always \nbeen under significant criticism when used for implant treatment \nplanning. However, with the advent of cone beam technology, the \nlimitations of medical CT have been overcome. With cone beam \ntechnology, there exists the ability to provide more accurate diag-\nnostic images, along with a fraction of the radiation exposure with \nconventional CT and adherence to the ALARA principle.18 Cone \nbeam scanners are made for “in-office” installation and use, allow-\ning the doctor and patient the convenience of on-site scanning \ncapabilities (Fig. 11.7).\nCBCT scanners use a rotating x-ray source that generates a \nconical-shaped beam that can be modified to acquire a desired \narea of interest. The attenuated x-ray beam data are collected by a \nDensity\nHounsfield Units\nD1\n1250\nD2\n850–1250\nD3\n350–850\nD4\n0–350\nD5\n<0\n\t • BOX 11.3\t    \u0007Bone Quality\nMaterial\nHounsfield Units (HU)\nAir\n–1000\nWater\n0\nMuscle\n35–70\nTrabecular bone\n150–900\nCortical bone\n900–1800\nDentin\n1600–2400\nEnamel\n2500–3000\nExtraction Socket\n–700\nInferior Alveolar Canal\n–700\nMental Foramen\n–400\nSoft Tissue\n300–0\nFrom Patrick, S., Birur, N. P., Gurushanth, K., Raghavan, A. S., & Gurudath, S. (2017). Comparison \nof gray values of cone-beam computed tomography with hounsfield units of multislice computed \ntomography: An in vitro study. Indian Journal of Dental Research, 28(1), 66.\n\t • BOX 11.4\t    \u0007Tissue Characterization\nX-ray source\nX-ray source\nObjects rotate in\nX-ray beam to take\nimage data from\nall angles\nObject rotates in\nX-ray beam to take\nimage data from\nall angles\nVolume CT\nreconstruction\nImaged section\nof object\nImage intensifier\nX-ray cone beam\nCollimator\nCross-sectional\nimage\nDetector array\nObject on\npart manipulator\nX-ray\nfan beam\nA\nB\n• Fig. 11.6  (A) A conventional computed tomography (CT) scan uses a \nvery narrow “fan beam” that rotates around the patient, acquiring one \nthin slice (image) with each revolution. Because of the numerous revolu-\ntions needed, the radiation dose is increased. (B) Cone beam volumetric \ntomography captures all data in one rotation, thus reducing radiation and \navoiding distortion and errors in reformatting. (From Resnik RR, Misch CE. \nRadiographic imaging in implant dentistry. In: Misch CE, ed. Dental Implant \nProsthetics. 2nd ed. St. Louis, MO: Elsevier; 2015.)"
  },
  {
    "page": 74,
    "content": "282\nPART III    Fundamental Science\nsingle collector. These data are then converted to various shades of \ngray, which are displayed on a computer screen. Reconstruction of \nthese images can be in any plane by simply realigning the image or \nvoxel data. This allows viewing of the data in axial, sagittal, coro-\nnal, panoramic, 3D, and soft tissue images (Fig. 11.8).\nFocal Spot. The clarity of CT scan images is not dependent on \nthe voxel size. Actually a CBCT unit may have a very small voxel \nsize; however, image quality may be compromised because of a \nlarge focal spot. The focal spot is the area of the x-ray tube that \nemits the x-rays. In general the smaller the focal spot, the sharper \nthe final image quality. Thus a larger source or focal spot will result \nin projections of shadows of the scanned area, which will result in \nblurring of the object. This penumbra or blurring of the edges cre-\nates a shadow with resultant poor image quality and clarity.\nCurrent CBCT units have focal spots ranging from 0.15 to 0.7 \nmm (Fig. 11.9). \nField of View. CBCT units vary on the area of interest or what \nis commonly termed the field of view (FOV) in radiology. The \nFOV describes the scan volume, which is dependent on many \nfactors, including the detector size and shape, beam projection \ngeometry, and beam collimation. Beam collimation is paramount \nin decreasing radiation exposure to the patient and ensuring only \nthe area of interest to be radiated. Usually smaller scan volumes \nproduce higher resolution images. Currently, CBCT units are \nclassified as small, mid, or large FOVs (Fig. 11.10). \nEffective Dose Range of Cone Beam Computed Tomography\nScanners. Because of the increasing number of CBCT units \nbeing developed and released on the market, it is difficult to gener-\nalize radiation dose of CBCT. These units exhibit a wide variation \nof exposure parameters, such as x-ray spectrum (voltage peak and \nfiltration), x-ray exposure (mA and number of projections), and \nFOV. Thus the range of units and imaging protocols will result in \ndifferent absorbed radiation doses.\nThe effective dose measured in microsieverts is still the most \naccepted way to determine radiation risk for patients. A number \nof studies have measured the effective dose on dental CBCT units \nusing thermoluminescent dosimeters with dosimetry phantoms. \nThe phantoms are placed into multiple layers along the axial plane \nto allow for access to internal anatomy. The thermoluminescent \ndosimeters are placed on the radiosensitive area to be tested (i.e., \nramus, symphysis, thyroid, salivary glands). The operator may \ncontrol the FOV, kVp, mA, and scanning times to reduce the \neffective dose. However, these reductions result in a decreased sig-\nnal and poorer image quality (Fig. 11.11). \nSensor (Detector) Type. The x-ray sensor receives the x-rays \nand converts them into electrical data, which are then converted \nto various images via special computer programs. Two types of sen-\nsors are used today in CBCT technology: (1) image intensifiers \n(IIs) with charged coupling devices, and (2) flat panel detectors. \nImage intensifiers have many disadvantages in comparison with flat \npanel detectors, including having poorer resolution, being bulkier, \nand requiring a higher patient radiation dose. Flat panel detectors, \nalthough more expensive than image intensifiers, produce images \nwith much higher quality and resolution. Most flat panel detectors \nused today in CBCT units utilize cesium iodide as the scintillator \ncrystal screen. Cesium iodide scintillators produce the highest spa-\ntial resolution possible among various CBCT screens. \nVoxel Size. The unit element in the 3D image is termed the \nvoxel, which is analogous to the 2D pixel. Images comprised of \nmultiple voxels are stacked in rows or columns that are isotropic. \nIsotropic correlates to equal dimensions in the x, y, and z planes, \nand ranges in size from 0.075 to 0.6 mm. Each individual voxel \nis assigned a grayscale value that corresponds to the attenuation \nvalue of the anatomic structure. Thus the smaller the voxel size, \nthe greater the resolution and quality of the image; however, the \ngreater the resultant radiation dose. A voxel size of 0.2 to 0.3 mm \nis considered ideal because it allows for an equitable trade-off \nbetween image quality and absorbed radiation dose (Fig. 11.12). \nSpatial Resolution. Spatial resolution is measured in lines per \nmillimeter (lp/mm) and relates to the ability to distinguish two \nanatomically close objects. On a CBCT image the higher the \nspatial resolution, the greater the ability to delineate two differ-\nent objects from one another. Normally, CBCT scanners (voxel \nsize, 0.075–0.6 mm) are most commonly associated with higher \nspatial resolution than medical-grade scanners (voxel size, 0.6–1 \nmm). However, decreased spatial resolution on CBCT images \nmay result from: (1) the use of a higher voxel size (>0.4; use of \nvoxel sizes > 0.3 mm for implants is not recommended because of \n  \u0007Comparison of Medical Spiral Scanners and \nCone Beam Computed Tomography\nSpecifications\nMedical\nCone Beam\nScanning time\n∼1–4 minutes\n∼5–60 seconds\nRadiation exposure\nMore\nLess\nScan\nMultiple slices\nOne rotation\nExposed field\nOne arch at a time\nBoth arches  \nsimultaneously\nScatter\nMore\nLess\nPositioning\nVery technique \nsensitive\nMuch easier\nTABLE \n11.1\n• Fig. 11.7  Cone beam computed tomography (CBCT) unit: I-Cat Unit with \nonly minimal space requirements (4 × 4 foot footprint)."
  },
  {
    "page": 75,
    "content": "283\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nA\nB\nC\nD\nE\nF\n• FIG. 11.8  Cone Beam Images.  (A) Three-dimensional soft tissue image. (B) Lateral cephalometric \nimage. (C) Coronal image. (D) Panoramic image. (E) Lateral osseous image. (F) Maximum intensity projec-\ntion image (MIP)."
  },
  {
    "page": 76,
    "content": "284\nPART III    Fundamental Science\nSource focal spot\nSource focal spot\nSubject\n0.5-mm focal spot\nBlurred\nSharp\n0.15-mm focal spot\nSmaller focal spot \u001f sharper image quality\nSubject\nDefector\nDefector\nPenumbra\n• Fig. 11.9  Focal Spot.  Example showing the difference between a 0.15- and a 0.5-mm focal spot depict-\ning a smaller focal spot is associated with a sharper image. (From Resnik RR, Misch CE. Radiographic \nimaging in implant dentistry. In: Misch CE, ed. Dental Implant Prosthetics. 2nd ed. St. Louis, MO: Elsevier; \n2015.)\nA\nB\nC\n• Fig. 11.10  The field of view of cone beam computed tomography units: (A) small, (B) mid, and (C) large. \n(From Resnik RR, Misch CE. Radiographic imaging in implant dentistry. In: Misch CE, ed. Dental Implant \nProsthetics. 2nd ed. St. Louis, MO: Elsevier; 2015.)"
  },
  {
    "page": 77,
    "content": "285\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\n• Fig. 11.11  Effective dose (microsieverts [mSv]) from cone beam computed tomography (CT) compared \nwith other dose metrics. FOV, field of view. (From Aanenson JW, Till JE, Grogan HA. Understanding and \ncommunicating radiation dose and risk from cone beam computed tomography in dentistry. J Prosthet \nDent. 2018;120:353-360.)"
  },
  {
    "page": 78,
    "content": "286\nPART III    Fundamental Science\nthe lower spatial resolution); (2) decreased radiation (kVp or mA), \nwhich results in increased noise; (3) metallic restorations or dental \nimplants resulting in artifacts; and (4) increased focal spot size. \nContrast Resolution. Contrast resolution is defined as the ability \nto differentiate tissues of different radiodensities. Ideally, in implant \ndentistry the ability to produce different shades of gray is important \nfor a clearly diagnostic image. Because CBCT images use less radia-\ntion and are produced with lower kVp and mA settings in comparison \nwith MDCT (Multi-Detector Computerized Tomography) units, \ndental CBCT is associated with slightly higher image contrast, modi-\nfiable through software settings. Dental CBCT generally has increased \nnoise and image scatter compared with medical units. A smaller FOV \nmay be used to minimize noise and scatter. However, smaller FOVs \nare usually associated with slightly higher radiation settings. \nBit Depth. The quality of CBCT images is directly related to the \nnumber of shades of gray (bit depth). CBCT units today produce up \nto 16-bit images, which corresponds to 216 (65,536 shades of gray). \nHowever, computer monitors may display up to only 8 bits (28; 256 \nshades of gray). The monitor brightness and contrast may be adjusted \nto display 8 bits per image, to increase the quality of the image. \nBone Density\nMDCT/CBCT. Medical CT data have inherently higher con-\ntrast resolution in comparison with dental CBCT images, and \nmedical units permit differentiating between tissues that have a \nphysical density of less than 1%. In contrast, conventional radiog-\nraphy requires a minimum of 10% difference in physical density \nto be seen.19 Each medical CT image is composed of pixels and \nvoxels, which are characterized by a given numerical value, which \nreflects the x-ray beam attenuation. These values are directly \naffected by the density and thickness of the tissue. These HUs or \nCT numbers correlate with the density of the medical CT image \nand range in value from −1000 (air) to +3000 (enamel). A specific \nshade of gray or density number is assigned to each CT number, \nwhich ultimately forms the image. The correlation of these CT \nnumbers has been used to associate the density of the area of inter-\nest with various bone densities used for surgical and prosthetic \ntreatment planning. Thus the gray values depicted on medical CT \nimages are considered true attenuation x-ray values (HUs) (Fig. \n11.13). When evaluating dental CBCT images in regard to bone \ndensity, a direct correlation (accuracy of measurement) does not \nexist compared with medical CT. Most dental CBCT systems \ninherently have an increased variation and inconsistency with \ndensity estimates. The density estimates of gray levels (brightness \nvalues) are not true attenuation values (HUs), thus inaccuracies \nin bone density estimates result.20 This is mainly due to the high \nlevel of noise in the acquired images and the slight inconsistencies \nin the sensitivity of the CBCT detectors. Dental imaging software \nfrequently provides attenuation values (HUs); however, such val-\nues should be recognized as approximations lacking the precision \nof HU values derived from medical CT units. \nScanning Technique\n\t1.\t \u0007Imaging protocol: The patient should be positioned within the \nCBCT unit as per manufacturer’s recommendations. When \ntaking the scan, the teeth should be slightly separated so that \nthe different arches may be easily differentiated on re-forma-\ntion. Cotton rolls, tongue depressors, or a bite registration may \nbe used. In addition, cotton rolls may be placed in the vestibule \nto separate the lips and cheeks from the buccal mucosa. This \nwill allow for a more accurate representation of the contour \nand thickness of the gingival tissues.\n\t2.\t \u0007Position of the scanning template: The position of the scanning \ntemplate/radiographic markers in the mouth during CBCT \nexamination is crucial for the accuracy of fabrication of the \nsurgical template. First, it is recommended that an index be \nused to position and maintain the scanning template in the \ncorrect position. This will prevent inaccuracies and help stabi-\nlize the template in the mouth. In addition, tissue conditioner \nor denture adhesive may be used for CBCT templates that are \nill fitting or have associated movement.\n\t3.\t \u0007Mucosal thickness: When fabricating mucosa-supported surgi-\ncal guides, the thickness of the mucosa may have a direct effect \non the accuracy of the of the planning of the implant sites. \nIncreased mucosa thickness may lead to inaccurate placement \nof the mucosa-borne guides during the surgical placement pro-\ncedure. Vasak et al.21 showed a 1.0-mm buccal mucosa thickness \nmay result in a buccal-lingual deviation larger than 0.41 mm. \nThis will inevitably cause inaccurate measurements and possible \nmisalignment of the surgical guide when placing the implants. \nArtifacts\n\t1.\t \u0007Beam hardening: Because metallic objects in the oral cavity are \nassociated with higher attenuation coefficients than soft tissue, \ndental CBCT images inherently are predisposed to these arti-\nfacts. One of the most common types of artifacts is termed beam \nhardening. Beam hardening occurs when x-rays travel through \nthe bone/implant, resulting in more low-energy photons being \nabsorbed than high-energy photons. Because of this, the image \nwill have compromised image quality.22 The titanium alloy \n• Fig. 11.12  Comparison of volume data sets obtained isotropically (left) \nand anisotropically (right). Because cone beam computed tomography \ndata acquisition depends on the pixel size of the area detector and not \non the acquisition of groups of rows with sequential translational motion, \nthe compositional voxels are equal in all three dimensions, rather than \ncolumnar, with height being different from the width and depth dimen-\nsions. (From Scarfe WC, Farman AG. What is cone-beam CT and how \ndoes it work? Dent Clin North Am. 2008;52:707-730.)\nD1:\n>1250 HU\nD2:\n850 – 1250 HU\nD3:\n350 – 850 HU\nD4:\n0 – 350 HU\n• Fig. 11.13  Hounsfield unit correlation with the Misch bone density clas-\nsification (D1–D4)."
  },
  {
    "page": 79,
    "content": "287\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nsurface is highly susceptible to these types of artifacts because of \nthe high-density nature of the metal. This results in inaccura-\ncies, especially when viewing peri-implant bone levels. Conven-\ntional intraoral images will not exhibit these beam hardening \nartifacts and may appropriately be used to better evaluate the \nquality and quantity of bone mesial and distal to an implant \nwhen beam hardening artifacts may obliterate visualization \nof interproximal bone, especially when multiple implants are \npresent in the same quadrant. In addition, higher density mate-\nrials commonly found in the oral cavity (i.e., dental implants, \nmetal based restorations) will lead to complete absorption of \nthe beam and beam hardening artifacts.23\nTwo types of beam hardening artifacts exist that result in linear \nareas of dark bands or streaks between dense objects and cupping \nartifacts. Cupping artifacts occur when x-rays pass through the \ncenter of a highly dense object and are absorbed more than the \nperipheral x-rays. This results in an image in which a uniformly \ndense object appears to be less dense (darker, lower CT numbers) \nat its center and appears as a “cup” (Fig. 11.14).\n\t2.\t \u0007Motion-related artifacts: Motion artifacts are usually the result \nof patient movement and result in the inaccurate depiction \nof bony landmarks, measurements, and implants.24 Patient \nmovements and incorrect patient positioning create blurring \nproblems, double-density line artifacts adjacent to major bony \nstructures, which result in nondiagnostic images. Patients should \nbe instructed to not move and avoid swallowing throughout the \nscan. The motion blurring causes “double contours” of anatomic \nstructures that result in decreased scan quality and spatial resolu-\ntion. This may lead to improper implant placement and pos-\nsible damage to neural structures.25 Motion-related artifacts may \nbe decreased by using sit-down CBCT units, head restraints, or \ndecreasing scanning times (Fig. 11.15).\n\t3.\t \u0007Streak (scatter) artifacts: CBCT images are susceptible to streak \nartifacts that are caused by x-rays traveling through objects \nwith a high atomic number (metallic restorations). Streak arti-\nfacts usually are seen as light and dark lines that arise from the \nsource object, resulting in images with decreased quality and \nobscuring of anatomic structures. This is caused by photons \n(x-rays) that are deflected from their original path by metallic \nobjects. When these deflected photons reach the sensor (detec-\ntor), the intensity of the signal is magnified in a nonuniform \nmagnitude. The end result is an image with decreased resolu-\ntion and image quality, which ultimately lead to inaccuracies \nin the reconstructed CT number or voxel density.26 The FOV \nof the CBCT is proportional to the amount of scattering, thus \nsmaller FOVs are associated with less scattering. In compari-\nson of scattering with MDCT and CBCT, CBCT images have \ninherently greater scatter radiation than medical-grade CT \nimages27 (Figs. 11.16 and 11.17).\n\t4.\t \u0007Noise: Two types of noise are associated with CBCT images: \nadditive (results from electrical noise) and photon count \n(quantum noise). Because CBCT scanners operate at much \n• Fig. 11.14  Beam Hardening Artifacts.  These radiolucent areas next to an implant are caused by the \ndense nature of titanium implants and the exposure of more low-energy photons (red arrows).\n• Fig. 11.15  Motion artifact due to movement of the patient, leading to \noverlapping “double images.” Usually stand-up CBCT units have a higher \nincidence of motion-related artifacts. (From Resnik RR, Preece JW. Radio-\ngraphic complications and evaluation. In: Resnik RR, Misch CE, eds. \nMisch’s Avoiding Complications in Oral Implantology. St. Louis, MO: Else-\nvier; 2018.)"
  },
  {
    "page": 80,
    "content": "288\nPART III    Fundamental Science\nlower amperage (mA) settings than MDCT scanners, CBCT \nimages are associated with greater quantum noise. The noise is \ndisplayed as a “graining” of the image and is the result of incon-\nsistent distribution of the signal, which results in inconsistent \nattenuation (gray) values in the projection images (Fig. 11.18).\n\t5.\t \u0007Bone dehiscence on 3D reformatted images: MDCT and den-\ntal CBCT data have the ability to be reformatted by software \nalgorithms to represent 3D images by projecting only the vox-\nels that represent the surface of the object (surface). The pixels \nare illuminated on the screen as if a light source is present in \nthe front of the object. The closer the pixels, the brighter they \nappear. This shading effect allows the object to be projected as \na 3D object with depth. However, some 3D images appear to \nhave large voids or no bone present on the surface because of \nthe software averaging volume elements, and the voids appear \nwhen the software attempts to reconstruct portions of the \nimage covered by a very thin layer of bone. When evaluat-\ning the cross-sectional images, bone will be present. This is a \ndirect result of the reformatting process, which usually selects \na higher HU re-formation, which results in decreased scatter \non the 3D image. Therefore the implant clinician should be \naware that 3D images do not accurately depict the bone in an \narea; it is only a stylized representation of the facial skeleton \n(Fig. 11.19). \nIncidental Findings\nThe role of CBCT is rapidly emerging in all aspects of diagnosis and \ntreatment planning with dental implants. Because of varying FOVs, \nthe implant clinician is placed in a position to evaluate maxillofacial \nareas which he or she may not be familiar. Therefore it is crucial \nthe implant clinician be able to interpret anatomic structures and \npathology outside his or her primary area of interest. In radiology an \nincidental finding is defined as an unexpected discovery found on a \nradiologic examination performed for an unrelated reason. Unfor-\ntunately many normal anatomic variants, developmental anomalies, \nand imaging artifacts may be misidentified as possible pathologic \nconditions by inexperienced clinicians.28 This may lead to unnec-\nessary concern and stress for patients, and embarrassment for the \nclinician. In addition, possible significant pathologies may exist that \ngo undiagnosed. This problem results in many professional, ethical, \nclinical, and potential legal issues for the implant clinician.\n• Fig. 11.17  Image showing significant streak artifacts that result in total \nobliteration of the associated anatomy. These artifacts result from full-arch \nporcelain fused to metal restoration.\n• Fig. 11.18  Image showing resultant noise (grainy appearance).\n• Fig. 11.19  Bone dehiscence on three-dimensional images that is caused \nby reformatting with too high of Hounsfield unit threshold.\n• Fig. 11.16  Image depicting “streaks” that result from the metal restora-\ntions."
  },
  {
    "page": 81,
    "content": "289\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nComplication Prevention\nUnderstanding Incidence of Incidental Findings. Incidental \nfindings on CBCT scans have been well documented in the litera-\nture. The exact frequency of incidental findings varies from study \nto study depending on age, gender, race, and FOV. Price et al.29 \nshowed a high incidence (3.2 findings/scan) of incidental find-\nings, with approximately 16% requiring intervention or referral. \nThese incidental findings ranged from common benign findings \nto significant pathologic conditions. Miles30 reported a minimum \nof two reportable findings per CBCT and also showed a high inci-\ndence of periapical lesions that went undetected on conventional \nradiographs. Cha et al.31 determined after evaluation of 500 scans \nan incidence rate of 24.6% of incidental findings, mostly in the \nairway region. Arnheiter et al.32 showed that patients 40 to 49 \nyears old had the largest percentage of reportable incidental find-\nings (70%), with patients aged 20 to 29 years with the lowest \npercentage (40%). \nObtaining a Radiology Report. Radiology reports immedi-\nately after CBCT examinations, before surgery, minimize the lia-\nbility that may present to the implant clinician. Formal radiology \nreports may be obtained from many sources, preferably from an \nappropriately qualified, board-certified maxillofacial radiologist. \nUnfortunately the geographic distribution of maxillofacial radi-\nologists is not uniform within states or regions within a state, and \na careful search will be required. Several, but not all, states require \nthat the report be made by a maxillofacial radiologist licensed in \nthe state, and it is therefore crucial to check with your local dental \nboard or dental practice act to determine whether in-state licen-\nsure is required. The implant clinician must be able to recognize \nand evaluate variations from normal and refer for appropriate \nmedical consultation any significant incidental finding that may \nbe contained in the radiology report. \nUse of the Smallest Field of View as Possible. Ideally the \nsmallest FOV should be used for scans when treatment planning \nfor dental implants. A smaller FOV (∼mid FOV) will reduce \nradiation dose to the patient, thus adhering to the ALARA prin-\nciple. However, caution should be exercised to not take an inad-\nequate FOV that includes insufficient view of the anatomic area \nof concern. The most common anatomic area for this to occur is \nthe maxillary posterior region, because many practitioners will set \nthe limits of the scan superiorly to exclude the maxillary ostium. \nWhen placing implants or bone grafting in the posterior max-\nilla area, confirming the patency of the ostium is important to \nminimize complications associated with an obstructed ostiomeatal \ncomplex (Fig. 11.20). \nNormal Radiographic Anatomy\nDue to the complex nature of implant treatment and the potential \nfor complications throughout the surgical and prosthetic phases, \nthe clinician must have a thorough understanding of the normal \nanatomy of the maxillofacial region. Traditional dental educa-\ntion has focused on the interpretation of conventional 2D radio-\ngraphic images for diagnosis, but with the introduction and rise of \nCBCT images, a deeper understanding of anatomy is necessary to \nexamine the patient’s structures in three dimensions. This section \nwill address the basic radiographic anatomy as viewed in the three \nplanes (axial, coronal, sagittal) typically shown on a CBCT image.\nMandibular Anatomy\nThe mandible is the largest, strongest, and lowest bone in the \nhuman face area.33 The mandible is formed by the fusion of the \nright and left processes, and join in the midline area. It consists of \nthe body (symphysis) and the right rami (ramus). The innervation \nof the mandible is via the inferior alveolar nerve, which is a branch \nof the trigeminal nerve. It enters the mandibular foramen on the \nlingual aspect of the ramus and courses anteriorly, where it divides \ninto two branches: mental nerve and incisive nerve. The mental \nnerve exits the mental foramen, which gives sensory innervation \nto the chin, lip, and anterior gingiva. The incisive nerve courses \nanteriorly to supply the anterior teeth.\nMandibular Canal and Associated Anatomy\nThe position of the MC as it courses through the mandible from \nposterior to anterior is highly variable. Although the pathways of \nthe inferior alveolar nerve and the mental nerve have been well \ndescribed in the literature, it is paramount the implant clinician \nhave a clear understanding of their anatomic features. When \nevaluating the intraosseous course of the MC buccal-lingually \nand inferior-superiorly within the mandible, many variations exist \nbased on gender, ethnicity, amount of bone resorption, and age.\nThe inferior alveolar canal or MC contains the neurovascular \nbundle, which consists of the inferior alveolar nerve, artery, vein, \nand lymphatic vessels. The inferior alveolar nerve bundle enters \nthe mandibular foramen, where it transverses anteroinferiorly \nfrom lingual to buccal within the body of the mandible. A 3D \nevaluation of the MC position is recommended when implant \nplacement is going to be positioned in proximity to the nerve. \nThe most accurate assessment of the anatomic position is with \nCBCT, because images may be enhanced via viewing software \n• Fig. 11.20  Newer cone beam computed tomography units allow for collimation or customized field of \nviews that decrease radiation exposure."
  },
  {
    "page": 82,
    "content": "290\nPART III    Fundamental Science\nadjustments for contrast, brightness, and grayscale to help depict \nthe anatomic location of the MC.\nImage Evaluation. Radiographically the MC appears as a linear, \nradiolucent shadow, with or without inferior and superior radiopaque \nborders. Studies have shown the total length to be approximately 62.5 \nmm, with slightly longer measurements in male individuals (∼2.5 \nmm).34 The average diameter of the MC is approximately 2.0 to \n3.4 mm, with the diameter being the greatest in the posterior near the \nmandibular foramen.35 The foramen is triangular in nature near the \nmandibular foramen, and as it progresses anteriorly, becomes more \novoid in shape.36 Location is variable depending on the patient’s race, \ngender, and amount of bone resorption. Usually the MC is located \non a bony ledge, the lingula, which is located on the medial surface \nof the ramus. Studies have shown the foramen to be located approxi-\nmately 19.7 mm from the anterior border of the ramus.37\nThe CBCT data are used with appropriate viewing software to \nidentify and trace the MC. The depiction of the MC enables the \nimplant clinician to assess the position in various multiplanar and \n3D re-formations. Initially the MC is most easily drawn on the \nCBCT reconstructed panoramic view with location confirmation \non the cross-sectional images. In most cases the endpoints are first \nidentified (e.g., mandibular foramen, mental foramen), then the \nlocation of the MC is extrapolated between these two landmarks.\nBuccal-Lingual Path of Mandibular Canal\nRadiographic Evaluation. In the posterior region of the man-\ndible the inferior alveolar nerve enters the mandibular foramen on \nthe lingual surface of the mandible and progresses anteriorly in the \nbody of the mandible. In between the MC and the mental fora-\nmen, the buccal-lingual position is extremely variable. Studies have \nshown the buccal-lingual location is dependent on such variables as \nthe amount of bone resorption, age, and ethnicity.38 The buccal-lin-\ngual position of the MC is easily depicted on cross-sectional images \nafter canal location is verified and highlighted (Fig. 11.21). \nClinical Significance. The intraosseous path of the MC is variable \nin the buccal-lingual position within the mandible, and a compre-\nhensive radiographic survey (CBCT) ideally should be completed \nbefore implant osteotomy initiation to determine the anatomic path. \nA 2-mm safety zone between the implant and the MC should always \nbe adhered to. Attempting to place an implant buccal or lingual to the \nneurovascular bundle may result in neurosensory impairment. \nInferior-Superior Path of Mandibular Canal\nEvaluation. The vertical position of the MC below the apices of \nthe natural teeth within the mandible is highly variable. Thus gen-\neralizations cannot be made because the distance of the canal to the \nroot apices is not consistent.39 An early classification of the vertical \npositions of the course of the alveolar nerve was reported by Carter \nand Keen.40 They described three distinct types: (1) in close approxi-\nmation to the apices of the teeth, (2) a large nerve approximately in \nthe middle of the mandible with individual nerve fibers supplying the \nmandibular teeth, and (3) a nerve trunk close to the inferior corti-\ncal plate with large plexuses to the mandibular teeth. After the MC \nis located and drawn on the reconstructed panoramic image using \nCBCT viewing software, the vertical position of the intraosseous path \nmay be determined by scrolling through the cross-sectional images. \nThe vertical position is then easily seen on individual cross sections or \nCBCT-generated reconstructed panoramic images (Fig. 11.22). \nClinical Significance. The intraosseous path of the MC is vari-\nable in the inferior-superior position within the mandible, and a \nA\nB\n• Fig. 11.21  Variable Buccal-Lingual Position.  (A) Buccal positioned. (B) \nLingual positioned. (From Resnik RR, Preece JW. Radiographic compli-\ncations and evaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding \nComplications in Oral Implantology. St. Louis, MO: Elsevier; 2018.)\nA\nB\nC\n• Fig. 11.22  Inferior Mandibular Nerves.  Type 1 (A), type 2 (B), and type \n3 (C) nerves. (Adapted from Resnik RR, Preece JW. Radiographic com-\nplications and evaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding \nComplications in Oral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 83,
    "content": "291\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\ncomprehensive radiographic survey (CBCT) ideally should be com-\npleted before implant osteotomy. Special care should be exercised in \ntype 1 nerves because their close approximation to the root apexes \nresults in compromised bone height for implant placement. Type \n3 nerves are most favorable for implant placement in the posterior \nmandible because there exists the most ideal amount of bone height. \nIn many instances the MC may not be easily depicted on the CBCT \nimage; thus identification can be extremely challenging. The visibil-\nity of the MC varies significantly, even within the same individual.\nThe MC walls usually are not made up of compact bone, show-\ning only a coalescence of trabecular bone with varying degrees of \ndensity.41 This complicates the determination and location of the \ntrue identification of the canal. Studies have shown the unreliability \nof identifying the entire MC course being a direct result of minimal \nto no dense cortical plates surrounding the nerve bundle, which has \nbeen shown to occur in approximately 30% of cases. The MC has \nan increased wall density in the posterior (∼mandibular foramen > \nthird molar region) in comparison with the anterior region.42\nWith CBCT, images are susceptible to noise and artifacts, with \nresulting low contrast. Because of these inherent quality issues, dis-\ntinguishing the MC from other aspects of the internal trabecular \ncomponents of the mandibular image is difficult. Thresholding, \nthe inability of the software to distinguish between two closely \nrelated densities, results in the inability to determine the correct \nposition because of the increased noise. If a highly accurate assess-\nment of the mandibular canal is warranted, the implant clinician \nmay order an MRI survey, which has been shown to depict the soft \ntissues much better than CBCT. \nMental Foramen\nThe mental foramen is an opening in the anterolateral aspect of \nthe mandible, commonly in the interproximal space between \nthe first and second premolars; however, individuals may rarely \nexhibit the position of the foramen as anterior to the cuspid area \nand as far posteriorly as the bifurcation of the first molar. One \nof the two terminal branches of the inferior alveolar nerve is the \nmental nerve, which exits the mental foramen with sensory inner-\nvation to the chin, lip, and anterior gingiva. The mental foramen \ncompletes after the 12th gestational week, when the mental nerve \nseparates into several fascicles. If the mental nerve separates before \nthe formation of the mental foramina, the formation of accessory \nforamen results.43 The mental foramen location, size, and number \nare highly variable, with many dependent factors, including gen-\nder, ethnic background, age, and skeletal makeup.\nImage Evaluation. The mental foramen may be most easily \nidentified on axial, coronal, and cross-sectional images. The rela-\ntionship between the mental foramen and teeth or vital structures \ncan be evaluated most easily on volumetric 3D images. The loca-\ntion of the mental foramen on 2D periapical and conventional \npanoramic radiographs has been shown to be inaccurate because \nthey do not show the true location in most cases. In addition, when \nplacing immediate implants in the premolar region, angulation and \navoidance of the foramen should be noted because the mental fora-\nmen has been shown to be located coronal to the root apex of pre-\nmolars in 25% to 38% of patients. Thus anytime an implant is to \nbe treatment planned in approximation of the foramen, a CBCT \nevaluation is recommended.44 However, the low contrast in CBCT \nimages may make it difficult to do this without obscuring the canal \nor including too much noise in the process (Fig. 11.23). \nIncisive Canal\nThe mandibular incisive canal is a bony canal within the anterior man-\ndible that is a continuation of the MC. This canal contains the termi-\nnal branch of the inferior alveolar nerve, which travels inferiorly to the \nmandibular anterior teeth and terminates in the midline. In approxi-\nmately the first molar region, the inferior alveolar nerve bifurcates into \nthe mental and incisive nerves. The mandibular incisive canal termi-\nnates as nerve endings within the anterior teeth or bone near the lateral \nincisor region and will extend only to the midline in 18% of patients \nand in some cases will anastomosis with the contralateral side.45\nRadiographic Evaluation. The incisive canal is not always seen \nradiographically on CBCT. The incisive nerve may be differenti-\nated from the mental nerve by determination of any canal that \nis anterior to the mental nerve/foramen exit. When present, this \nradiolucent canal will continue anteriorly from the mental fora-\nmen and can be seen as a bifurcation (Fig. 11.24). \nClinical Significance. The incisive canal is often mistaken \nfor an anterior loop of the mental nerve; however, this nerve \nA\nB\n• Fig. 11.23  (A) The mandibular canal is easily seen when a thick cortical component is present. (B) How-\never, in approximately 30% of patients, the mandibular canal will not have a cortical component."
  },
  {
    "page": 84,
    "content": "292\nPART III    Fundamental Science\ninnervates the anterior teeth and has no sensory innervation to \nthe soft tissue. However, if the incisive canal is traumatized, cases \nof excessive bleeding have been reported. \nAnterior Loop\nAs the mental nerve proceeds anteriorly in the mandible, it may on \noccasion extend beyond the anterior boundary of the mental fora-\nmen. This endosteal curved loop is proximal to the mental foramen \nand exits distally through the mental foramen, and is termed an \nanterior loop. Studies have shown a prevalence rate of approximately \n35% to 50%, with a mean distance of 1.16 mm anteriorly to the \nforamen.46 Clinically an anterior loop may be determined by prob-\ning within the mental foramen in a posterior direction; however, \nthis necessitates full reflection of the mental foramen.\nRadiographic Evaluation. The determination of an anterior loop \nis difficult to identify and cannot be determined accurately with 2D \nradiography. High false-positive and false-negative results have been \nnoted on conventional panoramic and periapical radiographs. To \nidentify an anterior loop on a reformatted CBCT image, the MC \nmust be highlighted, including the cross-sectional image depicting \nthe mental foramen slice. The anterior part of the mental foramen is \nmarked with a constant perpendicular line (see Fig. 11.25a). In axial \nimages, scrolling from superior to inferior is evaluated for any part \nof the nerve anterior to the line. If an anterior loop exists, the high-\nlighted nerve will be anterior to the perpendicular line (Fig. 11.25). \nA\nB\n• Fig. 11.24  Incisive Canal.  (A and B) The incisive canal is a continuation \nof the inferior alveolar canal that contains the incisive nerve, which inner-\nvates the mandibular anterior teeth.\nA\nB\nC\nD\n• Fig. 11.25  An anterior loop is determined by evaluating axial images in a superior to inferior direction. \n(A) The anterior aspect of the foramen should be marked (line that remains constant in the vertical plane). \n(B) As the axial images are sequentially evaluated from superior to inferior, if any part of the marked canal \nextends anterior to the line (C and D, arrows), an anterior loop exists. (From Resnik RR, Preece JW. Radio-\ngraphic complications and evaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in \nOral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 85,
    "content": "293\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nClinical Significance. The importance of determining the pres-\nence of an anterior loop is critical when placing implants anterior \nto the mental foramen. Inability to establish the existence of an \nanterior loop may result in implant placement too close to the \nmental nerve, resulting in possible neurosensory impairment. \nAccessory and Double Foramina\nIn approximately 6.6% to 12.4% of patients, an accessory (dou-\nble) foramen is present, with an average diameter of 1.0 mm.47-49 \nSpecial care should be noted to evaluate for an accessory canal \nbecause it may contain components of one of the three branches \nof the mental nerve. Accessory foramina are believed to be the \nresult of early branching of the inferior alveolar nerve, before exit-\ning the mental foramen during the 12th week of gestation.50\nRadiographic Evaluation. The ideal technique to determine \nan accessory foramen is evaluation of coronal images, along with \nevaluation of the 3D image. In the coronal image the mandibular \nforamen will be shown bifurcating into two canals, resulting in the \npresence of two foramina. The evaluation of 3D images will easily \ndepict two canals. Normally, accessory canals are located distal to \nthe mental foramen (Fig. 11.26). In some cases, small openings \nwhich represent nutrient vessels may perforate through the buccal \nplate. These aberrant vessels are of no neural consequence. \nClinical Significance. In the majority of patients, small acces-\nsory foramina usually contain a small branch of the mental nerve, \nwhich is not problematic because of cross-innervation. However, \nin some cases a larger branch of the mental nerve (equal or larger \nsize foramen) may exit the mental foramen. If a larger accessory \nforamen is present and resultant damage to the nerve exists, pos-\nsible neurosensory impairment is possible. However, usually these \naccessory foramina are smaller and do not result in any distur-\nbances because of collateral innervation. \nHypomineralization of the Mandibular Canal\nWhen locating the MC, approximately 41% of the time the canal is \nnot seen because of hypomineralization of the bone.51 Studies have \nshown that in 20.8% of CBCT scans the MC walls are hypomineral-\nized.52 This often results in poor localization of the MC and is some-\ntimes an early indication of osteopenia or osteoporosis (Fig. 11.27).\nRadiographic Evaluation. The brightness and contrast may be \naltered using imaging software to more clearly define the canal walls. \nClinical Significance. Lack of identification of the MC may \nresult in the inability to properly locate the MC. This may result in \nincreased morbidity, leading to placement of implants too close to \nthe nerve, with resultant nerve damage. In cases where a CBCT can-\nnot differentiate the canal, an MRI survey is a reasonable alternative. \nMandibular Ramus (Donor Site for Autogenous Grafting)\nThe mandibular ramus area has become a popular donor site for \nautogenous onlay and trephine bone grafting. This anatomic area of \nA\nB\n• Fig. 11.26  (A) 3D CBCT image depicting a small accessory foramen \ninferior to primary mental foramen. (B) Coronal Image showing large main \nforamen and smaller accessory foramen.\nA\nB\n• Fig. 11.27  (A) Accessory (Double) Foramina which are easily seen on 3D images. (B) Nutrient Canals are \nsmall openings which represent nutrient vessels (green arrow, mental foramen; blue arrow, nutrient canal). \n(A: From Resnik RR, Preece JW. Radiographic complications and evaluation. In: Resnik RR, Misch CE, \neds. Misch’s Avoiding Complications in Oral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 86,
    "content": "294\nPART III    Fundamental Science\nthe mandible is extremely variable in the amount of bone present, \nas well as the buccal-lingual and inferior-superior position of the \nMC. Most commonly the lateral aspect of the ramus is harvested \nas a block graft, which is used for ridge augmentation procedures.\nImage Evaluation. The mandibular ramus is quadrilateral in \nshape and contains two surfaces, four borders, and two processes. \nThe lateral surface is flat with two oblique ridges, the external and \ninternal. The masseter muscle attaches on the entire lateral ramus \nsurface. The medial surface gives rise to the lingula, which is the \nentrance of the inferior alveolar nerve and associated vessels. The \nantegonial notch, anterior to the angle of the mandible, when \npresent, is significant for the presence of parafunction.\nThe relationship between the lateral cortical plate in the ramus area \nand the position of the MC is easily seen on cross-sectional images, \nafter nerve location identification. In addition, 3D images and bone \nmodels assist in the determination of the osseous morphology in this \nregion to help the clinician select the most appropriate graft site.\nHistorically, standard 2D radiographs for evaluation of the ramus \narea as a donor site included conventional panoramic images, in which \nthe location of the external oblique and the MC may be noted. How-\never, 2D evaluation of this area can be difficult to use for determina-\ntion of the amount of bone present and position of the MC. With this \nprocedure, it is vital that the implant clinician be able to completely \ndetermine the exact position of the MC with respect to the external \noblique ridge and the lateral cortical bone. Thus overestimation of \navailable bone can result in increased morbidity, so a more accurate \nrepresentation of this area is with the use of CBCT (Fig. 11.28). \nLingual Concavities (Posterior)\nThe trajectory/angulation of the mandible, along with inherent \nundercuts, poses a significant problem to the implant clini-\ncian. Lingual concavities may occur in the anterior region as \nan hourglass or constriction of the mandibular bone. Butura \net  al.53 have shown the incidence to be approximately 4% \nof patients, which is most likely genetic or developmental in \norigin.\nIn the posterior region, concavities are much more com-\nmon, resulting in undercuts in approximately 35% of patients.54 \nBecause of these undercuts, implant placement may be difficult, \nand perforation of the lingual plate may result.\nRadiographic Evaluation. Posterior undercuts are most easily \nseen in cross-sectional and 3D images. \nClinical Significance. In the posterior region, overestimation \nof available bone is a common complication. If an implant oste-\notomy is completed in this area, perforation of the lingual plate \nmay result, leading to possible bleeding and possible implant mor-\nbidity. Life-threatening lingual bleeding may occur as a result of \nblood vessel injury, leading to bleeding into the soft tissues. In \naddition, damage to the lingual nerve may occur on perforation of \nthe lingual cortical plate (Fig. 11.29). \nRetromolar Canal/Foramen\nThe retromolar fossa of the mandible forms a triangular depres-\nsion, which borders the temporal crest medially and the ante-\nrior border of the mandibular ramus laterally. Within this fossa \nan anatomic variant termed the retromolar foramen is present in \napproximately 14% of patients.55 The retromolar foramen on the \nalveolar surface is the terminal end to the retromolar canal, which \nbranches from the MC.\nRadiographic Evaluation. The retromolar foramina are not \nlocated in a constant position and usually are not bilateral. Most \ncommonly, retromolar foramina should be initially evaluated via \nCBCT sagittal slices and then verified with cross-sectional images. \nClinical Significance. It is important to confirm the retromolar \nforamen and canal locations before surgical procedures, because this \narea is a common donor site for bone grafts. If perforation of the \nretromolar canal results, excessive bleeding may result (Fig. 11.30). \nMandibular Symphysis (Implant Placement and Bone \nDonor Site)\nThe mandibular symphysis area is a common area for implant \nplacement, as well as a donor site for autogenous block grafting. \nThis anatomic region has been shown to be one of the most ideal \nintraoral donor sites for bone harvesting. However, the mandibu-\nlar symphysis is susceptible to nonuniform bone resorption and \ncontains various anatomic variations that may lead to surgical \ncomplications.\nImage Evaluation. The anterior surface of the mandible is \ntermed the mandibular symphysis. A ridge divides the right and \nleft sides, which inferiorly forms the triangular eminence of the \nmental protuberance. The elevated center of this depressed area \nforms the mental tubercle, which is the origin of the mentalis \nmuscles. This area should be evaluated on cross-sectional, axial, \nand 3D images. Two-dimensional imaging of this area should be \nused only as a preliminary evaluation for bone quantity deter-\nmination. Poor angulation, bony undercuts, and measurements \ncannot be determined with 2D radiography. CBCT imaging is \nhighly recommended to prevent implant malposition or overesti-\nmation of available bone for harvest procedures, which may lead \nto increased complications (Fig. 11.31).\nA\nB\n• Fig. 11.28  The mandibular ramus area can be evaluated. (A and B) \nCross-sectional (outline for ramus block graft) (A) and axial 3D image (B) \nallowing for the evaluation of the proximity of the mandibular nerve to the \nfacial cortical plate. (A: From Resnik RR, Preece JW. Radiographic com-\nplications and evaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding \nComplications in Oral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 87,
    "content": "295\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nAnterior (Hourglass Shaped)\nRadiographic Evaluation. Anterior undercuts are most easily \nseen in cross-sectional and 3D images. \nClinical Significance. In the anterior region, perforation of the \nbony plates of the mandible during implant osteotomies may lead \nto extensive bleeding from sublingual vessels. A significant plexus \nof sublingual and submental arteries may lead to life-threatening \nfloor of the mouth hematoma formation. Therefore a thorough \nCBCT examination will determine the exact location and angula-\ntion for safe implant placement (Fig. 11.32). \nLingual Foramen/Canal. The interforaminal region in the ante-\nrior mandible is usually a relatively safe area for implant placement \nand bone grafting procedures. However, on the lingual aspect of \nthe mandible, in the midline, lies the lingual foramen or foramina. \nA\nB\nC\n• Fig. 11.29  (A) Three-dimensional images depicting sublingual undercut. (B) Cross section depicting sig-\nnificant undercut. (C) Nonideal placement of implant perforating the lingual plate that may predispose the \npatient to possible sublingual bleeding. (A and B: From Resnik RR, Preece JW. Radiographic complica-\ntions and evaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. \nSt. Louis, MO: Elsevier; 2018.)\n• Fig. 11.30  Cone beam computed tomography image showing large ret-\nromolar canal."
  },
  {
    "page": 88,
    "content": "296\nPART III    Fundamental Science\nThis anatomic structure houses the terminal branches of the lin-\ngual artery (sublingual artery), facial artery (submental artery), \nor the anastomosis of both. As the blood vessels enter within the \nmandible, they are termed the mandibular median vascular canal.\nRadiographic Evaluation. Lingual canals and foramina may \nbe seen radiographically as a radiolucent canal in the midline of \nthe mandible and easily depicted on cross-sectional or axial views. \nStudies have verified the median vascular canal is present in 96% \nto 100% of patients. The median vascular canal size is proportional \nto the diameter of the arteries entering the foramen. The average \ndiameter has been shown to be approximately 0.84 mm, with the \naverage distance from the inferior mandibular border to be 11.2 \nmm. With consideration to the extent of penetration within the \nmandible, 19.4% of canals end within the lingual third, 52.8% \nreached the middle third of the mandible, and 27.8% penetrated \nto the buccal third56 (Fig. 11.33). \nSignificance. Potentially, these vessels may cause extensive \nbleeding in the mandible during endosseous implant placement \nor symphysial bone grafts. When larger lingual canals exist (>1.0 \nmm), significant bleeding issues may present with a possible com-\npromised integration because of a potential soft tissue interface \nwith the implant. \nMaxillary Anatomy\nThe maxilla is composed of paired bones, which unite to form \nthe upper jaw, and is composed of four processes: posterolateral \n(zygomatic, horizontal and medial), palatine (arch and infe-\nrior), alveolar, and the superior projecting frontal process. In oral \nimplantology the maxilla presents a difficult and demanding chal-\nlenge in the treatment and placement of implants with its complex \nosseous makeup, anatomy, and anatomic variants.\nPremaxilla\nThe anterior premaxilla is one of the most difficult areas for the \nimplant clinician in preoperative assessment, surgical placement, \nesthetic, and prosthodontic demands. Numerous factors affect the \nanatomic makeup of the premaxilla that may predispose to surgi-\ncal complications and result in a decrease in implant survival.\nBiomechanics. As a result of the alveolar ridge resorption \nafter tooth loss, the residual available bone migrates to a more \npalatal position.57 This leads to difficulties in implant positioning \nthat place the implant clinician at risk because of esthetic issues. \nBecause bone resorption occurs at the result of the buccal plate, \nimplant placement usually occurs in a more palatal position. This \nA\nB\n• Fig. 11.31  (A and B) The symphysial area can be evaluated on cross-sectional images, along with axial \nslices.\nA\nC\nB\n• Fig. 11.32  Anterior Mandible.  (A) Cone beam computed tomography \nthree-dimensional image depicting large undercuts. (B) Cross-sectional \nimage showing hourglass mandibular shape. (C) Interactive treatment plan \ndisplaying perforation of an implant if placed in an hourglass mandible. \n(A and C: From Resnik RR, Preece JW. Radiographic complications and \nevaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications \nin Oral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 89,
    "content": "297\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nwill create a greater moment force leverage on the bone-implant \ninterface, abutment screws, and implants. Coupled with an angled \nforce in both centric and excursions, more stress is transmitted to \npremaxillary implants than those in anterior mandibles. Often, \nmore implants and larger-diameter implants are indicated, with \nbone augmentation by bone spreading or bone graft procedures \nbefore or in conjunction with implant placement. \nPoor Bone Density. In most patients the bone is less dense \nin the anterior maxilla than in the anterior mandible. The max-\nilla most often presents thin porous bone on the labial aspect, \nvery thin porous cortical bone on the floor of the nasal and sinus \nregion, and denser cortical bone on the palatal aspect.58 The tra-\nbecular bone in the premaxilla is usually fine and less dense than \nthe anterior region of the mandible. Due to this poor bone quality, \nincreased difficulty in implant placement and a higher probability \nof overload implant failures or crestal bone loss may result. \nAccelerated Bone Loss. Because of the poor bone quality in \nthe premaxilla, preexisting bone after extractions is predisposed \nto significant resorption. After tooth loss, the facial cortical plate \nrapidly resorbs during initial bone remodeling, and the anterior \nridge has been shown to lose up to 25% of its width within the \nfirst year, as well as 40% to 50% within the next 3 to 5 years, \nmostly at the expense of the labial contour (Fig. 11.34). \nNasopalatine Canal/Incisive Foramen\nThe nasopalatine canal (also termed the incisive canal or anterior \npalatine canal) is a passageway within the anterior maxilla midline \nthat connects the palate to the floor of the nasal cavity. The entrance \nof the canal into the oral cavity is via the incisive foramen, which \nis posterior to the central incisor teeth. The vital structures passing \nthrough the canal include the terminal branch of the internal max-\nillary artery and the nasopalatine nerve, which communicates with \nthe sphenopalatine artery and the greater palatine nerve. The ana-\ntomic structures in the nasopalatine canal may present with wide \nvariation in the location, shape, dimensions, and its existence.\nRadiographic Evaluation. The location and dimension of the \nnasopalatine canal is most likely seen on axial and coronal images. \nCross-sectional and 3D images may also depict the size, shape, \nA\nB\nC\n• Fig. 11.33  Mandibular Vascular Canal.  (A) The mandibular vascular canal that contains the sublingual \nartery anastomosis, which is usually present in the mandibular midline. (B and C) Canal that extends to the \nfacial plate and superiorly (B), and off the midline lingual vascular canal (C)."
  },
  {
    "page": 90,
    "content": "298\nPART III    Fundamental Science\nand location of the nasopalatine canal, along with evaluation of \nimplant impingement on this space. \nClinical Significance. Determining the morphology of the \nnasopalatine canal via CBCT images allows the clinician to ascer-\ntain whether available bone is present for dental implantation. \nPlacing implants in the anterior maxilla (central incisor area) is \nthe most challenging anatomic location for the implant dentist \nbecause of biomechanical, functional, esthetic, and phonetic \ndemands. Especially with immediate implant placement, consid-\neration must be given to the presence of the nasopalatine canal, \nincluding a careful evaluation of its morphology and position to \nminimize implant placement complications.\nImplant Placement. The incisive foramen often expands later-\nally within the palatal bone, and the central incisor implant oste-\notomy may inadvertently encroach on this structure, resulting in \nthe formation of fibrous tissue at the interface in the mesiopala-\ntal region. If the osteotomy invades the incisive canal, treatment \noptions include tissue removal within the canal and bone graft \nand/or implant placement. When a large nasopalatine canal exists, \na more distally placed implant placement in the central incisor \nregion prevents encroachment on this area. Because most resto-\nrations in an edentulous premaxilla are FP-2 or FP-3, the most \nfavorable sites for bone width are selected, even when they are in \nthe interproximal region of central and lateral incisor sites. \nEnlarged Incisive Foramen/Canal. When there exists an \nenlarged canal, the lack of available bone will most likely not \npermit ideal implant placement. However, it is important to \ndifferentiate enlarged canals from incisive canal cysts. Incisive \ncanal cysts are known to cause localized dilation of the canals, \nwith possible displacement of the teeth. In edentulous patients \nthe nasopalatine canal has been shown to be significantly larger in \ncomparison with dentate patients (Fig. 11.35). \nImplant Failure/Bleeding. When implants are positioned in \ncontact with neural tissue, lack of osseointegration and failure \nof the implant may result. In addition, placement of implants \nin close approximation to nasopalatine blood vessels may cause \nexcessive bleeding during surgical procedures; however, this is usu-\nally self-limiting and controlled by local hemostatic techniques. \nInfraorbital Foramen\nThe infraorbital foramen is located in the anterior aspect of the \nmaxillary bone below the infraorbital margin of the orbit. The \ninfraorbital artery, vein, and nerve exit the foramen. On average \nthe infraorbital foramen to infraorbital margin distance is approxi-\nmately 6.1 to 10.9 mm.59\nRadiographic Evaluation. The infraorbital foramen is easily \nseen on coronal images, along with 3D reformatted images. \nClinical Significance. Anatomic variants have been reported to \nbe as far as 14 mm from the orbital rim in some individuals. In the \nseverely atrophic maxilla the infraorbital neurovascular structures \nexiting the foramen may be close to the intraoral residual ridge \nand should be avoided when performing sinus graft procedures, to \nA\nB\n• Fig. 11.34  The premaxilla presents a challenging area for the implant clinician because of the (A) signifi-\ncant vertical and horizontal bone loss, and (B) minimal bone for implant placement, along with trajectory \nissues.\nA\nB\n• Fig. 11.35  The nasopalatine canal area should be evaluated as to the size and location because implant \nplacement in this area may predispose to placement within soft tissue. (A) Very large canal leading to mini-\nmal available bone. (B) Implant placement impinging on nasopalatine canal."
  },
  {
    "page": 91,
    "content": "299\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nminimize possible nerve impairment. This is of particular concern \non soft tissue reflection and the bone preparation of the superior \naspect of the window. Because the infraorbital nerve is responsible \nfor sensory innervations to the skin of the upper cheek; mucosa \nof the maxillary sinus; maxillary incisors, canines, and premolars; \nand gingiva, skin and conjunctiva of the eyelid, lateral nose, and \nmucosa of the upper lip, damage to this nerve may cause signifi-\ncant discomfort to the patient. Most often the nerve is not sev-\nered, and a neurotmesis presents that usually resolves within 1 \nmonth after the surgery (Fig. 11.36). \nParanasal Sinuses\nFrontal. The frontal sinuses are bilateral and funnel-shaped on \neach side of the midline superior to the orbital bones. The bor-\nders of the frontal sinus are inferior, orbital portion of the frontal \nbone; posterior, separates the dura of the frontal lobe from the lin-\ning mucosa; and posterior, separates the dura of the frontal lobe \nfrom the lining mucosa. The frontal sinuses extend to the middle \nmeatus, and drain through the nasofrontal duct and into the frontal \nrecess. The location of the frontal ostia is approximately two-thirds \nhigh on the posterior medial wall, which anatomically complicates \nclearing of the sinus after infection.60 The frontal recess, which is \nthe drainage pathway of the frontal sinus, drains into the middle \nmeatus or ethmoid infundibulum. On coronal CBCT images, the \nfrontal recess is superior and medial to agger nasi cells. \nEthmoid. The ethmoid sinuses are within the ethmoid bone \nand divided into two compartments, the anterior and posterior. \nThe anterior ethmoid sinus drains into the middle meatus, and \nthe posterior ethmoids drain into the sphenoethmoidal recess. The \nborders of the ethmoid sinuses include:\n   \nAnterior ethmoid\nLateral: lamina papyracea of the orbit\nMedial: middle turbinate\nSuperior: fovea ethmoidalis, cribriform plate\nPosterior ethmoid\nLateral: lamina papyracea of the orbit\nMedial: superior turbinate\nSuperior: fovea ethmoidalis, cribriform plate\n   \nThe ethmoid sinuses have various radiographic anatomic mark-\ners, which are termed air cells. The ethmoid bullae are the largest \nand most prominent radiographically in the anterior region. Agger \nnasi cells are usually the most anterior of the anterior air cells and \nare located in anterior/superior to the middle turbinate. Along the \ninferior border of the orbits are the Haller cells, which may impair \nmucociliary clearance when they enlarge and impinge on the eth-\nmoid infundibulum. The Onodi cells derive from the posterior eth-\nmoid and are located lateral and superior to the sphenoid sinus.61 \nSphenoid Sinus. The sphenoid sinus is located within the \nsphenoid bone and contains superiorly the pituitary fossa and \nolfactory nerves. Inferiorly the pterygoid canal courses beneath \nthe mucosa, with the cavernous portion of the internal carotid \nartery within the lateral wall. The ostium lies in the superior aspect \nand drains into the sphenoethmoidal recess.62 \nMaxillary Sinus. The maxillary sinuses are the largest of the \npaired paranasal sinuses and are often a problematic area for \nimplant clinicians. The posterior maxilla has many inherent \ndisadvantages, including poor bone density, the anatomic mini-\nmal interocclusal space, and insufficient bone quantity for ideal \nimplant placement. Thus the implant clinician must have compre-\nhensive knowledge of normal versus abnormal anatomy in associa-\ntion with the maxillary sinus and paranasal sinus anatomy. The \nmaxillary sinus has a high prevalence of anatomic variants and \npathology, which predispose the patient to increased morbidity. \nThus a comprehensive knowledge and understanding of this area \nis important for implant clinicians. Radiographically the maxillary \nsinus has the following borders: Superiorly, the maxillary sinus is \nbordered by the orbital floor, which houses the infraorbital canal. \nInferiorly, the floor of the maxillary sinus approximates the roots \nof the maxillary teeth. The medial wall coincides with the lateral \nwall of the nasal cavity and is the location of the maxillary ostium, \nthe area of drainage of the ethmoid infundibulum (Fig. 11.37). \nNasal Cavity\nThe borders of the nasal cavity are:\n   \nInferior: hard palate\nLateral: medial walls of the right and left maxillary sinus\nSuperior: nasal, ethmoid, and sphenoid bones\nMedial: nasal septum\n   \nA\nB\n• Fig. 11.36  (A) Normal location for infraorbital nerve. (B) Variation closer to \nridge that may result in neurosensory impairment from retraction or possible \ntransection on reflection of the tissue. (From Resnik RR, Preece JW. Radio-\ngraphic complications and evaluation. In: Resnik RR, Misch CE, eds. Misch’s \nAvoiding Complications in Oral Implantology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 92,
    "content": "300\nPART III    Fundamental Science\nThe lateral walls of the nasal cavity are made up of turbi-\nnates (concha), which are epithelium-lined bony structures \nthat protrude into the nasal cavity and function to warm/cool \nand filter inspired air. Below each turbinate are spaces, termed \nmeatuses. The middle meatus is most important because this \nis the area of drainage for the frontal, anterior ethmoid, and \nmaxillary sinuses. The inferior meatus is the drainage site for \nthe nasolacrimal duct. The superior meatus interconnects with \nthe posterior ethmoid and sphenoid sinuses through the sphe-\nnoethmoidal recess.63 \nMaxillary Sinus Membrane\nThe maxillary sinus is lined by the Schneiderian membrane, which \nis identical to respiratory epithelium. This pseudostratified colum-\nnar epithelium is continuous with the nasal epithelium through \nthe maxillary ostium in the middle meatus. The membrane has \nan average thickness of 0.8 mm and is usually thinner and less \nvascular than nasal epithelium.64\nRadiographic Evaluation. A CBCT scan of normal, healthy \nparanasal sinuses reveals a completely radiolucent (dark) maxil-\nlary sinus. Any radiopaque (whitish) area within the sinus cavity \nis abnormal, and a pathologic condition should be suspected. The \nnormal sinus membrane is radiographically invisible, whereas any \ninflammation or thickening of this structure will be radiopaque. \nThe density of the diseased tissue or fluid accumulation will be \nproportional to varying degrees of gray values (Fig. 11.38). \nOstiomeatal Complex\nThe ostiomeatal unit is composed of the maxillary ostium, eth-\nmoid infundibulum, anterior ethmoid cells, uncinate process, and \nthe frontal recess.\nRadiographic Evaluation. The ostiomeatal complex can be \nevaluated radiographically and most easily seen on a coronal scan \nthat includes the following structures:\n\t1.\t \u0007maxillary sinus ostium\n\t2.\t \u0007infundibulum\n\t3.\t \u0007ethmoid bulla\n\t4.\t \u0007uncinate process\n\t5.\t \u0007hiatus semilunaris \nHiatus\nsemilunaris\nInfundibulum\nOsteomeatal\ncomplex\nUncinate\nprocess\nMiddle\nmeatus\nMaxillary\nsinus\nostium\nMaxillary\nsinus\nMiddle turbinate\nInferior meatus\nInferior turbinate\nNasal septum\nEye\nEthmoid\nsinus\nEthmoid\nbulla\nFrontal\nsinus\n• Fig. 11.37  Diagram of Maxillary Sinus Anatomy.\n• Fig. 11.38  The maxillary sinus membrane (Schneiderian membrane) in \nhealth should be invisible (red arrow). When inflammation or pathology is \npresent, it will be depicted as an increase in density/radiopacity or a visible \nincrease in thickness (green arrow)."
  },
  {
    "page": 93,
    "content": "301\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nMaxillary Ostium\nThe main drainage avenue of the maxillary sinus is through the \nostium. The maxillary ostium is bounded superiorly by the eth-\nmoid sinuses and inferiorly by the uncinate process. The maxillary \nsinus ostium is on the superior aspect of the medial wall of the \nsinus, approximately halfway between the anterior and posterior \nwalls. The ostium is usually oval shaped and oriented horizontally \nor obliquely.65\nRadiographic Evaluation. The maxillary ostium is visualized on \ncoronal images usually in the anterior third of the maxillary sinus. \nThis opening is located in the superior aspect of the maxillary sinus \nmedial (lateral wall of nasal cavity). The patency of the maxillary \nostium should always be ascertained when placing implants or bone \ngrafts into the maxillary sinus. The opening can be verified by scroll-\ning through various coronal images (Fig. 11.39). \nClinical Significance. If the maxillary ostium is nonpatent, the \nmucociliary clearance of the maxillary sinus may be affected. This \ncan lead to an increased morbidity to implant-related procedures. \nUncinate Process\nThe uncinate process is an important structure in the lateral wall \nof the nasal cavity. This finger-like bony projection helps form the \nboundaries of the hiatus semilunaris and ethmoid bulla, which \nallow the draining of the frontal and maxillary sinuses.\nRadiographic Evaluation. On coronal or cross-sectional \nCBCT images, the uncinate process is bordered by the medial wall \nC\nB\nA\n• Fig. 11.39  (A and B) Maxillary sinus ostium patency is the mucociliary drainage area of the maxillary sinus. \n(C) Nonpatent ostium (red arrow, non-patent ostium; white arrow, membrane inflammation)."
  },
  {
    "page": 94,
    "content": "302\nPART III    Fundamental Science\nof the maxillary sinus and articulates with the ethmoid process \nand inferior nasal turbinate. Inferiorly it borders the semilunar \nhiatus, and posteriorly it has a free margin (Fig. 11.37). \nClinical Significance. A deflected uncinate process (either \nlaterally or medially) can narrow the ethmoid infundibulum, \nthus affecting the ostiomeatal complex. Perforations may also be \npresent within the uncinate process, leading to communication \nbetween the nasal cavity and ethmoid infundibulum. In addition, \nthe uncinate process may be pneumatized. Although this is rare, \nit may compromise adequate sinus clearance. Uncinate process \nvariations should be evaluated and treated before any procedure \nin which the physiology of the maxillary sinus is altered (e.g., \nimplant placement or bone grafting). \nHiatus Semilunaris\nThe hiatus semilunaris is a curved fissure on the lateral wall of the \nnasal cavity, inferior to the ethmoid bulla. It connects the middle \nmeatus to the anterior ethmoidal air cells and contains the openings \nfor the frontal, maxillary, and anterior ethmoidal sinus (Fig. 11.37).\nRadiographic Evaluation. The hiatus semilunaris gains its \nname from its arched appearance and is best identified in sagittal \nand cross-sectional images. This anatomic structure is bordered \nsuperiorly by the ethmoid bulla and posteriorly by the ethmoid \nprocess of the inferior nasal turbinate. \nClinical Significance. Because three different sinuses drain into \nthe hiatus semilunaris, any mechanical blockage in this region may \ncause inflammation and possible disease into one of the sinuses. \nAnatomic Variants\nConcha Bullosa\nThe middle turbinate plays a significant role in proper drainage \nof the maxillary sinus. Normally the middle turbinate is a thin, \nbony structure; however, it can be aerated, which is termed a \nconcha bullosa. This anatomic variant may be unilateral or bilat-\neral, and it has been shown to have a prevalence rate of up to \n53.6% of the population.66 In addition, there exists a strong \nassociation with conchae bullosae and a deviated septum of the \ncontralateral side.67\nRadiographic Evaluation. Conchae bullosa are easily identi-\nfied on a CT/CBCT coronal image depicting a radiolucent air \nspace in the center of the middle meatus and surrounded by an \novoid bony rim. \nClinical Significance. In most cases of concha bullosa, no para-\nnasal sinus pathology results. The larger the concha bullosa, the more \nlikely the probability of compromising the drainage of the middle \nmeatus. When enlarged, pressure against the uncinate process may \noccur, decreasing the infundibulum drainage, and thus affecting the \nphysiology of the maxillary sinus, leading to an increased drainage \nproblem. Caution must be exercised because patients with concha \nbullosa are more predisposed to postoperative complications from \nbone grafting and implants in the sinus area (Fig. 11.40). \nParadoxical Middle Turbinate\nA paradoxical middle turbinate is an anatomic variant of the \nmiddle turbinate, with a prevalence rate of approximately \n15% of the population.68 This anomaly is a reversal of the \nnormal medially directed convexity of the middle turbinate. \nThe inferior edge of the middle turbinate may have various \nshapes exhibiting excessive curvature, which may predispose \nthe patient to blockage in the nasal cavity, infundibulum, and \nmiddle meatus.69\nRadiographic Evaluation. A paradoxical middle turbinate is \nmost easily seen on a coronal CT/CBCT scan image. In certain \ncross-sectional images, it may also be seen. The convexity of the \nparadoxical middle turbinate is directed laterally, instead of medi-\nally toward the nasal septum. \nClinical Significance. When present, the implant clinician must \ntake into consideration the possibility of postoperative mucociliary \ncomplications after bone grafting or implant placement in the max-\nillary sinus from blockage of the ostium (Fig. 11.41). \nDeviated Septum\nOne of the most common anatomic variants in the oral region is a \ndeviated septum, which may be congenital or traumatic in origin. \nStudies have shown a prevalence rate of 70%, which increases the \npossibility of ostiomeatal complex blockage. This occurs when the \nnasal septum is displaced laterally toward one side of the nasal cav-\nity. When the deviation is severe, the flow of air through the nasal \ncavity is redirected and may cause nasal obstruction, hypoplasia \nof the ipsilateral turbinates, or hyperplasia of the contralateral \nturbinates.\nRadiographic Evaluation. A deviated septum can be seen \nmost easily via the coronal and axial image scans. In addition, a \n3D image of the midline structure will allow direct evaluation. \nThe nasal septum will be displaced toward one side of the nasal \ncavity (Fig. 11.42). \nClinical Significance. When the deviation is severe, the airflow \nthrough the nasal cavity is compromised, manifesting as nasal \ncongestion. Patients with deviated septums are predisposed to \nsinus clearance issues, which increase morbidity of bone grafting \nand implant placement procedures in the maxillary posterior area \non the side of deviation. Usually the contralateral side will have \nnormal mucociliary clearance. \nHaller Cells\nHaller cells are infraorbital ethmoidal air cells that project from \nthe maxillary sinus roof and the most inferior portion of the \nlamina papyracea. The Haller cells are usually present unilaterally, \nwith a prevalence rate of approximately 6% of the population.70 \nThe origin of Haller cells is the anterior ethmoid (88%) and pos-\nterior ethmoid (12%).71\n• Fig. 11.40  An anatomic variant that may predispose the implant patient \nto postoperative mucociliary impairment is a concha bullosa, which is an \naerated middle turbinate."
  },
  {
    "page": 95,
    "content": "303\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nRadiographic Evaluation. Haller cells are identified on coro-\nnal images and are located inferior to the ethmoid bulla and adher \nto the medial roof of the orbit, lateral to the uncinate process. \nClinical Significance. These air cells may expand into the orbit \nand narrow the ostium of the maxillary sinus, especially in the \npresence of an infection. Haller cells have been associated with a \nhigh incidence of chronic rhinosinusitis because they may impinge \non the patency of the maxillary ostium, thus inhibiting ciliary \nfunction. Procedures (implants, bone grafts) that may involve the \nmaxillary sinus have an increased morbidity when Haller cells are \npresent. \nAgger Nasi Cells\nAgger nasi cells are the most anterior ethmoidal air cells that \nextend anteriorly into the lacrimal bone. They can be identified \non CT/CBCT in more than 90% of patients and are associated \nwith a high incidence of frontal sinusitis.72\nRadiographic Evaluation. Agger nasi cells are most easily seen \nin CT/CBCT coronal images lateral to the nasal wall (Fig. 11.43). \nClinical Significance. Agger nasi cells may predispose the \npatient to postoperative sinus complications. \nA\nB\n• Fig. 11.41  Paradoxical Middle Turbinate (A) An anatomic variant that may predispose the implant patient to \npostoperative mucociliary impairments is termed a paradoxical middle turbinate. The convex side of the middle \nturbinate is directed laterally, instead of medially. (B) Image depicting no right or left middle turbinates, which is a \nrecent treatment for patients exhibiting chronic rhinosinusitis to improve mucociliary flow.\n• Fig. 11.42  An anatomic variant that may predispose the implant patient \nto postoperative mucociliary impairments is a deviated septum. The side \nof deviation may cause blockage of the maxillary ostium.\n• Fig. 11.43  Agger nasi cells that are anterior aerated ethmoid air cells \n(arrows). (From Koenig LJ, et al. Diagnostic Imaging: Oral and Maxillofacial. \n2nd ed. Philadelphia: Elsevier; 2017.)"
  },
  {
    "page": 96,
    "content": "304\nPART III    Fundamental Science\nMaxillary Sinus Septa\nAntral septa (of buttresses, webs, and struts) are the most common \nosseous anatomic variant seen in the maxillary sinus. Underwood, \nan anatomist, first described maxillary sinus septa in 1910. Kren-\nnmair et al.73 further classified these structures into two groups: \nprimary, which are a result of the development of the maxilla; and \nsecondary, which arise from the pneumatization of the sinus floor \nafter tooth loss. The prevalence rate of septa has been reported \nto be in the range of 33% of the maxillary sinuses in the dentate \npatient and as high as 22% in the edentulous patient. The most \ncommon location of septa in the maxillary sinus has been reported \nto be in the middle (second bicuspid to first molar) region of the \nsinus cavity. CT scan studies have shown that 41% of septa are \nseen in the middle region, followed by the posterior region (35%) \nand the anterior region (24%). For diagnosis and evaluation of \nsepta, CT scan is the most accurate method of radiographic eval-\nuation.74 Sinus septa may create added difficulty at the time of \nsurgery.\nRadiographic Evaluation. Three-dimensional images depict \nthe anatomic features of septa most easily on CBCT images. They \nmay also be easily seen on reformatted panoramic and axial and \nsagittal images (Fig. 11.44). \nClinical Significance. Maxillary septa complicate sinus graft \nsurgery and can prevent adequate access and visualization to the \nsinus floor; therefore inadequate or incomplete sinus grafting is \npossible. In addition, a higher incidence of membrane perforation \nresults when septa are present. \nMaxillary Sinus Hypoplasia\nHypoplasia of the maxillary sinus may be a direct result from \ntrauma, infection, surgical intervention, or irradiation to the \nmaxilla during the development of the maxillary bone. These \nor other congenital developmental conditions interrupt the \nmaxillary growth center, thus producing a smaller-than-nor-\nmal maxilla. A malformed and positioned uncinate process is \nassociated with this disorder, leading to chronic sinus drainage \nproblems.\nRadiographic Evaluation. Dimensionally smaller than normal \nmaxillary sinus can be seen on panoramic, cross-sectional, coro-\nnal, axial, or 3D images. \nClinical Significance. Most often maxillary sinus hypoplasia \npatients have adequate bone height for endosteal implant place-\nment, and a sinus graft is not required to gain vertical height. If \nimplant placement or bone grafting involves the maxillary sinus, \nA\nB\n• Fig. 11.44  The Maxillary Sinus Inferior Floor.  (A) Flat and smooth maxillary sinus floor. (B) Narrow maxil-\nlary sinus floor with septum separating the sinus cavity.\n• Fig. 11.45  Hypoplasia of the maxillary sinus with inflammation (white \narrow)."
  },
  {
    "page": 97,
    "content": "305\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\ncaution should be exercised, because this condition has been asso-\nciated with chronic sinus disease (Fig. 11.45). \nInferior Turbinate and Meatus Pneumatization (Big-Nose \nVariant)\nA rather uncommon anatomic variant is when the inferior third \nof the nasal cavity exhibits pneumatization within the maxilla and \nresides over the alveolar residual ridge. Studies have shown an inci-\ndence rate of approximately 3%. Because the maxillary sinus is \nlateral to the edentulous ridge, inadequate bone height exists.\nRadiographic Evaluation. Big-nose variants may be deter-\nmined by evaluation on reconstructed CBCT panoramic images, \nas the nasal cavity will extend distal or posterior to the premolar \narea. \nClinical Significance. If unaware of this condition, the implant \nmay be placed into the nasal cavity above the residual ridge, often \npenetrating into the inferior meatus and contacting the inferior \nturbinate. A sinus graft maybe contraindicated with this patient \ncondition, because the sinus is lateral to the position of the \nimplants. Most likely an onlay graft is required to increase bone \nheight (Fig. 11.46). \nBuccal Thickness of Bone in Premaxilla\nOn average, maxillary buccal cortical plates are less than 1 mm \nthick, significantly thinner than the mandibular alveolar bones, \nwhich are greater than 1 mm. Thin cortical plates (similar to voxel \nsize) tend to become indistinguishable from adjacent cementum \nor titanium implants on CBCT images.\nRadiographic Evaluation. Studies have shown that spatial \nresolution limitations of CBCT limit bone visibility of thick-\nness less than 0.6 mm, meaning this is the minimum thickness \nfor bone to be measurable. In addition, clinical studies show \nwhen bone dehiscence is present, a true dehiscence was present \nonly 50% of the time, and a fenestration was present 25% of the \ntime.75 \nA\nB\n• Fig. 11.46  (A and B) Big-nose variant, which results in the nasal cavity \nextending into the first molar region, leaving inadequate bone for implants \nin the bicuspid region.\nA\nB\n• Fig. 11.47  Buccal Image Thickness.  (A) The buccal bone can be very deceiving as depicted in this cone \nbeam computed tomography cross section showing no buccal bone thickness and (B) photo image after \nfull reflection showing buccal bone is present."
  },
  {
    "page": 98,
    "content": "306\nPART III    Fundamental Science\nClinical Significance. Because of the high degree of false-posi-\ntive results, diagnosis and treatment planning can be problematic. \nThe bone thickness should be correlated with all CBCT images, \nespecially the cross-sectional views (Fig. 11.47). \nIntraosseous Anastomosis\nWithin the lateral wall of the maxilla sinus is the intraosseous \nanastomosis, which is comprised of the posterior superior alveo-\nlar and infraorbital arteries. The vertical component of the lateral \naccess wall for the sinus graft often severs these blood vessels.\nRadiographic Evaluation. The intraosseous anastomosis is eas-\nily seen on cross-sectional or coronal views of a CBCT scan as a \ndiscontinuation of the lateral wall with a radiolucent notch. On \naverage, this structure is approximately 15 to 20 mm from the \ncrest of a dentate ridge. \nClinical Significance. When lateral wall sinus augmentation \nis indicated, evaluation of the CBCT scans should be completed \nto determine location and size. If bleeding does occur during the \nlateral wall osteotomy, this can be addressed by cauterization by \nthe handpiece and diamond bur without water, electrocautery, \nor pressure on a surgical sponge while the head is elevated (Fig. \n11.48). \nCanalis Sinuosus\nThe anterior superior alveolar nerve branches from the infraor-\nbital canal, just lingual to the cuspid area. This radiolucent canal is \ndenoted as the canalis sinuosus. The canal runs forward and infe-\nrior to the inferior wall of the orbit and follows the lower margin \nof the nasal aperture and opens to lateral to the nasal septum.76 \nThe canalis sinuosus transmits the anterior superior alveolar nerve, \nartery, and vein.\nRadiographic Evaluation. If the clinician is unaware of the \ncanalis sinuosus, this anatomic structure may be misinterpreted as \napical pathology on 2D radiographs. Therefore on CBCT scans, \nthis bilateral anatomic structure should be evaluated for its pres-\nence. It may be depicted on axial, cross-sectional, or 3D images. \nStudies have shown the canalis sinuosus to be present on 87.5% \nof CBCT scans77 (Fig. 11.49). \nClinical Significance. Because the anterior maxillary region \nis a common area for dental implant placement, the presence of \ncanalis sinuosus may lead to a high degree of implant morbidity. \nImpingement into the canal may lead to a soft tissue interface \nand failure of the implant, and temporary or permanent sensory \ndysfunction and possible bleeding issues.78 However, significant \nsensory impairments are rare because of cross-innervation. \nCalcified Carotid Artery Atheroma\nCalcified carotid artery atheromas are calcifications located in the \ncommon carotid, usually near the bifurcation of the internal and \nexternal carotid arteries. These calcifications give radiographic evi-\ndence of atherosclerosis, which is an indicator of possible stroke \nor metabolic disease. It has been shown that approximately 80% \nof strokes are ischemic and due to atherosclerotic disease in the \ncarotid bifurcation.79\nRadiographic Evaluation. Carotid artery calcifications are \nsmall, multiple radiopacities in the carotid space anterior and lat-\neral to cervical vertebrae C3-C4. These multiple and irregularly \nshaped calcifications may be vertical in orientation and are usu-\nally easily distinguished from the adjacent soft tissue. They can \neasily be seen on axial and 3D images (Fig. 11.50). An additional \ncommon site to evaluate for carotid artery calcifications in large-\nvolume CBCT images is lateral to the pituitary fossa. \nClinical Significance. Because of the significant complications \nthat may arise from the presence of carotid calcifications (isch-\nemic cerebrovascular disease is the second leading cause of death \nin most developed countries), the patient should be referred to his \nor her physician for assessment of carotid artery stenosis and pos-\nsible ultrasound evaluation. \nPathologic Conditions in the Paranasal Sinuses\nPathologic conditions observed on CBCT scans taken for other \nindications appear to be increasing in prevalence. Signs of inflam-\nmation or serious pathologic conditions are a concern when bone \naugmentation procedures or dental implants are planned for the \narea. Therefore the implant clinician must have a strong knowl-\nedge base for various pathologic conditions in the sinus to under-\nstand when proper referral is recommended. In the next part of \nthis chapter, a comprehensive evaluation of maxillary sinus pathol-\nogy will be discussed, with emphasis on differential diagnosis and \nclinical relevance.\nOdontogenic Rhinosinusitis (Periapical Mucositis)\nOdontogenic rhinosinusitis occurs when the sinus membrane is \nviolated by infection of teeth and pathologic lesions of the jaws. \nThe intimate approximation of the roots of the maxillary posterior \nteeth to the floor of the sinus results in inflammatory changes of \nthe periodontium or surrounding alveolar bone, which promotes \nthe development of pathologic conditions in the maxillary sinus.\nRadiographic Appearance. Odontogenic rhinosinusitis will \nusually produce generalized sinus mucosal hyperplasia, which is \nseen as a radiopaque band that follows the contours of the sinus \nfloor. A localized periapical mucositis reveals a thickening of the \nmucous membrane adjacent to the offending tooth and, on occa-\nsion, a perforation through to the floor of the sinus. This radio-\ngraphic appearance has been termed a halo effect (Fig. 11.51). \nDifferential Diagnosis. Odontogenic rhinosinusitis may be \nconfused with acute rhinosinusitis or mild mucosal thickening. \n• Fig. 11.48  Intraosseous anastomosis (arrow) shown on a cross-sectional \nimage seen as discontinuity of the lateral wall and ovoid radiolucency."
  },
  {
    "page": 99,
    "content": "307\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nHowever, in odontogenic rhinosinusitis the patient will most \nlikely have pathology associated with an existing tooth (e.g., pain \nfrom a posterior tooth or a recent extraction, exudate around the \nexisting natural posterior teeth) and radiographic evidence. \nAcute Rhinosinusitis\nA nonodontogenic pathologic condition may also result in inflam-\nmation in the maxillary sinus in the form of rhinosinusitis. The \nmost common type of rhinosinusitis in the maxillary sinus is \nacute rhinosinusitis. The signs and symptoms of acute rhinosi-\nnusitis are rather nonspecific, making it difficult to differentiate \nfrom the common cold, influenza type of symptoms, and allergic \nrhinitis. However, the most common symptoms include purulent \nnasal discharge, facial pain and tenderness, nasal congestion, and \npossible fever. Acute maxillary rhinosinusitis results in 22 to 25 \nmillion patient visits to a physician in the United States each year, \nwith a direct or indirect cost of $6 billion dollars. Although four \nparanasal sinuses exist in the skull, the most common involved in \nsinusitis are the maxillary and frontal sinuses.80\nB\nC\nA\n• Fig. 11.49  Canalis Sinuosus.  (A) CBCT panoramic image depicting the canalis sinuosus, which trans-\nmits the anterior superior alveolar vessels. (B) Cross-sectional image highlighting in red the nerve. (C) 3D \nimage showing course of the canal.\nA\nB\n• Fig. 11.50  (A and B) Carotid calcification atheroma at the level of cervical \nvertebrae C3-C4 (arrows).\nA\nB\n• Fig. 11.51  Odontogenic rhinosinusitis (A and B) associated with patho-\nlogic teeth that extends into the sinus cavity."
  },
  {
    "page": 100,
    "content": "308\nPART III    Fundamental Science\nRadiographic Appearance. The radiographic hallmark in \nacute rhinosinusitis is the appearance of an air-fluid level. A \nline of demarcation will be present between the fluid and the air \nwithin the maxillary sinus. If the patient is supine (CBCT), then \nthe fluid will accumulate in the posterior area; if the patient is \nupright during the imaging, the fluid will be seen on the floor \nand horizontal in nature. Additional radiographic signs include \nsmooth, thickened mucosa of the sinus, with possible opacifica-\ntion. In severe cases the sinus may fill completely with supportive \nexudates, which gives the appearance of a completely opacified \nsinus. The terms pyocele and empyema have been applied with these \ncharacteristics (Fig. 11.52). \nDifferential Diagnosis. The differential diagnosis of acute rhi-\nnosinusitis and prolonged viral upper respiratory infection are simi-\nlar. However, a classic air-fluid level in the maxillary sinus will give \nrise to the confirmation of acute rhinosinusitis. In addition, viral \nrhinosinusitis will usually improve within 7 to 10 days, whereas \nacute bacterial rhinosinusitis persists for longer than 10 days.81 \nChronic Rhinosinusitis\nIf the symptoms of acute rhinosinusitis do not resolve in 12 weeks, \nit is then termed chronic rhinosinusitis. It is the most common \nchronic disease in the United States, affecting approximately 37 \nmillion people. Symptoms of chronic rhinosinusitis are associated \nwith periodic episodes of purulent nasal discharge, nasal conges-\ntion, and facial pain.82\nRadiographic Appearance. Chronic rhinosinusitis has the \ncharacteristic feature of sclerotic, thickened cortical bone from \nlong-lasting mucoperiosteal inflammation. In addition, it may \nappear radiographically as thickened sinus mucosa to complete \nopacification of the antrum. \nAllergic Rhinosinusitis\nAllergic rhinosinusitis is a local response within the sinus \ncaused by an irritating allergen in the upper respiratory tract. \nTherefore the allergen may be the cause of the allergic rhino-\nsinusitis. This category of sinusitis may be the most common \nform, with 15% to 56% of patients undergoing endoscopy \nfor sinusitis showing evidence of allergy. Allergic rhinosinus-\nitis often leads to chronic rhinosinusitis in 15% to 60% of \npatients.83 The sinus mucosa becomes irregular or lobulated, \nwith resultant polyp formation.\nRadiographic Appearance. Polyp formation related to aller-\ngic rhinosinusitis is usually characterized by multiple, smooth, \nrounded, radiopaque shadows on the walls of the maxillary sinus. \nMost commonly, these polyps are located near the ostium and are \neasily observed on a CBCT scan. In advanced cases, ostium occlu-\nsion, along with displacement or destruction of the sinus walls, \nmay be present, with a radiographic image of a completely opaci-\nfied sinus (Fig. 11.53). \nFungal Rhinosinusitis (Eosinophilic Fungal Rhinosinusitis)\nGranulomatous rhinosinusitis is a very serious (and often over-\nlooked) disorder within the maxillary sinus. Patients who have \nfungal sinusitis are thought to have had an extensive history of \nantibiotic use, chronic exposure to mold or fungus in the environ-\nment, or are immunocompromised.\nDifferential Diagnosis. Three possible clinical signs may different­\niate fungal sinusitis from acute or chronic rhinosinusitis: (1) no response \n• Fig. 11.52  Cone beam computed tomography coronal image depicting \nan air-fluid level that is a classic radiographic sign of acute bacterial rhi-\nnosinusitis.\nA\nB\n• Fig. 11.53  (A) Bilateral polyposis, usually associated with allergies, showing the circumferential, polypoid \nnature of the lesions. (B) Bilateral partially opacified sinuses representing a severe case of allergic rhinosi-\nnusitis; severe cases may lead to complete opacification."
  },
  {
    "page": 101,
    "content": "309\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nto antibiotic therapy; (2) soft tissue changes in sinus associated with \nthickened reactive bone, with localized areas of osteomyelitis; (3) and \nassociation of inflammatory sinus disease that involves the nasal fossa \nand facial soft tissue. In some cases a positive diagnosis may require \nmycological and histologic studies. \nRadiographic Appearance. Fungal rhinosinusitis is usu-\nally unilateral (78% of cases), with bony destruction being rare. \nWithin the sinuses the presence of mild thickening to complete \nopacification may be present. In most cases varying degrees of \ndensity (“double densities”) are seen (Fig. 11.54).\nCystic lesions are a common occurrence in the maxillary sinus, \nand studies have reported a prevalence rate of 2.6% to 20%.84 \nThey may vary from microscopic lesions to large, destructive, \nexpansile pathologic conditions that include pseudocysts, reten-\ntion cysts, primary mucoceles, and postoperative maxillary cysts. \nPseudocysts (Mucous Retention Cyst)\nThe most common cysts in the maxillary sinus are mucous reten-\ntion cysts. After much controversy, in 1984 Gardner85 distin-\nguished these cysts into two categories: pseudocysts and retention \ncysts. Pseudocysts are more common and of much greater con-\ncern during sinus graft surgery, compared with retention cysts. \nPseudocysts reoccur in approximately 30% of patients and are \noften unassociated with sinus symptoms. As a consequence, many \nphysicians do not treat these lesions. However, when their size \nbecomes large in diameter, pseudocysts may occlude the maxillary \nostium during a sinus graft procedure and increase the risk for \npostoperative infection.\nRadiographic Appearance. Pseudocysts are depicted radio-\ngraphically as smooth, homogenous, dome-shaped, round to \novoid, well-defined homogeneous radiopacities. Pseudocysts do \nnot have a corticated (radiopaque) marginal perimeter and are \nalways on the floor of the sinus cavity (Fig. 11.55). \nRetention Cysts\nRetention cysts may be located on the sinus floor, near the ostium, \nor within antral polyps. Because they contain an epithelial lining, \nresearchers consider them to be mucous secretory cysts and “true” \ncysts. Retention cysts are often microscopic.\nRadiographic Appearance. Retention cysts are usually very \nsmall and not seen clinically or radiographically. In rare instances \nthey may achieve adequate size to be seen in a CT image and may \nresemble the appearance of a small pseudocyst. \nPrimary Maxillary Sinus Mucocele\nA primary mucocele is a cystic, expansile, destructive lesion that \nmay include painful swelling of the cheek, displacement of teeth, \nnasal obstruction, and possible ocular symptoms.86\nRadiographic Appearance. In the early stages the primary \nmucocele involves the entire sinus and appears as an opacified \nsinus. As the cyst enlarges, the walls become thin and eventually \nperforate. In the late stages, destruction of one or more surround-\ning sinus walls is evident (Fig. 11.56). \nPostoperative Maxillary Cyst\nA postoperative maxillary cyst of the maxillary sinus is a cystic \nlesion that usually develops secondary to a previous trauma or \n• Fig. 11.54  Coronal image showing a progressive fungal rhinosinusitis of \nthe left paranasal sinus area. Note the dense radiopacity, which is termed \na fungal ball.\nB\nC\nA\n• Fig. 11.55  Pseudocyst.  (A–C) Small pseudocyst (mucous retention cyst) located on the floor of the sinus \n(A), larger cyst (B), and very large pseudocyst that may lead to obstruction of the sinus (C)."
  },
  {
    "page": 102,
    "content": "310\nPART III    Fundamental Science\nsurgical procedure in the sinus cavity. It has also been termed a \nsurgical ciliated cyst, postoperative maxillary sinus mucocele, or \nsecondary mucocele.87\nRadiographic Appearance. The cyst radiographically presents \nas a well-defined radiolucency circumscribed by sclerosis. The \nlesion is usually spherical in the early stages, with no bone destruc-\ntion. As it progresses, the sinus wall becomes thin and eventually \nperforates. In later stages it will appear as two separated anatomic \ncompartments (Fig. 11.57). \nSquamous Cell Carcinoma and Adenocarcinoma\nMalignant tumors of the paranasal sinuses are rare, with a poorly \ndifferentiated squamous cell carcinoma comprising approximately \n80% of tumors. Seventy percent of these tumors are found in the \nmaxillary sinus.88 Symptoms can vary; however, neoplasms of the \nmaxillary sinus usually include nasal obstruction, rhinorrhea, epi-\nstaxis, cranial neuropathies, and pain. Advanced cases may include \nvisual disturbances, paresthesias, and possible malocclusion.\nRadiographic Appearance. Radiographic signs of neoplasms \nmay include various sized radiopaque masses, complete opacifica-\ntion, or bony wall changes. A lack of a posterior wall on a radio-\ngraph should be a sign of possible neoplasm (Fig. 11.58). \nMaxillary Sinus Antroliths\nMaxillary sinus antroliths are the result of complete or partial \nencrustation of a foreign body that is present in the sinus. These \nmasses found within the maxillary sinus originate from a central \nnidus, which can be endogenous or exogenous.89\nRadiographic Appearance. The radiographic appearance of \na maxillary antrolith resembles either the central nidus (retained \nroot) or appears as a radiopaque, calcified mass within the maxil-\nlary sinus (Fig. 11.59). \nDifferential Diagnosis. Because the calcified antrolith is com-\nposed of calcium phosphate (CaPO4), calcium carbonate salts, \nwater, and organic material, it will be considerably more radi-\nopaque than an inflammatory or cystic lesion.90 The central nidus \nFluid\nA\nB\n• Fig. 11.56  Primary Mucocele.  (A) Expansile nature of lesion causes destruction of sinus walls. (B) Clini-\ncal image depicting right side of a complete radiopaque sinus with expansion of walls.\nFluid\nB\nA\n• Fig. 11.57  (A) Secondary mucocele is a well-defined radiolucent lesion that separates the sinus cavity into \ntwo separate compartments, which is usually fluid filled. (B) Radiograph depicting cystic area surrounding \nthe implant."
  },
  {
    "page": 103,
    "content": "311\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nof the antrolith is similar to its usual radiographic appearance \n(Fig. 11.60). \nRadiology Reports\nA typical radiographic report template will include the following \nbasic information elements.91\nPatient/Office Identification Section\nThis section records: date of report, patient name, date of birth, \ngender, name of the referring doctor, date of the scan, and the name \nof the scanning center or dental office taking the scan/volume.\nClinical Significance. This section has critical patient record \ninformation. \nImages Provided\nEnter the type of images provided for review. A typical entry \nwould be: “Cone Beam CT images with bone window; Axial, \ncoronal and sagittal planes.” Optional information would include \nthe name of the CBCT unit, pixel resolution (e.g., 0.3 mm, size of \nthe volume: small, medium, or large).\nClinical Significance. Critical/patient record information. When \nvolume size and pixel resolution are included, patient dose recon-\nstruction is possible when the specific CBCT unit is identified. \nClinical Information\nThis section would include a brief relevant history and/or clinical \nnote. Entries might include such elements as: “Implant evalua-\ntion for edentulous areas of maxilla,” “Relationship of endosseous \nimplant to the mandibular canal,” etc.\nClinical Significance. This includes critical/patient record \ninformation providing the clinician’s rationale for taking the diag-\nnostic image. \nDiagnostic Objectives\nThe referring clinician enters his or her specific objectives for the \nreport such as: (1) sinus evaluation; (2) rule out pathology; (3) \nimplant measurements #3,10, 14, 19, 29; (4) rule out osteomyeli-\ntis; and (5) mandibular/maxillary pathology.\nClinical Significance. This includes the clinician’s specific \nrequest or potential concern for the radiologist to look for as a \npriority. \nRadiographic Findings\nThis section of the template provides the radiologist/volume inter-\npreter with a list of specific areas within the volume to be evalu-\nated. A standard listing would include:\n • \u0007maxilla\n • \u0007paranasal sinuses\n • \u0007nasal cavity\n • \u0007air space\n • \u0007temporomandibular joint (TMJ)\nDental Findings. The radiologist will provide limited com-\nments in this section and typically will not report on caries, cal-\nculus, and periodontal disease associated with individual teeth. \nTypically third molar positions will not be reported unless \n• Fig. 11.58  Squamous cell carcinoma of the right maxillary sinus showing \ncomplete radiopacity with associated expansion and destruction of sinus \nwalls.\nA\nB\n• Fig. 11.59  Antrolith or calcified masses present in the sinus (arrows). \n(A) Tooth root, and (B) Restorative material."
  },
  {
    "page": 104,
    "content": "312\nPART III    Fundamental Science\nspecifically requested by the clinician. The interpretation of these \nanomalies is within the diagnostic skill set of the dentist. \nClinical Significance. This provides a summary of radiographic \nfindings for the clinician to quickly identify areas of normality and \nabnormality within the patient volume.\n(note: With a digital template for reports, these areas may \nhave a “normal” response listed and subsequently edited as neces-\nsary when variations from the normal appearances are identified. \nFor example: “Maxilla: no abnormalities detected; Sinuses: no \nabnormalities detected, the right and left ostiomeatal complexes \nwere patent; Nasal Cavity: no abnormalities detected, etc.” for \neach area on the list.) \nRadiographic Impression\nThis section of the report template will identify specific variations \nand deviations from “normal” for each of the areas listed under the \nradiographic findings and provide the radiologist’s impression of \nthe deviation from normal.\nClinical Significance. This gives a summary of radiographic \nfindings providing the clinician with a differential radiographic \ninterpretation of deviations from normal. \nRecommendations\nThis section may be combined with the radiographic impression \nnoted earlier. However, it may be separated to provide general rec-\nommendations for clinician guidance related to the findings listed \nwithin the radiographic impression section earlier.\nThe “Recommendations” section would most likely include \nstatements such as: “Physician referral for more thorough evalua-\ntion of: … (Included here would refer any anomaly not within the \ndental scope of practice as defined by your state licensing board.) \nOther recommendations might include: “Biopsy suggested/rec-\nommended for more thorough evaluation of the biological pro-\ncesses involved in …” (e.g., a large, cystlike lesion in the anterior \ndental area could represent a cyst of the incisive canal/foramen, \nlarge radicular/periapical cyst, ameloblastoma, or central giant cell \ntumor, and a biopsy would be helpful in identifying the specific \nbiological nature of the lesion.)\nClinical Significance. This provides the clinician with general \nguidance related to a specific anomaly and basis for referral.\n(note: In general, the radiologist will not recommend a specific \ntype of treatment for any finding because this is a consultative \nreport that the clinician must integrate into the patient’s overall \ntreatment plan and outcome assessment.) \nRadiologist Name and Signature\nLevel 4: Clinical Significance. This is critical patient record \ninformation. \nTypical Radiographic Descriptions\nDescriptions and entities should be reported as radiographic \nfindings. \nRadiographic Findings\nMaxilla\nAsymmetries between right and left maxillae or sinuses are noted, \nas well as, changes in bone pattern or texture.\nTypical report findings might read:\nAn asymmetry was noted between the right and left maxillary \nsinuses; the right maxillary sinus and maxilla exhibit a smaller \nvolume and size than the left, potentially suggestive of maxillary \nhypoplasia. Correlation of the radiographic observation with the \npatient’s clinical evaluation is suggested.\nClinical Significance. This includes identification of possible \nhemimaxillary hypoplasia, previous trauma, fibrous dysplasia, etc. \nSinuses\nThis section will report on findings within all major sinus \ngroups: right and left maxillary, and ethmoid, frontal, and \nParadoxical middle turbinate\nDeflected\nucinate\nprocess\nPolyps\nNonpatent\nostium\nMucous\nretention cyst\nBig-nose\nvariant\nDeviated\nseptum\nConcha\nbullosa\n• Fig. 11.60  Summary of the most common pathologic conditions that occur in the paranasal sinuses."
  },
  {
    "page": 105,
    "content": "313\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nsphenoid sinuses. Under “normal” circumstances the linings of \nthe sinuses are not radiographically visible and are reported as \n“no abnormalities detected.” When the lining becomes visible, \nsinus pathology is present and reported if the lining is 3 mm or \nmore in thickness.\nCommon Findings and Sinus Descriptions\n   \nMucositis/sinusitis: “The right maxillary and sphenoid sinuses \nexhibited an increase in the thickness and density of the sinus \nlining.”\nMucous retention pseudocyst: “A homogeneous ovoid/dome-\nshaped increase in density was noted within the left maxillary \nsinus.”\nSinusitis: “The right maxillary sinus was partially occupied by ho-\nmogeneous area of increased density containing bubbles.”\nOstiomeatal complex: If the opening is not clearly visible, it \nshould be reported as obstructed/blocked.\nOther, less common sinus findings: A thickening, irregularity, \nand sclerosis of the walls of the sinus may potentially represent \na long-standing chronic inflammation of the sinuses. Small, ir-\nregular calcifications within the homogeneous density of the \ntissues of the sinus may be an indication of antrolith formation \nand an indication of a long-standing chronic sinusitis, small \nosteomas within the ethmoid sinus.\n   \nTypical report findings might read:\nThe radiographic findings appear consistent with a mild chronic \nsinusitis of the right and left maxillary sinuses. Review of patient’s \nhistory for chronic sinusitis/allergy is suggested. Physician referral \nfor more thorough evaluation is suggested if merited by clinical \nfindings and symptoms.\nClinical Significance. This includes identification of potential \nchanges on the sinus region meriting potential physician referral \nin the presence of symptoms. \nNasal Cavity\nThis section will include any findings of asymmetry associated \nwith the nasal cavity, including: inferior, middle, and superior tur-\nbinates; deviations of the nasal septum; and absence of internal \nnasal structures potentially associated with previous ear, nose, and \nthroat surgery. A variation in normal anatomy is a dilation within \nthe middle turbinate referred to as a concha bullosa.\nTypical report findings might read:\nA mild deviation of the nasal septum to the right; enlargement of \nthe middle turbinate consistent with a concha bullosa is consid-\nered a variation in normal anatomic form. Deviation of the nasal \nseptum is considered a variation in normal anatomy; referral and \ntreatment are not indicated unless the patient provides a history of \ndifficulty breathing through his nose.\nClinical Significance. This includes identification of possible \nchanges in the nasal cavity potentially influencing breathing \npatterns. \nAir Space\nVariations in the size of the airway are noted in the section, as well \nas potential enlargements of the adenoid and pharyngeal tonsils.\nTypical report findings might read:\nNarrowing of the airway has been associated with a variety of \nrespiratory disorders, including an increased risk for obstructive \nsleep apnea. Correlation of the radiographic observation with the \npatient’s clinical history is suggested. Clinical evaluation of the soft \ntissues of the oral pharynx is suggested.\nClinical Significance. This includes identification of possible \nairway changes that affect patient breathing patterns. \nTMJ\nThis section reports on variations and deviations in symmetry \nbetween the right and left condyles, articular fossae, and joint \nspaces.\nTypical report findings might read:\nThe right condyle, articular fossa, and joint space exhibited normal \nbony profiles and contours; the left articular fossa and joint space \nexhibited normal radiographic contours; the left condyle exhibits \na localized discontinuity of the cortical outline, the presence of \nresorption lacunae, and sclerosis of the underlying bony trabecular \npattern consistent with degenerative joint disease (DJD). Corre-\nlation of the radiographic observation with the patient’s clinical \nfindings and symptoms, if any, is suggested.\nClinical Significance. This includes identification of possible \nradiographic changes within the bony structures of the TMJ \nregion that affect patient symptoms/occlusion. TMJ-positive \nfindings may predispose the patient to prosthetic rehabilitation \ncomplications. \nOther Findings\nThis section is used to report radiographic changes in anatomic \nstructures not associated with the maxilla and mandible but \nincluded within the volume, including, but not limited to: cal-\ncifications within the carotid artery lateral to the pituitary fossa \nand within the lower neck, radiographically visible changes \nwithin the cervical vertebra, including osteophyte formation, \nsclerosis, narrowing, and irregularity of intervertebral disc space \nwidth with potential bone-to-bone contact; generalized loss or \nthinning of cortical bone and an absence of internal bony tra-\nbeculation suggestive of systemic metabolic disorders of bone/\nosteoporosis; and increased density noted within one or both \nmastoid processes. Common incidental radiographic findings \nincluded here would be: calcification of the stylohyoid ligament, \ncalcifications of pineal gland and cavernous sinus (middle cranial \nfossa area), idiopathic soft tissue calcifications within the soft \ntissues of the skin or soft tissues of the oral pharynx (tonsillo-\nliths), salivary gland/duct calcifications, metallic foreign bodies, \near wax, among others.\nTypical report findings might read:\n(1) The small areas of increased density noted lateral to the pitu-\nitary fossa are anatomically associated with the carotid arteries \nand are consistent with calcification of the carotid arteries. Vas-\ncular calcifications have been associated with an increased risk \nfor cardiovascular disease and stroke. Review of patient’s medi-\ncal history for increased risk factors, such as high blood pressure, \nelevated cholesterol, stress, and smoking, is suggested. Physician \nreferral is suggested with findings of elevated risk factors or if \npatient is not currently under the care of a physician. (2) Scle-\nrosis and osteophyte formation within the cervical vertebra may \nbe early indications of DJD of the cervical spine. Correlation of \nthe radiographic observation with the patient’s clinical findings \nand symptoms of chronic neck/muscle pain/headache or other \nneurologic symptoms is suggested. Physician referral is suggested"
  },
  {
    "page": 106,
    "content": "314\nPART III    Fundamental Science\nfor more thorough evaluation if merited by clinical findings and \nsymptoms. (3) Calcification of the pineal gland is considered \nto be a common incidental radiographic finding that does not \nrequire treatment or referral.\nClinical Significance. This provides identification of poten-\ntial changes indicative of systemic conditions that affect overall \npatient health and welfare. \nDental Findings\nThis area provides a summary of radiographic findings that affect \ndental structures immediately adjacent to the teeth. This area typi-\ncally reports periapical pathology or other maxillary/mandibular \npathology involving the teeth. Evaluation of impacted canines, \nresorptive changes of adjacent teeth and, dilaceration roots poten-\ntially preventing eruption of teeth are noted.\nTypical report findings might read:\nThe maxillary right canine is impacted adjacent to the lingual sur-\nface of the apex of the maxillary right lateral incisor; moderate to \nsevere resorptive changes were observed in the root of the lateral \nincisor.\nClinical Significance. This provides identification of potential \nchanges/conditions that affect treatment planning decisions. \nReporting Implant information\nThe radiology report template may include separate sections \nthat delineate existing implants or the evaluation of prospective \nimplant sites.\nExisting Implants\nThis section would include a brief notation of the areas that exhibit \nexisting implants and whether the implant exhibits integration \nwith the adjacent bone or the presence of potential changes asso-\nciated with peri-implantitis. \nImplant Measurements\nThis section typically corresponds to illustrations within the \nreport that exhibit measurements of requested implant sites and \nwill typically state: “Implant measurements have been provided \nfor the requested sites.” note: It is important for the clinician to \nbe very specific about the possible sites for which measurements \nare being requested; it should not be assumed that the radiologist \nwill know the sites for implant placement. \nAlternative Report Style for “Incidental Radiographic \nFindings”\nMost incidental findings are unlikely to compromise patient health \nor dental treatment outcomes, typically do not require referral to \na physician, and are found in a high percentage of volumes. They \nmay be provided as a separate list without illustrations depending \non the radiologist.\nTypical report findings using this format might read:\nIncidental findings: deviated nasal septum, concha bullosa, ton-\nsilloliths, ear wax, elongated/calcified stylohyoid ligaments, faint/\nsmall calcifications within the pineal gland and cavernous sinuses.\nClinical Significance. This includes identification of potential \nchanges/conditions that will not affect treatment planning deci-\nsions or require outside referral. \nStyles of Radiology Reports\nEach radiologist has her own style and format she uses to con-\nstruct a report, and it is appropriate for the referring clinician to \ndo his “due diligence” and select the radiologist who will provide \nthe type of report he is comfortable using as a basis for treatment \nplanning decisions (Fig. 11.61). For example, some radiologists \nspecify that their review of the volume is through the assessment \nof “axial cross sections only,” which limits the potential of visu-\nalization of radiographic anomalies when CBCT volumes and \nthe software used easily provide axial, coronal, and sagittal cross \nsections. Our suggestion is to identify a radiologist who provides \ninterpretation based on a complete analysis of the volume using \naxial, coronal, and sagittal cross sections. \nIntraoperative Imaging\nThe use of surgical imaging has dramatically changed the way that \nsurgical implantology is completed. In the past the disadvantage \nof periapical radiography perioperatively has been time ineffi-\nciency. To verify positioning and location of an osteotomy site or \nfor identification of a vital structure, processing of standard radio-\ngraph film can take up to 6 minutes. Because of this, practitioners \nrarely verified positioning of anatomic structures during surgery. \nWith digital radiography technology, instantaneous images are \nachieved, allowing for multiple images to be completed in a frac-\ntion of the time. Additional advantages of digital intraoperative \nimaging include manipulation of images, calibration, accurate \nmeasurements and positioning, and maintenance of aseptic pro-\ntocol (Fig. 11.62).\nImmediate Postsurgical Imaging\nA plain film radiograph (periapical or panoramic) or CBCT \nshould be taken postsurgically so that a baseline image may be \nused to evaluate against future films. With the ease of image acqui-\nsition after surgery, an immediate assessment of positioning and \ndisplacement of implants can be evaluated. Because the radia-\ntion dose with CBCT has become user-friendly with significantly \nreduced time and radiation levels (i.e., less than 5 seconds and \nas low as 15 mSv), immediate postoperative CBCT imaging is a \ncommon procedure in implant dentistry today. \nAbutment and Prosthetic Component Imaging\nWhen evaluating transfer impressions along with two-piece abut-\nment component placement, radiographs should be taken to ver-\nify ideal seating. Intraoral radiographs should be used because of \ntheir high geometric resolution to evaluate for any fit discrepancy. \nHowever, care must be taken so that the x-ray beam is directed \nat a right angle to the longitudinal axis of the implant. Even a \nslight angulation may allow a small opening gap to be unnoticed. \nWhen positioning is difficult for intraoral periapical radiographs, \nbitewing or panoramic radiographs may be used (Figs. 11.63 and \n11.64). \nPostprosthetic Imaging\nIn the past, postprosthetic imaging has been limited to intraoral \nand panoramic radiographs. However, with the advancements in \nCBCT technology, more accurate CBCT scans with less scatter-\ning are available in oral implantology. Therefore CBCT scans are \ngaining acceptance for use in postprosthetic imaging. There exists \nno conclusive scientific evidence that low-level ionizing radiation"
  },
  {
    "page": 107,
    "content": "A. Minimal Information Report:\nDate: xx-xx-xxxx\nGender: xxxx\nPatient Name: xxxx       xxxxxxx\nDOB: 8/20/1991\nScanning Center: or dental office taking volume\nReferring Doctor: xxxx xxxxxx\nDate of Scan: 5/26/15\nImages provided: Cone Beam CT images in the bone window. Axial, coronal and sagittal\nplanes. Closed and open scans provided.\nClinical Info: chronic headaches, jaw pain\nRelevant History: not available\nClient Notes: implant #3\nDiagnostic Objectives:\nRule out pathology\nFindings:\nAxial, coronal, and sagittal cross-sections of the patient volume were reviewed.\nRadiographic findings potentially affecting your proposed treatment objectives were not\nidentified.\nRadiologist name and signature:\nThank you for the referral of this patient and the opportunity to serve your practice.\nB. Medical Style [written only, no illustrations] Report:\nDate: xx-xx-xxxx\nGender: xxxx\nPatient Name: xxxx       xxxxxxx\nDOB: 8/20/1991\nScanning Center: or dental office taking volume\nReferring Doctor: xxxx xxxxxx\nDate of Scan: 5/26/15\nImages provided: Cone Beam CT images in the bone window. Axial, coronal and sagittal\nplanes.\nClinical Info: chronic headaches, jaw pain\nRelevant History: not available\nClient Notes: implant #3\nDiagnostic Objectives:\nRule out pathology\nFindings:\nMaxilla: no abnormalities detected\nSinuses: a small dome shaped area of increased density was noted within the right\nmaxillary sinus; the right and left osteomeatal complexes were patent.\nNasal Cavity: a deviation the nasal septum to the left was noted.\nMandible: no abnormalities detected\nAir Space: no abnormalities detected\nTMJs: Both condyles, their articular fossae and eminences exhibit good symmetry and\napparently normal bony anatomy; no abnormalities of the bony structures were noted.\nOther findings: Sclerosis and osteophyte formation, narrowing and irregularity of\nintervertebral disc space width with bone to bone contact was noted within the cervical\nvertebra.\nDental findings: no abnormalities detected\nRadiographic Impression:\nSinuses: the radiographic findings appear consistent with a mild chronic\nmucositis/sinusitis/mucus retention pseudocyst.  Review of patient's history for chronic\nsinusitis/allergy is suggested. Physician referral if merited by clinical findings and\nsymptoms.\nNasal Cavity: deviation of the nasal septum is considered a variation in normal anatomy;\nreferral and treatment is not indicated unless the patient provides a history of difficulty\nbreathing through their nose.\nOther Findings: Sclerosis and osteophyte formation, narrowing and irregularity of\nintervertebral disk space width with bone to bone contact within the cervical vertebra\nmay be indications of DJD of the cervical spine. Correlation of the radiographic\nobservation with the patient's clinical findings and symptoms of chronic neck/muscle\npain/headache or other neurological symptoms is suggested. Physician referral is\nsuggested for more thorough evaluation if merited by clinical findings and symptoms.\nRadiologist name and signature:\nThank you for the referral of this patient and the opportunity to serve your practice.\nComment: Using the medical model style of radiology report, the radiologist provides a\nwritten description of radiographic findings but does not provide illustrations of the\nvarious findings or implant measurements."
  },
  {
    "page": 108,
    "content": "316\nPART III    Fundamental Science\nhas a detrimental effect on bone metabolism and healing. A post-\nprosthetic radiograph needs to be taken to act as a baseline for \nfuture evaluation of component fit verification and also for mar-\nginal bone level evaluation.\nRecall and Maintenance Imaging\nFor the evaluation of implant success, immobility and radio-\ngraphic evidence of bone adjacent to the implant body are the \ntwo most accurate diagnostic aids in evaluating success. Follow-up \nor recall radiographs should be taken after 1 year of functional \nloading and yearly for the first 3 years.92 Multiple studies have \nshown that, in the first year, marginal bone loss and a higher rate \nof failure are seen. \nEvaluation of Alveolar Bone Changes\nRadiographically, lack or loss of integration is usually indicated \nas a radiolucent line around the implant. However, false-neg-\native diagnoses may be made when the soft tissue surrounding \nan implant is not wide enough to overcome the resolution of \nC. Hybrid Medical with Illustrations\nDate: xx-xx-xxxx\nGender: xxxx\nPatient Name: xxxx       xxxxxxx\nDOB: 8/20/1991\nScanning Center: or dental office taking volume\nReferring Doctor: xxxx xxxxxx\nDate of Scan: 5/26/15\nImages provided: Cone Beam CT images in the bone window. Axial, coronal and sagittal\nplanes.\nClinical Info:\nRelevant History:\nClient Notes:\nDiagnostic Objectives:\n1. TMJ Evaluation\n2. Rule Out Pathology\netc.\nFindings:\nMaxilla: no abnormalities detected\nSinuses: no abnormalities detected\nNasal Cavity: no abnormalities detected\nMandible: no abnormalities detected\nAir Space: no abnormalities detected\nTMJs: no abnormalities detected\nOther findings: no abnormalities detected\nDental findings: no abnormalities detected\nRadiographic Impression:\nRecommendations:\nRadiologist name and signature:\nThank you for the referral of this patient and the opportunity to serve your practice.\nComment: Many maxillofacial radiologists provide a hybrid medical model style of\nreport that will include selected images illustrating various radiographic findings. The\nreferring clinician values this kind of report because the illustrations provided allow them\nto evaluate the severity of the conditions the radiologist has identified and can be used to\neducate the patient with regard to the radiographic findings.\nPatient referral to a physician for additional evaluation based on a radiology report does\nnot have clearly defined guidelines and clearly professional clinical judgment is the key,\ntaking into consideration and integrating clinical findings and patient symptoms. We as\nhealthcare providers have an underlying responsibility to refer patients for additional\nevaluation when considered appropriate; however, we cannot force our patients to go to\nphysicians if they do not choose to. As a result, documenting in the patient's chart that the\nradiology report indicated the presence of potential pathology in an area outside of our\nscope of practice and that the patient was requested to seek a more thorough examination\nfrom a physician regarding the condition is prudent and critical.\n• Fig. 11.61  Sample Radiology Report.  (A) Minimal information report. (B) Medical style (written only, no \nillustrations). (C) Hybrid medical style with illustrations. (From Resnik RR, Preece JW. Radiographic com-\nplications and evaluation. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantol-\nogy. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 109,
    "content": "317\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nthe radiographic modality used (i.e., the implant may not have \na direct bone-implant interface). Also, false-positive diagnoses \nmay be made when a “Mach band effect” results from an area \nof lower radiographic density adjacent to an area of high density \n(implant), which results in a more radiolucent area than is actu-\nally present.93 However, studies have shown that the possibility of \nthe Mach band effect is significantly reduced with digital image \nprocessing. In addition, digital radiography has been shown to \nhave the advantage over conventional radiography with respect to \n“edge enhancement,” which is the ability to detect space between \nthe implant and the surrounding bone. Because of the variability \nof operator-controlled problems, a strict quality-assurance pro-\ntocol should be used to maintain ideal image quality over time. \nProper positioning, along with kVp and mA settings, should be \ndocumented for future reference.\nPeriapical Radiographs. In recall radiographic examinations \nthe marginal bone level is compared with the immediate postpros-\nthetic films. Therefore radiographs similar in geometry, density, \nand contrast are paramount. Standardized periapical radiographs \nare essential to ensure accuracy. However, reproducing positioning \nis difficult. Numerous film-holding devices have been documented \nthat attach to the implant, abutment, or prosthesis to standardize \nimage geometry. When proper projections are achieved, implant \nthreads on both sides of the implant are clearly seen. If the threads \nare not clearly seen in the radiographs, modification of the beam \nangle needs to be made. If diffuse threads are present on the right \nside of the implant, then the beam angle was positioned too much \nin the superior direction. If the threads are diffuse on the left \nside, then the beam angle was from an inferior angulation (Fig. \n11.65). With digital enhanced radiographs, numerous techniques \nhave been postulated to measure bone levels around implants. \nComputer-assisted measurements, rulers, calipers, and suprabony \nthread evaluation have been shown to have highly reproducible \nresults.94 \nBitewing Radiographs. In cases where the x-ray source cannot \nbe positioned perpendicular to the implant because of oral anat-\nomy or existing prosthesis, horizontal or vertical bitewings may \nbe taken to evaluate the crestal bone area. With this projection \nthe central beam is perpendicular to the implant and alveolus, the \nobject-film distance is relatively small, and very minor distortions \nare present. The only limitation of bitewing radiographs is that the \napical portion cannot be seen. \nPanoramic Radiographs. Panoramic radiographs usually are \nnot used routinely for evaluation of osseous bone levels and recall \nexaminations. Because panoramic radiographs use intensifying \nscreens, resolution is not as good as with intraoral radiographs. \nHowever, when film positioning or when multiple implants need \nto be evaluated, panoramic radiography is the imaging technique \nof choice. \nComputed Tomography. Two-dimensional radiographs (peri-\napical, panoramic) have limitations in that they relay no buc-\ncolingual information about the present condition of alveolar \nbone. CBCT does allow 3D information about the osseous status \naround an implant. Resolution and scattering have always been \na problem in evaluation of implants; however, with the advent \nof cone beam technology, this is greatly improved. CBCT can \nbe of great benefit in the evaluation of sinus augmentation graft \nprognosis. With the advantage of bone density evaluation using \nHounsfield units, important information on bone maturation \nmay be determined. Also, this radiographic modality is the image \nA\nB\nC\nD\n• Fig. 11.62  Intraoral Radiographs.  (A) Initial pilot orientation with slight \nmesial inclination. (B) Angulation corrected and verified with final depth \nindicator. (C) Implant placement. Note poor angulation of radiograph lead-\ning to distorted measurements. (D) Ideal implant placement radiograph. \nNote perpendicular orientation of x-ray beam as all threads are seen with-\nout distortion. (From Resnik R, Kircos LT, Misch CE. Diagnostic imaging \nand techniques. In: Misch CE, ed. Contemporary Implant Dentistry. St. \nLouis, MO: Elsevier; 2008.)\n• Fig. 11.63  Verification of direct transfer coping placement before final \nimpression. Note ideal angulation from thread alignment."
  },
  {
    "page": 110,
    "content": "318\nPART III    Fundamental Science\nof choice for evaluation of sinus infection or postsurgical sinusitis \ncomplications (Figs. 11.66 and 11.67). \nLegal Issues and Cone Beam Computed \nTomography\nWith CBCT becoming more prevalent in diagnosis and treat-\nment planning for dental implants, many legal issues are coming \nto light. The implant clinician, as a medical professional, is liable \nfor nondiagnosis of any abnormality on the CBCT scan. Dentists \nare held to a standard when diagnosing and treating patients. To \nhelp meet this standard, the implant clinician must use the CBCT \nsurvey in a proper and ideal manner, thus maximizing diagnostic \naccuracy. Therefore it is imperative for the practitioner to stay cur-\nrent with some of the many potential legal issues associated with \nCBCT.\nTo Take a Scan or Not\nIn medicine, radiographic equipment is usually not approved \nfor a particular purpose or indication. Nor is there any actual \nstandard of care or universally accepted guidelines for the use \nof CBCT technologies. Instead, any applicable standard of care \nis mandated by the legislature, a court, or dental board.95 On \nA\nB\n• Fig. 11.64  Seating of Final Prosthesis.  (A) Poor x-ray angulation showing a false-negative or complete \nseating of the prosthesis. Note the diffuse threads. (B) A corrected angulation image exposes the seating \nproblem.\nB\nA\n• Fig. 11.65  Alveolar Bone Level Evaluation.  (A) Ideal positioning showing ideal thread orientation. (B) \nImproper angulation showing diffuse thread orientation."
  },
  {
    "page": 111,
    "content": "319\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nthe other hand, even in the absence of an express guideline, an \nimplant clinician is more likely to be questioned for failing to \nuse available CBCT technologies preoperatively if a complica-\ntion arises. \nTechnical Parameters\nThe doctor ordering the scan must be careful to select the correct \nparameters of the scan. Inadequate or improper CBCT settings \nand settings may lead to liability. Examples include ordering a \nscan with low resolution when a high resolution is indicated (e.g., \ntooth fracture). \nField of View\nThe FOV (anatomic limits of the scan) is crucial in the pre-\noperative assessment of an implant patient. Ideally the FOV \nshould be the smallest possible to reduce the patient x-ray dos-\nage and improve spatial resolution. However, if the FOV is \ntoo small, inadequate sufﬁcient evaluation of the anatomic area \nwill result. This is most commonly seen in the posterior maxil-\nlary augmentation when too small a ﬁeld of view is used. If \nthere is any type of pathology in the sinus and the scan is not \ntaken high enough to determine the patency of the ostium, the \ndoctor is at risk of causing serious sinus issues because of the \ninability to determine the patency of the ostium and the nature \nof the pathology. \nInterpreting the Scan\nThere is no current consensus on the legal ramiﬁcations of inter-\npreting CBCT scans. However, as a general proposition the \nimplant dentist remains responsible for interpreting the entire \nscan.96 The implant clinician has three options. The implant clini-\ncian may: (1) interpret the scan themselves; (2) send the CBCT \ndata to a licensed radiologist, or (3) have the CBCT data evaluated \nby the hospital or imaging center radiologist. \nReferral to Radiologist\nIdeally, most clinicians will decrease their liability by referring \ntheir CBCT scans to a radiologist for evaluation. However, if the \ndoctor sends the scan to a radiologist who is unqualiﬁed to inter-\npret the scan, the dentist may have liability for the negligent refer-\nral.97 In addition, the CBCT scan must be read by a radiologist \nlicensed in the same state as the implant clinician. Otherwise, the \ndentist may be subject to disciplinary action by the state dental \nboard for aiding and abetting the radiologist’s unlicensed practice \nof medicine and for negligent referral of the patient’s scan to the \nunlicensed provider.98 The implant clinician also should conﬁrm \nthat the radiologist’ s malpractice insurance covers the reading of \nCBCT scans. \nWaiver of Liability\nMany implant clinicians who are untrained in CBCT interpre-\ntation request their patients sign a waiver of liability regarding \nthe interpretation of the CBCT scans or a waiver of the right to \nhave the scan read by a radiologist. In general, a patient cannot \nconsent to the negligence of their dentist or other health care pro-\nvider.99 Waivers of liability typically have no legal effect and are \ninadmissible. \nB\nA\n• Fig. 11.66  Maxillary sinus evaluation.  (A) Preoperative cone beam computed tomography (CBCT). (B) \nPostoperative CBCT depicting maxillary rhinosinusitis after sinus augmentation."
  },
  {
    "page": 112,
    "content": "320\nPART III    Fundamental Science\nA\nB\nC4 Vertebrae Level\nInferior Border of Mandible Level"
  },
  {
    "page": 113,
    "content": "321\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nC\nD\nMid-Mandible Level\nMandibular Teeth Level"
  },
  {
    "page": 114,
    "content": "322\nPART III    Fundamental Science\nE\nF\nMaxillary Teeth Level\nMid-Maxilla Level"
  },
  {
    "page": 115,
    "content": "323\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nG\nH\nNasal Floor  Level\nMid-Nasal Level"
  },
  {
    "page": 116,
    "content": "324\nPART III    Fundamental Science\nJ\nSuperior Orbital Level\nMid-Orbital Level\nI"
  },
  {
    "page": 117,
    "content": "325\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nK\nL\nAnterior Facial Level\nAnterior Incisor  Level"
  },
  {
    "page": 118,
    "content": "326\nPART III    Fundamental Science\nM\nN\nMid-Palatal Level\nPosterior Molar Level"
  },
  {
    "page": 119,
    "content": "327\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\nO\nP\nInfratemporal Fossa Level\nAnterior Airway Level"
  },
  {
    "page": 120,
    "content": "328\nPART III    Fundamental Science\nSummary\nOne of the keys to preventing potential complications during \nthe surgical and prosthetic phases of implant treatment is to have \nas clear a picture of the patient’s current anatomic makeup as \npossible. Identifying deficiencies of bone allows the clinician to \nmodify the bony architecture to achieve optimal implant loca-\ntion for prosthetic success. Knowing the exact locations of vital \nstructures allows us to plan safe zones during treatment to avoid \npotentially catastrophic complications. Proper planning is abso-\nlutely paramount to success in any endeavor, and having a strong \nplan in place before the initiation of implant treatment is no \nexception.\nCone beam technology has ushered in a new era of accuracy \nin treatment planning. Clinicians are no longer having to rely \non “guesswork” by extrapolating anatomic measurements from \na distorted 2D image. Templates may be made based on these \nnew 3D images to assist clinicians during tough surgical cases, \nespecially early on respective learning curves. There are just so \nmany benefits to using CBT technology that it is hard to distin-\nguish a reason not to possess one before the initiation of implant \ntreatment. The present legal climate is beginning to echo this \nsentiment, as CBT is closer to becoming the standard of care \nacross the board.\nWith the combination of 3D imaging and a thorough knowl-\nedge of the anatomic areas that are focused on in this chapter, \na clinician can acquire a further degree of confidence that the \nlikelihood of complications has been reduced, which makes the \nimplant treatment process less stressful for both patient and \nprovider.\nReferences\n\t 1.\t \u0007Beason RC, Brooks SL. Preoperative implant site assessment in \nsoutheast Michigan. J Dent Res. 2001;80:137.\n\t 2.\t \u0007Tyndall DA, Brooks SL. Selection criteria for dental implant site \nimaging: a position paper of the American Academy of Oral and \nMaxillofacial Radiology. Oral Surg Oral Med Oral Pathol Oral Radiol \nEndod. 2000;89(5):630–637.\n\t 3.\t \u0007Denio D, Torabinejad M, Bakland LK. Anatomical relationship of \nthe mandibular canal to its surrounding structures in mature man-\ndibles. J Endod. 1992;18(4):161–165.\n\t 4.\t \u0007Zarch SH Hoseini, et al. Evaluation of the accuracy of panoramic \nradiography in linear measurements of the jaws. Iran J Radiol. \n2011;8(2):97.\n\t 5.\t \u0007Yosue T, Brooks SL. The appearance of mental foramina on pan-\noramic radiographs. I. Evaluation of patients. Oral Surg Oral Med \nOral Pathol. 1989;68(3):360–364.\nQ\nMid-Airway Level\n• Fig. 11.67  Cone Beam Computed Tomography (CBCT) Images.  (A) Axial view at the C3 level below \nthe mandible. (B) Axial view at the inferior border of the mandible. (C) Axial view at the midmandible level \nof the mandible. (D) Axial view at the CEJ of the mandibular teeth. (E) Axial view at the incisal edges of the \nmaxillary and mandibular teeth. (F) Axial view at the midmandible level of the mandible. (G) Axial view at \nthe inferior border of the nasal cavity. (H) Axial view at the midnasal cavity level. (I) Axial view at the midorbit \nlevel. (J) Axial view at the superior orbit level. (K) Coronal view at the soft tissue anterior to the maxillary and \nmandibular teeth. (L) Coronal view at the maxillary and mandibular anterior teeth. (M) Coronal view at the \nmidpalate level. (N) Coronal view at the molar level. (O) Coronal view at the third molar region. (P) Coronal \nview just anterior to the airway. (Q) Coronal view within the airway region. CEJ, Cementoenamel Junction."
  },
  {
    "page": 121,
    "content": "329\nCHAPTER 11  Radiographic Evaluation in Oral Implantology\n\t 6.\t \u0007Lindh C, Petersson A, Klinge B. Measurements of distances related \nto the mandibular canal in radiographs. Clin Oral Implants Res. \n1995;6(2):96–103.\n\t 7.\t \u0007Yosue T, Brooks SL. The appearance of mental foramina on pan-\noramic radiographs. I. Evaluation of patients. Oral Surg Oral Med \nOral Pathol. 1989;68(3):360–364.\n\t 8.\t \u0007Sonick M, Abrahams J, Faiella RA. A comparison of the accuracy of \nperiapical, panoramic, and computerized tomographic radiographs \nin locating the mandibular canal. Int J Oral Maxillofac Implants. \n1994;9:455–460.\n\t 9.\t \u0007Kuzmanovic DV, Payne AG, Kieser JA, Dias GJ. Anterior loop of \nthe mental nerve: a morphological and radiographic study. Clin Oral \nImplants Res. 2003;14(4):464–471.\n\t10.\t \u0007Krennmair G, Ulm GW, Lugmayr H, et al. The incidence, location, \nand height of maxillary sinus septa in the edentulous and dentate \nmaxilla. J Oral Maxillofac Surg. 1999;57:667–671.\n\t11.\t \u0007Naitoh M, Yoshida K, Nakahara K, et  al. Demonstration of the \naccessory mental foramen using rotational panoramic radiogra-\nphy compared with cone-beam computed tomography. Clin Oral \nImplants Res. 2011;22:1415–1419.\n\t12.\t \u0007Lauterbur PC. Image Formation by Induced Local Interactions: Exam-\nples Employing Nuclear Magnetic Resonance; 1973.\n\t13.\t \u0007Gray CF, Redpath TW, Smith FW, Staff RT. Advanced imaging: \nmagnetic resonance imaging in implant dentistry. Clin Oral Implants \nRes. 2003;14(1):18–27.\n 14. \u0007Zabalegui J, Gil JA, Zabalegui B. Magnetic resonance imaging as \nan adjunctive diagnostic aid in patient selection for endosseous \nimplants: preliminary study. Int J Oral Maxillofac. 1990;5(3).\n\t15.\t \u0007Eggers G, Rieker M, Fiebach J, Kress B, Dickhaus H, Hassfeld S. \nGeometric accuracy of magnetic resonance imaging of the mandibu-\nlar nerve. Dentomaxillofac Radiol. 2005;34(5):285–291.\n\t16.\t \u0007Kircos LT. Magnetic resonance imaging of the mandible utilizing \na double scout technique for preprosthetic imaging. J Magn Reson \nMed. 1993;7:190–194.\n\t17.\t \u0007Wanner Laura, et al. Magnetic resonance imaging—a diagnostic tool \nfor postoperative evaluation of dental implants: a case report. Oral \nSurg Oral Med Oral Pathol Oral Radiol Endod. 2018;125(4):e103–\ne107.\n\t18.\t \u0007Engstrom H, Svendsen P. Computed tomography of the maxilla \nin edentulous patients: Normal Anatomy. Oral Surg Oral Med Oral \nPathol Oral Radiol Endod. 1981;52(5):557–560.\n\t19.\t \u0007Gulsahi Ayse. In: Turkyilmaz Ilser, ed. Bone Quality Assessment for \nDental Implants, Implant Dentistry - The Most Promising Discipline of \nDentistry, Prof. ; 2011. ISBN: 978-953-307-481-8.\n\t20.\t \u0007Angelopoulos Christos, Aghaloo Tara. Imaging technology in \nimplant diagnosis. Dental clinics of North America. 2011;55(1):141–\n158.\n\t21.\t \u0007Vasak C, Watzak G, Gahleitner A, Strbac G, Schemper M, Zech-\nner W. Computed tomography-based evaluation of Guided surgery \ntemplate (NobelGuide)-guided implant positions: a prospective \nradiological study. Clin Oral Implants Res. 2011;22:1157–1163.\n\t22.\t \u0007Schulze RK, Berndt D, d’Hoedt B. On cone-beam computed tomog-\nraphy artifacts induced by titanium implants. Clin Oral Implants Res. \n2010;21(1):100–107.\n\t23.\t \u0007Haramati N, Staron RB, Mazel-Sperling K, et al. CT scans through \nmetal scanning technique versus hardware composition. Comput \nMed Imaging Graph. 1994;18(6):429–434.\n\t24.\t \u0007Pettersson A, Komiyama A, Hultin M, Nasstrom K, Klinge B. Accu-\nracy of virtually planned and template guided implant surgery on \nedentate patients. Clin Implant Dent Relat Res. 2012;14:527–537.\n\t25.\t \u0007Visconti MA,PG, et al. Influence of maxillomandibular positioning \nin cone beam computed tomography for implant planning. Int J \nOral Maxillofac Surg. 2013;42(7):880–886.\n 26. \u0007Wang Jing, Mao Weihua, Solberg Timothy. “Scatter correction for \ncone-beam computed tomography using moving blocker strips.” \nSPIE Medical Imaging. International Society for Optics and Photonics. \n2011.\n\t27.\t \u0007Specialty Imaging: Dental Implants Tamimi.\n\t28.\t \u0007Scarfe William C. Incidental findings on cone beam computed \ntomographic images: a Pandora’s box? Oral surgery, oral medicine, oral \npathology and oral radiology. 2014;117(5):537–540.\n 29. \u0007Price JB, Thaw KL, Tyndall DA, Ludlow JB, Padilla RJ. Incidental \nfindings from cone beam computed tomography of the maxillofa-\ncial region: a descriptive retrospective study. Clin. Oral Impl. Res. \n2012;23:1261–1268.\n\t30.\t \u0007Miles DA, BA, DDS MS, FRCD(C). Clinical experience with cone-\nbeam volumetric imaging—report of findings in 381 cases. Available \nfrom: \nhttp://www.learndigital.net/articles/2007/CBCT_Touch_\nBriefings.pdf.\n 31. \u0007Cha JY, Mah J, Sinclair P. Incidental findings in the maxillofacial \narea with 3- dimensional cone-beam imaging. Am J Orthod Dentofa-\ncial Orthop. 2007;132:7–14.\n\t32.\t \u0007Arnheiter C, Scarfe WC, Farman AG. Trends in maxillofacial \ncone-beam computed tomography usage. Oral Radiol. 2006;22: \n80–85.\n\t33.\t \u0007Standring Susan, Ellis H, Healy J, et  al. Gray’s anatomy: the \nanatomical basis of clinical practice. Am J Neuroradiol. 2005; \n26(10):2703.\n\t34.\t \u0007Liu T, Xia B, Gu Z. Inferior alveolar canal course: a radiographic \nstudy. Clin Oral Impl Res. 2009;20:1212–1218.\n\t35.\t \u0007Ikeda K, Ho KC, Nowicki BH, Haughton VM. Multiplanar MR \nand anatomic study of the mandibular canal. Am J Neuroradiol. \n1996;17:579–584.\n\t36.\t \u0007Lopes PT, Pereira GA, Santos AM. Morphological analysis of the \nlingula in dry mandibles of individuals in Southern Brazil. J Morphol \nSci. 2010;27(3-4):136–138.\n 37. \u0007Hayward J, Richardson ER, Malhotra SK. The mandibular fora-\nmen: its anteroposterior position. Oral Surg Oral Med Oral Pathol. \n1997;44:837–843.\n\t38.\t \u0007Kim ST, Hu KS, Song WC, et al. Location of the mandibular canal \nand the topography of its neurovascular structures. J Craniofac Surg. \n2009;20:936–939.\n\t39.\t \u0007Anderson LC, Kosinski TF, Mentag PJ. A review of the intraosseous \ncourse of the nerves of the mandible. J Oral Implantol. 1991;17:394–\n403.\n\t40.\t \u0007Carter RB, Keen EN. The intramandibular course of the inferior \nalveolar nerve. J Anat. 1971;108(pt 3):433–440.\n\t41.\t \u0007Denio D, Torabinejad M, Bakland LK. Anatomical relationship of \nthe mandibular canal to its surrounding structures in mature man-\ndibles. J endod. 1992;18:161–165.\n 42. \u00075 Gowgiel JM. The position and course of the mandibular canal. J \nOral Implantol. 1992;18:383–385.\n\t43.\t \u0007Naitoh M, Hiraiwa Y, Aimiya H, Gotoh K, Ariji E. Accessory men-\ntal foramen assessment using cone-beam computed tomography. \nOral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:289–\n294.\n\t44.\t \u0007Fishel D, Buchner A, Hershkowith A, Kaffe I. Roentgenologic \nstudy of the mental foramen. Oral Surg Oral Med Oral Pathol. \n1976;41(5):682–686.\n 45. \u0007Jacobs R, Mraiwa N, Van Steenberghe D, Sanderink G, Quirynen \nM. Appearance of the mandibular incisive canal on panoramic \nradiographs. Surg Radiol Anat. 2004;26(4):329–333. Epub 2004 \nJun 10.\n\t46.\t \u0007Filo K, Schneider T, Locher MC, et al. The inferior alveolar nerve’s \nloop at the mental foramen and its implications for surgery. J Am \nDent Assoc. 2014;145:260–269.\n\t47.\t \u0007Hanihara T, Ishida H. Frequency variations of discrete cranial traits \nin major human populations IV. Vessel and nerve related variations. \nJ Anat. 2001;199:273–287.\n\t48.\t \u0007Singh Rajani, Srivastav AK. Study of position, shape, size and inci-\ndence of mental foramen and accessory mental foramen in Indian \nadult human skulls. Int J Morphol. 2010;28(4):1141–1146.\n 49. \u0007Juodzbalys G, Wang HL, Sabalys G. Anatomy of mandibular vital \nstructures. Part II: Mandibular incisive canal, mental foramen and \nassociated neurovascular bundles in relation with dental implantol-\nogy. J Oral Maxillofac Res. 2010;1:e3."
  },
  {
    "page": 122,
    "content": "330\nPART III    Fundamental Science\n\t50.\t \u0007Serman NJ. The mandibular incisive foramen. Anat. 1989;167:195–\n198.\n\t51.\t \u0007De Oliveira-Santos C, Souza PH, de Azambuja Berti-Couto S, et al. \nAssessment of variations of the mandibular canal through cone beam \ncomputed tomography. Clin Oral Investig. 2012;16:387–393.\n\t52.\t \u0007Leite Guilherme Mariano Fiuza, et  al. Anatomic variations and \nlesions of the mandibular canal detected by cone beam computed \ntomography. Surg Radiol Anat. 2014;36(8):795–804.\n\t53.\t \u0007Butura Caesar C, et al. Hourglass mandibular anatomic variant inci-\ndence and treatment considerations for all-on-four implant therapy: \nreport of 10 cases. J Oral Maxillofac Surg. 2011;69(8):2135–2143.\n\t54.\t \u0007Watanabe H, Mohammad Abdul M, Kurabayashi T, Aoki H. Man-\ndible size and morphology determined with CT on a premise of \ndental implant operation. Surg Radiol Anat. 2010;32:343e349.\n\t55.\t \u0007Athavale SA, et al. Bony and cadaveric study of retromolar region. \nPeople’s Journal of Scientific Research. 2013;7 6(2). July 2013.\n\t56.\t \u0007Babiuc IULIANA, Tarlungeanu Ioana, Pauna Mihaela. Cone beam \ncomputed tomography observations of the lingual foramina and \ntheir bony canals in the median region of the mandible. Rom J Mor-\nphol Embryol. 2011;52(3):827–829.\n\t57.\t \u0007Atwood DA, Coy WA. Clinical cephalometric and densitometric study \nof reduction of residual ridges. J Prosthet Dent. 1971;26:200–295.\n\t58.\t \u0007Misch CE. Density of bone: effect on treatment plans, surgical \napproach, healing and progressive bone loading. Int J Oral Implantol. \n1991;6:23–31.\n\t59.\t \u0007Macedo VC, Cabrini RR, Faig-Leite H. Infraorbital foramen loca-\ntion in dry human skulls. Braz. J. Morphol. Sci. 2009;26(1):35–38.\n\t60.\t \u0007DelBalso AM. Maxillofacial Imaging. Philadelphia: W.B. Saunders \nCO; 1990:72.\n\t61.\t \u0007Kantarci M, Karasen R, Alper F, et al. Remarkable anatomic varia-\ntions in paranasal sinus region and their clinical importance. Eur J \nRadiol. 2004;50:296–302.\n\t62.\t \u0007Seiden A, Tami T, Pensak M, et al. Otolaryngology the Essentials. New \nYork: Thieme Medical Publishers; 2002:77–118.\n\t63.\t \u0007Parks Edwin T. Cone Beam Computed Tomography for the Nasal Cav-\nity and Paranasal Sinuses. Dent Clin North Am. 2014;58(3):627–651.\n 64. \u0007Van den Bergh JPA, ten Bruggenkate CM, et al. Anatomical aspects \nof sinus floor elevations. Clin Oral Implants Res. 2000;11:256–265.\n\t65.\t \u0007Prasanna LC, Mamatha H. The location of maxillary sinus ostium \nand its clinical application. Indian J Otolaryngol Head Neck Surg. \n2010;62(4):335–337.\n\t66.\t \u0007Zinreich S, Albayram S, Benson M, Oliverio P. The ostiomeatal \ncomplex and functional endoscopic surgery. In: Som P, ed. Head \nand Neck Imaging. 4th ed. St Louis: Mosby; 2003:149–173.\n 67. \u0007Stallman Jamie S, Joao Lobo N, Som Peter M. The incidence of con-\ncha bullosa and its relationship to nasal septal deviation and parana-\nsal sinus disease. Am J Neuroradiol. 2004;25(9):1613–1618.\n\t68.\t \u0007Llyod GA. CT scan of the paransal sinuses: study of a control \nseries in relation to endoscopic sinus surgery. Laryngo Rhino Otol. \n1990;104:477–481.\n\t69.\t \u0007Wani Asif A, et al. CT scan evaluation of the anatomical variations \nof the ostiomeatal complex. Indian J Otolaryngol Head Neck Surg. \n2009;61(3):163–168.\n\t70.\t \u0007Arslan Halil, et  al. Anatomic variations of the paranasal sinuses: \nCT examination for endoscopic sinus surgery. Auris Nasus Larynx. \n1999;26(1):39–48.\n 71. \u0007Kainz J, Braun H, Genser P. [Haller’s cells: morphologic evalu-\nation and clinico-surgical relevance]. Laryngo-rhino-otologie. \n1993;72(12):599–604.\n\t72.\t \u0007Brunner E, Jacobs JB, Shpizner BA, et al. Role of the agger nasi \ncell in chronic frontal sinusitis. Ann. Otol. Rhinol. Laryngol. \n1996;105(9):694–700.\n\t73.\t \u0007Krennmair G, Ulm CW, Lugmayr H, et al. The incidence, location \nand height of maxillary sinus septa in the edentulous and dentate \nmaxilla. J Oral Maxillofac Surg. 1999;57:667–671.\n\t74.\t \u0007Kim MJ, Jung UW, Kim CS, et al. Maxillary sinus septa: prevalence, \nheight, location and morphology: a reformatted computed tomogra-\nphy scan analysis. J Periodontol. 2006;77:903–908.\n\t75.\t \u0007Leung Cynthia C, et al. Accuracy and reliability of cone-beam com-\nputed tomography for measuring alveolar bone height and detect-\ning bony dehiscences and fenestrations. Am J Orthod Dentofacial \nOrthop. 2010;137(4):S109–S119.\n\t76.\t \u0007Neves FS, Souza MC, Franco LCS, Caria PHF, Almeida PB, Rebello \nIC. Canalis sinuosus: a rare anatomical variation. Surg Radiol Anat. \n2012;34:563–566.\n\t77.\t \u0007Wanzeler Ana Márcia Viana, et al. Anatomical study of the canalis \nsinuosus in 100 cone beam computed tomography examinations. J \nOral Maxillofac Surg. 2014;19(1):49–53.\n 78. \u0007Jacobs RL, Martens W, Mraiwa N, Adriaenses P, Gelan J. Neurovas-\ncularization of the anterior jaw bones revisited using high resolution \nmagnetic resonance imaging. Oral Surg Oral Med Pathol Oral Radiol \nEndod. 2007;103:683–693.\n\t79.\t \u0007Almog DM, Tsimidis K, Moss ME, Gottlieb RH, Carter LC. Evalu-\nation of a training program for detection of carotid artery calcifica-\ntions on panoramic radiographs. Oral Surg Oral Med Oral Pathol \nOral Radiol Endod. 2000;90:111–117.\n\t80.\t \u0007American Academy of Otolaryngology—Head and Neck Surgery. \nFact sheet: 20 questions about your sinuses. Available at http://www.\nentnet.org/healthinfo/ sinus/sinus_questions.cfm.\n\t81.\t \u0007Rosenfeld RM, Andes D, Bhattacharyya N, et  al. Clinical prac-\ntice guideline: adult sinusitis. Otolaryngol Head Neck Surg. \n2007;137(suppl 3):S1–S31.\n\t82.\t \u0007Beule A. Epidemiology of chronic rhinosinusitis, selected risk \nfactors, comorbidities, and economic burden. GMS Curr Top \nOtorhinolaryngol Head Neck Surg. 2015;14(11):1–31.\n\t83.\t \u0007Beninger MS, Mickleson SA. Functional endoscopic sinus \nsurgery, morbidity and early results. Henry Ford Hosp Med J. \n1990;38:5.\n\t84.\t \u0007Yoshiura K, Ban S, Hijiya K, et al. Analysis of maxillary sinus-\nitis using computed tomography. Dentomaxillofac Radiol. \n1993;22:86.\n\t85.\t \u0007Gardner DG. Pseudocysts and retention cysts of the maxillary sinus. \nOral Surg Oral Med Oral Pathol. 1984;58:561–567.\n\t86.\t \u0007Kudo K, et al. Clinicopathological study of postoperative maxillary \ncysts. J Jpn Stomatol Soc. 1972;21:250–257.\n\t87.\t \u0007Misch CM, Misch CE, Resnik RR, et al. Postoperative maxillary \ncyst associated with sinus elevation procedure: a case report. J Oral \nImplantol. 1991;18:432–437.\n\t88.\t \u0007Tiwari R, Hardillo JA, Mehta D, et al. Squamous cell carcinoma of \nmaxillary sinus. Head Neck. Mar. 2000;22(2):164–169.\n\t89.\t \u0007Blaschke FF, Brady FA. The maxillary antrolith. Oral Surg Oral Med \nOral Pathol. 1979;48:187–191.\n\t90.\t \u0007Karges MA, Eversol LR, Poindexter BJ. Report of case and review of \nliterature. J Oral Surg. 1971;29:812–814.\n\t91.\t \u0007Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral \nImplantol­ogy. St. Louis, MO: Elsevier; 2018.\n\t92.\t \u0007Gröndahl K, Lekholm U. The predictive value of radiographic \ndiagnosis of implant instability. Int J Oral Maxillofac Implants. \n1997;12(1).\n\t93.\t \u0007Sunden S, Gröndahl K, Gröndahl HG. Accuracy and precision in \nthe radiographic diagnosis of clinical instability in Brånemark dental \nimplants. Clin Oral Implants Res. 1995;6(4):220–226.\n\t94.\t \u0007Wouters FR, Lavstedt S, Frithiof L, Söder PÖ, Hellden L, Salonen L. \nA computerized system to measure interproximal alveolar bone lev-\nels in epidemiologic, radiographic investigations: II. Intra-and inter-\nexaminer variation study. Acta Odontol Scand. 1988;46(1):33–39.\n\t95.\t \u0007Friedland B, Miles DA. Liabilities and risks of using cone beam \ncomputed tomography. Dental Clinics. 2014;58(3):671–685.\n\t96.\t \u0007Friedland B. Clinical radiological issues in orthodontic practice. In: \nSeminars in orthodontics . WB Saunders; 1998, June;4(2);64–78\n\t97.\t \u0007Estate of Tranor v Bloomsburg Hosp. 60 F. Supp. 2d 412, 416 (M.D. \nPa. 1999) .\n\t98.\t \u0007Texas Occupations Code, Title 3, Subtitle D, Chapter 251; Califor-\nnia Business and Professions Code x2264.\n\t99.\t \u0007Dahl D. Doctors’ ‘no sue’ contracts spark debate, Lawyers USA May 21, \n2007."
  },
  {
    "page": 123,
    "content": "331\n12\nApplied Anatomy for Dental \nImplants\nMOHAMED SHARAWY\nT\nhe surgical anatomy of the maxilla and mandible provide \nthe foundation required to safely insert dental implants. \nThe anatomy is also a requisite to the understanding of \ncomplications that may inadvertently occur during surgery, such \nas injury to blood vessels or nerves, as well as postoperative com-\nplications such as infection. This information also provides the \noperator with the confidence needed to deal with these complica-\ntions. This chapter addresses those issues important in the field of \noral implantology.\nSurgical Anatomy of the Maxilla as an Organ\nThe maxilla is pyramidal in shape, with the root of the zygoma as \nits apex (Figs. 12.1 and 12.2). The latter can be palpated in the \nbuccal vestibule of the oral cavity. The root of the zygoma divides \nthe facial surface of the maxilla into anterolateral and postero-\nlateral surfaces of the pyramid. The third surface of the pyramid \nis the orbital plate of the maxilla. The base of the pyramid is the \nlateral wall of the nose or the medial wall of the maxillary sinus. \nThe alveolar process of the maxilla related to the anterolateral sur-\nface carries the incisors, the canines, and the premolars, whereas \nthat of the posterolateral surface carries the molars and ends as the \nmaxillary tuberosity. The intraoral part of the maxilla is limited by \nthe mucobuccal fold and the orbicularis oris muscle anteriorly and \nby the buccinator muscle posteriorly. The posterolateral surface of \nthe maxilla above the mucobuccal fold forms the anterior wall of \nthe infratemporal fossa and is difficult to palpate. However, the \nanterolateral surface of the maxilla beyond the mucobuccal fold \ncan be palpated easily under the skin along with the anterior nasal \nspine, the anterior nasal aperture, and the frontal process of the \nmaxilla. Intraorally, it is possible to palpate the canine eminence, \nthe canine fossa (distal to the canine eminence and a common \nsite for facial access to the maxillary sinus), the maxillary tuberos-\nity, and the hamular notch. The maxilla extends as a horizontal \nplate medially to form the anterior two-thirds of the hard palate. \nThe horizontal plate of the palatine bone forms the posterior one-\nthird of the hard palate. The palatine bone has a vertical plate \nthat articulates with the base of the maxilla; it also has a pyrami-\ndal process that interposes between the maxillary tuberosity and \nthe pterygoid processes of the sphenoid bone. Mucosal incision \nat the maxillary tuberosity that extends into the hamular notch \nmay expose the pyramidal process of the palatine bone. Distal to \nthis point, one may expose the medial pterygoid muscle, which \ntakes origin from the tuberosity and the lateral pterygoid plate of \nthe sphenoid. The medial wall of the maxilla begins at the sharp \nedge of the anterior nasal aperture and extends posteriorly, with \na concavity that bounds the nasal fossa and continues distal to \nthe canine. Once there, it forms the medial wall of the maxillary \nsinus and continues all the way back to the maxillary tuberosity. \nThe medial wall of the maxilla provides attachment to the inferior \nnasal concha and to the vertical plate of the palatine bone. The \nopening of the maxillary sinus is found in the medial wall of the \nmaxilla, close to the floor of the orbit. The opening is reduced in \ndiameter by the uncinate process of the ethmoid bone. The latter \nprovides the superior and middle conchae of the lateral nasal wall. \nThe orbital plate of the maxilla forms the floor of the orbit and \nalso the roof of the maxillary sinus. The infraorbital canal carries \nthe infraorbital nerve and vessels, and it forms a ridge that can be \nseen in the sinus cavity.\nThe authors thank Francis T. Lake for contributing to the section on blood \nsupply of edentulous jaws and Lewis Hinley for skillful medical illustration.\n  1. Frontal process of maxilla\n  2. Infraorbital foramen\n  3. Anterior nasal spine\n  4. Pterygomaxillary fissure\n  5. Canine eminence\n  6. Canine fossa\n  7. Posterolateral surface\n      of maxilla\n  8. Coronoid process\n  9. Retromolar triangle\n10. External oblique ridge\n11. Mental eminence\n12. Mental foramen\n12\n11\n10\n9\n8\n7\n4\n6\n5\n3\n2\n1\n• Fig. 12.1  Anatomical features of the maxilla and mandible that are of \nclinical importance."
  },
  {
    "page": 124,
    "content": "332\nPART III     Fundamental Science\nMuscles Attached to the Maxilla\nAs the maxillary alveolar bone resorbs, the crest of the residual \nridge migrates toward the muscles that take their origin from \nthe basal bone of the maxilla. Descriptions of muscles of surgical \nimportance to oral implantologists follow (Figs. 12.3–12.5).\nOrbicularis Oris Muscle\nThe orbicularis oris muscle originates from the modiolus at each \ncorner of the mouth. The muscle fibers fan out into the upper and \nlower lips, in which they form upper and lower peripheral por-\ntions under the skin and marginal portions under the vermilion \nzone of the lips. Some of the orbicularis oris fibers attach to the ala \nof the nose and to the nasal septum. In the midline of the upper \nlip, the peripheral portions from both sides interdigitate to create \nthe philtrum. The marginal portions interdigitate and create the \nlabial tubercle. Although unattached to the bone of the maxilla, \nthe muscle limits the depth of the upper and lower facial vestibule. \nThe orbicularis oris receives innervation from the buccal and man-\ndibular branches of the facial nerve. \nIncisivus Labii Superioris Muscle\nThe incisivus labii superioris muscle originates from the floor of \nthe incisive fossa of the maxilla above the eminence of the lateral \nincisor and deep to the orbicularis oris. To expose the bone of the \npremaxilla between the canines, a mucoperiosteal flap reflection \nmay detach the incisivus labii superioris. It may also detach the \nseptalis and oblique fibers of the nasalis muscle. The first fiber is \nattached to the skin of the nasal septum and the latter fiber to the \nala of the nose. These small muscles will reattach after placement \nof the flap. However, if the muscles were damaged, then drooping \nof the septum and flaring of the ala of the nose may result. \nBuccinator Muscle\nThe buccinator muscle originates from the base of the alveolar \nprocess opposite to the first, second, and third molar of both jaws. \nThis muscle also takes origin from the pterygoid hamulus of the \nmedial pterygoid plate of the sphenoid bone, bridging the gap \nbetween the maxillary tuberosity anteriorly and the hamulus pos-\nteriorly. Extension of a subperiosteal frame design into the ptery-\ngoid plates may interfere with the fibers of these muscles without \nadding too much to the retention of the implant. When incis-\ning and reflecting the mucosa overlying the areas of the maxil-\nlary tuberosity and hamular notch before taking impressions for \nmaxillary subperiosteal implants, avoid injuring the tendon of the \n1. Maxillary sinus opening\n2. Middle meatus\n3. Medial wall of sinus\n4. Lateral wall of sinus\n5. Floor of sinus and alveolar recess\n4\n5\n3\n2\n1\n• Fig. 12.2  Anatomical features of the maxillary sinus.\nH\nD\nE\nF\nG\nB\nL\nJ\nK\nN\nM\nA\nO\nC\n• Fig. 12.3  A, Origin of depressor septi muscle; B, origin of superior inci-\nsivus muscle; C, origin of nasalis muscle; D, origin of levator labii superi-\noris muscle; E, infraorbital foramen; F, origin of levator anguli oris (caninus) \nmuscle; G, origin of buccinator muscle; H, insertion of lateral tendon of \ntemporalis muscle; I, insertion of masseter muscle; J, origin of depressor \nanguli oris (triangularis) muscle; K, insertion of platysma muscle; L, mental \nforamen; M, origin of inferior incisivus muscle; N, origin of depressor labii \ninferioris muscle; and O, origin of mentalis muscle.\nB\nA C\nD\nE\nF\nG\nH\n• Fig. 12.4  A, Genial tubercles, site of origin of genioglossus (superior \ntubercle) and geniohyoid (inferior tubercle) muscles; B, digastric fossa, site \nof origin of anterior belly of digastric muscle; C, sublingual fossa, location \nof sublingual gland; D, mylohyoid line, site of origin of mylohyoid muscle; \nE, insertion of medial tendon of temporalis muscle; F, mandibular foramen; \nG, mylohyoid groove, formed by mylohyoid nerve; and H, site of insertion \nof medial pterygoid muscle."
  },
  {
    "page": 125,
    "content": "333\nCHAPTER 12  Applied Anatomy for Dental Implants\ntensor veli transact muscle, which passes around the pterygoid \nhamulus. The tendon moves on an underlying bursa whenever \nthe soft palate moves; therefore it may become irritated by the \nsubperiosteal frame and result in inflammation and pain. Fibers of \nthe buccinator and medial pterygoid muscles are also found in the \narea of reflection. The majority of the fibers of the medial ptery-\ngoid muscle originate from the medial surface of the lateral ptery-\ngoid plate of the sphenoid bone, whereas the rest of the fibers form \nthe tuberal head, which takes origin from the maxillary tuberosity. \nNear the pterygoid hamulus, a fibrous tissue raphe or, in some \ncases, a broad fascialike structure is found between the transaction \nand the superior pharyngeal constrictor muscles. In some cases, \nno raphe or fascia is found. Injury to the latter muscle should be \navoided during reflection of the mucosa, particularly on the pala-\ntal aspect of the area of the hamulus. \nLevator Labii Superioris Muscle\nThe levator labii superioris muscle takes origin from the infraor-\nbital margin above the infraorbital foramen; therefore it is rarely \nof concern to the implant surgeon. The zygomatic branch of the \nfacial nerve innervates this muscle. \nLevator Anguli Oris (Caninus) Muscle\nThe levator anguli oris muscle originates in the maxilla below \nthe infraorbital foramen. The infraorbital nerve and vessels arise \nbetween this muscle and the levator labii superioris. In the severe \natrophic division D maxilla, the infraorbital foramen is relatively \nclose to the crest of the ridge. Reflection of the tissues for autog-\nenous grafts and implant placement into sinus grafts may approxi-\nmate this region and cause paresthesia. In subperiosteal implant \ncases that require extensive framework extension for retention, the \noperator should be aware of the location of the infraorbital neuro-\nvascular bundle in relation to the caninus and levator labii superi-\noris muscles. The zygomatic branch of the facial nerve innervates \nthe caninus muscle. \nSensory Innervation of the Maxilla\nThe maxillary nerve (V2) innervates the maxilla (Fig. 12.6). The \nnerve leaves the middle cranial fossa by passing through the foramen \nrotundum and appears in the pterygopalatine fossa. It exits the fossa \nand passes briefly into the infratemporal fossa; from there it enters \nthe floor of the orbit or the roof of the maxillary sinus by passing \nthrough the infraorbital fissure. The nerve then exits the orbit via \nthe infraorbital foramen. The pterygopalatine portion of the max-\nillary nerve provides the descending palatine and sphenopalatine \nbranches. The sphenopalatine nerve enters the nasal cavity from the \npterygopalatine fossa by passing through the sphenopalatine fora-\nmen. The nerve supplies the nasal cavity and becomes the incisive \nnerve that supplies the palatine mucosa opposite to the upper six \nanterior teeth. The descending palatine nerve terminates as the great \npalatine nerve, which supplies the mucosa of the hard palate, and the \nlesser palatine nerves, which supply the mucosa of soft palate. These \nsensory nerves also carry parasympathetic fibers from the spheno-\npalatine ganglion that innervate the mucous glands of the palate. \nThe infratemporal portion of V2 branches into the posterior alveolar \nnerve and zygomatic nerve. The latter divides into the zygomati-\ncofacial and zygomaticotemporal cutaneous nerves. The posterior \nsuperior alveolar nerve supplies the buccal gingiva, buccal alveolar \nbone, second and third molars, and two roots of the first molar. \nThe infraorbital portion of V2 gives rise to anterior superior alveo-\nlar and occasionally middle superior alveolar nerves. These nerves \nrun in bony grooves in the facial wall of the maxillary sinus under \nthe Schneiderian membrane. The nerves supply the sinus wall and \nthe premolars; the canine, lateral, and central incisor on the same \nside; and the central incisor at the contralateral side. The infraorbital \nnerve exits the maxilla at the infraorbital foramen and supplies cuta-\nneous branches to the lower eyelid, side of the nose, and upper lip. \nImplantologists often need to block V2 or several of its branches. \nLuckily this can be achieved by an intraoral route. V2 can be reached \nvia the great palatine foramen and descending palatine canal, or via \nthe pterygomaxillary fissure by following the slope of the posterolat-\neral surface of the maxilla into the pterygopalatine fossa.\nPosterior Superior Alveolar (Dental) Nerve\nThe nerve arises within the pterygopalatine fossa, courses down-\nward and forward, passing through the pterygomaxillary fissure, \nand enters the posterior aspect of the maxilla. It runs between the \nbone and the lining of the maxillary sinus. This nerve supplies the \nsinus, the molars, the buccal gingiva, and the adjoining portion \nof the cheek; it may be injured during a sinus augmentation with \n 1. Temporalis\n 2. Nasalis\n 3. Levator labii superioris alaque nasi\n 4. Levator labii superioris\n 5. Zygomaticus minor\n 6. Levator anguli oris\n 7. Zygomaticus major\n 8. Oblique portion of nasalis\n 9. Orbicularis oris\n10. Buccinator\n11. Risorius\n12. Medial tendon of temporalis\n13. Lateral tendon of temporalis\n14. Masseter\n15. Mentalis\n16. Depressor labii inferioris\n17. Depressor anguli oris\n17\n16\n15\n14\n13\n12\n11\n10\n9\n8\n7\n6\n5\n4\n3\n2\n1\n• Fig. 12.5  Muscles attached to the maxilla and mandible.\n13\n9\n10\n9\n11\n12\n7\n8\n4\n2\n1\n3\n5\n6\n 1. Maxillary n.\n 2. Pterygopalatine ganglion\n 3. Infraorbital n.\n 4. Posterior superior alveolar n.\n 5. Middle superior alveolar n.\n 6. Anterior superior alveolar n.\n 7. Buccal n.\n 8. Mandibular n.\n 9. Lingual  n.\n10. Inferior alveolar n.\n11. Nerve to mylohyoid\n12. Auriculotemporal n.\n13. Mental branch of inferior\n     alveolar n.\n• Fig. 12.6  Sensory innervation of the maxilla and mandible."
  },
  {
    "page": 126,
    "content": "334\nPART III     Fundamental Science\na lateral approach. Clinically this does not appear to be of major \nconsequence. \nInfraorbital Nerve\nThis nerve is a continuation of the main trunk of the maxillary \ndivision. It leaves the pterygopalatine fossa by passing through the \ninferior orbital fissure to enter the floor of the orbit. It runs in the \ninfraorbital groove and then in the infraorbital canal. The nerve \nexits the orbit through the infraorbital foramen to give cutaneous \nbranches to the lower eyelid, the ala of the nose and the skin, and \nthe mucous membrane of the lip and cheek. The infraorbital fora-\nmen is located between the levator labii superioris muscle, which \ntakes origin above the foramen, and the levator anguli oris (cani-\nnus) muscle, which takes origin below the foramen. The foramen \nand neurovascular contents are within 5 to 10 mm of an extremely \nresorbed maxilla. When applying onlay grafts, which expose the \nentire maxilla, the implant dentist must be very aware of this situ-\nation. Fixation screws or implants may cause paresthesia when \ninserted through the graft and into this structure. Subperiosteal \nimplants designed for an atrophied maxilla should not extend into \nthe site of the infraorbital nerve and vessels. In some cases of max-\nillary sinus disorder, the site of the infraorbital foramen becomes \ntender, probably as a result of inflammation of the infraorbital \nnerve. This is an important diagnostic test for possible postopera-\ntive involvement after sinus augmentation procedures. \nMiddle Superior Alveolar (Dental) Nerve\nThis branch of the infraorbital nerve is given off as the infraorbital \nnerve passes through the infraorbital groove. The middle superior \nalveolar nerve runs downward and forward in the lateral wall of \nthe sinus to supply the maxillary premolars. This region is rou-\ntinely violated in the lateral approach to sinus grafts, with appar-\nently no consequence. \nAnterior Superior Alveolar (Dental) Nerve\nThis branch of the infraorbital nerve arises within the infraorbital \ncanal. It initially runs laterally within the sinus wall and then \ncurves medially to pass beneath the infraorbital foramen. The \nbranch turns downward to supply the maxillary anterior teeth. \nA nasal branch passes into the nasal cavity to supply the mucosal \nlining of a portion of the nasal cavity. Before elevation of nasal \nmucosa and placement of grafts, this nerve must be anesthetized. \nThe infraorbital nerve block or V2 block anesthesia is suggested. \nImplant dentists must also anesthetize this branch before place-\nment of implants in the incisor region. The anterior, middle, and \nposterior superior alveolar nerves intermingle to form the superior \ndental plexus. The posterior, middle, and anterior superior alveo-\nlar nerves run in the facial wall of the maxillary sinus between its \nlining membrane and the bone. During antrostomy procedures \nto augment the floor of the sinus, the operator should be aware \nof these structures, which are present even in the absence of teeth. \nPalatine Nerve\nThe greater (anterior) and lesser (posterior) palatine nerves sup-\nply the hard and soft palate, respectively. They exit the pterygo-\npalatine fossa through the superior opening of the descending \npalatine canal, travel downward, and enter the oral cavity by way \nof the greater and lesser palatine foramina. The greater palatine \nnerve runs forward in a groove on the inferior surface of the hard \npalate to supply the palatal mucosa as far forward as the incisor \nteeth. Here the nerve communicates with the nasopalatine nerve. \nThe nerve supplies the gingiva, mucous membrane, and glands of \nthe hard palate. The greater palatine artery and vein accompany \nthe nerve during its course in the hard palate. As the maxillary \nalveolar process atrophies, it shifts to the palate and brings the \ncrest of the ridge closer to the groove in which the greater palatine \nneurovascular bundle is found. The restoring dentist should be \naware that an incision too palatal to the crest of the ridge in the \natrophied maxilla might injure these vital structures. This foramen \nis entered for a V2 block anesthesia. One may find it by taking a \nblunt instrument and pressing firmly along the alveolar palatal \nbone angle. The instrument will depress over the foramen when in \nthe correct position. \nNasopalatine (Sphenopalatine) Nerve\nThe nasopalatine nerve leaves the pterygopalatine fossa through \nthe sphenopalatine foramen located in the medial wall of the \nfossa. The nerve enters the nasal cavity and supplies portions of \nthe lateral and superior aspects of the nasal cavity. The longest \nbranch reaches the nasal septum, in which it turns downward \nand forward, traveling on the surface of the septum. While on \nthe septum it forms a groove on the vomer bone. The nerve sup-\nplies the nasal mucosa, descends to the floor of the nose near the \nseptum, passes through the nasopalatine canal, and then exits onto \nthe hard palate through the incisive foramen. The latter opening \nis deep in the incisive papilla. The nerve communicates with the \ngreater palatine nerve. The incisive nerve should be anesthetized \nbefore elevation of the mucosa of the floor of the nose for subnasal \ngrafts or implants that engage the nasal floor in the incisor region. \nArterial Supply to the Maxilla\nThe majority of arterial blood supply (Fig. 12.7) comes from the \nmaxillary artery, which is one of the terminal branches of the exter-\nnal carotid artery. The artery starts deep in the neck of the man-\ndibular condyle (mandibular portion) and then proceeds either \nsuperficial or deep to the lateral pterygoid muscle (pterygoid por-\ntion). It then branches close to the pterygomaxillary fissure, in \nwhich one branch enters the fossa (pterygopalatine portion). The \nother branch, called the infraorbital artery, enters the floor of the \norbit via the infraorbital fissure; it proceeds in the infraorbital \ncanal and exits on the face by passing through the infraorbital \nforamen. Branches of the maxillary artery are as follows:\n  1. Ophthalmic a.\n  2. Infraorbital a.\n  3. Deep temporal a.\n  4. Posterior superior alveolar a.\n  5. Middle superior alveolar a.\n  6. Anterior superior alveolar a.\n  7. Buccal a.\n  8. Inferior alveolar a.\n  9. Middle meningeal a.\n10. Maxillary a.\n11. Superior temporal a.\n12. External carotid a.\n13. Mental branch of inferior\n      alveolar a.\n14. Facial a.\n14\n13\n12\n11\n10\n9\n8\n7\n6\n5\n4\n3\n2\n1\n• Fig. 12.7  Arterial supply of the maxilla and mandible."
  },
  {
    "page": 127,
    "content": "335\nCHAPTER 12  Applied Anatomy for Dental Implants\n\t1.\t \u0007Mandibular portion: deep auricular, tympanic, middle menin-\ngeal, and inferior alveolar arteries\n\t2.\t \u0007Pterygoid portion: deep temporal, lateral pterygoid, medial \npterygoid, and masseteric arteries\n\t3.\t \u0007Pterygopalatine portion: posterior superior alveolar, descend-\ning palatine, and sphenopalatine arteries\n\t4.\t \u0007Infraorbital portion: anterior and middle superior alveolar, pal-\npebral, nasal, and labial arteries\nSupplemental arterial blood supply reaches the maxilla via two \nbranches from the cervical portion of the facial artery (ascend-\ning palatine and tonsillar arteries), two dorsolingual arteries from \nthe lingual artery, and the ascending pharyngeal branch of the \nexternal carotid artery. All the collateral circulation reaches the \nmaxilla from the area of the soft palate. During orthognathic sur-\ngery to correct maxillary prognathism, the surgeon often cuts the \nposterior, middle, and anterior superior alveolar arteries, as well \nas the descending palatine arteries, without compromising the \nblood supply to the maxilla because of the presence of supple-\nmental blood supply from the branches mentioned previously. \nIt is important to note that the maxillary artery supplies blood \nto the bone of the mandible via its inferior alveolar artery and \nits branches to the muscles of mastication. Detaching the mas-\nseter and medial pterygoid muscles without reattaching it could \nresult in necrosis of the ramus of the mandible. In addition, all \nthe arterial branches mentioned previously arise from the external \ncarotid; therefore bilateral arteriosclerosis of the carotids, which \nis common in old age and in uncontrolled diabetic patients, may \ncompromise the blood supply to the maxilla and could result in \ndelay of healing after insertion of implants or bone grafting to the \narea. More detailed consideration of applied anatomy of the arte-\nrial supply to both the maxilla and mandible is presented at the \nend of this chapter. \nVenous Drainage of the Maxilla\nThe veins follow the arteries and carry the same names. The \nmaxilla drains into the maxillary vein. The latter communi-\ncates freely with the pterygoid plexus of veins and then joins \nthe superficial temporal vein to form the posterior facial vein \nwithin the parotid gland. Infection from the maxilla may follow \nthe maxillary vein to the pterygoid plexus veins and then to the \ncavernous sinuses via emissary veins, causing infected cavernous \nsinus thrombosis. Adequate arterial supply and healthy venous \ndrainage are essential for bone regeneration and remodeling of \nbone grafts. \nLymphatic Drainage\nThe maxilla, including the maxillary sinuses, drains its lymphatics \ninto the submandibular lymph nodes. In addition, the posterior \nportion of the maxilla and soft palate drain into the deep facial \nlymph nodes, which are part of the deep cervical nodes. Palpation \nof lymph nodes is an essential part of the physical examination of \nthe head and neck. \nSurgical Anatomy of the Mandible\nThe clinician should be familiar with the anatomical features of \ndentulous and edentulous mandibles, not only from radiographs \nbut also from physical examination (see Figs. 12.1–12.4). The \nsymphysis, inferior border, premasseteric notch, gonial angle, lat-\neral pole of condyle, and coronoid process are all palpable under \nthe skin. Intraoral palpable features of the mandible from the \nfacial surface include the external oblique ridge and retromolar \ntriangle, with the coronoid process at its tip, the external oblique \nridge bordering it laterally, and the internal oblique ridge border-\ning it medially. The latter is called the temporal crest because this \nis the site for insertion of the medial tendon of the temporalis \nmuscle. The mental foramen can be located at the midpupillary \nline at the apices of the premolars. From the lingual aspect, pal-\npate the internal oblique ridge and torus mandibularis at the pre-\nmolar region. Reflection of the mucoperiosteal flap beyond the \nmucobuccal fold facially exposes the mentalis muscles lateral to \nthe midline, the mental foramen with the mental neurovascular \nbundle, the depressor labii inferiori, and the triangularis close to \nthe inferior border in the premolar region, the transaction at the \nbase of the alveolar process opposite to the molars, and the tem-\nporalis tendons at the anterior border of the ramus. An atrophied \nedentulous mandible loosens the alveolar process, and the crest \nof the ridge may be found at the same level as the external and \ninternal oblique ridge. It is possible to palpate the superior genial \ntubercle with its genioglossus muscle attachment. Reflection of \nthe mucoperiosteal flap after a midcrest incision may expose the \nmental neurovascular bundle, which is abnormally located at or \noccasionally lingual to the crest of the ridge. The transact muscle \nmay loosen its attachment to the external oblique ridge, whereas \nthe mylohyoid may rise above the level of the ridge. The lingual \nnerve, which has a close relationship to the alveolar bone of the \nthird molar in the dentulous mandible, may run close to the crest \nof the edentulous ridge; in some cases it may be found under the \nretromolar pad.\nMuscle Attachment to the Mandible\nThe loss of teeth begins a cascade of events that leads to alveo-\nlar bone loss in width and height. As the mandibular alveo-\nlar bone resorbs, the residual ridge migrates toward many of \nthe muscles that originate or insert on the mandible (see Figs. \n12.3–12.5). The origin, insertion, innervation, and function \nof the muscles of surgical importance to the implant dentist \nare discussed.1-7\nLingual or Medial Attachments\nMylohyoid Muscle. The mylohyoid muscle is the main muscle \nof the floor of the mouth. It takes origin from the entire length of \nthe mylohyoid lines on the medial aspect of the mandible bilater-\nally. The most posterior fibers of the mylohyoid insert into the \nbody of the hyoid bone, whereas the other fibers meet in the mid-\nline to form a median raphe that extends from the mandible to \nthe hyoid bone. The structures above the mylohyoid muscle are \nsublingual or intraoral in location, and the structures below the \nmylohyoid muscle are extraoral or subcutaneous. With a severely \nresorbed residual ridge, the origin of the mylohyoid muscle \napproximates the crest of the ridge, especially in the posterior \nmandible. In these cases surgical manipulation at the crest of the \nridge may injure the mylohyoid muscle. A mandibular periosteal \nreflection for subperiosteal implant often reflects this muscle to \nthe second molar region. The substructure of the implant then has \na permucosal site in the first molar area and a lingual primary strut \nabove and below the mylohyoid muscle. Surgical manipulation of \nthe tissue of the floor of the mouth may lead to edematous swell-\ning of the sublingual space (above the mylohyoid muscle), swell-\ning of the submandibular space (below the mylohyoid muscle), or \nboth. Ecchymosis resulting from blood accumulation may occur"
  },
  {
    "page": 128,
    "content": "336\nPART III     Fundamental Science\nsubcutaneously and/or submucosally. In some cases, infection \nmay start and spread lingually and lead to an abscess or celluli-\ntis either sublingually (intraoral) or submandibularly (extraoral), \ndepending on the site of origin of the infection in relation to the \norigin of the mylohyoid muscle. Extensive bilateral cellulitis of the \nsublingual spaces may push the tongue backward or compress the \npharynx, which may result in airway obstruction and necessitate a \ntracheotomy or cricothyroidotomy to maintain the airway. Func-\ntionally, the mylohyoid muscle raises the hyoid bone and floor \nof the mouth, or it can depress the mandible if the hyoid bone is \nfixed. The mylohyoid nerve that innervates the muscle is a motor \nbranch of the inferior alveolar nerve. The latter is a branch of the \nmandibular nerve (V3). \nGenioglossus Muscle. The genioglossus muscle forms the bulk \nof the tongue. It takes origin from the superior genial tubercle. The \nanterior fibers insert into the dorsal surface of the tongue from the \nroot to its tip, and the posterior fibers insert into the body of the \nhyoid bone. The genioglossus muscle is the main protruder of the \ntongue. The genial tubercles, particularly the superior pair, may be \nlocated near the crest of the alveolar ridge in divisions C to D of \nthe atrophic mandible. During the elevation of the lingual mucosa \nand before making an impression for a subperiosteal implant, one \nshould be aware of the origin of this structure to avoid causing \ninjury during the procedure. A portion of this muscle may be \nreflected from the genial tubercle. However, the muscle should \nnot be completely detached from the tubercle because this may \nresult in retrusion of the tongue and possible airway obstruction. \nA branch of the hypoglossal nerve (cranial nerve XII) supplies the \ngenioglossus. \nMedial Pterygoid Muscle. The majority of the fibers of the \nmedial pterygoid muscle take origin from the medial surface of \nthe lateral pterygoid plate of the sphenoid bone. A small slip of \nmuscle originates from the tuberosity of the maxilla. The muscle \ninserts on the medial surface of the angle of the mandible. The \nmedial pterygoid muscle bounds the pterygomandibular space \nmedially. This space is entered when an inferior dental nerve block \nis administered. Furthermore, during surgical procedures medial \nto the medial tendon of the temporalis muscle, such as in prepa-\nration for the insertion of a unilateral subperiosteal implant, the \npterygomandibular space is usually involved. Infection of this \nspace is dangerous because of its proximity to the parapharyngeal \nspace and the potential for spread of the infection to the medi-\nastinum. Surgical exposure of tissue posterior to the maxillary \ntuberosity may also involve the medial pterygoid muscle because \na portion of the muscle takes origin from the maxillary tuberosity. \nHowever, the numbers of fibers originating from the tuberosity \nare few compared with the fibers from the medial surface of the \nlateral pterygoid plate. A branch of the mandibular division (V3) \nof the trigeminal nerve innervates the muscle. \nLateral Pterygoid Muscle. Although the lateral pterygoid \nmuscles rarely are involved in surgery for implants, their possible \naction in mandibular flexure or adduction during opening, as well \nas the effect of this phenomenon on subperiosteal implants or \nprosthetic full-arch splitting of mandibular implants in the molar \nregion, warrants their consideration. The lateral pterygoid muscle \nconsists of superior and inferior heads. The superior head takes \norigin from the infratemporal surface and crest of the greater wing \nof the sphenoid bone (roof of the infratemporal fossa), whereas \nthe inferior head takes origin from the lateral surface of the lateral \nplate of the pterygoid process of the sphenoid bone. The fibers of \nthe superior head run downward to insert on the anterior band of \nthe temporomandibular joint (TMJ) disk (about 15% of its fibers) \nand the pterygoid fovea on the neck of the mandible. The fibers \nof the inferior head run upward to insert on the pterygoid fovea \nand also on the medial pole of the condyle, median capsule, and \nmedian collateral ligament of the TMJ disk. Because of the angu-\nlation of the lateral pterygoid muscles, many authors believe that \nthe mandibular flexure causing alteration in the mandibular arch \nwidth, and sometimes pain in patients with a full-arch subperios-\nteal implant or prosthetic splint, may be caused by contraction of \nthe lateral pterygoid muscles. The muscles normally function in \nprotraction of the mandible and are innervated by a branch of the \nmandibular nerve (V3). \nTemporalis Muscle. The temporalis is a fan-shaped muscle of \nmastication. It takes origin from the temporal fossa and inserts \ninto the coronoid process of the mandible and the anterior border \nof the ramus as far inferiorly as the last molar at the site of the \nretromolar fossa. The muscle has two tendons that insert into the \nmandible. The superficial tendon is located laterally, and the deep \ntendon is inserted medially. The temporalis tendons and their \nassociated fascia project anteromedially and inferiorly and serve as \na common point for attachment for the temporalis, masseter, and \nmedial pterygoid muscles, as well as for the transaction and supe-\nrior pharyngeal constrictor muscles. The long buccal nerve and \nvessels are also located in this area. This temporalis tendon–fas-\ncial complex extends into what is traditionally called the retromo-\nlar triangle. Surgical exposure of the mandibular ramus medially \nwould involve this tendon–fascial complex, with its contents of \nmuscle fibers, nerves, and vessels, and may lead to transaction \nand postoperative pain. Incisions placed on the anterior ascend-\ning ramus for subperiosteal implants or harvesting bone from the \nexternal oblique and ramus should be inferior to the insertion of \nthe two tendons of the temporalis muscle. The temporalis muscle \nis a powerful elevator and retractor of the mandible and, like all \nthe major muscles of mastication, is innervated by a branch of V3. \nBuccal or Facial Muscle Attachments\nMentalis Muscle. The external surface of the mandible in the \nmidline presents a ridge indicative of the location of the symphysis \nmenti (see Fig. 12.5). The ridge leads inferiorly to a triangular ele-\nvation known as the mental protuberance. The base of the triangle \nis raised on either side into the mental tubercles. The mentalis \nmuscles take origin from the periosteum of the mental tubercles \nand the sides of the mental eminence and insert into the skin of \nthe chin and superiorly interdigitate with the orbicularis oris of \nthe lower lip. Above the mentalis origin, the incisivus muscles \ntake origin from small fossae called the incisivus fossae. Complete \nreflection of the mentalis muscles for the purpose of extension of \na subperiosteal implant or symphyseal intraoral graft may result in \n“witch’s chin,” probably caused by the failure of muscle reattach-\nment. If the muscle is completely detached to expose the symphy-\nsis, then an elastic bandage is applied externally to the chin for 4 \ndays to help in the reattachment of the muscle. Another approach \nis to incise the muscle and leave a proximal portion attached \nto bone and reflect the distal portion. The distal and proximal \nportions should be approximated with resorbable sutures before \nsuturing the mucosa. The mentalis muscle receives its nerve supply \nfrom the marginal (mandibular) branch of the facial nerve. \nBuccinator Muscle. The fibers of the transaction muscle (cheek \nmuscle) take origin from the lateral surfaces of the alveolar pro-\ncesses of the maxilla and the mandible in the area of the molars, \nthe maxillary tuberosity, the pterygoid hamulus, the pterygo-\nmandibular raphe, and the retromolar fossa of the mandible. The \ninsertion of the muscle is complex. The upper and lower fibers of"
  },
  {
    "page": 129,
    "content": "337\nCHAPTER 12  Applied Anatomy for Dental Implants\nthe transaction blend with the fibers of the orbicularis oris at the \nupper and lower lips. The central fibers decussate at the modiolus \nbefore they insert into the orbicularis oris. The modiolus is the \nsite of crossing and intermingling of fibers from the transaction \nmuscle with fibers from the elevator and depressor muscles of the \nangle of the mouth. The modiolus forms a palpable node inside \nthe angle of the mouth opposite the upper first premolar tooth. \nThe parotid duct opposite the maxillary second molar pierces the \ntransaction muscle. The buccopharyngeal fascia, which is a part \nof the visceral fascia of the neck, covers the muscle. Lateral to the \nfascia is the buccal pad of fat.\nSome patients wearing lower subperiosteal implants complain \nof episodic swelling and pain at the site of origin of the transaction \nmuscle, particularly after periods of heavy mastication or brux-\nism. Incision of these swellings does not usually yield exudate or \npurulence. The condition responds well to heat application, trans-\nactionary drugs, and rest. Although the cause for this condition is \nnot known, one may speculate that myositis of a detached transac-\ntion muscle may cause it. The process of muscle reattachment to \nthe implant surface or to a new site should be investigated. The \nbuccal branch of the facial nerve innervates the muscle. \nMasseter Muscle. This strong muscle of mastication covers \nthe lateral surface of the ramus and angle of the mandible. The \nmasseter has a dual origin from superficial and deep heads. The \nsuperficial head takes origin from the anterior two-thirds of the \nlower border of the zygomatic arch. The deep head originates \nfrom the posterior one-third of the zygomatic arch and the entire \ndeep surface of the arch. The muscle inserts into the outer sur-\nface of the ramus of the mandible from the sigmoid notch to the \nangle. However, the muscle can be deflected easily during surgery \nto expose the bone for the ramus extension needed for lateral sup-\nport of a subperiosteal implant. The space between the masse-\nteric fascia and the muscle is a potential surgical space, known as \nthe masseteric space, into which an infection may spread, causing \nmyositis and trismus. The masseter is one of the main elevators \nof the jaw. The masseteric nerve provides the innervation of the \nmuscle and is a branch of the mandibular division (V3) of the \ntrigeminal nerve. \nInnervation of the Lower Jaw and Associated \nStructures\nInferior Alveolar (Dental) Nerve\nThis nerve arises as a branch of the mandibular nerve (V3) in the \ninfratemporal fossa (see Fig. 12.6). It appears at the inferior border \nof the inferior head of the lateral pterygoid muscle, courses down-\nward, and enters the mandibular foramen on the medial aspect \nof the ramus. Before the nerve enters the mandibular foramen, it \ngives numerous sensory branches that innervate the mandibular \nbone. These small nerves are in association with small vessels in \nneurovascular channels. The inferior dental nerve can run as one \nunit through the mandibular canal until it reaches the premolar \nregion, in which it divides into the mental and the incisive nerves. \nThe mental nerve exits the canal through the mental foramen. In \nan excessively resorbed ridge, the mental foramen, with its con-\ntents of mental nerve and vessels, can be found on the crest of the \nridge. When making an incision or reflection of the mucosa in \nthis area, avoid injury to these vital structures. Knowledge of the \nposition of the inferior dental canal in vertical and buccolingual \ndimensions is of paramount importance during site preparation \nfor implants. The potential use of reconstruction techniques on \ncomputed tomographic scans and magnetic resonance imaging \nmay increase clinicians’ ability to locate the inferior dental canal \nprecisely within the jawbone. Much less expensive techniques \nusing panoramic cross-sectional tomographic imaging are also \navailable. In some cases the inferior dental nerve may divide into \ntwo or three rami that occupy separate canals as the nerve travels \nin the mandible to supply the bone. These variations can be deter-\nmined by conventional radiographic techniques, and the operator \nshould modify the surgical approach and type of implant to avoid \ninjury to the portion of the nerve that exits the foramen. Injury \nto the portion of the inferior alveolar nerve that remains in the \natrophied bone and does not innervate soft tissues is of far less \nconsequence. The nerves in the bone, when in contact with an \nimplant, may account for the rare but occasional observation of \ntenderness, even though the implant is rigid and appears healthy. \nIn addition, the fibrous tissue around these nerves may cause an \nincrease in the amount of fibrous tissue around an implant that is \ninserted in contact with these structures. \nLingual Nerve\nThe lingual nerve is a branch of the mandibular nerve that is given \noff in the infratemporal fossa. It appears at the inferior border of \nthe inferior head of the lateral pterygoid muscle anterior to the \ninferior alveolar nerve. It passes downward and forward between \nthe ramus of the mandible and the medial pterygoid muscle. \nThe nerve enters the oral cavity above the posterior edge of the \nmylohyoid muscle close to its origin at the third molar region. \nBecause the nerve lies just medial to the retromolar pad, incisions \nin this region should remain lateral to the pad, and the mucosal \nreflection should be done with the periosteal elevator in constant \ncontact with bone to prevent injury to the nerve. The nerve pro-\nceeds on the surface of the hyoglossus muscle and then crosses the \nduct of the submandibular gland medially to enter the floor of \nthe mouth and the tongue. While in the infratemporal fossa, the \nnerve is joined by the chorda tympani nerve, which is a branch of \ncranial nerve VII. The chorda tympani nerve carries taste fibers \nfrom the anterior two-thirds of the tongue and parasympathetic \npreganglionic fibers to the submandibular autonomic ganglion. \nThe ganglion is connected to the lingual nerve on the surface of \nthe hyoglossus muscle. The postganglionic neurons from the sub-\nmandibular ganglion supply the submandibular and sublingual \nsalivary glands. The branches of the lingual nerve in the oral cavity \ncarry sensory information from the lingual mucosa, the mucosa of \nthe floor of the mouth, and the anterior two-thirds of the tongue. \nImproper reflection of a lingual mucoperiosteal flap may injure \nthe lingual nerve and produce ipsilateral paresthesia or anesthesia \nof the innervated mucosa, loss of taste, and reduction of salivary \nsecretion. The extent of involvement depends on the degree of \ninjury to the nerve. \nNerve to the Mylohyoid\nThe mylohyoid motor branch of the inferior dental nerve is given \noff just before the nerve enters the mandibular foramen. This \nbranch descends in a groove on the medial surface of the man-\ndibular ramus and then appears in the submandibular triangle \nat the posterior border of the mylohyoid muscle. The nerve sup-\nplies the mylohyoid muscle and then proceeds on its surface with \nthe submental artery (branch of the facial artery) until it reaches \nthe anterior belly of the digastric muscle, which it also supplies. \nBecause the nerve is so closely related to the ramus of the man-\ndible, surgical intervention in this area may lead to injury of this \nimportant motor nerve."
  },
  {
    "page": 130,
    "content": "338\nPART III     Fundamental Science\nLong Buccal Nerve\nThis nerve is a sensory branch of the mandibular division of the \ntrigeminal nerve and is distributed to the skin and mucous mem-\nbrane of the cheek and the buccal transact opposite the mandibu-\nlar molar region. The nerve courses between the two heads of the \nlateral pterygoid muscle, then precedes medial to, or sometimes \nwithin, the medial temporalis tendon to gain access to the surface \nof the buccinator muscle. The nerve supplies the skin of the cheek \nand runs down to the level of the external oblique ridge, pen-\netrates the buccinator, and spreads its branches under the cheek \nmucosa, alveolar mucosa, and attached gingivae opposite to molar \nteeth. The implantologist who is planning to access the ramus for \nthe purpose of excising a block graft should be aware of the buccal \nnerve and avoid injuring it. In addition, surgical manipulation in \nthis area (e.g., during insertion of a subperiosteal implant) may \ninjure this nerve. \nBlood Supply to the Maxilla and Mandible\nThe head and neck region has an abundant blood supply, with \nmany anastomoses (see Fig. 12.7). The upper and lower jaws are \nno exception. The blood supply to both the mandible and maxilla \nis derived from a common source, the external carotid artery. The \nexternal carotid artery is a branch of the common carotid artery, \nwhich is a direct branch off the arch of the aorta on the left side \nand a branch of the brachiocephalic artery on the right side of the \nbody.\nThe main artery supplying the mandible is the inferior alveolar \n(dental) artery, which serves as the nutrient artery to the bone and \nother tissues within the lower jaw. The bone tissue of the max-\nillae is supplied by branches of two major vessels, the posterior \nsuperior alveolar (dental) artery, and the infraorbital artery. The \nmajor branch of the infraorbital artery that supplies the maxilla is \nthe anterior superior alveolar (dental) artery. The posterior supe-\nrior alveolar and infraorbital arteries are branches of the maxillary \nartery, which is one of the two terminal branches of the external \ncarotid artery.\nGeneral Concepts\nThe circulation of blood within long bones is centrifugal; that is, \nthe blood circulates from the marrow (medullary) region outward \nthrough the cortical bone to end in vessels located in the perios-\nteum and soft tissues associated with the bone.8,9 The blood supply \nto the medullary region is by way of nutrient arteries, which are \nrelatively large vessels that pass through the bone by way of nutri-\nent canals to enter the marrow spaces. Within the marrow spaces, \nthe nutrient artery forms a network of vessels called the endosteal \nor medullary plexus. Vessels from this plexus enter the cortical bone \nthrough Volkmann canals and eventually reach the surface of the \nbone. While blood is passing through the cortical bone, numer-\nous vessels are given off at right angles to these intraosseous ves-\nsels within Volkmann canals. These branches are the vessels that \nare found within the haversian canals of the osteons.8,9 Osteonal \nbone is the major type of bone found in the cortical bone of the \njaws. Once the intraosseous vessels reach the outer surface of the \nbone, they anastomose with vessels within the fibrous layer of the \nperiosteum or with arteries supplying the soft tissues. The network \nof vessels associated with the periosteum is called the periosteal \nplexus. The periosteal plexus in turn communicates with vessels \nthat are supplying arterial blood to muscles and other soft tissues \nin the area.\nThe mandible and maxilla are membrane bones and as such do \nnot develop in the same manner as long bones. Most researchers \nagree that the circulation of blood within the body of the man-\ndible10 and in the maxilla11,12 is centrifugal under normal con-\nditions. As in the long bones, endosteal and periosteal plexuses \nexist that are connected with one another.12,13 In addition to these \nvascular networks, a periodontal plexus is found associated with \nthe teeth.12,13 When teeth are present, intraosseous vessels send \nbranches into the alveolar processes (intraalveolar arteries), to the \nteeth (apical arteries), and to branches of the periodontal plexus. \nThe intraalveolar arteries and periodontal plexus in turn connect \nwith vessels of the periosteal plexus, as well as with vessels within \nthe soft tissues surrounding the bone. Once a tooth is removed, \nits periodontal plexus is lost. When abnormal circulatory condi-\ntions exist within the mandible or maxilla, such as occlusion of \nthe nutrient artery, the blood supply to the bone is reversed so \nthat the direction of flow is from the outside to the inside of the \nbone.10,11,14 This is called centripetal circulation.\nMaxilla\nThe vessels that supply the maxilla are branches of the third part \nof the maxillary artery. The posterior superior alveolar artery leaves \nthe maxillary artery and travels on the infratemporal portion of \nthe maxilla, in which it divides into several branches. Some of the \nbranches enter alveolar canals within the posterior aspect of the \nmaxilla to become intraosseous arteries, which supply the molar \nand premolar teeth and the lining of the maxillary sinus. Other \nbranches of the posterior superior alveolar artery travel on the sur-\nface of the maxilla to supply the transact of the posterior maxillary \nteeth. Injury to this artery within the bone during lateral-approach \nsinus elevation procedures may cause hemorrhage, which requires \ncoagulation or the use of bone wax to control the bone bleeding.\nThe infraorbital artery leaves the maxillary artery and enters \nthe orbital cavity by way of the inferior orbital fissure. The artery \nruns in the infraorbital groove and later in the infraorbital canal. \nBoth of these structures are located in the floor of the orbit. The \ninfraorbital canal opens on the face as the infraorbital foramen. \nWithin the canal the artery gives off the anterior superior alveolar \nartery, which descends through anterior alveolar canals to supply \nthe maxillary anterior teeth and the mucous membrane of the \nmaxillary sinus. The anterior and posterior superior alveolar arter-\nies join together to form an arterial loop. The middle superior \nalveolar artery is rarely a separate branch.15 The infraorbital artery \nalso supplies branches to the maxillary sinus.16\nGingival, buccal, labial, palatal, nasal, and maxillary sinus \nblood vessels anastomose with the arterial networks associated \nwith the maxilla. These vessels not only join with the periosteal \nplexus, but they also penetrate the bone to connect with vessels \nof the endosteal and periodontal plexuses. In addition, abundant \nmidline crossover is possible in the soft tissues of the palate and \nface.13\nThe mucoperiosteum of the anterior maxilla is supplied by \nbranches of the infraorbital artery and the branches of the supe-\nrior labial artery, which is a major branch of the facial artery.13 \nThe buccal mucoperiosteum of the maxilla is supplied by ves-\nsels of the posterior superior alveolar, anterior superior alveolar, \nand buccal arteries. Branches from the greater (anterior) palatine \nand the nasopalatine arteries supply the mucoperiosteum of the \nhard palate. The lesser (posterior) palatine artery supplies the soft \npalate. Communications of the lesser palatine arteries with the \nascending pharyngeal branch of the external carotid artery and the \nascending palatine branch of the facial artery are critical in many"
  },
  {
    "page": 131,
    "content": "339\nCHAPTER 12  Applied Anatomy for Dental Implants\nof the surgical orthognathic procedures that are performed on the \nmaxilla.12 In these surgical procedures, the major nutrient arter-\nies to the maxilla are sometimes severed, but the blood supply is \nmaintained by means of the anastomoses present in the soft palate. \nThe vessels of the soft palate unite with vessels of the hard palate, \nwhich in turn communicate with the periosteal, periodontal, and \nendosteal plexuses of the upper jaw. Thus the vitality of the tissues \nof the maxilla is maintained through an arterial supply derived \nentirely from vessels that normally supply the soft palate. \nMandible\nThe major artery supplying the blood of the mandible is the infe-\nrior alveolar artery. The artery enters the medial aspect of the \nramus of the mandible and courses downward and forward within \nthe mandibular canal to enter the body of the mandible. The \nartery branches in the premolar region to give rise to two terminal \nbranches: the mental and incisive arteries. The incisive artery con-\ntinues medially within the body to anastomose with the artery of \nthe opposite side. This artery is often severed during the harvest \nof a monocortical symphyseal block of bone for grafting resorbed \nridges. Crushing bone around the vessel or using bone wax eas-\nily controls the bleeding. The mental artery exits the body of the \nmandible through the mental foramen and supplies the region of \nthe chin and anastomoses with the submental and inferior labial \narteries. Near its origin the inferior alveolar artery gives off a lin-\ngual branch, which supplies blood to the oral mucosa.16\nStudies in animals have demonstrated that the coronoid pro-\ncess, the condylar process, and the angle of the mandible are sup-\nplied by arteries that provide blood to the muscles that attach to \nthese sites.16 Studies of human cadaver material show that the con-\ndylar process is supplied by the vascular network of the TMJ joint \ncapsule and the lateral pterygoid muscle. In addition, researchers \nfound that vessels from the temporalis muscle supplied the coro-\nnoid process exclusively, and the inferior alveolar artery supplied \nthe angle of the mandible, as well as the muscles attached to the \narea. The same researchers found that the vessels that supply the \npterygomasseteric sling (i.e., the medial pterygoid and masseter \nmuscles) also supply the anterior portion of the ramus.17 Empiri-\ncal findings from mandibular osteotomy procedures in humans \nsupport many of these findings.18 Thus the repositioning of the \ninferior alveolar artery laterally, which is a procedure that may be \nneeded in some cases before implant insertion, should not elimi-\nnate the blood supply to the bone in this region (see the discussion \nthat follows).\nChanges in Blood Supply to the Mandible with Age. \nAlthough the normal circulation within the body of the mandible \nis centrifugal in young individuals, the direction of blood flow \nmay reverse with aging. It has been shown that the inferior alveo-\nlar artery is susceptible to arteriosclerotic changes and tends to \nbecome tortuous and narrow with age.19,20 Blockage of the inferior \nalveolar artery occurs years before any clinical evidence of block-\nage in the carotid vessels is found. Angiographic studies of living \nhuman subjects of all ages demonstrated blockage of the inferior \nalveolar artery in 79% of all individuals studied, and in 33% of \nthe patients arterial flow was absent.20 The incidence of absence of \nflow in the inferior alveolar artery increased with age. The reduc-\ntion or absence in flow within the inferior alveolar artery may be \nassociated with tooth extraction.20 Studies in completely edentu-\nlous humans indicated that the inferior alveolar artery degenerates \nto such an extent as to be negligible in the supply of blood to the \nmandible.19 In these cases the blood supply to the bone and inter-\nnal structures was dependent on the connections with the external \nblood supply located within the periosteum and soft tissues associ-\nated with the mandible.19,20 Major arteries that probably supply \nblood to the mandible after the interruption of the inferior alveo-\nlar artery blood flow include the mental artery,14 the mandibular \nbranch of the sublingual artery,14 the facial artery,10 and muscular \nbranches of the maxillary artery. These anastomoses are critical in \nsurgical procedures in which mucoperiosteal flaps are created in \nthe mandible. The changes in pattern of blood flow to the atrophic \nmandible are of special importance to implant dentistry. Muco-\nperiosteal flap reflection for subperiosteal implant usually exposes \n75% of the body of the mandible and approximately 50% of the \ninferior one-third of the rami. Dehiscence of the mucosa at the \nincision lines has been reported. The reduction in atrophied bone \nblood supply may be a contributing factor. Onlay grafts from \nthe iliac crest to severely atrophied mandibles are also associated \nwith occasional incision line opening postoperatively. Limitation \nof surgical reflection of muscles that attach to the bone improves \nblood supply but may complicate primary closure without ten-\nsion. However, muscle attachments at the basal bone of the man-\ndible, which are not in the way of the graft placement, should \nnot be reflected. In addition, endosteal implants placed in an \natrophied anterior mandible may have less blood supply to the \ninterface and may require longer time for load-bearing bone to \ndevelop. Misch has suggested 5 months of healing in very dense \nbone when found in an atrophied anterior mandible.21 These \nspeculations, of course, require experimental verification. Similar \nblood flow reversal with age has not been reported in the maxilla, \nbut final comment concerning blood flow in the aged edentulous \nmaxilla awaits further investigation.\nImplantologists may encounter neurovascular bundles such \nas the infraorbital, incisal, greater palatine, anterior, middle, and \nposterior superior alveolar nerves in the maxilla (e.g., during \nantral augmentation procedures or mucoperiosteal flap reflection) \nand the mental nerve, inferior dental nerve, and the lingual nerve \nin the mandible (e.g., during placement of root or blade implants \nor reflection of microperiosteal flaps). Stretching, compression, \npartial resection, or total transaction can mechanically injure the \nnerve.\nFactors that affect nerve response to mechanical injury include \nthe following:\n\t1.\t \u0007Size and number of funiculi (nerve bundles) within the nerve \ntrunk.\n\t2.\t \u0007Funicular pattern: The branching within the nerve trunk will \nlead to an increase in density or number of nerve fibers per \ncross section of the nerve. Therefore injury to the nerve at one \nspot may cause damage to more fibers than to the adjacent area \nof the nerve that has less funicular branching.\n\t3.\t \u0007The amount of epineural tissue: The connective tissue that sur-\nrounds the nerve is called the epineurium. The thinner the epi-\nneurium is, the greater the possibility is that partial injury to \nthe nerve could damage the nerve fibers.\n\t4.\t \u0007Position of the nerve fibers in the nerve trunk: The peripheral \nfibers leave the nerve first, whereas the central fibers innervate \nthe most distal tissue. If a patient develops paresthesia of the \nlower lip after surgical placement of implants in the molar \nregion, then it means that the nerve damage went through the \ncenter of the nerve to affect the mental nerve fibers.\n\t5.\t \u0007Physiologic susceptibility: For an unknown reason, the motor \nfibers respond differently when subjected to mechanical defor-\nmation compared with sensory fibers.\nNerve fibers of the peripheral nervous system (PNS) show \ngreater capacity for regeneration than nerves of the central nervous"
  },
  {
    "page": 132,
    "content": "340\nPART III     Fundamental Science\nsystem (CNS). The axons of both myelinated and unmyelinated \nfibers in the PNS are surrounded by Schwann cells, which are \ncovered by basal lamina. They later provide a continuous tube, \neven after the nerve fiber is cut into distal and proximal segments. \nThe proximal segment is still connected to a living nerve cell body, \nwhereas the distal segment gradually degenerates and eventually \ndisappears. This is known as Wallerian degeneration. The Schwann \ncells of the distal segment proliferate and form a cell strand known \nas a Schwann cell column or band of Büngner within the basal lam-\nina tube.22 The Schwann cells also become phagocytic, and along \nwith macrophages they clean the distal segment from degenerating \naxons. Sprouting of new axons takes place approximately 4 weeks \nafter injury, and it takes 5 weeks for a sizeable number of axons to \noccupy the distal segment. The excess sprouts degenerate, and one \nfiber finds its way into the distal segments. If regenerating axons \nevade the Schwann cell column and enter the connective tissue, \nthen they cease to grow after elongation of a few millimeters. The \nSchwann cells and the basal lamina are indispensable for axonal \nregeneration because they retain growth factors. The Schwann \ncells also provide new myelin for the regenerating fibers, although \nthe conduction property is less efficient and the functional recov-\nery may never be complete. The sprouting stage may cause pain \nto the patient, and the area may be sensitive to touch. The rate of \nrecovery will depend on the type of injury (e.g., a crushed nerve \nregenerates faster than a severed nerve).\nReferences\n\t 1.\t \u0007Sharawy M. Companion of Applied Anatomy. 4th ed. Augusta, Ga: \nMedical College of Georgia Printing Service; 1999.\n\t 2.\t \u0007Hickey JC, Zarb GA, Bolender CL. Boucher’s Prosthetic Treatment \nfor Edentulous Patients. 9th ed. St Louis: Mosby; 1982.\n\t 3.\t \u0007Atwood DA, Coy WA. Clinical cephalometric and densitometric \nstudy of reduction of residual ridges. J Prosthet Dent. 1977;26:280–\n299.\n\t 4.\t \u0007DuBrul EL. Sicher’s Oral Anatomy. St Louis: Mosby; 1982.\n\t 5.\t \u0007Atwood DA. Some clinical factors related to rate of resorption of \nresidual ridges. J Prosthet Dent. 1962;12:441–450.\n\t 6.\t \u0007Atwood DA. Reduction of residual ridges: a major oral disease entity. \nJ Prosthet Dent. 1971;29:266–279.\n\t 7.\t \u0007Bays RA. The pathophysiology and anatomy of edentulous bone \nloss. In: Fonseca RJ, Davis WH, eds. Reconstructive Pre-Prosthetic \nOral and Maxillofacial Surgery. Philadelphia: WB Saunders; 1986.\n\t 8.\t \u0007Brookes M. The Blood Supply of Bone. London: Butterworths; 1971.\n\t 9.\t \u0007Rhinelander FW. Circulation of bone. In: Bourne GH, ed. The \nBiochemistry and Physiology of Bone. New York: Academic Press; \n1972:10.\n\t10.\t \u0007Hellem S, Ostrup LT. Normal and retrograde blood supply to \nthe body of the mandible in the dog. II. The role played by peri-\nosteo-medullary and symphyseal anastomoses. Int J Oral Surg. \n1981;10:31–42.\n\t11.\t \u0007Bell WH, Levy BM. Revascularization and bone healing after ante-\nrior mandibular osteotomy. J Oral Surg. 1970;28:196–203.\n\t12.\t \u0007Bell WH. Biologic basis for maxillary osteotomies. Am J Phys \nAnthropol. 1973;38:279–290.\n\t13.\t \u0007Bell WH. Revascularization and bone healing after anterior maxil-\nlary osteotomy: a study using adult rhesus monkeys. J Oral Surg. \n1969;27:249–255.\n\t14.\t \u0007Castelli WA, Nasjleti CE, Diaz-Perez R. Interruption of the arterial \ninferior alveolar flow and its effects on mandibular collateral circula-\ntion and dental tissues. J Dent Res. 1975;54:708–715.\n\t15.\t \u0007Perint J. Surgical anatomy and physiology: detailed roentgenologic \nexamination of the blood supply in the jaws and teeth by applying \nradiopaque solutions. J Oral Surg. 1949;2:2–20.\n\t16.\t \u0007Williams PL, Warwick R. Gray’s Anatomy. 36th ed. Philadelphia: \nWB Saunders; 1980.\n\t17.\t \u0007Castelli W. Vascular architecture of the human adult mandible. J \nDent Res. 1963;42:786–792.\n\t18.\t \u0007Bell WH. Biologic basis for modification of the sagittal ramus split \noperation. J Oral Surg. 1977;35:362–369.\n\t19.\t \u0007Bradley JC. Age changes in the vascular supply of the mandible. Br \nDent J. 1972;132:142–144.\n\t20.\t \u0007Bradley JC. A radiological investigation into the age changes of the \ninferior dental artery. Br J Oral Surg. 1975;13:82–90.\n\t21.\t \u0007Misch CE. Density of bone, its effect on treatment planning, sur-\ngery, healing, and progressive bone loading. Int J Oral Implantol. \n1990;6:23–31.\n\t22.\t \u0007Ide C. Peripheral nerve regeneration. Neurosci Res. 1996;25:101–\n121."
  },
  {
    "page": 133,
    "content": "341\n13\nDental Implant Infections\nJOSEPH E. CILLO, JR.\nIntroduction\nDental implants are a contemporary solution to tooth loss and \noral reconstruction with a known high success rate of osseointe-\ngration. It is estimated that between 100,000 and 300,000 dental \nimplants are placed per year.1 Although the success rate is high, \ndental implant infections may occur that lead to lack or loss of \nosseointegration and may result in subsequent implant failure. \nThese failures may be divided into either early or late based on the \ntime of their occurrence during a dental implant’s life span. Early \ndental implant failure occurs before osseointegration and pros-\nthetic loading, whereas late failures occur after loading and may \noccur years to decades later. Early dental implant failure may be \nattributed to bacterial contamination, such as pellicle or biofilm \nformation, and inflammation that prevents or prolongs osseointe-\ngration. Similarly, long-term survival of dental implants depends, \nin part, on control of bacterial infection in the peri-implant region. \nPeri-implant disease may contribute to increased bone loss and \neventual dental implant failure. The capability to diminish the \npotential early deleterious effects of bacterial contamination dur-\ning both the surgical and prosthetic aspects of dental implant ther-\napy and later effects of bacterial involvement in the peri-implant \ntissues begins with the understanding of the microenvironment \nand its denizens. This understanding of the oral microenviron-\nment and its influence on dental implant surgery and prosthetics \nmay allow for strategies to decrease the occurrence and spread of \ndental implant infections. \nOverview of Oral, Head, and Neck Infection \nand Spread\nDental implants are uniquely engineered biomaterials ubiquitously \nused to replace teeth for restoration of oral function. The most \ncommon form of dental implant is the screw-type, or endosseous, \nimplant comprised of a single implant unit that is inserted within \na dentoalveolar or basal bone osteotomy. An implant’s presence in \nthe bacteria-laden milieu of the oral cavity would indicate the high \nlikelihood of an increase in infection risk. However, the failure rate \nbecause of infection for dental implants (0.0%–1.1%) placed in \nthis contaminated environment is similar to that of orthopedic \njoint arthroplasties performed in a near-sterile environment (0.1%–\n1.3%).2 Conversely, orthopedic device placement that breaches the \nimmune barrier of the epidermis and exposes the underlying sterile \ntissue to an unsterile external environment results in much higher \ninfection-associated failure rates of up to 23.0%.2\nThe success of dental implant resistance to infection-associated \nfailure may be caused by the ability of oral tissues to heal rapidly in \nthe continuous presence of commensal bacteria and opportunis-\ntic pathogens, and the tolerance of the oral immune system. The \nmain cause of infection-associated dental implant failure is when \nlocal tissue is unable to adhere, spread, and heal in the presence \nof microbial contaminants and an intolerant immune system. The \nrole of saliva in the development of dental implant infection is \ncomplicated. Saliva has been shown to have antimicrobial3,4 and \nantifungal5 properties that may be a contributing factor to infec-\ntion prevention. However, saliva is responsible for pellicle forma-\ntion to which viable bacteria may adhere and mature to hinder \nhealing and yield infection.\nSigns and Symptoms of Oral Infection\nThe signs and symptoms of surgical site infections (SSI) have \nremained consistent and are generally similar throughout the \nhuman body. Diagnosis is based on the clinical signs of infection \nsuch as hyperplastic soft tissues, suppuration, color changes of the \nmarginal peri-implant tissues, and gradual bone loss. The four fun-\ndamental signs of infection are pain or tenderness (dolor), local-\nized swelling (tumor), redness (rubor), and heat or fever (>38°C) \n(calor) are the hallmark signs of infection.6 This may or may not \nbe associated with purulent drainage (pus) or fistula formation.\nThe occurrence of hematologic bacterial seeding with dental \nimplant surgery is common and may occur as soon as 30 min-\nutes after placement. Hematologic spread of oral microorganisms \ncaused by this transient bacteremia may result in bacterial coloni-\nzation in extraoral sites and is a proposed mechanism for systemic \ninjury by free toxins and systemic inflammation caused by soluble \nantigens of oral pathogens. Some of the numerous species involved \ninclude Staphylococcus epidermidis, Eubacterium spp., Corynebac­\nterium spp., and Streptococcus viridans, Fusobacterium nucleatum, \nPorphyromonas gingivalis, S. mutans, and Campylobacter rectus.7,8 \nSystemic hematologic spread of oral commensals and pathogens to \ndistant body sites may cause extraoral infections and inflammation, \nleading to cardiovascular disease, such as infective endocarditis with \nearly colonizers S. gordonii, S. sanguinis, and S. oligofermentans,9-11 \nadverse pregnancy outcomes, rheumatoid arthritis, inflammatory \nbowel disease, and colorectal cancer (direct and specific carcino-\ngenesis of colonic adenomas from F. nucleatum induces tumor \ngrowth,12 respiratory tract infections, organ inflammation, and \nabscesses by virulent oral species). Development of dangerous and \nlife-threatening conditions, such as Ludwig angina, airway com-\npromise, or carotid cavernous sinus fistula may also occur.13"
  },
  {
    "page": 134,
    "content": "342\nPART III    Fundamental Science\nSpread of Head and Neck Infection\nRegardless of their pathogenic potentials in the oral cavity, once \ncolonized in the extraoral sites, oral bacteria often become bona \nfide pathogens, especially in immunocompromised individuals, \ncausing disease manifestation (Figs. 13.1–13.4).7 Spread of infec-\ntion from a dental implant, or any oral source, will travel through \nthe path of least resistance, which is generally fascial spaces. Fas-\ncial spaces are potential spaces that exist without the presence of \npathology or infection and lay between loose fibrous connective \ntissue fasciae and underlying organs and other tissues. The loose \nfibrous connective tissue that makes up the fascia of the head and \nneck is found in varying degrees of density with a tensile strength \nsomewhat less than dense fibrous connective tissue located else-\nwhere in the body. In the head and neck, fascia may be divided \ninto the superficial and deep layers with 16 fascial spaces divided \ninto four subtypes. These four subtypes are the fascial spaces of the \nface, suprahyoid fascial spaces, infrahyoid fascial spaces, and the \nfascial spaces of the neck.\nThe superficial fascia of the head and neck lies just under the \nskin (as it does in the entire body), invests the superficially situ-\nated mimetic muscles (platysma, orbicularis oculi, and zygomati-\ncus major and minor), and, located in distinct anatomic areas, \nis composed of two layers, an outer fatty layer and a thin inner \nmembrane.14 The deep fascia is absent in the face and scalp and \nbegins at the anterior border of the masseter muscle and invests \nthe muscles of mastication\nThe fascial spaces of the face are subdivided into five spaces: \ncanine, buccal, masticatory (further divided into the masseteric, \npterygomandibular, and temporal spaces), parotid, and infratem-\nporal. The canine space is located between the levator anguli oris \nand the levator labii superioris muscles. Infection may spread to \nthis space from dental abscess or dental implant–related proce-\ndures performed in the anterior maxillary region. Direct surgi-\ncal access is achieved by incision through the maxillary vestibular \nmucosa above the mucogingival junction. The buccal space is \nbounded anterior to the masticator space and lateral to the bucci-\nnator muscle with no true superior or inferior boundary and con-\nsists of adipose tissue (the buccal fat pad that fills the greater part of \nthe space), Stensen duct, the facial artery and vein, lymphatic ves-\nsels, minor salivary glands, and branches of cranial nerves VII and \nIX.15 The buccal space frequently communicates posteriorly with \nthe masticator space where it joins the buccopharyngeal fascia.16 \nWhen infection is involved in the buccal space, the buccal space \ncan serve as a conduit for spreading disease between the mouth \nand the parotid gland. The lack of fascial compartmentalization in \nthe superior, inferior, and posterior directions permits the spread \nof pathology both to and from the buccal space.17 Surgical access \nto the buccal space infections may be easily accomplished through \nthe intraoral approach. However, more complicated infections, \ndirected by location within the buccal space and suspicion of \nmalignancy, may require a preauricular and/or submandibular \napproach. The masticator space is a well-defined fibrous tissue \nthat surrounds the muscles of mastication and contains the inter-\nnal maxillary artery and the inferior alveolar nerve. Most masse-\nteric space infections result from spread in the mandibular molar \nregion,18 with trismus being the most pronounced clinical feature, \nand often precludes intraoral examination. Computed tomogra-\nphy (CT) and/or magnetic resonance imaging (MRI) may be an \ninvaluable resource in the assessment of masseteric space infec-\ntions because they can often influence the surgical approach and \ndistinguish abscess from cellulitis.18 Abscess formation in this area \nis easily reached by intraoral surgical access for simple, isolated \nabscesses for incision and drainage, but with extension into adja-\ncent spaces, an external approach may be required. The pterygo-\nmandibular space is bounded by the mandible laterally and by \nthe medial pterygoid muscle medially and inferiorly. The posterior \nborder is formed by parotid glandular tissue, which curves medi-\nally around the posterior mandibular ramus and anteriorly by the \npterygomandibular raphe, the fibrous junction of the buccinator, \nand superior constrictor muscles. Other structures in this space are \nimportant in the administration of local anesthesia, including the \ninferior alveolar vessels, the sphenomandibular ligament, and the \ninterpterygoid fascia.19 Surgical access to this space for incision \nand drainage may be achieved intraoral in the case of simple infec-\ntions, but it may require extraoral access when multiple adjacent \nspaces are involved.20 The temporal fascia surrounds the tempo-\nralis muscle in a strong fibrous sheet that is divided into clearly \ndistinguishable superficial and deep layers that originate from the \nsame region, with the muscle fibers of the two layers intermingled \nin the superior part of the muscle.21\nThe sublingual space is bounded between the mylohyoid \nmuscle and the geniohyoid and genioglossus muscles. This space \ncontains the lingual artery and nerve, the hypoglossal nerve, the \nglossopharyngeal nerve, Wharton duct, and the sublingual sali-\nvary gland, which drains into the oral cavity through several small \nA\nB\n• Fig. 13.1  (A) Extraoral and intraoral edema and fluctuance involving the floor of mouth and (B) submental \nand submandibular spaces from dental implant infection."
  },
  {
    "page": 135,
    "content": "343\nCHAPTER 13  Dental Implant Infections\nA\nB\nC\n• Fig. 13.2  (A–C) Coronal, sagittal, and axial computed tomography scan of submandibular/sublingual and \nsubmental spaces of dental implant infection.\nA\nB\n• Fig. 13.3  Intraoperative images of (A) extraoral incision and (B) drainage of submental and submandibular \nspace abscess."
  },
  {
    "page": 136,
    "content": "344\nPART III    Fundamental Science\nexcretory ducts in the floor of the mouth and a major duct known \nas the Bartholin duct. The submental space is bounded anteriorly \nby the symphysis of the mandible, laterally by the anterior bel-\nlies of digastric muscles, superiorly by the mylohyoid muscle, and \ninferiorly by the superficial fascia of the platysma muscle. There \nare no vital structures that traverse the submental space. This space \nis usually involved in odontogenic infections from the anterior \nmandibular teeth with surgical access for drainage of infection \ngenerally through an extraoral incision below the chin.22 The sub-\nmandibular space extends from the hyoid bone to the mucosa of \nthe floor of the mouth and is bound anteriorly and laterally by the \nmandible and inferiorly by the superficial layer of the deep cervical \nfascia. The mylohyoid muscle separates it superiorly from the sub-\nlingual space, which communicates with it freely around the pos-\nterior border of the mylohyoid. Most oral infections that perforate \nthe lingual mandible above the mylohyoid line will involve the \nsublingual space. When infection has spread to the bilateral sub-\nmandibular, sublingual, and submental spaces, it represents Lud-\nwig angina, a potentially life-threatening condition that requires \nimmediate surgical drainage and intravenous antibiotic therapy.\nThe lateral pharyngeal space (also called the parapharyngeal \nspace) is an inverted cone with its base at the base of skull and \napex at the hyoid bone and is bounded posteriorly by the preverte-\nbral fascia, anteriorly by the raphe of the buccinator and superior \nconstrictors muscles, and laterally by the mandible and parotid \nfascia. The lateral pharyngeal space can be divided into anterior \n(prestyloid) and posterior (retrostyloid) compartments by the sty-\nloid process. The anterior compartment contains only fat, lymph \nnodes, and muscle, whereas the posterior compartment contains \nthe carotid artery, the internal jugular vein, and cranial nerves IX \nthrough XII. Infections in the anterior space may present with \npain, fever, and neck swelling below the angle of the mandible and \ntrismus. Rotation of the neck away from the side of the swelling \ncauses severe pain from tension on the ipsilateral sternocleidomas-\ntoid muscle. Because this space communicates with the other fascia \nspaces, spread of infection may also arise from numerous sources, \nincluding the tonsils, parotid, and submandibular, peritonsil-\nlar, masticator, or retropharyngeal spaces. Airway impingement \ncaused by medial bulging of the pharyngeal wall and supraglottic \nedema may occasionally occur, which may require the procure-\nment of a stable airway by either tracheotomy or intubation.23 The \ntreatment of lateral pharyngeal space infections requires surgical \ndrainage through either a transoral or extraoral approach.24 \nFascial Spaces of the Neck\nThe fascial spaces of the neck all lie between the deep cervical \nfascia surrounding the pharynx anteriorly and the spine posteri-\norly. The retrovisceral space is divided into the retropharyngeal \nand danger spaces by the alar fascia and serves as the main route \nfor oropharyngeal infections to descend into the mediastinum. \nThe other fascial spaces of the neck include the prevertebral and \ncarotid sheath spaces.\nThe retropharyngeal space is bounded anteriorly by the con-\nstrictor muscles and posteriorly by the alar layer of the deep cervi-\ncal fascia and connects posteriorly to the danger space. Infections \nin this space may present with symptoms of fever, stiff neck, drool-\ning, dysphagia, and bulging of the posterior pharyngeal wall. They \nmay be complicated by the development of supraglottic edema \nwith airway obstruction, aspiration pneumonia caused by rupture \nof the abscess, and acute mediastinitis that may lead to empy-\nema or pericardial effusions. Proximity to the danger space may \nallow infection to spread to the mediastinum to the level of the \ndiaphragm and possibly posteriorly to the prevertebral space. Sur-\ngical drainage should be performed in the operating room via a \ntransoral approach with the head down to prevent rupture during \nintubation and septic aspiration.\nThe danger space is bounded superiorly by the skull base, ante-\nriorly by the alar fascia, and posteriorly by the prevertebral fascia, \nending at the level of the diaphragm. Danger space infections may \ntrack from the anteriorly located retropharyngeal space between \nthe buccopharyngeal fascia and alar fascia and pass inferiorly to \nthe mediastinum and the pericardium and may result in condi-\ntions such as purulent pericarditis.25 \nMicrobiology of Dental Implant Infection\nThe oral cavity is awash in a milieu of different microbial spe-\ncies and colonies. More than 19,000 types of eukaryotic and \nprokaryotic bacteria, fungal, protozoan, and viral species coexist \nin the oral microenvironment.26-28 This diverse microbiome con-\nsists of beneficial, pathologic, and opportunistic organisms, and \nwhen in balance may produce a benign or even beneficial result \nto the individual. When development of dysbiotic polymicrobial \ncommunities ensue with a misrepresentation between normally \ndominating species and normally outcompeted or contained spe-\ncies, more deleterious microbial species may increase in number \nto fill the void. Longitudinal studies have shown that successful \nimplants are colonized by a predominantly gram-positive, faculta-\ntive flora, which is established shortly after implantation, with no \nchange in composition in patients with clinically stable implants \nover 5 years.29 The transition from a gram-positive, facultative \nflora in health to a gram-negative, anaerobic flora in disease is the \nhallmark of impending dental implant infection and failure. In \npatients with bone loss and pocket formation around implants, \nsignificantly different flora develops consisting of gram-negative \nanaerobic bacteria, particularly fusobacteria, spirochetes, and \nblack-pigmenting organisms such as high proportions of Prevotella \n• Fig. 13.4  Postoperative recovery from extraoral incision and drainage of \ndental infection."
  },
  {
    "page": 137,
    "content": "345\nCHAPTER 13  Dental Implant Infections\nintermedia. Although there may be nonmicrobial primary causes \nfor implant failure, gram-negative anaerobes play a role in peri-\nimplant infections, and their elimination may lead to improve-\nment of the clinical condition. The introduction and growth of \ndeleterious microorganisms may also occur within the implant \nand on the prosthesis because the dental implant/abutment inter-\nface cannot totally seal the passage of microorganisms. Therefore \nthe implant interior may become a reservoir of pathogenic micro-\norganisms that produce and maintain chronic inflammation in \nthe tissues around implants.\nThe numerically predominant species in the oral microbiota \nis the streptococci species. Most of the oral streptococci are com-\nmensal, nonperiodontopathogenic bacteria, but some are known \nto cause local and distant disease. Oral streptococci are divided \ninto five different groups: (1) Mutans group (prominent members \nare S. mutans and S. sobrinus), (2) Salivarius group (S. salivarius), \n(3) Anginosus group (S. anginosus and S. intermedius), (4) Sangui-\nnis group (S. sanguinis and S. gordonii), and (5) Mitis group (S. \nmitis and S. oralis).30-32 These oral streptococci species are known \nto be the early colonizers for oral biofilm formation and heavily \ninfluence the development of further infection and biofilm forma-\ntion. As an early colonizer, oral streptococci have been found to \nhave metabolic interactions between other members of the oral \nbiofilm, which may develop either a corporative or disobliging \nrelationship. Symbiotic relationships exist between oral strepto-\ncocci and the genus Veillonella, V. atypica, and V. parvula most \nprominently33,34; Actinomyces naeslundii35,36; F. nucleatum37; and \nthe periodontal pathogen Aggregatibacter actinomycetemcomitans.38 \nThese symbiotic relationships include such events as coaggrega-\ntion between S. cristatus and F. nucleatum and lactic acid–based \ncross-feeding between S. gordonii and the late colonizer and peri-\nodontal pathogen A. actinomycetemcomitans.\nAnaerobic bacteria genera in the oral cavity include Actinomy­\nces, Arachnia, Bacteroides, Bifidobacterium, Eubacterium, Fusobac­\nterium, Lactobacillus, Leptotrichia, Peptococcus, Peptostreptococcus, \nPropionibacterium, Selenomonas, Treponema, and Veillonella. In \nadults, anaerobes are always present with greatest proportions \nfound in the gingival sulcus rather than in the gingival margin, \ntooth surfaces, buccal mucosa, tongue, or saliva.39 Proportions \nof anaerobic bacteria from the healthy gingival sulcus consist of \ngram-positive bacilli (5%–14%), gram-negative bacilli (13%–\n29%), Veillonella (2%–8%), and gram-positive cocci (1%–15%) \nof the cultivable flora.39 Marginal plaque and tooth surface plaque \nconsist mainly of gram-positive bacilli and gram-positive cocci, \nwhereas Veillonella is the most numerous anaerobe in saliva.\nSpirochetes are distinctive double-membrane bacteria that \ngenerally have characteristic helically coiled or spiraled cells and \nare known to be an abundant phylum in periodontitis.40 Trepo­\nnema denticola, a gram-negative, obligate anaerobic, motile, and \nhighly proteolytic bacterium, is the most common spirochete in \nboth periodontitis and peri-implantitis. Once spirochetes have \ndeveloped in the dental implant site, they are responsible for bone \nloss and may be extremely difficult to eradicate. Spirochetes have \ndeveloped a defense mechanism against antibiotic administration \nby transformation into spherical dense granular bodies, which \nmake them highly resistant to antibiotics.41 This phenomenon is \nseen with serial infections treated by multiple rounds of oral anti-\nbiotics that seem to resolve and then recur repeatedly.\nGenera of fungi frequently found in the mouth include Can­\ndida, Cladosporium, Aspergillus, Fusarium, Glomus, Alternaria, \nPenicillium, and Cryptococcus.42 Interactions between the myco-\nbiome and the bacterial microbiome may play a role in health \nand disease. In some cases, the occurrence of bacteria correlates \npositively with the presence of fungi, such as when Mycobacterium \nsuperinfection occurs occasionally with aspergillosis43 or when \nbacteria compete with fungi, such as when the growth of Candida \nspecies and possibly other fungi is suppressed when Pseudomo­\nnas aeruginosa dominates.44 These microorganisms are known to \ncolonize dental implants, dental implant prostheses surfaces, and \ninternal components that may lead to peri-implant mucositis and \nperi-implantitis.45,46\nArchaea are prokaryotic organisms (which means they do not \npossess nuclei) that have been isolated in the oral cavity as a source \nof disease. The presence or increase in level of methanogenic \nArchaea alters the composition of the polymicrobial community, \nresulting in changes in virulence and composition of microflora at \ndiseased sites. Antagonistic interactions of methanogenic Archaea \nand treponemes,47 and Synergistes spp. have been suggested to \nbe possible syntrophic partners of the methanogens.48 Methano­\nbrevibacter oralis is a species of coccobacillary, nonmotile, gram-\npositive, methane-producing archaeon considered to be the major \nmethanogenic archaea found in the oral cavity and associated \nwith severe periodontitis.49 It has a high prevalence in subgingival \nplaque of chronic periodontitis patients while being undetectable \nin healthy subjects.50 An increase in the inoculum of methano-\ngenic Archaea and sulfate-reducing bacteria have been reported \nto be associated with the severity of periodontitis51,52 and has a \nsignificant increased prevalence in peri-implantitis sites.53 Metha­\nnobacterium congelense/curvum is also an archaeon that is found in \nperi-implantitis sites but at a significantly lower volume.\nPeriodontal pathogens such as Porphyromonas gingivalis, Tan­\nnerella forsythia, Prevotella intermedia, and Capnocytophaga ochra­\ncea have been shown clustered together in peri-mucositis sites, \nsuggesting that periodontal pathogens may play important roles \nin the pathogenesis of peri-implant diseases. Progression to peri-\nimplantitis reveals a relative abundance of Eubacterium minutum, \nPrevotella intermedia, and Propionibacterium acnes in peri-­\nimplantitis.54,55 Various microorganisms have been identified as \npossible pathogenic determinants in the multispecies infection of \nperi-implantitis. Some, such as Enterococcus faecalis, are persistent \nand may vegetate in bone after tooth extraction and colonize a \ndental implant after placement in the healed site that may cause \nfixture loss, marginal bone loss, or progression to osteomyelitis.56\nRecent evidence has suggested that the peri-implant crevice may \nbe immunologically, histologically, and microbiologically distinct \nfrom the subgingival sulcus.57-59 Certain periodontal pathogens \n(such as P. gingivalis and T. denticola) may be shared between \ntooth and implants in certain individuals.60-64 However, most of \nthe flora, especially the abundant species, remain distinct between \nthe two ecosystems, which may indicate that proximity is not suf-\nficient to fully determine the local environmental microbiology. \nThe diverse anatomy of the oral cavity has allowed unique micro-\nenvironments that shape the evolution of a diverse bacterial flora. \nThe buccal epithelium, subgingival crevice, maxillary anterior ves-\ntibule, tongue, soft and hard palate, tonsils, and the tooth surface \nare all colonized by different combinations of bacterial species or \nphylotypes.27 As such, the periodontal microbiome tends to be \nmore diverse than the peri-implant microbiome, particularly in \nhealth. The disease process appears to shape the microbial popula-\ntions through increased diversity in the diseased microenviron-\nments in both periodontal and peri-implant healthy and diseased \nindividuals.58 Not all species present in the subgingival sulcus are \ncapable of surviving and thriving in the peri-implant sulcus, and \nevidence to support that bacteria can translocate from diseased"
  },
  {
    "page": 138,
    "content": "346\nPART III    Fundamental Science\nteeth to healthy teeth and do not necessarily colonize the niche65 \nand the architecture, surface energy, and surface characteristics of \nabiotic structures such as dental implants dictates the composition \nof the ecosystem around them.66,67 \nCauses and Risks of Dental Implant Infection\nInfection is one of the most important causes of early dental \nimplant failure and may be an indication of a much more critical \nresult than if the same complications occur later because of distur-\nbance of the primary bone healing process. Several authors have \ndefined the criteria for implant failure and postoperative infec-\ntion. Esposito and colleagues68,69 defined dental implant failure \nand infection as implant mobility measured manually and/or any \ninfection directing implant removal with any biologic complica-\ntions such as wound dehiscence, suppuration, fistula, abscess, and \nosteomyelitis. Similarly, Abu-Ta’a and colleagues70 defined dental \nimplant failures caused by infection as the presence of signs of \ninfection and/or radiographic peri-implant radiolucencies that \ncould not respond to antibiotics and/or judged a failure after per-\nforming explorative flap surgery by an experienced surgeon. Qui-\nrynen and colleagues classified dental implant infection failures \ninto one of four groups: infection before the implant placement, \nperisurgical infection, severe postsurgical infection, and peri-\nimplant disease.71 \nInfection Before the Implant Placement\nActive Infection Site\nImmediate dental implant placement and function after tooth \nextraction has become a widely accepted practice in contempo-\nrary dental implantology (Fig. 13.5).72 Whether completed with \nor without immediate function, comparative clinical studies have \nfound that implant survival rates (SRs) after immediate dental \nimplant placement are similar to rates seen with delayed dental \nimplant placement. Immediate dental implant placement has \nseveral advantages, such as reduction in the number of surgical \ntreatments, reduction of the time between tooth extraction, and \nplacement of a definitive prosthesis and maintenance of alveolar \nridge dimensions. However, there are certain situations that may \nendanger the success of the immediate dental implant placement, \nincluding periodontal disease or periapical lesions. Active infec-\ntion in a fresh extraction site may be considered a harbinger for \nimmediate dental implant placement failure. Placement of a den-\ntal implant in the presence of an active infection has tradition-\nally been considered a contraindication because of the possibility \nof septic embolism that may cause immediate or late postsurgi-\ncal infection, such as osteomyelitis or peri-implant abscess, and \nmay increase the risk of implant nonintegration. This remains a \ncontroversial subject in dental implantology because of a lack of \nhigh-level prospective research to substantiate these claims73 and a \nbody of literature that consists mainly of retrospective case reports \nand series.74\nClinical case series have shown favorable results in immediate \ndental implant placement into chronically infected sites.75-83 High \nimplant SRs have been reported even when implants were placed \nimmediately in infected extraction sockets and provisionalized \nwithin 36 hours. Early or immediate loading of dental implants \nplaced into periodontally or endodontically infected sites pro-\nduced no statistically significant difference in failure rates between \nchronically infected or noninfected sites.82 In immediately placed \nand loaded dental implants into chronically infected sites in the \nesthetic zone of the anterior maxilla, Anitua and colleagues75 \nfound no failures and a success rate of 93%, leading them to con-\nclude that immediate loading of implants inserted into fresh and \ninfected extraction sockets is not a risk factor for implant sur-\nvival. Systematic reviews of the literature reveal a high SR and \nsupport the hypothesis that implants may be successfully osseo-\nintegrated when placed immediately after extraction of teeth that \npresent with endodontic76,81 or periodontal lesions.77 This was \ncontingent on appropriate clinical decontamination procedures \nbeing performed before dental implant placement, such as metic-\nulous cleaning, socket curettage/debridement, and chlorhexidine \n(0.12%) rinse/irrigation.78,80,83 Nonocclusal loading on implants \nplaced in cleaned periodontically or endodontically infected \nA\nB\nC\n• Fig. 13.5  Periapical radiographs of (A) nonrestorable tooth #9 with periapical radiolucency, (B) extraction \nof tooth #9 with immediate implant placement, and (C) 1-year postprosthesis loading."
  },
  {
    "page": 139,
    "content": "347\nCHAPTER 13  Dental Implant Infections\nextraction sites has shown complete initial primary stability \n(100%) and a 98.7% success rate on postoperative reverse torque \ntesting of osseointegration at 3 and 4 months.84 Similarly, Bell \nand colleagues79 found high, comparable, and statistically insig-\nnificant success rates, defined as successful osseointegration and \nrestoration, and absence of evidence of bone loss or peri-implantitis \nat last follow-up, between implants placed in fresh extraction \nsockets with chronic periapical pathology (97.5%) and healed \nsites (98.7%). A statistically significant higher failure rate is seen \nfor dental implants placed adjacent to retained teeth with periapi-\ncal pathology. Placement of dental implants in sockets affected by \nchronic periapical pathology can be considered a safe and viable \ntreatment option, but placement adjacent to teeth with periapical \nradiolucencies carries a high risk of failure.\nA metaanalysis of dental implant failure and marginal bone \nloss after immediate placement into infected versus noninfected \nsites found that immediate placement into an infected site showed \n116% increase in the risk of implant failure, with no statisti-\ncally significant difference in marginal bone loss.85 However, the \nreviews and analyses used have been found to be of low or mod-\nerate methodological quality86 and with the presence of uncon-\ntrolled confounders, respectively, and should also be interpreted \nwith caution.85 It would be recommended that sound clinical \njudgment be used in determining whether immediate dental \nimplant placement into an actively infected site is prudent, despite \ndecontamination procedures, and whether a delayed protocol \nuntil proper site healing has been achieved should be followed. \nPeriodontal Disease\nPeriodontal disease is a chronic infectious and inflammatory \nresponse to pathologic changes in periodontium to an anaerobic \nmicroenvironment. These changes generally result in an imbal-\nance and aggregation of deleterious microorganisms that may lead \nto the development of peri-mucositis, peri-implantitis, and bone \nloss. Comparisons of clinical, microbiologic, and host response \ncharacteristics between healthy dental implants and healthy teeth \nand between infected implants and periodontally diseased teeth \nhave been found to be similar, respectively, with subjects at risk for \nperiodontal disease also at risk for peri-implantitis.87 The bacteria \nassociated with periodontal diseases are predominantly gram-neg-\native anaerobic bacteria and may include A. actinomycetemcomi­\ntans, P. gingivalis, P. intermedia, B. forsythus, C. rectus, E. nodatum, \nP. micros, S. intermedius, and Treponema sp., with bacterial num-\nbers associated with disease up to 100,000 times larger than those \nassociated with healthy teeth. The frequency of four periodonto-\npathogenic bacteria in tooth sulci (A. actinomycetemcomitans, P. \ngingivalis, T. forsythia, and T denticola) are significantly higher \naround natural teeth with deeper periodontal pockets but not \nin peri-implant sulci in partially edentulous subgroups or in the \nperi-implant sulci or the alveolar gingiva of completely edentu-\nlous patients. Cytokine and interleukin creation from periodontal \npathogens stimulate the production of inflammatory mediators \nsecreted in peri-implant sulcus fluid, leading to peri-implant tissue \ndestruction.88\nA systematic review of implant failure rates, postoperative \ninfection, and marginal bone loss from dental implant placement \nin periodontally compromised patients compared with periodon-\ntally healthy patients found some evidence that patients treated for \nperiodontitis may experience more implant loss and complications \naround implants, including higher bone loss and peri-implantitis, \nthan patients without periodontitis.89 Similarly, individuals with \nboth aggressive or chronic periodontal disease have a greater sig-\nnificant risk for implant loss, peri-implant bone loss, and peri-\nimplantitis compared with patients without periodontal disease. \nThe risk is greater for patients with aggressive periodontitis com-\npared with patients with chronic periodontitis.90\nThere are different types of periodontal disease, including gin-\ngivitis, which is the mildest form, and aggressive periodontitis, \nwhich is a form of periodontitis that occurs in patients who are \notherwise clinically healthy and may include rapid attachment \nloss, bone destruction, and familial aggregation. Another type is \nchronic periodontitis, which results in inflammation within the \nsupporting tissues of the teeth, progressive attachment and bone \nloss, and is characterized by pocket formation and/or gingival \nrecession (Fig. 13.6). Necrotizing periodontal diseases are another \ntype and are characterized by necrosis of gingival tissues, peri-\nodontal ligament, and alveolar bone. General and local periodon-\ntitis have been implicated as “microbial reservoirs” in the etiology \nof peri-implant diseases.\nGingivitis is a reversible inflammatory process in the soft tissue \nsurrounding teeth. When this phenomenon surrounds an osseoin-\ntegrated dental implant without the loss of marginal bone beyond \nnormal resorption it is known as peri-implant mucositis. Gingivitis \nis ubiquitous in the adult population and if left untreated may \nprogress to periodontal disease and bone loss. Gingivitis is gener-\nally very treatable and, regarding dental implants, rarely leads to \nimplant loss or infection; it is not a contraindication for implant \nsurgery or prosthetics when an appropriate oral hygiene regimen \nis established.\nDental implant placement in patients with a history of gener-\nalized aggressive periodontal disease might be considered a viable \noption to restore oral function despite the aggressive nature of this \nA\nB\n• Fig. 13.6  Aggressive periodontal disease consisting of (A) generalized \npathologic migration, calculi deposits, purulent exudate, gingival inflamma-\ntion, grades II and III mobility, greater than 5-mm probing depths, and (B) \nradiographic signs of severe bone resorption with multiple bone defects."
  },
  {
    "page": 140,
    "content": "348\nPART III    Fundamental Science\ndisease and its assault on local bone levels. Outcomes similar to \nthose seen in chronic periodontal disease and healthy periodon-\ntium91 with high SRs and low marginal bone loss92 have been \nfound in generalized aggressive periodontal disease subjects. A \nsystematic review of the literature revealed that the 3-year SR was \nhigh but statistically significantly lower in generalized aggressive \nperiodontal disease subjects (SR 97.98% versus 100%) compared \nwith healthy periodontal and chronic periodontitis subjects.93 The \nonly significant difference seen at the 3-year time point between \nthese groups was an increased probing depth and attachment loss \nin the generalized aggressive periodontal disease subjects.91 At \n10-year follow-up, bone and attachment loss were higher with a \nlower SR, 83% compared with 100% in generalized aggressive \nperiodontal disease subjects compared with healthy individuals.94 \nSimilarly, the probability of a dental implant infection failure \nin individuals with a history of aggressive periodontal disease is \nsignificantly higher (almost four times as great) compared with \nindividuals with either healthy or chronic periodontal disease.95 \nLong-term dental implant success may be achievable with post-\nperiodontal treatment long-term stability with excellent patient \ncooperation and strict periodontal maintenance protocol.96 \nSeveral case reports have detailed medium-term dental implant \nreconstruction success in aggressive periodontal management, \ninvolving scaling and root planning and periodontal surgery, in \nthe treatment and implant maintenance.96-98 The functioning SRs \nof fixtures and superstructures of osseointegrated implants also \ntend to be generally high in subjects with aggressive periodon-\ntal disease (between 95.9% and 100%) over short- and long-term \nfollow-up.99\nImmediate dental implant placement into fresh extraction \nsockets with periodontal infection has been evaluated at single-\nand multiple-tooth reconstruction and shown to be a valid option \nwith predictable results. Single dental implants placed into peri-\nodontally infected extraction sites have shown, at 12-month fol-\nlow-up, to be asymptomatic with no signs of infection or bleeding \non probing, no decrease in radiographic bone–implant contact, \nand no loss of clinical attachment level or keratinized mucosa \nwidth at the midbuccal location per implant.100 \nChronic Periodontitis\nThere is conflicting evidence over medium- and long-term suc-\ncess between dental implants placed to restore periodontitis- and \nnonperiodontitis-associated tooth loss. Over a 10-year period, \ndental implants have lower SRs and more biologic complications \nbetween periodontitis- and nonperiodontitis-associated tooth \nloss.101 However, although this difference was significant between \nthese two groups, the success rate was still high between the \nchronic periodontitis group (90.5%) and nonperiodontitis group \n(96.5%). Similarly, dental implant suprastructures and dental \nimplant survival are not significantly different over a 10-year \nperiod, but they have significantly increased incidences of peri-\nimplantitis at 10 years and peri-implant marginal bone loss at 5 \nyears with periodontitis-associated tooth loss.102 The important \naspect of dental implant treatment associated with existing peri-\nodontitis or a history of chronic periodontitis is proper periodontal \ntherapy. Implant reconstruction can be successfully accomplished \nin patients with periodontitis when appropriate regular periodon-\ntal therapy and maintenance are achieved. Residual pockets, non-\nattendance to a periodontal maintenance program, and smoking \nare negative factors for long-term dental implant outcomes in \nperiodontitis-associated tooth loss.103 \nImmediate Loading in Periodontal Disease\nImmediately placed and immediately loaded dental implants \nhave been shown to be predictable and successful.104 Immedi-\nate implant loading of complete mandibular implant–retained \nprostheses may be a viable treatment option for edentulous indi-\nviduals with a history of chronic periodontal infection. Dental \nimplants immediately placed in chronically infected sockets \nand immediately loaded with a fixed full-arch maxillary and \nmandibular prosthesis have been shown to have excellent short-\nterm success105 and a 3-year cumulative surgical and prosthetic \nSR.106 Crestal bone height is also an indicator of dental implant \nsuccess because increased bone loss may lead to a change in \nthe microenvironment and microorganism composition. This \nwill eventually lead to dental implant failure and need for \nremoval. Immediately restored dental implants in patients with \nperiodontal disease, after 1 year, exhibit crestal bone loss rates \nsimilar to those seen for conventionally restored implants.107 \nImmediate dental implant rehabilitation in subjects with \nuntreated periodontitis may also be feasible when appropriate \nperiodontal therapy is provided and regularly maintained.108 \nThis shows that immediate dental implant placement and res-\ntoration is possible in individuals with periodontal disease as \nlong as periodontal maintenance is regularly and consistently \nsustained. \nPerisurgical Infection\nIntraoral surgery, in general, and dental implant surgery, spe-\ncifically, are classified as clean-contaminated surgery because \nthe surgical field may be contaminated by many sources of \nmicroorganisms that can easily infiltrate the surgical site. There \nare numerous sources of potential perisurgical-site infections. \nSeveral specific potential sources of perisurgical contamina-\ntion are mostly derived from surgical instrumentation, such \nas air, aspiration, instrumentation, and saliva in the surgical \nfield, and its relationship with the skin of the face, lips, and \nnose.109 Several techniques have been used to avoid perisurgi-\ncal cross-contamination of the surgical field, including saliva \nsecretion reduction with atropine,110 double aspiration to avoid \nsalivary contamination of surgery, and chlorhexidine rinses to \nreduce oral microbial load.71 Chlorohexidine has been shown \nto have effective antibacterial activity on the salivary flora and \ndevelopment of oral biofilms111-113 but not on developed and \nmature biofilms.114 Additionally, chlorhexidine has been shown \nto be affected by its local salivary environment, such as pH. \nChlorhexidine is more effective in alkaline than in acidic envi-\nronments,115 and the presence of organic substances and food \ncompounds will reduce antimicrobial activity.116 However, the \neffect of saliva on the antimicrobial activity of chlorhexidine has \nbeen shown to be weak but statistically significant.117 Extraoral \nmicrobial organism presentation has been suggested in peri-\nsurgical contamination, such as from the nose. A meshed nose \nguard to prevent contact with the highly contaminated nasal \nskin is highly recommended for field isolation to prevent infec-\ntion; otherwise, covering the nostrils by a mask and sterile adhe-\nsive plastic film is not essential in avoiding airborne microbial \ncontamination during dental implant surgery.118 Clinical mani-\nfestations of the infections caused by perioperative contamina-\ntion are usually in the form of peri-implant abscesses, periapical \nradiolucency, marginal bone loss, orocutaneous fistulas, and/or \nosteomyelitis."
  },
  {
    "page": 141,
    "content": "349\nCHAPTER 13  Dental Implant Infections\nSevere Postsurgical Infection\nPostoperative infections are rare complications that usually occur \nwithin the first month after dental implant placement, with an \nincidence as high as 11.5%. These infections generally occur dur-\ning the osseointegration period. Dental implant placement in \nthe mandible and submerged healing are more prone to postop-\nerative infections.119 Signs and symptoms of postoperative dental \nimplant infection are similar to other oral infections and include \npain, swelling, heat, and redness. If the infected implant is not \nremoved and the area debrided and decontaminated, an orocuta-\nneous fistula120,121 and/or osteomyelitis may develop.\nOsteomyelitis\nDental implant–related osteomyelitis of the jaws is a rare com-\nplication that has been reported in the literature (Figs. 13.7 \nand 13.8).122-130 The incidence of dental implant–related \nA\nB\nC\nD\nE\n• Fig. 13.7  (A–E) Advanced osteomyelitis from a mandibular subperiosteal implant resulting in significant \nbone loss, implant mobility, chronic infection, and pain. After removal, note the amount of calculus and \nslime layer as evidence of suspected developed biofilm."
  },
  {
    "page": 142,
    "content": "350\nPART III    Fundamental Science\nA\nB\nC\nD\nE\nF\n• Fig. 13.8  (A–F) Clinical and radiographic presentation of dental implant–related mandibular osteomyelitis. \nExtension of osteomyelitis necessitated placement of a mandibular fracture plate to prevent pathologic \nfracture during debridement."
  },
  {
    "page": 143,
    "content": "351\nCHAPTER 13  Dental Implant Infections\nosteomyelitis of the jaws has ranged from 5%131 to 26%130 \nof all cases. Osteomyelitis of the jaws is an acute and chronic \ninflammatory process in the medullary spaces or cortical \nsurfaces of bone that extends away from the initial site of \ninvolvement. Several local and systemic factors are generally \ninvolved in the development and spread of osteomyelitis of \nthe jaws. Local factors, such as trauma from tooth extraction \nor dental implant placement, can decrease vascularity and \nvitality of bone in the area. Systemic factors, such as immu-\nnosuppression or diabetes mellitus, can impair host defense \nmechanisms.\nThe mandible is a much more prevalent location for osteo-\nmyelitis than the maxilla because of the latter’s rich vascular-\nity.124,130,132-135 Introduction of bacterial pathogens into the \nbone, such as in the surgical placement of a dental implant, \nallows the bacteria access into the jaw bone to initiate a local \ninfection and inflammatory response. The inflammatory \nresponse developed toward these pathogens leads to a com-\npromise of local blood flow. Medullary infection then spreads \nthroughout the marrow spaces and vessel thrombosis leads to \nextensive bone necrosis. Lacunae in the bone then empty the \nosteocytes, fill with purulence, and proliferate in the necrotic \ntissue. Suppurative inflammation may then extend through \ncortical bone to the periosteum, which further compromises \nvascular supply. This predisposes the bone to further become \nnecrotic, which leads to sequestrum that separates from the \nsurrounding vital bone.\nLocal and systemic host factors may increase the patient \nsusceptibility. Comorbidities such as chronic systemic diseases, \nalcoholism, immunosuppression, malnutrition, diabetes mel-\nlitus, intravenous drug abuse, malignancy, and diseases can \nresult in hypovascularized bone (such as osteopetrosis, Paget dis-\nease, florid cemento-osseous dysplasia, and radiation therapy), \nor, more recently, medication-related osteonecrosis of the jaw \n(MRONJ) caused by antiresorptive and antiangiogenic thera-\npies has also been associated with an increased frequency of \nosteomyelitis.\nThe classic presentation of osteomyelitis of the jaws indicates \nan acute phase that can present either as a suppurative or nonsup-\npurative infection causing vascular compromise, which results in \nlocal tissue ischemia and necrosis with bony sequestrum. The two \nmajor groups of osteomyelitis (acute and chronic) are differenti-\nated by the clinical course of the disease after onset, relative to \nsurgical and antimicrobial therapy with an arbitrary time limit of \n1 month used to differentiate the two groups.135-138\nChronic osteomyelitis of the jaws is classified into various \ntypes based on clinical characteristics by the Zurich classifica-\ntion system, which is primarily based on the clinical course and \nappearance of the disease and on imaging studies.134 Chronic \nosteomyelitis of the jaws can be divided into primary and sec-\nondary chronic osteomyelitis, with secondary types further sub-\nclassified into three major clinical types: suppurative chronic \nosteomyelitis, osteoradionecrosis of the jaw, and MRONJ. Sup-\npurative chronic osteomyelitis has major symptoms of abscess/\npurulence formation, sequestration, and exposed bone.134 This \nis in contrast to primary chronic osteomyelitis, which may pres-\nent with nonsuppurative chronic inflammation of the jawbone, \nthe absence of causative dental infection, pus formation, fistula \nformation, or sequestration.\nRadiologic features of mandibular dental implant–related \nosteomyelitis are generally similar to other types of osteomy-\nelitis of the jaws. Early stages may initially appear normal \nradiographically and may not manifest itself until at least 10 \ndays after initiation of the inflammatory process. Progression \nof the infection may include radiolucent or mixed radiolu-\ncent-radiopaque lesions with poorly defined borders that may \nbe limited to the area of the failed implant or may extend to \na large part of the mandible.123 After sufficient bone resorp-\ntion has occurred, an irregular moth-eaten area of radiolu-\ncency may appear, which is generally pathognomonic for \nosteomyelitis.\nHistopathologic findings may range from acute osteomy-\nelitis and chronic osteomyelitis with features of a fibroosseous-\nlike lesion and occasional rimming of atypical osteoblasts.123 \nRoutine histology will show loss of osteocytes from lacunae \nin addition to peripheral resorption, bacterial colonization, \nand acute inflammatory infiltrate consisting of polymorpho-\nnuclear leukocytes in haversian canals and peripheral bone. \nFurthermore, inflamed connective tissue in the intertrabec-\nular bone, scattered sequestrum, and pockets of abscess are \ngenerally seen.\nProgression of dental implant–related osteomyelitis \ninvolves a host of virulent causative organisms. These may \ninclude Streptococcus, Peptococcus, and Peptostreptococcus spe-\ncies in general128 and S. anginosus130 and S. intermedius,134,139 \nspecifically. Osteomyelitis of the jaw may also exhibit large \nareas of bone occluded with well-developed biofilms that \ncomprise microbial organisms embedded in an extracellular \npolymeric substance with a predominance of the Actinomyces \ngenus.140\nConservative treatment alone is often insufficient to pro-\nvide a cure for chronic osteomyelitis.141,142 Progression of an \nincorrectly diagnosed or treated osteomyelitis of the jaws can \nresult in serious complications such as pathologic fracture and/\nor osteolytic extension to the inferior border of the mandible. \nThis generally will require an aggressive surgical intervention to \ninclude debridement of the infected area until bleeding bone is \nvisualized. The condition may progress to the point in which \nit will require either marginal mandibulectomy or segmental \nmandibular resection. The resultant continuity defect from man-\ndibular resection may also require titanium reconstruction plate \nstabilization with or without hard- and soft-tissue reconstructive \nprocedures.125 \nMedication-Related Osteonecrosis of the Jaws\nAlthough the reason remains unknown, current literature \nreveals a low rate of MRONJ in dental implant patients taking \nantiresorptive medication compared with other invasive pro-\ncedures, such as tooth extraction.143-145 Although the mecha-\nnism in the development of dental implant–related MRONJ \nis believed to be mainly mechanical, such as in dental implant \nplacement,146 a microbial biofilm component has been identi-\nfied.147 These cases have shown large areas of necrotic bone \noccluded with biofilms that compromise many bacterial mor-\nphotypes and species, such as Fusobacterium, bacillus, Acti­\nnomyces, staphylococcus, streptococcus, Selenomonas, and \ntreponemes and yeast (Candida species), all with observed \ncoaggregation.147 This represents some more diverse bacterial \norganisms in addition to fungal organisms not generally seen \nin osteomyelitis of the jaws,140 which may provide an impor-\ntant therapeutic implication because microorganisms present \nin biofilm represent a clinical antibiofilm target for prevention \nand treatment efforts."
  },
  {
    "page": 144,
    "content": "352\nPART III    Fundamental Science\nBiologics\n“Biologics” are monoclonal antibodies used against specific \ntargets in the treatment of autoimmune diseases such as \nrheumatoid arthritis, psoriatic arthritis, and ulcerative coli-\ntis. Commonly prescribed medications include adalimumab \n(Humira), infliximab (Remicade), and certolizumab (Cim-\nzia). Serious postoperative infections may occur when biologic \ndrugs that suppress the immune system have been used and \nare more likely when combined with other drugs that also \nsuppress the immune system. Individuals that are to undergo \nany oral or dental implant surgical procedures should have \nprior consultation with their prescribing physician to evaluate \ninfection risks and the possible need for discontinuation of the \nmedication in question. \nPeri-implant Disease\nPeri-mucositis and Peri-implantitis\nPeri-implant mucositis is characterized by biofilm-induced \ninflammation localized on the soft peri-implant mucosa but \nwith no evidence of destruction of the supporting bone (Fig. \n13.9). Progression of the inflammation may lead to gradual \ndestruction of the bone, manifesting as peri-implantitis. Peri-\nimplant mucositis and peri-implantitis are analogous to gingi-\nvitis and periodontitis of natural teeth.148 Mucositis occurs in \napproximately 80% of patients with dental implants and in \n50% of the implants. The prevalence of peri-implantitis has var-\nied reportedly from 28% to 56% among patients, and 12% to \n43% among implants.149 Evidence indicates that peri-implant \nmucositis occurs in 50% to 90% of implants, whereas 20% \nof implants with an average function time of 5 to 11 years \ndevelop peri-implantitis.149 Putative pathogens associated with \nperi-implantitis are present at a moderate relative abundance in \nperi-implant mucositis, suggesting that peri-implant mucositis \nis an important early transitional phase during the develop-\nment of peri-implantitis.54 Peri-implant mucositis and peri-\nimplantitis are analogous to gingivitis and periodontitis of \nnatural teeth.148 The current literature does not warrant devel-\nopment of a correlation of potential bacterial initiators or pro-\nmoters of peri-implantitis.\nPeri-implantitis is an irreversible inflammatory reaction in the \nsoft and hard peri-implant tissues. Plaque accumulation around \ndental implants has been shown to result in the development of \nperi-implant inflammation. Contributing factors for the develop-\nment of peri-implantitis include periodontal disease, smoking, \nexcess cement, and lack of supportive therapy.150 Periodonto-\npathogenic bacteria that have been implicated in peri-implantitis \ninclude P. gingivalis, P. intermedia, Prevotella nigrescens, and A. \nactinomycetemcomitans.151,152 Peri-implantitis has more floral clin-\nical symptoms because in the initial phase it may present the same \nsigns as peri-implant mucositis, but these are later accompanied \nby the symptoms of bone loss itself.\nB\nC\nA\n• Fig. 13.9  (A and B) Advanced peri-implantitis involving two mandibular overdenture dental implants. Note \nthe excessive amount of peri-implant bone loss. (C) Although stable, the implants required removal because  \nof chronic infection."
  },
  {
    "page": 145,
    "content": "353\nCHAPTER 13  Dental Implant Infections\nThe most common signs of peri-implantitis are the presence of \nbacterial plaque and calculus, edema and redness of peri-implant \ntissues, peri-implant mucosal hyperplasia with a lack of keratin-\nized gingiva, increased probing depths that may reach the apex \nof the implant, bleeding and purulence on probing and/or palpa-\ntion, vertical bone destruction in relation to a peri-implant pocket, \nradiologic presence of bone reabsorption, implant mobility, and \npossibly pain.153\nLack of treatment of peri-implantitis will progress to marginal \nbone loss. A continuously moving implant and peri-implant radio-\nlucency indicate that the disease is reaching its outcome, char-\nacterized by total loss of the bone–implant interface. Radiologic \nexamination is very important because although radiographs only \nshow bone on mesial and distal implant surfaces, the bone defects \nhave a circular or funnel-shaped form; therefore they are larger \nthan those observed on radiographs. \nBiofilm\nMost infections of the oral cavity are caused by bacteria, fungi, and \nyeast organized into biofilms. Oral microbial flora comprises one \nof the most diverse human-associated biofilms that is heavily influ-\nenced by oral streptococci as the main group of early colonizers. \nOral streptococci species are believed to make up over 80% of the \nearly biofilm constituents.154 Their initial attachment determines \nthe composition of later colonizers in the oral biofilm. Biofilms \nare a complex, multispecies, highly communicative community \nof multilayered accumulations of bacteria or fungi, immersed in \nan extracellular polymeric matrix.155,156 Biofilms form in a rapid \nsequence of events and mature into a complex, interacting com-\nmunity of microorganisms that have different properties than \nwhen present in isolation, resulting in a community that is more \nresistant to antimicrobial agents, stress, and host defenses. This \nmakes the treatment of biofilm infections with traditional anti-\nbiotics alone ineffective, and surgical removal of diseased tissue is \nrequired.\nThe earliest stage of biofilm formation is adhesion of micro-\nbial cells to a surface, such as dental implant or prostheses, \nwith an acquired salivary pellicle. The salivary pellicle is a thin \nacellular organic film that forms on any type of surface on \nexposure to saliva. The role of the pellicle is diverse, with func-\ntions known to be highly influenced by the physicochemical \nproperties of both substrata and ambient media, which include \nprotection, lubrication, remineralization, hydration, and act-\ning as a diffusion barrier and buffer.157 The next stage involves \ndevelopment of an irreversible bond between bacterial adhesins \nand the acquired salivary pellicle surface with the degree of \nadherence dependent on the microbial species, the number of \ncells, and the physicochemical properties of a given surface. \nSecretory IgA, α-amylase, and cystatins have been identified as \ndominant proteins in the salivary pellicle that strengthen adher-\nence to smooth titanium surfaces and cause an upregulation of \nmetabolic activity in early oral microbial colonizers, such as S. \noralis.158 Once colonized, the involved microorganisms begin \nto produce an extracellular polysaccharide matrix.156 Within \nthis matrix, the subsequent growth in layers of biofilm depend \non many factors such as salivary flow, nutrient content, iron \navailability, pH, osmolarity, oxygen content, concentration of \nantibacterial agents, and ambient temperature.159 As micro-\ncolonies form, maturation of the biofilm ensues such that the \nstructure and function of microorganisms within the biofilm \nmay resemble multicellular organisms caused by interactions \nand communication between cells, even of different species, \nwhich function as a consortium, cooperating in a relatively \ncomplicated and coordinated manner.156 Once established, \nbiofilm may cause a pathogenic process even in anatomically \ndistant sites because of dislodged fragments that contain aggre-\ngates of bacterial cells, production of endotoxin, evasion of the \nimmunologic response of the host, and formation of a niche \nfor replication of bacterial cells resistant to antimicrobials.\nMicrobial samples obtained by traditional methods tend to \ndestroy the three-dimensional structure of biofilm, resulting in \nmixtures of bacteria from unspecified districts of biofilm associ-\nated with peri-implant diseases. Advances in microbial analyses \nmethods indicate that peri-implant disease may be viewed as a \nmixed anaerobic infection, and in most cases the composition of \nthe flora is comparable to subgingival flora of chronic periodon-\ntitis dominated by gram-negative bacteria, such as P. gingivalis, P. \nintermedia, B. forsythus, and gram-positive bacteria, such as pepto­\nstreptococci or staphylococci.61\nThe presence of biofilm also effects dental implant restor-\native materials. Biofilm may lead to a friction coefficient and \nthreaten the biomechanical behavior of a single implant-\nsupported restoration and lead to infection-related failure.160 \nEffects of dental implant restorative material/surface prop-\nerties (such as surface charge, hydrophobicity, roughness, \ntopography, and chemistry) on bacterial adhesion and bio-\nfilm formation have shown that negatively charged surfaces, \nsuper-hydrophobic surfaces, super-hydrophilic surfaces, and \nnanometer-scale surface roughness reduce bacterial adhesion. \nThe presence of an acquired pellicle-containing host and bac-\nterially derived proteins poses a great challenge to the control \nof bacterial adhesion and biofilm formation based on surface \nmodifications. Factors other than surface properties, such as \ndietary intake and complex oral microbiome, also affect bio-\nfilm formation.\nBiofilms may act as directors or promoters of cell-mediated \n(osteoclast) bone resorption or induce bone resorption via vari-\nous microbial mechanisms. Once established, local host defenses \nand repair mechanisms act to wall off and eradicate the dead bone \nvia sequestration.161 Therefore biofilms play an important role in \nthe pathogenesis of osteonecrosis of the jaw (ONJ) in addition to \nexplicating the septic nature of this condition. \nProphylactic Antibiotics\nAdministration of preoperative, perioperative, or postopera-\ntive systemic antibiotics is generally undertaken to prevent \ndental implant infection. Although numerous prophylactic \nsystemic antibiotic regimens have been suggested to minimize \nfailure, the role of antibiotics in implant dentistry remains \ncontentious. There appears to be no consensus regarding anti-\nbiotics in association with routine dental implant placement, \nthe type of regimen to use, or effectiveness in preventing \nearly implant loss. Furthermore, most of the antibiotic regi-\nmens used are not in accordance with the recommendations \ncurrent in the published data.162,163 Systematic antibiotic \nadministration in patients that receive dental implants sig-\nnificantly reduces implant failure, but there are no apparent \nsignificant effects of prophylactic antibiotics on the occur-\nrence of postoperative infections in healthy patients receiving \nimplants.164,165"
  },
  {
    "page": 146,
    "content": "354\nPART III    Fundamental Science\nReferences\n\t 1.\t \u0007Gupta A, Dhanraj M, Sivagami G. Status of surface treatment \nin endosseous implant: a literary overview. Indian J Dent Res. \n2010;21(3):433–438. https://doi.org/10.4103/0970-9290.70805.\n\t 2.\t \u0007Yue C, Zhao B, Ren Y, et al. The implant infection paradox: why \ndo some succeed when others fail? Opinion and discussion paper. \nEur Cell Mater. 2015;29:303–310.\n\t 3.\t \u0007Farnaud SJ, Kosti O, Getting SJ, Renshaw D. Saliva: physiol-\nogy and diagnostic potential in health and disease. Sci World J. \n2010;10:434–456. https://doi.org/10.1100/tsw.2010.38.\n\t 4.\t \u0007Malamud D, Abrams WR, Barber CA, Weissman D, Rehtanz \nM, Golub E. Antiviral activities in human saliva. Adv Dent Res. \n2011;23(1):34–37. https://doi.org/10.1177/0022034511399282.\n\t 5.\t \u0007Hanasab H, Jammal D, Oppenheim FG, Helmerhorst EJ. The \nantifungal activity of human parotid secretion is species-specific. \nMed Mycol. 2011;49(2):218–221. https://doi.org/10.3109/13693\n786.2010.512299.\n\t 6.\t \u0007Young PY, Khadaroo RG. Surgical site infections. Surg Clin \nNorth Am. 2014;94(6):1245–1264. https://doi.org/10.1016/j \n.suc.2014.08.008.\n\t 7.\t \u0007Han YW, Wang X. Mobile microbiome: oral bacteria in extra-oral \ninfections and inflammation. J Dent Res. 2013;92(6):485–491. \nhttps://doi.org/10.1177/0022034513487559.\n\t 8.\t \u0007Bölükbaşı N, Özdemir T, Öksüz L, Gürler N. Bacteremia follow-\ning dental implant surgery: preliminary results. Med Oral Patol \nOral Cir Bucal. 2012;17(1):e69–e75.\n\t 9.\t \u0007Herzberg MC. Platelet-streptococcal interactions in endocarditis. \nCrit Rev Oral Biol Med. 1996;7:222–236.\n\t10.\t \u0007Herzberg MC, Meyer MW, Kilic A, Tao L. Host-pathogen interac-\ntions in bacterial endocarditis: streptococcal virulence in the host. \nAdv Dent Res. 1997;11:69–74.\n\t11.\t \u0007Matta M, Gousseff M, Monsel F, et al. First case of Streptococcus \noligofermentans endocarditis based on sodA gene sequences deter-\nmined after amplification directly from valvular samples. J Clin \nMicrobiol. 2009;47:855–856.\n\t12.\t \u0007Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum \npotentiates intestinal tumorigenesis and modulates the tumor-\nimmune microenvironment. Cell Host Microbe. 2013;14(2): \n207–215. https://doi.org/10.1016/j.chom.2013.07.007.\n\t13.\t \u0007Shimizu Y, Tsutsumi S, Yasumoto Y, Ito M. Carotid cavernous \nsinus fistula caused by dental implant-associated infection. Am \nJ Otolaryngol. 2012;33(3):352–355. https://doi.org/10.1016/j \n.amjoto.2011.08.002.\n\t14.\t \u0007Stuzin JM, Baker TJ, Gordon HL. The relationship of the super-\nficial and deep facial fascias: relevance to rhytidectomy and aging. \nPlast Reconstr Surg. 1992;89(3):441–449.\n\t15.\t \u0007Kim HC, Han MH, Moon MH, Kim JH, Kim IO, Chang KH. \nCT and MR imaging of the buccal space: normal anatomy and \nabnormalities. Korean J Radiol. 2005;6(1):22–30.\n\t16.\t \u0007Tart RP, Kotzur IM, Mancuso AA, Glantz MS, Mukherji SK. CT \nand MR imaging of the buccal space and buccal space masses. \nRadioGraphics. 1995;15:531–550.\n\t17.\t \u0007Smoker WRK. Oral cavity. In: Som PM, Curtin HD, eds. Head \nand Neck Imaging. 3rd ed. St. Louis: Mosby; 1996:488–544.\n\t18.\t \u0007Schuknecht B, Stergiou G, Graetz K. Masticator space abscess \nderived from odontogenic infection: imaging manifestation and \npathways of extension depicted by CT and MR in 30 patients. Eur \nRadiol. 2008;18(9):1972–1979. https://doi.org/10.1007/s00330-\n008-0946-5.\n\t19.\t \u0007Khoury JN, Mihailidis S, Ghabriel M, Townsend G. Applied \nanatomy of the pterygomandibular space: improving the success of \ninferior alveolar nerve blocks. Aust Dent J. 2011;56(2):112–121.\n\t20.\t \u0007Bratton TA, Jackson DC, Nkungula-Howlett T, Williams CW, \nBennett CR. Management of complex multi-space odontogenic \ninfections. J Tenn Dent Assoc. 2002;82(3):39–47.\n\t21.\t \u0007Lee JY, Kim JN, Kim SH, et al. Anatomical verification and desig-\nnation of the superficial layer of the temporalis muscle. Clin Anat. \n2012;25(2):176.\n\t22.\t \u0007Ural A, Imamoğlu M, Umit Işık A., et al. Neck masses confined to \nthe submental space: our experience with 24 cases. Ear Nose Throat \nJ. 2011;90(11):538.\n\t23.\t \u0007Potter JK, Herford AS, Ellis 3rd E. Tracheotomy versus endotra-\ncheal intubation for airway management in deep neck space infec-\ntions. J Oral Maxillofac Surg. 2002;60(4):349–354.\n\t24.\t \u0007Dzyak WR, Zide MF. Diagnosis and treatment of lateral pharyn-\ngeal space infections. J Oral Maxillofac Surg. 1984;42(4):243–249.\n\t25.\t \u0007Goodman LJ. Purulent pericarditis. Curr Treat Options Cardiovasc \nMed. 2000;2(4):343–350.\n\t26.\t \u0007Kulik EM, Sandmeier H, Hinni K, Meyer J. Identification of \narchaeal rDNA from subgingival dental plaque by PCR amplifica-\ntion and sequence analysis. FEMS Microbiol Lett. 2001;196:129–\n133.\n\t27.\t \u0007Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defin-\ning the normal bacterial flora of the oral cavity. J Clin Microbiol. \n2005;43:5721–5732.\n\t28.\t \u0007Keijser BJ, Zaura E, Huse SM, et al. Pyrosequencing analysis of the \noral microflora of healthy adults. J Dent Res. 2008;87:1016–1020.\n\t29.\t \u0007Mombelli A. Microbiology of the dental implant. Adv Dent Res. \n1993;7(2):202–206.\n\t30.\t \u0007Whiley RA, Beighton D. Current classification of the oral strepto-\ncocci. Oral Microbiol Immunol. 1998;13(4):195–216.\n\t31.\t \u0007Facklam R. What happened to the streptococci: overview of \ntaxonomic and nomenclature changes. Clin Microbiol Rev. \n2002;15:613–630.\n\t32.\t \u0007Burton JP, Wescombe PA, Cadieux PA, Tagg JR. Beneficial \nmicrobes for the oral cavity: time to harness the oral streptococci? \nBenef \nMicrobes. \n2011;2(2):93–101. \nhttps://doi.org/10.3920/\nBM2011.0002.\n\t33.\t \u0007Delwiche EA, Pestka JJ, Tortorello ML. The veillonellae: gram-\nnegative cocci with a unique physiology. Annu Rev Microbiol. \n1985;39:175–193.\n\t34.\t \u0007Distler W, Kroncke A. The lactate metabolism of the oral bacterium \nVeillonella from human saliva. Arch Oral Biol. 1981;26:657–661.\n\t35.\t \u0007McNab R, Ford SK, El-Sabaeny A, Barbieri B, Cook GS, Lamont \nRJ. LuxS-based signaling in Streptococcus gordonii: autoinducer 2 \ncontrols carbohydrate metabolism and biofilm formation with Por­\nphyromonas gingivalis. J Bacteriol. 2003;185:274–284.\n\t36.\t \u0007Rickard AH, Palmer Jr RJ, Blehert DS, et  al. Autoinducer 2: a \nconcentration-dependent signal for mutualistic bacterial biofilm \ngrowth. Mol Microbiol. 2006;60:1446–1456.\n\t37.\t \u0007Edwards AM, Grossman TJ, Rudney JD. Fusobacterium nucleatum \ntransports noninvasive Streptococcus cristatus into human epithelial \ncells. Infect Immun. 2006;74:654–662.\n\t38.\t \u0007Brown SA, Whiteley M. A novel exclusion mechanism for carbon \nresource partitioning in Aggregatibacter actinomycetemcomitans. \nJ Bacteriol. 2007;189:6407–6414.\n\t39.\t \u0007Sutter VL. Anaerobes as normal oral flora. Rev Infect Dis. \n1984;6(suppl 1):S62–S66.\n\t40.\t \u0007Park OJ, Yi H, Jeon JH, et al. Pyrosequencing analysis of subgin-\ngival microbiota in distinct periodontal conditions. J Dent Res. \n2015;94(7):921–927.  https://doi.org/10.1177/0022034515583531.\n\t41.\t \u0007Nordquist WD. Oral spirochetosis associated with dental implants: \nimportant clues to systemic disease. Int J Clin Implant Dent. \n2009;1(1):32–39.\n\t42.\t \u0007Cui L, Morris A, Ghedin E. The human mycobiome in health and \ndisease. Genome Med. 2013;5(7):63. https://doi.org/10.1186/gm467.\n\t43.\t \u0007Darling WM. Co-cultivation of mycobacteria and fungus. Lancet. \n1976;2:740. 40.\n\t44.\t \u0007Kerr J. Inhibition of fungal growth by Pseudomonas aeruginosa and \nPseudomonas cepacia isolated from patients with cystic fibrosis. J \nInfect. 1994;28:305–310."
  },
  {
    "page": 147,
    "content": "355\nCHAPTER 13  Dental Implant Infections\n\t45.\t \u0007Matsubara VH, Igai F, Tamaki R, Tortamano Neto P, Nakamae \nAE, Mori M. Use of silver nanoparticles reduces internal con-\ntamination of external hexagon implants by candida albicans. \nBraz Dent J. 2015;26(5):458–462. https://doi.org/10.1590/0103-\n644020130087.\n\t46.\t \u0007Trindade LA, de Araújo Oliveira J, de Castro RD, de Oliveira Lima \nE. Inhibition of adherence of C. albicans to dental implants and \ncover screws by Cymbopogon nardus essential oil and citronel-\nlal. Clin Oral Investig. 2015;19(9):2223–2231. https://doi.org/ \n10.1007/s00784-015-1450-3.\n\t47.\t \u0007Lepp PW, Brinig MM, Ouverney CC, Palm K, Armitage GC, Rel-\nman DA. Methanogenic Archaea and human periodontal disease. \nProc Natl Acad Sci U S A. 2004;101(16):6176–6181.\n\t48.\t \u0007Vianna ME, Conrads G, Gomes BP, Horz HP. T-RFLP-based \nmcrA gene analysis of methanogenic archaea in association with \noral infections and evidence of a novel Methanobrevibacter phy-\nlotype. Oral Microbiol Immunol. 2009;24(5):417–422. https://doi \n.org/10.1111/j.1399-302X.2009.00539. x.\n\t49.\t \u0007Huynh HT, Nkamga VD, Drancourt M, Aboudharam G. \nGenetic variants of dental plaque Methanobrevibacter oralis. Eur \nJ Clin Microbiol Infect Dis. 2015;34(6):1097–1101. https://doi \n.org/10.1007/s10096-015-2325-x.\n\t50.\t \u0007Li CL, Liu DL, Jiang YT, et al. Prevalence and molecular diver-\nsity of Archaea in subgingival pockets of periodontitis patients. \nOral Microbiol Immunol. 2009;24(4):343–346. https://doi.org/ \n10.1111/j.1399-302X.2009.00514.x.\n\t51.\t \u0007Bringuier A, Khelaifia S, Richet H, Aboudharam G, Drancourt \nM. Real-time PCR quantification of Methanobrevibacter oralis in \nperiodontitis. J Clin Microbiol. 2013;51(3):993–994. https://doi \n.org/10.1128/JCM.02863-12.\n\t52.\t \u0007Vianna ME, Holtgraewe S, Seyfarth I, Conrads G, Horz HP. \nQuantitative analysis of three hydrogenotrophic microbial groups, \nmethanogenic archaea, sulfate-reducing bacteria, and acetogenic \nbacteria, within plaque biofilms associated with human periodon-\ntal disease. J Bacteriol. 2008;190(10):3779–3785. https://doi \n.org/10.1128/JB.01861-07.\n\t53.\t \u0007Faveri M, Gonçalves LF, Feres M, et al. Prevalence and microbio-\nlogical diversity of Archaea in peri-implantitis subjects by 16S ribo-\nsomal RNA clonal analysis. J Periodontal Res. 2011;46(3):338–344. \nhttps://doi.org/10.1111/j.1600-0765.2011.01347.x.\n\t54.\t \u0007Zheng H, Xu L, Wang Z, et al. Subgingival microbiome in patients \nwith healthy and ailing dental implants. Sci Rep. 2015;5:10948. \nhttps://doi.org/10.1038/srep10948.\n\t55.\t \u0007Shiono Y, Ishii K, Nagai S, et al. Delayed Propionibacterium acnes \nsurgical site infections occur only in the presence of an implant. Sci \nRep. 2016;6:32758. https://doi.org/10.1038/srep32758.\n\t56.\t \u0007Flanagan D. Enterococcus faecalis and dental implants. J Oral \nImplantol. \n2017;43(1):8–11. \nhttps://doi.org/10.1563/aaid-joi-\nD-16-00069.\n\t57.\t \u0007Berglundh T, Zitzmann NU, Donati M. Are peri-implantitis \nlesions different from periodontitis lesions? J Clin Periodontol. \n2011;38(suppl 11):188–202.\n\t58.\t \u0007Kumar PS, Mason MR, Brooker MR, O’Brien K. Pyrosequencing \nreveals unique microbial signatures associated with healthy and fail-\ning dental implants. J Clin Periodontol. 2012;39:425–433.\n\t59.\t \u0007Salvi GE, Aglietta M, Eick S, Sculean A, Lang NP, Ramseier CA. \nReversibility of experimental peri-implant mucositis compared \nwith experimental gingivitis in humans. Clin Oral Implants Res. \n2012;23:182–190.\n\t60.\t \u0007Leonhardt A, Adolfsson B, Lekholm U, Wikstrom M, Dahlen G. \nA longitudinal microbiological study on osseointegrated titanium \nimplants in partially edentulous patients. Clin Oral Implants Res. \n1993;4:113–120.\n\t61.\t \u0007Mombelli A, Décaillet F. The characteristics of biofilms in peri-\nimplant disease. J Clin Periodontol. 2011;38(suppl 11):203–213. \nhttps://doi.org/10.1111/j.1600-051X.2010.01666.x.\n\t62.\t \u0007Rutar A, Lang NP, Buser D, Burgin W, Mombelli A. Retrospective \nassessment of clinical and microbiological factors affecting peri-\nimplant tissue conditions. Clin Oral Implants Res. 2001;12:189–\n195.\n\t63.\t \u0007Tabanella G, Nowzari H, Slots J. Clinical and microbiological \ndeterminants of ailing dental implants. Clin Implant Dent Relat Res. \n2009;11:24–36.\n\t64.\t \u0007Takanashi K, Kishi M, Okuda K, Ishihara K. Colonization by Por­\nphyromonas gingivalis and Prevotella intermedia from teeth to osseo-\nintegrated implant regions. Bull Tokyo Dent Coll. 2004;45:77–85.\n\t65.\t \u0007Christersson LA, Slots J, Rosling BG, Genco RJ. Microbiological \nand clinical effects of surgical treatment of localized juvenile peri-\nodontitis. J Clin Periodontol. 1985;12:465–476.\n\t66.\t \u0007Größner‐Schreiber B, Teichmann J, Hannig M, Dörfer C, \n­Wenderoth DF, Ott SJ. Modified implant surfaces show different \n­biofilm compositions under in vivo conditions. Clin Oral Implants \nRes. 2009;20(8):817–826. https://doi.org/10.1111/j.1600-0501 \n.2009.01729.x.\n\t67.\t \u0007Yoshinari M, Oda Y, Kato T, Okuda K, Hirayama A. Influence \nof surface modifications to titanium on oral bacterial adhesion \nin vitro. J Biomed Mater Res. 2000;52(2):388–394.\n\t68.\t \u0007Esposito M, Cannizzaro G, Bozzoli P, Chec-chi L, Ferri V, Landri-\nani S, et al. Effectiveness of prophylactic antibiotics at placement of \ndental implants: a pragmatic multicentre placebo-controlled ran-\ndomised clinical trial. Eur J Oral Implantol. 2010;3:135–143.\n\t69.\t \u0007Esposito M, Cannizzaro G, Bozzoli P, et  al. Efficacy of pro-\nphylactic antibiotics for dental implants: a multicentre pla-\ncebo-controlled randomised clinical trial. Eur J Oral Implantol. \n2008;1:23–31.\n\t70.\t \u0007Abu-Ta’a M, Quirynen M, Teughels W, van Steenberghe D. Asep-\nsis during periodontal surgery involving oral implants and the \nusefulness of peri-operative antibiotics: a prospective, randomized, \ncontrolled clinical trial. J Clin Periodontol. 2008;35:58–63. 25.\n\t71.\t \u0007Quirynen M, De Soete M, van Steenberghe D. Infectious risks \nfor oral implants: a review of the literature. Clin Oral Impl Res. \n2002;13:1–19.\n\t72.\t \u0007Jensen OT. Dental extraction, immediate placement of dental \nimplants, and immediate function. Oral Maxillofac Surg Clin North \nAm. 2015;27(2):273–282. https://doi.org/10.1016/j.coms.2015 \n.01.008.\n\t73.\t \u0007Aghaloo TL, Mardirosian M, Delgado B. Controversies in implant \nsurgery. Oral Maxillofac Surg Clin North Am. 2017;29(4):525–535. \nhttps://doi.org/10.1016/j.coms.2017.07.007.\n\t74.\t \u0007Hegde R, Krishna Prasad D, Shetty DV, Shetty M. Immediate \nplacement and restoration of implant in periapical infected site in \nthe maxillary esthetic zone: a case report. J Indian Prosthodont Soc. \n2014;14(suppl 1):299–302. https://doi.org/10.1007/s13191-014-\n0357-z.\n\t75.\t \u0007Anitua E, Piñas L, Alkhraisat MH. Long-term outcomes of \nimmediate implant placement into infected sockets in asso-\nciation with immediate loading: a retrospective cohort study. J \nPeriodontol. 2016;87(10):1135–1140. https://doi.org/10.1902/\njop.2016.160104.\n\t76.\t \u0007Corbella S, Taschieri S, Tsesis I, Del Fabbro M. Postextrac-\ntion implant in sites with endodontic infection as an alternative \nto endodontic retreatment: a review of literature. J Oral Imp­\nlantol. 2013;39(3):399–405. https://doi.org/10.1563/AAID-JOI-\nD-11-00229.\n\t77.\t \u0007Crespi R, Capparé P, Crespi G, Lo Giudice G, Gastaldi G, Gher-\nlone E. Dental implants placed in periodontally infected sites \nin humans. Clin Implant Dent Relat Res. 2017;19(1):131–139. \nhttps://doi.org/10.1111/cid.12425.\n\t78.\t \u0007Chrcanovic BR, Martins MD, Wennerberg A. Immediate place-\nment of implants into infected sites: a systematic review. Clin \nImplant Dent Relat Res. 2015;17(suppl 1):e1–e16. https://doi \n.org/10.1111/cid.12098."
  },
  {
    "page": 148,
    "content": "356\nPART III    Fundamental Science\n\t79.\t \u0007Bell CL, Diehl D, Bell BM, Bell RE. The immediate placement of \ndental implants into extraction sites with periapical lesions: a ret-\nrospective chart review. J Oral Maxillofac Surg. 2011;69(6):1623–\n1627. https://doi.org/10.1016/j.joms.2011.01.022.\n\t80.\t \u0007Blus C, Szmukler-Moncler S, Khoury P, Orrù G. Immediate \nimplants placed in infected and noninfected sites after atraumatic \ntooth extraction and placement with ultrasonic bone surgery. Clin \nImplant Dent Relat Res. 2015;17(suppl 1): e287–e297. https://doi \n.org/10.1111/cid.12126.\n\t81.\t \u0007Montoya-Salazar V, Castillo-Oyag R, Torres-Sanchez C, Lynch \nCD, Gutirrez-Perez JL, Torres-Lagares D. Outcome of single \nimmediate implants placed in post-extraction infected and non-\ninfected sites, restored with cemented crowns: a 3-year prospective \nstudy. J Dent. 2014;42(6):645–652.\n\t82.\t \u0007Zuffetti F, Capelli M, Galli F, Del Fabbro M, Testori T. Post-extrac-\ntion implant placement into infected versus non-infected sites: a \nmulticenter retrospective clinical study. Clin Implant Dent Relat \nRes. 2017;19(5):833–840. https://doi.org/10.1111/cid.12523.\n\t83.\t \u0007Waasdorp JA, Evian CI, Mandracchia M. Immediate placement \nof implants into infected sites: a systematic review of the litera-\nture. J Periodontol. 2010;81(6):801–808. https://doi.org/10.1902/\njop.2010.090706.\n\t84.\t \u0007Meltzer AM. Immediate implant placement and restoration in infected \nsites. Int J Periodontics Restorative Dent. 2012;32(5):e169–e173.\n\t85.\t \u0007Zhao D, Wu Y, Xu C, Zhang F. Immediate dental implant \nplacement into infected vs. non-infected sockets: a meta-analy-\nsis. Clin Oral Implants Res. 2016;27(10):1290–1296. https://doi \n.org/10.1111/clr.12739.\n\t86.\t \u0007de Oliveira-Neto OB, Barbosa FT, de Sousa-Rodrigues CF, de Lima \nFJC. Quality assessment of systematic reviews regarding immedi-\nate placement of dental implants into infected sites: an overview. \nJ Prosthet Dent. 2017;117(5):601–605. https://doi.org/10.1016/j \n.prosdent.2016.09.007.\n\t87.\t \u0007Ata-Ali J, Ata-Ali F, Ata-Ali F. Do antibiotics decrease implant \nfailure and postoperative infections? a systematic review and meta-\nanalysis. Int J Oral Maxillofac Surg. 2014;43(1):68–74. https://doi \n.org/10.1016/j.ijom.2013.05.019.\n\t88.\t \u0007Melo RF, Lopes BM, Shibli JA, Marcantonio Junior E, Marcan-\ntonio RA, Galli GM. Interleukin-1β and interleukin-6 expression \nand gene polymorphisms in subjects with peri-implant disease. \nClin Implant Dent Relat Res. 2012;14:905–914.\n\t89.\t \u0007Chrcanovic BR, Albrektsson T, Wennerberg A. Periodontally com-\npromised vs. periodontally healthy patients and dental implants: a \nsystematic review and meta-analysis. J Dent. 2014;42(12):1509–\n1527. https://doi.org/10.1016/j.jdent.2014.09.013.\n\t90.\t \u0007Lee DW. Periodontitis and dental implant loss. Evid Based Dent. \n2014;15(2):59–60. https://doi.org/10.1038/sj.ebd.6401031.\n\t91.\t \u0007Mengel R, Schroeder T, Flores-de-Jacoby L. Osseointegrated \nimplants in patients treated for generalized chronic periodontitis \nand generalized aggressive periodontitis: 3- and 5-year results of a \nprospective long-term study. J Periodontol. 2001;72(8):977–989.\n\t92.\t \u0007Brignardello-Petersen R. Implants placed in patients with a his-\ntory of aggressive periodontitis had high survival rates and low \nmarginal bone loss. J Am Dent Assoc. 2017;148(4):e37. https://doi \n.org/10.1016/j.adaj.2017.02.023.\n\t93.\t \u0007Theodoridis C, Grigoriadis A, Menexes G, Vouros I. Outcomes of \nimplant therapy in patients with a history of aggressive periodon-\ntitis. A systematic review and meta-analysis. Clin Oral Investig. \n2017;21(2):485–503. https://doi.org/10.1007/s00784-016-2026-6.\n\t94.\t \u0007Mengel R, Behle M, Flores-de-Jacoby L. Osseointegrated implants \nin subjects treated for generalized aggressive periodontitis: 10-year \nresults of a prospective, long-term cohort study. J Periodontol. \n2007;78(12):2229–2237.\n\t95.\t \u0007Monje A, Alcoforado G, Padial-Molina M, Suarez F, Lin GH, \nWang HL. Generalized aggressive periodontitis as a risk factor \nfor dental implant failure: a systematic review and meta-analysis. \nJ Periodontol. 2014;85(10):1398–1407. https://doi.org/10.1902/\njop.2014.140135.\n\t96.\t \u0007Ramesh A, Ravi S, Kaarthikeyan G. Comprehensive rehabilita-\ntion using dental implants in generalized aggressive periodon-\ntitis. J Indian Soc Periodontol. 2017;21(2):160–163. https://doi \n.org/10.4103/jisp.jisp_213_17.\n\t97.\t \u0007Rajan G, Natarajarathinam G, Kumar S, Parthasarathy H. Full \nmouth rehabilitation with zygomatic implants in patients with \ngeneralized aggressive periodontitis: 2-year follow-up of two \ncases. J Indian Soc Periodontol. 2014;18(1):107–111. https://doi \n.org/10.4103/0972-124X.128262.\n\t98.\t \u0007Rasaeipour S, Siadat H, Rasouli A, Sajedinejadd N, Ghodsi S. \nImplant rehabilitation in advanced generalized aggressive peri-\nodontitis: a case report and literature review. J Dent (Tehran). \n2015;12(8):614–620.\n\t99.\t \u0007Kim KK, Sung HM. Outcomes of dental implant treatment \nin patients with generalized aggressive periodontitis: a system-\natic review. J Adv Prosthodont. 2012;4(4):210–217. https://doi \n.org/10.4047/jap.2012.4.4.210.\n\t100.\t \u0007Marconcini S, Barone A, Gelpi F, Briguglio F, Covani U. Immedi-\nate implant placement in infected sites: a case series. J Periodontol. \n2013;84(2):196–202. https://doi.org/10.1902/jop.2012.110279.\n\t101.\t \u0007Karoussis IK, Salvi GE, Heitz-Mayfield LJ, Brägger U, Hämmerle \nCH, Lang NP. Long-term implant prognosis in patients with and \nwithout a history of chronic periodontitis: a 10-year prospective \ncohort study of the ITI dental implant system. Clin Oral Implants \nRes. 2003;14(3):329–339.\n\t102.\t \u0007Schou S, Holmstrup P, Worthington HV, Esposito M. Outcome \nof implant therapy in patients with previous tooth loss due to peri-\nodontitis. Clin Oral Implants Res. 2006;17(suppl 2):104–123.\n\t103.\t \u0007Zangrando MS, Damante CA, Sant’Ana AC, Rubo de Rezende ML, \nGreghi SL, Chambrone L. Long-term evaluation of periodontal \nparameters and implant outcomes in periodontally compromised \npatients: a systematic review. J Periodontol. 2015;86(2):201–221. \nhttps://doi.org/10.1902/jop.2014.140390.\n\t104.\t \u0007Del Fabbro M, Testori T, Francetti L, Taschieri S, Weinstein R. \nSystematic review of survival rates for immediately loaded dental \nimplants. Int J Periodontics Restorative Dent. 2006;26(3):249–263.\n\t105.\t \u0007Gomes JA, Sartori IAM, Able FB, de Oliveira Silva TS, do Nasci-\nmento C. Microbiological and clinical outcomes of fixed complete-\narch mandibular prostheses supported by immediate implants in \nindividuals with history of chronic periodontitis. Clin Oral Implants \nRes. 2017;28(6):734–741. https://doi.org/10.1111/clr.12871.\n\t106.\t \u0007Alves CC, Correia AR, Neves M. Immediate implants and imme-\ndiate loading in periodontally compromised patients-a 3-year \nprospective clinical study. Int J Periodontics Restorative Dent. \n2010;30(5):447–455.\n\t107.\t \u0007Horwitz J, Machtei EE. Immediate and delayed restoration of \ndental implants in patients with a history of periodontitis: a pro-\nspective evaluation up to 5 years. Int J Oral Maxillofac Implants. \n2012;27(5):1137–1143.\n\t108.\t \u0007Malo P, Nobre Mde A, Lopes A, Ferro A, Gravito I. Immediate \nloading of implants placed in patients with untreated periodontal \ndisease: a 5-year prospective cohort study. Eur J Oral Implantol. \n2014;7(3):295–304.\n\t109.\t \u0007Lang NP, Wet AC. Histologic probe penetration in healthy \nand inflamed peri-implant tissues. In: Brånemark PI, Zarb GA, \nAlbrektsson T, eds. Tissue-Integrated Prostheses: Osseointegration in \nClinical Dentistry. Chicago: Quintessence; 1985:211–232.\n\t110.\t \u0007Haanaes HR. Implants and infections with special reference to oral \nbacteria. J Clin Periodontol. 1990;17:516–524.\n\t111.\t \u0007Ribeiro LG, Hashizume LN, Maltz M. The effect of different for-\nmulations of chlorhexidine in reducing levels of mutans strepto-\ncocci in the oral cavity: a systematic review of the literature. J Dent. \n2007;35:359–370. https://doi.org/10.1016/j.jdent.2007.01.007.\n\t112.\t \u0007Roldan S, Herrera D, Santa-Cruz I, O’Connor A, Gonzalez I, Sanz \nM. Comparative effects of different chlorhexidine mouth-rinse \nformulations on volatile sulphur compounds and salivary bacte-\nrial counts. J Clin Periodontol. 2004;31:1128–1134. https://doi \n.org/10.1111/j.1600-051X.2004.00621.x."
  },
  {
    "page": 149,
    "content": "357\nCHAPTER 13  Dental Implant Infections\n\t113.\t \u0007van der Mei HC, White DJ, Atema-Smit J, van de Belt-Gritter E, \nBusscher HJ. A method to study sustained antimicrobial activity \nof rinse and dentifrice components on biofilm viability in vivo. J \nClin Periodontol. 2006;33:14–20. https://doi.org/10.1111/j.1600-\n051X.2005.00859.x.\n\t114.\t \u0007Vitkov L, Hermann A, Krautgartner WD, et al. Chlorhexidine-\ninduced ultrastructural alterations in oral biofilm. Microsc Res Tech. \n2005;68:85–89. https://doi.org/10.1002/jemt.20238.\n\t115.\t \u0007Gilbert P, Moore LE. Cationic antiseptics: diversity of action under \na common epithet. J Appl Microbiol. 2005;99:703–715. https://\ndoi.org/10.1111/j.1365-2672.2005.02664.x.\n\t116.\t \u0007Spijkervet FK, van Saene JJ, van Saene HK, Panders AK, Vermey A, \nFidler V. Chlorhexidine inactivation by saliva. Oral Surg Oral Med \nOral Pathol. 1990;69:444–449. https://doi.org/10.1016/0030-\n4220(90)90377-5.\n\t117.\t \u0007Abouassi T, Hannig C, Mahncke K, et al. Does human saliva decrease \nthe antimicrobial activity of chlorhexidine against oral bacteria? BMC \nResearch Notes. 2014;7:711. https://doi.org/10.1186/1756-0500-7-711.\n\t118.\t \u0007Van Steenberghe D. Complete nose coverage to prevent airborne \ncontamination. Clinical Oral Implants Research. 1997;8:512–516.\n\t119.\t \u0007Figueiredo R, Camps-Font O, Valmaseda-Castellón E, Gay-\nEscoda C. Risk factors for postoperative infections after \ndental implant placement: a case-control study. J Oral Maxil­\nlofac Surg. 2015;73(12):2312–2318. https://doi.org/10.1016/j \n.joms.2015.07.025.\n\t120.\t \u0007Mahmood R, Puthussery FJ, Flood T, Shekhar K. Dental \nimplant complications –extra-oral cutaneous fistula. Br Dent J. \n2013;215(2):69–70. https://doi.org/10.1038/sj.bdj.2013.683.\n\t121.\t \u0007Fujioka M, Oka K, Kitamura R, Yakabe A, Endoh H. Extra-oral fis-\ntula caused by a dental implant. J Oral Implantol. 2011;37(4):477–\n479. https://doi.org/10.1563/AAID-JOI-D-09-00008.1.\n\t122.\t \u0007Schlund M, Raoul G, Ferri J, Nicot R. Mandibular osteomyelitis fol-\nlowing implant placement. J Oral Maxillofac Surg. 2017;75(12):2560.\ne1–2560.e7. https://doi.org/10.1016/j.joms.2017.07.169.\n\t123.\t \u0007Shnaiderman-Shapiro A, Dayan D, Buchner A, Schwartz I, Yaha-\nlom R, Vered M. Histopathological spectrum of bone lesions asso-\nciated with dental implant failure: osteomyelitis and beyond. Head \nNeck Pathol. 2015;9(1):140–146. https://doi.org/10.1007/s12105-\n014-0538-4.\n\t124.\t \u0007Semel G, Wolff A, Shilo D, Akrish S, Emodi O, Rachmiel A. Man-\ndibular osteomyelitis associated with dental implants. A case series. \nEur J Oral Implantol. 2016;9(4):435–442.\n\t125.\t \u0007Yahalom R, Ghantous Y, Peretz A, Abu-Elnaaj I. The possible \nrole of dental implants in the etiology and prognosis of osteo-\nmyelitis: a retrospective study. Int J Oral Maxillofac Implants. \n2016;31(5):1100–1109. https://doi.org/10.11607/jomi.4527.\n\t126.\t \u0007Naval L, Molini MS, Herrera G, Naval B. Dental implants and \nosteomyelitis in a patient with osteopetrosis. Quintessence Int. \n2014;45(9):765–768. https://doi.org/10.3290/j.qi.a32443.\n\t127.\t \u0007Pigrau C, Almirante B, Rodriguez D, et al. Osteomyelitis of the \njaw: resistance to clindamycin in patients with prior antibiotics \nexposure. Eur J Clin Microbiol Infect Dis. 2009;28(4):317–323. \nhttps://doi.org/10.1007/s10096-008-0626-z.\n\t128.\t \u0007Kesting MR, Thurmuller P, Ebsen M, Wolff KD. Severe osteomy-\nelitis following immediate placement of a dental implant. Int J Oral \nMaxillofac Implants. 2008;23:137.\n\t129.\t \u0007O’Sullivan D, King P, Jagger D. Osteomyelitis and pathologi-\ncal mandibular fracture related to a late implant failure: a clinical \nreport. J Prosthet Dent. 2006;95(2):106–110.\n\t130.\t \u0007Chatelain S, Lombardi T, Scolozzi P. Streptococcus angi-\nnosus dental implant-related osteomyelitis of the jaws: an \ninsidious and calamitous entity. J Oral Maxillofac Surg. 2018; \nS0278–2391 \n(18):30032–30036. \nhttps://doi.org/10.1016/j \n.joms.2018.01.010.\n\t131.\t \u0007Baltensperger M. A Retrospective Analysis of 290 Osteomyelitis Cases \nTreated in the Past 30 Years at the Department of Cranio-Maxillo­\nfacial Surgery Zurich with Special Recognition of the Classification. \nZurich: Med Dissertation; 2003.\n\t132.\t \u0007Hudson JW. Osteomyelitis of the jaws: a 50-year perspective. J \nOral Maxillofac Surg. 1993;51:1294.\n\t133.\t \u0007Topazian RG. Osteomyelitis of the jaws. In: Topazian RG, Gold-\nberg MH, Hupp JR, eds. Oral and Maxillofacial Infections. 4th ed. \nPhiladelphia, PA: WB Saunders; 2002:214–242.\n\t134.\t \u0007Baltensperger M, Eyrich GK. Osteomyelitis of the jaws: Definition \nand classification. In: Baltensperger M, Eyrich GK, eds. Osteomyeli­\ntis of the Jaws. Berlin: Springer-Verlag; 2009:5–47.\n\t135.\t \u0007Koorbusch GF, Deatherage JR, Curé JK. How can we diagnose \nand treat osteomyelitis of the jaws as early as possible? Oral Max­\nillofac Surg Clin North Am. 2011;23(4):557–567. https://doi \n.org/10.1016/j.coms.2011.07.011.\n\t136.\t \u0007Marx RE. Chronic osteomyelitis of the jaws. Oral Maxillofac Surg \nClin North Am. 1991;3(2):367–381.\n\t137.\t \u0007Mercuri LG. Acute osteomyelitis of the jaws. Oral Maxillofac Surg \nClin North Am. 1991;3(2):355–365.\n\t138.\t \u0007Koorbusch GF, Fotos P, Goll KT. Retrospective assessment of \nosteomyelitis. Etiology, demographics, risk factors, and manage-\nment in 35 cases. Oral Surg Oral Med Oral Pathol. 1992;74(2):149–\n154.\n\t139.\t \u0007Doll C, Hartwig S, Nack C, Nahles S, Nelson K, Raguse JD. Dra-\nmatic course of osteomyelitis in a patient treated with immediately \nplaced dental implants suffering from uncontrolled diabetes: a case \nreport. Eur J Oral Implantol. 2015;8(4):405–410.\n\t140.\t \u0007Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, \nCosterton JW. Microbial biofilms in osteomyelitis of the jaw and \nosteonecrosis of the jaw secondary to bisphosphonate therapy. J Am \nDent Assoc. 2009;140(10):1259–1265.\n\t141.\t \u0007Coviello V, Stevens MR. Contemporary concepts in the treatment \nof chronic osteomyelitis. Oral Maxillofac Surg Clin North Am. \n2007;19:523.\n\t142.\t \u0007Baur DA, Altay MA, Flores-Hidalgo A, et al. Chronic osteomyeli-\ntis of the mandible: Diagnosis and management—an institution’s \nexperience over 7 years. J Oral Maxillofac Surg. 2015;73:6559.\n\t143.\t \u0007Chadha GK, Ahmadieh A, Kumar S, Sedghizadeh PP. Osseointe-\ngration of dental implants and osteonecrosis of the jaw in patients \ntreated with bisphosphonate therapy: a systematic review. J Oral \nImplantol. 2013;39(4):510–520. https://doi.org/10.1563/AAID-\nJOI-D-11-00234.\n\t144.\t \u0007Kwon TG, Lee CO, Park JW, Choi SY, Rijal G, Shin HI. \nOsteonecrosis associated with dental implants in patients \nundergoing bisphosphonate treatment. Clin Oral Implants Res. \n2014;25(5):632–640. https://doi.org/10.1111/clr.12088.\n\t145.\t \u0007Yuan K, Chen KC, Chan YJ, Tsai CC, Chen HH, Shih CC. Dental \nimplant failure associated with bacterial infection and long-term \nbisphosphonate usage: a case report. Implant Dent. 2012;21(1):3–7. \nhttps://doi.org/10.1097/ID.0b013e3182425c62.\n\t146.\t \u0007Pichardo SE, van Merkesteyn JP. Bisphosphonate related osteone-\ncrosis of the jaws: spontaneous or dental origin? Oral Surg Oral \nMed Oral Pathol Oral Radiol. 2013;116(3):287–292. https://doi \n.org/10.1016/j.oooo.2013.05.005.\n\t147.\t \u0007Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, \nCosterton JW. Identification of microbial biofilms in osteone-\ncrosis of the jaws secondary to bisphosphonate therapy. J Oral \nMaxillofac Surg. 2008;66(4):767–775. https://doi.org/10.1016/j \n.joms.2007.11.035.\n\t148.\t \u0007Heitz-Mayfield LJ, Lang NP. Comparative biology of chronic \nand aggressive periodontitis vs. periimplantitis. Periodontol 2000. \n2010;53:167–181.\n\t149.\t \u0007Zitzmann NU, Berglundh T. Definition and prevalence of peri-\nimplant diseases. J Clin Periodontol. 2008;35(suppl 8):286–291.\n\t150.\t \u0007Renvert S, Quirynen M. Risk indicators for peri-implantitis. A \nnarrative review. Clin Oral Implants Res. 2015;26(suppl 11):15–44. \nhttps://doi.org/10.1111/clr.12636.\n\t151.\t \u0007Botero JE, González AM, Mercado RA, Olave G, Contreras \nA. Subgingival microbiota in peri-implant mucosa lesions and \nadjacent teeth in partially edentulous patients. J Periodontol. \n2005;76(9):1490–1495."
  },
  {
    "page": 150,
    "content": "358\nPART III    Fundamental Science\n\t152.\t \u0007Renvert S, Roos-Jansåker AM, Lindahl C, Renvert H, ­Rutger Pers-\nson G. Infection at titanium implants with or without a clinical \ndiagnosis of inflammation. Clin Oral Implants Res. 2007;18(4):509–\n516.\n\t153.\t \u0007Bowen-Antolín A, Pascua-García MT, Nasimi A. Infections in \nimplantology: from prophylaxis to treatment. Med Oral Patol Oral \nCir Bucal. 2007;12:e323–e330.\n\t154.\t \u0007Rosan B, Lamont RJ. Dental plaque formation. Microbes Infect. \n2000;2:1599–1607.\n\t155.\t \u0007Donlan RM, Costerton JW. Biofilms: survival mechanisms of clini-\ncally relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193.\n\t156.\t \u0007Dufour D, Leung V, Levesque C. Bacterial biofilm: structure, func-\ntion, and antimicrobial resistance. Endodontic Topics. 2010;22(1):2–\n16. 03.\n\t157.\t \u0007Lindh L, Aroonsang W, Sotres J, Arnebrant T. Salivary pel-\nlicles. Monogr Oral Sci. 2014;24:30–39. https://doi.org/ \n10.1159/000358782.\n\t158.\t \u0007Dorkhan M, Svensäter G, Davies JR. Salivary pellicles on titanium \nand their effect on metabolic activity in Streptococcus oralis. BMC \nOral Health. 2013;13:32. https://doi.org/10.1186/1472-6831-13-\n32.\n\t159.\t \u0007Davey ME, O’Toole GA. Microbial biofilms: from ecology to \nmolecular genetics. Microbiol Mol Biol Rev. 2000;64:847–867.\n\t160.\t \u0007Bordin D, Cavalcanti IM, Jardim Pimentel M, et  al. Biofilm \nand saliva affect the biomechanical behavior of dental implants. \nJ Biomech. 2015;48(6):997–1002. https://doi.org/10.1016/j.jbio-\nmech.2015.02.004.\n\t161.\t \u0007Nelson CL, McLaren AC, McLaren SG, et al. Is aseptic loosening \ntruly aseptic? Clin Orthop Rel Res. 2005;437:25.\n\t162.\t \u0007Camps-Font O, Viaplana-Gutiérrez M, Mir-Mari J, Figueiredo \nR, Gay-Escoda C, Valmaseda-Castellón E. Antibiotic prescription \nfor the prevention and treatment of postoperative complications \nafter routine dental implant placement. A cross-sectional study per-\nformed in Spain. J Clin Exp Dent. 2018;10(3):e264–e270. https://\ndoi.org/10.4317/jced.54637.\n\t163.\t \u0007Deeb GR, Soung GY, Best AM, Laskin DM. ­Antibiotic \nprescribing habits of oral and maxillofacial surgeons in \nconjunction with routine dental implant placement. J Oral Max­\nillofac Surg. 2015;73(10):1926–1931. https://doi.org/10.1016/j \n.joms.2015.05.024.\n\t164.\t \u0007Chrcanovic BR, Albrektsson T, Wennerberg A. Prophylactic \nantibiotic regimen and dental implant failure: a meta-analysis. J \nOral Rehabil. 2014;41(12):941–956. https://doi.org/10.1111/\njoor.12211.\n\t165.\t \u0007Keenan JR, Veitz-Keenan A. Antibiotic prophylaxis for dental \nimplant placement? Evid Based Dent. 2015;16(2):52–53. https://\ndoi.org/10.1038/sj.ebd.6401097.\n\t166.\t \u0007Esposito M, Grusovin MG, Worthington HV. Interventions for \nreplacing missing teeth: antibiotics at dental implant placement to pre-\nvent complications. Cochrane Database Syst Rev. 2013;(7):CD004152. \nhttps://doi.org/10.1002/14651858.CD004152.pub4."
  },
  {
    "page": 151,
    "content": "359\n14\nPharmacology in Implant \nDentistry\nRANDOLPH R. RESNIK\nB\necause of the increase in demand and use of dental implants \nin dentistry today, a thorough understanding of the indica-\ntions and protocol for the use of pharmacologic agents in \nimplant dentistry is essential for the implant clinician. The mor-\nbidity of implant-related complications may on occasion be sig-\nnificant; therefore ideal medication selection and sufficient dosage \nlevels of medications are preoperatively and postoperatively indi-\ncated. In addition, the scope of implant treatment often encom-\npasses an older population with more complex cases and medical \nhistories. As a result, treatment requires a greater understanding \nof the use of pharmacologic agents to decrease implant morbidity \nand possible complications.\nCurrently in implant dentistry, no consensus exists on the \npharmacologic protocol based on both the patient’s health status \nand procedure type. Many practitioners use medications empiri-\ncally or generically with respect to all procedures with little basis \non scientific facts and studies. The author has developed a phar-\nmacologic protocol with the goal of decreasing complications \nand increasing the success rate of implants with an emphasis on \nthe patient’s health status and the invasiveness of the procedure. \nTherefore this chapter will provide the implant dentist with an \noverview of the pharmacokinetics and pharmacodynamics of vari-\nous classifications of medications, together with an understanding \nof the proper prescribing protocol used in implant dentistry today \nwith respect to different patient and procedure characteristics.\nAntimicrobials\nAn important complication to prevent after implant surgery is \ninfection. Infectious episodes may lead to a multitude of prob-\nlems, including pain, swelling, loss of bone, and possible failure \nof the implant. Because of the risk for morbidity resulting from \ninfections, antimicrobial therapy is an essential component of the \nsurgical protocol. Although adverse effects are associated with \nantibiotic therapy, these are usually mild and infrequent. The most \ncommon antimicrobials used in implant dentistry today consist of \nantibiotics (local and systemic) and antimicrobial rinses (0.12% \nchlorhexidine gluconate).\nAntibiotics\nThe use and understanding of the various antibiotic regimens \navailable in implant dentistry are beneficial for the initial success \nand long-term maintenance of implant therapy. Antibiotic ther-\napy in implant dentistry may be classified as either prophylactic \n(prevent infection) or therapeutic (treat infection). The field of \ndentistry has been shown to prescribe a considerable amount of \nantibiotics administered in the United States (7%–11%).1\nProphylactic Antibiotics\nIn general surgery, including its subspecialties, principles of anti-\nbiotic prophylaxis are well established. Guidelines are specifically \nrelated to the procedure, the type of antibiotic, and the dosage reg-\nimen.2,3 The use of prophylactic antibiotics in dentistry has also \nbeen documented in the prevention of complications for patients \nat risk for development of infectious endocarditis and immu-\nnocompromised patients. However, in oral implantology, there \nexists no consensus on the use and indications for prophylactic \nantibiotics. Disadvantages with the use of antibiotics include cost, \ndevelopment of resistant bacteria, adverse reactions, and pos-\nsible resultant lax surgical technique.4-6 As a result the need for \nprophylactic antibiotics in healthy patients, type of antibiotic, \ndosage, and duration of coverage is controversial. On the other \nhand, postoperative surgical wound infections can have a signifi-\ncant impact on the well-being of the patient and the survival of \nthe implant or bone graft. Documented cases of potential conse-\nquences of infection range from increased pain and edema to even \npatient death. According to Esposito and Hirsch,7 one of the main \ncauses of dental implant failure is due to bacterial contamination \nat implant insertion.\nA local inoculum must be present for a surgical wound infec-\ntion to occur, to overcome the host’s defenses and allow growth \nof the bacteria. This process has many variables, including various \nhost, local tissue, systemic and microbial virulence factors. Antibi-\notic prophylaxis is only one component of this complex cascade; \nhowever, the efficacy and impact of antimicrobial prophylaxis has \nbeen proven to be significant.4\nSeveral studies have concluded there is a benefit of preopera-\ntive antibiotics for dental implantology.8-10 In the most compre-\nhensive and controlled study to date, 33 hospitals formed the \nDental Implant Clinical Research Group and concluded the use \nof preoperative antibiotics significantly improved dental implant \nsurvival, both in early and later stages. In the evaluation of 2973 \nimplants, a significant difference was found with the use of pre-\noperative antibiotics (4.6% failure) compared with no antibiotics \n(10% failure).8,9"
  },
  {
    "page": 152,
    "content": "360\nPART III    Fundamental Science\nThe main goal of the use of prophylactic antibiotics is to pre-\nvent infection during the initial healing period from the surgical \nwound site, thus decreasing the risk for infectious complications \nof the soft and hard tissues. Although there is no conclusive evi-\ndence on the mechanism of preoperative antibiotics, most likely \na greater aseptic local environment is achieved. A landmark study \nby Burke11 defined the scientific basis for the perioperative use of \nantibiotics to prevent surgical wound infection. From this work, \nseveral accepted principles have been established in the periopera-\ntive use of prophylactic antibiotics.12\nPrinciple 1: The Procedure Should Have a Significant Risk \nfor and Incidence of Postoperative Infection. To evaluate the \nrisk for postoperative wound infection, the American College \nof Surgeons (Committee on Control of Surgical Wound Infec-\ntions) developed a classification of operative wounds and risk \nfor infection. All surgical procedures were classified according \nto four levels of contamination and infection rates (Box 14.1). \nWithin these classifications, it is generally accepted that all class \n2, 3, and 4 procedures warrant the use of prophylactic antibiot-\nics.13 By definition, elective dental implant surgery falls within the \nclass 2 (clean-contaminated) category. Class 2 medical and dental \nsurgical procedures have been shown to have an infection rate of \napproximately 10% to 15%. However, with proper surgical tech-\nnique and prophylactic antibiotics, the incidence rate of infection \nmay be reduced to less than 1%.14,15 In a healthy patient, risk for \ninfection after dental implant surgery is influenced by numerous \nfactors, such as type and location of surgery, skill of the surgeon, \nmethods of intraoperative management, patient factors, and asep-\ntic technique.14,16 Moreover, additional patient-related (systemic \nand local) risk factors that are not addressed in these classifications \nhave also been correlated with increased susceptibility to infec-\ntion. These factors must be addressed in reference to evaluation for \nthe use and duration of antibiotic prophylaxis (Box 14.2).\nOne of the most significant surgical factors that may con-\ntribute to infection is poor aseptic technique. Various routes of \ntransmission of virulent bacteria include: (1) direct contact with \nthe patient’s blood or other body fluids; (2) indirect contact with \ncontaminated objects; (3) contact of infected nasal, sinus, or oral \nmucosa; and (4) inhalation of airborne microorganisms. To pre-\nvent these conditions, a controlled, well-monitored aseptic setting \nshould be achieved for the surgical procedures that are at high \nrisk of infection. The aseptic surgical site includes proper disin-\nfection and draping procedures of the patient, hand scrubbing, \nsterile gowns worn by all surgical members, and maintenance of \ncomplete sterility of the instrumentation.\nAnother important surgical factor related to postoperative \ninfection is the duration of the surgical procedure. This factor \nhas been shown to be the second most critical risk factor (after \nwound contamination) affecting postoperative infection rates.17 \nIn general, surgical operations lasting less than 1 hour have an \ninfection rate of 1.3%, whereas those lasting 3 hours increase the \nrate to more than 4%.18-20 It is postulated that the rate of infec-\ntion doubles with every hour of the procedure.21 The skill and the \nexperience of the surgeon with the placement of implants has been \nshown to be significant in postoperative infections and implant \nfailures. A recent study has shown that less-experienced surgeons \n(<50 implants placed) have a 7.3% increase in failure rates in com-\nparison with experienced surgeons.9\nIn the medical literature it is well documented that the inser-\ntion of any prosthetic implant or device increases the chance of \ninfection at the surgical site. A dental implant can act as a for-\neign body, and the host’s defenses may therefore be compromised. \nThe surface of the implant has been shown to facilitate bacterial \nadherence, and the presence of an implant can compromise the \nhost’s defenses. This may result in normal flora with low virulence \npotential to cause infections at the implant-host interface, which \nhas been shown to be very difficult to treat.22-24\nThe probability of risk for infection for a given procedure is \nrelated to local, systemic, and surgical factors. The patient’s Ameri-\ncan Society of Anesthesiologists (ASA) score may be used as the \nsystemic factor and then correlated with various local and surgical \nfactors. A risk index may then be modified from the literature to \ncorrelate these factors to dental implant surgeries (Table 14.1). \nThe probability of wound infection may then be correlated with \nthe type of wound contamination (class 1–4) and the risk index. \nTherefore a class 2 wound with a risk index 2 has a greater risk for \ncomplications, and a class 1 wound with risk index 0 has the least \nrisk for postoperative infection.18,25 \nClass 1: clean (<2%)\n \n• \u0007Elective, nontraumatic surgery; no acute inflammation; respiratory, \ngastrointestinal (GI), and biliary tracts not entered\nClass 2: clean-contaminated (10%–15%)\n \n• \u0007Elective opening of the respiratory, GI, and biliary tracts entered\n \n• \u0007Elective dental implant and bone graft procedures\nClass 3: contaminated (20%–30%)\n \n• \u0007Inflammation, gross spillage from GI and biliary tracts, along with \nfresh traumatic injuries\nClass 4: dirty/infected (50%)\n \n• \u0007Established clinical infection; perforation of respiratory, GI, and \nbiliary tracts\n\t • BOX 14.1\t    \u0007Surgical Wound Classifications with \nAssociated Infection Rates\nSystemic Factors\n • \u0007Diabetes\n • \u0007Long-term corticosteroid use\n • \u0007Smoking, Alcohol Abuse\n • \u0007Immunocompromised systemic disorders\n • \u0007Malnutrition, obesity\n • \u0007Elderly population\n • \u0007American Society of Anesthesiologists score 3 or 4 \nLocal Factors\n • \u0007Use/type of grafting material (autogenous, allograft, alloplast)\n • \u0007Periodontal disease\n • \u0007Tissue inflammation\n • \u0007Odontogenic infections\n • \u0007Ill-fitting provisional prosthesis\n • \u0007Incision line opening\n • \u0007Inadequate hygiene \nSurgical Factors\n • \u0007Poor aseptic technique\n • \u0007Skill/experience of the surgeon\n • \u0007Increased duration of surgery\n • \u0007Wound contamination during surgery\n • \u0007Foreign body (implant)\n\t • BOX 14.2\t    \u0007Factors Associated with Increased \nRisk for Infection with Dental Implant \nProcedures"
  },
  {
    "page": 153,
    "content": "361\nCHAPTER 14  Pharmacology in Implant Dentistry\nPrinciple 2: The Appropriate Antibiotic for the Surgi-\ncal Procedure Must Be Selected. The prophylactic antibiotic \nshould be effective against the bacteria that are most likely to \ncause an infection. In the majority of cases, infections after sur-\ngery are from organisms that originate from the site of surgery.12 \nMost postoperative infections are caused by endogenous bacteria, \nincluding aerobic gram-positive cocci (streptococci), anaerobic \ngram-positive cocci (peptococci), and anaerobic gram-negative \nrods (bacteroides)14 (Box 14.3).\nAlthough oral infections are usually mixed infections in which \nanaerobes outnumber aerobes 2:1, it has been shown that anaer-\nobes need the aerobes to provide an environment to proliferate.26 \nSubsequent studies have shown that the early phase of intraoral \ninfections involves streptococci that prepare the environment for \nsubsequent anaerobic invasion.27,28 With that in mind, the ideal \nantibiotic must be effective against these pathogens.\nThe second factor in selecting the correct antibiotic is to use the \nantibiotic with the least amount of adverse effects. These effects \nmay vary from mild nausea to the extreme allergic reaction.\nThe final selection factor is that the antibiotic should ideally \nbe bactericidal. The goal of antibiotic prophylaxis is to kill and \ndestroy the bacteria. Bacteriostatic antibiotics work by inhibit-\ning growth and reproduction of bacteria, thus allowing the host \ndefenses to eliminate the resultant bacteria. However, if the \nhost’s defenses are compromised in any way, the bacteria and \ninfection may flourish. Bactericidal antibiotics are advantageous \nover bacteriostatic antibiotics in that: (1) there is less reliance \non host resistance, (2) the bacteria may be destroyed by the \nantibiotic alone, (3) results are faster than with bacteriostatic \nmedications, and (4) there is greater flexibility with dosage \nintervals.14 \nPrinciple 3: An Appropriate Tissue Concentration of the \nAntibiotic Must Be Present at the Time of Surgery. For an anti-\nbiotic to be effective, a sufficient tissue concentration must be \npresent at the time of bacterial invasion. To accomplish this goal, \nthe antibiotic should be given in a dose that will reach plasma \nlevels that are three to four times the minimum inhibitory con-\ncentration of the expected bacteria.29 The minimum inhibitory \nconcentration is defined as the lowest antibiotic concentration to \ndestroy the specific bacteria. Usually the antibiotic must be given \nat twice the therapeutic dose and at least 1 hour before surgery to \nachieve this cellular level.16 It has been shown that normal thera-\npeutic blood levels are ineffective to counteract bacterial invasion. \nIf antibiotic administration occurs after bacterial contamination, \nno preventive influence has been seen compared with taking no \npreoperative antibiotic. \nPrinciple 4: Use of the Shortest Effective Antibiotic. In a \nhealthy patient, continuing antibiotics after surgery often does not \ndecrease the incidence of surgical wound infections.3,30,31 Therefore, \ndepending on the procedure and infection risk, in some patients a \nsingle dose of antibiotics is usually sufficient. However, for patients \nor procedures with increased risk factors (see Box 14.2), a longer \ndose of antibiotics is warranted.12 With the high degree of morbid-\nity associated with dental implant infections, one must weigh the \nbenefits versus risk involved for the extended use of antibiotics. \nComplications of Antibiotic Prophylaxis\nWith the use of prophylactic antibiotics for dental implant \nprocedures, many side effects may develop. It is estimated that \napproximately 6% to 7% of patients who are taking antibiotics \nwill have some type of adverse event.32 Incidence of significant \ncomplications with the use of prophylactic antibiotics are mini-\nmal; however, a small percentage can be life-threatening. The \nrisks associated with antibiotics include gastrointestinal (GI) tract \ncomplications, colonization of resistant or fungal strains, cross-\nreactions with other medications, and allergic reactions.\nAllergic reactions have a wide range of complications, rang-\ning from mild urticaria to an anaphylaxis and death. Studies have \nshown that 1% to 3% of the population receiving penicillin will \nexhibit the urticaria type of reactions, with 0.04% to 0.011% hav-\ning true anaphylactic episodes. Of this small percentage of ana-\nphylactic reactions, 10% will be fatal.33\nAn unusual but increasing complication in the general popula-\ntion after antibiotic use is pseudomembranous colitis (PMC). This \ncondition is caused by the intestinal flora being altered and colo-\nnized by Clostridium difficile. Penicillin and clindamycin use have \nbeen significantly associated with PMC; however, all antibiotics \nhave been shown as potential causative agents. The risk levels of \ncolitis related to antibiotics are outlined in Table 14.2. The most \ncommon treatment for antibiotic-induced colitis is vancomycin \nor metronidazole.\nThe most recent concern of antibiotic use is the development \nof resistant bacteria. It has been observed that the overgrowth \nof resistant bacteria begins only after the host’s susceptible bac-\nteria are killed, which usually takes at least 3 days of antibi-\notic use. Therefore short-term (1 day) use of antibiotics has \nbeen shown to have little influence on the growth of resistant \nbacteria.14 \n  \u0007Probability of Wound Infection by Type of \nWound, Risk Index, and American Society of \nAnesthesiologists Status\nRISK INDEX\nOperation Classification\n0\n1\n2\nClean\n1.0%\n2.3%\n5.4%\nClean-contaminated\n2.1%\n4.0%\n9.5%\nRisk index classification: 0: ASA 1 or ASA 2, and no local or surgical factors; 1: ASA ≥2, at \nleast one of the local or surgical factors is present; 2: ASA ≥2, both local and surgical factors \nare present.\nASA, American Society of Anesthesiologists.\nData are from Cruse PJ, Foord R. A 5-year prospective study of 23,649 surgical wounds. Arch \nSurg. 1973;107:206-210.\n   \nTABLE \n14.1\n • \u0007Staphylococcus spp.\n • \u0007Actinomyces spp.\n • \u0007Surface translocating bacteria\n • \u0007Wolinella spp.\n • \u0007Capnocytophaga spp.\n • \u0007Fusobacterium spp.\n • \u0007Entamoeba gingivalis\n • \u0007Motile rods\n • \u0007Fusiforms\n • \u0007Spirochetes\n • \u0007Enteric gram-negative bacteria\n • \u0007Candida albicans\n\t • BOX 14.3\t    \u0007Microorganisms Most Commonly \nAssociated with Peri-implant \nComplications"
  },
  {
    "page": 154,
    "content": "362\nPART III    Fundamental Science\nAntibiotics Used in Implant Dentistry\nBeta-Lactam Antibiotics. The most common beta-lactam \nantibiotics used in implant dentistry are the penicillins and cepha-\nlosporins. These antibiotics have similar chemical structures, and \nthe mechanism of action is by inhibiting bacterial cell wall synthe-\nsis (bacteriocidal) via the interruption of the cross-linking between \npeptidoglycan molecules.\nPenicillin V. Penicillin V is one of the more common antibiot-\nics currently used in dentistry. It is well absorbed and will achieve \npeak serum levels within 30 minutes of administration with \ndetectable blood levels for 4 hours. Penicillin V is effective against \nmost Streptococcus species and oral anaerobes. The main disadvan-\ntages of penicillin are four times per day dosing and susceptibility \nto resistant bacteria. \nAmoxicillin. Amoxicillin is a derivative of ampicillin, with the \nadvantage of superior absorption and a bioavailability of 70% to \n80% with a very low toxicity. It has excellent diffusion in infected \ntissues, and adequate tissue concentrations are easily achieved. \nAmoxicillin is considered broad spectrum and is effective against \ngram-negative cocci and gram-negative bacilli. This antibiotic also \nhas greater activity than penicillin V against streptococci and oral \nanaerobes. \nAmoxicillin/Clavulanic Acid (Augmentin). A combination \nof two antibiotics was synthesized to counteract the activity of \nbeta-lactamase destruction of penicillins by resistant bacteria such \nas Streptococcus aureus. Clavulanic acid, a beta-lactam antibiotic, \nwas added to amoxicillin to form Augmentin. This combination \nantibiotic has an affinity for penicillinase-producing bacteria. It \nfunctions as a “suicide molecule” that inactivates the resistant bac-\nteria. As a result of an increase in the prevalence of these specific \nbacteria (especially in the sinus), Augmentin is becoming more \npopular in oral implantology. This antibiotic is used mainly in \ncases in which penicillinase bacteria are suspected (or known by \nculture) and is practical as a perioperative antibiotic for sinus aug-\nmentation procedures (Fig. 14.1 and Box 14.4). \nCephalosporins. The cephalosporin family is designated \naccording to their generation (generations 1–5), with increas-\ning generation equaling increasing spectrum activity. The first \ngeneration (cephalexin) has coverage similar to amoxicillin (i.e., \ngram-positive cocci with a limited activity against gram-negative \npathogens). The second-generation cephalosporins have greater \ngram-negative pathogen and anaerobic coverage. Third-generation \ncephalosporins exhibit even greater gram-negative activity, with \nthe fourth generation demonstrating efficacy against most gram-\npositive and -negative activity. Fifth-generation cephalosporins \nhave activity against methicillin-resistant Staphylococcus aureus.\nA disadvantage that is often discussed is the cross-reactivity \nwith patients who are allergic to penicillin. They are often used \nin dentistry as an alternative for the patient who is allergic to \npenicillin, although cross-reactivity between these two drugs may \noccur. Rates of cross-reactivity to first-generation cephalosporins \nwith patients who are allergic to penicillin have been cited to be \napproximately 8% to 18%. The most recent gram-positive and \n-negative bacteria studies have shown that only patients who have \nhad type I (immunoglobulin E: immediate hypersensitivity reac-\ntions) should not be administered a cephalosporin. If the patient \nhas a previous history of a reaction that was not immunoglobulin \nE mediated (types II, III, or IV, or idiopathic reactions), a first-\ngeneration cephalosporin may be administered. Newer second- \nand third-generation cephalosporins exhibit a broader spectrum, \nless cross-reactivity, and a greater resistance to beta-lactamase \ndestruction (Box 14.5).34 \nMacrolides\nFor years the most common macrolide used in dentistry was \nerythromycin. It is active against most streptococci, staphylococci, \nand some anaerobes, and it is an alternative for patients who are \nallergic to penicillin. Erythromycin has the advantage of excellent \nabsorption and, unlike many drugs, is affected by the presence of \nfood. It is administered primarily by the oral route and has a rela-\ntively low toxicity. However, this antibiotic has a high incidence \n  \u0007Risks for Antibiotic-Induced \nPseudomembranous Colitis\nHigh\nMedium\nLow\n • \u0007Ampicillin\n • \u0007Amoxicillin\n • \u0007Cephalosporin\n • \u0007Clindamycin\n • \u0007Penicillin\n • \u0007Erythromycin\n • \u0007Quinolones\n • \u0007Tetracyclines\n • \u0007Metronidazole\n • \u0007Vancomycin\n   \nTABLE \n14.2\nBacteria\nBeta-lactam\nring\nBeta-lactam\nring\nBeta-lactamase\n(Destroys bacteria)\n(Binds to clavulanate)\nClavulanate\nCHCH2OH\nCOOH\nCH3\nCH3\nR1\nPenicillin \u001f\nCOOH\nO\nO\nC\nR\nN\nN\nN\nH\nO\n• Fig. 14.1  Beta-lactamase inactivation by the addition of clavulanic acid to \namoxicillin (Augmentin). Because of the high binding affinity of clavulanic \nacid, beta-lactamase will be inactivated, allowing penicillin to destroy the \nbacteria.\nGeneric\nBrand Name\nAmoxicillin\nAmoxil, Polymox, Trimox, Wymox\nAmpicillin\nOmnipen, Polycillin, Polycillin-N\nBacampicillin\nSpectrobid\nCarbenicillin\nGeocillin, Geopen\nCloxacillin\nCloxapen\nDicloxacillin\nDynapen, Dycill, Pathocil\nFlucloxacillin\nFlopen, Floxapen, Staphcillin\nMezlocillin\nMezlin\nNafcillin\nNafcil, Nallpen, Unipen\nOxacillin\nBactocill, Prostaphlin\nPenicillin G\nBicillin L-A\nPenicillin V\nBeepen-VK, Betapen-VK, V-Cillin K\nTicarcillin\nTicar\n\t• BOX 14.4\t   \u0007Common Penicillin Antibiotics"
  },
  {
    "page": 155,
    "content": "363\nCHAPTER 14  Pharmacology in Implant Dentistry\nof nausea and is bacteriostatic rather than bacteriocidal, and it is \ntherefore not an ideal first-line choice for infections in the oral \ncavity.\nErythromycin has questionable use when a severe infection \nexists or when the patient is immunocompromised and requires \nbacteriocidal activity. Even more disturbing is its implication in \nnumerous drug interactions, including its proclivity for elevating \nserum levels of digoxin, theophylline, and carbamazepine. Eryth-\nromycin has also been found to retard conversion of terfenadine \n(Seldane), a nonsedating antihistamine, to its active metabolite. \nAs a result, elevated serum concentrations of the predrug may \nresult and lead to cardiotoxicity, presenting a particular form of \nventricular tachycardia called torsades de pointes.\nTherefore two novel macrolides have shown to be advantageous \nover erythromycin (i.e., clarithromycin [Biaxin] and azithromy-\ncin [Zithromax]). Unlike other macrolides, they do not appear \nto inhibit hepatic cytochrome P450 isozymes, which account for \nmost drug interactions inherent with erythromycin. Biaxin has \nbeen shown to produce less nausea and has better gram activity; \nZithromax appears to be more effective against Haemophilus influ-\nenzae (Box 14.6). \nClindamycin\nThe use of clindamycin is popular for the treatment of dental infec-\ntions primarily because of its activity against anaerobic bacteria. \nIt also is active against aerobic bacteria, such as streptococci and \nstaphylococci, and it has superior effects against Bacteroides fra-\ngilis. Clindamycin (Cleocin phosphate) is supplied as an aqueous \n(300 mg/2 mL) solution that is sometimes used in the incorpora-\ntion of graft material for sinus augmentation procedures. How-\never, it is bacteriostatic in normal concentrations and has a rather \nhigh toxicity in larger concentrations. As a result the main disad-\nvantage of clindamycin is the occurrence of diarrhea in 20% to \n30% of patients treated. This antibiotic also has a higher incidence \nof antibiotic-associated PMC caused by C. difficile when adminis-\ntrated for extended periods. PMC has been reported to occur with \nmost long-term antibiotics.\nThe toxicity of antibiotics related to PMC is elevated with ampi-\ncillin, amoxicillin, cephalosporin, and clindamycin. Penicillin, \nerythromycin, and quinolones are moderate risk, and the lowest \noccurrence is with tetracycline, metronidazole, and vancomycin. \nThe latter group is often used even to treat PMC conditions.\nThe patient should be informed that if either diarrhea or \nabdominal cramping occurs during or shortly after antibiotic ther-\napy, the drug should be discontinued and the physician should \nbe notified. Antidiarrheal medications should be avoided in these \ncases because they hinder the fecal elimination of the pathogen. \nIf it is necessary to continue management of the dental infection, \nconsultation with the patient’s physician is warranted. \nTetracyclines\nTetracycline is a bacteriostatic antibiotic that inhibits protein syn-\nthesis. Tetracycline has been available since the 1950s and has a \nwide spectrum of activity against streptococci, staphylococci, oral \nanaerobes, and gram-negative aerobic rods. Because this antibiotic \nhas been so extensively used in the past, there exists a high degree \nof bacterial resistance. Tetracycline is an attractive adjunct for the \ntreatment of gingival and periodontal disease with a high bioavail-\nability in the gingival sulcus. For these reasons tetracyclines are \nprimary agents for treating implant disease and infections around \nimplant posts. Their efficacy for managing infrabony infections \nis questionable, considering their inactivity when chelated with \ncalcium complexes. The disadvantages of this antibiotic include \na high incidence of promoting Candida spp. infections, and it \nmay be associated with photosensitivity reactions. Tetracycline has \nbeen shown to be advantageous in allowing for reosseointegration \nresulting from peri-implant disease. Case reports have shown that \napplication of 50 mg/mL tetracycline for 5 minutes and then bone \ngrafting resulted in bone growth fill in the peri-implant defects.35 \nFluoroquinolones\nFluoroquinolones are bactericidal antibiotics and have a broad \nantibacterial spectrum, which may be used either orally or par-\nenterally. Ciprofloxacin is one of the first-generation quinolones \nand is the prototype antibiotic for this antibiotic classification. \nNewer third-generation (Levaquin, Avelox) quinolones have been \ndeveloped with great activity against resistant bacteria and anaero-\nbic bacteria. However, the U.S. Food and Drug Administration \nhas placed warnings on this antibiotic class because of the poten-\ntial for disabling and potentially permanent side effects related to \ntendon damage. Therefore these antibiotics are no longer used to \nGeneric\nBrand Name\nFirst Generation\n • \u0007Cefadroxil (cefadroxyl)\n • \u0007Cefalexin (cephalexin)\n • \u0007Cefalotin (cephalothin)\n • \u0007Cefapirin (cephapirin)\n • \u0007Cefazolin (cephazolin)\nDuricef, Ultracef\nKeflex, Keftab\nKeflin\nCefadyl\nAncef, Kefzol\nSecond Generation\n • \u0007Cefaclor\n • \u0007Cefprozil (cefproxil)\n • \u0007Cefuroxime\nCeclor, Ceclor-CD, Keflor\nCefzil\nCeftin, Kefurox\nThird Generation\n • \u0007Cefdinir\n • \u0007Cefixime\n • \u0007Cefmenoxime\n • \u0007Cefotaxime\n • \u0007Cefpodoxime\n • \u0007Ceftizoxime\n • \u0007Cefoperazone\n • \u0007Ceftazidime\nOmnicef, Cefdiel\nSuprax\nCefmax\nClaforan\nVantin\nCefizox\nCefobid\nCeptaz, Fortum, Fortaz\nFourth Generation\n • \u0007Cefepime (parenteral)\n • \u0007Cefpirome (parenteral)\nMaxipime\nCefrom\nFifth Generation\n • \u0007Ceftobiprole (parenteral)\n • \u0007Ceftaroline (parenteral)\nZeftera\nTeflaro\n\t • BOX 14.5\t    \u0007Common Cephalosporin Antibiotics\nGeneric\nBrand Name\n • \u0007Azithromycin\n • \u0007Erythromycin\n • \u0007Clarithromycin\nZithromax\nBiaxin\n\t • BOX 14.6\t   \u0007Common Macrolides Antibiotics"
  },
  {
    "page": 156,
    "content": "364\nPART III    Fundamental Science\ntreat dental implant–related issues unless no other options exist. \nPhysician consultation and approval are recommended in these \nsituations (Box 14.7). \nMetronidazole\nMetronidazole is a bacteriocidal antibiotic that is most often used \nfor anaerobic infections. Because metronidazole has no activity \nagainst aerobic bacteria, it is seldom used for mixed infections \nunless it is combined with another antibiotic. However, it may \nbe combined with penicillin when managing severe infections. \nPatients should be cautioned against drinking alcoholic bever-\nages while taking this medication, because disulfiram-like reac-\ntions have been reported. These consist of severe nausea and \nabdominal cramping caused by the formation of a toxic com-\npound resembling formaldehyde. Metronidazole should not be \nprescribed for patients who are taking the oral anticoagulant war-\nfarin (Coumadin). \nThe more common antibiotics and dosages used in oral \nimplantology for prophylaxis, grafting and implant insertion, \npostoperative infection, and long-term complications are listed in \nTable 14.3\nGeneric\nBrand Name\nFirst Generation\n • \u0007Nalidixic acid\n • \u0007Oxolinic acid\nNegGam, Wintomylon\nUroxin\nSecond Generation\n • \u0007Ciprofloxacin\n • \u0007Norfloxacin\n • \u0007Ofloxacin\nCipro, Cipro XR, Ciprobay, Ciproxin\nLexinor, Noroxin, Quinabic, \nJanacin\nFloxin, Oxaldin, Tarivid\nThird Generation\n • \u0007Gatifloxacin\n • \u0007Levofloxacin\n • \u0007Moxifloxacin\n • \u0007Temafloxacin\nTequin\nLevaquin\nAvelox\nOmniflox\nFourth Generation\n • \u0007Trovafloxacin\nTrovan\n\t • BOX 14.7\t    \u0007Common Fluoroquinolones Antibiotics\n  \u0007Commonly Used Antibiotics in Oral Implantology\nTHERAPEUTIC\nGeneric Name\nBrand Name\nBactericidal/Bacteriostatic\nUsual Adult Dosage\nMaximum Adult \nDosage\nProphylactic Dosages\nAmoxicillin\nAmoxil\nPolymox\nTrimox\nBactericidal\n250–500 mg\nTID\n4 g/day\nSBE: 2 g 1 hr before\nSurgical: 1 g 1 hr before\nAmoxicillin/Clavulanic \nacid\nAugmentin\nBactericidal\n250–500 mg TID or \n825 mg BID\n4 g/day\nSurgical: 825 mg\nCephalexin\nBiocef\nCefanex\nKeftab\nKeflex\nBactericidal\n250 mg QID\nor 500 mg BID\n4 g/day\nSBE: 2 g 1 hr before\nSurgical: 1 g 1 hr before\nCefadroxil\nDuricef\nUltracef\nBactericidal\n500 mg BID\n4 g/day\nSBE: 2 g 1 hr before\nSurgical: 1 g 1 hr before\nAzithromycin\nZithromax\nBacteriostatic\n500 mg immediately, \n1000 mg/day\n—\nSBE: 500 mg 1 hr before\nClarithromycin\nBiaxin\nBacteriostatic\n250 mg\n—\nSBE: 500 mg 1 hr before\nErythromycin\nE-mycin\nE-tab\nBacteriostatic\n250 mg QID\n4 g/day\n—\nTetracycline\nAchromycin\nSumycin\nBacteriostatic\n250 mg QID\n4 g/day\n—\nClindamycin  \nhydrochloride\nCleocin HCl\nBacteriostatic\n150–300 mg TID or \nQID\n1.8 mg/day\nSBE: 600 mg 1 hr before\nSurgical: 600 mg 1 hr before\nMetronidazole\nFlagyl\nBactericidal\n250 mg TID or QID\n4 g/day\nLevofloxacin\nLevaquin\nBactericidal\n500 mg/day\n500 mg/day\nSurgical: 500 mg\nMoxifloxacin\nAvelox\nBactericidal\n400 mg/day\n400 mg/day\n—\nTrimethoprim/sulfa-\nmethoxazole\nBactrim Septra\nBacteriostatic\n160 mg (DS) BID\n80 mg BID\n—\n—\nDS, Double strength; SBE, subacute bacterial endocarditis.\nLevofloxacin and Moxifloxacin: Physician approval prior to prescribing.\n   \nTABLE \n14.3"
  },
  {
    "page": 157,
    "content": "365\nCHAPTER 14  Pharmacology in Implant Dentistry\nProphylactic Antibiotics in Oral Implantology\nPostoperative wound infections can have a significant effect on \nthe success of dental implants and bone-grafting procedures. \nThe occurrence of surgical host defenses allows an environ-\nment conducive to bacterial growth. This process is complex, \nwith interactions of host, local, systemic and microbial viru-\nlence factors. Various measures attempt to minimize infec-\ntion by modifying the host and local tissue factors. The use \nof antimicrobials has been shown to be significant in reducing \npostoperative infections and decreases failure rate in implant \ndentistry.36-38\nThe antibiotic chosen for prophylaxis should encompass the \nbacteria most known to be responsible for the type of infection \nrelated to the surgical procedure. Therefore the following anti-\nbiotics are suggested against pathogens known to cause postop-\nerative surgical wound infections in bone grafting or implant \nsurgery:\n\t1.\t \u0007Amoxicillin is the usual drug of choice; however, if the patient \nis allergic to amoxicillin, use\n\t2.\t \u0007Cephalexin (nonanaphylactic allergy to penicillin) or\n\t3.\t \u0007Clindamycin (anaphylactic allergy to penicillin).\nFor sinus involvement procedures (e.g., sinus grafts) the fol-\nlowing antibiotics are suggested:\n\t1.\t \u0007Augmentin\n\t2.\t \u0007Ceftin (if history of recent use of antibiotics [within 4 weeks]) \nor doxycycline \nTherapeutic Use of Antibiotics: Postoperative \nInfections\nAcute postoperative infections have been shown to most com-\nmonly occur on the third to fourth day after surgery. The most \ncommon microorganisms associated with peri-implant, postope­\nrative complications have been previously listed in Box 14.3.\nLocal signs of infection are pain, inflammation, bleeding, and \nexudate at the site of surgery. Systemic signs include fever, head-\nache, nausea, muscle aches, vomiting, and weakness. When sur-\ngical wound infections arise, a specific diagnosis is advantageous \nto treat the complication. When evaluating the various antibiot-\nics that are possibly effective against the bacteria in question, a \nbroad-spectrum beta-lactam antibiotic is most often the first-line \nmedication. The duration of treatment should include antibiotic \nadministration for 3 days beyond the occurrence of significant \nclinical improvement (i.e. usually the fourth day), and therefore \nfor a minimum of 7 days.39\nTherapeutic Antibiotics in Implant Dentistry\nThe recommended treatment for intraoral infections associated \nwith grafting or implant therapy includes:\n\t1.\t \u0007Surgical drainage\n\t2.\t \u0007Systemic antibiotics:\nAmoxicillin (500 mg): two immediately, then one tablet three \ntimes daily for 1 week or if penicillin allergy exists\nClindamycin (300 mg): two immediately, then one tablet three \ntimes daily for 1 week\nnote: If no improvement is seen after 4 days, a culture and \nsensitivity test may be obtained to select the antibiotic that \nis most effective against the responsible organisms.\n\t3.\t \u00070.12% chlorhexidine gluconate rinse (½ oz twice daily for 2 \nweeks) \nChlorhexidine\nAnother medication used for antimicrobial prophylaxis for \nimplant surgery is the use of an oral rinse, 0.12% chlorhexi-\ndine digluconate (Peridex; Procter & Gamble, Cincinnati, OH). \nChlorhexidine gluconate is a potent antibacterial that causes lysis \nby binding to bacterial cell membranes. It has high substantiv-\nity that allows it, at high concentrations, to exhibit bacteriocidal \nqualities by causing bacterial cytoplasm precipitation and cell \ndeath.40,41 In the oral cavity, chlorhexidine has been shown to \nhave a slow release from tissue surfaces over a 12-hour period.42,43\nIn vitro studies have shown an inhibitory effect of chlorhexi-\ndine on cultured epithelium and cell growth; however, clinical \nstudies have not shown this effect.44-46 To the contrary, the use of \nchlorhexidine has been shown to be an effective adjuvant in reduc-\ning plaque accumulation, enhancing mucosal health,46-48 improv-\ning soft tissue healing,49,50 treating periodontal disease, preventing \nalveolar osteitis,51,52 improving tissue healing after extractions,53 \nand reversing peri-implantitis,54 and has been shown to have no \nadverse effect on implant surfaces.55\nWhen evaluating the effect of preoperative chlorhexidine before \ndental implant surgery, a significant reduction in the number of infec-\ntious complications (2 to 1) and a sixfold difference in implant fail-\nures in comparison with no use of chlorhexidine have been shown.56\nUse of Chlorhexidine in Oral Implantology\nAs a consequence of many reported benefits of chlorhexidine, this \nantiseptic has been advocated for many uses in oral implantology \n(Box 14.8). \nMiscellaneous\nCitric Acid\nCitric acid has been reported in the literature for the detoxification \nof exposed implant surfaces resulting from bone loss. Citric acid is \nstated to remove the smear layer, lipopolysaccharides, and exposure \nof collagen fibrils. The detoxification results in the improvement of \nthe blood clot formation with a greater fibrin retention fibrin.57,58 \nNumerous articles have evaluated the in vitro and in vivo effec-\ntiveness of citric acid; however, there is no agreement on the ideal \nconcentration and duration for application. In a rhesus monkey \nstudy, implants were decontaminated with citric acid with a 40% \nconcentration and developing reosseointegration 40 months after \nsurgery.59 In most detoxification protocols, citric acid is used in \ndifferent concentrations (10%, 20%, or 40%) with a cotton pellet \nto burnish the exposed surfaces (Fig. 14.2). \nManagement of Postoperative Inflammation\nThe management of postsurgical swelling is crucial to pain \nmanagement, control of edema, and incidence of postoperative \nPrescription: 0.12% chlorhexidine gluconate (16 oz)\n 1. \u0007Patient presurgical rinse: used in the aseptic protocol before surgery for \nreduction of bacterial load\n 2. \u0007Surface antiseptic: intraoral and extraoral scrub of patient, scrubbing of \nhands before gowns and gloves\n 3. \u0007Postsurgical rinse: rinse twice a day until incision line closure\n 4. \u0007Peri-implant maintenance on daily basis\n 5. \u0007Treatment of postoperative infections\n\t • BOX 14.8\t    \u0007Chlorhexidine Use in Oral Implantology"
  },
  {
    "page": 158,
    "content": "366\nPART III    Fundamental Science\ninfection. In most dental implant surgeries, tissue is trauma-\ntized, which results in some degree of an inflammatory reac-\ntion. By controlling the extent of inflammation associated with \nsurgical procedures, edema, trismus, pain, and infection may be \nreduced.\nThe mediators of the inflammatory process include cyclo-\noxygenase (COX) and prostaglandins, which play a signifi-\ncant role in the development of postoperative inflammation \nand pain (Fig. 14.3). When tissue manipulation or damage \noccurs, phospholipids are converted into arachidonic acid by \nway of phospholipase A2. Arachidonic acid, which is an amino \nacid, is released into the tissue, which produces prostaglan-\ndins by enzymatic breakdown by COXs. The end result is the \nformation of leukotrienes, prostacyclins, prostaglandins, and \nthromboxane A2, which are the mediators for inflammation \nand pain. For postoperative treatment, medications such as \nibuprofen (nonsteroidal antiinflammatory drugs [NSAIDs]) \nand glucocorticosteroids (steroids) are used, which play an \nintegral part in counteracting the negative effects of this \ncascade.\nNonsteroidal Antiinflammatory Drugs\nNSAIDs have an analgesic effect, as well as an antiinflammatory \neffect. This drug class reduces inflammation by inhibiting the syn-\nthesis of prostaglandins from arachidonic acid. Therefore the use \nof the popular analgesic drug ibuprofen has a secondary beneficial \nantiinflammatory effect. NSAIDs do not have a ceiling effect for \ninflammation; however, higher doses to achieve antiinflammatory \nqualities are accompanied by serious side effects. In implant den-\ntistry the use of ibuprofen is suggested as a preemptive analgesic \nagent, because it has antiinflammatory properties in type 1 to 5 \nprocedures. \nGlucocorticosteroids\nThe adrenal cortex, which uses cholesterol as a substrate, synthe-\nsizes and secretes two types of steroid hormones—androgens and \ncorticosteroids. The corticosteroids are classified by their actions: \n(1) glucocorticoids, which have effects on carbohydrate metabo-\nlism and have potent antiinflammatory actions; and (2) miner-\nalocorticoids, which have sodium-retaining qualities. The use of \nsynthetic glucocorticosteroids has become popular in the postop-\nerative management of pain and inflammation after oral surgical \nprocedures. These synthetic glucocorticoids have greater antiin-\nflammatory potency in comparison with natural steroids with \nvery little sodium and water retention. Most of these steroids have \nsimilar chemical structures; however, they differ in their milligram \npotency.60 Their antiinflammatory effects are achieved by altering \nthe connective tissue response to injury, thus causing a decrease in \nhyperemia, which results in less exudation and cellular migration, \nalong with infiltration at the site of injury.61,62\nA wide range of glucocorticoid preparations are available \nfor local, oral, and parenteral administration. In relation to the \nnaturally occurring cortisol (hydrocortisone), synthetic gluco-\ncorticoids are longer acting and more potent. The main differ-\nences are based on the classification as short-acting (<12 hours), \nA\nB\n• Fig. 14.2  Citric Acid.  (A) 40% citric acid solution. (B) Citric acid is used to detoxify implant surface before \nbone grafting in the treatment of peri-implantitis.\nReduction of edema\nTissue damage\nArachidonic acid release\nProduces prostaglandins\n1. Steroids\nCyclooxygenase\n2. NSAIDs\nEdema\n• Fig. 14.3  Mechanism of action for nonsteroidal antiinflammatory drugs \n(NSAIDs) and steroids in the reduction of inflammation."
  },
  {
    "page": 159,
    "content": "367\nCHAPTER 14  Pharmacology in Implant Dentistry\nintermediate-acting (12–36 hours), and long-acting (>36 hours). \nA summary of the most common glucocorticosteroids is shown in \nTable 14.4.60\nMechanism of Action\nGlucocorticoids bind to glucocorticoid receptors within cells and \nform a glucocorticoid-GR complex. This complex alters the syn-\nthesis of messenger RNA from the DNA molecule, thus affecting \nthe production of different proteins. By suppressing the produc-\ntion of proteins that are involved in inflammation, glucocorticoids \nalso activate lipocortins, which have been shown to inhibit the \naction of phospholipase A2. Phospholipase A2 is a key enzyme \ninvolved in the release of arachidonic acid from cell membranes.\nArachidonic acid is an omega-6 fatty acid that is incorporated \ninto cell membranes. When a cell is damaged, arachidonic acid \nis released from cell membranes and is converted into inflam-\nmatory and pain prostaglandins by cyclooxygenase-2 (COX-2) \nenzymes. The release of arachidonic acid requires the activation \nof the enzyme phospholipase A2. However, lipocortins, which \ncause the inhibition of phospholipase A2, prevent the release of \narachidonic acid, thereby reducing the amounts of inflammatory \nprostaglandins. \nAdrenal Suppression\nGlucocorticoids are essential for the body to adapt to stressful \nsituations. Adrenal insufficiency may predispose a person to an \ninability to respond to stress. Adrenal suppression has been shown \nto occur after 7 to 10 days of steroid administration. In stressful \nsituations, cardiovascular collapse may occur and, if not treated \nappropriately, may be life-threatening. Because most dental \nimplant procedures maintain a high level of stress, the implant \ndentist must be able to assess the level of adrenal suppression on \npatients taking glucocorticoid replacement therapy.\nProlonged, long-term steroid therapy causing adrenal suppres-\nsion is a well-known phenomenon. The amount of suppression is \na function of both the duration of treatment and the dose admin-\nistered. Studies have shown that short-term use of corticosteroids \ndoes not significantly affect the hypothalamus-pituitary-adrenal \n(HPA) axis, and normal levels of cortisol, which are initially sup-\npressed, recover to normal levels after 7 days.63 The conclusion \nis that the HPA axis, although altered by the initial dexametha-\nsone therapy, is restored completely. In addition, the amount of \nsurgical stress involved with oral surgical procedures appears to be \nof insufficient magnitude to overcome the HPA suppression of the \nnegative feedback mechanism caused by the steroid administra-\ntion. Therapeutic levels of steroid are present at a cellular level to \nprevent any manifestations of adrenal insufficiency.64 \nTiming\nThe use of synthetic steroids should be based on the production \nof the natural steroid cortisol (hydrocortisone) in the body. Nor-\nmally, cortisol is produced from plasma cholesterol at a rate of 15 \nto 30 mg/day.65 Under stressful situations (e.g., infection, illness, \ntrauma), as much as 300 mg of cortisol can be secreted. Plasma \nconcentrations of cortisol are several-fold higher in the morning \ncompared with the afternoon. Studies have shown that a dose of \ndexamethasone given in the morning (8:00 a.m.) does not sig-\nnificantly alter the level of endogenous circulating cortisol. How-\never, the same dose in the late afternoon (4:00 p.m.) can cause \ncomplete suppression of the HPA cycle.66 This secretion rate is \ndictated by the pituitary-adrenal axis with a feedback-inhibition \ncycle.67 Therefore administration of glucocorticoids should ideally \nbe given in the early morning so that simulation of normal diur-\nnal rhythm is achieved, thus minimizing the possibility of HPA \nsuppression.68 \nGlucocorticoid Use in Implant Dentistry\nSince the advent of glucocorticoids in 1942, these medications \nhave been used clinically in two ways: (1) therapeutic treatments \nin various inflammatory diseases and autoimmune diseases, and \n(2) prophylactic treatment of inflammation and associated pain. \nThey are still used for an array of autoimmune diseases. Glucocor-\nticoids have been well documented in the dental literature as being \nadvantageous in the prevention of postoperative complications \nafter traumatic oral surgery,69 intraoral sagittal osteotomy,70 ves-\ntibuloplasty with palatal mucosal grafts, and reduction of edema \nand pain after oral surgical procedures.61,62,71,72 In addition, they \nhave been shown to be associated with less need of pain medi-\ncation after oral surgical procedures.73,74 These drugs have been \nshown to have the ability to be long-lasting in duration and cause \nminimal effects on wound healing, infection, and adrenal suppres-\nsion, with minimal central nervous system (CNS) alteration.66\nAntiinflammatory/Analgesic. The use of glucocorticoids is an \nintegral part in the treatment of postsurgical edema after dental \nimplant procedures. The selection of the ideal synthetic gluco-\ncorticoid for dental implant surgery should maintain high antiin-\nflammatory potency with minimal mineralocorticoid effects. The \nglucocorticoid that best suits the requirements is the long-acting \nglucocorticoid dexamethasone (Decadron). It is imperative that \nthis drug be administered before surgery so that adequate blood \nlevels are obtained. Also, it should be given in the morning in \nconjunction with the natural release of cortisol. This timing will \ninterfere the least with the adrenocortical system. Because inflam-\nmation usually peaks between 48 and 72 hours, the postoperative \nregimen of dexamethasone should not exceed 3 days after implant \nsurgery unless a nerve impairment is present. The dose should not \nexceed the equivalence of 300 mg cortisol and with high doses, a \ndecreasing dose the second and third day to reduce possible side \neffects. This high-dose, short-term glucocorticoid therapy has \nbeen shown not to significantly affect the HPA axis.64,75,76 Stud-\nies evaluating the efficacy of dexamethasone have shown positive \nresults with preventing and controlling postoperative pain and \ndiscomfort after implant placement surgery (Box 14.9).77 \n  \u0007Synthetic Glucocorticoids\nGlucocorticoids\nAntiinflammatory \nPotency\nEquivalent \nDose (mg)\nDuration \n(hr)\nShort-acting\nHydrocortisone\n1.0\n20\n<12\nCortisone\n0.8\n25\n<12\nIntermediate-acting\nPrednisone\n4.0\n5\n24–36\nPrednisolone\n4.0\n5\n24–36\nLong-acting\nDexamethasone\n25\n0.75\n>48\n   \nTABLE \n14.4"
  },
  {
    "page": 160,
    "content": "368\nPART III    Fundamental Science\nNeurosensory Impairment. The use of dexamethasone has \nbeen shown to decrease the morbidity of neurosensory impair-\nments. Not only does dexamethasone reduce the inflammation at \nthe site of nerve injury, it has been shown to improve the regenera-\ntion of severed and compressed inferior alveolar nerves.78 \nPostoperative Nausea and Vomiting. A significant additional \nbenefit of the administration of dexamethasone is the potent anti-\nemetic effects for the prophylactic treatment of postoperative nausea \nand vomiting. This is now an accepted medication for hospital-\nbased outpatient surgery, usually given in doses of 8 to 10 mg intra-\nvenously.79-81 When using intravenous (conscious) sedation for \ndental implant procedures, it is highly effective in reducing pain and \ninflammation, along with preventing postoperative nausea and vom-\niting. Usually an 8-mg dose is recommended split into two adminis-\ntrations to reduce the possibility of perineal pain and itching. \nContraindication to Glucocorticosteroids\nContraindications to the use of corticosteroids include active infec-\ntions (viral, bacterial, fungal), tuberculosis, ocular herpes simplex, \nprimary glaucoma, acute psychosis, and diabetes mellitus. Special \nattention must be given to patients with diabetes, because glucocor-\nticoids have an antiinsulin action that results in increased serum glu-\ncose and glycosuria.82 Dexamethasone has been reported to induce \nimmunosuppression when prescribed for long periods, which could \nbe a concern with implant therapy.83 However, the recommended \nuse in our pharmacologic protocol involves only short-term use, \nthus minimizing the risks for these unwanted complications. \nCryotherapy\nAn additional therapeutic regimen to help reduce the amount and \nduration of postoperative inflammation is the application of cold \ndressings. It is reported that cold dressings in the form of ice bags \nor premanufactured ice packs applied extraorally to the surgical \nsite will minimize edema.84 The application of cold dressings is \nbelieved to cause vasoconstriction of the capillary vessels, thus \nreducing the flow of blood and lymph in this region, resulting \nin less inflammation.85 Also, with the lower temperature at the \nsurgical site, cell metabolism is reduced. As a result the cells in \nthe region of trauma consume less oxygen, which allows them to \nsurvive a longer period of ischemia. Localized hypothermia will \ninduce vasoconstriction and lowers microcirculation by more \nthan 60%, and these effects may last for up to 30 minutes after \ncessation. In addition, there exists a reduction in pain as a result \nof less edema as well as restoration of motor and sensory nerve \nconduction.86\nWhen applying ice to the surgical site, caution should be \nexercised to not cause a thermal necrosis of the tissue from too \nlong of an application. Ideally cryotherapy should be applied \nfor 20 minutes, followed by 20 minutes of rest. The rationale \nfor this protocol includes possible vasodilation (reactive hyper-\nemia) after the initial cryotherapy-induced vasoconstriction. The \nvasodilation is a compensatory reaction also termed a “hunting \nresponse,” which results from the blood flow through the arte-\nriovenous anastomoses.87 Therefore to prevent the possibility of \nincreased edema, the 20 minutes on/20 minutes off protocol is \nrecommended (Box 14.10). \nPostsurgical Pain Management\nPain has been documented to be inadequately treated in 50% of \nall surgical procedures.88 These painful experiences predispose \nthe patient to amplification of noxious stimuli (hyperalgesia) and \ncause typically painless sensations to be experienced as pain (allo-\ndynia).89,90 Therefore patients who have had painful experiences \nmay have increased pain and the need for additional analgesic use \nin future surgeries. The goal for pain control in oral implantology \nis to obtain analgesic levels before the cessation of local anesthe-\nsia and a well-administrated postoperative analgesic regimen for \npatient comfort.\nMechanism of Pain\nThe mechanism of painful stimuli is modulated by the \nperipheral nervous system and CNS. Noxious stimuli (tis-\nsue damage) cause peripheral nociceptors to transmit signals \nalong nerve fibers lying in the dorsal root ganglion. Their \naxons synapse in the dorsal horn of the spinal cord and then \ntravel along the spinothalamic tract of the spinal cord to the \nthalamus and the cortex. Within the cortex and thalamus, the \nsignals originating from tissue damage form the subjective \ninterpretation of pain.\nWith repeated noxious stimuli, peripheral nociceptors become \nmore responsive. The sensitivity to these receptors is further \nenhanced by tissue factors and inflammatory mediators released \nin the course of tissue damage. Numerous inflammatory media-\ntors are present that include prostaglandins, kinins, leukotrienes, \nsubstance P, and histamine. These mediators initiate and magnify \nthe nociceptive impulses that are transmitted to the CNS for the \nperception of pain.\nThe most important mediators, prostaglandins, are extremely \nimportant in sensitizing peripheral neurons to the local stimuli. \nProstaglandins are also synthesized in the spinal cord and brain, \nand enhance pain sensitivity by recruiting secondary neurons to \nrespond to the primary stimulus.91\nOne of most commonly used analgesics, NSAIDs, works at \nthe site of tissue damage and the spinal cord and brain to prevent \nprostaglandin formation by inhibiting COX. COX is an enzyme \nPrescription: \n • \u0007Dexamethasone (Decadron Tablets 0.5 mg, 0.75 mg,  \n4 mg, and 6 mg)\n • \u0007Dexamethasone Injectable (4 mg/mL—30-mL vial)\n 1. \u0007Antiinflammatory/Analgesic: administer 4 mg according to \npharmacologic protocol\n 2. \u0007Neurosensory impairment: 8 mg for days 1–3, 4 mg for days 4–6\nNote: Also may use injectable form to be placed locally at site of nerve injury \n(1–2 mL of 4 mg/mL)\n 3. \u0007Postoperative nausea and vomiting: 8 mg to be administered in two 4 \nmg doses intravenously\na\u0007Methylprednisolone (Medrol) is an alternative to dexamethasone but has significantly less \nantiinflammatory potency.\n\t • BOX 14.9\t   \u0007Glucocorticoid Use in Oral Implantologya\nPrescription: Ice Packsa\n 1. \u0007Ice packs (cold dressings) should be applied extraorally over the surgical \nsite for 20 minutes on/20 minutes off for first 24 to 36 hours.\na\u0007Caution must be taken to limit the application of ice for no longer than 36 hours, because \nprolonged use may cause rebound swelling and cell destruction.\n\t• BOX 14.10\t   \u0007Cryotherapy Use in Oral Implantology"
  },
  {
    "page": 161,
    "content": "369\nCHAPTER 14  Pharmacology in Implant Dentistry\nthat breaks down arachidonic acid to prostaglandin synthesis. In \nthe tissue, two well-identified COXs exist, COX-1 and COX-2. \nCOX-1 enzymes support hemostasis (platelet degranulation and \nadhesion), stomach mucosal integrity, and regulation of kidney \nfunction. COX-2 enzymes are an inducible form whose synthesis \nis activated in damaged tissue, which leads to the formation of \nproinflammatory prostaglandins that play a major role in inflam-\nmation, pain, and fever. A relatively new COX has been described \n(COX-3) that is found in the brain and is thought to be the site of \naction of acetaminophen.92\nIn contrast with NSAIDs, opioids have a different mechanism \nof action to reduce pain. Opioids act on the CNS by binding \nto specific receptors (μ-opioid), thus preventing transmission of \nnociceptive pathways, while also activating inhibitory pathways \nthat descend to the spinal cord. By binding to these μ-opioid \nreceptors, substance P is barred from being released, thus prevent-\ning painful stimuli.93 \nProtocols Postoperative Pain\nIn implant dentistry different classifications and mechanisms \nof pain suppression may be used. The most effective technique \nto decrease pain is a combination of preemptive analgesia and a \nmultimodal pain management protocol. By using a multimodal \ntherapy protocol, lower dosages of medication can be used, \nwhich results in fewer side effects and advantageous outcomes. \nTherefore the author has developed a pain control protocol that \nsimplifies and standardizes the various aspects of pain relief \n(Fig. 14.4, Box 14.11, and Table 14.5).\nProphylactic Analgesics\n\t\n1.\t \u0007Preemptive Analgesia\nPostoperative Analgesics\n\t\n1.\t \u0007Nonopioid Analgesics (Nonnarcotics)\n\t\n2.\t \u0007Opioid Analgesics (Narcotics)\n\t\n3.\t \u0007Adjuvants\nPreemptive Analgesia\nPreemptive analgesia is defined as the introduction of an analgesic \nregimen before the onset of noxious stimuli. In relation to den-\ntal implant surgery, it is advantageous to have adequate analgesic \nblood levels present before the initiation of surgery. The concept of \npreemptive analgesia is based on advances in evidence-based clini-\ncal research. It has recently been refined and evolved to a broader \nconcept that surgical incision alone is not the trigger for central \nsensitization. The goal is to prevent sensitization of the nervous \nsystem to subsequent stimuli that could possibly amplify pain. \nDental implant surgery is ideal for this type of treatment because \nit is usually elective, and the timing of noxious stimuli is known.\nManipulation of hard and soft tissues during implant and \nbone grafting procedures predisposes the patient to postoperative \npain. The extent of tissue reflection, amount of bone preparation, \ninherent patient factors, and duration of the surgical procedure \nhave an effect on the intensity and duration of postoperative pain. \nHyperalgesia is characterized by enhanced sensations of pain, a \npain threshold reduction, and an increase in the suprathreshold \nnoxious stimuli. With administration of analgesics before tissue \nTissue damage\nGI cytoprotection\nPlatelet activity\nProstaglandins\nProstaglandins\nCox-1\nCox-2\n(Cox-3??)\nAcetaminophen??\nNSAIDs\nCox-2\ninhibitors\nArachidonic acid\nPain\nInflammation\nFever\n• Fig. 14.4  Mechanism of action of the various cyclooxygenase enzymes. \nCOX, Cyclooxygenase; GI, gastrointestinal; NSAIDs, nonsteroidal antiin-\nflammatory drugs.\nNonopioids\n • \u0007Nonsteroidal antiinflammatory drugs\n • \u0007Acetaminophen\n • \u0007Tramadol\n • \u0007Cyclooxygenase-2 inhibitors \nOpioids\n • \u0007Codeine\n • \u0007Hydrocodone\n • \u0007Oxycodone\n • \u0007Meperidine \nAdjuvants\n • \u0007Glucocorticoids\n • \u0007Long-acting anesthetics\n • \u0007Tricyclic antidepressants\n\t• BOX 14.11\t   \u0007Analgesic Classifications in Dentistry\n  \u0007Common Analgesic Medications in Oral \nImplantology\nMedication\nAdvantages\nDisadvantages\nNSAIDs\nNonselective\nInexpensive\nOver the counter\nExcellent pain relief\nExcellent antiinflamma-\ntory effects\nMany drug interactions\nLimited use in patients \nwith gastrointesti-\nnal issues\nAcetaminophen\nInexpensive\nOver the counter\nGood pain relief\nNo antiinflammatory \neffects\nOpioids\nGood to excellent pain \nrelief\nAddiction potential\nDrug interactions\nNo antiinflammatory \neffects\nCorticosteroids\nExcellent antiinflamma-\ntory action\nUse in patients \nwith diabetes is \nrestricted\nAlteration of the \nhypothalamus-\npituitary-adrenal \naxis\nNSAID, Nonsteroidal antiinflammatory drug.\n   \nTABLE \n14.5"
  },
  {
    "page": 162,
    "content": "370\nPART III    Fundamental Science\ndamage, the sensitivity of these receptors is dramatically reduced \nand may be eliminated.94 Many studies on the ideal medication to \nuse for preemptive analgesia with ibuprofen (400 mg), acetamino-\nphen (1000 mg), or celecoxib (200 mg) show positive results for \nthe reduction of postoperative pain95 (Box 14.12). \nPostoperative Medications\nNonopioid Medications\nThe nonopioid analgesics used in implant dentistry include acet-\naminophen, NSAIDs, COX-2 inhibitors, and tramadol (Box 14.13).\nAcetaminophen (Paracetamol). The mode of action of acet-\naminophen is not known; however, it is believed to involve the prosta-\nglandin pathways within the CNS, with little influence on peripheral \nprostaglandin synthesis. The COX-3 enzyme has been described that \nis fully expressed in the brain, spinal cord, and heart. The primary \nfunction of this enzyme is to regulate pain responses and fever, and it \nhas been postulated to be the site of action of acetaminophen.96\nAcetaminophen is indicated for mild-to-moderate pain and is \na safe alternative to NSAIDs. It has excellent analgesic and anti-\npyretic properties, and is void of side effects that are associated \nwith NSAIDs. Like NSAIDs, acetaminophen also has a ceiling \ndose (4 g/day) for analgesic effects. However, unlike NSAIDs, \nacetaminophen is limited in that it has minimal antiinflammatory \nqualities. The main side effect is liver damage, which is associated \nwith long-term use of this drug. \nNonsteroidal Antiinflammatory Drugs. NSAIDs are one of \nthe most commonly used analgesics in implant dentistry today. \nClinical trials have shown that NSAIDs are effective in all levels \nof pain (mild, moderate, severe).97,98 The mechanism of action of \nNSAIDs is thought to arise from the inhibition of the synthesis \nof prostaglandins from arachidonic acid. With the inhibition of \nCOX, conversion of arachidonic acid to the immediate precursors \nof prostaglandins is prevented. Thus with the lack of prostaglan-\ndins in the tissue, the hyperanalgesia and edema associated with \nthe acute inflammation are minimized.99\nThe main reasons that NSAIDs are so widely used is the fact \nthat they work very well as analgesics and have variable effects \non inflammation (drug and dose dependent). Inflammation and \npain are two separate entities, with analgesic doses having a ceiling \neffect100 and antiinflammatory doses not having a ceiling effect. In \nregard to the analgesic effect, there exists no reason to exceed the \nanalgesic ceiling for the treatment of acute pain, because higher \ndoses give no additional pain relief while increasing the likelihood \nof side effects.\nThere are two classes of NSAIDs: “nonselective” (e.g., ibupro-\nfen) and “selective” (e.g., celecoxib). The COX enzyme is actu-\nally present in two different forms, COX-1 and COX-2. COX-1 \nenzymes protect the gastric mucosa from the acid that the stomach \nnaturally produces and also is involved with platelet aggregation. \nCOX-2 enzymes are responsible for producing prostaglandins that \nmediate pain and inflammation. The selective NSAIDs target only \nthe COX-2 enzymes, which decrease pain and inflammation while \nmaintaining the protective factors of the stomach, along with \nnot interrupting platelet function. The side effects of NSAIDs \nare numerous, including GI disturbances (dyspepsia, erosions, \nulcerations) and liver, renal, and cardiac effects.101 This group of \nmedications is responsible for the largest number of serious drug-\nrelated complications, surpassing all other drugs by a wide mar-\ngin.102 The various types of NSAIDs and their associated risks are \nlisted in Table 14.6.103 NSAIDs have very little effect on platelet \naggregation because bleeding times are not prolonged. With pro-\nlonged use of NSAIDs, interference with most classes of antihy-\npertensives has been noted. Therefore if patients take NSAIDs for \nmore than 5 days postoperatively, blood pressure should be moni-\ntored. Although NSAIDs have numerous advantages, they may \nhave a potential detrimental effect on bone metabolism. Numer-\nous animal studies have been inconclusive. Some have shown that \nNSAIDs may impair angiogenesis and osteoblast/osteoclast pre-\ncursor differentiation, especially in the first month after implant \nplacement. However, other studies have shown no differences in \nlong-term healing outcomes.104\nIbuprofen. Ibuprofen was first introduced in 1969 as a new \nNSAID and has since been the most popular prescribed NSAID.105 \nIbuprofen is a nonselective COX inhibitor because it inhibits \ntwo isoforms of COX, COX-1 and COX-2. It is available under \na number of different trade names, including Advil and Motrin \n(200 mg). Ibuprofen is used to treat mild-to-moderate pain and \nhas been proven to significantly reduce postoperative dental pain \nin clinical studies.106,107 The analgesic ceiling dose is 400 mg/dose \nPrescriptions\n • \u0007Ibuprofen (400 mg)\n • \u0007Acetaminophen (1000 mg)\n • \u0007Celecoxib (200mg)\nGiven 1 hour before the procedure.\n\t• BOX 14.12\t   \u0007Preemptive Analgesics\nPrescriptions\n • \u0007Ibuprofen (400–600 mg): 400 mg every 4 hours; not to exceed 1200 \nmg/day\n • \u0007Acetaminophen (500 mg): 1 g every 6 hours; not to exceed 4 g/day\n • \u0007Celecoxib (50, 100, 200, 400 mg): 200 mg twice daily as needed\n • \u0007Tramadol: 50–100 mg oral dose every 4–6 hours as needed; not to \nexceed 400 mg/day\n • \u0007Ultram: 50 mg tramadol\n • \u0007Ultracet: 37.5 mg tramadol/1000 mg acetaminophen\n • \u0007Ultram ER: 100 mg tramadol–extended release once daily\n\t• BOX 14.13\t   \u0007Nonopioid Analgesics\n  \u0007Relative Risks of Nonsteroidal \nAntiinflammatory Drugs for Gastrointestinal \nComplications\nNSAID\nRelative Risk\nNone\n1\nIbuprofen\n2.1\nKetoprofen\n3.2\nNaproxen\n4.3\nIndomethacin\n5.5\nAspirin\n8–11\nKetorolac\n24.7\nNSAID, Nonsteroidal antiinflammatory drug.\n   \nTABLE \n14.6"
  },
  {
    "page": 163,
    "content": "371\nCHAPTER 14  Pharmacology in Implant Dentistry\nand 1200 mg/day108; at these doses it has been shown to be as \nsafe as acetaminophen, while achieving better analgesia with less \nnausea and cramping.109 \nAspirin. Acetylsalicylic acid was the first prototypical NSAID. \nIt has analgesic, antiinflammatory, and antipyretic properties. \nHowever, at analgesic doses its relative risk for GI complications \nis high. Acetylsalicylic acid is not a drug of choice in the manage-\nment of dental implant surgical patients because of its very signifi-\ncant antiplatelet effects. \nCOX-2 Inhibitors. An additional type of NSAID specifically targets \nthe COX-2. Because this class of medications is selective for COX-2, \nthe risk for GI side effects is reduced. These drugs do not block COX-1 \nenzymes, which produce prostaglandins that protect the stomach and \npromote blood clotting. Because COX-1 is not altered, the possibility \nof ulcers or increase in bleeding is reduced. Recently rofecoxib (Vioxx) \nand valdecoxib (Bextra) have been taken off the market because of \na possible increase in heart attacks and strokes. Currently celecoxib \n(Celebrex) 200 mg is available in the United States.\nAcetaminophen + Nonsteroidal Antiinflammatory Drugs \n(Ibuprofen). Prescribing acetaminophen and NSAIDs together \nhas become popular in clinical practice with positive results.110 \nAlthough NSAIDs have few regulatory restrictions, many signifi-\ncant adverse effects may be present at high doses or with longer \ncourses of treatment. Acetaminophen is safe and widely accepted; \nhowever, it has minimal pain relief by itself. Combining an NSAID \nand acetaminophen allows for the benefits of both medications \nwithout increasing dose or risk. Typically acetaminophen is given \nin a dosage regimen of 1 g every 6 hours, and ibuprofen in a dos-\nage of 400 mg every 8 hours. This dosage regimen is advantageous \nbecause asynchronous dosing has been shown to be less effective.111 \nTramadol. Tramadol represents a unique classification of anal-\ngesic because it is a synthetic analog of codeine; however, it has \na reduced affinity for opioid receptors while having an action on \n5-hydroxytryptamine-noradrenaline reuptake inhibitors. There-\nfore it is a centrally acting analgesic with two complementary \ncharacteristics: opioid and antidepressant. It works by inhibition \nof norepinephrine and serotonin reuptake within pain pathways \nof the CNS and also by its relative weak affinity for the μ-opioid \nreceptor.109 Tramadol is a nonscheduled drug and is associated \nwith fewer opioid-like side effects, such as dependence, sedation, \nrespiratory depression, and constipation.112,113 The analgesic effi-\ncacy of tramadol is similar to codeine (60 mg) and is indicated for \nmoderate to moderately severe pain management. This drug is an \nappropriate analgesic alternative for the treatment of postoperative \npain in patients who have NSAID-related GI and opioid intoler-\nance. Tramadol has been shown to be effective in the reduction \nof pain when used in combination with acetaminophen. Ultracet \n(tramadol/acetaminophen) has demonstrated excellent efficacy in \npain studies and is supplied as a combination analgesic containing \n37.5 mg tramadol and 325 mg acetaminophen.114,115 \nNarcotics (Opioids)\nNarcotics (opioids) are the primary medications for analgesia of \nmoderate-to-severe pain from dental origin. They are centrally \nacting analgesics that act as agonists at μ- and κ-opioid recep-\ntors. Morphine, which is a naturally occurring opioid, is generally \naccepted as the prototypical narcotic. All other narcotics are com-\npared in potency to morphine.\nUnlike nonopioids, opioids do not have a ceiling effect for \nanalgesia. As the dose increases, the analgesic effect increases. \nHowever, in addition to relieving pain by μ-receptor binding, \neuphoria, nausea, vomiting, and constipation may occur. With \nhigh doses, sedation and respiratory depression are possible. With \nchronic use, physical and psychological dependence are common.\nThe following section discusses the most commonly used nar-\ncotics in oral implantology. Structurally these narcotics are similar \nto morphine and provide the same degree of pain relief and unlim-\nited efficacy at equipotent doses.\nCodeine. Codeine is a naturally occurring alkaloid that is clas-\nsified as a mild analgesic. Codeine has excellent antitussive prop-\nerties; however, it is associated with high degrees of nausea and \nconstipation. Orally administered codeine is only 60% bioavail-\nable, which results in only 10% being demethylated to morphine. \nThis 10% is the only part responsible for analgesic properties, thus \nallowing 90% to have no analgesic efficacy. Because of the side \neffects and low potency compared with other opioids, codeine is \nusually not the first choice of narcotics used in oral implantology. \nHydrocodone. Hydrocodone bitartrate is a semisynthetic nar-\ncotic analgesic and antitussive with multiple actions qualitatively \nsimilar to codeine. It is usually used as a combination analgesic, \nbeing combined with either acetaminophen or ibuprofen. For sev-\neral years this narcotic has been the most frequently dispensed pre-\nscription medication in the United States. Hydrocodone is habit \nforming, and the most frequent adverse reactions are dizziness, \nsedation, nausea, and vomiting. \nOxycodone. Oxycodone is a semisynthetic opioid with analge-\nsic action similar to morphine. It is recommended for moderate-to-\nsevere pain, with its principal actions being analgesia and sedation. \nIt has excellent oral bioavailability because it retains half of its anal-\ngesic activity when administered orally. Oxycodone has the same \nadverse effects as most other opioids, with an increased potential \nfor abuse and drug dependence. Oxycodone is marketed as a com-\nbination narcotic, combined with either acetaminophen (Percocet) \nor aspirin (Percodan). A slow-release oxycodone (Oxycontin) has \nrecently been released, which has a high abuse potential. \nMeperidine. Meperidine is mostly used in hospital settings via \nintramuscular administration. A majority of meperidine is con-\nverted to normeperidine, which is a metabolite that has no analgesic \nproperty; however, it is a strong CNS stimulant. Because meperi-\ndine in oral form has a poor oral bioavailability (25%), a greater \nrisk evolves with the accumulation of normeperidine. As a result, \nmeperidine is a poor choice for an orally administered opioid. \nCombination Analgesic Therapy for \nPostoperative Pain\nA pain management strategy using multiple analgesics with differ-\nent mechanisms of action is termed combination analgesic therapy. \nThe goal of combining different types of analgesics is to increase \nthe analgesic effect while decreasing possible side effects. When \nmultiple drugs are used in combination, synergistic and additive \neffects allow for the use of lower doses of each individual drug.\nWith combination therapy, acetaminophen or NSAIDs are used \nwith an opioid. Because of the ceiling effects of acetaminophen and \nNSAIDs, further increases in dosage will not provide any additional \nanalgesia; however, they will increase side effects (Table 14.7).\nAnalgesic Agents in Oral Implantology\nThe selection of an analgesic or analgesic regimen for manage-\nment of postsurgical pain is ideally related to the expected pain \nintensity. This may be based on the patient’s medical history, past \npain threshold, type of procedure, extent of tissue reflection, and"
  },
  {
    "page": 164,
    "content": "372\nPART III    Fundamental Science\nduration of procedure. Because of the various agents and numer-\nous options for the treatment of postsurgical pain after dental \nimplant surgery, a pain control protocol was formulated to aid in \nthe proper administration of these agents. According to the World \nHealth Organization guidelines, the procedure and patient must \nbe evaluated and classified as mild, moderate, or severe.\nMild Pain\nMild pain is self-limited and usually will be resolved with regular \nrecommended doses of NSAIDs. \nModerate Pain\nModerate pain involves more intense pain than mild and usually \nwill not be resolved totally by NSAIDs. The expected pain will \ninterfere with function and disrupt the activities of daily living. \nSevere Pain\nSevere pain is defined as pain that interferes with some or all of \nthe activities of daily living. The patient may be confined to bed, \nand strong opioid treatment will need to be continued for days. \nAdjuvant drug therapies may be needed for supplementation. \nControl of Postoperative Surgical Pain\nCurrently in the United States an alarming increase in prescription \nopioid deaths has been reported. A source of a substantial num-\nber of opioids are from leftover postoperative medications that are \nlater shared among friends and family members. Among health care \nproviders who prescribe opioids, dentists have been shown to be \nthe most prevalent providers of these medications.116 Therefore the \ndental profession has an obligation to counsel patients on the misuse \nof opioids and to use caution in the prescribing practices of opioids.\nThe implant dentist is placed in a challenging position with \nrespect to the management of postoperative pain. Many of the \nprocedures performed are rather invasive, which may lead to \nintense pain postoperatively. Identifying patients who may be \nsusceptible to poor pain management or uncontrolled acute pain \nis difficult. Therefore it is advantageous for implant clinicians to \nbe able to assess patients and propose pain management plans \nthat will minimize the risk and maximize inherent benefits. \nThus good practice involves a comprehensive initial assessment, \nindividualized pain management strategy, and reassessment if \nnecessary.\nThe goal of postsurgical pain management is to optimize \npatient comfort through pharmacologic and behavioral strategies. \nThe World Health Organization formulated an analgesic “ladder” \nfor the treatment of pain management. The following protocol \ndescribes three steps in the treatment of acute pain (Box 14.14)103:\n\t1.\t \u0007The first step is to maximize the use of NSAIDs (acetamino-\nphen, ibuprofen) for mild-to-moderate pain.\n\t2.\t \u0007When moderate pain is expected or persists, an opioid (hydro-\ncodone, codeine) should be added to the NSAID. The fixed \ndose of opioids with the NSAIDs provides additive analgesia. \nAdjuvant medications such as glucocorticoids and cryotherapy \nare often suggested.\n\t3.\t \u0007Moderate-to-severe pain that is expected or persists should be \ntreated by increasing the dosage of the opioid. Adjuvant medica-\ntions such as glucocorticoids and cryotherapy are often suggested.\nWith the guidelines from the World Health Organization, a \npain control protocol was formulated for treatment of procedures \nbased on the expected postoperative pain. \nPain Control Protocol\nPreoperative Evaluation\n\t1.\t \u0007A thorough evaluation that includes a comprehensive medi-\ncal and dental history: This should include screening for past \nor current use of opioids, benzodiazepines, sedative-hypnotics, \nantidepressants, or anxiolytics.\n  \u0007Combination Analgesics\nGeneric Name\nBrand Name\nAverage Adult Dosage\nSchedule\n5 mg codeine/300 mg acetaminophen\nTylenol #1\n1–2 tablets every 4 hr\nIII\n15 mg codeine/300 mg acetaminophen\nTylenol #2\n1–2 tablets every 4 hr\nIII\n30 mg codeine/300 mg acetaminophen\nTylenol #3\n1–2 tablets every 4 hr\nIII\n60 mg codeine/300 mg acetaminophen\nTylenol #4\n1 tablet every 4 hr\nIII\n5 mg hydrocodone/500 mg acetaminophen\nVicodin/Lortab 5/500\n1–2 tablets every 4–6 hr (maximum: 8 tablets/24 hr)\nIII\n7.5 mg hydrocodone/750 mg acetaminophen\nVicodin ES\n1 tablet every 4–6 hr\nIII\n7.5 mg hydrocodone/650 mg acetaminophen\nLorcet\n1 tablet every 4–6 hr\nIII\n10 mg hydrocodone/660 mg acetaminophen\nVicodin\n1 tablet every 4–6 hr\nIII\n10 mg hydrocodone/650 mg acetaminophen\nLorcet 10/650\n1 tablet every 4–6 hr\nIII\n7.5 mg hydrocodone/200 mg ibuprofen\nVicoprofen\n1–2 tablets every 6 hr\nIII\n5 mg oxycodone/325 mg acetaminophen\nPercocet 5/325\n1–2 tablets every 4–6 hr\nII\n7.5 mg oxycodone/500 mg acetaminophen\nPercocet 7.5/500\n1–2 tablets every 4–6 hr (maximum: 8 per day)\nII\n10 mg oxycodone/650 mg acetaminophen\nPercocet 10/650\n1 tablet every 4–6 hr\nII\n5 mg oxycodone/400 mg ibuprofen\nCombunox\n1 tablet every 6 hr (maximum: 4 per day)\nII\n   \nTABLE \n14.7"
  },
  {
    "page": 165,
    "content": "373\nCHAPTER 14  Pharmacology in Implant Dentistry\n\t2.\t \u0007Access and check the Prescription Monitoring Program for \nthe past and current use of the earlier drug categories. This \ninformation can be compared with the patient’s medical and \ndental history, along with determining the extent of a patient’s \nhistory of chronic opioid or sedative medications. In some \ncases a physician consultation and clearance may be recom-\nmended. \nDevelopment of a Pain Control Protocol\nAfter obtaining this information, the following prescribing proto-\ncol may be followed:\nStep 1: Preemptive analgesics—the use of ibuprofen (400 mg), \nacetaminophen (1000 mg), or celecoxib (200 mg)—should be \ntaken 1 hour before the procedure.\nStep 2: Nonopioid analgesics should be used as the first line of \npain control.\n\t\na.\t \u0007NSAIDs are ideally used because they exhibit great pain \ncontrol together with antiinflammatory effects. Avoid \nNSAIDs if there exists a known hypersensitivity, GI bleed-\ning, or history of aspirin allergy. For patients at risk for \nbleeding, a selective COX‐2 inhibitor (e.g., celecoxib) may \nbe considered.\n\t\nb.\t \u0007If an increased analgesic effect is required, the combina-\ntion of an NSAID with acetaminophen may be used. Avoid \nacetaminophen if there is a history of liver disease or hyper-\nsensitivity to the medication.\n\t\nc.\t \u0007Adjuvant multimodal pain strategies should be integrated \ninto the management of acute postoperative pain (e.g., \ncryotherapy, long-acting anesthetics, glucocorticoste-\nroids).\nStep 3: If an opioid is warranted, the following protocols should \nbe adhered to:\n\t\na.\t \u0007The lowest effective opioid dose of immediate-release opi-\noids should be prescribed.\n\t\nb.\t \u0007Quantity should be proportional to the expected dura-\ntion of pain; usually this will cover 3 days, and a quantity \nexceeding 7 days is rare.\n\t\nc.\t \u0007Obtain medical clearance before prescribing opioid medi-\ncation to any patient with a history of chronic use. \nLocal Anesthetics\nLocal anesthetics are an integral component of all dental implant \nsurgical procedures. They are necessary to perform surgery with-\nout pain and are effective for decreasing onset and duration of \npain. The dental surgeon must have significant knowledge of \nthe pharmacokinetics of the different local anesthetics used in \nimplant dentistry. The most commonly used dental anesthetics \nare amides, which are known for their low toxicity and relative \nlack of allergenicity.\nLocal anesthetics prevent postoperative pain by blocking the \ngeneration and conduction of action potentials in sensory neu-\nrons. This will prevent surgically induced nociceptive impulses \nfrom reaching the CNS and causing centrally mediated postop-\nerative hyperalgesia. Table 14.8 provides local anesthetic dosage \ninformation.\nLidocaine\nThe compound with which most other local anesthetics are com-\npared is 2% lidocaine-1/100,000 epinephrine. This solution \nis most commonly used in infiltration or block anesthesia, and \nis considered a medium-duration anesthetic. Lidocaine is sup-\nplied in two other forms: a higher-concentration vasoconstrictor \n(1/50,000 epinephrine) and with no vasoconstrictor (plain). \nMepivacaine\nMepivacaine is an anesthetic that is very similar to lidocaine in \nonset of action, duration, and toxicity. The usual dosage used in \ndentistry is a 2% solution with the addition of 1/20,000 levonor-\ndefrin (Neo-Cobefrin) as the vasoconstrictor. This local anesthetic \nis also made in a 3% (plain) solution, which is used for short pro-\ncedures or when a vasoconstrictor is contraindicated. \nArticaine\nArticaine is a newer amide type of anesthetic that was approved in \n2000 by the U.S. Food and Drug Administration for use in the \nUnited States. Articaine differs structurally from other amide anes-\nthetics, allowing it to have a better lipid solubility, which improves \npermeability of the lipid barriers in nerve membranes. Articaine \nThree-Step Conceptual Model\n 1. \u0007Nonopioid + adjuvant\n 2. \u0007Nonopioid + adjuvant + opioid (moderate)\n 3. \u0007Nonopioid + adjuvant + opioid (severe)\n\t• BOX 14.14\t   \u0007World Health Organization Analgesic \nLadder\n  \u0007Local Anesthetic Dosage Information\nAnesthetic Solution\nMaximum Dose\npKa\nOnset (min)\nDURATION (MIN)\nElimination Half-Life \n(min)\nMaxilla\nMandible\n2% lidocaine (1:100,000 epinephrine)\n7 mg/kg\n7.9\n2–4\n170\n190\n90\n2% mepivacaine (1:20,000 Neo-Cobefrin)\n6.6 mg/kg\n7.6\n2–4\n130\n185\n115\n4% articaine (1:100,000 epinephrine)\n7 mg/kg\n7.8\n2–4\n140\n270\n20\n0.5% bupivacaine (1:200,000 epinephrine)\n1.3 mg/kg\n8.1\n5–8\n340\n440\n210\n3% mepivacaine, no epinephrine\n6.6 mg/kg\n7.6\n2–4\n90\n165\n115\nData are from Haas DA. An update on local anesthetics in dentistry. J Can Dent Assoc. 2002;68:546-551.\n   \nTABLE \n14.8"
  },
  {
    "page": 166,
    "content": "374\nPART III    Fundamental Science\nalso has a very short half-life (20 minutes) in comparison with the \nother amide anesthetics. This shorter half-life results because it is \nhydrolyzed over 90% by plasma esterases and not by the liver as \nwith the other amides. As a result, articaine is of less concern in \nliver-impaired individuals and is a safer drug for reinjections in \nlonger-duration procedures. \nLong-Acting Anesthetics\nPostoperative dental pain has been shown to reach its maximum \nintensity during the first 12 hours postoperatively.117 When com-\nparing analgesia (reduction in the sensation of pain) with anesthesia \n(complete elimination of feeling and sensation of pain), complete \nelimination of pain can be beneficial throughout the immediate \npostoperative period. Local anesthetics play a key role in the post-\noperative pain experience for the patients. If the implant surgeon \ncan keep the patient comfortable during the initial period, pain and \ndiscomfort in the short term will also be minimized. The greater \nduration of anesthesia and decreased postoperative pain is effective \nin reducing the amount of analgesics required after surgery.118\nThe most common long-acting amide anesthetic is bupivacaine \n(Marcaine). This local anesthetic can play a vital role in pain manage-\nment. Because of its unique pharmacokinetics, bupivacaine has been \nstudied extensively and has been proven to be safe and far superior \nto other long-acting local anesthetics. Bupivacaine is an amide local \nanesthetic that is structurally similar to lidocaine and mepivacaine. It \nis more potent and less toxic than other types of amide anesthetics. \nBecause of its high pKa (8.1), bupivacaine lasts two to three times \nlonger than lidocaine or mepivacaine. The epinephrine concentration \nof bupivacaine is much lower (1/200,000 epinephrine) than standard \nanesthetics, thus limiting its ability to affect hemostasis. \nLocal Anesthetic Overdosage\nA serious complication, local anesthetic overdosage, is of great con-\ncern in implant dentistry. Because many implant-related surger-\nies are of longer duration, a greater amount of anesthetic is often \nadministered. Special attention must be taken during implant sur-\ngery as to the number of cartridges and type of anesthetic used \nduring a procedure. Table 14.9 lists anesthetics and the manu-\nfacturers’ maximum recommended dose by weight of patient to \ncarpules. However, the maximum number of cartridges is time \ndependent. The elimination half-life is not indicative of anesthetic \nduration; however, it may be used as a guide for repeated anes-\nthetic administration during a lengthy procedure. After one half-\nlife, as much as 50% of the permissible dose can be administered \nwith reasonable safety if liver function is normal.\nSpecial care must be given to the use of combination local anes-\nthetics. In implant dentistry, it is common to use two amide anes-\nthetics together—lidocaine and bupivacaine. Although acceptable, \ntotal doses should not exceed combined maximum recommended \ndoses. Calculations should factor in the total dose of the combina-\ntion and whether sufficient time has elapsed for elimination of the \ninitial dose.81 If local anesthetic toxicity reactions occur,119 CNS \nexcitation, convulsions, respiratory depression, and cardiac arrest \nmay occur (Box 14.15).\nMost amide anesthetics (except for articaine) are metabolized \nby the liver by a microsomal enzyme system. Therefore special \nattention should be given to patients with decreased liver func-\ntion, especially in elderly patients (e.g., chronic alcoholism, hepa-\ntitis). The half-life of lidocaine has been shown to be greater than \n2.5 times the normal values in patients with hepatic disease.120 \nSpecial attention must be given to the amount of anesthetic used, \nand concern for reinjection must be strictly evaluated in these \n  \u0007Maximum Manufacturer-Recommended Number of Anesthetic Capsules\nWeight of Patient (lb)\n2% Lidocaine  \n1/100,000 Epinephrine\n2% Mepivacaine  \n1/20,000 Neo-Cobefrin\n4% Articaine  \n1/100,000 Epinephrine\n5% Bupivacaine  \n1/200,000 Epinephrine\n80\n6.5\n6.5\n3.5\n5\n100\n8\n8\n4.5\n6.5\n120\n10\n10\n5.5\n8\n140\n11.5\n11\n6\n9\n160\n13\n11\n7\n10\n180\n13.5\n11\n7\n10\n200\n13.5\n11\n7\n10\nData are from Malamed SF. Handbook of Local Anesthesia. 4th ed. St. Louis, MO: Mosby; 1997.\n   \nTABLE \n14.9\nMild Symptoms\n • \u0007Talkativeness\n • \u0007Slurred speech\n • \u0007Apprehension\n • \u0007Localized muscle twitching\n • \u0007Light-headedness/dizziness\n • \u0007Tinnitus\n • \u0007Disorientation \nProgressive Symptoms\n • \u0007Lethargy\n • \u0007Unresponsiveness\n • \u0007Drowsiness/sedation\n • \u0007Lack of muscle tone\n • \u0007Mild drop in blood pressure, heart, and respiratory rate\n\t• BOX 14.15\t   \u0007Signs and Symptoms of Local Anesthetic \nToxicity"
  },
  {
    "page": 167,
    "content": "375\nCHAPTER 14  Pharmacology in Implant Dentistry\npatients. In addition to liver dysfunction, the kidneys are the pri-\nmary organs responsible for excretion of the local anesthetics and \nits metabolites. Patients with significant renal impairment will \nalso have difficulty in removing the anesthetics from the blood, \nresulting in an increased chance of toxicity.\nPatients with cardiovascular disease should be well evaluated \nbefore the use of epinephrine-containing anesthetics, and care \nshould be taken as to the amount of epinephrine administered. \nRecommendations on the maximum safe dose for a healthy \npatient are 0.2 versus 0.04 mg epinephrine for the patient with \ncardiac impairment. It should be noted that when epinephrine is \nnot included in the anesthetic, the systemic uptake of the drug is \nmore rapid and the maximum number of carpules given is signifi-\ncantly less in comparison with anesthetics with vasoconstrictors. \nPost-Surgical Anesthetic Use\nTo keep the patient as comfortable as possible, the use of long-acting \nanesthetics is highly recommended both in the beginning and at the \nend of the procedure. By administering a long-acting anesthetic at the \nend, the patient will remain “pain free” longer and will have a decrease \nin the initiation of noxious stimuli. However, care must be given to \nthe number and amount of local anesthetic to avoid overdosage. \nSedative Agents\nThe use of conscious sedation is a valuable adjunct to dental \nimplant procedures. The American Dental Association defines \nconscious sedation as a minimally depressed level of consciousness \nthat retains the patient’s ability to independently and continuously \nmaintain an airway and respond appropriately to physical stimula-\ntion or verbal command, and that is produced by a pharmacologic \nor nonpharmacologic method or combination thereof.121 Several \nsedative agents are currently available for oral and intravenous \nsedation. Table 14.10 provides the most commonly used oral and \nintravenous sedative agents.\nBenzodiazepines\nThe benzodiazepines are the most effective drugs available for \ndental-related anxiety. These drugs have depressant effects on the \nsubcortical levels of the CNS. Benzodiazepines produce anxiolysis \nand anterograde amnesia, which are extremely useful for patients \nundergoing conscious sedation for dental procedures. The exact \nmechanism is not known, but benzodiazepines are thought to \nhave an effect on the limbic system and the thalamus, which are \ninvolved with emotions and behavior.122\nDiazepam (Valium)\nDiazepam is usually not an effective agent for highly apprehen-\nsive patients unless administered intravenously. However, it is \nextremely effective if given orally the night before the procedure \nwith a dose of 5 to 10 mg. Advantages of diazepam for dental pro-\ncedures are that it reduces salivary flow and relaxes skeletal muscles.\nThe main disadvantage of diazepam is the 24-hour half-life \nfor adults and an 85-hour half-life for elderly patients. The active \nmetabolites (desmethyldiazepam and oxazepam) are responsible \nfor the prolonged sedation and recovery, along with impaired psy-\nchomotor impairment.122,123 \nMidazolam (Versed)\nMidazolam is a fast-acting benzodiazepine that is twice as potent \nas diazepam. It is available as a syrup and also as a formulated \ninjectable solution. Midazolam possesses anticonvulsant proper-\nties and also is an excellent muscle relaxant, sedative, and amne-\nsic. The inhibitory effects in the CNS are intensified; therefore \nmidazolam should not be combined with other CNS depressant \ndrugs. \n  \u0007Most Commonly Used Oral and Intravenous Sedative Agents\nSedative \nAgent\nClass\nAdministration\nOnset (min)\nDuration\nHalf-Life \n(hr)\nActive \nMetabolites\nOral Dose\nIV Dose\nAmnesia Analgesia\nTriazolam\nBenzodiazepine\nPO\n60\n1–2 hr\n2–3\nNo\n0.125–0.25 \nmg\n—\nYes\nNo\nDiazepam\nBenzodiazepine\nPO/IV\nPO: 60\nIV: 1–2\n0.25–0.5 hr 21–37\nYes\n0.2–0.5 mg/kg \n(maximum: \n15 mg)\n0.1 mg/kg\nYes\nNo\nLorazepam Benzodiazepine\nPO/IV\nPO:  \n120–240\nIV: 1–2 hr\n10–20\nNo\n0.053 mg/kg \n(maximum: \n4 mg)\n0.03–0.04 \nmg/kg\nYes\nNo\nBrevital\nBarbiturate\nIV\n0.5\n0.3 hr\n4\nNo\n—\n0.2–0.4 \nmg/kg\nYes\nNo\nFentanyl\nNarcotic\nIV\n0.5\n0.75–1 hr\n3–4\nNo\n—\n1–2 mg/kg\nNo\nYes\nPropofol\nSedative hyp-\nnotic\nIV\n0.2–0.5\n3–8 min\n0.5–1.5\nNo\n—\n25–100 \nmg/kg/\nmin\nYes\nNo\nMidazolam\nBenzodiazepine\nPO/IV\n0.5–1\n0.25–1.25 \nhr\n1–4\nNo\n0.5 mg/kg\n0.01–0.1 \nmg/kg\nYes\nNo\nIV, Intravenous; PO, by mouth.\n   \nTABLE \n14.10"
  },
  {
    "page": 168,
    "content": "376\nPART III    Fundamental Science\nTriazolam (Halcion)\nTriazolam is an orally administered benzodiazepine and short-\nterm hypnotic drug. When given orally, this drug is fast acting \nand has been shown to be safe and effective for dental procedures. \nStudies have shown that triazolam given in doses of 0.25 to 0.5 \nmg does not produce adverse effects in respiration, heart rate, or \narterial pressure. This drug is also ideal for patients with hyperten-\nsion, because blood pressure has been shown to decrease by five \npoints.122,123 \nAdditional Sedative Anxiolytics\nFentanyl\nFentanyl is a synthetic opioid agonist narcotic that produces anal-\ngesia, drowsiness, sedation, and euphoria, but no amnesia. All opi-\noid agonists produce dose-dependent depression of ventilation. \nRespiratory depression is a result of a decreased response of the \nventilatory centers to carbon dioxide. For this reason, care should \nbe taken when administering opioid agonists, especially in com-\nbination with other sedatives. Nausea and vomiting are another \nundesirable effect of opioid agonists. Opioid-induced nausea and \nvomiting are caused by direct stimulation of dopamine receptors \nin the chemoreceptor trigger zone in the fourth floor of the fourth \nventricle.122 \nPropofol (Diprivan)\nPropofol is an intravenous sedative-hypnotic agent commercially \nintroduced in the United States in 1989 by Zeneca Pharmaceu-\nticals. It was the first of a new class of intravenous anesthetic \nagents: the alkylphenols. Propofol is an ideal sedative anesthetic \nfor dentistry because it is fast-acting and possesses a short half-\nlife. The elimination half-life of propofol has been estimated to \nbe between 2 and 24 hours. However, its duration of clinical \neffect is much shorter because propofol is rapidly distributed \ninto peripheral tissues. Because of its pronounced respiratory \ndepressant effect and its narrow therapeutic range, propofol \nshould be administered only by individuals trained in airway \nmanagement.122,123 \nReversal Agents\nFlumazenil (Anexate, Lanexat, Mazicon, Romazicon) is a benzo-\ndiazepine antagonist used as a reversal agent for the treatment of \nbenzodiazepine overdose. It reverses the effects of benzodiazepines \nby competitive inhibition at the benzodiazepine binding site on \nthe GABAA receptor. It was introduced in 1987 by Hoffman-\nLaRoche under the name Anexate.\nThe onset of action is rapid, and usually effects are seen \nwithin 1 to 2 minutes. The peak effect is seen at 6 to 10 min-\nutes. The recommended dose for adults is 200 mg every 1 to \n2 minutes until the effect is seen, to a maximum of 3 mg per \nhour. It is available as a clear, colorless solution for intrave-\nnous injection, containing 500 mg in 5 mL. It is hepatically \nmetabolized to inactive compounds, which are excreted in the \nurine.122,123\nnote: Many benzodiazepines have longer half-lives than flu-\nmazenil. Therefore repeated doses of flumazenil may be required \nto prevent recurrent symptoms of overdosage after the initial dose \nof flumazenil wears off. It is hepatically metabolized to inactive \ncompounds that are excreted in the urine.\nNaloxone (Narcan) is a drug used as a reversal for narcotic \ntoxicity. Naloxone is injected intravenously for fastest action. The \ndrug acts after about 2 minutes, and its effects may last about 45 \nminutes.\nMany opioids have a longer half-life than naloxone. Therefore \npatients who are receiving naloxone should be monitored for rese-\ndation and may require repeated doses of naloxone if resedation or \nrespiratory depress occurs.122,123 \nComprehensive Pharmacologic Protocol\nBecause of the many variables (e.g., local, systemic, surgical) that \nneed to be considered with the use of pharmacologic agents in \nimplant dentistry, a protocol has been developed to standardize \nthe prophylactic use of these agents. A five-category classification \nis proposed based on the patient’s ASA status and procedure type \n(Table 14.11).\n\ta.\t \u0007Patient selection: Patients are evaluated according to their \nASA status: ASA1—normal, healthy patient; ASA2—mild \nsystemic disease; ASA3—severe systemic disease; and ASA4—\npatient with severe systemic disease that is a threat to life.\n\tb.\t \u0007Procedures: The specific procedures are categorized into the \nprotocol according to the extent, invasiveness, surgery dura-\ntion, and expected bleeding.\n\tc.\t \u0007Antimicrobials: The type of antibiotic is selected that is most \nspecific to combat the type of bacteria present in the surgical \narea. The duration of antibiotic administration can be either a \nsingle preoperative dose or extended postoperatively. The dura-\ntion of antibiotic use is dictated by the patient’s health status \nand invasiveness of the procedure. The first-line antibiotic is \namoxicillin for type 1 to 4 categories and Augmentin for type \n5 category. Second-line antibiotics include clindamycin (types \n1–4) and Ceftin or doxycycline for type 5. The use of chlorhex-\nidine is recommended with all implant procedures before and \nafter surgery.\n\td.\t \u0007Glucocorticoid: Dexamethasone (4 mg) is recommended for \ntype 2 to 5 surgeries, with an increase dose and duration in \nrelation to the extent and invasiveness of surgery.\n\te.\t \u0007Analgesic: Ibuprofen is the ideal preemptive analgesic to be \nused in all surgeries. Alternatives to ibuprofen would include \nacetaminophen. See earlier Pain Control Protocol section con-\nsisting of maximizing nonopioid medications first and adding \nnarcotics only if warranted. \nPossible Drug Interactions in Oral \nImplantology\nSee Table 14.12 for possible drug interactions."
  },
  {
    "page": 169,
    "content": "377\nCHAPTER 14  Pharmacology in Implant Dentistry\n  \u0007Pharmacologic Protocol for Oral Implantology\nPatient Selection\nProcedures\nAntibiotic\nGlucocorticoid\nAntimicrobial\nAnalgesic\nCATEGORY 1\nASA1/ASA2\n>ASA2 = Category 2\n • \u0007Single implants with minimal reflection\nAmoxicillin 1 g: 1 hr before \nsurgery\nNone\nChlorhexidine:\n½ oz BID for 2\nweeks\nPain control \nprotocol\nPCP 1–2\nCATEGORY 2\nASA1/ASA2\n>ASA2 = Category 4\n • \u0007Traumatic extractions with pathology\n • \u0007Socket grafting\n • \u0007Single-tooth implants with extensive reflection\n • \u0007Multiple implants with minimal tissue reflection\n • \u0007SA-1 sinus procedures\n • \u0007Immediate implants without pathology\nAmoxicillin 1 g: 1 hr before \nsurgery, then 500 mg 6 hours \nafter\nDecadron 4 mg\n • \u00071 tablet a.m. day of \nsurgery\nChlorhexidine:\n½ oz BID for 2\nweeks\nPain control \nprotocol\nPCP 1–2\nCATEGORY 3\nASA1/ASA2\n>ASA2 = Category 4\n • \u0007Single implants with bone grafting and excessive \ntissue reflection\n • \u0007Multiple implants with extensive reflection\n • \u0007Bone grafting (allograft/autograft)\nAmoxicillin 1 g: 1 hr before \nsurgery, then 500 mg TID for \n3 days\nDecadron 4 mg\n • \u00071 tablet a.m. day of \nsurgery\n • \u00071 tablet a.m. day \nafter surgery\n • \u00071 tablet a.m. 2 \ndays after surgery\nChlorhexidine:\n½ oz BID for 2\nweeks\nPain control \nprotocol\nPCP 2–3\nCATEGORY 4\nAny of the following:\n • \u0007>ASA2\n • \u0007Long-duration surgery\n • \u0007Less experienced \u0007surgeon\n • \u0007Immunocompromised\n • \u0007Active periodontal disease\n • \u0007Any category 3 procedures with surgical or patient \nfactors\n • \u0007Immediate implants with pathology\n • \u0007Autogenous onlay grafting\nAmoxicillin 1 g: 1 hr before \nsurgery, then 500 mg TID for \n5 days\nDecadron 4 mg\n • \u00072 tablets a.m. day \nof surgery\n • \u00072 tablets a.m. day \nafter surgery\n • \u00071 tablet a.m. 2 \ndays after surgery\nChlorhexidine:\n½ oz BID for 2\nweeks\nPain control \nprotocol\nPCP 3–4\nCATEGORY 5\nAll SA-3/SA-4 sinus patients\nAll SA-2, SA-3, and SA-4 sinus procedures\nAugmentin (875 mg/125 mg): \n1 tablet BID starting 1 day \nbefore, then 1 tablet BID for \n5 days\nDecadron 4 mg\n • \u00072 tablets a.m. day \nbefore surgery\n • \u00072 tablets a.m. day \nof surgery\n • \u00071 tablet a.m. day \nafter surgery\n • \u00071 tablet a.m. 2 \ndays after surgery\nChlorhexidine:\n½ oz BID for 2\nweeks\nPain control \nprotocol\nPCP 2–3\nASA, American Society of Anesthesiologists; PCP, pain control protocol; SA, subantral; SBE, subacute bacterial endocarditis.\nAlternative Medications\nAmoxicillin (1 g) = cephalexin (1 g), clindamycin (600 mg)\nAugmentin (875/125) = Ceftin (500 mg) = doxycycline (100 mg)\nSBE prophylaxis: change preoperative antibiotic dose to amoxicillin (2 g), cephalexin (2 g), or clindamycin\nTABLE \n14.11\nContinued"
  },
  {
    "page": 170,
    "content": "378\nPART III    Fundamental Science\nPain control protocol:\nPCP 1: ibuprofen 400 mg 1 hour before surgery\nPCP 2: ibuprofen 400 mg + 5 mg/300 mg hydrocodone PRN\nPCP 3: ibuprofen 400 mg + 7.5 mg/300 mg hydrocodone\nPR PCP 4: ibuprofen 400 mg + 10 mg/300 mg hydrocodone PRN\nRecommended Pain Control Protocol:\nPCP 1: mild pain expected\nIbuprofen: 400 mg 1 hour before surgery\nPCP 2: mild-to-moderate pain expected\nIbuprofen: 400 mg 1 hour before surgery (continue QID for 2 days)\n+Hydrocodone (Vicodin): 5 mg/300 mg as needed\nPCP 3: moderate pain expected\nIbuprofen: 400 mg 1 hour before surgery (continue QID for 2 days, then PRN)\n+Hydrocodone (Vicodin ES): 7.5 mg/350 mg (QID) for 2 days, then PRN\nPCP 4: severe pain expected\nIbuprofen: 400 mg 1 hour before surgery (continue qid for 4 days, then PRN)\n+Hydrocodone (Vicodin HP): 10 mg/300 mg (QID) for 2 days, then PRN\nAlternative Medications:\nIbuprofen (400 mg) > acetaminophen (500 mg) or naproxen sodium (375 mg)\nHydrocodone (5 mg/500 mg) > Tylenol #2/tramadol (50 mg)\nHydrocodone (7.5 mg/750 mg) > Tylenol #3/tramadol (100 mg)/Nucynta (50, 75, 100 mg)\nHydrocodone (10 mg/660 mg) > oxycodone (Percocet) 7.5/500 mg\nIf the patient cannot take medication by mouth:\n1. Ibuprofen oral suspension (over the counter)\n2. Lortab Elixir (7.5 mg hydrocodone/500 mg APAP/15 mL)\nFrom Misch International Implant Institute.\nAPAP, acetyl-para-aminophenol.\n   \n  \u0007Pharmacologic Protocol for Oral Implantology—cont’d\nTABLE \n14.11"
  },
  {
    "page": 171,
    "content": "379\nCHAPTER 14  Pharmacology in Implant Dentistry\n  \u0007Drug Interactions\nMedication\nInteracting Medication\nAdverse Effects\nAll penicillins\nBacteriostatic antibiotics\nStatic drug will impair action of penicillin\nMethotrexate (Rheumatrex)\nDecreases secretion of methotrexate\nAll cephalosporins\nBacteriostatic antibiotics\nStatic drug will impair action of penicillin\nAnticoagulants\nRisk for bleeding disorders might be increased in anticoagulated \npatients\nLincomycins\nClindamycin (Cleocin)\nErythromycin\nPossibility of antagonism\nAVOID CONCURRENT USE\nMacrolides:\nDirithromycin (Dynabac)\nClarithromycin (Biaxin)\nErythromycin\nAnticoagulants\nRisk for bleeding disorders is increased in anticoagulated patients—\nmonitor patient\nBenzodiazepines\nPossible increased benzodiazepine levels resulting in CNS depression, \navoid in elderly\nCCBs diltiazem (Cardizem) and verapamil (Isoptin, \nCalan, Verelan)\nQT interval prolongation, could cause sudden death\nCyclosporine (Sandimmune, Neoral)\nIncreased cyclosporine renal toxicity\n“Statins” (Lipitor, Zocor, Mevacor)\nIncreased statin levels with possible muscle toxicity\nMetronidazole (Flagyl)\nAnticoagulants (Coumadin)\nRisk for bleeding disorders is increased in anticoagulated patients\nEthanol\nSevere disulfiram-like reactions\nTacrolimus (Prograf)\nMetronidazole doubles Prograf levels\nQuinolones:\nCiprofloxacin (Cipro)\nGatifloxacin (Tequin)\nLevofloxacin (Levaquin)\nMoxifloxacin (Avelox)\nAntacids\nDecreased quinolone absorption\nAnticoagulants (Coumadin)\nIncreased risk for bleeding disorders\nMonitor international normalized ratio\nAntineoplastics\nQuinolone serum levels may be decreased\nCyclosporine (Sandimmune, Neoral)\nCyclosporine renal toxicity may be enhanced\nNSAIDs\nEnhanced CNS stimulation\nCaffeine\nIncreased caffeine effects\nMuscle weakness—tendon damage\nNSAIDs and aspirin\nAnticoagulants (warfarin [Coumadin])\nIncrease risk for bleeding disorders in anticoagulated patient, possible \nGI hemorrhage\nAntihypertensives (all but CCBs) (angiotensin-\nconverting enzyme inhibitor, beta blockers, \ndiuretics)\nDecreased antihypertensive effect\nMonitor blood pressure\nBisphosphonates\nGI toxicity\nCyclosporine (Neoral, Sandimmune)\nNephrotoxicity of both agents may be increased\nMethotrexate (Rheumatrex, Mexate)\nToxicity of methotrexate may be increased, and increased possibility \nof stomatitis\nSSRIs\nGI bleeding, depletion of platelet serotonin required for aggregation\nNSAID + salicylates\nBlockage of antiplatelet action with increased GI effects\nAcetaminophen\nBarbiturates, carbamazepine, phenytoin, rifampin, \nsulfinpyrazone\nThe hepatotoxicity of APAP may be increased by high-dose or long-\nterm administration of these drugs\nSedatives/anxiolytics\nIncreased sedation and respiratory depression\nEthanol\nIncreased hepatotoxicity of APAP with chronic ethanol ingestion\nTramadol (Ultram, Ultracet)\nAny drug that enhances serotonin activity (SSRI \nantidepressants, “triptans” for acute migraine\nPossible serotonin syndrome\nMAOIs (Marplan, Nardil, Parnate)\nMAOI toxicity enhanced\nQuinidine\nTramadol increased/metabolite decreased\nAll opioids\nAlcohol, CNS depressants, local anesthetics, anti-\ndepressants, antipsychotics, antihistamines, \ncimetidine\nIncreased CNS and respiratory depression may occur\nUse with caution\nHydrocodone/Codeine\n2D6 inhibitors, amiodarone, cimetidine, desip-\nramine, fluoxetine, paroxetine, propafenone, \nquinidine, ritonavir\nInhibition of biotransformation of codeine to active analgesic form\nUse different narcotic on patients taking 2D6 inhibitor\nSSRI antidepressants and bupropion\nAnalgesic effect reduced\nTABLE \n14.12\nContinued"
  },
  {
    "page": 172,
    "content": "380\nPART III    Fundamental Science\nReferences\n\t 1.\t \u0007Dana R, Azarpazhooh A, Laghapour N, et al. Role of dentists in \nprescribing opioid analgesics and antibiotics: an overview. Dent \nClin North Am. 2018;62(2):279–294.\n\t 2.\t \u0007Munckhof W. Antibiotics for surgical prophylaxis. Aust Prescr. \n2005;28(2):38–40.\n\t 3.\t \u0007Stone HH, Haney BB, Kolb LD, et al. Prophylactic and preventa-\ntive antibiotic therapy. Ann Surg. 1979;189:691–699.\n\t 4.\t \u0007Peterson LJ, Booth DF. Efficacy of antibiotic prophylaxis in intra-\noral orthognathic surgery. J Oral Surg. 1976;34:1088.\n\t 5.\t \u0007Peterson JA, Cardo VA, Stratigos GT. An examination of anti-\nbiotic prophylaxis in oral and maxillofacial surgery. J Oral Surg. \n1970;28:753.\n\t 6.\t \u0007Gynther GW, Kondell PA, Moberg LE, et  al. Dental implant \ninstallation without antibiotic prophylaxis. Oral Surg Oral Med \nOral Pathol Oral Radiol Endod. 1998;85:509–511.\n\t 7.\t \u0007Esposito M, Hirsch JM. Biological factors contributing to failure of \nosseointegrated oral implants. Eur J Oral Sci. 1998;106:721–764.\n\t 8.\t \u0007Laskin D, Dent C, Morris H. The influence of preoperative antibi-\notics on success of endosseous implants at 36 months. Annu Peri-\nodontol. 2000;5:166–174.\n\t 9.\t \u0007Dent CD, Olson JW, Farish SE, et al. Influence of preoperative \nantibiotics on success of endosseous implants up to and including \nstage 2 surgery. J Oral Maxillofac Surg. 1997;55:19–24.\n\t10.\t \u0007Larsen P, McGlumphy E. Antibiotic prophylaxis for placement of \ndental implants. J Oral Maxillofac Surg. 1993;51:194.\n\t11.\t \u0007Burke JF. The effective period of preventive antibiotic action in \nexperimental incisions and dermal lesions. Surgery. 1961;50:161.\n\t12.\t \u0007Peterson LJ. Antibiotics: their use in therapy and prophylaxis. In: \nKruger GO, ed. Oral and Maxillofacial Surgery. St Louis: Mosby; \n1984.\n\t13.\t \u0007Woods RK, Dellinger MD. Current guidelines for antibiotic pro-\nphylaxis surgical wounds. Am Fam Physician. 1998;57:2731–2740.\n\t14.\t \u0007Peterson LJ. Antibiotic prophylaxis against wound infections in \noral and maxillofacial surgery. J Oral Maxillofac Surg. 1990;48:617.\n\t15.\t \u0007Olson M, O’Connor M, Schwartz ML. Surgical wound infection: a \n5-year prospective study of 10,193 wounds at the Minneapolis VA \nMedical Center. Ann Surg. 1984;199:253.\n\t16.\t \u0007Page CP, Bohnen JMA. Antimicrobial prophylaxis for surgical \nwounds: guidelines for clinical care. Arch Surg. 1993;128:79.\n\t17.\t \u0007Haley RW, Culver DH, Morgan WM, et al. Identifying patients \nat risk of surgical wound infection: a simple multivariate index of \npatient susceptibility and wound contamination. Am J Epidemiol. \n1985;121:206–215.\n\t18.\t \u0007Garibaldi RA, Cushing D. Risk factors for post-operative infection. \nAm J Med. 1991;91(suppl 3B). 158S–157S.\n\t19.\t \u0007Cruse PJ, Foord R. A five-year prospective study of 23,649 surgical \nwounds. Arch Surg. 1973;107:206–210.\n\t20.\t \u0007Cruse PJ, Foord R. The epidemiology of wound infection: a \n10-year prospective study of 62,939 wounds. Surg Clin North Am. \n1980;60:27–40.\n\t21.\t \u0007Rider CA. Infection control within the oral surgeon’s office. Com-\npend Contin Educ Dent. 2004;25:529–534.\n\t22.\t \u0007Gristina AG, Costerton JW. Bacterial adherence and the glycocalyx \nand their role in musculoskeletal infections. Orthop Clin North Am. \n1984;15:517–535.\n\t23.\t \u0007Lee KH, Maiden MF. Microbiata of successful osseointegrated \ndental implants. J Periodontol. 1999;70:131.\n\t24.\t \u0007Drake DR, Paul J. Primary bacterial colonization of implant sur-\nfaces. Int J Oral Maxillofac Implants. 1999;14:226.\n\t25.\t \u0007Culver DH, Horan TC, Gaynes RP, et al. Surgical wound infection \nrates by wound class, operative procedure and patient risk index: \nNational Nosocomial Infections Surveillance System. Am J Med. \n1991;91:152–157.\n\t26.\t \u0007Greenberg RN, James RB, Marier RL, et  al. Microbiologic and \nantibiotic aspects of infections in the oral and maxillofacial region. \nJ Oral Surg. 1979;37:873–884.\nMedication\nInteracting Medication\nAdverse Effects\nAmides (e.g., lidocaine)\nAlcohol, CNS depressants, opioids, antidepres-\nsants, antipsychotics, antihistamines\nIncreased CNS and respiratory depression \n may occur\nAntiarrhythmic drugs\nIncreased cardiac depression\nBeta blockers, cimetidine\nMetabolism of lidocaine is reduced\nBupivacaine\nToxicity is additive, total dose should not exceed the combined maxi-\nmum dosages\nVasoconstrictors (epinephrine, \nlevonordefrin)\nTCAs—high dose (amitriptyline, desipramine, \nimipramine, nortriptyline, etc.)\nIncreased sympathomimetic effects possible\nLimit epinephrine to 0.04 mg with high-dose TCAs\nBeta blockers (nonselective) (e.g., propranolol, \nnadolol)\nHypertensive and/or cardiac prescription possible\nLimit epinephrine to 0.04 mg/2 hour visit\nPhenothiazines (e.g., chlorpromazine)\nVasoconstrictor action inhibited, leading to possible hypotensive \nresponses\nUse with caution\nAntihistamines:\nDiphenhydramine (Bena-\ndryl)\nHydroxyzine (Atarax, \nVistaril)\nPromethazine (Phenergan)\nAnticholinergics\nIncreased dry mouth, tachycardia, urinary retention\nCNS depressants (alcohol, narcotics)\nEnhanced duration and intensity of sedation\nReduce dosages\nBenzodiazepines (Triazolam)\nRifampin, carbamazepine\nIncreased metabolism leading to decreased sedative response\nAPAP,  Acetyl-para-aminophenol; CCB, calcium channel blocker; CNS, central nervous system; GI, gastrointestinal; MAOI, monoamine oxidase inhibitor; NSAID, nonsteroidal antiinflammatory drug; SSRI, \nselective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.\nFrom Resnik RR, Resnik RJ. Medical/medication complications in oral implantology. In: Misch’s Avoiding Complications in Oral Implantology. Philadelphia: Elsevier; 2018.\n   \n  \u0007Drug Interactions—cont’d\nTABLE \n14.12"
  },
  {
    "page": 173,
    "content": "381\nCHAPTER 14  Pharmacology in Implant Dentistry\n\t27.\t \u0007Aderhold L, Knothe H, Frenkel G. The bacteriology of den-\ntogenous pyogenic infections. Oral Surg Oral Med Oral Pathol. \n1981;52:583–587.\n\t28.\t \u0007Lewis MA, MacFarlane TW, McGowan DA. Quantitative bac-\nteriology of acute dento-alveolar abscesses. J Med Microbiol. \n1986;21:101–104.\n\t29.\t \u0007Norris LH, Doku HC. Antimicrobial prophylaxis in oral surgery. \nOral Maxillofacial Surg Infect. 1992;2:85–92.\n\t30.\t \u0007Hossein K, Dahlin C. Influence of different prophylactic antibiotic \nregimens on implant survival rate: a retrospective clinical study. \nClin Dent Res Relat Res. 2005;7:32–35.\n\t31.\t \u0007Binhamed A, Stowkeych A. Single preoperative dose versus long-\nterm prophylactic regimens in dental implant surgery. Int J Oral \nMax Implants. 2005;20:115–117.\n\t32.\t \u0007Alanis A, Weinstein AJ. Adverse reactions associated with the \nuse of oral penicillins and cephalosporins. Med Clin North Am. \n1983;67:113.\n\t33.\t \u0007Parker CW. Allergic reactions in man. Pharmacol Rev. 1982;34:85–\n104.\n\t34.\t \u0007Pichichero ME. Prescribing cephalosporins to penicillin-allergic \npatients. North Am Pharmacother. 2006;54:1–4.\n\t35.\t \u0007Tinti C, Parma-Benfenati S. Treatment of peri-implant defects with \nthe vertical ridge augmentation procedure: a patient report. Int J \nOral Maxillofac Implants. 2001;16(4):572–577.\n\t36.\t \u0007Esposito M, Grusovin MG, Worthington HV. Interventions \nfor replacing missing teeth: antibiotics at dental implant place-\nment to prevent complications. Cochrane Database Syst Rev. \n2013;7:CD004152.\n\t37.\t \u0007Ata-Ali J, Ata-Ali F, Ata-Ali F. Do antibiotics decrease implant \nfailure and postoperative infections? A systematic review and meta-\nanalysis. Int J Oral Maxillofac Surg. 2014;43:68–74.\n\t38.\t \u0007Chrcanovic BR, Albrektsson T, Wennerberg A. Prophylactic anti-\nbiotic regimen and dental implant failure: a meta-analysis. J Oral \nRehabil. 2014;41:941–956.\n\t39.\t \u0007Newman MG, Van Winkehoff AJ. Antibiotic and Antimicrobial use \nin Dental Practice. 2nd ed. Chicago: Quintessence; 2001.\n\t40.\t \u0007Hugo WB, Longworth AR. The effects of chlorhexidine on the \nelectrophoretic mobility, cytoplasmic constituents, dehydrogenase \nactivity and cell walls of E. coli and S. aureus. J Pharmacy Pharma-\ncol. 2001;18:569–578.\n\t41.\t \u0007Ciancio SG, Bourgault PC. Clinical Pharmacology for Dental Profes-\nsionals. 3rd ed. Chicago: Year Book Medical Publishers; 1989.\n\t42.\t \u0007Schiott C, Loe H. The effect of chlorhexidine mouthrinses on the \nhuman oral flora. J Periodont Res. 1970;5:84–89.\n\t43.\t \u0007Bonesvoll P, Lokken P. Influence of concentration, time, tempera-\nture and pH on the retention of chlorhexidine in the oral cavity \nafter mouth rinses. Arch Oral Biol. 1974;19:1025–1029.\n\t44.\t \u0007Helgeland K, Heyden G. Effect of chlorhexidine on animal cells \nin vitro. Scand J Dent Res. 1971;79:209–215.\n\t45.\t \u0007Goldschmidt P, Cogen R. Cytopathologic effects of chlorhexidine \non human cells. J Periodontol. 1977;48:212–215.\n\t46.\t \u0007Sanz M, Newman MG. Clinical enhancement of post-periodontal \nsurgical therapy by a 0.12% chlorhexidine gluconate mouthrinse. J \nPeriodontol. 1989;60:570–576.\n\t47.\t \u0007Langeback J, Bay L. The effect of chlorhexidine mouthrinse on \nhealing after gingivectomy. Scand J Dent Res. 1976;84:224–228.\n\t48.\t \u0007Newman MG, Sanz M. Effect of 0.12% chlorhexidine on bacte-\nrial recolonization following periodontal surgery. J Periodontol. \n1989;60:577–581.\n\t49.\t \u0007Brownstein CN, Briggs SD. Irrigation with chlorhexidine to \nresolve naturally occurring gingivitis: a methodologic study. J Clin \nPeriodontol. 1990;17:558.\n\t50.\t \u0007Beiswanger DD, Mallat ME. Clinical effects of a 0.12% chlorhexi-\ndine rinse as an adjunct to scaling and root planning. J Clin Dent. \n1992;3:33.\n\t51.\t \u0007Larson PE. The effect of a chlorhexidine rinse on the incidence of \nalveolar osteitis following the surgical removal of impacted third \nmolars. J Oral Maxillofac Surg. 1991;49:932.\n\t52.\t \u0007Ragano JR, Szkutnik AJ. Evaluation of 0.12% chlorhexidine rinse \non the prevention of alveolar osteitis. Oral Surg Oral Med Oral \nPathol. 1991;72:524.\n\t53.\t \u0007Lang NP, Schild U. Effect of chlorhexidine (0.12%) rinses on peri-\nodontal tissue healing after tooth extraction. I. Clinical parameters. \nJ Clin Periodontol. 1994;21:422.\n\t54.\t \u0007Hammerle CHF, Fourmousis I. Successful bone fill in late peri-\nimplant defects using guided tissue regeneration: a short communi-\ncation. J Periodontol. 1995;66:303.\n\t55.\t \u0007Thomson-Neal D, Evans GH. Effects of various prophylactic treat-\nments on titanium, sapphire and hydroxyapatite-coated implants: \nan SEM study. Int J Perodont Restorative Dent. 1989;9:300.\n\t56.\t \u0007Lambert PM, Morris HF. The influence of 0.12% chlorhexi-\ndine digluconate rinses on the incidence of infectious compli-\ncations and implant success. J Oral Maxillofac Surg. 1997;55: \n25–30.\n\t57.\t \u0007Leite FR, Sampaio JE, Zandim DL, et al. Influence of root-surface \nconditioning with acid and chelating agents on clot stabilization. \nQuintessence Int. 2010;41(4):341–349.\n\t58.\t \u0007Valderrama P, Wilson Jr TG. Detoxification of implant surfaces \naffected by peri-implant disease: an overview of surgical methods. \nInt J Dent. 2013:740680.\n\t59.\t \u0007Hanisch O, Tatakis DN, Boskovic MM, et  al. Bone formation \nand reosseointegration in peri-implantitis defects following sur-\ngical implantation of rhBMP-2. Int J Oral Maxillofac Implants. \n1997;12(5):604–610.\n\t60.\t \u0007Accepted Dental Therapeutics. 40th ed. Chicago: American Dental \nAssociation; 1984.\n\t61.\t \u0007Esen E, Tasar F. Determination of the anti-inflammatory effects of \nmethylprednisolone on the sequelae of third molar surgery. J Oral \nMaxillofac Surg. 1999;57:1201–1206.\n\t62.\t \u0007Messer EJ, Keller JJ. The use of intraoral dexamethasone after extrac-\ntion of mandibular third molars. Oral Surg. 1975;40:594–597.\n\t63.\t \u0007Hooley JR, Hohl TH. Use of steroids in the prevention of some \ncomplications after traumatic surgery. J Oral Surg. 1974;32:8634–\n8866.\n\t64.\t \u0007Williamson LW, Lorson EL, Osborn DB. Hypothalamic-pituitary-\nadrenal suppression after short-term dexamethasone therapy for \noral surgical procedures. J Oral Surg. 1980;38:20–28.\n\t65.\t \u0007Misch CE, Moore P. Steroids and the reduction of pain, edema \nand dysfunction in implant dentistry. Int J Oral Implant. 1989;6: \n27–31.\n\t66.\t \u0007Nichols T, Nugent CA, Tyle FH. Diurnal variation in suppression \nof adrenal function by glucocorticoids. J Clin Endocrinol Metab. \n1965;25:343.\n\t67.\t \u0007Bahn SL. Glucocorticosteroids in dentistry. J Am Dent Assoc. \n1982;105:476–481.\n\t68.\t \u0007Messer EJ, Keller JJ. The use of intraoral dexamethasone after \nextraction of mandibular third molars. Oral Surg. 1975;40:594–\n597.\n\t69.\t \u0007Ross R, White CP. Evaluation of hydrocortisone in prevention of \npostoperative complications after oral surgery: a preliminary report. \nJ Oral Surg. 1958;16:220.\n\t70.\t \u0007Guernsey LH, DeChamplain RW. Sequelae and complications of \nthe intraoral sagittal osteotomy in the mandibular. Oral Surg Oral \nMed Oral Pathol. 1971;32:176–192.\n\t71.\t \u0007Neuper EA, Lee JW, Philput CB, et al. Evaluation of dexametha-\nsone for reduction of postsurgical sequelae of third molar removal. \nJ Oral Maxillofac Surg. 1992;50:1177–1182.\n\t72.\t \u0007Moore PA, Barr P, Smiga ER, et  al. Preemptive rofecoxib and \ndexamethasone for prevention of pain and trismus following third \nmolar surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. \n2005;99:E1–E7.\n\t73.\t \u0007Hooley JR, Francis FH. Betamethasone in traumatic oral surgery. J \nOral Surg. 1969;27:398–403.\n\t74.\t \u0007Baxendale BR, Vater M, Lavery KM. Dexamethasone reduces pain \nand swelling following extraction of third molar teeth. Anaesthesia. \n1993;48:961–964."
  },
  {
    "page": 174,
    "content": "382\nPART III    Fundamental Science\n\t75.\t \u0007Sisk A, Bonnington GJ. Evaluation of methylprednisolone and \nflurbiprofen for inhibition of postoperative inflammatory response. \nOral Surg Oral Med Oral Pathol. 1985;60:137–145.\n\t76.\t \u0007Montgomery MT, Hogg JP, Roberts DL, et al. The use of gluco-\ncorticosteroids to lessen the inflammatory sequelae following third \nmolar surgery. J Oral Maxillofac Surg. 1990;48:179–187.\n\t77.\t \u0007Bahammam MA, Kayal RA, Alasmari DS, et  al. Comparison \nbetween dexamethasone and ibuprofen for postoperative pain pre-\nvention and control after surgical implant placement: a double‐\nmasked, parallel‐group, placebo‐controlled randomized clinical \ntrial. J Periodontol. 2017;88(1):69–77.\n\t78.\t \u0007Gao W, Tong D, Li Q, et al. Dexamethasone promotes regenera-\ntion of crushed inferior alveolar nerve by inhibiting NF-κB activa-\ntion in adult rats. Arch Oral Biol. 2017;80:101–109.\n\t79.\t \u0007Wang JJ, Ho ST, Lee SC, et al. The prophylactic effect of dexa-\nmethasone on postoperative nausea and vomiting in women under-\ngoing thyroidectomy: a comparison of droperidol with saline. \nAnesth Analg. 1999;89:200–203.\n\t80.\t \u0007Liu K, Hsu CC, Chia YY. Effect of dexamethasone on post-opera-\ntive emesis and pain. Br J Anaesth. 1998;80:85–86.\n\t81.\t \u0007Moore PA. Adverse drug interactions in dental practice: interac-\ntions associated with local anesthetics, sedatives and anxiolytics. J \nAm Dent Assoc. 1999;130:541–554.\n\t82.\t \u0007Beaver WT. Combination analgesics. Am J Med. 1984;77:38–53.\n\t83.\t \u0007Coutinho AE, Chapman KE. The anti-inflammatory and immu-\nnosuppressive effects of glucocorticoids, recent developments and \nmechanistic insights. Mol Cell Endocrinol. 2011;335:2–13.\n\t84.\t \u0007Filho JRL, Silva EDO. The influence of cryotherapy of reduction \nof swelling, pain, trismus after third molar extraction. J Am Dent \nAssoc. 2005;136:774–778.\n\t85.\t \u0007Forsgren H, Heimdahl A. Effect of application of cold dressings on \npostoperative course in oral surgery. Int J Oral Surg. 1985;14:223–\n228.\n\t86.\t \u0007Meeusen R, Lievens P. The use of cryotherapy in sports injuries. \nSports Med. 1986;3:398–414.\n\t87.\t \u0007Laureano Filo JR, de Oliveira e Silva ED, Batista CI, et al. The \ninfluence of cryotherapy on reduction of swelling, pain and trismus \nafter third-molar extraction: a preliminary study. J Am Dent Assoc. \n2005;136(6):774–778.\n\t88.\t \u0007Carr DB, Jacox AK. Clinical Practice Guidelines for Acute Pain Man-\nagement: Operative or Medical Procedures and Trauma. Washington, \nDC: Agency for Health Care Policy and Research, DHHS publica-\ntion no. 95-0034; 1992.\n\t89.\t \u0007Bachiocco V, Scesi M. Individual pain history and familial pain \ntolerance models: relationships to post-surgical pain. Clin J Pain. \n1993;9:266–271.\n\t90.\t \u0007Taenzer P, Melzack R. Influence of psychological factors on postoper-\native pain, mood and analgesic requirements. Pain. 1986;24:331–342.\n\t91.\t \u0007Huynh MP, Yagiela JA. Current concepts in acute pain manage-\nment. J Calif Dent Assoc. 2003:1–13.\n\t92.\t \u0007Chandraasekharan NV, Dai H. COX-3, a cyclooxygenase-1 vari-\nant inhibited by acetaminophen and other analgesic/antipyretic \ndrugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. \n2002;99:13926–13931.\n\t93.\t \u0007Basbaum AL, Leveine JD. Opiate analgesia. How central is a \nperipheral target? N Engl J Med. 1991;325:1168–1169.\n\t94.\t \u0007Gottschalk A, Smith DS. New concepts in acute pain therapy: pre-\nemptive analgesia. Am Fam Physician. 2001;63:1979–1984.\n\t95.\t \u0007Al-Sukhun J, Al-Sukhun S, Penttila H, et al. Preemptive analge-\nsic effect of low doses of celecoxib is superior to low doses of tra-\nditional nonsteroidal anti-inflammatory drugs. J Craniofac Surg. \n2012;23(2):526–529.\n\t96.\t \u0007Schwab JM, Schluesener HJ. COX-3: just another COX or the \nsolitary elusive target of paracetamol? Lancet. 2003;361:981–982.\n\t97.\t \u0007Ahmad N, Grad HA. The efficacy of non-opioid analgesics for post-\noperative dental pain: a meta-analysis. Anesth Prog. 1997;44:119–126.\n\t98.\t \u0007Dionne RA, Gordon SM. Nonsteroidal anti-inflammatory drugs \nfor acute pain control. Dent Clin North Am. 1994;38:645–667.\n\t99.\t \u0007Jackson DL, Moore PA. Preoperative nonsteroidal anti-inflamma-\ntory medication for the prevention of postoperative dental pain. J \nAm Dent Assoc. 1989;119:641–647.\n\t100.\t \u0007Ruffalo RL, Jackson RL, Ofman JJ, et al. The impact of NSAID \nselection on gastrointestinal injury risk for cardiovascular events: \nidentifying and treating patients at risk. Therapy. 2002;20:570–576.\n\t101.\t \u0007Hernández-Diaz S, García-Rodríguez LA. Epidemiologic assess-\nment of the safety of conventional nonsteroidal anti-inflammatory \ndrugs. Am J Med. 2001;110(suppl 3A):20S–27S.\n\t102.\t \u0007Smalley WE, Griffin MR. The risks and costs of upper gastroin-\ntestinal complications attributable to NSAIDS. Gastointerol Clin \nNorth Am. 1996;25:373–379.\n\t103.\t \u0007United States Department of Health and Human Services. Agency \nfor Health Care Policy and Research Clinical Practice Guidelines, \nNumber 9. Washington, DC: U.S. Government Printing Office; \n1994.\n\t104.\t \u0007Bryce G, Bomfim DI, Bassi GS. Pre- and post-operative manage-\nment of dental implant placement. Part 1: management of post-\noperative pain. Br Dent J. 2014;217(3):123–127.\n\t105.\t \u0007Busson M. Update on ibuprofen: review article. J Int Med Res. \n1986;14:53–62.\n\t106.\t \u0007Cooper SA. Five studies on ibuprofen for post-surgical dental pain. \nAm J Med. 1984;77:70–77.\n\t107.\t \u0007Winter L, Bass W. Analgesic activity of ibuprofen (Motrin) in \npost-operative oral surgical pain. Oral Surg Oral Med Oral Pathol. \n1978;45:159–166.\n\t108.\t \u0007Seymour RA, Ward-Booth P. Evaluation of different doses of ibu-\nprofen and ibuprofen tablets in postoperative dental pain. Br J Oral \nMaxillofac Surg. 1996;34:110–114.\n\t109.\t \u0007Driessen B, Reimann W. Interaction of the central analgesic, tra-\nmadol, with the uptake and release of 5-hydroxytryptamine in the \nrat brain in vitro. Br J Pharmacol. 1992;105:147–151.\n\t110.\t \u0007Bailey E, Worthington HV, van Wijk A, et al. Ibuprofen and/or \nparacetamol (acetaminophen) for pain relief after surgical removal \nof lower wisdom teeth. Cochrane Database Syst Rev. 2013;(12): \nCD004624.\n\t111.\t \u0007TGA Medicines Evaluation Committee, 2003. Australia: Thera-\npeutic Goods Administration; 2003. Review of Non-Prescription \nAnalgesics: Multiple Strength of Oral Liquids.\n\t112.\t \u0007Moore PA. Pain management in dental practice: tramadol vs. \ncodeine combinations. J Am Dent Assoc. 1999;130:1075–1079.\n\t113.\t \u0007Vickers MD, O’Flaherty D. Tramadol: pain relief by an opioid \nwithout depression of respiration. Anaesthesia. 1992;47:291–296.\n\t114.\t \u0007Mullican WS, Lacy JR. Tramadol/acetaminophen combination tab-\nlets and codeine/acetaminophen combination capsules for the treat-\nment of pain: a comparative trial. Clin Ther. 2001;23:1429–1445.\n\t115.\t \u0007Medve RA, Wang A. Tramadol and acetaminophen tablets for den-\ntal pain. Anesth Prog. 2001;48:79–81.\n\t116.\t \u0007Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss \nSR. Characteristics of opioid prescriptions in 2009. JAMA. \n2011;305:1299–1301.\n\t117.\t \u0007Seymour RA, Blair GS. Postoperative dental pain and analgesic effi-\ncacy. Br J Oral Surg. 1983;21:290–297.\n\t118.\t \u0007Kaurich MJ, Otomo-Corgel J. Comparison of postoperative bupi-\nvacaine with lidocaine on pain and analgesic use following periodon-\ntal surgery. J West Soc Periodontol Periodontal Abstr. 1997;45:5–8.\n\t119.\t \u0007Moore PA. Prevention of local anesthesia toxicity. J Am Dent Assoc. \n1992;123:60–64.\n\t120.\t \u0007Thomson PD, Melmo KL. Lidocaine pharmacokinetics in advanced \nheart failure, liver disease, and renal failure in humans. Ann Intern. \n1973;78:499–513.\n\t121.\t \u0007American Dental Association. American Dental Association guide-\nlines for the use of conscious sedation, deep sedation and general anes-\nthesia for dentists. http://www.ada.org/prof/resources/positions/\nstatements/anesthesia_guidelines.pdf. Accessed July 16, 2007.\n\t122.\t \u0007Stoelting RK. Pharmacology and Physiology in Anesthetic Practice. \n4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.\n\t123.\t \u0007Mosby’s Dental Drug Reference. 8th ed. St Louis: Elsevier; 2008."
  }
]